<SEC-DOCUMENT>0001193125-23-256667.txt : 20231016
<SEC-HEADER>0001193125-23-256667.hdr.sgml : 20231016
<ACCEPTANCE-DATETIME>20231016112339
ACCESSION NUMBER:		0001193125-23-256667
CONFORMED SUBMISSION TYPE:	F-1/A
PUBLIC DOCUMENT COUNT:		30
FILED AS OF DATE:		20231016
DATE AS OF CHANGE:		20231016

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Abivax S.A.
		CENTRAL INDEX KEY:			0001956827
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		F-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-274780
		FILM NUMBER:		231326695

	BUSINESS ADDRESS:	
		STREET 1:		7 BD HAUSSMANN
		CITY:			PARIS
		STATE:			I0
		ZIP:			75009
		BUSINESS PHONE:		01 53 83 09 63

	MAIL ADDRESS:	
		STREET 1:		7 BD HAUSSMANN
		CITY:			PARIS
		STATE:			I0
		ZIP:			75009
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1/A
<SEQUENCE>1
<FILENAME>d609070df1a.htm
<DESCRIPTION>F-1/A
<TEXT>
<HTML><HEAD>
<TITLE>F-1/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on October 16, 2023. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333-274780 </B></P>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, DC 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>Amendment
No. 1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>to </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">F-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>ABIVAX SA </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of
registrant as specified in its charter) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>France</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not Applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Abivax SA </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">7-11</FONT> boulevard Haussmann </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>75009 Paris </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>France
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>+33 (0) 1 53 83 08 41 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of Registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>C T Corporation System </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>1015 15th Street N.W., Suite 1000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20005 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Phone:&nbsp;+1&nbsp;202&nbsp;572&nbsp;3133 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Divakar Gupta</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Marc Recht</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Ryan
Sansom</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Denny Won</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Minkyu Park</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cooley
LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>55 Hudson Yards</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New York, NY 10001</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tel: +1
212 479 6000</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Alain Decombe</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Vianney Toulouse</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Dechert
(Paris) LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>22 rue Bayard</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>75008 Paris</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tel: +33 1 57 57 80 00</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Nathan Ajiashvili</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Alison Haggerty</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Latham
&amp; Watkins LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>1271 Avenue of the Americas</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New York, NY 10020</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tel: +1
212 906 1200</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Arnaud Duhamel</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Guilhem Richard</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Gide
Loyrette Nouel A.A.R.P.I.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>15 rue de Laborde</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>75008 Paris</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tel: +33 1 40 75 60 00</B></P></TD></TR>
</TABLE>  <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public: As soon as practicable after effectiveness of this registration statement.
</B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, as amended, or the Securities Act, check the following box.&#8194;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this Form is filed to register
additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&#8194;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Emerging growth
company.&#8194;&#9746; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial account standards&#134; provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&#8194;&#9744; </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">The term &#147;new or revised financial accounting standard&#148; refers to any update issued by the Financial
Accounting Standards Board to its Accounting Standards Codification after April&nbsp;5, 2012. </P></TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>The registrant
hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become
effective in accordance with Section&nbsp;8(a) of the Securities Act or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine.
</B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#de1a1e"><B>The information in this preliminary prospectus is not complete and may be changed. We
may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities, and we are not soliciting offers to buy these
securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#de1a1e"><B>SUBJECT TO COMPLETION, DATED OCTOBER 16, 2023 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman"><B>PRELIMINARY PROSPECTUS </B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>18,675,500
Ordinary Shares </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>(Including Ordinary Shares in the Form of American Depositary Shares) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g43a95.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>&#128;&#8195;&#8195;&#8195; per Ordinary Share </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>$&#8195;&#8195;&#8195; per American Depositary Share </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">We are
offering an aggregate of 18,675,500 ordinary shares in a global offering. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">We are offering &#8195;&#8195;&#8195;&#8195; ordinary
shares in the form of American Depositary Shares, or ADSs, in the United States, referred to herein as the U.S. offering. Each ADS represents the right to receive one ordinary share and the ADSs may be evidenced by American Depositary Receipts, or
ADRs. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">We are concurrently offering &#8195;&#8195;&#8195;&#8195; ordinary shares in Europe (including France) and countries outside of the
United States in a private placement exclusively offered to &#147;qualified investors,&#148; as such term is defined in article 2(e) of Regulation (EU) No.&nbsp;2017/1129 of the European Parliament and Council of June&nbsp;14, 2017, referred to
herein as the European private placement. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">This is our initial public offering of our ADSs in the United States. We have applied to
list our ADSs on the Nasdaq Global Market under the symbol &#147;ABVX.&#148; There is no assurance that such application will be approved, and if our application is not approved, this offering will not be completed. Our ordinary shares are listed on
Euronext Paris under the symbol &#147;ABVX.&#148; The offering price per ADS in U.S. dollars and the corresponding offering price per ordinary share in euros will be determined through negotiations between us and the representatives of the
underwriters, and by reference to the prevailing market prices of our ordinary shares on Euronext Paris after taking into account market conditions and other factors. However, in accordance with French law and the shareholders&#146; resolutions
applicable to this offering, such prices will not be lower than 10% below the volume-weighted average price of our ordinary shares on Euronext Paris for the three trading days preceding the appropriate reference date. On October 13, 2023, the last
reported closing price of our ordinary shares on Euronext Paris was &#128;12.72 per ordinary share, equivalent to a price of $13.39 per ADS, assuming an exchange rate of &#128;0.9502 per U.S. dollar, the exchange rate on October 13, 2023 as reported
by the European Central Bank. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">The closings of the U.S. offering and the European private placement, which are together referred to
as the global offering, will occur simultaneously. The total number of ordinary shares (including in the form of ADSs) in the U.S. offering and European private placement is subject to reallocation between these offerings, as permitted under
applicable laws and regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of
2012 and, as such, have elected to comply with certain reduced public company reporting requirements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:11pt; font-family:Times New Roman"><B>Investing in the ordinary shares
and ADSs involves a high degree of risk. See &#147;<A HREF="#toc609070_5">Risk Factors</A>&#148; beginning on page 17 of this prospectus. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any U.S. state or other securities commission has approved or disapproved of these
securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PER&nbsp;ORDINARY</B><br><B>SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PER&nbsp;ADS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Underwriting commissions<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">We refer you to &#147;Underwriters&#148; beginning on page 235 of this prospectus for additional information
regarding underwriting compensation. </P></TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">We have granted an option to the underwriters, exercisable within 30&nbsp;days
from the date of this prospectus, to purchase up to an aggregate of 2,801,325 additional ADSs and/or ordinary shares (representing up to 15% of the initial size of the global offering) in the global offering to be sold to the several underwriters at
the applicable offering price. If the underwriters exercise this option in full, the total underwriting commissions payable by us will be &#128;&#8195;&#8195;&#8195; ($&#8195;&#8195;) and the total proceeds to us, before expenses, will be
&#128;&#8195;&#8195; ($&#8195;&#8195;), based on the exchange rate on&#8195;&#8195;&#8195; , 2023. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">The underwriters expect to
deliver the ADSs to purchasers in the U.S. offering on or about &#8195;&#8195;&#8195;, 2023 through the book-entry facilities of The Depository Trust Company. The underwriters expect to deliver the ordinary shares to purchasers in the European
private placement on or about &#8195;&#8195;&#8195;, 2023 through the book-entry facilities of Euroclear France. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:13pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="33%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:13pt">
<TD VALIGN="top"><B>Morgan Stanley</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Leerink Partners</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:13pt">
<TD VALIGN="top"><FONT STYLE="font-size:11pt"><B>LifeSci Capital</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-size:11pt"><B>Bryan,&nbsp;Garnier&nbsp;&amp;&nbsp;Co</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">The date of this prospectus is &#8195;&#8195;&#8195;, 2023. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_4">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_5">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_6">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_7">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_8">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_9">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_10">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_11">ENFORCEMENT OF CIVIL LIABILITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_12">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_13">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_14">MANAGEMENT </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_15">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_16">PRINCIPAL SHAREHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_17">DESCRIPTION OF SHARE CAPITAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_18">LIMITATIONS AFFECTING SHAREHOLDERS OF A FRENCH COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_19">DESCRIPTION OF AMERICAN DEPOSITARY SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_20">ORDINARY SHARES AND ADSs ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_21">MATERIAL UNITED STATES FEDERAL INCOME AND FRENCH TAX
CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_22">UNDERWRITERS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_23">EXPENSES RELATING TO THE GLOBAL OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_24">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_25">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_25a">DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_26">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_27">INDEX TO THE FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>For investors outside the United States: Neither we nor any of the underwriters have done anything that would permit the global offering or
possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about,
and observe any restrictions relating to, the offering of the ordinary shares and ADSs and the distribution of this prospectus outside the United States. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are incorporated in France, and under the rules of the U.S. Securities and Exchange Commission (the &#147;SEC&#148;), we are currently
eligible for treatment as a &#147;foreign private issuer.&#148; As a foreign private issuer, we will not be required to file periodic reports and financial statements with the SEC as frequently or as promptly as domestic registrants whose securities
are registered under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Throughout this prospectus,
references to ADSs mean ADSs or ordinary shares represented by ADSs, as the case may be. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_1"></A>MARKET, INDUSTRY AND OTHER DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, information contained in this prospectus concerning our industry and the markets in which we operate, including
our general expectations and market position, market opportunity and market size estimates, is based on information from independent industry analysts, third-party sources and management estimates. Management estimates are derived from publicly
available information released by independent industry analysts and third-party sources, as well as data from our internal research, and are based on assumptions made by us based on such data and our knowledge of such industry and market, which we
believe to be reasonable. In addition, while we believe the market opportunity information included in this prospectus is reliable and is based on reasonable assumptions, such data involves risks and uncertainties and is subject to change based on
various factors, including those discussed under the heading &#147;Risk Factors.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_2"></A>PRESENTATION OF FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus includes our audited financial statements as of and for the years ended December&nbsp;31, 2022 and 2021 prepared in accordance
with International Financial Reporting Standards (&#147;IFRS&#148;), as issued by the International Accounting Standards Board (&#147;IASB&#148;). None of our financial statements were prepared in accordance with U.S. generally accepted accounting
principles (&#147;U.S. GAAP&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our financial statements are presented in euros and, unless otherwise stated, all monetary amounts
are in euros. All references in this prospectus to &#147;$&#148;, &#147;U.S. dollars&#148; and &#147;dollars&#148; mean U.S. dollars, and all references to &#147;&#128;&#148;, &#147;EUR&#148; and &#147;euros&#148; mean European Monetary Union euros,
unless otherwise noted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The European Union uses a flexible exchange rate system to determine the value of the euro against the
U.S.&nbsp;dollar. The following table sets forth the rate of exchange for the euro at the end of the five most recent fiscal periods ended December 31, the average rates for the period, and the range of high and low rates for the period. The data
for the six months ended June&nbsp;30, 2023 is also included. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this table, the rate of exchange means the closing daily
rate used by the U.S. Department of Treasury. The table sets forth the number of euros required under that formula to buy one U.S. dollar. The average rate means the average of the exchange rates on the last day of each month during the period. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Close</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Six Months Ended June 30, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fiscal Year Ended December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fiscal Year Ended December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fiscal Year Ended December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fiscal Year Ended December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fiscal Year Ended December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_3"></A>TRADEMARKS AND SERVICE MARKS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Abivax&#148; and the Abivax logo and other trademarks or service marks of Abivax SA appearing in this prospectus are the property of
Abivax SA. Solely for convenience, the trademarks, service marks and trade names referred to in this prospectus are listed without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and
<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their right thereto. All
other trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. We do not intend to use or display other companies&#146; trademarks and trade names to imply any relationship with, or
endorsement or sponsorship of us by, any other companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_4"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained elsewhere in this prospectus and does not contain all of the information you should consider
before investing in our ordinary shares (including ordinary shares in the form of ADSs). You should read the entire prospectus carefully, including &#147;Risk Factors&#148; &#147;Cautionary Note Regarding Forward-Looking Statements&#148;
&#147;Business&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements and the related notes appearing elsewhere in this prospectus before making an investment
decision. Unless otherwise indicated or the context otherwise requires, &#147;Abivax,&#148; &#147;the company,&#148; &#147;our company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Abivax SA and its consolidated subsidiary,
taken as a whole. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are a clinical-stage biotechnology company focused on developing therapeutics that harness the body&#146;s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. We are currently evaluating our
lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis (&#147;UC&#148;). We are also in the planning stages of initiating a Phase 2a clinical trial of obefazimod
in patients with Crohn&#146;s disease (&#147;CD&#148;), as well as evaluating other potential inflammatory indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We focus on
indications where existing treatments have left patients with significant unmet needs, and where we believe our investigational agents have the potential to be meaningfully differentiated from currently available therapies. The indications we target
have substantial populations and represent large commercial opportunities, pending regulatory approvals and successful commercialization. Our initial focus is on inflammatory bowel diseases (&#147;IBD&#148;), chronic conditions involving
inflammation of the gastrointestinal (&#147;GI&#148;) tract, of which the two most common forms are UC and CD. As of 2022, an aggregate of approximately 2.9&nbsp;million patients across the United States, EU4 (France, Germany, Italy and Spain), the
United Kingdom and Japan suffered from IBD, with 1.5&nbsp;million of these patients in the United States alone. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the primary goals
of IBD therapy is to achieve durable&nbsp;clinical remission while simultaneously taking into consideration a patient&#146;s quality of life and concerns regarding potential side effects. Despite a number of different therapies approved for UC and
CD, the vast majority of these therapies require chronic administration via injections or intravenous infusions, and may come with serious and concerning warnings, including, but not limited to, risks of serious infections leading to
hospitalizations or death and increased risks of various malignancies. A vast majority of IBD patients do not achieve clinical remission with existing therapies, and a significant number of patients will lose response over time, especially those
patients on TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitor therapy where anti-drug antibodies are very common. Further, despite the increased number of biosimilars, such as TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitor
therapies, becoming available for the treatment of IBD, biosimilars unfortunately do not alleviate any of the potential side&nbsp;effect concerns that often cause patients to delay, or avoid altogether, stepping up to more advanced therapies. In
addition, although a small number of oral therapies have more recently been approved for the treatment of IBD, these therapies also come with concerning potential side effects, which can discourage patients from initiating treatment with advanced
therapies. Therefore, there continues to be significant unmet need for novel oral therapies with durable efficacy, improved safety profiles and minimal preinitiation requirements for patients with moderately to severely active IBD. Moreover, we
believe the IBD market has significant growth potential driven by growing diagnosis of these diseases and increased penetration of oral treatments with improved benefit/risk profiles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our lead drug candidate, obefazimod, is differentiated from competing approaches for the treatment of IBD via its novel mechanism
of action. Obefazimod was demonstrated to specifically enhance the expression of a single <FONT STYLE="white-space:nowrap">micro-RNA,</FONT> <FONT STYLE="white-space:nowrap">miR-124,</FONT> which plays a critical role in the regulation of the
inflammatory response. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
In the context of inflammation, <FONT STYLE="white-space:nowrap">miR-124</FONT> is a natural regulator of the inflammatory response, controlling progression of inflammation and restoring
homeostasis of the immune system, without causing broader immunosuppression. In contrast to currently available advanced therapies, prescribed post-conventional therapies, some of which target only a single cytokine or pathway, <FONT
STYLE="white-space:nowrap">miR-124</FONT> modulates the expression of several key cytokines and pathways. Modulating multiple inflammatory pathways simultaneously may lead to more durability of efficacy results over the long-term, which is critical
in lifelong conditions such as IBD, potentially differentiating obefazimod from currently available IBD treatments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our Phase 2
clinical trials for the treatment of moderately to severely active UC, consistent with the pharmacological effects observed in our preclinical studies, obefazimod demonstrated an onset of symptom relief by day 8 of dosing, with meaningful reductions
in rectal bleeding and stool frequency scores. In our induction Phase 2b clinical trial, which included 252 patients, obefazimod met the primary endpoint of a statistically significant reduction in Modified Mayo Score, a measure of disease activity
relative to placebo. In addition, we observed high rates of sustained and newly achieved clinical remission in the subsequent open-label maintenance extension trial of up to two years of treatment, of which approximately 45% of patients were
previously exposed to biologics or Janus kinase (&#147;JAK&#148;) inhibitors. Greater than 90% of patients previously exposed to advanced therapy prior to enrollment were highly refractory, having failed at least two advanced therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2023, we reported the results from the final analysis of our Phase 2b open-label maintenance trial, including 217 patients of which
164 patients (76%) completed the second year of once-daily oral treatment with 50 mg obefazimod. At the conclusion of the second year of treatment, 114 of the 217 patients enrolled (53%) achieved clinical remission and 158 patients (73%) achieved
clinical response. Among the 98 <FONT STYLE="white-space:nowrap">bio-refractory</FONT> patients, 66 patients (67%) had a clinical response, 38 patients (39%) were in clinical remission, 46 patients (47%) had endoscopic improvement and 20 patients
(20%) had endoscopic remission at week 96. Among the 124 patients that achieved clinical response at the end of the 8-week induction period of the double-blind study, 82 patients (66%) achieved clinical remission at week 48, mimicking the
re-randomization of responders approach typically utilized in Phase 3 maintenance trials. Of the 124 patients in clinical response at week 8, 74&nbsp;patients (60%) achieved clinical remission, 95 patients (77%) had clinical response, 79 patients
(64%) achieved endoscopic improvement and 52 patients (42%) achieved endoscopic remission at week 96. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2023, we reported
an interim analysis of step-down dosing from 50 mg to 25 mg for the third and fifth year of open-label maintenance treatment with obefazimod in UC patients. These patients were treated with 50 mg of oral, once-daily obefazimod for approximately four
years in the Phase 2a clinical trial and approximately two years in the Phase 2b clinical trial. Patients were eligible to enroll in the trial if they had a Mayo endoscopic subscore of 0 or 1. Eligible patients were switched to 25 mg, and an interim
analysis was performed at week 48 with a cut-off date of July 31, 2023. Of the 71 eligible patients, 63 completed their 48-week visit. Among these patients, 53 out of 63 patients (84%) demonstrated disease control (stable or improved Modified Mayo
Score). No new safety signals were detected in UC patients treated up to five years with oral, once-daily obefazimod. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obefazimod&#146;s
tolerability profile indicates potentially important clinical differentiation. As of November&nbsp;30, 2022 (the last safety data <FONT STYLE="white-space:nowrap">cut-off</FONT> date), 1,074 patients and volunteers had been treated with obefazimod,
of which 209 patients were treated with 50 mg obefazimod for one year or more with no change in the observed tolerability profile underscored by 76% of patients that remained on therapy throughout the <FONT STYLE="white-space:nowrap">two-year</FONT>
open-label maintenance trial period. No new adverse safety signals were observed. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We initiated our pivotal Phase 3 clinical trials of
obefazimod for the treatment of moderately to severely active UC in October 2022, which consist of two induction trials <FONT STYLE="white-space:nowrap">(ABTECT-1</FONT> and <FONT STYLE="white-space:nowrap">ABTECT-2)</FONT> and one ABTECT
maintenance trial. <FONT STYLE="white-space:nowrap">Top-line</FONT> data from the <FONT STYLE="white-space:nowrap">ABTECT-1</FONT> and <FONT STYLE="white-space:nowrap">ABTECT-2</FONT> induction trials is expected to be announced in the first quarter
of 2025, and <FONT STYLE="white-space:nowrap">top-line</FONT> data from the ABTECT maintenance trial is expected to be announced in the first quarter of 2026. We intend to (i) file an Investigational New Drug Application (&#147;IND&#148;) in the
fourth quarter of 2023, (ii) initiate a Phase&nbsp;2a </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical trial in patients with CD in the first quarter of 2024 and (iii) announce Phase 2a induction trial top-line results in the second half of 2025 with the objective to demonstrate clinical
response and tolerability profile consistent with that already observed in our clinical trials for moderately to severely active UC. Based on the results from this Phase 2a clinical trial, we intend to proceed directly to a Phase 3 clinical trial.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our team is comprised of industry leaders in the fields of biology, data analytics and drug development, as well as scientific
experts in chronic inflammatory diseases, including IBD. We are led by Marc de Garidel, our Chief Executive Officer, who has more than 40 years of experience in the pharmaceutical and biotechnology sector. Collectively, our team has decades of
experience and a proven track record of advancing compounds into and through clinical development and commercialization, including at the following organizations: Amgen, Arena Pharmaceuticals, AstraZeneca, BioNTech, Boehringer Ingelheim, Eli Lilly,
Genentech/Roche, Guerbet, Ipsen Pharmaceuticals, J&amp;J, Pfizer, Sanofi, Sanofi-Pasteur and Shire/Takeda. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead drug candidate, obefazimod, is in clinical development for the treatment of moderately to severely active UC. We are continuing to
develop obefazimod for the treatment of CD and are evaluating additional potential inflammatory indications to pursue, subject to the availability of necessary resources and funding. In parallel, we are in the process of generating <FONT
STYLE="white-space:nowrap">follow-on</FONT> compounds based on the <FONT STYLE="white-space:nowrap">miR-124</FONT> platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The chart
below sets forth details relating to the current stages of development of our lead drug candidate: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g00r08.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Decision subject to results of the Phase 3 monotherapy induction trials. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IBD Overview and Limitations of Existing Treatments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IBD, such as UC and CD, is a chronic life-long immune-mediated inflammatory condition of the GI tract with many contributing factors, including
genetic, environmental and immunologic. UC and CD are the two most common forms of IBD and are characterized by dysregulation of lymphocytes contributing to inflammation. Both UC and CD are chronic, relapsing, remitting, inflammatory conditions of
the GI tract that begin most commonly during adolescence and young adulthood. UC involves the innermost lining of the large intestine, and symptoms include abdominal pain and diarrhea, frequently with blood and mucus. CD can affect the entire
thickness of the bowel wall and all parts of the GI tract from mouth to anus. CD symptoms include abdominal pain, diarrhea and other more systemic symptoms, such as weight loss, nutritional deficiencies and fever. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IBD, as of 2022, affected approximately 1.5&nbsp;million patients in the United States alone. As of 2022, the prevalence of UC and CD in the
United States were estimated at approximately 0.9&nbsp;million and 0.6&nbsp;million patients, respectively. The prevalence of IBD in the EU4 and the United Kingdom is estimated at 1.2&nbsp;million with
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approximately 0.7&nbsp;million patients with UC and 0.5&nbsp;million patients with CD. As of 2022, an aggregate of approximately 2.9&nbsp;million patients across the United States, EU4, the
United Kingdom and Japan suffered from IBD. This figure is expected to grow to approximately 3.0 million patients by 2028. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2022,
pharmaceutical sales in IBD were $16.3&nbsp;billion in the United States and $7.4&nbsp;billion in the rest of the world, totaling $23.7&nbsp;billion worldwide. In 2028, pharmaceutical sales in IBD are estimated to be $17.5&nbsp;billion and
$26.8&nbsp;billion in the United States and worldwide, respectively. Worldwide sales in the UC market were $7.4&nbsp;billion in 2022 and are estimated to be $10.2&nbsp;billion in 2028, while in the CD market worldwide sales reached
$16.3&nbsp;billion in 2022 and are estimated to be $16.6&nbsp;billion in 2028. We believe the IBD market has significant growth potential driven by growing diagnosis of these diseases and increased penetration of oral treatments with improved
benefit/risk profiles. We believe the potential for oral agents to gain significant market share is supported by physician and patient preference for the convenience of oral administration over injectable agents, increasing demand for therapies with
long-term efficacy profiles and the opportunity for potent and well-tolerated oral agents to expand the overall segment of the moderately to severely active UC population undergoing treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the widespread use of conventional therapies to treat mild to moderately active IBD, due to the progressive and lifelong nature of
both UC and CD, for many patients the severity of their disease progresses in activity and are considered moderately to severely active. This requires patients and their physicians to consider using more targeted therapies typically termed
&#147;advanced therapies.&#148; The majority of advanced therapies require chronic parenteral administration including <FONT STYLE="white-space:nowrap">TNF-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitors (e.g., infliximab,
adalimumab and golimumab), Interleukin <FONT STYLE="white-space:nowrap">(&#147;IL&#148;)-12/23</FONT> inhibitor (ustekinumab), anti-integrin antibodies (vedolizumab) or <FONT STYLE="white-space:nowrap">IL-23</FONT> inhibitors (mirikizumab). There
are also two classes of oral treatments including JAK inhibitors (e.g., tofacitinib, filgotinib and upadacitinib) and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sphingosine-1-phosphate</FONT></FONT> (&#147;S1P&#148;) receptor
agonists (ozanimod). Although these therapies have demonstrated efficacy in UC and/or CD, the majority of IBD patients do not achieve clinical remission, and a significant number of patients lose response over time, especially those treated with
TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitor therapies where anti-drug antibodies are common. Due to mechanisms of action that are poorly understood, with each line of advanced therapy that is exhausted, patients become less likely
to respond to the next advanced therapy utilized in the sequence of care. Moreover, each of the advanced therapy classes are associated with notable side effect and safety tradeoffs that must be considered before initiating treatment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strengths </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the following
strengths will allow us to advance our proprietary drug candidates through clinical trials, while building upon our advanced position in the development of therapeutics for IBD and other chronic inflammatory diseases: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our focus on indications of high unmet need and substantial commercial potential, with an initial focus on
IBD. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We focus on indications where existing treatments have left patients with significant unmet needs, and where we
believe our investigational agents have the potential to be meaningfully differentiated from currently available therapies. The indications we target have substantial populations and represent large commercial opportunities, pending regulatory
approvals and successful commercialization. Our initial focus is on IBD, chronic conditions involving inflammation of the GI tract, of which the two most common forms are UC and CD. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We believe the IBD market has significant growth potential driven by growing diagnosis of these diseases and increased penetration of oral
treatments with improved benefit/risk profiles. We believe the need for differentiated treatment options is high, in particular for patients with moderate and severe forms of IBD, for whom available therapies often have limited efficacy and
durability while carrying significant safety and tolerability challenges. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>We believe we are market leaders in leveraging <FONT STYLE="white-space:nowrap">micro-RNA</FONT> biology to
target inflammation. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We believe our lead drug candidate, obefazimod, is differentiated from competing approaches for
the treatment of IBD via its novel mechanism of action. Obefazimod was demonstrated to specifically enhance the expression of a single <FONT STYLE="white-space:nowrap">micro-RNA,</FONT> <FONT STYLE="white-space:nowrap">miR-124,</FONT> which plays a
critical role in the regulation of the inflammatory response. In the context of inflammation, <FONT STYLE="white-space:nowrap">miR-124</FONT> is a natural regulator of the inflammatory response, controlling progression of inflammation and restoring
homeostasis of the immune system, without causing broader immunosuppression. In contrast to currently available advanced therapies, prescribed post-conventional therapies, some of which target only a single cytokine or pathway, <FONT
STYLE="white-space:nowrap">miR-124</FONT> modulates the expression of several key cytokines and pathways. Modulating multiple inflammatory pathways simultaneously may lead to more durability of efficacy results over the long-term, which is critical
in lifelong conditions such as IBD, potentially differentiating obefazimod from currently available IBD treatments. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Robust data generated from our Phase 2 clinical trials of obefazimod for the treatment of moderately to
severely active UC. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In our Phase 2 clinical trials for the treatment of moderately to severely active UC, consistent
with the pharmacological effects observed in our preclinical studies, obefazimod demonstrated an onset of symptom relief by day 8 of dosing, with meaningful reductions in rectal bleeding and stool frequency scores. In our induction Phase 2b clinical
trial, which included 252 patients, obefazimod met the primary endpoint of a statistically significant reduction in Modified Mayo Score, a measure of disease activity relative to placebo. In addition, we observed high rates of sustained and newly
achieved clinical remission in the subsequent open-label maintenance extension trial of up to two years of treatment, of which approximately 45% of patients were previously exposed to biologics or JAK inhibitors. Greater than 90% of patients
previously exposed to advanced therapy prior to enrollment were highly refractory, having failed at least two advanced therapies. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our lead drug candidate, obefazimod, has been well-tolerated in our clinical trials to date.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Obefazimod&#146;s tolerability profile indicates potentially important clinical differentiation. Many existing
therapies for IBD have been limited by safety and tolerability concerns, including increased risks of serious infections or various malignancies, sometimes requiring warning labels. By contrast, as of November&nbsp;30, 2022 (the last safety data <FONT
STYLE="white-space:nowrap">cut-off</FONT> date), the tolerability profile of obefazimod is supported by more than 1,074 patients and volunteers that had been treated with obefazimod, of which 209 patients were treated with 50 mg obefazimod for one
year or more with no change in the observed tolerability profile. In addition, to date, the entire obefazimod safety database presents no death or malignancies and no reported clinically significant changes in laboratory parameters, such as liver
function, hemoglobin levels and white blood cell counts. The most common treatment emergent adverse event (&#147;TEAE&#148;) reported has been mild to moderate headache, which has been transient and manageable with or without <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> medications. Furthermore, at present, no increased rate of opportunistic infections or malignancies compared with placebo have been observed across all
clinical trials. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Compelling and differentiating clinical characteristics position obefazimod as a potential <FONT
STYLE="white-space:nowrap">first-line</FONT> advanced therapy for moderately to severely active UC. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Therapies
currently available to patients with UC in the first-line setting are limited to older, broad immunosuppressive agents with safety, tolerability and efficacy challenges. Advanced therapies, which include biologic agents such as TNF-<FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitors, <FONT STYLE="white-space:nowrap">IL-12/23</FONT> inhibitors or <FONT STYLE="white-space:nowrap">IL-23</FONT> inhibitors, carry significant safety and tolerability challenges and their
administration, as injectable agents, is not convenient to patients. Newer oral molecules, such as JAK inhibitors and S1P receptor agonists, while addressing convenient route of administration for patients, also present safety and tolerability
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
challenges. Comparatively, obefazimod is being developed as a once-daily, oral medication which, combined with its observed tolerability to date, would represent a meaningfully differentiated
clinical profile from existing therapies. We believe this may position obefazimod as a potential first-line advanced therapy choice for both prescribers and patients, if approved. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our experienced team is comprised of global industry leaders in the development of therapeutics for chronic
inflammatory diseases. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We believe that the breadth of experience and accomplishments of our management team, board
of directors and scientific advisory board, combined with our broad network of established relationships with leaders in the industry and medical community, provide us with fresh insights into drug development and commercialization, and have allowed
us to bring together top researchers to build interdisciplinary research and development teams. We are led by Marc de Garidel, our Chief Executive Officer, who has more than 40 years of experience in the pharmaceutical and biotechnology sector and
successfully led the sales of CinCor Pharma to AstraZeneca in 2023 and Corvidia Therapeutics to Novo Nordisk in 2020. Collectively, our team has decades of experience and a proven track record of advancing compounds into and through clinical
development and commercialization, including at the following organizations: Amgen, Arena Pharmaceuticals, AstraZeneca, BioNTech, Boehringer Ingelheim, Eli Lilly, Genentech/Roche, Guerbet, Ipsen Pharmaceuticals, J&amp;J, Pfizer, Sanofi,
Sanofi-Pasteur and Shire/Takeda. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary goal is to develop and commercialize obefazimod for the treatment of inflammatory diseases, starting with moderately to severely
active UC. We have already generated compelling data in moderately to severely active UC from our Phase 2a and 2b clinical trials, which we believe provides us with potential readthrough into a broader set of inflammatory diseases. We focus on
indications with high unmet needs with substantial commercial potential. To achieve our goal, we are pursuing the following key elements of our strategy: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Advance obefazimod through pivotal clinical trials and establish obefazimod as a potential first-line advanced
therapy for IBD. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We believe that the strength of the data we have generated in our Phase 2 clinical trials,
specifically the potential to demonstrate rapid onset of action and durability of safety and efficacy results (as evidenced by a clinical remission rate of 53%, clinical response rate of 73% and no new adverse safety signals observed from our
two-year Phase 2b open-label maintenance trial), if supported by the results of our Phase 3 clinical trials, uniquely positions obefazimod as a potential first-line advanced therapy choice for moderately to severely active UC, if approved. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Based on the positive clinical data generated in our UC trials, preclinical studies in dextran sulfate sodium mouse model which provide support
for pursuing further development in CD, and underlying biological and mechanistic rationale, we plan to initiate a Phase 2a clinical trial in patients with CD in the first quarter of 2024 to potentially demonstrate outcomes consistent with those
observed in our Phase 2 clinical trials for moderately to severely active UC. CD shares many of the underlying pathophysiological processes and clinical manifestations of UC, and, as a result, the current treatment paradigm of CD is similar to UC.
In addition, we believe that obefazimod&#146;s clinical profile observed to-date lends itself to potential combinations with existing or new therapies, which we are exploring. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Disrupt the IBD landscape in the near-term with our Phase 3 data beginning in 2025. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Currently available therapies have limited efficacy and durability that wanes over time, have extensive pre-initiation requirements, carry
significant safety and tolerability challenges (such as black box safety </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
warnings), and most of them are injectable biologics. We believe the potential for oral agents to gain significant market share is supported by physician and patient preference for the
convenience of oral administration over injectable agents, increasing demand for therapies with long-term efficacy profiles and the opportunity for potent and well-tolerated oral agents to expand the overall segment of the moderately to severely
active UC population undergoing treatment. We believe obefazimod&#146;s novel mechanism of action that modulates multiple inflammatory pathways simultaneously offers a potentially differentiated oral treatment option that may lead to more durability
of efficacy results as we observed in our Phase 2 clinical trials. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Leverage library of <FONT STYLE="white-space:nowrap">miR-124</FONT> enhancers to expand our pipeline.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Based on the mechanistic concept of obefazimod, we have launched a research and development program to generate new
potential drug candidates to strengthen our intellectual property portfolio on the miR-124 platform and to identify additional drug candidates from our proprietary small molecule library that includes additional miR-124 enhancers. Our strategy is to
conduct proof-of-concept studies with obefazimod to show that enhanced expression of miR-124 demonstrates disease-modifying effects in other inflammatory conditions where there is unmet medical need. To further our strategy, our first follow-on drug
candidate is expected to be selected and enter preclinical development in 2024. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Opportunistically evaluate strategic partnerships to maximize the value of obefazimod and our therapeutic
pipeline. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We currently hold and intend to retain worldwide development and commercialization rights for obefazimod.
For certain geographies, we may opportunistically enter into strategic partnerships to accelerate development activities in order to realize the commercial potential of obefazimod as well as other assets in our pipeline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Team </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our team is comprised of
industry leaders in the fields of biology, data analytics and drug development, as well as scientific experts in chronic inflammatory diseases including IBD, with 34 full-time employees as of June&nbsp;30, 2023. Collectively, our team has decades of
experience and a proven track record of advancing compounds into and through clinical development and commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Marc de Garidel,
our Chief Executive Officer, has more than 40 years of experience in the pharmaceutical and biotechnology sector, including 12 years of experience as Chief Executive Officer of pharmaceutical and biotechnology companies. Between July 2021 and April
2023, he served as Chief Executive Officer of CinCor Pharma and led its successful sale for up to $1.8&nbsp;billion, subject to the achievement of certain milestones, to AstraZeneca in February 2023. From April 2018 until August 2020, he was Chief
Executive Officer of Corvidia Therapeutics and led its sale to Novo Nordisk for $2.1&nbsp;billion in total consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management
team also consists of other top industry veterans such as Didier Blondel, our Chief Financial Officer and Board Secretary, who was previously Chief Financial Officer at Sanofi Pasteur MSD; Sheldon Sloan, MD, M Bioethics, our Chief Medical Officer,
who has over 30 years of experience in academia and the biopharmaceutical industry, with an extensive track record in the field of gastroenterology and IBD; Michael Ferguson, MBA, our Chief Commercial Officer, who has over 22 years of experience in
the biopharmaceutical industry, including 13 years in leading commercial positions at Shire/Takeda, followed by Arena Pharmaceuticals; Pierre Courteille, Pharmacist, MBA, our Chief Business Officer, who has more than 25 years of experience in
marketing, sales and business development within the pharmaceutical industry; and Didier Scherrer, Ph.D., our Chief Scientific Officer, who has extensive experience in the development of a portfolio of therapeutics in oncology, viral diseases and
autoimmune / inflammatory diseases. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is led by our Chairman and Chief Executive Officer, Marc de Garidel.
Additional board members include: Corinna zur Bonsen-Thomas, <FONT STYLE="white-space:nowrap">Co-founder</FONT> and Chief Executive Officer of RetInSight and former General Counsel at Baxter International; Carol Brosgart, MD, Clinical Professor of
Medicine, Epidemiology and Biostatistics at the University of California, San Francisco; Kinam Hong MD, MBA, CFA, Partner at the Crossover Fund of Sofinnova; Troy Ignelzi, CFO of Karuna Therapeutics; June Lee, MD, Venture Partner at 5AM Ventures;
Paolo Rampulla, representing Sant&eacute; Holdings SRL; and Philippe Pouletty, MD, our founder and Managing Partner at Truffle Capital, representing Truffle Capital. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with Our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An
investment in our securities involves a high degree of risk. Any of the factors set forth under &#147;Risk Factors&#148; may limit our ability to successfully execute our business strategy. You should carefully consider all of the information set
forth in this prospectus and, in particular, should evaluate the specific factors set forth under &#147;Risk Factors&#148; in deciding whether to invest in our ordinary shares or ADSs. Among these important risks are the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are a clinical-stage company with a limited operating history and no approved products and no historical
product revenues, which makes it difficult to assess our future prospects and financial results. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have incurred considerable losses historically, which we anticipate will continue and may increase in the
future. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if we consummate the offering, we will require substantial additional funding, which may not be available on
acceptable terms or at all, and failure to obtain this necessary capital may force us to delay, limit or terminate our product development efforts or other operations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our financial statements contain a footnote describing management&#146;s assumption regarding our ability to
continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have significant debt commitments, which require us to meet certain operating covenants, and if we fail to
comply with those covenants the bondholders would be able to accelerate our repayment obligations. Additionally, the conversion of some or all of our bonds into ordinary shares would dilute the ownership interests of existing shareholders.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our principal tangible and intangible assets serve as collateral under the terms of debt agreements for the Kreos
/ Claret Financing. If we default on these debt obligations, the Secured Lenders could foreclose on those assets, and we would be unable to continue our business and operations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Drug candidates under development must undergo costly, rigorous and highly regulated preclinical studies and
clinical trials, whose time of completion, number and outcomes are uncertain. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are heavily dependent on the success of our drug candidates, in particular obefazimod, and we cannot be
certain that obefazimod or any of our other current or future drug candidates will receive regulatory approval, and, without regulatory approval, we will not be able to market our drug candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical failure can occur at any stage of clinical development. The results of earlier clinical trials as well
as data from any interim analysis of ongoing trials are not necessarily predictive of future results and any drug candidate we advance through clinical trials may not have favorable results in later clinical trials. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our future may depend on our most advanced clinical development program, obefazimod, since our other drug
candidates are in a less advanced stage of development. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We expect to expand our organization, and as a result, we may encounter difficulties in managing our growth,
which could disrupt our operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on a small number of third-party suppliers, and in certain cases a single-source supplier, and we may be
in a position of dependence with respect to our subcontractors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our future success depends on our ability to retain our key executives and to attract, retain and motivate
qualified personnel. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There are material weaknesses in our internal controls over financial reporting and if we are unable to maintain
effective internal controls over financial reporting, the accuracy and timeliness of our financial reporting may be adversely affected, which could adversely affect our business, investor confidence and the market price of our securities.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our ability to exclusively commercialize our drug candidates may decrease if we are unable to protect our
intellectual property rights or if these rights are insufficient for our purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August 20, 2023, we entered into a framework subscription agreement (the &#147;Framework Subscription Agreement&#148;) with entities
affiliated with Kreos Capital (&#147;KC&#148;) and entities affiliated with Claret European Growth Capital (&#147;Claret&#148;) (together, the &#147;Secured Lenders&#148;). Under this Framework Subscription Agreement, we may draw up to &#128;75
million in structured debt financing (the &#147;Kreos / Claret Financing&#148;), in three tranches of &#128;25&nbsp;million in aggregate principal amount each. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, on August 20, 2023, we entered into a subscription agreement (the &#147;Heights Subscription Agreement&#148;) with entities
affiliated with Heights Capital Management (&#147;Heights&#148;). Under the Heights Subscription Agreement, we may draw up to &#128;75 million in amortizing senior convertible notes (the &#147;Heights Convertible Notes&#148;), in two tranches of
&#128;35 million and &#128;40&nbsp;million (the &#147;Heights Financing&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional details, see &#147;Business&#151;Key
Collaborations and Partners&#151;Financing Arrangements.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Corporate and Other Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated as a <I>soci&eacute;t&eacute; anonyme</I> (limited liability company) on December&nbsp;4, 2013 and registered at the Paris
Trade and Company Register on December&nbsp;27, 2013 for a period of 99 years until December&nbsp;22, 2112, subject to extension or early dissolution, under the number 799&nbsp;363&nbsp;718. Our principal executive offices are located at <FONT
STYLE="white-space:nowrap">7-11</FONT> boulevard Haussmann 75009 Paris, France, and our telephone number is +33&nbsp;(0)&nbsp;1&nbsp;53&nbsp;83&nbsp;08&nbsp;41. We have one wholly owned subsidiary, Abivax LLC, a Delaware limited liability company,
formed on March 20, 2023. Our agent for service of process in the United States is CT Corporation System, 1015 15th Street N.W., Suite 1000, Washington, D.C. 20005. We also maintain a website at www.abivax.com. The reference to our website is an
inactive textual reference only, and the information contained in, or that can be accessed through, our website is not a part of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to make our reports and other information filed with or furnished to the SEC pursuant to Section&nbsp;13(a) or 15(d) of the Exchange
Act available, free of charge, through our website, as soon as reasonably practicable after those reports and other information are electronically filed with or furnished to the SEC. Information on our website or any other website is not
incorporated by reference into this prospectus and does not constitute a part of this prospectus. The SEC maintains an internet site at www.sec.gov that contains reports and other information regarding issuers that file electronically with the SEC.
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#147;JOBS Act&#148;).
As an emerging growth company, we may take advantage of certain reduced disclosure and other requirements that are otherwise generally applicable to public companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemption from the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 (the
&#147;Sarbanes-Oxley Act&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to present only two years of audited financial statements in addition to any required interim
financial statements and correspondingly reduced disclosure in management&#146;s discussion and analysis of financial condition and results of operations in the registration statement for the global offering of which this prospectus forms a part;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to the extent that we no longer qualify as a foreign private issuer: (i)&nbsp;reduced disclosure obligations
regarding executive compensation in our periodic reports and proxy statements; and (ii)&nbsp;exemptions from the requirements of holding a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on executive compensation, including golden
parachute compensation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these provisions for up to five years or until such earlier time that
we no longer qualify as an emerging growth company. We would cease to be an emerging growth company upon the earliest to occur of: (i)&nbsp;the last day of the fiscal year in which our annual gross revenues exceed $1.235&nbsp;billion; (ii)&nbsp;the
first day of the year following the first year in which, as of the last business day of our most recently completed second fiscal quarter, the market value of our common equity held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds
$700&nbsp;million; (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the previous three years; and (iv)&nbsp;the last day of the fiscal year
ending after the fifth anniversary of our initial public offering of our ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may choose to take advantage of some but not all of
these exemptions. For example, Section&nbsp;107 of the JOBS Act provides that an emerging growth company can use the extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act of 1933, as amended (&#147;the Securities
Act&#148;), for complying with new or revised accounting standards. Given that we currently report and expect to continue to report under IFRS, as issued by the IASB, we have irrevocably elected not to avail ourselves of this extended transition
period, and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required by the IASB. Since IFRS make no distinction between public and private companies for purposes of
compliance with new or revised accounting standards, the requirements for our compliance as a private company and as a public company are the same. We have taken advantage of reduced reporting requirements in this prospectus. Accordingly, the
information contained herein may be different than the information you receive from other public companies in which you hold equity securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being a Foreign Private Issuer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also considered a &#147;foreign private issuer&#148; under U.S. securities laws. In our capacity as a foreign private issuer, we are
exempt from certain rules under the Exchange Act, which impose certain disclosure obligations and procedural requirements for proxy solicitations under Section&nbsp;14 of the Exchange Act. In addition, our officers, directors and principal
shareholders are exempt from the reporting and short-swing profit recovery provisions of Section&nbsp;16 of the Exchange Act and the rules under the Exchange Act with respect to their purchases and sales of our securities. Moreover, we are not
required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. In addition, we are not required to comply with Regulation FD, which
restricts the selective disclosure of material information. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these exemptions until such time as we are no longer a foreign
private issuer. We would cease to be a foreign private issuer at such time as more than 50% of our outstanding voting securities are held by U.S.&nbsp;residents and any of the following three circumstances applies: (i)&nbsp;the majority of our
executive officers or directors are U.S. citizens or residents; (ii)&nbsp;more than 50% of our assets are located in the United States; or (iii)&nbsp;our business is administered principally in the United States. For additional information relating
to our principal shareholders, see &#147;Principal Shareholders.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have taken advantage of certain reduced reporting and other
requirements in this prospectus. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold equity securities. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE GLOBAL OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Global&nbsp;offering </P></TD>
<TD>18,675,500 ordinary shares offered by us, consisting of &#8195;&#8195;&#8195;&#8195;&#8195;&nbsp;ordinary shares in the form of ADSs offered in the U.S. offering and &#8195;&#8195;&#8195;&#8195;&#8195; ordinary shares offered in the European
private placement. The closing of the U.S. offering and the European private placement will occur simultaneously. The total number of ordinary shares (including in the form of the ADSs) in the U.S. offering and the European private placement is
subject to reallocation between these offerings, as permitted under the applicable laws and regulations. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">U.S. offering </P></TD>
<TD>&#8195;&#8195;&#8195;&#8195;&#8195; ADSs, each representing one ordinary share. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">European private placement </P></TD>
<TD>&#8195;&#8195;&#8195;&#8195;&#8195; ordinary shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Offering&nbsp;price </P></TD>
<TD>The offering price per ADS in U.S. dollars and the corresponding offering price per ordinary share in euros will be determined through negotiations between us and the representatives of the underwriters, and by reference to the prevailing market
prices of our ordinary shares on Euronext Paris after taking into account market conditions and other factors. However, in accordance with French law and the shareholders&#146; resolutions applicable to this offering, such prices will not be lower
than 10% below the volume-weighted average price of our ordinary shares on Euronext Paris for the three trading days preceding the appropriate reference date. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Ordinary shares (including ordinary shares in the form of ADSs) to be outstanding immediately after the
global offering </P></TD>
<TD>61,223,068 ordinary shares. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional ADSs and/or ordinary shares in the global offering </P></TD>
<TD>We have agreed to issue, at the option of the underwriters, within 30&nbsp;days after the date of this prospectus, up to an aggregate of 2,801,325 additional ordinary shares (representing up to 15% of the initial size of the global offering).
</TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">American Depositary Shares (or ADSs) </P></TD>
<TD>Each ADS represents one ordinary share, par value &#128;0.01 per share. Purchasers of ADSs in the U.S. offering will have the rights of an ADS holder as provided in the deposit agreement among us, the depositary and all holders and beneficial
owners of ADSs issued thereunder. To better understand the terms of the ADSs, purchasers of ADSs should carefully read the section in this prospectus titled &#147;Description of American Depositary Shares.&#148; We also encourage purchasers of ADSs
to read the deposit agreement, which is filed as an exhibit to the registration statement of which this prospectus forms a part. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Depositary </P></TD>
<TD>Citibank, N.A. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that we will receive net proceeds from the global offering of approximately &#128;214.3&nbsp;million ($225.5&nbsp;million), based on an assumed initial offering price of &#128;12.72&nbsp;per ordinary share ($13.39&nbsp;per ADS),
which is the last reported closing price of our ordinary shares on Euronext Paris on October 13, 2023, after deducting the estimated underwriting commissions and estimated offering expenses payable by us. We intend to use the net proceeds from the
global offering as follows: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately &#128;170.0 million ($178.9 million, assuming an exchange rate of &#128;0.9502 per U.S. dollar, the
exchange rate on October 13, 2023 as reported by the European Central Bank) to fund the development of obefazimod for UC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately &#128;15.0 million ($15.8 million, assuming an exchange rate of &#128;0.9502 per U.S. dollar, the
exchange rate on October 13, 2023 as reported by the European Central Bank) to fund the development of obefazimod for CD; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remainder for working capital and for other general corporate purposes, including in the continued research
to identify new compounds and the payment of maturities of existing debt agreements as they become due (mostly allocated to payments under the Kreos / Claret Financing, and assuming that we will repay the Heights Financing through the issuance of
new shares instead of making cash payments). </P></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may also use a portion of the remaining net proceeds and our existing cash and cash equivalents to in-license, acquire, or invest in complementary businesses, technologies, products or assets. However, we have no
current commitments or obligations to do so. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Use of Proceeds&#148; for more information. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Dividend policy </P></TD>
<TD>We do not expect to pay any dividends on the ordinary shares or ADSs in the foreseeable future. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>You should read the &#147;Risk Factors&#148; section of this prospectus for a discussion of factors to consider carefully before deciding to invest in the ordinary shares or ADSs. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Proposed Nasdaq Global Market symbol for our ADSs </P></TD>
<TD>&#147;ABVX&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Euronext Paris trading symbol for our ordinary shares </P></TD>
<TD>&#147;ABVX&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, the number of ordinary shares (including ordinary shares in the form of
ADSs) that will be outstanding after the global offering is based on 42,547,568 ordinary shares outstanding as of June&nbsp;30, 2023 and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">308,984 ordinary shares issuable upon the exercise of share warrants (BSA) outstanding as of June&nbsp;30, 2023
at a weighted-average exercise price of &#128;7.57 per ordinary share (or $8.27 based on the exchange rate in effect as of June&nbsp;30, 2023), which figure includes 32,800 ordinary shares that were issued pursuant to exercises of share warrants
(BSA) subsequent to June 30, 2023; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">385,409 ordinary shares issuable upon the exercise of founder&#146;s share warrants (BCE) outstanding as of
June&nbsp;30, 2023 at a weighted-average exercise price of &#128;9.64 per ordinary share (or $10.53 based on the exchange rate in effect as of June&nbsp;30, 2023); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,413,543 ordinary shares reserved for future issuance as of June&nbsp;30, 2023 under our share-based
compensation plans and other delegations of authority from our shareholders, which include (i) 1,482,796 ordinary shares issuable upon the vesting of free shares (AGA) allocated to certain of our officers and employees in July 2023, of which 106,369
free shares (AGA) are subject to vesting conditions that include the successful completion of this offering with at least $100.0 million in gross proceeds, and (ii) 985,750 ordinary shares issuable upon the vesting of free shares (AGA) allocated to
certain of our officers and employees in September 2023, of which 254,250 free shares (AGA) are subject to vesting conditions that include the successful completion of this offering with at least $200.0 million in gross proceeds. For additional
details regarding the vesting conditions of the foregoing free shares (AGA), please see the section of this prospectus titled &#147;Certain Relationships and Related Person Transactions&#151;Arrangements with our Directors and Executive
Officers&#151;Free Shares (<I>attributions gratuites d&#146;actions</I>)&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,178,084 ordinary shares issuable upon the conversion of the convertible bonds with warrants attached (the
&#147;Kreos / Claret OCABSA&#148;) issued to KC and Claret in connection with the drawdown of the first tranche of the Kreos / Claret Financing, at a conversion price of &#128;21.22 per ordinary share (or $23.17 based on the exchange rate in effect
as of June&nbsp;30, 2023); </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">214,198 ordinary shares issuable upon the exercise of share warrants (BSA) issued to KC and Claret in connection
with the drawdown of the first tranche of the Kreos / Claret Financing, at an exercise price of &#128;18.67 per ordinary share (or $20.39 based on the exchange rate in effect as of June 30, 2023); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">261,004 ordinary shares issuable upon the exercise of share warrants (BSA) that could be issued to KC and Claret
in connection with the future drawdown of the second and third tranches of the Kreos / Claret Financing, assuming an exercise price of &#128;15.33 per ordinary share (or $16.74 based on the exchange rate in effect as of June 30, 2023), which
represents a 10% premium to the 15-day VWAP price of our ordinary shares as of the date of this prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,472,606 ordinary shares issuable upon the conversion of the Heights Convertible Notes in connection with the
drawdown of the first tranche of the Heights Financing, at a conversion price of &#128;23.77 per ordinary share (or $25.96 based on the exchange rate in effect as of June 30, 2023) and up to 2,830,201 ordinary shares issuable in the event of
repayment in ordinary shares of the principal and interest of the Heights Convertible Notes, assuming a price of &#128;14.43 per ordinary share (or $15.76 based on the exchange rate in effect as of June 30, 2023) retained for the repayment; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,208,488 ordinary shares issuable upon the conversion of the Heights Convertible Notes that could be issued to
Heights in connection with the future drawdown of the second tranche of the Heights Financing, assuming a conversion price of &#128;18.11 per ordinary share (or $19.78 based on the exchange rate in effect as of June 30, 2023), which represents a 30%
premium to the 15-day VWAP price of our ordinary shares as of October 13, 2023, and up to 3,855,841 ordinary shares issuable in the event of repayment in ordinary shares of the principal and interest of the second tranche of the Heights Convertible
Notes, assuming a price of &#128;11.84 per ordinary share (or $12.93 based on the exchange rate in effect as of June 30, 2023) retained for the repayment, which represents a 15% discount to the 15-day VWAP price of our ordinary shares as of October
13, 2023. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional details relating to the Kreos / Claret Financing and the Heights Financing, see
&#147;Business&#151;Key Collaborations and Partners&#151;Financing Arrangements.&#148; References to outstanding ordinary shares included in this prospectus include 11,487 treasury shares issued by us as of June 30, 2023. Except as otherwise noted,
the information in this prospectus assumes no exercise by the underwriters of their option to purchase 2,801,325 additional ADS and/or ordinary shares in the global offering and no exercise of share warrants (BSA), founder&#146;s share warrants
(BCE) or vesting of free shares (AGA) or other equity awards subsequent to June&nbsp;30, 2023. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUMMARY FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize our historical financial data. We derived the summary statement of income (loss) for the years ended
December&nbsp;31, 2022 and 2021 from our audited financial statements included elsewhere in this prospectus. Our audited financial statements have been prepared in accordance with International Financial Reporting Standards (&#147;IFRS&#148;), as
issued by the International Accounting Standards Board (&#147;IASB&#148;) and endorsed by the European Union (the &#147;EU&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
summary interim condensed consolidated statements of income (loss) for the six months ended June&nbsp;30, 2023 and 2022 and summary interim condensed consolidated financial position data as of June&nbsp;30, 2023 have been derived from our unaudited
interim condensed consolidated financial statements included elsewhere in this prospectus, prepared in accordance with IAS 34, Interim Financial Reporting, the standard of IFRS applicable to interim financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary financial data for the periods as of the dates indicated are qualified by reference to and should be read in conjunction
with our audited financial statements and related notes and our unaudited interim condensed consolidated financial statements and related notes included elsewhere in this prospectus, as well as the sections entitled &#147;Presentation of Financial
Information&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our historical results for any prior period do not necessarily indicate our expected results for any future period, and our interim results
are not necessarily indicative of the results that may be expected for a full fiscal year. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Statement of Income (Loss) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(In thousands of euros)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the six&nbsp;months&nbsp;ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">11,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">4,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2,255</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,961</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,583</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,284</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,255</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(155</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and Development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,781</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,107</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,622</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,580</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,492</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,758</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill impairment loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,632</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,986</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(53,361</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(69,419</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>(28,317</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>(39,535</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(41,400</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(64,836</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>(26,033</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>(37,280</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,561</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,022</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,346</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,030</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">357</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,052</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,096</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,849</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(14,673</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(42,452</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(60,740</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(21,183</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(51,953</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss per share (&#128;/share)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of outstanding shares used for computing basic/diluted loss per
share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,455,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,092,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,759,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,903,802</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic / diluted loss per share (&#128;/share)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2.75</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3.18</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1.26</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1.45</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Condensed Consolidated Statement of Financial Position Data </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(In thousands of euros)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro<BR>Forma<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>As&nbsp;Adjusted<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">114,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">138,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">354,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Gives effect to the (i) issuance of the Kreos / Claret OCABSA, (ii) issuance of the Heights Convertible Notes
(based on a valuation as of August 24, 2023) and (iii) repayments of all outstanding amounts that remained due under the First KC Agreement, the Second KC Agreement and the OCEANE bonds (each as defined below). The Kreos / Claret Financing and the
Heights Convertible Notes consist of elements that need to be fair valued under IFRS. We have performed a preliminary valuation to estimate the fair value for the purposes of preparing the pro forma as adjusted figures in this table and therefore
such figures may be subject to further adjustments. See &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Liquidity and Capital Resources&#151;Indebtedness&#148; for additional information.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Gives further effect to the issuance and sale of 18,675,500 ordinary shares (including ordinary shares in the
form of ADSs) in the global offering, based on an assumed initial offering price of &#128;12.72 per ordinary share ($13.39 per ADS), which is the last reported closing price of our ordinary shares on Euronext Paris on October 13, 2023, after
deducting the estimated underwriting commissions and estimated offering expenses payable by us. The pro forma as adjusted information presented above is illustrative only and will depend on the actual initial public offering price and other terms of
the global offering determined at pricing, including the amount by which actual offering expenses are higher or lower than estimated. Each &#128;1.00 ($1.05) increase or decrease in the assumed initial offering price of &#128;12.72 per ordinary
share ($13.39 per ADS), which is the last reported closing price of our ordinary shares on Euronext Paris on October 13, 2023 would increase or decrease the pro forma as adjusted amount of each of cash and cash equivalents, total assets and total
shareholders&#146; equity by &#128;17.4 million ($18.3 million), assuming that the number of ordinary shares (which may be in the form of ADSs) offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting
the estimated underwriting commissions and estimated offering expenses payable by us. We may also increase or decrease the number of ordinary shares (including ordinary shares in the form of ADSs) we are offering. An increase or decrease in the
number of ordinary shares (which may be in the form of ADSs) offered by us by 1,000,000 ordinary shares (which may be in the form of ADSs) would increase or decrease the pro forma as adjusted amount of each of cash and cash equivalents, total assets
and total shareholders&#146; equity by &#128;11.8&nbsp;million ($12.4&nbsp;million), assuming that the assumed initial offering price remains the same, and after deducting the estimated underwriting commissions and estimated offering expenses
payable by us. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_5"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>An investment in our ordinary shares (including ordinary shares in the form of ADSs) involves a high degree of risk. You should carefully
consider the risks and uncertainties described below, together with all of the information contained in this prospectus, including our financial statements and the related notes, before making an investment decision regarding the ordinary shares
(including ordinary shares in the form of ADSs). If any of the following risks are realized, our business, financial condition, results of operations or prospects could be materially and adversely affected. In that event, the market price of our
securities could decline, and you could lose part or all of your investment. The risks discussed below also include forward-looking statements, and our actual results may differ substantially from those discussed in these forward-looking statements.
See &#147;Cautionary Note Regarding Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Financial Position and Need for Additional Capital
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are a clinical-stage company with a limited operating history and no approved products and no historical product revenues, which makes it
difficult to assess our future prospects and financial results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company with a limited
operating history upon which you can evaluate our business and prospects. We were incorporated as a <I>soci</I><I>&eacute;</I><I>t</I><I>&eacute;</I><I> anonyme</I> (limited liability company) on December&nbsp;4, 2013 and, to date, we have focused
primarily on organizing and staffing our company, business planning, raising capital, identifying, acquiring <FONT STYLE="white-space:nowrap">and&nbsp;in-licensing&nbsp;our</FONT> drug candidates, establishing our intellectual property portfolio,
conducting research, preclinical studies and clinical trials, establishing arrangements with third parties for the manufacture of our drug candidates and related raw materials and providing general and administrative support for these
operations.&nbsp;Investment in product development in the healthcare industry, including of biopharmaceutical products, is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential drug
candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval or become commercially viable. As a result, our ability to reduce our losses and reach consistent profitability from product sales is
unproven, and we may never sustain profitability. We have no products approved for commercial sale and have not generated any revenue from product sales to date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to generate revenue from product sales and achieve and maintain profitability depends on our ability, alone or with any future
collaborators, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, our lead drug candidate, obefazimod. Our prospects, including our ability to finance our operations and generate revenue from
product sales, therefore will depend substantially on the development and commercialization of obefazimod, as other programs in our preclinical portfolio are still in earlier stages of development. Since our inception in 2013, the majority of our
operating income has been derived from our reliance on research collaborations unrelated to obefazimod, and we do not anticipate generating revenue from product sales for the next several years, if ever. Our ability to generate revenue from product
sales depends heavily on our or any future collaborators&#146; success in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timely and successful completion of clinical development of obefazimod, our lead drug candidate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining regulatory and marketing approval for obefazimod and any future drug candidates for
which we successfully complete clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launching and commercializing any drug candidates for which we obtain regulatory and marketing approval by
establishing a sales force, marketing and distribution infrastructure or, alternatively, collaborating with a commercialization partner; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining coverage and adequate reimbursement from government and third-party payors for our current or any
future drug candidates, if approved, both in the United States and internationally, and reaching acceptable agreements with foreign government and third-party payors on pricing terms; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing, validating and maintaining a commercially viable, sustainable, scalable, reproducible and
transferable manufacturing process for obefazimod or any future drug candidates that are compliant with current good manufacturing practices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing and maintaining supply and manufacturing relationships with third parties that can provide an
adequate amount and quality of drugs and services to support our planned clinical development, as well as the market demand for obefazimod and any future drug candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining market acceptance, if and when approved, of obefazimod or any future drug candidates as a viable
treatment option by physicians, patients, third-party payors and others in the medical community; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effectively addressing any competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">implementing additional internal systems and infrastructure, as needed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter, and
performing our obligations pursuant to such arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade
secrets and <FONT STYLE="white-space:nowrap">know-how;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">avoiding and defending against third-party interference or infringement claims; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attracting, hiring and retaining qualified personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred considerable losses historically, which we anticipate will continue and may increase in the future. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have incurred net losses. For the six-month periods ended June 30, 2023 and 2022 and the years ended December&nbsp;31,
2022 and 2021, we reported net losses of &#128;52.0 million, &#128;21.2 million, &#128;60.7&nbsp;million and &#128;42.5&nbsp;million, respectively. As of June 30, 2023, we carried forward accumulated tax losses of &#128;355.4&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have devoted most of our financial resources to research and development, including our clinical and preclinical development activities.
Even if we obtain regulatory approval to market a drug candidate, our future revenues will depend upon the size of any markets in which our drug candidates have received approval and our ability to achieve sufficient market acceptance, reimbursement
from third-party payors and adequate market share for our drug candidates in those markets. There can be no assurance that we will ever earn any revenues or revenues sufficient to offset past, current and future losses or achieve profitability,
which would impair our ability to sustain our operations. Moreover, even if we achieve profitability, such profitability may not be sustainable. Any inability to generate sustained profits could have a material adverse effect on our business,
prospects, financial condition, cash flows and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to incur significant expenses and operating
losses for the foreseeable future. We do not anticipate achieving profitability in the future unless we obtain the regulatory approvals necessary to commercialize obefazimod and any additional drug candidates that we may pursue in the future. We
anticipate that our expenses will increase substantially if, and as, we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timely and successfully complete clinical development of obefazimod, our clinical-stage drug candidate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek and maintain regulatory and marketing approvals for obefazimod and any future drug candidates for which we
successfully complete clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue the preclinical and clinical development of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand the scope of our current clinical trials for our drug candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">begin new clinical trials for our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">develop, scale and validate our commercial manufacturing capabilities for our drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a sales, marketing and distribution infrastructure to commercialize any drugs for which we may obtain
marketing approval for which we have not entered into a collaboration with a third-party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to discover, identify and validate additional drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other drug candidates and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make milestone, royalty or other payments under <FONT STYLE="white-space:nowrap">in-license</FONT> or
collaboration agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain, maintain, protect, enforce and expand our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract new and retain existing skilled personnel; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">create additional infrastructure to support our operations as a U.S. public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, following the issuance of royalty certificates in September 2022 and other royalties that may become payable under our royalty
agreements, the payment of royalties in the event of commercialization of obefazimod will result in a decrease in cash flows generated by sales of the product, which could have an unfavorable impact on our financial position, particularly at the
beginning of the commercialization phase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net losses we incur may fluctuate significantly from <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year,</FONT></FONT> such that a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparison of our results of operations may not be a good indication of our future performance. In any particular period or periods, our operating
results could be below the expectations of securities analysts or investors, which could cause the price of the ordinary shares (which may be in the form of ADSs) to decline. An increase in operational losses would have a material adverse effect on
our business, financial position, income, growth and outlook. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we consummate the offering, we will require substantial additional funding,
which may not be available on acceptable terms or at all, and failure to obtain this necessary capital may force us to delay, limit or terminate our product development efforts or other operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have consumed substantial amounts of cash since inception. We are currently advancing obefazimod through clinical development
and conducting preclinical studies with respect to other programs. Developing drug candidates is expensive, lengthy and risky, and we expect our research and development expenses to increase substantially in connection with our ongoing activities,
particularly as we seek to advance obefazimod toward commercialization. If our clinical trials are successful and we obtain regulatory approval for drug candidates that we develop, we will incur commercialization expenses before these drug
candidates are marketed and sold. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2023, our cash and cash equivalents were &#128;114.4&nbsp;million. We believe
that based on our anticipated net proceeds from this offering, together with (a) our existing cash and cash equivalents of &#128;114.4 million as of June&nbsp;30, 2023, (b) the net proceeds of the August 2023 drawdown of the first tranches of the
Kreos / Claret Financing and the Heights Financing, collectively amounting to &#128;27.2 million (net of repayments of all outstanding amounts that remained due under the First KC Agreement, the Second KC Agreement and the OCEANE bonds), (c) the
anticipated net proceeds from the drawdown of the second tranche of the Kreos / Claret Financing, amounting to &#128;25&nbsp;million (which is a portion of the total available drawdown of &#128;65 million from the Kreos / Claret Financing and the
Heights Financing) and (d)&nbsp;the expected Research Tax Credit (CIR) reimbursements would enable us to fund our operations through the fourth quarter of 2025. Under these assumptions and based on our current clinical plan, we would have sufficient
funds to finance our operations through (i) the announcement of our top-line data from the Phase 3 ABTECT-1 and ABTECT-2 induction trials for UC and (ii) the announcement of our top-line data from the Phase 2a induction trial for CD. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we further draw down on the third tranche of the Kreos / Claret Financing, amounting
to &#128;25 million and the second tranche of the Heights Financing amounting to &#128;40 million, we expect to have sufficient funds to finance our operations into the second quarter of 2026. Under these assumptions and based on our current
clinical plan, we would have sufficient funds to finance our operations through the announcement of our top-line data from the Phase 3 ABTECT maintenance trial for UC. For additional details relating to the Kreos / Claret Financing and the Heights
Financing, see &#147;Business&#151;Key Collaborations and Partners&#151;Financing Arrangements.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This takes into account our
assumption that R&amp;D expenditure will be substantially increased in 2023 driven by the progression of the Phase 3 clinical trials of obefazimod, which started enrollment of patients with moderately to severely active UC in October 2022. We have
based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. For instance, there is no guarantee that we would be able to meet our conditions to be able to draw down on
the remaining tranches of the Kreos / Claret Financing and the second tranche of the Heights Financing. We anticipate that we will require additional capital as we seek regulatory approval of our drug candidates. We intend to assess and plan for any
such funding requirements and aim to regularly update the market on our financing need projections. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until we can generate sufficient
product or royalty revenue to finance our cash requirements, which we may never do, we may seek additional financing in the form of public or private equity or debt financings, government or other third-party funding, marketing and distribution
arrangements and collaborations, strategic alliances and licensing arrangements or a combination of these sources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount and timing
of our funding needs will depend on factors that are largely outside of our control, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">higher costs and slower-than-expected progress on our research and development programs and clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to preparing, filing, enforcing and maintaining our patents and other intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of the research required and time needed to sign licensing agreements with industrial partners;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expenses needed to respond to technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">higher costs and longer-than-expected lead times obtaining regulatory authorizations, including time for
preparing application dossiers for the relevant authorities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">new opportunities for developing new products or acquiring technologies, products or companies.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any additional fundraising efforts may divert our management from their <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop and, if approved, commercialize our drug candidates. In addition, we cannot guarantee that future financing will be available in
sufficient amounts or on terms acceptable to us, if at all. Under French law, our share capital may be increased only with shareholders&#146; approval at an extraordinary general shareholders&#146; meeting on the basis of a report from the board of
directors. In addition, the French Commercial Code imposes certain limitations on our ability to price certain offerings of our share capital without preferential subscription rights (<I>droit pr&eacute;f&eacute;rentiel de souscription</I>), which
limitation may prevent us from successfully completing any such offering. See &#147;Description of Share Capital&#151;Rights, Preferences and Restrictions Attaching to Ordinary Shares (Articles 7, 11, 30, 31 and 32 of the <FONT
STYLE="white-space:nowrap">By-Laws).&#148;</FONT> To the extent that we raise additional capital, the terms of any financing may adversely affect the holdings or the rights of our shareholders and the issuance of additional securities, whether
equity or debt, by us, or the possibility of such issuance, may cause the market price of our ordinary shares (which may be in the form of ADSs) to decline. The sale of additional equity or convertible securities will dilute our shareholders
ownership interest. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating
restrictions that could adversely impact our ability to conduct our business. To the extent that we raise additional funds through arrangements with research and development partners or otherwise, we may be required to relinquish some of our
technologies, drug candidates or revenue streams, license our technologies or drug candidates on unfavorable terms, or otherwise agree to terms unfavorable for us. If we are unable to obtain adequate financing, we may be required to delay, reduce or
eliminate the number or scope of our projects and drug candidates (including our preclinical studies and clinical trial programs). In order to obtain financing, we may be required to relinquish rights to some of our technologies or drug candidates
or otherwise agree to terms unfavorable to us. If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of
any drug candidate or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could impair our prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our financial statements contain a footnote describing management&#146;s assumption regarding our ability to continue as a going concern, which could
prevent us from obtaining new financing on reasonable terms or at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our independent registered public accounting firm included
an emphasis of matter in its report that our financial statements, included elsewhere in this prospectus, have been prepared assuming that we will continue as a going concern. For the six-month periods ended June 30, 2023 and 2022 and the years
ended December&nbsp;31, 2022 and 2021, we reported net losses of &#128;52.0 million, &#128;21.2 million, &#128;60.7 million and &#128;42.5 million, respectively. As of June&nbsp;30, 2023, we carried forward accumulated tax losses of
&#128;355.4&nbsp;million. Recurring losses may cast significant doubt or raise substantial doubt about our ability to continue as a going concern. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There cannot be any assurance that we will be successful in obtaining necessary financing in the future to continue as a going concern or
achieve profitability. We expect that we will need to raise additional capital following the completion of this equity offering in order to complete the necessary trials to achieve commercial viability of some or all of our drug candidates. If funds
are not available, we may be required to delay, reduce the scope of, or eliminate research or development plans or commercialization efforts with respect to our products. The sale of additional equity may dilute existing shareholders and newly
issued shares may contain senior rights and preferences compared to currently outstanding ordinary shares. Issued debt securities may contain covenants and limit our ability to pay dividends or make other distributions to our shareholders. If we are
unable to obtain such additional financing, future operations (such as our clinical development programs) would need to be scaled back or discontinued. These factors may raise substantial doubt about our ability to continue as a going concern. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There are material weaknesses in our internal controls over financial reporting and if we are unable to maintain effective internal controls over
financial reporting, the accuracy and timeliness of our financial reporting may be adversely affected, which could adversely affect our business, investor confidence and the market price of our securities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial
reporting for external purposes in accordance with international financial reporting standards. Internal control over financial reporting includes maintaining records that in reasonable detail accurately and fairly reflect our transactions;
providing reasonable assurance that transactions are recorded as necessary for preparation of our financial statements; providing reasonable assurance that receipts and expenditures of our assets are made in accordance with management authorization;
and providing reasonable assurance that unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements would be prevented or detected on a timely basis. Because of its inherent limitations,
internal control over financial reporting is not intended to provide absolute assurance that a misstatement of our financial statements would be prevented or detected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We must maintain effective internal controls over financial reporting in order to accurately and timely report our results of operations and
financial condition. In addition, as a public company listed in the United States, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Sarbanes-Oxley Act will require, among other things, that we assess the effectiveness of our internal controls over financial reporting at the end of each fiscal year, starting with the end of
the first full fiscal year after the completion of the U.S. offering. However, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting for so long as we
are an &#147;emerging growth company,&#148; which may be up to five fiscal years following the date of this U.S. offering. An independent assessment of the effectiveness of our internal controls could detect problems that our management&#146;s
assessment might not. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management has not completed an assessment of the effectiveness of our internal controls over financial
reporting, and our independent registered public accounting firm has not conducted an audit of our internal controls over financial reporting. In conjunction with preparing our financial statements as of and for the years ended December&nbsp;31,
2022 and 2021 and as of and for the six-month period ended June 30, 2023 for this offering, material weaknesses in our internal controls over financial reporting were identified. The material weaknesses related to a lack of risk assessment as well
as formal, documented and implemented processes, controls and review procedures, specifically due to a lack of a sufficient number of professionals with an appropriate level of internal control knowledge, training and experience. These material
weaknesses did not result in a material misstatement to our financial statements included herein, however these material weaknesses could result in material inaccuracies in our financial statements and impair our ability to comply with applicable
financial reporting requirements and related regulatory filings on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a remediation plan to address these
material weaknesses and strengthen our controls in these areas. In this regard, we have started to reorganize our finance and accounting function by hiring additional experienced employees to provide more review and oversight over our financial
processes. While we are working to remediate the material weaknesses as quickly and efficiently as possible, we cannot at this time provide the expected timeline in connection with implementing our remediation. As of June&nbsp;30, 2023, we had not
yet completed remediation of these material weaknesses. These remediation measures may be time-consuming and costly and might place significant demands on our financial and operational resources. There is no assurance that the actions we may take in
the future will be sufficient to remediate the control deficiencies that led to these material weaknesses in our internal control over financial reporting or that they will prevent or avoid potential future material weaknesses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules governing the standards that will have to be met for our management to assess our internal controls over financial reporting
pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act are complex and require significant documentation, testing and possible remediation. These stringent standards require that our audit committee be advised and regularly updated on
management&#146;s review of internal controls over financial reporting. We have begun the process of designing, implementing, and testing the internal controls over financial reporting required to comply with this obligation. This process is
time-consuming, costly, and complicated. Our management may not be able to effectively and timely implement controls and procedures that adequately respond to the increased regulatory compliance and reporting requirements that will be applicable to
us as a public company listed in the United States. If we fail to staff our accounting and finance function adequately or maintain internal controls over financial reporting adequate to meet the demands that will be placed upon us as a public
company listed in the United States, our business and reputation may be harmed and the price of our ordinary shares and ADSs may decline. In addition, undetected material weaknesses in our internal controls over financial reporting could lead to
restatements of financial statements and require us to incur the expense of remediation. Any of these developments could result in investor perceptions of us being adversely affected, which could cause a decline in the market price of our
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our growth
will place significant additional pressure on our system of internal control over financial reporting. Any failure to maintain an effective system of internal control over financial reporting could limit our ability to report our financial results
accurately and timely or to detect and prevent fraud. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Significant impairment of our goodwill could materially impact our financial position and results of
our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We carry a goodwill balance, which is allocated to obefazimod and ABX196 cash generating units, on our balance
sheet as a result of past business acquisitions, including with respect to obefazimod and ABX196. We are required to review our goodwill for impairment on an annual basis or more frequently if events or changes in circumstances indicate evidence of
impairment. For the year ended December 31, 2022, we recorded a goodwill impairment loss of &#128;13.6 million. The goodwill impairment loss was related to an impairment test conducted with respect to the ABX196 cash-generating unit as a result of
significant external changes in the hepatocellular carcinoma treatment landscape, which are expected to require a new, lengthy, heavy and risky internal development process (use of a combination of compounds). As such, due to the lack of progress
made in the negotiation of a development partnership, we made the decision to freeze the development program for ABX196 in the treatment of hepatocellular cancer, which led to full impairment of ABX196 goodwill. In July 2023, we have decided to
completely stop our ABX196 program, which will be reflected in our next financial statements. After full impairment of the goodwill allocated to ABX196, we continue to carry a goodwill balance allocated to obefazimod amounting to
&#128;18.4&nbsp;million in the aggregate as of June&nbsp;30, 2023. We have not currently identified reasons to impair the goodwill allocated to obefazimod. However, there can be no assurance that, based on the results of our annual goodwill
impairment tests, we will not be required to identify further goodwill impairment losses, which could have a material adverse effect on our results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have significant debt commitments, which require us to meet certain operating covenants, and if we fail to comply with those covenants the
bondholders would be able to accelerate our repayment obligations. Additionally, the conversion of some or all of our bonds into ordinary shares would dilute the ownership interests of existing shareholders. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August 20, 2023, we entered into the Framework Subscription Agreement with KC and Claret, as the Secured Lenders. Under this Framework
Subscription Agreement, we may draw up to &#128;75 million in structured debt financing, in three tranches of &#128;25 million in aggregate principal amount each. The Kreos / Claret Financing provides for certain restrictive covenants (subject to
customary exceptions), which include, among other things, restrictions on the incurrence of indebtedness, cross-default, the distribution of dividends and the grant of security interests. As security for the Kreos / Claret Financing, the Secured
Lenders benefit from the grant of first-ranking collateral on our principal tangible and intangible assets, including pledges over our business (<I>fonds de commerce</I>) as a going concern and intellectual property rights in our lead drug
candidate, as well as pledges over our bank accounts and receivables. Such securities apply to all tranches of the Kreos / Claret Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, on August 20, 2023, we entered into the Heights Subscription Agreement with Heights. Under the Heights Subscription Agreement, we
may draw up to &#128;75 million in amortizing senior convertible notes, in two tranches of &#128;35 million and &#128;40&nbsp;million, respectively, as further described below. The terms and conditions of the Heights Convertible Notes include a
negative pledge providing that any security granted in favor of other borrowed debt or debt instruments should also be granted in favor of the Heights Convertible Notes on an equal basis (with the exception of the securities issued pursuant to the
Kreos / Claret Financing). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2020, we obtained a <FONT STYLE="white-space:nowrap">non-dilutive</FONT> financing in the form of a
State-guaranteed loan of &#128;5.0&nbsp;million. The loan was structured with an initial maturity of 12 months at 0.25% and a five-year extension option. In March 2021, we exercised the five-year extension option with a <FONT
STYLE="white-space:nowrap">one-year</FONT> deferral of principal repayment, with the following conditions: (i)&nbsp;a revised interest rate of 0.58% <I>per annum,</I> excluding insurance and State-guaranteed premium; and (ii)&nbsp;a State-guaranteed
premium of &#128;0.1&nbsp;million to be paid by installments over the contract period starting in June 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The loan includes certain
customary covenants and prepayment provisions. The negative covenants include an undertaking not to dispose of all or part of our assets for more than 50% of the gross value of our fixed assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is also no guarantee that we will have sufficient cash to pay the bonds issued to the Secured Lenders or Heights at maturity, which
could have a negative impact on our business as security interests have been </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
granted on our principal tangible and intangible assets: in particular, on our goodwill, intellectual property rights relating to our lead drug candidates, as well as a pledge of our bank
accounts and claims. There is also no guarantee that we will have sufficient cash to make the scheduled payments on the Kreos / Claret Financing, the Heights Financing or the State-guaranteed loan, which could have a material adverse effect on our
business, financial position and results of operations. Any failure to make scheduled payments or trigger for early repayment of the loan could have a material adverse effect on our business, financial position, income, growth and outlook. If we
breach our obligations under any of these agreements, it could result in default and trigger an early repayment of the bonds. There is no guarantee that we would have the necessary resources to fund an advance repayment of the bonds. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our principal tangible and intangible assets serve as collateral under the terms of debt agreements for the Kreos / Claret Financing. If we default on
these debt obligations, the Secured Lenders could foreclose on those assets, and we would be unable to continue our business and operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2023, we entered into the Kreos / Claret Financing. In connection with the financing, we have granted the Secured Lenders with
first-ranking collateral on our principal tangible and intangible assets, including pledges over our business (<I>fonds de commerce</I>) as a going concern and intellectual property rights in our lead drug candidate, as well as pledges over our bank
accounts and receivables until our debt obligations thereunder are repaid in full. There can be no assurance that we will not breach the covenants or other terms of, or that an event of default will not occur under, the debt agreements for the Kreos
/ Claret Financing. If a breach or event of default occurs, there can be no assurance that we will be able to cure the breach within the time permitted. In the event of any failure to pay our obligations when due, any breach or default of our
covenants or other obligations, or any other event that causes an acceleration of payment at a time when we do not have sufficient resources to meet these obligations, the Secured Lenders could foreclose on the collateral. If the Secured Lenders
were to be successful, we would lose our intellectual property rights in our lead drug candidate and be unable to commercialize our lead drug candidate and conduct our business. Any of these consequences would have a material adverse effect on our
business, financial condition and share price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on grants and subsidies, which may not continue to be available and we may be forced to
repay conditional advances prematurely if we fail to comply with our contractual obligations under certain innovation grant agreements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have received various grants and conditional advances from Bpifrance under various development programs, in a total amount of
&#128;20.1&nbsp;million as of December 31, 2022. In the event that we do not comply with the contractual conditions stipulated in the aid agreements we have entered into, we may have to repay the sums advanced early. Such premature repayment could
deprive us of the necessary financial resources for our research and development projects and we cannot guarantee that we will find necessary additional financial resources, the timeline for or the possibility of replacing these financial resources
with others. We cannot guarantee that we will have the necessary resources to cope with an early repayment. A material repayment would result in a material adverse effect on our business, operations, financial position, income, growth, and outlook.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the amount and date of payment of current and future grants and subsidies depend on many factors that are not in our
control, including possible <FONT STYLE="white-space:nowrap">non-distribution</FONT> decisions or the freezing of funds, as well as the achievement of key milestones previously agreed on with Bpifrance. Delays or failure in obtaining or replacing
these grants and subsidies in the future could have a material adverse effect on our business, financial position, income, growth and outlook. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Current equity agreements and convertible debt instruments may dilute our equity resulting in dilution to our shareholders, including purchasers of our
ordinary shares (including in the form of ADSs) in this offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our incorporation, we have issued and granted
founder&#146;s share warrants (BCE) and share warrants (<B></B>BSA) and granted free shares (AGA) to persons linked to us and financing entities. We have also issued </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
convertible bonds. See &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Liquidity and Capital Resources.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The theoretical exercise of all the founder&#146;s share warrants (BCE) and share warrant (BSA) instruments giving access to our capital
issued and outstanding as of June&nbsp;30, 2023, excluding securities held by financing entities, would allow for the subscription of 731,893 potential new ordinary shares, resulting in a hypothetical dilution equal to 1.7% based on our existing
share capital as of June&nbsp;30, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The OCEANE bonds that were outstanding as of June 30, 2023 conferred an entitlement to subscribe
for 769,834 ordinary shares, given the adjustment of the conversion parity on January 30, 2023 in accordance with the terms and conditions of the OCEANE bonds. The OCEANE bonds were repaid in full on August 24, 2023 and, therefore, may no longer be
converted into new ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, our general meeting of June 5, 2023 delegated authority to the board of directors (the
&#147;Board&#148;) to carry out one or more capital increases and/or issues of securities giving access to our capital subject to the following limitations: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a total maximum nominal amount of the capital increases set at &#128;500,000 (or the equivalent value of that
amount in the event of an issue in another currency) with a total maximum nominal amount of the debt securities that may be issued set at &#128;150,000,000 (or the equivalent value of that amount in the event of an issue in another currency); and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the shares that may be issued or allotted in the context of equity incentive plans (share warrants (BSA), share
options and/or free shares (AGA)) may not exceed 10% of the share capital on a fully diluted basis recorded as of June 5, 2023. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Using such delegation, we issued in August 2023 the following securities in connection with the Kreos / Claret Financing and the Heights
Financing: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">25,000,000 convertible bonds with warrants attached with an individual nominal value of &#128;1.00 issued to KC
and Claret, which allow for the subscription of up to 1,178,084 new ordinary shares at a conversion price of &#128;21.22 per ordinary share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">214,198 share warrants (BSA) issued to KC and Claret, which allow for the subscription of up to 214,198 new
ordinary shares at an exercise price of &#128;18.67 per ordinary share; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">350 convertible notes due 2027 with an individual nominal value of &#128;100,000 issued to Heights, which allow
for the subscription of up to 1,472,606 new shares at a conversion price of &#128;23.77 per ordinary share. In case we opt to repay the principal and accrued interest of such notes entirely in shares, we may issue up to 2,830,201 new ordinary shares
in connection with such repayment. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our failure to maintain certain tax benefits applicable to French biopharmaceutical companies
may adversely affect our operations and finances. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a French biopharmaceutical company, we have benefited from certain tax
advantages, including, for example, the Research and Development Tax Credit (<I>cr</I><I>&eacute;</I><I>dit imp</I><I>&ocirc;</I><I>t recherche</I>) (&#147;CIR&#148;), which is a French tax credit aimed at stimulating research and development. CIR
can be offset against French corporate income tax due and the portion in excess, if any, may be refunded. CIR is calculated based on our claimed amount of eligible research and development expenditures in France and represents &#128;4.5 million for
2022. The French tax authorities, with the assistance of the Higher Education and Research Ministry, may audit each research and development program in respect of which a CIR benefit has been claimed and assess whether such program qualifies in its
view for the CIR benefit. The French tax authorities may challenge our eligibility for, or our calculation of, certain tax reductions or deductions in respect of our research and development activities and, should the French tax authorities be
successful, our credits may be reduced, which would have a negative impact </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on our results of operations and future cash flows. Furthermore, the French Parliament may decide to eliminate, or to reduce the scope or the rate of, the CIR benefit, either of which it could
decide to do at any time. If we fail to receive future CIR amounts, our business, prospects, financial condition, cash flows or results of operations could be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to carry forward existing tax losses. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2023, we carried forward accumulated tax losses of &#128;355.4&nbsp;million. In 2014, we acquired the companies Splicos,
Wittycell and Zophis by means of a universal transfer of assets and liabilities. The tax losses carried forward of the three companies combined (Splicos, Wittycell and Zophis) amounted to &#128;26.0&nbsp;million on the date of the mergers and
transfer of remaining assets. The transfer to us of these losses was subject to a post-merger approval by the French tax authorities, which approved the transfer of a total amount of &#128;22.5 million. As a result of the transfer of these tax
losses to us, our tax losses carried forward amounted to &#128;308.8 million as at the end of 2022. To the extent we have continued conducting the business that led to these losses for a minimum period of three years, without making significant
changes during this period, the transfer of such tax losses should be definitive. In France, the maximum amount of carried forward tax losses that can be written off against the tax profits of a given financial year is limited to
&#128;1&nbsp;million plus 50% of the amount of taxable profits for the financial year exceeding &#128;1&nbsp;million. The outstanding tax losses remain valid and can be carried forward to be written off against tax profits of subsequent financial
years subject to the same limit, for an unlimited period of time (subject to any &#147;significant change of activity&#148; at our level). It cannot be ruled out that regulatory or legislative changes in corporate taxation may suppress or limit all
or part of the ability to use carried forward tax losses, or limit how long they can be used, to offset future profits. Changes in corporate taxation regarding the use of carried forward tax losses to offset future tax profits could have a material
adverse effect on our financial position and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Product Development, Regulatory Approval and Commercialization
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Drug candidates under development must undergo costly, rigorous and highly regulated preclinical studies and clinical trials, whose time of
completion, number and outcomes are uncertain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development of a drug candidate is a long and expensive process with an
uncertain outcome, progressing in several phases, where the objective is to demonstrate the therapeutic benefit provided by the drug candidate for one or more indications. Any failure during the various preclinical and clinical phases for a given
indication could delay development, production and commercialization of the therapeutic product concerned or even lead to discontinuing its development. Identifying potential drug candidates and conducting preclinical testing and clinical trials is
a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the data or required results required to obtain regulatory approval and achieve commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During clinical trials, we may encounter difficulties determining and recruiting patients with the appropriate profile. This profile could
also vary depending on the different phases of these clinical trials. Patients might then not be recruited according to a timetable compatible with our financial resources which may result in a harm to our operation results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At each phase of clinical development, we must ask for authorization from the relevant authorities of various countries, according to our
development plan, to conduct clinical trials and then present the results of the clinical trials to these authorities. The authorities may refuse to provide the authorizations necessary for clinical trials or have additional requirements (for
example, relating to study protocols, patient characteristics, treatment durations, post-treatment <FONT STYLE="white-space:nowrap">follow-up,</FONT> certain differences in interpreting results between local regulatory agencies), and in some cases
may require additional studies. Any refusal or decision by health authorities to require additional trials or examinations would be likely to result in the discontinuation or delay of the development of the products concerned. An absence of or delay
in therapeutic response could also result in the delay or even discontinuation of the development of our drug candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot guarantee that the development of our drug candidates will ultimately be
successful, especially within time frames compatible with our financial resources or market needs. Any failure or delay in the development of these products would have a material adverse effect on our business, income, financial position and
outlook. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing drug candidates for inflammatory diseases. To our knowledge, currently, there are no similar immunological
treatments with a mechanism of action based on enhanced expression of a single microRNA miR-124, with marketing authorization granted by competent regulatory authorities. As a result, the outlook is uncertain for the development and profitability of
obefazimod in the area of inflammatory diseases, its efficacy and acceptance by patients, doctors and paying agencies. Animal testing does not necessarily predict the results that will be obtained in humans. Positive results for obefazimod during
Phase 1, Phase 2b or Phase&nbsp;3 clinical trials or those for all the products in the portfolio during their research or preclinical phases might not be confirmed by subsequent phases. Such outcomes could have a material adverse impact on our
business, income, financial position and growth. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are heavily dependent on the success of our drug candidates, in particular obefazimod, and we
cannot be certain that obefazimod or any of our other current or future drug candidates will receive regulatory approval, and, without regulatory approval, we will not be able to market our drug candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no drug candidates approved for sale, and we cannot guarantee that we will ever have marketable drug candidates. Our ability
to generate revenue related to sales, if any, will in the near future depend entirely on the successful development and regulatory approval of obefazimod. In Europe and the United States, as well as in many other countries, access to the drug market
is controlled and marketing must be authorized by a regulatory authority. Most of the time, this registration application is filed with a national health authority, except in the case of the European Union, where a centralized procedure for
reviewing marketing authorization application (&#147;MAA&#148;) managed by the European Medicines Agency (&#147;EMA&#148;) exists for specific kind of medicinal products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The research, testing, manufacturing, safety, efficacy, labeling, approval, sale, marketing and distribution of our drug candidates are, and
will remain, subject to comprehensive and extensive regulation by the EMA in the European Union, the Food and Drug Administration (&#147;FDA&#148;) in the United States, the Pharmaceuticals and Medical Devices Agency (&#147;PMDA&#148;) in Japan and
regulatory authorities in other countries, with regulations differing from country to country. Subject to limited exceptions, we are not permitted to market our drug candidates in the European Union, the United States or Japan until we receive
approval of an MAA from the European Commission or (a) Member State(s) authority(ies) or a new drug application (&#147;NDA&#148;) from the FDA or the PMDA. We have not submitted any marketing applications for any of our drug candidates. Regulators
of each jurisdiction have their own procedures for approval of drug candidates. Failure to obtain regulatory approval for our drug candidates in any jurisdiction will prevent us from commercializing and marketing our drug candidates in such
jurisdictions, and marketing authorizations may be granted for narrow indications which may significantly reduce the market of our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining and maintaining marketing authorization, by country or by geographical area in the case of the European Union, presupposes
compliance with the mandatory standards imposed by the regulatory authorities and submission to the authorities of a great deal of information about the new product regarding its toxicity, dosage, quality, efficacy and safety all over its life
cycle. The authorization process is long and expensive, and the result of this process remains uncertain. We are therefore careful to continuously comply with good practices in order not to jeopardize our chances of ultimately obtaining, directly or
via our business partners, marketing authorization for the products we are developing. Obtaining marketing authorization in a given country or geographical area does not automatically ensure or immediately lead to obtaining marketing authorization
in other countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to obtain marketing authorization for one of our products, we may have to perform preclinical animal studies
and complete human clinical trials in order to demonstrate the safety and efficacy of the product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
In the event patients are exposed to unforeseen and serious risks, we or the regulatory authorities may choose to suspend or terminate these clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAs, NDAs and similar authorizations must include extensive preclinical and clinical data and supporting information to establish the drug
candidate&#146;s safety and effectiveness for each desired indication. NDAs, MAAs and similar authorizations must also include significant information regarding the chemistry, manufacturing and controls for the drug. Obtaining approval of a MAA or a
NDA is a lengthy, expensive and uncertain process, and we may not be successful in obtaining approval. The EMA, Member States national authorities, FDA and PMDA review processes can take years to complete and approval is never guaranteed. If we
submit an NDA to the FDA, the FDA must decide whether to accept or reject the submission for filing. We cannot be certain that any submissions will be accepted for filing and review by the FDA. Regulators of other jurisdictions, such as the EMA and
the PMDA, have their own procedures for the scientific evaluation or approval of drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if a drug is approved, the FDA,
the EMA or the PMDA, as the case may be, may limit the indications for which the drug may be marketed, require extensive warnings on the drug labeling or require expensive and time-consuming clinical trials or reporting as conditions of approval.
Regulatory authorities in countries outside the European Union, the United States and Japan also have requirements for approval of drug candidates with which we must comply prior to marketing in those countries. Obtaining regulatory approval for
marketing of a drug candidate in one country does not ensure that we will be able to obtain regulatory approval in any other country. In addition, delays in approvals or rejections of marketing applications in the European Union, the United States
or other countries may be based upon many factors, including regulatory requests for additional analyses, reports, data, preclinical studies and clinical trials, regulatory questions regarding different interpretations of data and results, changes
in regulatory policy during the period of drug development and the emergence of new information regarding our drug candidates or other drug candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive regulatory approval for any drug candidate, we will be subject to ongoing regulatory obligations and continued regulatory review,
which may result in significant additional expense </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we receive approval of any of our drug candidates, such regulatory
approval may be withdrawn, or such approvals may be contingent on ongoing obligations and continued regulatory review, which may result in significant additional expense. As a general matter, any regulatory approvals that we may receive for our drug
candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our drug candidates will be subject to extensive and ongoing regulatory
requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as ongoing compliance with current Good Manufacturing Practice (&#147;GMP&#148;) and Good Clinical Practice
requirements (&#147;GCPs&#148;) for any clinical trials that we may continue to conduct. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other
regulatory authorities for compliance with GMP regulations and standards. In addition, any regulatory approvals we may receive will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of
the drug candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, our drug candidates, even if approved, may include limitations related to use restrictions for
specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a risk evaluation and mitigation strategy (&#147;REMS&#148;) as a
condition of approval of our drugs candidates, which could include requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries
and other risk minimization tools. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may need to maintain or obtain a Good Manufacturing Practice (&#147;GMP&#148;) certificate in order
to produce the immunotherapies that we are developing (for clinical trial purposes or during the commercialization phase). We cannot guarantee that we will obtain or be able to maintain this certificate, nor that certain additional constraints
related to this certificate will not be imposed on us in the future. Any failure to follow and document </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adherence to such GMP regulations or other regulatory requirements may lead to significant delays in the availability of products for commercial sale or clinical trials, may result in the
termination of or a hold on a clinical trial, or may delay or prevent filing or approval of marketing applications for our products. Failure to comply with applicable regulations could also result in the FDA or other applicable regulatory
authorities taking various actions, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">levying fines and other civil penalties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposing consent decrees or injunctions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requiring us to suspend or put on hold one or more of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspending or withdrawing regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delaying or refusing to approve pending applications or supplements to approved applications;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requiring us or our third-party manufacturers to suspend manufacturing activities or product sales, imports or
exports; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requiring us to communicate with physicians and other customers about concerns related to actual or potential
safety, efficacy and other issues involving our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mandating product recalls or seizing products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposing operating restrictions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seeking criminal prosecutions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA generally requires two adequate and well-controlled clinical trials to support approval. In addition, we must scale up manufacturing
and complete other standard preclinical studies and clinical trials. We cannot predict whether our future trials will be successful or whether regulators will agree with our conclusions regarding the preclinical studies and clinical trials we have
conducted to date and will conduct in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to obtain authorization for our drug candidates in one or more jurisdictions,
particularly in respect of our lead drug candidate, obefazimod, would have a material adverse effect on our business, outlook, financial position, results and development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our drug candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, or, if approval
is received, require our drug candidates to be withdrawn from the market, require them to include safety warnings or otherwise limit their sales. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Undesirable side effects caused by our drug candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials, or
even discontinuation and could result in a more restrictive label or the delay or denial of regulatory approval by the European Commission, FDA, PDMA or other comparable authorities in other jurisdictions. If severe side effects were to occur, or if
one of our drug candidates is shown to have other unexpected characteristics, we may need to either restrict the use of such product to a smaller population or abandon development of such drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If one or more of our drug candidates received marketing approval, and we or others later identify undesirable side effects caused by such
drugs or negative interactions with other products or treatments (including, for example, as a result of interactions with other products once on the market), a number of potentially significant negative consequences could result, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw approvals of such product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require additional warnings on the product&#146;s label; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to create a medication guide outlining the risks of such side effects for distribution to
patients; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be sued and held liable for harm caused to patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">physicians, healthcare payors, patients or the medical community in general may not recommend/use our products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of the product may decrease significantly; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market acceptance of the particular drug candidate, if approved, and could
have a material adverse effect on our business, prospects, financial condition, cash flows or results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical failure can occur at
any stage of clinical development. The results of earlier clinical trials as well as data from any interim analysis of ongoing trials are not necessarily predictive of future results and any drug candidate we advance through clinical trials may not
have favorable results in later clinical trials. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive and can take many years to complete, and its
outcome is inherently uncertain. Clinical failure can occur at any stage of our clinical development. Success in preclinical studies and early clinical trials, as well as data from any interim analysis of ongoing trials do not ensure that subsequent
clinical trials will generate the same or similar results. A number of companies in the pharmaceuticals industry, including those with greater resources and experience than us, have suffered significant setbacks in Phase 3 clinical trials, even
after seeing promising results in earlier clinical trials, and we could face similar setbacks. In some instances, there can be significant variation in safety or efficacy results between different clinical trials of the same drug candidate due to
numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout
among clinical trial participants. Moreover, data obtained from preclinical and clinical activities is subject to varying interpretations, which may delay, limit or prevent regulatory approval. Any such delays or failures could negatively impact our
business, financial condition, results of operation and prospects. The positive results generated in preclinical and clinical trials for obefazimod does not ensure that current or future trials will continue to demonstrate similar safety and/or
efficacy results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drug candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite
having progressed through preclinical studies and earlier clinical trials. In addition to the safety and efficacy traits of any drug candidate, clinical trial failures may result from a multitude of factors including flaws in trial design, dose
selection, placebo effect and patient enrollment criteria. Based upon negative or inconclusive results, we or our collaborators may decide, or regulators may require us, to conduct additional clinical trials or preclinical studies. Further, data
obtained from trials and studies are susceptible to varying interpretation, and regulators may not interpret our data as favorably as we do, which may delay, limit or prevent regulatory approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We cannot guarantee the commercial success of the drug candidates that we develop. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or one or more of our commercial partners succeeds in obtaining marketing authorization, allowing us or them to market the therapeutic
products developed by us, it may nevertheless take time to gain the support of the medical community, health care providers and third-party payers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The level of market acceptance for each of our products will depend on several factors, notably on the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prescribers&#146; perception of the product&#146;s therapeutic benefit; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">healthcare policies established in each of the countries in which we are considering marketing our products;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">possible occurrence of adverse reactions once marketing authorization has been obtained; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ease of use of the product, especially relating to its mode of administration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost of treatment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reimbursement policies of governments and other third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effectiveness of sales and marketing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effective implementation of a scientific publication strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prevalence and severity of any side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">development of one or more competing products for the same indication; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the use of the product together with medications. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the products we are developing are intended to provide a therapeutic response to a need that is presently unmet, poor market
penetration resulting from one or more of the factors described above would have a negative impact on their commercialization and on our ability to generate profits, which could have a material adverse effect on our business, outlook, financial
position, income and growth. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future may depend on our most advanced clinical development program, obefazimod, since our other drug candidates
are in a less advanced stage of development. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obefazimod is our most advanced drug candidate. Obefazimod has required, and may
continue to require, significant investments of our time and financial resources, as well as the special attention of highly qualified staff. Consequently, if we were unable to obtain conclusive results in ongoing maintenance trials, Phase 3 of
obefazimod in UC or Phase 2 of obefazimod in CD, it could have a material adverse effect on our business, outlook, financial position, results and development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may experience setbacks that could delay or prevent regulatory approval of our drug candidates or our ability to commercialize any
products, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative or inconclusive results from our preclinical studies or clinical trials or the clinical trials of others
for drug candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product-related side effects experienced by subjects in our clinical trials or by individuals using drugs or
therapeutics comparable to our drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in submitting investigational new drug applications in the United States or comparable foreign
applications or delays or failure in obtaining the necessary approvals from regulators or institutional review boards (&#147;IRBs&#148;) or ethics committees to commence a clinical trial, or a suspension or termination of a clinical trial once
commenced; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the FDA or comparable foreign authorities do not accept the earlier preclinical and clinical trial work, then
we may need to conduct additional preclinical studies or clinical trials beyond that which we currently have planned and significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive
right to commercialize our drug candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our drug candidates and may harm our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conditions imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical
trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in contracting with clinical sites or enrolling subjects in clinical trials, including due to any health
pandemic and/or other macroeconomic factors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or interruptions in the supply of materials necessary for the conduct of our clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators or IRBs or ethics committees may not authorize us or our investigators to commence a clinical trial or
conduct a clinical trial at a prospective trial site; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other comparable regulatory authorities may disagree with our clinical trial design, including with
respect to dosing levels administered in our planned clinical trials, which may delay or prevent us from initiating our clinical trials with our originally intended trial design; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching, or failure to reach, agreement on acceptable terms with prospective trial sites,
investigators and prospective contract research organizations (&#147;CROs&#148;) which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of subjects required for clinical trials of any drug candidates may be larger than we anticipate or
subjects may drop out of these clinical trials or fail to return for post-treatment <FONT STYLE="white-space:nowrap">follow-up</FONT> at a higher rate than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our CROs for preclinical studies or clinical trials may fail to comply with regulatory requirements or meet their
contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or take actions that could cause clinical sites or clinical investigators to drop out of the trial, which may require that we add new
clinical trial sites or investigators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater than anticipated clinical trial costs, including as a result of delays or interruptions that could
increase the overall costs to finish our clinical trials as our fixed costs are not substantially reduced during delays; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may elect to, or regulators, IRBs or Data Safety Monitoring Boards (&#147;DSMBs&#148;) may require that we or
our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not have the financial resources available to begin and complete the planned trials, or the cost of
clinical trials of any drug candidates may be greater than we anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the supply or quality of our drug candidates or other materials necessary to conduct clinical trials of our drug
candidates may be insufficient or inadequate to initiate or complete a given clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other comparable foreign regulatory authorities may require us to submit additional data such as long
term toxicology studies, or impose other requirements before permitting us to initiate a clinical trial, including because the FDA has not reviewed our preclinical or clinical data, to date, having been developed outside the United States;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to compete with other therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">poor efficacy of our drug candidates during clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable FDA or other regulatory agency inspection and review of clinical trial sites or manufacturing
facilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable product labeling associated with any product approvals and any requirements for a Risk Evaluation and
Mitigation Strategy (&#147;REMS&#148;) that may be required by the FDA or comparable requirements in other jurisdictions to ensure the benefits of an individual product outweigh its risks; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable acceptance of our clinical trial data by the patient or medical communities or third-party payors;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional
regulatory oversight around clinical testing generally or with respect to our technology in particular; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">varying interpretations of data by the FDA and similar foreign regulatory agencies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission
process, potential threats to our intellectual property rights and our manufacturing, marketing, distribution and sales efforts or that of any future collaborator. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may find it difficult to enroll patients in our clinical trials. If we encounter difficulties enrolling patients in our clinical trials, our clinical
development activities could be delayed or otherwise adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient enrollment is a significant factor in the timing
of clinical trials, and the timing of our clinical trials will depend, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required follow-up periods. We may not be able to initiate or
continue clinical trials for our drug candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials to such trial&#146;s conclusion as required by applicable regulatory authorities. The
eligibility criteria of our clinical trials, once established, may further limit the pool of available trial participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient
enrollment in clinical trials may be affected by other factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">size and nature of the targeted patient population; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">severity of the disease or condition under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">availability and efficacy of approved therapies for the disease or condition under investigation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient eligibility criteria for the trial in question as defined in the protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">perceived risks and benefits of the drug candidate under study; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinicians&#146; and patients&#146; perceptions as to the potential advantages of the drug candidate being
studied in relation to other available therapies, including any products that may be approved for, or any drug candidates under investigation for, the indications we are investigating; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">efforts to facilitate timely enrollment in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient referral practices of physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to monitor patients adequately during and after treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">proximity and availability of clinical trial sites for prospective patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continued enrollment of prospective patients by clinical trial sites; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that patients enrolled in clinical trials will drop out of such trials before completion.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, other pharmaceutical companies targeting these same diseases are recruiting clinical trial patients from
these patient populations, which may make it more difficult to fully enroll any clinical trials. We also rely on, and will continue to rely on, CROs and clinical trial sites to ensure proper and timely conduct of our clinical trials and preclinical
studies. Though we have entered into agreements governing their services, we will have limited influence over their actual performance. Our inability to enroll a sufficient number of patients for our clinical trials would result in significant
delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our drug candidates and jeopardize our ability to obtain regulatory approval for the
sale of our drug candidates. Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining enrollment of such patients in our clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are developing certain of our drug candidates in combination with other therapies, and safety or
supply issues with combination use products may delay or prevent development and approval of our therapeutic candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
developing certain of our drug candidates in combination with one or more approved or investigational therapies. Even if any drug candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing
therapies, we would continue to be subject to the risks that the FDA, European Commission, PDMA or similar foreign regulatory authorities could revoke approval of the therapy used in combination with our product or that safety, efficacy,
manufacturing or supply issues could arise with any of those existing therapies. If the therapies we use in combination with our drug candidates are replaced as the standard of care for the indications we choose for any of our drug candidates, the
EMA, FDA, PDMA or similar foreign regulatory authorities outside may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less
successful commercially. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also may evaluate our drug candidates in combination with one or more therapies that have not yet been
approved for marketing by the FDA, European Commission, PDMA or similar foreign regulatory authorities. We will not be able to market and sell any drug candidate we develop in combination with an unapproved therapy if that unapproved therapy does
not ultimately obtain marketing approval. In addition, unapproved therapies face the same risks described with respect to our drug candidates currently in development, including the potential for serious adverse effects, delay in their clinical
trials and lack of FDA, European Commission, or PDMA, or similar foreign regulatory authorities or PDMA approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA, European
Commission or similar foreign regulatory authorities do not approve these other therapies or revoke their approval of, or if safety, efficacy, manufacturing or supply issues arise with, the therapies we choose to evaluate in combination with our
drug candidates, we may be unable to obtain approval of or market any such drug candidate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may conduct clinical trials for our drug candidates
outside of the U.S., and the FDA may not accept data from such trials, in which case our development plans may be delayed, which could materially harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have in the past conducted clinical trials or a portion of our clinical trials for our drug candidates outside the U.S. The acceptance of
study data from clinical trials conducted outside the U.S. or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical
trials are intended to serve as the sole basis for marketing approval in the U.S., for example, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S.
medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA
considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the
FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite
inspection if deemed necessary. Many foreign regulatory authorities have similar requirements for clinical data gathered outside of their respective jurisdictions. In addition, such foreign trials would be subject to the applicable local laws of the
foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the relevant jurisdiction. If the FDA or any
comparable foreign regulatory authority does not accept such data, it may result in the need for additional trials, which could be costly and time-consuming, and which may result in current or future drug candidates that we may develop not receiving
approval for commercialization in the applicable jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interim, &#147;top-line&#148; and preliminary data from our clinical trials and preclinical studies
that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may publicly disclose interim, top-line or preliminary data from our clinical trials and preclinical studies, which is
based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions,
estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, top-line or preliminary results that we report may
differ from future results of the same studies or trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line and preliminary data also remain subject to audit
and verification procedures that may result in the final data being materially different from the top-line or preliminary data we previously published. As a result, top-line and preliminary data should be viewed with caution until the final data are
available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interim data from clinical trials that we may complete are further subject to the risk that one or more of the clinical
outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim, top-line or preliminary data and final data could significantly harm our business prospects. Further,
disclosure of such data by us or by our competitors could result in volatility in the price of our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, others, including
regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the
approvability or commercialization of the particular drug candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically
extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with
respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug candidate or our business. If the interim, top-line or preliminary data that we report differ from actual results, or if others, including
regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our drug candidates may be harmed, which could harm our business, operating results, prospects or financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or
deploy key leadership and other personnel, prevent new or modified products from being developed, review, approved or commercialized in a timely manner or at all, which could negatively impact our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA and foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including
government budget and funding levels, statutory, regulatory and policy changes, the FDA&#146;s or foreign regulatory authorities&#146; ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise
affect the FDA&#146;s or foreign regulatory authorities&#146; ability to perform routine functions. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent years as a result. In addition, government funding of
other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies, such as the EMA following its relocation to
Amsterdam and resulting staff changes, may also slow the time necessary for new drugs or modifications to approved drugs and to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example,
over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Separately, in response to the global COVID-19 pandemic, the FDA postponed most inspections
of domestic and foreign manufacturing facilities at various points. Even though the FDA has since resumed standard inspection operations of domestic facilities where feasible, the FDA has continued to monitor and implement changes to its
inspectional activities to ensure the safety of its employees and those of the firms it regulates, and any resurgence of the virus or emergence of new variants may lead to further inspectional delays.&nbsp;Regulatory authorities outside the United
States have adopted similar policy measures in response to COVID-19. If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other
regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates marketing, labeling, advertising and promotion of prescription drugs. These regulations include standards and
restrictions for direct-to-consumer advertising, industry-sponsored scientific and educational activities, promotional activities involving the internet and off-label promotion. Any regulatory approval that the FDA grants is limited to those
specific diseases and indications for which a product is deemed to be safe and effective by FDA. While physicians in the United States may choose, and are generally permitted, to prescribe drugs for uses that are not described in the product&#146;s
labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities, our ability to promote any products will be narrowly limited to those indications that are specifically approved by the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied
large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or
permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion any drug candidates, if approved, we could become subject to significant liability, which would materially
adversely affect our business and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to find industrial partners to pursue the clinical and commercial
development of obefazimod. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We aim to enter into licensing and distribution partnerships with pharmaceutical companies in order to
fund the completion of the clinical development and marketing preparation of our lead drug candidate, obefazimod. Consequently, we should find partners with sufficient capacity to perform Phase 1, 2 and/or 3 clinical trials on a national or
international scale and mass-produce, distribute and market immunotherapies and anti-inflammatory treatments such as obefazimod. If we were to enter into such partnerships, the commercialization of our products would depend, in part, on the
clinical, industrial, marketing and commercial development efforts of our business partners and the ability of these partners to produce and sell obefazimod. Any failure on the part of our partners could have a material adverse effect on our growth
and outlook. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is also possible that we may not be able to enter into partnerships under economically reasonable conditions or at all.
This could have a material adverse effect on our business, outlook, financial position, results and development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to conduct, or
contract others to conduct, animal testing in the future, which could harm our research and development activities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain laws
and regulations relating to drug development require us to test our drug candidates on animals before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and
by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted or delayed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Operations and Strategic Development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to expand our organization, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to manage our anticipated development and expansion, including the potential commercialization of our drug candidates in
Europe and the United States we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources
and the limited experience of our management team in managing a company with such expected growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our
operations may lead to significant costs and may divert the attention of our management and business development resources away from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and devote a
substantial amount of time to managing internal or external growth. Our inability to manage growth or unexpected difficulties encountered during expansion could have a material adverse effect on our business, income, financial position, growth and
outlook. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our international operations subject us to various risks, and our failure to manage these risks could adversely affect our results of
operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face significant operational risks as a result of doing business internationally, such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fluctuations in foreign currency exchange rates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differing payor reimbursement regimes, governmental payors or
<FONT STYLE="white-space:nowrap">patient&nbsp;self-pay&nbsp;systems</FONT> and price controls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential changes to the accounting standards, which may influence our financial situation and results;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">becoming subject to the different, complex and changing laws, regulations and court systems of multiple
jurisdictions and compliance with a wide variety of foreign laws, treaties and regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced protection of, or significant difficulties in enforcing, intellectual property rights in certain
countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in attracting and retaining qualified personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions imposed by local labor practices and laws on our business and operations, including unilateral
cancellation or modification of contracts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">rapid changes in global government, economic and political policies and conditions, political or civil unrest or
instability, terrorism or epidemics and other similar outbreaks or events, and potential failure in confidence of our suppliers or customers due to such changes or events; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tariffs, trade protection measures, import or export licensing requirements, trade embargoes and other trade
barriers. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market opportunities for our drug candidates may be limited to patients who are ineligible for or have failed prior
treatments and may be small or different from our estimates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current IBD treatment approach is influenced by multiple factors,
including disease severity, previous response to treatment, side effects and <FONT STYLE="white-space:nowrap">co-morbidities.</FONT> The current standard of care for treatment of patients with mild IBD involves the use of conventional
anti-inflammatory therapies. Conventional anti-inflammatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
therapies include: aminosalicylates (e.g., <FONT STYLE="white-space:nowrap">5-ASA),</FONT> immunosuppressants or immunomodulators (e.g., <FONT STYLE="white-space:nowrap">6-mercaptopurine</FONT> <FONT
STYLE="white-space:nowrap">(&#147;6-MP&#148;),</FONT> methotrexate (&#147;MTX&#148;)) and corticosteroids that are usually prescribed for <FONT STYLE="white-space:nowrap">short-term</FONT> treatment to manage
<FONT STYLE="white-space:nowrap">flare-ups.</FONT> Despite these conventional therapies, patients suffering from mild IBD may evolve towards moderate and severe forms of IBD requiring the use of advanced therapies. However, available therapies often
only have moderate efficacy that changes or may wane over time, as patients have the potential to stop responding or do not respond at all to these treatments and thus require new therapeutic management options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we hope to position obefazimod as a potential first-line advanced therapy, there is no guarantee that even if approved, it would be
approved for first-line advanced therapy. This could limit our potential market opportunity. In addition, we may have to conduct additional clinical trials prior to gaining approval for first-line advanced therapy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The estimates of market opportunity and forecasts of market growth included in this prospectus may prove to be inaccurate, and even if the markets in
which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market opportunity
estimates and growth forecasts included in this prospectus are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. The estimates and forecasts included in this prospectus relating to size
and expected growth of our target market may prove to be inaccurate. Even if the markets in which we compete meet the size estimates and growth forecasts included in this prospectus, our business may not grow at similar rates, or at all. Our growth
is subject to many factors, including our success in implementing our business strategy, which is subject to many risks and uncertainties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales of
our drug candidates could be adversely impacted by the reluctance of physicians, healthcare payors, patients or the medical community in general to adopt them and by the availability of competing drugs. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we obtain regulatory approval for one or more of our drug candidates, physicians, healthcare payors, patients or the medical community
in general may be reluctant to try a new drug due to the high degree of risk associated with the application of new drugs in the field of human medicine, especially if the new drug differs from the currently prevailing medication for a given
complaint. We will need to expend significant sums of money to market our products to increase the public&#146;s awareness within numerous limits set by the regulations concerning the promotion of drugs. If our products do not achieve an adequate
level of acceptance, we may not generate enough revenues to become profitable or the profitability may occur much later. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competing drug
candidates in the chronic inflammatory disease field are being manufactured and marketed by other companies, including, but not limited to, AbbVie, Pfizer, Eli Lilly, Takeda and Johnson&nbsp;&amp; Johnson. To compete with other drugs, particularly
any that sell at lower prices, our drug candidates will have to provide medically significant advantages or be more cost-effective. Even if we can overcome physician reluctance and compete with products that are currently on the market, our
competitors may succeed in developing new, safer, more accurate or more cost-effective treatments or therapeutic indications that could render our drug candidates obsolete or <FONT STYLE="white-space:nowrap">non-competitive.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Global economic conditions could materially adversely impact demand for our drug candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations and performance depend significantly on economic conditions. Global financial conditions continue to be subject to volatility
arising from international geopolitical developments, such as the war in Ukraine and global economic phenomena, as well as general financial market turbulence, natural phenomena and any public health outbreak. Uncertainty about global economic
conditions could result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party suppliers being unable to produce components for our drug candidates in the same quantity or on the
same timeline or being unable to deliver such parts and components as quickly as before or subject to price fluctuations, which could have a material adverse effect on our production or the cost of such production; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">once our drug candidates are available for sale, customers postponing purchases of our drug candidates in
response to tighter credit, unemployment, negative financial news and/or declines in income or asset values and other macroeconomic factors, which could have a material adverse effect on demand for our drug candidates, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">either of which could, accordingly, have a material adverse effect on our business, results of operations or financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Access to public financing and credit can be negatively affected by the effect of these events on European, U.S. and global credit markets.
The health of the global financing and credit markets may affect our ability to obtain equity or debt financing in the future and the terms at which financing or credit is available to us. These instances of volatility and market turmoil could
adversely affect our operations and the trading price of our ordinary shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes to trade policy, tariffs, and import/export regulations may
have a material adverse effect on our business, financial condition, and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in laws and policies
governing foreign trade could adversely affect our business. As a result of recent and future policy changes, there may be greater restrictions and economic disincentives on international trade. Such changes have the potential to adversely impact
the global and local economies, our industry and global demand for our drug candidates and, as a result, could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fluctuations in currency exchange rates may significantly impact our results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is located, and our operations are conducted, in Europe. As a result, we are exposed to an exchange rate risk between the U.S.
dollar and the Euro. The exchange rates between these currencies in recent years have fluctuated significantly and may continue to do so in the future. An appreciation of the Euro against the U.S.&nbsp;dollar could increase the relative cost of our
drug candidates outside of Europe, which could have a negative effect on sales. Conversely, to the extent that we are required to pay for goods or services in U.S.&nbsp;dollars, the depreciation of the Euro against the U.S.&nbsp;dollar would
increase the cost of such goods and services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not hedge our currency exposure and, therefore, we incur currency transaction risk
whenever we enter into either a purchase or sale transaction using a currency other than the Euro. Given the volatility of exchange rates, we might not be able to effectively manage our currency transaction risks, and volatility in currency exchange
rates might have a material adverse effect on our business, financial condition or results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on a small number of third-party
suppliers and manufacturers, and in certain cases a single-source supplier, and we may be in a position of dependence with respect to these third parties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not own or operate manufacturing facilities and have no current plans to develop our own clinical or commercial-scale manufacturing
capabilities. We currently rely, and expect to continue to rely, on a small number of third-party suppliers, and in certain cases a single-source supplier, for the supply of various raw materials and chemical products and clinical batches needed for
our preclinical studies and clinical trials. In the case of certain manufactured and clinical supplies, we rely on single-source suppliers. The supply of specific raw materials and products required for conducting clinical trials and manufacturing
our products cannot be guaranteed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are dependent on third parties for the supply of various materials, including chemical or
biological products that are necessary to produce drug candidates for our clinical trials and, ultimately, commercial supply for any of our drug candidates that may receive approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The facilities used by our third-party manufacturers must be approved for the manufacture of
our drug candidates by the FDA, the EMA and any comparable foreign regulatory authorities in other jurisdictions, pursuant to inspections that will be conducted after we submit an NDA to the FDA, MAA to the EMA, or submit a comparable marketing
application to a comparable regulatory authority. We do not control the manufacturing process of, and are completely dependent on, third-party manufacturers for compliance with GMP requirements for manufacture of our drug candidates. If these
third-party manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of any applicable regulatory authority, they will not be able to secure and/or maintain regulatory approval
for the use of their manufacturing facilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have no control over the ability of third-party manufacturers to maintain
adequate quality control, quality assurance and qualified personnel. If any regulatory authority does not approve these facilities for the manufacture our drug candidates, or if such authorities withdraw any such approval in the future, we may be
required to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our drug candidates, if approved. Our failure, or the failure of our third-party manufacturers,
to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls, operating restrictions and
criminal prosecutions, any of which could significantly and adversely affect our financial position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our or a third party&#146;s failure
to execute on our manufacturing requirements on commercially reasonable terms and in compliance with GMP or other regulatory requirements could adversely affect our business in a number of ways, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an inability to initiate or complete clinical trials of our drug candidates in a timely manner;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay in submitting regulatory applications, or receiving regulatory approvals, for our drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subjecting third-party manufacturing facilities to additional inspections by regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements to cease development or to recall batches of our drug candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the event of approval to market and commercialize any drug candidate, an inability to meet commercial demands.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we do not have any long-term commitments or supply agreements with any third-party manufacturers. We may
be unable to establish any long-term supply agreements with third-party manufacturers or to do so on acceptable terms, which increases the risk of failing to timely obtain sufficient quantities of our drug candidates or such quantities at an
acceptable cost. Any performance failure on the part of our existing or future manufacturers or suppliers could delay clinical development or marketing approval, and any related remedial measures may be costly or time consuming to implement. We do
not currently have second source for all required raw materials used in the manufacture of our drug candidates. If our existing or future third-party manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may
be unable to replace them on a timely basis or at all, which would have a material adverse impact on our financial position. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third
parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug
candidates and our business could be substantially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are dependent on third parties to conduct our clinical trials and
preclinical studies. Specifically, we rely on, and will continue to rely on, medical institutions, clinical investigators, CROs and consultants to conduct preclinical studies and clinical trials, in each case in accordance with trial protocols and
regulatory requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
These CROs, investigators and other third parties play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. Though we expect to carefully
manage our relationships with such CROs, investigators and other third parties, there can be no assurance that we will not encounter challenges or delays in the future, or that these delays or challenges will not have a material adverse impact on
our business, financial condition and prospects. Further, while we have and will have agreements governing the activities of our third-party contractors, we have limited influence over their actual performance. Nevertheless, we are responsible for
ensuring that each of our clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards and requirements, and our reliance on our CROs and other third parties does not relieve us of our
regulatory responsibilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we and our CROs are required to comply with stringent standards governing the conduct of
preclinical studies and clinical trials, including Good Laboratory Practice (&#147;GLP&#148;) and GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities, for our drug candidates in
clinical development. Regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs or trial sites fail to comply with applicable GLP, GCP or other requirements,
the data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications, if ever. Furthermore, our
clinical trials must be conducted with materials manufactured in accordance with GMP regulations. Failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no guarantee that any of our CROs, investigators or other third parties will devote adequate time and resources to such trials or
studies or perform as contractually required. If any of these third parties fails to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, or otherwise perform in a substandard manner, our clinical trials may be
extended, delayed or terminated. In addition, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other
activities that could harm our competitive position. In addition, principal investigators for our clinical trials may be asked to serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in
connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the study, the
integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection by the FDA of any NDA we submit. Any such delay or
rejection could prevent us from commercializing our drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our CROs have the right to terminate their agreements
with us in the event of an uncured material breach and under other specified circumstances. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties on commercially
reasonable terms or at all. Switching or adding additional CROs, investigators and other third parties involves additional cost and requires our management&#146;s time and focus. In addition, there is a natural transition period when a new CRO
commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we work to carefully manage our relationships with our CROs, investigators and other third parties, there
can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties
on commercially reasonable terms or at all. Switching or adding additional CROs, investigators and other third parties involves additional cost and requires our management&#146;s time and focus. In addition, there is a natural transition period when
a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we work to carefully manage our relationships with our CROs, investigators and other third
parties, there can be no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and
prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to retain our key executives and to attract, retain and motivate qualified personnel.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are highly dependent on our management, scientific and medical personnel whose services are critical to our success. Our
success depends greatly on the involvement and expertise of our senior executives and qualified scientific staff. While Dr.&nbsp;Philippe Pouletty, MD, our founder and Chairman of our Board since our inception in 2013, resigned from his Chairman
position in August 2022, he continues to support our development as a member of our Board as the representative for Truffle Capital. We do not maintain key person insurance. The temporary or permanent unavailability of our management and scientific
staff, as well as Dr.&nbsp;Pouletty, could lead to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of <FONT STYLE="white-space:nowrap">know-how</FONT> and weakening of certain activities, especially in the
case of transfer to the competition; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">deficiencies in terms of technical skills that could slow down activity and ultimately impair our ability to
reach our objectives. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recruiting and retaining additional qualified management and scientific, clinical, manufacturing
and sales and marketing personnel will also be critical to our success, particularly as we expand in order to acquire additional skills, such as manufacturing, quality assurance and regulatory and medical affairs. The loss of the services of our
senior management team or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive
officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of
and commercialize drug candidates. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and
biotechnology companies for similar personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also experience intense competition for the hiring of scientific and clinical personnel
from other companies, universities and research institutions. We may not be able to attract or retain qualified management and scientific personnel in the future due to intense competition for a limited number of qualified personnel. Many of those
that compete with us for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. Our competitors may also provide more diverse opportunities and better chances for
career advancement. An inability to attract and retain high quality personnel will have a material adverse effect on our business, prospects, financial condition, cash flow or results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and
development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we
are unable to continue to attract and retain high quality personnel, the marketing and production of our drugs could be delayed or prevented, which could, in turn, have a material adverse effect on our business, prospects, financial condition, cash
flows or results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other
improper activities, including noncompliance with regulatory standards and requirements and insider trading. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the
risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures, reckless and/</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or negligent conduct or unauthorized activity that violates (i)&nbsp;the laws and regulations of the European Economic Area (&#147;EEA&#148;) countries, the European Commission, FDA and other
regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities, (ii)&nbsp;manufacturing standards, (iii)&nbsp;federal and state data privacy, security, fraud and abuse and other
healthcare laws and regulations in Europe, the United States and elsewhere and (iv)&nbsp;laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the
healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting,
marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct also could involve the improper use of individually identifiable information, including, without limitation, information obtained
in the course of clinical trials, creating fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not
always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from
government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none
occurred. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in significant civil, criminal and administrative penalties, damages, fines, disgorgement,
imprisonment, exclusion from participating in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to
resolve allegations of noncompliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations, any of which could have a negative impact on our business, financial condition, results of
operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have limited infrastructure in market access, sales, marketing and distribution. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We lack infrastructure and resources in the fields of sales, marketing and distribution. We need to develop our own marketing and sales
capacity, either alone or with partners once marketing authorizations have been obtained. As part of setting up our sales and marketing infrastructure, we will need to incur additional expenses, mobilize management resources, implement new skills
and take the time necessary to set up the appropriate organization and structure to support the products in accordance with current legislation and, more generally, optimize commercialization efforts. We compete with many companies that currently
have extensive, experienced and well-funded market access, marketing and sales operations to recruit, hire, train and retain marketing and sales personnel, and will have to compete with those companies to recruit, hire, train and retain any of our
own market access, marketing and sales personnel. If we are unable to expand our sales and marketing team, we may be unable to compete successfully against these more established companies. Alternatively, if we choose to collaborate, either globally
or on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">territory-by-territory</FONT></FONT> basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and
distribution systems or in lieu of our own sales force and distribution systems, we will be required to negotiate and enter into arrangements with such third parties relating to the proposed collaboration. If we are unable to enter into such
arrangements when needed, on acceptable terms, or at all, we may not be able to successfully commercialize any of our drug candidates that receive regulatory approval or any such commercialization may experience delays or limitations. Factors that
may inhibit our efforts to build a sales, marketing and distribution organization: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of sales personnel to obtain access to physicians, educate physicians about patients for whom our
drug candidates may be appropriate treatment options and attain adequate numbers of physicians to prescribe any drugs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement and
other acceptance by payors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restricted or closed distribution channels that make it difficult to distribute our products to segments of the
patient population; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of complementary medicines to be offered by sales personnel, which may put us at a competitive
disadvantage relative to companies with more extensive product lines; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There are numerous competitors in the market for therapeutic treatments of inflammatory diseases. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industries are highly competitive and subject to significant and rapid technological change as researchers
learn more about diseases and develop new technologies and treatments. Many pharmaceutical companies, biotech companies, institutions, universities and other research organizations are actively engaged in the research, discovery, development and
commercialization of therapeutic responses for the treatment of the diseases targeted by us. Significant competitive factors in our industry include: (i)&nbsp;product efficacy and safety; (ii)&nbsp;quality and breadth of an organization&#146;s
technology; (iii)&nbsp;skill of an organization&#146;s employees and its ability to recruit and retain key employees; (iv)&nbsp;timing and scope of regulatory approvals; (v)&nbsp;government reimbursement rates for, and the average selling price of,
pharmaceutical products; (vi)&nbsp;the availability of raw materials and qualified manufacturing capacity; (vii)&nbsp;manufacturing costs; (viii)&nbsp;intellectual property and patent rights and their protection; and (ix)&nbsp;sales and marketing
capabilities. Given the intense competition in our industry, we cannot assure you that any of the products that we successfully develop will be clinically superior or scientifically preferable to products developed or introduced by our competitors.
In addition, significant delays in the development of our drug candidates could allow our competitors to succeed in obtaining European Commission, FDA, PMDA or other regulatory approvals for their drug candidates more rapidly than us, which could
place us at a significant competitive disadvantage or deny us marketing exclusivity rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our competitors in the chronic inflammatory
disease field are primarily large pharmaceuticals companies including, but not limited to AbbVie, Pfizer, Eli Lilly, Takeda and Johnson&nbsp;&amp; Johnson. Several lines of research are being developed to improve the treatment of IBD. Many companies
are working to develop new, more effective and better tolerated treatments with more practical formulations, especially small molecules administered orally, better accepted than monoclonal antibodies that require administration by injection. See
&#147;Business&#151;Competition.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our competitors may be more effective at using their technologies to develop commercial
products. Many of the organizations competing with us have significantly greater financial resources and expertise in research and development, manufacturing, preclinical studies, conducting clinical trials, obtaining regulatory approvals and
marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or <FONT STYLE="white-space:nowrap">early-stage</FONT>
companies may also prove to be significant competitors, particularly through partnership arrangements with large and established companies. These companies also compete with us in recruiting and retaining qualified scientific and management
personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development potential in the markets in which we operate is such that the arrival of new competition is probable. New market entrants,
increased competition in specific areas, or in general, would have a material adverse effect on our business, income, financial position and outlook for growth. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on, and will continue to depend on, collaboration and strategic alliances with third partners. To the extent we are able to enter into
collaborative arrangements or strategic alliances, we will be exposed to risks related to those collaborations and alliances. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An
important element of our strategy for developing, manufacturing and commercializing our drug candidates is entering into partnerships and strategic alliances with other pharmaceutical companies or other
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
industry participants. The collaboration agreements that we have established, and any collaboration arrangements that we may enter into in the future, may not be successful, which would have a
negative impact on our business, results of operations, financial condition and growth prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any partnerships or alliance we have or
may have in the future may be terminated for reasons beyond our control or we may not be able to negotiate future alliances on acceptable terms, if at all. These arrangements may result in us receiving less revenue than if we sold our products
directly, may place the development, sales and marketing of our products outside of our control, may require us to relinquish important rights or may otherwise be on unfavorable terms. Collaborative arrangements or strategic alliances will also
subject us to a number of risks, including the risk that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to control the amount and timing of resources that our strategic partner/collaborators may
devote to the drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">strategic partner/collaborators may experience financial difficulties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure to successfully collaborate with third parties may delay, prevent or otherwise impair the development
or commercialization of our drug candidates or revenue expectations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">products being developed by partners/collaborators may never reach commercial stage resulting in reduced or even
no milestone or royalty payments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business combinations or significant changes in a collaborator&#146;s business strategy may also adversely affect
a collaborator&#146;s willingness or ability to complete their obligations under any arrangement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator could independently move forward with a competing product developed either independently or in
collaboration with others, including our competitors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborative arrangements are often terminated or allowed to expire, which would delay the development and may
increase the cost of developing drug candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our partnerships and licensing agreements relating to the technologies belonging
to us may not be successful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The various drug candidates developed by us arise from proprietary or licensed technologies with
leading academic partners, including Scripps Research Institute, University of Chicago, Brigham Young University, the Montpellier Institute of Molecular Genetics at the <I>Centre National de la Recherche Scientifique</I> (&#147;CNRS&#148;) and the
<I>Institut Curie</I>. If the clinical trials conducted by us were to reveal safety and/or therapeutic efficacy problems or if the use of one of the platforms were to violate an intellectual property right held by a third party, this could threaten
the use and operation of some of our technology platforms and require additional research and development efforts and additional time and expense to address these difficulties, with success not being guaranteed. The development of a portion of our
product portfolio would be affected, which would have a material adverse effect on our business, outlook, growth, financial position and income. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The reimbursement of drugs and treatments is beyond our control. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After achieving regulatory authorization and once marketing authorization is granted, the process of setting the sales price of drugs and their
reimbursement rates begins. The conditions for setting the sales price and reimbursement rate for drugs are beyond the control of pharmaceutical companies. They are decided by competent public committees and bodies and by social security or private
insurance companies. In this context, we or our partners could be asked to perform additional studies on our products. These studies could generate additional costs for us or our partners and lead to delays in marketing the drug, which could have an
impact on our financial position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the reimbursement of newly-approved drugs. The level of
reimbursement will impact market acceptance and sale of our drug candidates. Reimbursement by a third-party is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dependent on a number of factors, including, without limitation, the third-party payor&#146;s determination that use of a product is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The possibility that we could receive royalties from our industrial partner or partners on the sale of some of our products and our ability to
make sufficient profits on the marketing of our treatments or those for which we have entered into distribution contracts will depend on these reimbursement conditions. If delays in the price negotiation procedure result in a significant delay in
marketing, if our product does not obtain an appropriate level of reimbursement, or if the accepted price level and reimbursement rate of the treatments we market are changed, our profitability will be reduced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also unable to guarantee that we will succeed in maintaining, over time, the price level of our products or those for which licenses
have been granted, or the accepted reimbursement rate. Under these conditions, there could be a material adverse effect on our business, financial position and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The pricing, insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and
reimbursement for our drug candidates, if approved, could limit our ability to market those products and decrease our ability to generate product revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Successful sales of our drug candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors
including governmental healthcare programs, such as Medicare and Medicaid in the United States, managed care organizations and commercial payors, among others. Significant uncertainty exists as to the coverage and reimbursement status of any drug
candidates for which we obtain regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, no uniform policy for coverage and reimbursement exists, and
coverage and reimbursement for drug products can differ significantly from payor to payor. Therefore, one payor&#146;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug
product. Third-party payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage
determination process is often a <FONT STYLE="white-space:nowrap">time-consuming</FONT> and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that
coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Moreover, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is
attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reimbursement may impact the demand for, and/or the price of, any product for which we obtain marketing approval. Assuming we obtain coverage
for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. Patients who are prescribed
medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use our products
unless coverage is provided, and reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement is critical to new product acceptance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we or our collaborators may develop companion diagnostic tests for use with
our drug candidates. We or our collaborators will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we seek for our drug candidates, once approved. Similar challenges to obtaining
coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics. Our inability to promptly obtain coverage and adequate reimbursement from both third-party payors for the drug candidates and
companion diagnostic tests that we or our collaborators develop and for which we obtain regulatory approval could have a material and adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only
after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular drug candidate to currently available therapies. EU member states may approve a specific
price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products, but monitor and
control company profits. The downward pressure on health care costs has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from <FONT
STYLE="white-space:nowrap">low-priced</FONT> markets exert competitive pressure that may reduce pricing within a country. Any country that has price controls or reimbursement limitations may not allow favorable reimbursement and pricing
arrangements, and prices are usually revised periodically, such that any given price may decrease upon various occurrences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally,
the containment of healthcare costs has become a priority of federal and state governments, and the prices of drugs have been a focus of this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in
implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive
policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Price controls may be imposed in
markets in which we operate, which may negatively affect our future profitability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some countries, particularly EU member
states, Japan, Australia and Canada, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a
product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate
pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states and parallel distribution, or arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT>
and high-priced member states, can further reduce prices. In some countries, we or our collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our drug candidates to other available therapies
in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries.
If reimbursement of our drug candidates is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, there could be a material adverse effect on our business, financial condition or results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has been highly disruptive to our business, industry and in general. An outbreak of other
communicable diseases around the world may cause further disruption. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any public health outbreak may cause any of the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in recruiting patients for our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in launching clinical trial sites, including difficulties in recruiting investigators and
clinical site staff; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of health care resources from the conduct of clinical trials, of hospital staff supporting the conduct
of clinical trials. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the risks listed above, and as part of our clinical trials in countries in pandemic
zones, we may also experience the following adverse effects: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential delays in the conduct of our research and preclinical studies, preventing research and preclinical
studies from being conducted as planned; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in obtaining authorizations from the administrative and regulatory authorities required to launch the
planned preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in the receipt of supplies and equipment necessary for the completion of our research activities and our
preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption or delays affecting the activity of contractors who provide research services to us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the competent regulatory authorities to accept data from clinical trials conducted in the geographical
areas affected by the pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interruption of global maritime trade could affect the transportation of research materials for preclinical
studies and clinical trials, such as experimental drugs and comparator drugs used in our clinical trials; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in the necessary interactions with local authorities, ethics committees or other important and third-party
<FONT STYLE="white-space:nowrap">co-contracting</FONT> bodies due to limitations in human resources or forced leave of state employees. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If one or more of the above risks were to materialize, the planned and ongoing clinical trials and, therefore, the publication of the data and
results of these studies and all subsequent steps leading to the commercialization of drug candidates being studied, could be significantly delayed. Such a situation could have a material adverse effect on our business, income, financial position
and growth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The extent to which the outbreak of communicable diseases around the world may impact our activity and clinical trials will
depend on future developments, which cannot be predicted with certainty, such as the emergence of diseases that may be resistant to the vaccines or treatments currently available, access to vaccines and treatments for the various populations
worldwide, the final geographical spread of the disease, its duration, travel restrictions and social distancing measures in the European Union, the United States and other countries, business closures or disruptions, and the effectiveness of
measures taken in those countries to contain and treat the disease. There can be no assurance that the outbreak of communicable diseases around the world will not result in an adverse effect on financial markets, our share price and our ability to
obtain finance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The war between Ukraine and Russia may affect our business, industry and the markets in which we operate. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2022, Russia invaded Ukraine. The conflict has already had major implications for the global economy and the rate of inflation,
particularly in relation to the supply of energy, raw materials and food products. It has also caused intense volatility on the financial markets, something that is still ongoing at the reporting date and has pushed down stock market prices around
the world. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given these developments, we have decided not to include Russia and Belarus in our global Phase&nbsp;3 program for
obefazimod in UC. However, the global scale of this conflict cannot be predicted at this stage. We, therefore, cannot rule out an adverse impact of this conflict on our business, including in terms of access to raw materials, logistics, the
performance of clinical trials and in relation to any future financing we may seek. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase 2b maintenance trial of obefazimod in
moderately to severely active UC is our only clinical trial currently in progress in Ukraine. We have, however, terminated a few trial sites since the Russia/Ukraine war </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
began. The 12-month assessment was carried out in all the Ukrainian patients before the war broke out and these patients are therefore included in the one-year maintenance results that were
reported on April 6, 2022. Ukrainian patients who completed the two-year Phase 2b maintenance trial have been transitioned to the long-term safety and efficacy trial that is still on-going. None of these sites are located in the Crimea Region of
Ukraine, the so-called Donetsk People&#146;s Republic, or the so-called Luhansk People&#146;s Republic. We are also evaluating the possibility to include a few Ukrainian sites in the western part of Ukraine in the ABTECT Phase 3 clinical trials.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our
ability to exclusively commercialize our drug candidates may decrease if we are unable to protect our intellectual property rights or if these rights are insufficient for our purposes. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our ability and the ability of our partners to obtain, maintain and ensure, against third parties,
the protection of our patents, trademarks and related applications and other intellectual property rights or similar rights (such as trade secrets, business secrets and <FONT STYLE="white-space:nowrap">know-how)</FONT> or those we are authorized to
use in the course of our business in Europe, the United States, Asia and other key countries. We dedicate substantial financial and human resources to this and intend to continue our policy of protection through new patent applications as soon as we
deem it appropriate.<B><I></I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our technology is currently protected by patents and patent applications that we have filed or for
which we have an exclusive license. However, we or our partners might not be able to maintain the protection of our intellectual property rights and we could, thereby, lose our technological and competitive advantage in whole or in part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Firstly, our intellectual property rights and those of our partners offer protection for a period that may vary from one territory to another.
The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we have obtained or are seeking patent protection for our drug candidates, the patent term is 20 years
from the earliest filing date of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. In the United States, the term of a patent may be lengthened by a patent term adjustment, which provides for term extension in the case of
administrative delays at the United States Patent and Trademark Office (&#147;USPTO&#148;) in granting a patent, or may be shortened if a patent is terminally disclaimed over another patent with an earlier expiration date. Furthermore, in the United
States, the term of a patent covering an FDA approved drug may be eligible for a patent term extension under the Hatch-Waxman Amendments as compensation for the loss of patent term during the FDA regulatory review process. The period of extension
may be up to five years beyond the expiration of the patent but cannot extend the term of a patent beyond a total of 14 years from the date of product approval. Only one patent covering a single FDA-approved product among those eligible for an
extension may be extended. In the future, if any of our drug candidates receives FDA approval, we expect to apply for a patent term extension, if available, to extend the term of the patent covering such approved drug product. In France and the rest
of Europe generally, the term of a patent is 20 years from the date the patent application is filed, with the understanding that this period may be extended up to another five years if a supplementary protection certificate is filed and an
additional six months if a pediatric investigation plan is applied. We expect to seek patent term extensions in any jurisdictions where they are available, however, there is no guarantee that the applicable authorities, including the FDA, will agree
with our assessment of whether such an extension should be granted, and even if granted, the length of such an extension. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Secondly, we
and our partners could encounter difficulties in the filing or examination of some of our patent, trademark or other intellectual property rights applications currently being examined/registered. During the patent application process, we may receive
Office Actions from the USPTO or from comparable agencies in foreign jurisdictions rejecting the claims of the patent application. Although we would be given an opportunity to respond to those objections, we may be unable to overcome such
rejections. At the time a patent application is filed, there may be other patents that could constitute opposable prior art that may have not yet been published. Despite prior art searches and monitoring, we cannot be certain that we are the first
to conceive of an invention </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and file a patent application relating thereto; in particular, it should be noted that in most countries, the publication of patent applications takes place 18 months after the earliest priority
date of patent filing, or in some cases not at all, and that discoveries are sometimes only the subject of publication or patent application months or even years later. Likewise, when filing one of our trademarks in a country where it is not
covered, we could find that the trademark in question is not available in that country. A new trademark would then need to be sought for the country in question or an agreement negotiated with the prior holder of the trademark. We may not be able to
prevent a disclosure of information to third parties that could have an impact on our future intellectual property rights. Therefore, it is in no way certain that our current and future applications for patents, trademarks and other intellectual
property rights will result in registrations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Thirdly, the simple granting or registration of a patent, trademark or other intellectual
property right does not guarantee validity or enforceability. Our competitors may at any time contest the validity or enforceability of our or our partners&#146; patents, trademarks or applications relating thereto before a court or in the context
of other specific procedures which, depending on the outcome of such disputes, could reduce their scope, result in their invalidation or allow them to be circumvented by competitors. In addition, developments, changes or divergences in the
interpretation of the legal framework governing intellectual property in Europe, the United States or other countries could allow competitors to use our or our partners&#146; inventions or intellectual property rights to develop or market our
products or technologies without financial compensation. Moreover, there are still certain countries that do not protect intellectual property rights in the same way as in Europe and the United States, and the effective procedures and rules
necessary to ensure the defense of our rights may not exist in these countries. There is therefore no certainty that our existing and future patents, trademarks and other intellectual property rights will not be disputed, invalidated or
circumvented, or that they will provide effective protection against competition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consequently, our rights to our owned or licensed
patents, trademarks and related applications and other intellectual property rights may not confer the protection expected against competition. We therefore cannot guarantee with certainty that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will be able to develop novel inventions for which a patent could be filed or issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">applications for patents and other property rights currently under review will actually result in the granting of
patents, trademarks or other registered intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patents or other intellectual property rights granted to us or our partners will not be contested, invalidated or
circumvented; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection conferred by our or our partners&#146; patents, trademarks and intellectual property
rights is and will remain sufficient to protect us against competition. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Were these eventualities to occur, they could
have a material adverse effect on our business and growth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, third parties (or even our employees) could use or attempt to use
elements of our technologies protected by an intellectual property right, which would create a detrimental situation for us. We may therefore be compelled to bring legal or administrative proceedings against these third parties in order to enforce
our intellectual property rights (patents, trademarks, designs and models or domain names) in court. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enforcing a claim that a party
illegally infringed or misappropriated our intellectual property is difficult, expensive and time-consuming, and the outcome is unpredictable. Any litigation or dispute, regardless of the outcome, could lead to substantial costs, affect our
reputation, negatively influence our income and financial position and possibly not lead to the desired protection or sanction. Some competitors with more substantial resources than us may be able to bear the costs of litigation more easily. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations in any agreements under which we may license intellectual
property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose rights that are important to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to pursue the development of some of our drug-based candidates depends on the maintenance in force of the licensing agreements
entered into with various institutes. We have licenses granted by the CNRS, the University of Montpellier and/or the <I>Institut Curie</I> for certain patents or patent <FONT STYLE="white-space:nowrap">co-ownership</FONT> rights resulting from
cooperation with the CNRS, the University of Montpellier and the <I>Institut Curie</I>, which allowed obefazimod to be developed and a chemical library of more than 2,200 small molecules to be generated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These license contracts provide the possibility for the licensor to end an agreed exclusivity or terminate the contracts in certain events,
including the event of <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees, a dispute over the validity of the patents licensed or a violation by us of our obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may from time to time be party to license or collaboration agreements with third parties to advance our research or allow commercialization
of current or future drug candidates. Such agreements may impose numerous obligations, such as development, diligence, payment, commercialization, funding, milestone, royalty, sublicensing, insurance, patent prosecution, enforcement and other
obligations on us and may require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses. In spite of our best efforts, our licensors might
conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technologies covered by these license
agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any termination of these licenses, or if the underlying licensed rights fail to provide the intended exclusivity, could
result in the loss of significant rights and could harm our ability to commercialize our current or future drug candidates, and competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products
identical to ours and we may be required to cease our development and commercialization of certain of our current or future drug candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial
conditions, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disputes may also arise between us and our licensors regarding intellectual property
subject to a license agreement, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which our technology and processes infringe, misappropriate or otherwise violate
intellectual property rights of the licensor that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and
commercialization of our current or future drug candidates, and what activities satisfy those diligence obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of any patented technology; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ownership of inventions and&nbsp;know-how&nbsp;resulting from the joint creation or use of intellectual
property by our future licensors and us and our partners. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the agreements under which we may license
intellectual property or technology from third parties are likely to be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The adverse resolution of any contract interpretation disagreement that may
arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations
and prospects. Moreover, if disputes over intellectual property that we have licensed or may license prevent or impair our ability to maintain future licensing arrangements on acceptable terms, we may be unable to successfully develop and
commercialize the affected current or future drug candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be sued for infringing or misappropriating the intellectual property rights of third parties, and if we are, such litigation could be costly and
time consuming and could prevent or delay us from developing or commercializing our drug candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success will
also depend on our ability to develop products and technologies that do not infringe the patents or other rights of third parties. It is important for the success of our business that we are able to use our products and conduct research and
development efforts leading to commercialization of our products without infringing patents or other third-party rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We continue to
carry out, as we have done to date, the preliminary studies that we consider necessary in view of the above risks, before investing in the development of our various products and technologies. With the help of intellectual property consulting and
law firms, we monitor our competitors&#146; activity (particularly with respect to patent filings). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We therefore cannot guarantee with
certainty that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there are no prior patents or other intellectual property rights of third parties covering certain of our
products, methods, technologies, results or activities and that, consequently, third parties might bring an action for infringement or violation of their rights against us with a view to obtaining damages and interest and/or the cessation of our
activities in the manufacture and/or commercialization of products, methods and the like thus disputed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there are no trademark rights or other prior rights of third parties that could be the basis of an infringement
or liability action against us; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our domain names are not subject, on the part of third parties who have prior rights (for example trademark
rights), to a Uniform Domain-Name Dispute-Resolution Policy (&#147;UDRP&#148;) or similar policy, or an infringement action. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of intellectual property litigation, we may have to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stop developing, making, selling, offering for sale or using the product or products that depended on the
disputed intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain a license from the holder of the intellectual property rights, however, such a license may be unobtainable
or only be obtainable under unfavorable economic conditions for us; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">revise the design of some of our products/technologies or, in the case of trademark applications, rename our
products to avoid infringing the intellectual property rights of third parties, which may prove impossible or time-consuming and expensive, and could impact our marketing efforts. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Litigation can also result in an order to pay damages (including treble damages) and being subject to injunctions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent terms may be inadequate to protect our competitive position on our drugs for an adequate amount of time, and we may seek to rely, but may not be
able to rely, on other forms of protection, such as regulatory exclusivity. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the amount of time required for the development,
testing and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such candidates are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercialized. For example, the certain patents protecting obefazimod&#146;s composition of matter expire in 2030 and the certain patents protecting obefazimod methods of use expire in 2035
which pose a risk to its successful commercialization. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are prosecuting patents. In the United States, the Drug Price Competition and
Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the approved indication (or any additional indications approved during the period of extension).
However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to
grant extensions to our patents, or may grant more limited extensions than we request. We may also seek to rely on other forms of protection, such as regulatory exclusivity, but there can be no assurance that such other forms of protection will be
available or sufficient. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will not seek to protect our intellectual property rights in all jurisdictions throughout the world and we may not be
able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing,
prosecuting and defending patents on our drug candidates in all countries and jurisdictions throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less
extensive than those in the United States, assuming that rights are obtained in the United States. Competitors may use our technologies in jurisdictions where we do not pursue and obtain patent protection to develop their own products and further,
may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our drugs and our patents or other intellectual property rights
may not be effective or sufficient to prevent them from competing. Even if we pursue and obtain issued patents in particular jurisdictions, our patent claims or other intellectual property rights may not be effective or sufficient to prevent third
parties from so competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent
as the federal and state laws in the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly
developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to biopharmaceuticals or biotechnologies. This could make it difficult for us to stop the infringement of our
patents, if obtained, or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries
limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Patent protection must ultimately be sought on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain
countries, and we will not have the benefit of patent protection in such countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proceedings to enforce our patent rights in foreign
jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not
being issued and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, changes in the law and
legal decisions by courts in the United States and foreign countries may affect our ability to obtain adequate protection for our technology and the enforcement of our intellectual property. In addition, monitoring the unauthorized use of our
products and technology and the infringement of our intellectual property rights is challenging. We cannot guarantee with certainty that we will be able to prevent, take legal action against and obtain compensation for infringement, misappropriation
or unauthorized use of our products and technologies, particularly in foreign countries where our rights are less well protected because of the territorial scope of intellectual property rights. Accordingly, our efforts to enforce our intellectual
property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, in Europe, a new unitary patent system took effect June 1, 2023, which
significantly impacts European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications have the option, upon grant of a patent, of becoming a Unitary Patent which will be
subject to the jurisdiction of the Unitary Patent Court, or the UPC. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have
the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if
successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, geo-political actions in the United States and in foreign countries could increase the uncertainties and costs surrounding the
prosecution or maintenance of our patent applications and the maintenance, enforcement or defense of our issued patents. For example, the United States and foreign government actions related to Russia&#146;s invasion of Ukraine may limit or prevent
filing, prosecution, and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications, resulting
in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on our business. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies
and individuals to exploit inventions owned by patentees from the United States without consent or compensation. Consequently, we would not be able to prevent third parties from practicing our inventions in Russia or from selling or importing
products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names are not adequately protected by us or our partners that develop trademarks for our future products, then we may not be
able to build name or brand recognition in our markets of interest, and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our registered or
unregistered trademarks and trade names and the registered or unregistered trademarks and trade names that our partners will develop may be challenged, infringed, diluted, circumvented or declared generic or determined to be infringing on other
marks. We and our partners may not be able to protect our rights to these trademarks and trade names, which we need to build name and brand recognition among potential partners or customers in our markets of interest. We expect to rely on our
partners to protect the trade names and trademarks that they will develop, and they may not adequately protect such tradenames and trademarks, and we may have little or no recourse in respect thereof. At times, competitors may adopt trademarks and
trade names similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. During the trademark registration process, we may receive Office Actions from the USPTO or from comparable agencies in
foreign jurisdictions objecting to the registration of our trademark. Although we would be given an opportunity to respond to those objections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in
many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and/or to seek the cancellation of registered trademarks. Opposition or cancellation proceedings may be filed against our trademark
applications or registrations, and our trademark applications or registrations may not survive such proceedings. In addition, there could be potential trademark infringement claims brought by owners of other registered trademarks or trademarks that
incorporate variations of our registered or unregistered trademarks. Over the long term, if we are unable to establish name and brand recognition based on our trademarks, then we may not be able to compete effectively and our business may be
adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and
other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and applications are required to be paid
to the USPTO and various governmental patent agencies outside of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
United States in several stages over the lifetime of the patents and applications. The USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> governmental patent agencies require
compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and after a patent has issued. There are situations in which <FONT STYLE="white-space:nowrap">non-compliance</FONT>
can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our trade secrets and <FONT STYLE="white-space:nowrap">know-how,</FONT> our business and competitive
position could be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to seeking patent protection for our drug candidates, we also rely on trade secrets,
including unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary information, to establish and maintain our competitive position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is also important for us to protect against the unauthorized use and disclosure of our confidential information, <FONT
STYLE="white-space:nowrap">know-how</FONT> and trade secrets. Unpatented and/or unpatentable technologies, processes, methods, <FONT STYLE="white-space:nowrap">know-how</FONT> and data are considered trade secrets that we seek to protect, in part,
by entering into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to them, such as our employees, collaborators, consultants, advisors, university and/or institutional researchers and
other third parties. We also have entered or seek to enter into confidentiality and invention or patent assignment agreements with our employees, advisors and consultants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the context of collaboration, partnership or research contracts, or other types of cooperation between us and researchers from academic
institutions, and with other public or private entities, subcontractors, or any <FONT STYLE="white-space:nowrap">co-contracting</FONT> third parties, various information and/or products may be entrusted to them in order to conduct certain tests and
clinical trials. In such cases, we require that confidentiality agreements be signed. Furthermore, as a general rule, we take care that the collaboration or research contracts that we are party to give us access to full ownership or <FONT
STYLE="white-space:nowrap">co-ownership</FONT> of results and/or inventions resulting from the collaboration, or to an exclusive license based on these results and/or inventions resulting from the collaboration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite these efforts, counterparties may breach our agreements and disclose our proprietary information, including our trade secrets, and we
may not be able to obtain adequate remedies for such breaches. Our trade secrets may also be obtained by third parties by other means, such as breaches of our physical or computer security systems. Enforcing a claim that a party illegally disclosed
or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, if any of
our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our
trade secrets were to be disclosed to, or independently developed by, a competitor, our competitive position would be harmed and our business may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that the agreements put in place to protect our technology and trade secrets and/or the <FONT
STYLE="white-space:nowrap">know-how</FONT> being used will provide the protection sought or will not be violated, that we will have appropriate solutions for such violations, or that our trade secrets will not be disclosed to or independently
developed by our competitors. In the context of contracts that we enter into with third parties, we sometimes take the precaution of providing that they are not authorized to use third-party services or that they may only do so with our prior
approval. However, it cannot be ruled out that some of these <FONT STYLE="white-space:nowrap">co-contractors</FONT> may nevertheless use third parties. In this event, we have no control over the conditions under which third parties with which we do
not contract protect their confidential information, irrespective of whether we provide in our agreements with our <FONT STYLE="white-space:nowrap">co-contractors</FONT> that they undertake to pass on confidentiality obligations to their own <FONT
STYLE="white-space:nowrap">co-contractors.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such contracts therefore expose us to the risk of having the third parties concerned
(i)&nbsp;claim the benefit of intellectual property rights on our inventions or other intellectual property rights, (ii)&nbsp;fail to ensure the confidentiality of unpatented innovations or improvements of our confidential information and <FONT
STYLE="white-space:nowrap">know-how,</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(iii)&nbsp;disclose our trade secrets to our competitors or independently develop these trade secrets and/or (iv)&nbsp;violate such agreements, without our having an appropriate solution for such
violations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consequently, our rights to our confidential information, trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT>
may not confer the expected protection against competition and we cannot guarantee with certainty that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our knowledge and trade secrets will not be obtained, stolen, circumvented, transmitted or used without our
authorization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors have not already developed similar technologies or products, or ones similar in nature or purpose
to ours; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no <FONT STYLE="white-space:nowrap">co-contracting</FONT> party will claim the benefit of all or part of the
intellectual property rights relating to inventions, knowledge or results that we hold in our own right or in <FONT STYLE="white-space:nowrap">co-ownership,</FONT> or for which we would be entitled to a license; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our employees will not claim rights or payment of additional compensation or fair price for inventions in the
creation of which they participated. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The occurrence of one or more of these risks could have a material adverse effect
on our business, outlook, financial position, income and growth. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to cyber risks. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are dependent upon the availability, capacity, reliability and security of our information technology infrastructure to conduct daily
operations. We depend on various information technology systems to process and record financial data, research data and confidential information, process clinical data, manage financial resources and communicate with employees and third parties. In
particular, we store information about drug candidates, which is critical to our research and development, on our computer systems. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third
parties on which we rely have in the past been affected by cyberattacks and may in the future fail, or are perceived to have failed, to maintain sufficient cyber-security safeguards, which could compromise data they hold on our behalf. If our
suppliers or other third parties we collaborate with suffer from cyberattacks or cybersecurity breaches, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties,
audits, inspections, and similar); litigation (including class-action claims); additional reporting requirements and/or oversight; bans on processing personal data; and orders to destroy or not use personal data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we maintain industry-standard backups and procedures, we are at risk of financial loss, reputational damage and general disruption
from a failure of our information technology infrastructure or an attack for the purposes of espionage, extortion, terrorism or to cause embarrassment. Any failure of, or attack against, our information technology infrastructure may be difficult to
prevent or detect, and our internal policies to mitigate these risks may be inadequate or ineffective. We may not be able to recover any losses that may arise from such a failure or attack, which could have a material adverse effect on our business,
outlook, financial position, income and growth. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not address all potential threats to our competitive advantage.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights
have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Competitors may be able to formulate compositions that are similar to ours but that are not covered by our
intellectual property rights. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Competitors may independently develop similar or alternative compositions or otherwise circumvent any of our
applications or registrations without infringing our intellectual property rights. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We or any of our collaboration partners might not have been the first to conceive and reduce to practice the
inventions covered by the patents or patent applications that we own, license or will own or license. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We or any of our collaboration partners might not have been the first to file patent applications covering
certain of the patents or patent applications that we or they own or have licensed, or will own or will have licensed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It is possible that any pending patent applications that we have filed, or will file, will not lead to issued
patents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Issued patents that we own may not provide us with any competitive advantage, or may be held invalid or
unenforceable, as a result of legal challenges by our competitors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our competitors might conduct research and development activities in countries where we do not have patent
rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ownership of our patents or patent applications may be challenged by third parties. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may infringe on the patents of third parties or pending or future applications of third parties, if issued,
and the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Legal and Compliance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business
is subject to a restrictive and changing regulatory framework. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the major issues for a growing company like ours is to
successfully develop, alone or with the help of partners, products incorporating our technologies in an increasingly restrictive regulatory environment. The pharmaceutical industry faces constant changes in its legal and regulatory environment and
increased oversight by the competent authorities, such as the National Agency for Medicines and Health Products Safety (&#147;ANSM&#148;) in France, the EMA in the European Union, the FDA in the United States or the PMDA in Japan, and other
regulatory authorities in the rest of the world. At the same time, the public is demanding more guarantees regarding drug safety and efficacy. This may at any time lead to a more restrictive regulatory environment for our drug candidates which may
have a material adverse effect on business, financial position, income, growth and outlook. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Health authorities oversee research and
development, preclinical studies, clinical trials, the regulation of pharmaceutical companies, and drug manufacturing and commercialization. This increasing stringency of the legislative and regulatory framework is common worldwide; however,
requirements may vary from country to country. In particular, health authorities, especially the ANSM, EMA, FDA and PMDA, have imposed increasingly burdensome requirements in terms of the volume of data required to demonstrate the efficacy and
safety of a product. These increased requirements may have thus reduced the number of products authorized in comparison to the number of applications filed. Products on the market are also subject to regular reassessment of the risk/benefit ratio
after their authorization. The delayed discovery of problems not identified at the research stage can lead to marketing restrictions, suspension or withdrawal of the product, and to an increased risk of litigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Therefore, the authorization process is long and expensive; it can take many years and the result is not predictable. Insofar as new legal or
regulatory provisions would result in an increase in the cost of obtaining and maintaining product marketing authorizations or limit the targeted indications for a product that a product targets or the economic value of a new product to its
inventor, the growth prospects for the pharmaceutical industry, and us, could be reduced. If we experience delays completing, or if we terminate, any of our clinical trials, or if we are required to conduct additional clinical trials, the commercial
prospects for our drug candidates may be harmed and our ability to generate product revenue will be delayed. The occurrence of one or more of these risks could have a material adverse effect on our business, outlook, financial position, income and
growth. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to healthcare laws and regulations which may require substantial compliance efforts and
could expose us to criminal sanctions, civil and administrative penalties, contractual damages, reputational harm and diminished profits and future earnings, among other penalties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers, including physicians, and others will play a primary role in the recommendation and prescription of our products, if
approved. Our arrangements with such persons and third-party payors and our general business operations will expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial
arrangements and relationships through which we research, market, sell and distribute our drugs, if we obtain marketing approval. Restrictions under applicable U.S. federal, state and foreign healthcare laws and regulations include, but are not
limited to, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly
and willfully soliciting, offering, receiving or providing remuneration, including any kickback, bribe or rebate, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the
purchase or lease, order or recommendation of, any item, good, facility or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the
statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. federal civil and criminal false claims laws and civil monetary penalties laws, including the civil False
Claims Act (&#147;FCA&#148;), which impose criminal and civil penalties, including those from civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims
for payment that are false or fraudulent or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government. For example, pharmaceutical companies have been prosecuted under the FCA in connection with
their alleged <FONT STYLE="white-space:nowrap">off-label</FONT> promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and allegedly providing free
product to customers with the expectation that the customers would bill federal health care programs for the product. In addition, the government may assert that a claim including items and services resulting from a violation of the federal
Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal Health Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;), which created
additional federal criminal statutes that impose criminal and civil liability for, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or knowingly and willingly falsifying, concealing or
covering up a material fact or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or
specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#147;HITECH&#148;)
and its implementing regulations, which impose certain requirements on covered entities and their business associates, as well as their covered subcontractors, including mandatory contractual terms, with respect to safeguarding the privacy, security
and transmission of individually identifiable health information; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities
and activities that potentially harm consumers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. federal transparency requirements under the Physician Payments Sunshine Act, enacted as part of the
Affordable Care Act (&#147;ACA&#148;), that require applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program, with
specific exceptions, to track and annually report to Concerned Member States (&#147;CMS&#148;) payments and other transfers of value provided to physicians, certain other healthcare providers (such as physicians assistants and nurse practitioners),
and teaching hospitals, and require certain manufacturers and group purchasing organizations to report annually certain ownership and investment interests held by physicians or their immediate family members; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state or foreign laws and regulations, such as state anti-kickback and false claims laws, which may
apply to items or services reimbursed by any third-party payor, including commercial insurers, state marketing and/or transparency laws applicable to manufacturers that may be broader in scope than the federal requirements, state laws that require
biopharmaceutical companies to comply with the biopharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and state laws governing the privacy and security of health
information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect as HIPAA, thus complicating compliance efforts. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. It
cannot be excluded that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our
operations were found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment,
possible exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could substantially disrupt
our operations. If the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from
government funded healthcare programs. We may incur significant costs achieving and maintaining compliance with applicable federal and state privacy, security, and fraud laws. Any action against us for violation of these laws, even if we
successfully defend against it, could cause us to incur significant legal expenses and divert our management&#146;s attention from the operation of our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Current and future health reform measures could adversely affect our business operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and some foreign jurisdictions there have been, and we expect there will continue to be, several legislative and
regulatory changes and proposed reforms of the healthcare system to contain costs, improve quality, and expand access to care. For example, in March 2010, President Obama signed the ACA into law, which substantially changed the way healthcare is
financed by both governmental and private insurers and continues to significantly impact the United States pharmaceutical industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There
have been judicial, congressional and executive branch challenges to certain aspects of the ACA. For example, on June&nbsp;17, 2021, the United States Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional
in its entirety because the individual mandate was repealed by Congress. Moreover, there have been a number of health reform initiatives by the Biden administration that have impacted the ACA. For example, on August&nbsp;16, 2022, President Biden
signed the Inflation Reduction Act of 2022 (&#147;IRA&#148;), into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the
&#147;donut hole&#148; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cost through a
newly-established manufacturer discount program. It is unclear how other healthcare reform measures, if any, will impact our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, on August&nbsp;2, 2011, the Budget Control Act of 2011 was signed into law which among other things, led to aggregate
reductions in Medicare payments to providers. These reductions went into effect on April&nbsp;1, 2013, and, due to subsequent legislative amendments, will remain in effect until 2032, with the exception of a temporary suspension from May&nbsp;1,
2020, through March&nbsp;31, 2022, due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, unless additional Congressional action is taken. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, there have been several recent U.S. presidential executive orders, congressional inquiries and proposed and enacted legislation
at the federal and state levels designed to, among other things, bring more </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement
methodologies for drugs. For example, on March 11, 2023, the American Rescue Plan Act of 2021 was signed into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#146;s average manufacturer price, beginning
January 1, 2024. In addition, the IRA, among other things, (1)&nbsp;directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2)&nbsp;imposes rebates under Medicare Part B and Medicare Part D to
penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs
are implemented. These provisions took effect progressively starting in fiscal year 2023, although the Medicare drug price negotiation program is currently subject to litigation. It is currently unclear how the IRA will be implemented but is likely
to have a significant impact on the pharmaceutical industry. Further, in response to the Biden administration&#146;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS
Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. We&nbsp;expect
that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our
drug candidates or additional pricing pressures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the state level, legislatures have increasingly passed legislation and implemented
regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in
some cases, designed to encourage importation from other countries and bulk purchasing. If healthcare policies or reforms intended to curb healthcare costs are adopted, or if we experience negative publicity with respect to the pricing of our
products or the pricing of pharmaceutical drugs generally, the prices that we charge for any approved products may be limited, our commercial opportunity may be limited and/or our revenues from sales of our products may be negatively impacted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in
additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of
cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drug candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail
to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, which could adversely affect our business, results of operations and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to other laws and regulations governing our international operations, including regulations administered by the governments of
the United States, and authorities in the European Union and in Japan, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, collectively referred to as
the trade control laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act of 1977, as amended
(&#147;FCPA&#148;), which prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party, or candidate for the purpose of
influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct
activities, including the French <FONT STYLE="white-space:nowrap">anti-corruption</FONT> laws: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Article <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">433-1-1</FONT></FONT> of the French
Criminal Code (bribery of domestic public officials); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Article <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">433-1-2</FONT></FONT> of the French
Criminal Code (influence peddling involving domestic public officials); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Article <FONT STYLE="white-space:nowrap">434-9</FONT> of the French Criminal Code (bribery of domestic judicial
staff); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Article <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">434-9-1</FONT></FONT> of the French
Criminal Code (influence peddling involving domestic judicial staff); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Articles <FONT STYLE="white-space:nowrap">435-1</FONT> and <FONT STYLE="white-space:nowrap">435-3</FONT> of the
French Criminal Code (bribery of foreign or international public officials); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Articles <FONT STYLE="white-space:nowrap">435-7</FONT> and <FONT STYLE="white-space:nowrap">435-9</FONT> of the
French Criminal Code (bribery of foreign or international judicial staff); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Articles <FONT STYLE="white-space:nowrap">435-2,</FONT> <FONT STYLE="white-space:nowrap">435-4,</FONT> <FONT
STYLE="white-space:nowrap">435-8</FONT> and <FONT STYLE="white-space:nowrap">435-10</FONT> of the French Criminal Code (active and passive influence peddling involving foreign or international public officials and foreign or international judicial
staff); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Articles <FONT STYLE="white-space:nowrap">445-1</FONT> and <FONT STYLE="white-space:nowrap">445-2</FONT> of the
French Criminal Code (bribery of private individuals); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">French Law No.&nbsp;2016-1691 of December&nbsp;9, 2016 on Transparency, the Fight Against Corruption and the
Modernization of the Economy (Sapin 2 Law), which provides for numerous new obligations for large companies such as the obligation to draw up and adopt a code of conduct defining and illustrating the different types of behavior to be proscribed as
being likely to characterize acts of corruption or influence peddling, to set up an internal warning system designed to enable the collections of reports from employees relating to the existence of conduct or situations contrary to the
company&#146;s code of conduct, to set up accounting control procedures, whether internal or external, designed to ensure that the books, registers and accounts are not used to conceal acts of corruption or influence peddling, to set up a
disciplinary system for sanctioning company employees in the event of a breach of the company&#146;s code of conduct or a system for monitoring and evaluating the measures implemented. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company
to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.
Activities that violate the FCPA, even if they occur wholly outside the United States, can result in criminal and civil fines, imprisonment, disgorgement, oversight, and debarment from government contracts. The scope and enforcement of these laws is
uncertain and subject to rapid change. Further, enforcement bodies have increased their scrutiny of interactions between healthcare companies and healthcare providers. This has resulted in an increase in the number of investigations, prosecutions,
convictions and settlements in the healthcare industry. Responding to investigations can be both resource and time consuming and can divert management&#146;s attention from the business. Any such investigation or settlement could increase our costs
or otherwise have a material adverse effect on our business, outlook, financial position, income and growth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FCPA and other
anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of
value to recipients in the public or private sector. We may engage third parties to sell our products outside the United States, to conduct clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other regulatory
approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of
our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no complete assurance that we will be effective in ensuring our compliance with all applicable anti-corruption laws, including the
FCPA, the French anti-corruption laws or other legal requirements, including trade control laws. If we are not in compliance with the FCPA, the French anti-corruption laws and other anti-corruption laws or trade control laws, we may be subject to
criminal and civil penalties, disgorgement and other sanctions and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
remedial measures and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation of any potential
violations of the FCPA, the French anti-corruption laws, other anti-corruption laws or trade control laws by U.S. or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial condition.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, changes in our products and drug candidates or changes in applicable export or import laws and regulations may create delays
in the introduction or provision of our products and drug candidates in other jurisdictions, prevent others from using our products and drug candidates or, in some cases, prevent the export or import of our products and drug candidates to certain
countries, governments or persons altogether. Any limitation on our ability to export or provide our products and drug candidates could adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product liability and other lawsuits could divert our resources, result in substantial liabilities and reduce the commercial potential of our drug
candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The risk that we may be sued on product liability claims is inherent in the development and commercialization of our
drug candidates. Side effects of, or manufacturing defects in, drugs that we develop could result in the deterioration of a patient&#146;s condition, injury or even death. For example, our liability could be sought after by patients participating in
the clinical trials in the context of the development of the therapeutic products tested and unexpected side effects resulting from the administration of these drugs. In addition, we could face liability due to undetected side-effects caused by the
interaction of our drugs with other drugs following release of the drug candidate to the market. Once a product is approved for sale and commercialized, the likelihood of product liability lawsuits increases. Criminal or civil proceedings might be
filed against us by patients, regulatory authorities, biopharmaceutical companies and any other third party using or marketing our drugs. These actions could include claims resulting from actions by our partners, licensees and subcontractors, over
which we have little or no control. These lawsuits may divert our management from pursuing our business strategy and may be costly to defend. In addition, if we are held liable in any of these lawsuits, we may incur substantial liabilities, may be
forced to limit or forgo further commercialization of the affected products and may suffer damage to our reputation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could be exposed
to the risk of liability claims during the clinical development of our products, in particular product liability claims, related to the manufacture of therapeutic products and trials in humans and animals. We could be held liable by patients
participating in clinical trials as part of the development of the therapeutic products tested for unexpected side effects resulting from the administration of these products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could also be held liable during the commercialization phase of our products. Criminal complaints or lawsuits could be filed or brought
against us by patients, regulatory agencies, pharmaceutical companies and any other third parties using or marketing our products. These actions may include claims arising from acts of our partners, licensees or subcontractors, over which we have
little or no control. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain product liability insurance coverage for our clinical trials at levels which we believe are appropriate for our clinical trials.
Nevertheless, we cannot guarantee that the insurance policy taken out or the contractually limited indemnification, if applicable, granted by our subcontractors will be sufficient to cover the claims that could be brought against us or losses we may
suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our liability, or that of our partners, licensees and subcontractors, was thereby activated, if we or our partners, licensees
and subcontractors were unable to obtain and maintain appropriate insurance coverage at an acceptable cost or protect ourselves in any way against liability claims, this would seriously affect the commercialization of our products and, more
generally, have a material adverse effect on our business, income, financial position and outlook for growth. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual
obligations, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our
business operations; reputational harm; loss of revenue or profits; and other adverse business consequences. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary
course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, processing) personal data and other sensitive information, including
proprietary and confidential business data, trade secrets, intellectual property, sensitive third-party data, business plans, transactions, and financial information (collectively, sensitive data). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our data processing activities may subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance,
industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach
notification laws, personal data privacy laws, consumer protection laws (e.g., Section&nbsp;5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). For example, the California Consumer Privacy Act of 2018
(&#147;CCPA&#148;) requires businesses to provide specific disclosures in privacy notices and honor requests of California residents to exercise certain privacy rights. The CCPA provides for civil penalties of up to $7,500 per violation and allows
private litigants affected by certain data breaches to recover significant statutory damages. In addition, the California Privacy Rights Act of 2020 (&#147;CPRA&#148;), which becomes operative January&nbsp;1, 2023, will expand the CCPA&#146;s
requirements, including applying to personal information of business representatives and employees and establishing a new regulatory agency to implement and enforce the law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other states, such as Virginia, Colorado, Utah and Connecticut have also passed comprehensive privacy laws, and similar laws are being
considered in several other states, as well as at the federal and local levels. These developments may further complicate compliance efforts and may increase legal risk and compliance costs for us and the third parties upon whom we rely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, an increasing number of laws, regulations, and industry standards may govern data privacy and security. For
example, the European Union&#146;s Regulation (EU) 2016/679 of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, as amended (&#147;EU GDPR&#148;), the United
Kingdom&#146;s GDPR (&#147;UK GDPR&#148;), Brazil&#146;s General Data Protection Law (Lei Geral de Prote&ccedil;&atilde;o de Dados Pessoais, or &#147;LGPD&#148;) (Law No.&nbsp;13,709/2018), and China&#146;s Personal Information Protection Law
(&#147;PIPL&#148;) impose strict requirements for processing personal data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, we seek to obtain marketing authorization from
the European Union for our drug candidates. Moreover, a significant portion of the personal data that we may use is managed by third parties (primarily clinical sites and CROs in clinical trials). The collection and use of personal health data in
the European Union is governed by the provisions of the EU GDPR. Under the EU GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to &#128;20&nbsp;million or 4% of annual global revenue,
whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due to
data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the EEA and the
United Kingdom (&#147;UK&#148;) have significantly restricted the transfer of personal data to countries whose privacy laws it believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and
cross-border data transfer laws. Although there </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the Trans-Atlantic Data Privacy Framework or
the EEA and UK&#146;s standard contractual clauses, being specified that these mechanisms of standard contractual clauses are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer
personal data to the United States. If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could
face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions at significant expense, increased exposure
to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our
business. Some European regulators have prevented companies from transferring personal data out of Europe for allegedly violating the EU GDPR&#146;s cross-border data transfer limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to data privacy and security laws, we may be contractually subject to industry standards adopted by industry groups and may become
subject to such obligations in the future. We may also be bound by other contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may publish privacy policies, marketing materials, and other statements, such as compliance with certain certifications or self-regulatory
principles, regarding data privacy and security. If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement
actions by regulators, or other adverse consequences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obligations related to data privacy and security are quickly changing, becoming
increasingly stringent, and creating regulatory uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with
these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations. Moreover,
despite our efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business operations. If we or the third parties on which we rely fail, or are perceived to have failed,
to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and
similar); litigation (including class-action claims); additional reporting requirements and/or oversight; bans on processing personal data; and orders to destroy or not use personal data. Any of these events could have a material adverse effect on
our reputation, business, or financial condition, including but not limited to: loss of customers; inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of
time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our
information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or
actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of our business, we and the third parties upon which we rely may process sensitive data, and, as a result, we and the
third parties upon which we rely face a variety of evolving threats, including but not limited to ransomware attacks, which could cause security incidents. Cyber-attacks, malicious internet-based </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
activity, online and offline fraud and other similar activities threaten the confidentiality, integrity and availability of our sensitive data and information technology systems, and those of the
third parties upon which we rely. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#147;hackers,&#148; threat actors, &#147;hacktivists,&#148;
organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states and nation-state-supported actors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for
geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including
retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain and ability to produce, sell and distribute our services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the third parties upon which we rely may be subject to a variety of evolving threats, including but not limited to social-engineering
attacks (including through phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions),
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks (such as credential stuffing), credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs,
server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fires, floods and other similar threats. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, loss
of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or
regulations prohibiting such payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Remote work has become more common and has increased risks to our information technology systems
and data, as more of our employees utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit and in public locations. Additionally, future or past business transactions (such as
acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#146; systems and technologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our reliance on third-party service providers could introduce new cybersecurity risks and vulnerabilities, including supply-chain
attacks, and other threats to our business operations. We may rely on third-party service providers and technologies to operate critical business systems to process sensitive data in a variety of contexts, including, without limitation, cloud-based
infrastructure, data center facilities, employee email, and other functions. We may also rely on third-party service providers to provide other products, services, parts, or otherwise to operate our business. Our ability to monitor these third
parties&#146; information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could
experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to
recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#146; infrastructure in our supply chain or our third-party partners&#146; supply chains have not been
compromised. One of our CROs has experienced a data breach that involved personal data being compromised, affecting all the CRO&#146;s customers, including fully pseudonymized and encoded electronic case report forms relating to 14 of our trials.
While our Data Protection Committee concluded in October 2021 that there is no critical risk to the privacy of data subjects, we have conducted additional corrective and preventive measures to ensure any such data breach incident can be prevented in
the future (including root cause analysis audits and risk analysis). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of the previously identified or similar threats could cause a
security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive data or our information technology
systems, or those of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
third parties upon whom we rely. A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to provide our services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may expend significant resources or modify our business activities to try to protect against security incidents. Additionally, certain data
privacy and security obligations may require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will
be effective. We may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security
incident has occurred. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are
costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we (or a third party
upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines,
penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive data (including personal data); litigation (including class claims); indemnification obligations; negative publicity;
reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause customers to stop using our services,
deter new customers from using our services, and negatively impact our ability to grow and operate our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our contracts may not
contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security
obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on
commercially reasonable terms or at all, or that such coverage will pay future claims. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Offering, Ownership of Our ADSs and Our
Status as a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Company with Foreign Private Issuer Status </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There has been no market for our ADSs
prior to the U.S. offering and an active and liquid market for our securities may fail to develop, which could harm the market price of our ADSs. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although our ordinary shares have been traded on Euronext Paris since <FONT STYLE="white-space:nowrap">mid-2015,</FONT> there has been no
public market on a U.S. national securities exchange for our ADSs in the United&nbsp;States. Although we anticipate that our ADSs will be approved for listing on the Nasdaq Global Market, an active trading market for our ADSs may never develop or be
sustained following the offering. The offering price of our ADSs was determined through negotiations between us and the underwriters based on a number of factors. This offering price may not be indicative of the market price of our ADSs after the
offering. In the absence of an active trading market for our ADSs, investors may not be able to sell their ADSs at or above the offering price or at the time that they would like to sell. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, our business will be harmed, and
the price of our securities could decline as a result. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We sometimes estimate for planning purposes the timing of the
accomplishment of various scientific, clinical, regulatory and other product development objectives. These milestones may include our expectations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regarding the commencement or completion of scientific studies, clinical trials, the submission of regulatory filings, or commercialization objectives. From time to time, we may publicly announce
the expected timing of some of these milestones, such as the completion of an ongoing clinical trial, the initiation of other clinical programs, receipt of marketing approval, or a commercial launch of a product. The achievement of many of these
milestones may be outside of our control. All of these milestones are based on a variety of assumptions which may cause the timing of achievement of the milestones to vary considerably from our estimates, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our available capital resources or capital constraints we experience; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate of progress, costs and results of our clinical trials and research and development activities, including
the extent of scheduling conflicts with participating clinicians and collaborators, and our ability to identify and enroll patients who meet clinical trial eligibility criteria; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our receipt of approvals by the European Commission, FDA and other regulatory agencies and the timing thereof;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other actions, decisions or rules issued by regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to access sufficient, reliable and affordable supplies of compounds and raw materials used in the
manufacture of our drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efforts of our collaborators with respect to the commercialization of our products; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the securing of, costs related to, and timing issues associated with, product manufacturing as well as sales and
marketing activities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to achieve announced milestones in the timeframes we expect, the commercialization of
our drug candidates may be delayed, our business and results of operations may be harmed, and the trading price of the ADSs may decline as a result. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be a &#147;passive foreign investment company&#148; for U.S. federal income tax purposes, which could result in adverse U.S. federal income tax
consequences to U.S. investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, if, for any taxable year, at least 75% of our gross income is passive income
(&#147;income test&#148;), or at least 50% of the value of our assets (based on an average of the quarterly values of the assets during a taxable year) is attributable to assets that produce passive income or are held for the production of passive
income, including cash, we would be characterized as a passive foreign investment company (&#147;PFIC&#148;) for U.S. federal income tax purposes. For purposes of these tests, passive income includes, among other things, dividends, interest, and
gains from the sale or exchange of investment property and rents or royalties other than rents or royalties which are received from unrelated parties in connection with the active conduct of a trade or business. Cash and cash equivalents are
generally treated as passive assets. Goodwill is treated as an active asset to the extent associated with business activities that produce active income. For purposes of the PFIC rules, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation
that owns, directly or indirectly, at least 25% by value of the equity interests of another corporation or partnership is treated as if it held its proportionate share of the assets of the other corporation or partnership, and received directly its
proportionate share of the income of the other corporation or partnership. Equity interests of less than 25% by value in any other corporation or partnership are treated as passive assets, regardless of the nature of the other corporation or
partnership&#146;s business. If we are a PFIC for any taxable year in which a U.S. Holder (as defined in &#147;Material United States Federal Income and French Tax Considerations&#151;Material U.S. Federal Income Tax Considerations for U.S.
Holders&#148;) holds an ADS, certain adverse U.S. federal income tax consequences could apply to such U.S. Holder including increased tax liability on disposition gains and certain &#147;excess distributions&#148; and additional reporting
requirements. See &#147;Material United States Federal Income and French Tax Considerations&#151;Material U.S. Federal Income Tax Considerations for U.S. Holders&#151;Passive Foreign Investment Company Rules.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our analysis of our financial statements, activities and relevant market and shareholder data, we do not believe that we were a PFIC
for the taxable year ended December 31, 2022. Whether we are a PFIC for any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
taxable year will depend on the composition of our income and the composition, nature and value of our assets from time to time (including the value of our goodwill, which may be determined by
reference to the value of our ADSs, which could fluctuate considerably). We currently do not generate product revenues and therefore we may be a PFIC for any taxable year in which we do not generate sufficient amounts of non-passive income to offset
our passive financing income. As a result, there can be no assurance that we will not be treated as a PFIC for the current or any future taxable year and our U.S. counsel expresses no opinion with respect to our PFIC status for any prior, current or
future taxable year. Even if we determine that we are not a PFIC for a taxable year, there can be no assurance that the Internal Revenue Service, or the IRS, will agree with our conclusion and that the IRS would not successfully challenge our
position. Each U.S. holder is strongly urged to consult its tax advisor regarding these issues and any available elections to mitigate such tax consequences. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If a United States person is treated as owning at least 10% of the value or voting power of our ADSs, such holder may be subject to adverse U.S. federal
income tax consequences. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a United States person is treated as owning (directly, indirectly, or constructively) at least 10% of
the aggregate value or voting power of our ADSs, such person may be treated as a &#147;United States shareholder&#148; with respect to each &#147;controlled foreign corporation&#148; in our group (if any), which may subject such person to adverse
U.S. federal income tax consequences. Our group currently includes one U.S. subsidiary corporation and, therefore, under current law our current non-U.S. subsidiary and any future newly formed or acquired non-U.S. subsidiaries that are treated as
corporations for U.S. federal income tax purposes will be treated as controlled foreign corporations, regardless of whether we are treated as a controlled foreign corporation. A United States shareholder of a controlled foreign corporation generally
is required to report annually and include in its U.S. taxable income its pro rata share of &#147;Subpart F income,&#148; &#147;global intangible <FONT STYLE="white-space:nowrap">low-taxed</FONT> income,&#148; and investments in U.S. property by
controlled foreign corporations, regardless of whether we make any distributions. An individual that is a United States shareholder with respect to a controlled foreign corporation generally would not be allowed certain tax deductions or foreign tax
credits that would be available to a United States shareholder that is a U.S. corporation. Failure to comply with these reporting obligations may subject a United States shareholder to significant monetary penalties and may prevent the statute of
limitations with respect to such shareholder&#146;s U.S. federal income tax return for the year for which reporting was due from starting. We cannot provide any assurances that we will assist investors in determining whether we are treated as a
controlled foreign corporation or whether any holder of our ADSs is treated as a United States shareholder with respect to any such controlled foreign corporation or furnish to any United States shareholders information that may be necessary to
comply with the aforementioned reporting and tax paying obligations. The United States Internal Revenue Service provided limited guidance on situations in which investors may rely on publicly available information to comply with their reporting and
tax paying obligations with respect to foreign-controlled CFCs. Each U.S. holder of our ADSs should consult its advisors regarding the potential application of these rules to an investment in our ADSs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in the use of the net proceeds from the global offering and may use them in ways with which you do not agree and in ways that
may not increase the value of your investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the application of the net proceeds
that we receive from the global offering. We may spend or invest these proceeds in a way with which our shareholders and ADS holders disagree. The failure by our management to apply these funds effectively could harm our business and financial
condition. Pending their use, we may invest the net proceeds from the global offering in a manner that does not produce income or that loses value. These investments may not yield a favorable return to our investors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase ADSs in the offering, you will experience substantial and immediate dilution. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you purchase ADSs in the offering, you will experience substantial and immediate dilution of $8.66 per ADS in pro forma net tangible book
value as of June&nbsp;30, 2023, after giving effect to the global offering of approximately &#128;214.3&nbsp;million ($225.5&nbsp;million), based on an assumed initial offering price of &#128;12.72&nbsp;per ordinary share ($13.39 per ADS), which is
the last reported closing price of our ordinary shares on Euronext Paris on October 13, 2023. This dilution is due in large part to the fact that our earlier investors paid substantially less </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
than the offering price when they purchased their ordinary shares. You will experience additional dilution upon exercise of any outstanding warrants to purchase ordinary shares or if we otherwise
issue additional ordinary shares or ADSs below the offering price. For a further description of the dilution that you will experience immediately after the offering, see the section of this prospectus titled &#147;Dilution.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future, or the possibility of future sales, of a substantial number sales of our ordinary shares or ADSs by existing shareholders could depress the
market price of the ordinary shares. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future sales of a substantial number of our ADSs, or the perception that such sales will
occur, could cause a decline in the market price of our ADSs. Based upon the number of shares outstanding as of June&nbsp;30, 2023, after giving effect to the closing of the offering, we will have 61,223,068 ordinary shares outstanding (including
ordinary shares in the form of ADSs), assuming the underwriters do not exercise their option to purchase 2,801,325 additional ADSs. ADSs issued and sold in the U.S. offering may be resold in the public market immediately without restriction, unless
purchased by our affiliates. A significant portion of these ADSs will be subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described in &#147;Ordinary Shares and ADSs Eligible for Future Sale&#148; and
&#147;Underwriters.&#148; If, after the end of such <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, these shareholders or ADS holders sell substantial amounts of ADSs in the public market, or the market perceives that such sales may
occur, the market price of our ADSs and our ability to raise capital through an issuance of equity securities in the future could be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The rights of shareholders in companies subject to French corporate law differ in material respects from the rights of shareholders of corporations
incorporated in the United States. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a French company with limited liability. Our corporate affairs are governed by our <FONT
STYLE="white-space:nowrap">by-laws</FONT> and by the laws governing companies incorporated in France. The rights of shareholders and the responsibilities of members of our Board are in many ways different from the rights and obligations of
shareholders in companies governed by the laws of U.S. jurisdictions. For example, in the performance of its duties, our Board is required by French law to consider the interests of our company, its shareholders, its employees and other
stakeholders, rather than solely our shareholders and/or creditors. It is possible that some of these parties will have interests that are different from, or in addition to, your interests as a shareholder or holder of ADSs. See the sections of this
prospectus titled &#147;Management&#151;Board Practices&#151;Corporate Governance Practices&#148; and &#147;Description of Share Capital.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. investors may have difficulty enforcing civil liabilities against our company and directors and senior management and the experts named in this
prospectus. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain members of our Board and senior management and certain experts named in this prospectus are <FONT
STYLE="white-space:nowrap">non-residents</FONT> of the United States, and all or a substantial portion of our assets and the assets of such persons are located outside the United States. As a result, it may not be possible to serve process on such
persons or us in the United States or to enforce judgments obtained in U.S. courts against them or us based on civil liability provisions of the securities laws of the United States. Additionally, it may be difficult to assert U.S. securities law
claims in actions originally instituted outside of the United States. Courts outside the United States may refuse to hear a U.S. securities law claim because <FONT STYLE="white-space:nowrap">non-U.S.</FONT> courts may not be the most appropriate
forums in which to bring such a claim. Even if a court outside the United States agrees to hear a claim, it may determine that the law of the jurisdiction in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> court resides, and not U.S. law,
is applicable to the claim. Further, if U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process, and certain matters of procedure would still be governed by
the law of the jurisdiction in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> court resides. In particular, there is some doubt as to whether French courts would recognize and enforce certain civil liabilities under U.S. securities laws
in original actions or judgments of U.S. courts based upon these civil liability provisions. In addition, awards of punitive damages in actions brought in the United States or elsewhere may be unenforceable in France. An award for monetary damages
under the U.S. securities laws would be considered punitive if it does not seek to compensate the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
claimant for loss or damage suffered but is intended to punish the defendant. French law provides that a shareholder, or a group of shareholders, may initiate a legal action to seek
indemnification from the directors of a corporation in the corporation&#146;s interest if it fails to bring such legal action itself. If so, any damages awarded by the court are paid to the corporation and any legal fees relating to such action may
be borne by the relevant shareholder or the group of shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The enforceability of any judgment in France will depend on the
particular facts of the case as well as the laws and treaties in effect at the time. The United States and France do not currently have a treaty providing for recognition and enforcement of judgments, other than arbitration awards, in civil and
commercial matters. See &#147;Enforcement of Civil Liabilities.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may face difficulties protecting your interests, and your ability to
protect your rights through the U.S.&nbsp;federal courts may be limited because we are incorporated under the laws of France, all of our assets are in the European Union and a majority of our directors and executive officers reside outside the
United&nbsp;States. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are constituted under the laws of France. A majority of our officers and directors reside outside the
United&nbsp;States. In addition, a substantial portion of their assets and our assets are located outside of the United&nbsp;States. As a result, you may have difficulty serving legal process within the United&nbsp;States upon us or any of these
persons. You may also have difficulty enforcing, both in and outside of the United&nbsp;States, judgments you may obtain in U.S.&nbsp;courts against us or these persons in any action, including actions based upon the civil liability provisions of
U.S.&nbsp;Federal or state securities laws. Furthermore, there is substantial doubt as to the enforceability in France against us or against any of our directors, officers and the expert named in this prospectus who are not residents of the
United&nbsp;States, in original actions or in actions for enforcement of judgments of U.S.&nbsp;courts, of liabilities based solely upon the civil liability provisions of the U.S.&nbsp;federal securities laws. In addition, shareholders in French
corporations may not have standing to initiate a shareholder derivative action in U.S.&nbsp;federal courts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, our public
shareholders may have more difficulty in protecting their interests through actions against us, our management, our directors or our major shareholders than would shareholders of a corporation incorporated in a jurisdiction in the
United&nbsp;States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The dual listing of our ordinary shares and the ADSs may adversely affect the liquidity and value of the ADSs. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following this global offering and after the ADSs begin trading on the Nasdaq Global Market, our ordinary shares will continue to be listed on
Euronext Paris. Trading of the ADSs or ordinary shares in these markets will take place in different currencies (U.S. dollars on Nasdaq and euros on Euronext Paris), and at different times (resulting from different time zones, different trading days
and different public holidays in the United States and France). The trading prices of our ordinary shares on these two markets may differ due to these and other factors. Any decrease in the price of our ordinary shares on Euronext Paris could cause
a decrease in the trading price of the ADSs on Nasdaq. Investors could seek to sell or buy our ordinary shares to take advantage of any price differences between the markets through a practice referred to as arbitrage. Any arbitrage activity could
create unexpected volatility in both our share prices on one exchange, and the ordinary shares available for trading on the other exchange. In addition, holders of ADSs will not be immediately able to surrender their ADSs and withdraw the underlying
ordinary shares for trading on the other market without effecting necessary procedures with the depositary. This could result in time delays and additional cost for holders of ADSs. We cannot predict the effect of this dual listing on the value of
our ordinary shares and the ADSs. However, the dual listing of our ordinary shares and the ADSs may reduce the liquidity of these securities in one or both markets and may adversely affect the development of an active trading market for the ADSs in
the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our <FONT STYLE="white-space:nowrap">by-laws</FONT> and French corporate law contain provisions that may delay or discourage a
takeover attempt. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions contained in our <FONT STYLE="white-space:nowrap">by-laws</FONT> and French corporate law could make
it more difficult for a third party to acquire us, even if doing so might be beneficial to our shareholders. In addition, provisions of our <FONT STYLE="white-space:nowrap">by-laws</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
impose various procedural and other requirements, which could make it more difficult for shareholders to effect certain corporate actions. These provisions include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, the owner of 90% of the share capital or voting rights of a public company listed on a
regulated market in a Member State of the European Union or in a state party to the EEA Agreement, including from the main French stock exchange, has the right to force out minority shareholders following a tender offer made to all shareholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, a <FONT STYLE="white-space:nowrap">non-resident</FONT> of France as well as any French entity
controlled by <FONT STYLE="white-space:nowrap">non-residents</FONT> of France may have to file a declaration for statistical purposes with the Bank of France (<I>Banque de France</I>) within 20 working days following the date of certain direct
foreign investments in us, including any purchase of our ADSs. In particular, such filings are required in connection with investments exceeding &#128;15&nbsp;million that lead to the acquisition of at least 10% of our share capital or voting rights
or cross such 10% threshold. See &#147;Limitations Affecting Shareholders of a French Company&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, certain foreign investments in companies incorporated under French laws are subject to the
prior authorization from the French Minister of the Economy, where all or part of the target&#146;s business and activity relate to a strategic sector, such as energy, transportation, public health, telecommunications, research and development in
biotechnologies, activities relating to public health, etc.; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a merger (i.e.,&nbsp;in a French law context, a share for share exchange following which our company would be
dissolved into the acquiring entity and our shareholders would become shareholders of the acquiring entity) of our company into a company incorporated in the European Union would require the approval of our Board as well as a <FONT
STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes held by the shareholders present, represented by proxy or voting by mail at the relevant meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a merger of our company into a company incorporated outside of the European Union would require 100% of our
shareholders to approve it; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, a cash merger is treated as a share purchase and would require the consent of each
participating shareholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our shareholders have granted and may grant in the future our Board broad authorizations to increase our share
capital or to issue additional ordinary shares or other securities, such as warrants, to our shareholders, the public or qualified investors, including as a possible defense following the launching of a tender offer for our shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our shareholders have preferential subscription rights on a <I>pro rata</I> basis on the issuance by us of any
additional securities for cash or a <FONT STYLE="white-space:nowrap">set-off</FONT> of cash debts, which rights may only be waived by the extraordinary general meeting by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority vote of our
shareholders or on an individual basis by each shareholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Board has the right to appoint directors to fill a vacancy created by the resignation or death of a director,
subject to the approval by the shareholders of such appointment at the next shareholders&#146; meeting, which prevents shareholders from having the sole right to fill vacancies on our Board; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Board can be convened by our chairman, including upon request from our Chief Executive Officer (<I>directeur
g&eacute;n&eacute;ral</I>), if the positions of Chief Executive Officer and Chairman of the Board are not held by the same person, or, when no board meeting has been held for more than two consecutive months, from directors representing at least <FONT
STYLE="white-space:nowrap">one-third</FONT> of the total number of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Board meetings can only be regularly held if at least half of the directors attend either physically or by
way of videoconference or teleconference enabling the directors&#146; identification and ensuring their effective participation in the Board&#146;s decisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our shares are registered or bearer, if the legislation so permits, according to the shareholder&#146;s choice;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval of at least a majority of the votes held by shareholders present, represented by a proxy, or voting by
mail at the relevant ordinary shareholders&#146; general meeting is required to remove directors with or without cause; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance notice is required for nominations to the Board or for proposing matters to be acted upon at a
shareholders&#146; meeting, except that a vote to remove and replace a director can be proposed at any shareholders&#146; meeting without notice; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our <FONT STYLE="white-space:nowrap">by-laws</FONT> can be changed in accordance with applicable French laws and
regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the crossing of certain thresholds must be disclosed and can impose certain obligations (including filing a
mandatory public tender offer). See &#147;Description of Share Capital&#151;Disclosure Requirements for Holdings Exceeding Certain Thresholds&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers of shares shall comply with applicable insider trading rules and regulations and, in particular, with
the EU Market Abuse Directive and Regulation dated April&nbsp;16, 2014; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pursuant to French law, the sections of our <FONT STYLE="white-space:nowrap">by-laws</FONT> relating to the
number of directors and election and removal of a director from office, may only be modified by a resolution adopted by <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes of our shareholders present, represented by a proxy or voting by
mail at the meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Existing and potential investors in our ordinary shares or ADSs may have to request the prior authorization
from the French Ministry of Economy prior to acquiring a significant ownership position in our ordinary shares or ADSs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under
French law, direct and indirect acquisition of control of all or part of a branch of activity, and investments of more than 25% by foreign individuals or entities (except, in the last case, EU/EEA investors) in a French company deemed to be a
strategic industry is subject to prior authorization of the French Ministry of Economy pursuant to Articles L. <FONT STYLE="white-space:nowrap">151-1</FONT> et seq. and R. <FONT STYLE="white-space:nowrap">151-1</FONT> et seq. of the French Monetary
and Financial Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an investment requiring the prior authorization of the French Minister of Economy is completed without such
authorization having been granted, the French Minister of Economy might direct the relevant investor to (i)&nbsp;submit a request for authorization, (ii)&nbsp;have the previous situation restored at its own expense or (iii)&nbsp;amend the
investment. The relevant investor might also be found criminally liable and might be sanctioned with a fine which cannot exceed the greater of: (i)&nbsp;twice the amount of the relevant investment, (ii) 10% of the annual turnover before tax of the
target company and (iii) &#128;5&nbsp;million (for an entity) or &#128;1&nbsp;million (for an individual). The French Minister of Economy may also adopt precautionary measures it deems necessary to protect strategic sovereign assets , including the
suspension of voting rights or the prohibition or limitation of the distribution of dividends and remuneration attached to shares whose ownership by the investor should have been subject to prior authorization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the context of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the Decree (<I>d&eacute;cret</I>) No.&nbsp;2020-892 dated
July&nbsp;22, 2020, as amended by the Decree (<I>d&eacute;cret</I>) No.&nbsp;2020-1729 dated December&nbsp;28, 2020, on December&nbsp;22, 2021 by the Decree (d&eacute;cret) n&deg; 2021-1758 and lastly on December&nbsp;23, 2022 by the Decree
(<I>d&#233;cret</I>) n&deg; 2022-1622, has implemented a 10% threshold of the voting rights for the non-EU/EEA investments made (i)&nbsp;in an entity incorporated under the laws of France and (ii)&nbsp;whose shares are admitted to trading on a
regulated market, in addition to the 25% above-mentioned threshold. Set to expire on December 31, 2023, this 10% threshold could become permanent. The transactions falling within the scope of the Decree (<I>d&eacute;cret</I>) <FONT
STYLE="white-space:nowrap">No.&nbsp;2020-892,</FONT> as amended, benefit from a &#147;fast-track procedure&#148; pursuant to which the investor is exempt from the authorization request provided for in Article R.
<FONT STYLE="white-space:nowrap">151-5</FONT> of the Monetary and Financial Code, provided that the investment project has been the subject of prior notification to the French Minister of Economy and that the transaction is carried out within six
months following the notification. Unless the French Minister of Economy objects, the authorization is granted at the end of a period of ten working days following notification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with such measures could result in significant consequences in the concerned investment. Such measures could also delay or
discourage a takeover or more broadly a foreign investment attempt, and we cannot predict whether these measures will result in a lower or more volatile market price of our ADSs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more details on the French foreign investment control regime see &#147;Limitations
Affecting Shareholders of a French Company.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may not be able to exercise your right to vote the ordinary shares underlying your ADSs.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of ADSs may exercise voting rights with respect to the ordinary shares represented by the ADSs only in accordance with the
provisions of the deposit agreement. The deposit agreement provides that, upon receipt of notice of any meeting of holders of our ordinary shares, the depositary will fix a record date for the determination of ADS holders who shall be entitled to
give instructions for the exercise of voting rights. Upon timely receipt of notice from us, if we so request, the depositary shall distribute to the holders as of the record date (i)&nbsp;the notice of the meeting or solicitation of consent or proxy
sent by us and (ii)&nbsp;a statement as to the manner in which instructions may be given by the holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchasers of ADSs may instruct
the depositary of their ADSs to vote the ordinary shares underlying their ADSs. Otherwise, purchasers of ADSs will not be able to exercise voting rights unless they withdraw the ordinary shares underlying the ADSs they hold. However, a holder of
ADSs may not know about the meeting far enough in advance to withdraw those ordinary shares. If we ask for a holder of ADSs&#146; instructions, the depositary, upon timely notice from us, will notify him or her of the upcoming vote and arrange to
deliver our voting materials to him or her. We cannot guarantee to any holder of ADSs that he or she will receive the voting materials in time to ensure that he or she can instruct the depositary to vote his or her ordinary shares or to withdraw his
or her ordinary shares so that he or she can vote them. If the depositary does not receive timely voting instructions from a holder of ADSs, it may give a proxy to a person designated by us to vote the ordinary shares underlying his or her ADSs. In
addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. This means that a holder of ADSs may not be able to exercise his or her right to vote,
and there may be nothing he or she can do if the ordinary shares underlying his or her ADSs are not voted as he or she requested. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Purchasers of
ADSs are not holders of our ordinary shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of ADSs will not be treated as one of our shareholders and will not have
direct shareholder rights. French law governs our shareholder rights. The depositary will be the holder of the ordinary shares underlying ADSs held by purchasers of ADSs. Purchasers of ADSs will have ADS holder rights. The deposit agreement among
us, the depositary and purchasers of ADSs, as ADS holders, and all other persons directly and indirectly holding ADSs, sets out ADS holder rights, as well as the rights and obligations of the depositary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A double voting right is attached to each registered ordinary share (except treasury shares) that is held in the name of the same shareholder
for at least two years. However, the ordinary shares underlying our ADSs will not be entitled to double voting rights as the depositary will hold the ordinary shares underlying our ADSs in bearer form. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The right as a holder of ADSs to participate in any future preferential subscription rights or to elect to receive dividends in shares may be limited,
which may cause dilution to the holdings of purchasers of ADSs in the ADS offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to French law, if we issue
additional securities for cash, current shareholders will have preferential subscription rights for these securities on a <I>pro rata</I> basis unless they waive those rights at an extraordinary meeting of our shareholders by a <FONT
STYLE="white-space:nowrap">two-thirds</FONT> majority vote or individually by each shareholder. However, ADS holders will not be entitled to exercise or sell such rights unless we register the rights and the securities to which the rights relate
under the Securities Act or an exemption from the registration requirements is available. In addition, the deposit agreement provides that the depositary will not make rights available to purchasers of ADSs unless the distribution to ADS holders of
both the rights and any related securities are either registered under the Securities Act or exempted from registration under the Securities Act. Further, if we offer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
holders of our ordinary shares the option to receive dividends in either cash or shares, under the deposit agreement the depositary may require satisfactory assurances from us that extending the
offer to holders of ADSs does not require registration of any securities under the Securities Act before making the option available to holders of ADSs. We are under no obligation to file&nbsp;a registration statement with respect to any such rights
or securities or to endeavor to cause such a registration statement to be declared effective. Moreover, we may not be able to establish an exemption from registration under the Securities Act. Accordingly, ADS holders may be unable to participate in
our rights offerings or to elect to receive dividends in shares and may experience dilution in their holdings. In addition, if the depositary is unable to sell rights that are not exercised or not distributed or if the sale is not lawful or
reasonably practicable, it will allow the rights to lapse, in which case you will receive no value for these rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Purchasers of ADSs may be
subject to limitations on the withdrawal of the underlying ordinary shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Temporary delays in the cancellation of ADSs and
withdrawal of the underlying ordinary shares may arise because the depositary has closed its transfer books or we have closed our transfer books, the transfer of ordinary shares is blocked to permit voting at a shareholders&#146; meeting or we are
paying a dividend on our ordinary shares. In addition, a holder of ADSs may not be able to cancel his or her ADSs and withdraw the underlying ordinary shares when he or she owes money for fees, taxes and similar charges and when it is necessary to
prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities. See the section of this prospectus titled &#147;Description of American
Depositary Shares.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ADSs holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could
result in less favorable outcomes to the plaintiffs in any such action. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The deposit agreement governing the ADSs representing our
ordinary shares provides that, to the fullest extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our shares, the ADSs or the deposit agreement,
including any claim under the U.S. federal securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or the depositary opposed a jury trial demand based on the waiver, the
court would determine whether the waiver was enforceable based on the facts and circumstances of that case in accordance with the applicable state and federal law. To our knowledge, the enforceability of a contractual
<FONT STYLE="white-space:nowrap">pre-dispute</FONT> jury trial waiver in connection with claims arising under the federal securities laws has not been finally adjudicated by the United States Supreme Court. However, we believe that a contractual <FONT
STYLE="white-space:nowrap">pre-dispute</FONT> jury trial waiver provision is generally enforceable, including under the laws of the State of New York, which govern the deposit agreement, by a federal or state court in the City of New York, which has
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> jurisdiction over matters arising under the deposit agreement. In determining whether to enforce a contractual <FONT STYLE="white-space:nowrap">pre-dispute</FONT> jury trial waiver provision,
courts will generally consider whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. We believe that this is the case with respect to the deposit agreement and the ADSs. It is advisable that you consult legal
counsel regarding the jury waiver provision before entering into the deposit agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you or any other holders or beneficial owners
of ADSs bring a claim against us or the depositary in connection with matters arising under the deposit agreement or the ADSs, including claims under federal securities laws, you or such other holder or beneficial owner may not be entitled to a jury
trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us and the depositary. If a lawsuit is brought against either or both of us and the depositary under the deposit agreement, it may be heard
only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have, including results that could be less favorable to the
plaintiffs in any such action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nevertheless, if this jury trial waiver provision is not permitted by applicable law, an action could
proceed under the terms of the deposit agreement with a jury trial. No condition, stipulation or provision of the deposit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with U.S. federal securities laws and the rules and regulations promulgated
thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As a foreign private issuer, we are exempt from a number of rules under the U.S. securities laws and are permitted to file less
information with the SEC than a U.S. company. This may limit the information available to holders of ADSs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a foreign
private issuer, as defined in the SEC&#146;s rules and regulations and, consequently, we are not subject to all of the disclosure requirements applicable to public companies organized within the United States. For example, we are exempt from certain
rules under the Exchange Act that regulate disclosure obligations and procedural requirements related to the solicitation of proxies, consents or authorizations applicable to a security registered under the Exchange Act, including the U.S. proxy
rules under Section&nbsp;14 of the Exchange Act. In addition, our officers and directors are exempt from the reporting and &#147;short-swing&#148; profit recovery provisions of Section&nbsp;16 of the Exchange Act and related rules with respect to
their purchases and sales of our securities. Moreover, while we currently make annual and semi-annual filings with respect to our listing on Euronext Paris and expect to file financial reports on an annual and semi-annual basis, we will not be
required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. public companies and will not be required to file quarterly reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> or current
reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> under the Exchange Act. Accordingly, there will be less publicly available information concerning our company than there would be if we were not a foreign private issuer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As a foreign private issuer, we are permitted, and we expect, to follow certain home country practices in relation to corporate governance matters that
differ significantly from Nasdaq&#146;s corporate governance standards. These practices may afford less protection to shareholders than they would enjoy if we complied fully with the corporate governance standards of the Nasdaq Global Market.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a foreign private issuer listed on the Nasdaq Global Market, we will be subject to Nasdaq&#146;s corporate governance
standards. However, Nasdaq rules provide that foreign private issuers are permitted to follow home country corporate governance practices in lieu of Nasdaq&#146;s corporate governance standards as long as notification is provided to Nasdaq of the
intention to take advantage of such exemptions. We intend to rely on exemptions for foreign private issuers and follow French corporate governance practices in lieu of Nasdaq&#146;s corporate governance standards, to the extent possible. Certain
corporate governance practices in France, which is our home country, may differ significantly from Nasdaq corporate governance standards. For example, as a French company, neither the corporate laws of France nor our
<FONT STYLE="white-space:nowrap">by-laws</FONT> require a majority of our directors to be independent and we can include <FONT STYLE="white-space:nowrap">non-independent</FONT> directors as members of our remuneration committee, and our independent
directors are not required to hold regularly scheduled meetings at which only independent directors are present. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also exempt from
provisions set forth in Nasdaq rules which require an issuer to provide in its <FONT STYLE="white-space:nowrap">by-laws</FONT> for a generally applicable quorum, and that such quorum may not be less than
<FONT STYLE="white-space:nowrap">one-third</FONT> of the outstanding voting stock. Consistent with French law, our <FONT STYLE="white-space:nowrap">by-laws</FONT> provide that a quorum requires the presence of shareholders having at least
(i)&nbsp;20% of the shares entitled to vote in the case of an ordinary shareholders&#146; general meeting or at an extraordinary shareholders&#146; general meeting where shareholders are voting on a capital increase by capitalization of reserves,
profits or share premium, or (ii)&nbsp;25% of the shares entitled to vote in the case of any other extraordinary shareholders&#146; general meeting. If a quorum is not present, the meeting is adjourned. There is no quorum requirement when an
ordinary general meeting is reconvened, but the reconvened meeting may consider only questions which were on the agenda of the adjourned meeting. When an extraordinary general meeting is reconvened, the quorum required is 20% of the shares entitled
to vote, except where the reconvened meeting is considering capital increases through capitalization of reserves, profits or share premium. For these matters, no quorum is required at the reconvened meeting. If a quorum is not present at a
reconvened meeting requiring a quorum, then the meeting may be adjourned for a maximum of two months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a foreign private issuer, we are
required to comply with <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3</FONT> of the Exchange Act, relating to audit committee composition and responsibilities. Under French law, the audit committee may only have an
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
advisory role and appointment of our statutory auditors, in particular, must be decided by the shareholders at our annual meeting. Therefore, our shareholders may be afforded less protection than
they otherwise would have under Nasdaq&#146;s corporate governance standards applicable to U.S. domestic issuers. For an overview of our corporate governance practices, see &#147;Management&#151;Board Practices&#151;Corporate Governance
Practices.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company&#148; under the JOBS Act and will be able to avail ourselves of reduced disclosure
requirements applicable to emerging growth companies, which could make our ADSs less attractive to investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an
&#147;emerging growth company,&#148; as defined in the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &#147;emerging growth
companies&#148;, including not being required to comply with the auditor attestation requirements of Section&nbsp;404(b) of the Sarbanes-Oxley Act of 2002 (&#147;Sarbanes-Oxley Act&#148;), and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. In addition, Section&nbsp;107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended
transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. We will not take advantage of the extended transition period provided under Section&nbsp;7(a)(2)(B) of the
Securities Act for complying with new or revised accounting standards. Since IFRS makes no distinction between public and private companies for purposes of compliance with new or revised accounting standards, the requirements for our compliance as a
private company and as a public company are the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict if investors will find our ADSs less attractive because we may
rely on these exemptions. If some investors find our ADSs less attractive as a result, there may be a less active trading market for our ADSs and the price of our ADSs may be more volatile. We may take advantage of these reporting exemptions until
we are no longer an emerging growth company. We will remain an emerging growth company until the earliest of (1)&nbsp;the last day of the fiscal year in which we have total annual gross revenue of $1.235&nbsp;billion or more; (2)&nbsp;the last day
of our fiscal year following the fifth anniversary of the date of the completion of the offering; (3)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt during the previous three years; and (4)&nbsp;the date on
which we are deemed to be a large accelerated filer under the rules of the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may lose our foreign private issuer status in the future, which
could result in significant additional cost and expense. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we currently qualify as a foreign private issuer, the determination
of foreign private issuer status is made annually on the last business day of an issuer&#146;s most recently completed second fiscal quarter and, accordingly, the next determination will be made with respect to us on June&nbsp;30, 2024. In the
future, we could lose our foreign private issuer status if we fail to meet the requirements necessary to maintain our foreign private issuer status as of the relevant determination date. We will remain a foreign private issuer until such time that
more than 50% of our outstanding voting securities are held by U.S. residents and any of the following three circumstances applies: (i)&nbsp;the majority of our executive officers or directors are U.S. citizens or residents; (ii)&nbsp;more than 50%
of our assets are located in the United States; or (iii)&nbsp;our business is administered principally in the United States. For additional information relating to our principal shareholders, see &#147;Principal Shareholders.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly more than costs we incur
as a foreign private issuer. If we are not a foreign private issuer, we will be required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are more detailed and extensive in certain respects than
the forms available to a foreign private issuer. We would be required under current SEC rules to prepare our financial statements in accordance with U.S.&nbsp;GAAP, rather than IFRS, and modify certain of our policies to comply with corporate
governance practices associated with U.S. domestic issuers. Such conversion of our financial statements to U.S.&nbsp;GAAP would involve significant time </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and cost. In addition, we may lose our ability to rely upon exemptions from certain corporate governance requirements on U.S. stock exchanges that are available to foreign private issuers such as
the ones described herein and exemptions from procedural requirements related to the solicitation of proxies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through
acquisitions <FONT STYLE="white-space:nowrap">and&nbsp;in-licenses.</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The growth of our business may depend in part on our
ability to <FONT STYLE="white-space:nowrap">acquire,&nbsp;in-license&nbsp;or</FONT> use third-party proprietary rights. For example, our drug candidates may require specific formulations to work effectively and efficiently, we may develop drug
candidates containing our compounds <FONT STYLE="white-space:nowrap">and&nbsp;pre-existing&nbsp;pharmaceutical</FONT> compounds, or we may be required by the FDA or comparable foreign regulatory authorities to provide a companion diagnostic test or
tests with our drug candidates, any of which could require us to obtain rights to use intellectual property held by third parties. In addition, with respect to any patents we <FONT STYLE="white-space:nowrap">may&nbsp;co-own&nbsp;with</FONT> third
parties, we may require licenses to <FONT STYLE="white-space:nowrap">such&nbsp;co-owner&#146;s&nbsp;interest</FONT> to such patents. We may be unable to acquire <FONT STYLE="white-space:nowrap">or&nbsp;in-license&nbsp;any</FONT> compositions,
methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary or important to our business operations. In addition, we may fail to obtain any of these licenses at a reasonable cost or on
reasonable terms, if at all. Were that to happen, we may need to cease use of the compositions or methods covered by those third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on those
intellectual property rights, which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may
<FONT STYLE="white-space:nowrap">be&nbsp;non-exclusive,&nbsp;which</FONT> means that our competitors may also receive access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to
develop or license replacement technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we sometimes collaborate with academic institutions to accelerate our
preclinical research or development under written agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#146;s rights in technology resulting from the
collaboration. Even if we hold such an option, we may be unable to negotiate a license from the institution within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the
intellectual property rights to others, potentially blocking our ability to pursue our program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The licensing and acquisition of
third-party intellectual property rights is a competitive area, and companies that may be more established or have greater resources than we do may also be pursuing strategies to license or acquire third-party intellectual property rights that we
may consider necessary or attractive in order to commercialize our drug candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization
capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. There can be no assurance that we will be able to successfully complete these types of negotiations and ultimately acquire
the rights to the intellectual property surrounding the additional drug candidates that we may seek to develop or market. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing
intellectual property rights we have, we may have to abandon development of certain programs and our business financial condition, results of operations and prospects could suffer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price of our equity securities may be volatile, and purchasers of our ADSs could incur substantial losses. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price for our ADSs may be volatile. The stock market in general and the market for biopharmaceutical companies in particular have
experienced extreme volatility that has often been unrelated to the operating performance of particular companies. In particular, our share price in Paris has fluctuated from a <FONT STYLE="white-space:nowrap">52-week</FONT> high of &#128;19.70 to a
low of &#128;5.60 as of October 13, 2023. As a result of this volatility, investors may not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be able to sell their ADSs at or above the price originally paid for the security. The market price for our ADSs and ordinary shares may be influenced by many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated fluctuations in our financial condition and operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated changes in our growth rate relative to our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competition from existing products or new products that may emerge; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures,
collaborations, or capital commitments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to meet or exceed financial estimates and projections of the investment community or that we provide to
the public; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issuance of new or updated research or reports by securities analysts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fluctuations in the valuation of companies perceived by investors to be comparable to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions or departures of key management or scientific personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lawsuits threatened or filed against us, disputes or other developments related to proprietary rights, including
patents, litigation matters, and our ability to obtain patent protection for our technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to coverage policies or reimbursement levels by commercial third-party payors and government payors and
any announcements relating to coverage policies or reimbursement levels; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcement or expectation of additional debt or equity financing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of our ordinary shares or ADSs by us, our insiders or our other shareholders; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic and market conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These and other market and industry factors may cause the market price and demand for our ADSs to fluctuate substantially, regardless of our
actual operating performance, which may limit or prevent investors from readily selling their ADSs and may otherwise negatively affect the liquidity of the trading market for our ADSs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the price of our ADSs and
their trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our ADSs depends in part on the research and reports that securities or
industry analysts publish about us or our business. If no or few securities or industry analysts cover our company, the trading price for our ADSs would be negatively impacted. If one or more of the analysts who covers us downgrades our equity
securities or publishes incorrect or unfavorable research about our business, the price of our ADSs would likely decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, or downgrades our
securities, demand for our ADSs could decrease, which could cause the price of our ADSs or their trading volume to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The requirements of
being a U.S. public company may strain our resources and divert management&#146;s attention. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to comply with
various corporate governance and financial reporting requirements under the Sarbanes-Oxley Act, the Exchange Act, and the rules and regulations adopted by the SEC and the Public Company Accounting Oversight Board. Further, compliance with various
regulatory reporting requires significant commitments of time from our management and our directors, which reduces the time available for the performance of their other responsibilities. Our failure to track and comply with the various rules may
materially adversely affect our reputation, ability to obtain the necessary certifications to financial statements, lead to additional regulatory enforcement actions, and could adversely affect the value of our ordinary shares or ADSs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>After the completion of the offering, we may be at an increased risk of securities class action
litigation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, securities class action litigation has often been brought against a company following a decline in the
market price of its securities. This risk is especially relevant for us because biotechnology and biopharmaceutical companies have experienced significant share price volatility in recent years. If we were to be sued, it could result in substantial
costs, which could be insufficiently covered by insurance, and a diversion of management&#146;s attention and resources, which could harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not currently intend to pay dividends on our securities and, consequently, your ability to achieve a return on your investment will depend on
appreciation in the price of the ordinary shares and our ADSs. In addition, French law may limit the amount of dividends we are able to distribute. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our ordinary shares and do not currently intend to do so for the foreseeable future. We
currently intend to invest our future earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on your ADSs for the foreseeable future and the success of an investment in ADSs will depend upon any future
appreciation in its value. Consequently, investors may need to sell all or part of their holdings of ADSs after price appreciation, which may never occur, as the only way to realize any future gains on their investment. There is no guarantee that
the ADSs will appreciate in value or even maintain the price at which our shareholders have purchased them. Investors seeking cash dividends should not purchase our ADSs. Furthermore, certain of our debt instruments restrict the payment of dividends
or require consent to pay dividends. See &#147;Dividend Policy.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, under French law, the determination of whether we have
been sufficiently profitable to pay dividends is made on the basis of our statutory financial statements prepared and presented in accordance with accounting standards applicable in France. In addition, payment of dividends may subject us to
additional taxes under French law. Therefore, we may be more restricted in our ability to declare dividends than companies not based in France. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, exchange rate fluctuations may affect the amount of euros that we are able to distribute, and the amount in U.S. dollars that our
shareholders receive upon the payment of cash dividends or other distributions we declare and pay in euros, if any. These factors could harm the value of our ADSs, and, in turn, the U.S. dollar proceeds that holders receive from the sale of our
ADSs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_6"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements that involve substantial risks and uncertainties. The forward-looking statements are
contained principally in the sections titled &#147;Prospectus Summary&#148; &#147;Risk Factors&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and &#147;Business&#148; but are also
contained elsewhere in this prospectus. In some cases, you can identify forward-looking statements by the words &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148;
&#147;future,&#148; &#147;goals,&#148; &#147;intend,&#148; &#147;likely,&#148; &#147;may,&#148; &#147;might,&#148; &#147;ongoing,&#148; &#147;objective,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148;
&#147;seek,&#148; &#147;should,&#148; &#147;strategy,&#148; &#147;will&#148; and &#147;would&#148; or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and
unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we
believe that we have a reasonable basis for each forward-looking statement contained in this prospectus, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future,
about which we cannot be certain. Forward-looking statements include but are not limited to statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prospects of attaining, maintaining and expanding marketing authorization for our drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential attributes and clinical advantages of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress and results of our preclinical and clinical trials (and those conducted by third
parties) and other research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of the availability of data from our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of and our ability to advance drug candidates through clinical development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing or likelihood of regulatory meetings and filings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of and our ability to obtain and maintain regulatory approvals for any of our drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify and develop new drug candidates from our preclinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop sales and marketing capabilities and transition into a commercial-stage company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects of increased competition as well as innovations by new and existing competitors in our industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enter into strategic relationships or partnerships; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain, maintain, protect and enforce our intellectual property rights and propriety technologies
and to operate our business without infringing the intellectual property rights and proprietary technology of third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the use of proceeds from the global offering and our existing cash and cash
requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding expenses, future revenues, capital requirements and the need for additional financing,
including the period of time over which we expect the net proceeds of the global offering together with cash and cash equivalents will be sufficient to fund our operations and capital requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of government laws and regulations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitive position. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should refer to the &#147;Risk Factors&#148; section of this prospectus for a discussion of important factors that may cause our actual
results to differ materially from those expressed or implied by our forward-looking </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statements. The Private Securities Litigation Reform Act of 1995 and Section&nbsp;27A of the Securities Act, do not protect any forward-looking statements that we make in connection with the
global offering. The forward-looking statements and opinions contained in this prospectus are based upon information available to us as of the date of this prospectus and, while we believe such information forms a reasonable basis for such
statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. In addition, statements
that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. As a result of these factors, we cannot assure you that the forward-looking statements in this prospectus will prove to be accurate.
Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or
warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. We undertake no
obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required <FONT STYLE="white-space:nowrap">by-law.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus also contains certain data and information that we obtained from various government and private publications. Statistical data
in these publications also include projections based on a number of assumptions. Our industry may not grow at the rate projected by market data or at all. Failure of this market to grow at the projected rate may have a material and adverse effect on
our business and the market price of our ordinary shares (including ordinary shares in the form of ADSs). Furthermore, if any one or more of the assumptions underlying the market data are later found to be incorrect, actual results may differ from
the projections based on these assumptions. You should not place undue reliance on this data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, statements that &#147;we
believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable
basis for such statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements
are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that we will receive net proceeds from the global offering of approximately &#128;214.3 million ($225.5 million), based on an
assumed initial offering price of &#128;12.72&nbsp;per ordinary share ($13.39 per ADS), which is the last reported closing price of our ordinary shares on Euronext Paris on October 13, 2023, after deducting the estimated underwriting commissions and
estimated offering expenses payable by us, and assuming no exercise of the underwriters&#146; option to purchase additional ordinary shares (which may be in the form of ADSs). If the underwriters exercise in full their option to purchase additional
ordinary shares (which may be in the form of ADSs) in the global offering, we estimate that we will receive net proceeds from the offering of approximately &#128;247.5 million ($260.4 million), based on an assumed initial offering price of
&#128;12.72 per ordinary share ($13.39 per ADS), which is the last reported closing price of our ordinary shares on Euronext Paris on October 13, 2023, after deducting the estimated underwriting commissions and estimated offering expenses payable by
us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each &#128;1.00 ($1.05) increase (decrease) in the assumed initial offering price of &#128;12.72 per ordinary share ($13.39 per ADS),
which is the last reported closing price of our ordinary shares on Euronext Paris on October&nbsp;13, 2023, would increase or decrease our net proceeds from the offering by &#128;17.4 million ($18.3 million), assuming the number of ordinary shares
offered by us (which may be in the form of ADSs), as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting commissions and estimated offering expenses payable by us. We may also increase or
decrease the number of ordinary shares (which may be in the form of ADSs) we are offering. An increase or decrease of 1,000,000 ordinary shares offered by us (which may be in the form of ADSs) would increase or decrease the net proceeds to us from
the sale of the ordinary shares (which may be in the form of ADSs) we are offering by &#128;11.8 million ($12.4 million), assuming that the assumed initial offering price remains the same and after deducting the estimated underwriting commissions
and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from the global offering as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately &#128;170.0 million ($178.9 million, assuming an exchange rate of &#128;0.9502 per U.S. dollar, the
exchange rate on October 13, 2023 as reported by the European Central Bank) to fund the development of obefazimod for UC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately &#128;15.0 million ($15.8 million, assuming an exchange rate of &#128;0.9502 per U.S. dollar, the
exchange rate on October 13, 2023 as reported by the European Central Bank) to fund the development of obefazimod for CD; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remainder for working capital and for other general corporate purposes, including in the continued research
to identify new compounds and the payment of maturities of existing debt agreements as they become due (mostly allocated to payments under the Kreos / Claret Financing, and assuming that we will repay the Heights Financing through the issuance of
new shares instead of making cash payments). </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also use a portion of the remaining net proceeds and our
existing cash and cash equivalents to in-license, acquire, or invest in complementary businesses, technologies, products or assets. However, we have no current commitments or obligations to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the anticipated net proceeds from this offering, together with our current cash and cash equivalents, will allow us to finance
our operations through (i) the announcement of our top-line data from our Phase 3 ABTECT-1 and ABTECT-2 induction trials for UC and (ii) the announcement of our top-line data from our Phase 2a induction trial for CD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This expected use of net proceeds from the global offering represents our intentions based upon our current plans and business conditions,
which could change in the future as our plans and business conditions evolve. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our development, the status of and results from clinical trials, as
well as any collaborations that we may enter into with third parties for our drug candidates, and any unforeseen cash needs. As a result, our management retains broad discretion over the allocation of the net proceeds from the global offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending our use of the net proceeds from the global offering, we intend to invest the net proceeds in a variety of capital preservation
investments, including short-term, investment-grade, interest-bearing instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_8"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our ordinary shares. We do not have any present plan to pay any cash dividends on our
equity securities in the foreseeable future after the global offering. We currently intend to retain all of our available funds and any future earnings to operate and expand our business. For as long as any amount is outstanding under the
Kreos&nbsp;/ Claret Financing, we are not permitted to declare or make any dividend without consent from KC or Claret. In the event a dividend is made or declared, the terms and conditions of the OCABSAs and BSAs issued to KC and Claret and the
terms and conditions of the convertible notes issued to Heights provide for an adjustment of the conversion ratio. We do not anticipate paying cash dividends on our equity securities in the foreseeable future and intend to retain all available funds
and any future earnings for use in the operation and expansion of our business, given our state of development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the
requirements of French law and our <FONT STYLE="white-space:nowrap">by-laws,</FONT> dividends may only be distributed from our distributable profits, plus any amount held in our available reserves, which are those reserves other than the legal and
statutory reserves and the revaluation surplus. See &#147;Description of Share Capital&#148; for further details on the limitations on our ability to declare and pay dividends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we pay any dividends, we will pay our ADS holders to the same extent as holders of our ordinary shares, subject to the terms of the deposit
agreement, including deduction in respect of the fees and expenses payable thereunder. See &#147;Description of American Depositary Shares&#148; for further information. Cash dividends on our ordinary shares, if any, will be paid in euros and
converted into U.S. dollars with respect to ADSs, as provided in the deposit agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_9"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below sets forth our cash and cash equivalents and total capitalization as of June&nbsp;30, 2023 on: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a pro forma basis to give effect to the (i) issuance of the Kreos / Claret OCABSA, (ii) issuance of the Heights
Convertible Notes (based on a valuation as of August 24, 2023) and (iii) repayments of all outstanding amounts that remained due under the First KC Agreement, the Second KC Agreement and the OCEANE bonds; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a pro forma as adjusted basis to reflect the pro forma items described above and the issuance and sale of
18,675,500 ordinary shares (which may be in the form of ADSs) in the global offering, consisting of (i) &#8195;&#8195;&#8195;&#8195; ADSs in the U.S. offering, based on an assumed initial offering price of $13.39 per ADS and (ii)
&#8195;&#8195;&#8195;&#8195; ordinary shares in the European private placement based on an assumed initial offering price of &#128;12.72&nbsp;per ordinary share ($13.39 per ADS), which is the last reported closing price of our ordinary shares on
Euronext Paris on October 13, 2023, after deducting the estimated underwriting commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our pro forma as adjusted capitalization following the global offering will depend on the actual initial public offering price and other terms
of the global offering determined at pricing, including the amount by which actual offering expenses are higher or lower than estimated. The Kreos / Claret Financing and the Heights Convertible Notes consist of elements that need to be fair valued
under IFRS. We have performed a preliminary valuation to estimate the fair value for the purposes of preparing the capitalization table and therefore such figures may be subject to further adjustments. The table should be read in conjunction with
the information contained in &#147;Use of Proceeds,&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; as well as our financial statements and the related notes included elsewhere in this
prospectus. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">114,381</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">138,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">354,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial Liabilities &#150; current
portion<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">12,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial Liabilities &#150; non-current
portion<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity attributable to shareholders:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares &#128;0.01&nbsp;par value: 42,547,568 shares outstanding actual;
42,547,568&nbsp;shares outstanding pro forma; and 61,223,068 shares outstanding pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Premiums related to share capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275,383</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">276,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">490,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(143,366</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(143,366</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(143,366</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51,953</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,992</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,992</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,489</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">136,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">163,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">377,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Our pro forma as adjusted capitalization following the global offering will depend on the actual initial public
offering price and other terms of the global offering determined at pricing, including the amount by which actual offering expenses are higher or lower than estimated. Each &#128;1.00 ($1.05) increase or decrease in the assumed initial offering
price of &#128;12.72 per ordinary share ($13.39 per ADS), which is the last reported closing price of our ordinary shares on Euronext Paris on October 13, 2023 would increase or decrease pro forma as adjusted cash and cash equivalents, total
shareholders&#146; equity and total capitalization by &#128;17.4 million ($18.3 million), assuming that the number of ordinary shares (which may be in the form of ADSs) offered by us, as set forth on the cover page of this prospectus, remains the
same and after deducting the estimated underwriting commissions and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
estimated offering expenses payable by us. We may also increase or decrease the number of ordinary shares (which may be in the form of ADSs) we are offering. An increase or decrease in the number
of ordinary shares (which may be in the form of ADSs) offered by us by 1,000,000 ordinary shares (which may be in the form of ADSs) would increase or decrease pro forma as adjusted cash and cash equivalents, total shareholders&#146; equity and total
capitalization by &#128;11.8 million ($12.4 million), assuming that the assumed initial offering price remains the same, and after deducting the estimated underwriting commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of borrowings, convertible loan notes and other financial liabilities as shown in Note 15 - Financial
Liabilities to our unaudited interim condensed consolidated financial statements included elsewhere in this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of borrowings, convertible loan notes, derivative instruments, royalty certificates and other
financial liabilities as shown in Note 15 - Financial Liabilities to our unaudited interim condensed consolidated financial statements included elsewhere in this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Net of &#128; 2.6 million in unamortized debt discount and issuance costs related to the Kreos / Claret
Financing and the Heights Financing. Based on a valuation of the convertible bonds as of August 24, 2023. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless
otherwise indicated, the number of ordinary shares (including ordinary shares in the form of ADSs) that will be outstanding after the global offering is based on 42,547,568 ordinary shares outstanding as of June&nbsp;30, 2023 and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">308,984 ordinary shares issuable upon the exercise of share warrants (BSA) outstanding as of June&nbsp;30, 2023
at a weighted-average exercise price of &#128;7.57 per ordinary share (or $8.27 based on the exchange rate in effect as of June 30, 2023), which figure includes 32,800 ordinary shares that were issued pursuant to exercises of share warrants (BSA)
subsequent to June&nbsp;30, 2023; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">385,409 ordinary shares issuable upon the exercise of founder&#146;s share warrants (BCE) outstanding as of
June&nbsp;30, 2023 at a weighted-average exercise price of &#128;9.64 per ordinary share (or $10.53 based on the exchange rate in effect as of June&nbsp;30, 2023); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,413,543 ordinary shares reserved for future issuance as of June&nbsp;30, 2023 under our share-based
compensation plans and other delegations of authority from our shareholders, which include (i) 1,482,796 ordinary shares issuable upon the vesting of free shares (AGA) allocated to certain of our officers and employees in July 2023, of which 106,369
free shares (AGA) are subject to vesting conditions that include the successful completion of this offering with at least $100.0&nbsp;million in gross proceeds, and (ii) 985,750 ordinary shares issuable upon the vesting of free shares (AGA)
allocated to certain of our officers and employees in September 2023, of which 254,250 free shares (AGA) are subject to vesting conditions that include the successful completion of this offering with at least $200.0&nbsp;million in gross proceeds.
For additional details regarding the vesting conditions of the foregoing free shares (AGA), please see the section of this prospectus titled &#147;Certain Relationships and Related Person Transactions&#151;Arrangements with our Directors and
Executive Officers&#151;Free Shares (<I>attributions gratuites d&#146;actions</I>)"; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,178,084 ordinary shares issuable upon the conversion of the Kreos / Claret OCABSA issued to KC and Claret in
connection with the drawdown of the first tranche of the Kreos / Claret Financing, at a conversion price of &#128;21.22 per ordinary share (or $23.17 based on the exchange rate in effect as of June&nbsp;30, 2023); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">214,198 ordinary shares issuable upon the exercise of share warrants (BSA) issued to KC and Claret in connection
with the drawdown of the first tranche of the Kreos / Claret Financing, at an exercise price of &#128;18.67 per ordinary share (or $20.39 based on the exchange rate in effect as of June&nbsp;30, 2023); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">261,004 ordinary shares issuable upon the exercise of share warrants (BSA) that could be issued to KC and Claret
in connection with the future drawdown of the second and third tranches of the Kreos / Claret Financing, assuming an exercise price of &#128;15.33 per ordinary share (or $16.74 based on the exchange rate in effect as of June 30, 2023), which
represents a 10% premium to the 15-day VWAP price of our ordinary shares as of the date of this prospectus; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,472,606 ordinary shares issuable upon the conversion of the Heights Convertible Notes in connection with the
drawdown of the first tranche of the Heights Financing, at a conversion price of &#128;23.77 per ordinary share (or $25.96 based on the exchange rate in effect as of June&nbsp;30, 2023) and up to 2,830,201 ordinary shares issuable in the event of
repayment in ordinary shares of the principal and interest of the Heights Convertible Notes, assuming a price of &#128;14.43 per ordinary share (or $15.76 based on the exchange rate in effect as of June 30, 2023) retained for the repayment and;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,208,488 ordinary shares issuable upon the conversion of the Heights Convertible Notes that could be issued to
Heights in connection with the future drawdown of the second tranche of the Heights Financing, assuming a conversion price of &#128;18.11 per ordinary share (or $19.78 based on the exchange rate in effect as of June 30, 2023), which represents a 30%
premium to the 15-day VWAP price of our ordinary shares as of October 13, 2023, and up to 3,855,841 ordinary shares issuable in the event of repayment in ordinary shares of the principal and interest of the second tranche of the Heights Convertible
Notes, assuming a price of &#128;11.84 per ordinary share (or $12.93 based on the exchange rate in effect as of June 30, 2023) retained for the repayment, which represents a 15% discount to the 15-day VWAP price of our ordinary shares as of October
13, 2023. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional details relating to the Kreos / Claret Financing and the Heights Financing, see
&#147;Business&#151;Key Collaborations and Partners&#151;Financing Arrangements.&#148; References to outstanding ordinary shares included in this prospectus include 11,487 treasury shares issued by us as of June 30, 2023. Except as otherwise noted,
the information in this prospectus assumes no exercise by the underwriters of their option to purchase 2,801,325 additional ADS and/or ordinary shares in the global offering and no exercise of share warrants (BSA), founder&#146;s share warrants
(BCE) or vesting of free shares (AGA) or other equity awards subsequent to June&nbsp;30, 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_10"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our ordinary shares or ADSs in the global offering, your ownership interest will be diluted to the extent of the difference
between the public offering price per ordinary share or ADS paid by purchasers in the global offering and the pro forma as adjusted net tangible book value per ordinary share or ADS, as applicable, after completion of the global offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net tangible book value as of June&nbsp;30, 2023 was &#128;55.5 million ($60.6 million), or &#128;1.30 per ordinary share ($1.42 per ADS),
based on the exchange rate of &#128;1.00&nbsp;= $1.0919 as of June&nbsp;30, 2023. Net tangible book value per ordinary share is determined by dividing (i)&nbsp;our total assets less our intangible assets, our goodwill and our total liabilities by
(ii)&nbsp;the number of ordinary shares outstanding as of June&nbsp;30, 2023 or 42,547,568 ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our pro forma net tangible
book value as of June&nbsp;30, 2023 was &#128;58.4&nbsp;million ($63.8&nbsp;million), or &#128;1.37&nbsp;per ordinary share ($1.50&nbsp;per ADS), based on the exchange rate of &#128;1.00&nbsp;= $1.0919 as of June&nbsp;30, 2023. Pro forma net
tangible book value per ordinary share is our net tangible book value as of June 30, 2023, after giving effect to the (i) issuance of the Kreos / Claret OCABSA, (ii) issuance of the Heights Convertible Notes (based on a valuation as of August 24,
2023) and (iii) repayments of all outstanding amounts that remained due under the First KC Agreement, the Second KC Agreement and the OCEANE bonds. The Kreos / Claret Financing and the Heights Convertible Notes consist of elements that need to be
fair valued under IFRS. We have performed a preliminary valuation to estimate the fair value for the purposes of preparing the pro forma as adjusted figures in the table below and therefore such figures may be subject to further adjustments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to the receipt of the estimated net proceeds from our sale of 18,675,500 ordinary shares (which may be in the form of
ADSs) in the global offering, based on an assumed initial offering price of &#128;12.72&nbsp;per ordinary share ($13.39 per ADS), which is the last reported closing price of our ordinary shares on Euronext Paris on October 13, 2023, and after
deducting the estimated underwriting commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of June&nbsp;30, 2023 would have been &#128;272.7 million ($289.3 million), or &#128;4.45 per
ordinary share ($4.73 per ADS). This represents an immediate increase in pro forma net tangible book value of &#128;3.08 per ordinary share ($3.23 per ADS) to existing shareholders and an immediate dilution in net tangible book value of &#128;8.27
per ordinary share ($8.66 per ADS) to new investors. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table illustrates this dilution on a per ordinary share and per
ADS basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Ordinary</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;ADS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial offering price per ordinary share<SUP STYLE="font-size:75%; vertical-align:top">
</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">12.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13.39</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value per ordinary share or ADS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per ordinary share or ADS attributable to the adjustments
described above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per ordinary share or ADS as of June 30, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value per ordinary share or ADS attributable to new
investors participating in the global offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per ordinary share or ADS after the global
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution in pro forma as adjusted net tangible book value per ordinary share or ADS to new
investors participating in the global offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">8.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The dilution information discussed above is illustrative only and will depend on the actual offering
price and other terms of the offering determined at pricing. Each &#128;1.00 ($1.05) increase or decrease in the assumed initial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
offering price of &#128;12.72 per ordinary share ($13.39 per ADS), which is the last reported closing price of our ordinary shares on Euronext Paris on October 13, 2023, would increase or
decrease our pro forma as adjusted net tangible book value by approximately &#128;17.4 million ($18.3 million), or &#128;0.28 per ordinary share ($0.30 per ADS), and the dilution to new investors participating in the offering would be
&#128;8.98&nbsp;per ordinary share ($9.42&nbsp;per ADS) in case of a &#128;1.00 ($1.05) increase in the assumed initial offering price, and &#128;7.55&nbsp;per ordinary share ($7.91&nbsp;per ADS) in case of a &#128;1.00 ($1.05) decrease in the
assumed initial offering price, assuming that the number of ordinary shares offered by us (which may be in the form of ADSs), as set forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriting
commissions and estimated offering expenses payable by us. We may also increase or decrease the number of ordinary shares we are offering. An increase of 1,000,000 ordinary shares offered by us would increase the pro forma as adjusted net tangible
book value by &#128;11.8 million ($12.4&nbsp;million), or &#128;0.12 per ordinary share ($0.12 per ADS), and the dilution to new investors participating in the offering would be &#128;8.15 per ordinary share ($8.54 per ADS), assuming that the
assumed initial offering price remains the same, and after deducting the estimated underwriting commissions and estimated offering expenses payable by us. Similarly, a decrease of 1,000,000 ordinary shares (which may be in the form of ADSs) offered
by us would decrease the pro forma as adjusted net tangible book value by &#128;11.8 million ($12.4&nbsp;million), or &#128;0.12 per ordinary share ($0.13 per ADS), and the dilution to new investors participating in the offering would be
&#128;8.39&nbsp;per ordinary share ($8.79 per ADS), assuming that the assumed initial offering price remains the same, and after deducting the estimated underwriting commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option to purchase 2,801,325 additional ordinary shares and/or ADSs in full, the pro forma as adjusted net
tangible book value per ordinary share after the offering would be &#128;4.78 per ordinary share ($5.06 per ADS), the increase in the pro forma as adjusted net tangible book value to existing shareholders would be &#128;0.32 per ordinary share
($0.34 per ADS), and the dilution to new investors participating in the offering would be &#128;7.94 per ordinary share ($8.32 per ADS). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth, as of June&nbsp;30, 2023, the number of ordinary shares purchased from us, the total consideration paid to us
and the average price per ordinary share paid by existing shareholders and to be paid by new investors participating in the global offering, based on an assumed initial offering price of &#128;12.72 per ordinary share ($13.39&nbsp;per ADS), which is
the last reported closing price of our ordinary shares on Euronext Paris on October 13, 2023, after deducting the estimated underwriting commissions and estimated offering expenses payable by us. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary&nbsp;Shares</B><br><B>(Which&nbsp;May&nbsp;Be&nbsp;In</B><br><B>The&nbsp;Form&nbsp;Of&nbsp;ADSs)</B><br><B>Purchased From</B><br><B>Us</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average&nbsp;Price</B><br><B>Per&nbsp;Ordinary</B><br><B>Share </B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Price Per<BR>ADS</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,547,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">333,932,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,675,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237,552,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">12.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,223,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">571,484,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each &#128;1.00 ($1.05) increase or decrease in the assumed initial offering price of &#128;12.72 per
ordinary share ($13.39&nbsp;per ADS), which is the last reported closing price of our ordinary shares on Euronext Paris on October&nbsp;13, 2023, would increase or decrease the total consideration paid by new investors participating in the offering
by &#128;18.7 million ($19.7&nbsp;million), assuming that the number of ordinary shares offered by us (which may be in the form of ADSs), as set forth on the cover page of the prospectus, remains the same and before deducting underwriting
commissions and estimated offering expenses payable by us. We may also increase or decrease the number of ordinary shares we are offering. An increase or decrease in 1,000,000 ordinary shares offered by us would increase or decrease the total
consideration paid by new investors participating in the global offering by &#128;12.7 million ($13.4 million), assuming that the assumed initial offering price remains the same and before </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
deducting underwriting commissions and estimated offering expenses payable by us. The pro forma as adjusted information discussed above is illustrative only and will be adjusted based on the
actual offering price, the actual number of ordinary shares offered by us (which may be in the form of ADSs) and other terms of the offering determined at pricing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table above assumes no exercise of the underwriters&#146; option to purchase 2,801,325 additional ADS and/or ordinary shares in the global
offering and no exercise of share warrants (BSA), founder&#146;s share warrants (BCE) or vesting of free shares (AGA) or other equity awards subsequent to June&nbsp;30, 2023. If the underwriters exercise their option to purchase 2,801,325 additional
ADSs and/or ordinary shares (which may be in the form of ADSs) in full, the number of ordinary shares held by the existing shareholders after the global offering would be reduced to 66.5% of the total number of ordinary shares (including ordinary
shares represented by ADSs) outstanding after the global offering, and the number of shares held by new investors participating in the global offering (including ordinary shares represented by ADSs) would increase to 33.5% of the total number of
ordinary shares outstanding after the global offering (including ordinary shares represented by ADSs). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated,
the number of ordinary shares (including ordinary shares in the form of ADSs) that will be outstanding after the global offering is based on 42,547,568 ordinary shares outstanding as of June&nbsp;30, 2023 and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">308,984 ordinary shares issuable upon the exercise of share warrants (BSA) outstanding as of June&nbsp;30, 2023
at a weighted-average exercise price of &#128;7.57 per ordinary share (or $8.27 based on the exchange rate in effect as of June&nbsp;30, 2023), which figure includes 32,800 ordinary shares that were issued pursuant to exercises of share warrants
(BSA) subsequent to June&nbsp;30, 2023; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">385,409 ordinary shares issuable upon the exercise of founder&#146;s share warrants (BCE) outstanding as of
June&nbsp;30, 2023 at a weighted-average exercise price of &#128;9.64 per ordinary share (or $10.53 based on the exchange rate in effect as of June&nbsp;30, 2023); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,413,543 ordinary shares reserved for future issuance as of June 30, 2023 under our share-based compensation
plans and other delegations of authority from our shareholders, which include (i)&nbsp;1,482,796 ordinary shares issuable upon the vesting of free shares (AGA) allocated to certain of our officers and employees in July 2023, of which 106,369 free
shares (AGA) are subject to vesting conditions that include the successful completion of this offering with at least $100.0 million in gross proceeds, and (ii) 985,750 ordinary shares issuable upon the vesting of free shares (AGA) allocated to
certain of our officers and employees in September 2023, of which 254,250 free shares (AGA) are subject to vesting conditions that include the successful completion of this offering with at least $200.0&nbsp;million in gross proceeds. For additional
details regarding the vesting conditions of the foregoing free shares (AGA), please see the section of this prospectus titled &#147;Certain Relationships and Related Person Transactions&#151;Arrangements with our Directors and Executive
Officers&#151;Free Shares (<I>attributions gratuites d&#146;actions</I>)&#148;; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,178,084 ordinary shares issuable upon the conversion of the Kreos / Claret OCABSA issued to KC and Claret in
connection with the drawdown of the first tranche of the Kreos / Claret Financing, at a conversion price of &#128;21.22 per ordinary share (or $23.17 based on the exchange rate in effect as of June&nbsp;30, 2023); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">214,198 ordinary shares issuable upon the exercise of share warrants (BSA) issued to KC and Claret in connection
with the drawdown of the first tranche of the Kreos / Claret Financing, at an exercise price of &#128;18.67 per ordinary share (or $20.39 based on the exchange rate in effect as of June&nbsp;30, 2023); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">261,004&nbsp;ordinary shares issuable upon the exercise of share warrants (BSA) that could be issued to KC and
Claret in connection with the future drawdown of the second and third tranches of the Kreos / Claret Financing, assuming an exercise price of &#128;15.33 per ordinary share (or $16.74 based on the exchange rate in effect as of June&nbsp;30, 2023),
which represents a 10% premium to the 15-day VWAP price of our ordinary shares as of the date of this prospectus; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,472,606 ordinary shares issuable upon the conversion of the Heights Convertible Notes in connection with the
drawdown of the first tranche of the Heights Financing, at a conversion price of &#128;23.77 per ordinary share (or $25.96 based on the exchange rate in effect as of June&nbsp;30, 2023) and up to 2,830,201 ordinary shares issuable in the event of
repayment in ordinary shares of the principal and interest of the Heights Convertible Notes, assuming a price of &#128;14.43 per ordinary share (or $15.76 based on the exchange rate in effect as of June 30, 2023) retained for the repayment; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,208,488 ordinary shares issuable upon the conversion of the Heights Convertible Notes that could be issued to
Heights in connection with the future drawdown of the second tranche of the Heights Financing, assuming a conversion price of &#128;18.11 per ordinary share (or $19.78 based on the exchange rate in effect as of June 30, 2023), which represents a 30%
premium to the 15-day VWAP price of our ordinary shares as of October 13, 2023, and up to 3,855,841 ordinary shares issuable in the event of repayment in ordinary shares of the principal and interest of the second tranche of the Heights Convertible
Notes, assuming a price of &#128;11.84 per ordinary share (or $12.93 based on the exchange rate in effect as of June 30, 2023) retained for the repayment, which represents a 15% discount to the 15-day VWAP price of our ordinary shares as of October
13, 2023. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional details relating to the Kreos / Claret Financing and the Heights Financing, see
&#147;Business&#151;Key Collaborations and Partners&#151;Financing Arrangements.&#148; References to outstanding ordinary shares included in this prospectus include 11,487 treasury shares issued by us as of June 30, 2023. Except as otherwise noted,
the information in this prospectus assumes no exercise by the underwriters of their option to purchase 2,801,325 additional ADS and/or ordinary shares in the global offering and no exercise of share warrants (BSA), founder&#146;s share warrants
(BCE) or vesting of free shares (AGA) or other equity awards subsequent to June&nbsp;30, 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_11"></A>ENFORCEMENT OF CIVIL LIABILITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a <I>soci&eacute;t&eacute; anonyme</I>, organized under the laws of France. The majority of our directors and officers are residents of
countries other than the United States, and the majority of our assets are located outside of the United States. We have appointed an agent for service of process in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, U.S. investors may find it difficult and may be unable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to obtain jurisdiction over us or our officers and directors in U.S. courts in actions predicated on the civil
liability provisions of the U.S. federal securities laws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to enforce, either inside or outside of the United States, judgments obtained in U.S. or <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> courts in actions predicated upon the civil liability provisions of the U.S. federal securities laws against us or our officers and directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to bring an original action in a French court to enforce liabilities based upon the U.S. federal securities laws
against us or our officers or directors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to enforce against us or our directors our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> courts, including
French courts, judgments of U.S. courts predicated upon the civil liability provisions of the U.S. federal securities laws. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, actions in the United States under U.S. federal securities laws could be affected under certain circumstances by French Law <FONT
STYLE="white-space:nowrap">No.&nbsp;68-678</FONT> of July&nbsp;26, 1968, as amended by French Law <FONT STYLE="white-space:nowrap">No.&nbsp;80-538</FONT> of July&nbsp;16, 1980 and French Ordinance
<FONT STYLE="white-space:nowrap">No.&nbsp;2000-916</FONT> of September&nbsp;19, 2000 (relating to the communication of documents and information of an economic, commercial, industrial, financial or technical nature to foreign authorities or
persons), which may preclude or restrict the obtaining of evidence in France or from French persons in connection with those actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nevertheless, a final judgment for the payment of money rendered by any federal or state court in the United&nbsp;States based on civil
liability, whether or not predicated solely upon the U.S. federal securities laws, would be recognized and enforced in France provided that a French judge considers that this judgment meets the French legal requirements concerning the recognition
and the enforcement of foreign judgments and is capable of being immediately enforced in the United States. A French court is therefore likely to grant the enforcement of a foreign judgment without a review of the merits of the underlying claim,
only if: (i)&nbsp;that judgment does not contravene international public order and public policy of France, both pertaining to the merits and to the standards of due process; and (ii) the dispute is clearly connected to the territory of the court
which rendered the judgement, and French courts did not have exclusive jurisdiction on the matter. The French court would also require that the U.S. judgment is not tainted with fraud and is not incompatible with a judgment rendered by a French
court in the same matter, or with an earlier judgment rendered by a foreign court which has become effective in France in the same matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, French law guarantees full compensation for the harm suffered but is limited to the actual damages, so that the victim does not
suffer or benefit from the situation. Such system excludes damages such as, but not limited to, punitive and exemplary damages. Therefore, there is some uncertainty as to whether a foreign judgement awarding punitive and exemplary damages well above
actual damages would be granted enforcement in France. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, the enforcement, by U.S. investors, of any judgments obtained in U.S.
courts in civil and commercial matters, including judgments under the U.S. federal securities law against us or members of our Board, officers or certain experts named herein who are residents of France or countries other than the United States
would be subject to the above conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, there may be doubt as to whether a French court would impose civil liability on us,
the members of our Board, our officers or certain experts named herein in an original action predicated solely upon the U.S.&nbsp;federal securities laws brought in a court of competent jurisdiction in France against us or such members, officers or
experts, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_12"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion of our financial condition and results of operations in conjunction with our financial statements
and the related notes thereto included elsewhere in this prospectus. In addition to historical information, the following discussion and analysis contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results
and the timing of events could differ materially from those anticipated in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this prospectus, particularly in
the sections titled &#147;Risk Factors&#148; and &#147;Cautionary Note Regarding Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biotechnology company focused on developing therapeutics that harness the body&#146;s natural regulatory mechanisms to
modulate the immune response in patients with chronic inflammatory diseases. We are currently evaluating our lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative
colitis (&#147;UC&#148;). We are also in the planning stages of initiating a Phase 2a clinical trial of obefazimod in patients with Crohn&#146;s disease (&#147;CD&#148;), as well as evaluating other potential inflammatory indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We focus on indications where existing treatments have left patients with significant unmet needs, and where we believe our investigational
agents have the potential to be meaningfully differentiated from currently available therapies. The indications we target have substantial populations and represent large commercial opportunities, pending regulatory approvals and successful
commercialization. Our initial focus is on inflammatory bowel diseases (&#147;IBD&#148;), chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD. As of 2022, an aggregate of
approximately 2.9&nbsp;million patients across the United States, EU4 (France, Germany, Italy and Spain), the United Kingdom and Japan suffered from IBD, with 1.5 million of these patients in the United States alone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our lead drug candidate, obefazimod, is differentiated from competing approaches for the treatment of IBD via its novel mechanism
of action. Obefazimod was demonstrated to specifically enhance the expression of a single micro-RNA, miR-124, which plays a critical role in the regulation of the inflammatory response. In the context of inflammation, miR-124 is a natural regulator
of the inflammatory response, controlling progression of inflammation and restoring homeostasis of the immune system, without causing broader immunosuppression. In contrast to currently available advanced therapies, prescribed post-conventional
therapies, some of which target only a single cytokine or pathway, miR-124 modulates the expression of several key cytokines and pathways. Modulating multiple inflammatory pathways simultaneously may lead to more durability of efficacy results over
the long-term, which is critical in lifelong conditions such as IBD, potentially differentiating obefazimod from currently available IBD treatments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our team is comprised of industry leaders in the fields of biology, data analytics and drug development, as well as scientific experts in
chronic inflammatory diseases, including IBD. We are led by Marc de Garidel, our Chief Executive Officer, who has more than 40 years of experience in the pharmaceutical and biotechnology sector. Collectively, our team has decades of experience and a
proven track record of advancing compounds into and through clinical development and commercialization, including at the following organizations: Amgen, Arena Pharmaceuticals, AstraZeneca, BioNTech, Boehringer Ingelheim, Eli Lilly, Genentech/Roche,
Guerbet, Ipsen Pharmaceuticals, J&amp;J, Pfizer, Sanofi, Sanofi-Pasteur and Shire/Takeda. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated as a
<I>soci&eacute;t&eacute; anonyme </I>on December 4, 2013 and, in 2014, we acquired Splicos, Wittycell and Zophis by means of a universal transfer of assets and liabilities (<I>Transmission Universelle du Patrimoine </I>(&#147;TUP&#148;)). We have
been listed on Euronext Paris since June&nbsp;26, 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April 1, 2022, we acquired 100% of the share capital of Prosynergia S.&agrave;.r.L
(&#147;Prosynergia&#148;), a Luxembourg-based biotechnology company, with the aim of strengthening our research and development portfolio, for an amount of &#128;3.25&nbsp;million. On December 12, 2022, we completed the merger with Prosynergia
through a TUP and all of Prosynergia&#146;s assets and liabilities were transferred to us. Following the merger, Prosynergia was dissolved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March 20, 2023, our United States-based subsidiary Abivax LLC (the &#147;Subsidiary&#148;) was formed as a limited liability company under
the laws of the State of Delaware. The Subsidiary hosts our operations in the United States. We have prepared unaudited interim condensed consolidated financial statements as of and for the six-month period ended June 30, 2023. As of June 30, 2023,
the Subsidiary&#146;s contribution to our consolidated results of operations was a net operating loss of &#128;0.6 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our
inception<I> </I>in 2013, we have devoted substantially all of our efforts to organizing and staffing our company, business planning, raising capital, establishing our intellectual property portfolio, acquiring or discovering drug candidates,
research and development activities for obefazimod and other compounds, establishing arrangements with third parties for the manufacture of our drug candidates and component materials, and providing general and administrative support for these
operations. We do not have any products approved for sale and have not generated any revenue from product sales or otherwise. We do not expect to generate significant revenue from product sales or royalties unless and until our drug candidates are
approved for marketing and successfully commercialized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred significant operating losses since inception, and we expect to
continue to incur significant expenses and operating losses for the foreseeable future. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of
obefazimod and any future drug candidates. For the six-month periods ended June 30, 2023 and 2022 and the years ended December 31, 2022 and 2021, we reported net losses of &#128;52.0 million, &#128;21.2 million, &#128;60.7&nbsp;million and
&#128;42.5&nbsp;million, respectively. As of June&nbsp;30, 2023, we carried forward accumulated tax losses of &#128;355.4&nbsp;million. We expect to continue to incur net operating losses for at least the next several years, and we do not anticipate
achieving profitability in the future unless we obtain regulatory approvals necessary to commercialize obefazimod and any additional drug that we may pursue in the future. We expect that our research and development expenses, general and
administrative expenses, and capital expenditures will increase substantially in connection with our ongoing activities, particularly if and as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to advance our existing drug candidates through clinical development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timely and successfully complete clinical development of obefazimod, our clinical-stage drug candidate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek and maintain regulatory and marketing approvals for obefazimod and any future drug candidates for which we
successfully complete clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue the preclinical and clinical development of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand the scope of our current clinical trials for our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">begin new clinical trials for our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">develop, scale and validate our commercial manufacturing capabilities for our drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a sales, marketing and distribution infrastructure to commercialize any drugs for which we may obtain
regulatory and marketing approval for which we have not entered into a collaboration with a third-party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to discover, identify and validate additional drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other drug candidates and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make milestone, royalty or other payments under <FONT STYLE="white-space:nowrap">in-license</FONT> or
collaboration agreements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain, maintain, protect, enforce and expand our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacture, or have manufactured, <FONT STYLE="white-space:nowrap">non-clinical,</FONT> clinical and potentially
commercial supplies of obefazimod and any future drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract new and retain existing clinical, scientific, operational, financial and management personnel; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur additional legal, accounting, and other costs associated with operating as a U.S. public company following
the completion of this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net losses may fluctuate significantly from period to period, depending on the
timing of expenditures related to our research and development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not generate revenue from product sales unless and
until we successfully complete clinical development and obtain regulatory approval for a drug candidate. In particular, following the issuance of royalty certificates in September 2022 and other royalties that may become payable under our royalty
agreements, the payment of royalties in the event of commercialization of obefazimod will result in a decrease in cash flows generated by sales of the product, which could have an unfavorable impact on our financial position, particularly at the
beginning of the commercialization phase. In addition, if we obtain regulatory approval for a drug candidate and do not enter into a third-party commercialization partnership, we expect to incur significant expenses related to developing our
commercialization capability to support product sales, marketing, manufacturing and distribution activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, we will need
substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through equity offerings,
debt financings or other capital sources, which could include collaborations, strategic alliances or additional licensing arrangements. We may be unable to raise additional funds or enter into such arrangements when needed, on favorable terms, or at
all. Our failure to raise capital or enter into such agreements as, and when, needed, could have a material adverse effect on our business, results of operations and financial condition, including requiring us to have to delay, reduce or eliminate
product development or future commercialization efforts. The amount and timing of our future funding requirements will depend on many factors, including the successful advancement of obefazimod or any future drug candidates. Our ability to raise
additional funds may also be adversely impacted by potential worsening global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide, such as those resulting from the ongoing war
in Ukraine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with development of treatment of chronic inflammatory diseases, we
are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are
unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, we have financed our operations through the issuance of ordinary shares with gross aggregate proceeds of &#128;333.9 million,
of which &#128;130&nbsp;million of gross proceeds were from offerings of our ordinary shares on Euronext Paris in February 2023, bank borrowings and structured loans for &#128;125.0&nbsp;million, reimbursements of CIR in an amount of
&#128;26.6&nbsp;million, subsidies received from Bpifrance (including &#128;13.5&nbsp;million of subsidies and &#128;6.6&nbsp;million of conditional advances) and royalty certificates in an amount of &#128;2.9 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2023, we had cash and cash equivalents of &#128;114.4&nbsp;million. We believe that based on our anticipated net proceeds
from this offering, together with (a) our existing cash and cash equivalents of &#128;114.4 million as of June&nbsp;30, 2023, (b) the net proceeds of the August 2023 drawdown of the first tranches of the Kreos / Claret Financing and the Heights
Financing, collectively amounting to &#128;27.2 million (net of repayments of all outstanding amounts that remained due under the First KC Agreement, the Second KC Agreement and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
OCEANE bonds), (c) the anticipated net proceeds from the drawdown of the second tranche of the Kreos / Claret Financing, amounting to &#128;25 million (which is a portion of the total available
drawdown of &#128;65&nbsp;million from the Kreos / Claret Financing and the Heights Financing) and (d)&nbsp;the expected Research Tax Credit (CIR) reimbursements would enable us to fund our operations through the fourth quarter of 2025. Under these
assumptions and based on our current clinical plan, we would have sufficient funds to finance our operations through (i) the announcement of our top-line data from the Phase 3 ABTECT-1 and ABTECT-2 induction trials for UC and (ii) the announcement
of our top-line data from the Phase 2a induction trial for CD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we further draw down on the third tranche of the Kreos / Claret
Financing, amounting to &#128;25 million and the second tranche of the Heights Financing amounting to &#128;40 million, we expect to have sufficient funds to finance our operations into the second quarter of 2026. Under these assumptions and based
on our current clinical plan, we would have sufficient funds to finance our operations through the announcement of our top-line data from the Phase 3 ABTECT maintenance trial for UC. For additional details relating to the Kreos / Claret Financing
and the Heights Financing, see &#147;Business&#151;Key Collaborations and Partners&#151;Financing Arrangements.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This takes
into account our assumption that R&amp;D expenditure will be substantially increased in 2023 driven by the progression of the Phase 3 clinical trials of obefazimod, which started enrollment of patients with moderately to severely active UC in
October 2022. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We anticipate that we will require additional capital as we seek regulatory approval of
our drug candidates. We intend to assess and plan for any such funding requirements and aim to regularly update the market on our financing need projections. See &#147;&#151;Liquidity and Capital Resources.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beyond that date, our ability to fund operations will depend upon our ability to raise additional capital from existing and/or new specialized
investors and/or debt from lenders. In particular, we may consider carrying out one or more capital increases, entering into loan agreements or issuing bonds and entering into regional licensing agreements for obefazimod, specifically targeting
third-party partners in Asia. Our operating plans may change as a result of a variety of factors, and we may need to seek additional funds sooner than planned. In any event, we will require additional capital to pursue preclinical and clinical
activities, obtain regulatory approval for and commercialize our drug candidates. If sufficient funds on acceptable terms are not available when needed, or at all, we could be required to significantly reduce our operating expenses and delay, reduce
the scope of, or eliminate one or more of our development programs. See the subsection titled &#147;&#151;Liquidity and Capital Resources.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Presentation of Financial Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audited financial statements as of, and for the years ended, December 31, 2022 and 2021 were prepared in accordance with International
Financial Reporting Standards (&#147;IFRS&#148;), as issued by the International Accounting Standards Board (&#147;IASB&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
unaudited interim condensed consolidated financial statements as of June 30, 2023, and for the <FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June 30, 2023 and 2022 were prepared in accordance with IAS 34, Interim Financial
Reporting, the standard of IFRS applicable to interim financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Principal Factors Affecting Our Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following factors have affected, and we expect will continue to affect, our results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development activities are central to our business. Since our inception, most of our resources have been allocated to research and
development and it accounts for the majority of our operating expenses. For </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the year ended December 31, 2022, research and development expenses accounted for 87%, excluding goodwill impairment loss, of our total operating expenses, as compared to 90% for the year ended
December 31, 2021. For the six-month period ended June 30, 2023, research and development expenses accounted for 83% of our total operating expenses, as compared to 87% (excluding goodwill impairment loss) for the six-month period ended June 30,
2022. Drug candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. Accordingly,
we expect that our research and development expenses will increase in the foreseeable future as we seek to advance the development of our drug candidates. The successful development of our drug candidates remains highly uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At this time, we cannot accurately determine or estimate the nature, timing and costs of the research and development activities that will be
necessary to complete the remainder of the development of obefazimod, and we may never succeed in obtaining regulatory approval for obefazimod or any future drug candidates we may develop. The duration, costs and timing of clinical trials and the
development of our drug candidates will depend on numerous risks and uncertainties associated with clinical development, including risks and uncertainties related to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, outcome and expenses of our clinical trials and other research and development activities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the length of time required to enroll suitable patients and successful patient enrollment in, and the initiation
and completion of, clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, receipt and terms of any marketing approvals from applicable regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the establishment of commercial manufacturing capabilities or making arrangements with third-party manufacturers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expense of filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual
property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changing government regulation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launching commercial sales of our drug candidates, if and when approved, whether alone or in collaboration with
others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining a continued acceptable safety profile of the drug candidates following regulatory approval;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to market, commercialize and achieve market acceptance for obefazimod or any other drug candidate
that we may develop in the future; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant competition and rapidly changing technologies within the biopharmaceutical industry.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these variables with respect to the development of any of our drug candidates could
significantly change the costs and timing associated with the development of that drug candidate. The actual probability of success for our drug candidates will be affected by a variety of factors, including the safety and efficacy of our drug
candidates, investment in our clinical programs, manufacturing capability and competition with other products and drug candidates. As a result of these variables, we are unable to determine the duration and completion costs of our research and
development projects or when and to what extent we may generate revenue from the commercialization and sale of our drug candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Regulatory
Approval and Market Acceptance of our Drug Candidates </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may never succeed in achieving regulatory approval for any of our drug
candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
drug candidates or focus on others. A change in the outcome of any of these factors with respect to the development of drug candidates that we are developing could result in a significant change
in the costs and timing associated with the development of such drug candidates. For example, if the EMA or the FDA or other regulatory authority were to require us to conduct <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and clinical
trials beyond those that we currently anticipate will be required for the completion of clinical development, or if we experience significant delays in enrollment in any clinical trials, we could be required to spend significant additional financial
resources and time on the completion of clinical development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Equity and Debt Financing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At this stage, we have not generated any revenue from sales of products or otherwise, and we do not expect to do so unless and until we
successfully complete development of, obtain marketing approval for, and successfully commercialize, one or more of our drug candidates. Until such time that we can generate substantial revenue from sales of products, if ever, we expect to finance
our operating activities through a combination of equity offerings, debt financings and government or other third-party funding. However, we may be unable to raise additional funds or enter into such arrangements when needed on favorable terms, or
at all, which would have a negative impact on our financial condition and could force us to delay, limit, reduce or terminate our development programs or commercialization efforts or grant to others the rights to develop or market drug candidates
that we would otherwise prefer to develop and market ourselves. Failure to receive additional funding could cause us to cease operations, in part or in full. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Acquisition of Prosynergia </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April 1,
2022, we acquired 100% of the share capital of Prosynergia with the aim of strengthening our research and development portfolio, for an amount of &#128;3.25&nbsp;million. On December 12, 2022, we completed the merger with Prosynergia through a TUP
and all of Prosynergia&#146;s assets and liabilities were transferred to us. Following the merger, Prosynergia was dissolved. Accordingly, as Prosynergia was dissolved in December 2022, we did not prepare consolidated financial statements as of
December&nbsp;31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Impact of the Ukraine/Russia Hostilities on our Business </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2022, Russia invaded Ukraine. The conflict has already had major implications for the global economy and the rate of inflation,
particularly in relation to the supply of energy, raw materials and food products. It has also caused intense volatility on the financial markets, something that is still ongoing at the reporting date and has pushed down stock market prices the
world over. The global scale of this conflict cannot be predicted at this stage. We, therefore, cannot rule out an adverse impact of this conflict on our business, including in terms of access to raw materials, logistics, the performance of clinical
trials and in relation to any future financing we may seek. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase 2b maintenance trial of obefazimod in moderately to severely active
UC is our only clinical trial currently in progress in Ukraine. We have, however, terminated a few trial sites since the Russia/Ukraine war began. The <FONT STYLE="white-space:nowrap">12-month</FONT> assessment was carried out in all the Ukrainian
patients before the war broke out and these patients are therefore included in the <FONT STYLE="white-space:nowrap">one-year</FONT> maintenance results that were reported on April&nbsp;6, 2022. Ukrainian patients who completed the <FONT
STYLE="white-space:nowrap">two-year</FONT> Phase 2b maintenance trial have been transitioned to the long-term safety and efficacy trial that is still <FONT STYLE="white-space:nowrap">on-going.</FONT> None of these sites are located in the Crimea
Region of Ukraine, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, or the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic. We are also evaluating the possibility to include a few
Ukrainian sites in the western part of Ukraine in the ABTECT Phase 3 clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Together with our CRO, we are making considerable
efforts to ensure the <FONT STYLE="white-space:nowrap">follow-up</FONT> of patients who are unable to come to the study centers. Monitoring takes place through a remote monitoring system that was established and used successfully during the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Our Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion sets forth certain components of our results of operations, as well as factors that impact those items. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Total Operating Income </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
not generated any revenue from product sales or from other sources, and we do not expect to generate any revenue from the sale of products or otherwise, even if approved, in the near future. Our ability to generate revenue in the future, if ever,
will depend almost entirely on our ability to successfully develop, obtain regulatory approval for, and then commercialize our drug candidates or conclude a partnering business development agreement within our product portfolio. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Operating Income </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other operating
income comprises subsidies in the form of <FONT STYLE="white-space:nowrap">non-refundable</FONT> subsidies from Bpifrance and CIR, each as described below. Subsidies that are upfront payments are presented as deferred income and recognized as other
income for the amount of the expenses incurred as part of the research program to which the subsidy relates. Subsidies that are received either as compensation for expenses or losses already incurred, or for our immediate financial support without
associated future costs, are recognized as other income when there we have reasonable assurance that the subsidies will be received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsidies are <FONT STYLE="white-space:nowrap">non-repayable</FONT> grants received by us. They are recognized in the financial statements in
the period in which the related expenses are incurred when there is reasonable assurance that the subsidies will be received and that we will comply with their conditions. We have received various subsidies and other assistance from Bpifrance since
our creation. The funds are intended to finance our operations or specific projects. See &#147;&#151;Liquidity and Capital Resources&#151;Sources of Liquidity&#151;Bpifrance &#150; Conditional Advances and Subsidies.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The French tax authorities grant a CIR to companies to encourage technical and scientific research by French companies. Companies
demonstrating that they have incurred research expenses that meet the required criteria, including research expenses located in France or certain other European countries, receive a tax credit that can be used against the payment of the corporate
tax due for the fiscal year in which the expenses were incurred and during the next three fiscal years. Companies may receive cash reimbursement for any excess portion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We apply for the CIR for research expenses incurred in each fiscal year and recognize the amounts claimed in the same fiscal year. As we meet
the EU definition of a small and <FONT STYLE="white-space:nowrap">medium-sized</FONT> enterprise (&#147;SME&#148;), we are eligible for payment in cash of our CIR in the year following the request for reimbursement, which corresponds to the period
after which we incurred the eligible costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have concluded that the CIR meets the definition of a government grant as defined in IAS
20, Accounting for Government Grants and Disclosure of Government Assistance, and, as a result, they have been classified as &#147;Other income&#148; within operating income in our statements of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We received the CIR for 2021 in October 2022 and we expect to receive the CIR for 2022 in the second half of 2023, in each case under the
community tax rules for SMEs and in compliance with the current regulations. The CIRs we are granted may be subject to audit by the French tax authorities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Total Operating Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
operating expenses consist of research and development expenses and general and administrative expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development expenses consist primarily of the following items: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">personnel expenses, including salaries, benefits, and share-based compensation expenses, for employees engaged in
research and development activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">sub-contracting,</FONT> collaboration and consultant expenses that primarily
include the cost of third-party contractors such as CROs who conduct our <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and clinical trials, and research related to our proprietary platforms, as well as investigative sites and
consultants that conduct our preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred under agreements with contract manufacturing organizations (&#147;CMOs&#148;), including
manufacturing <FONT STYLE="white-space:nowrap">scale-up</FONT> expenses and the cost of acquiring and manufacturing preclinical study and clinical trial materials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses relating to preclinical studies and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses relating to regulatory affairs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allocated expenses for facility costs, including rent, utilities and maintenance; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses relating to the implementation of our quality assurance system. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We allocate these costs by drug candidate and by therapeutic indication. Costs that are not directly attributable to a specific therapeutic
indication are included under the category of transversal activities, which include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical developments, such as clinical trials relating to the compound and not indication related (e.g<I>.</I>,
Phase 1 trials); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preclinical activities, such as studies relating to the compound and not indication related (e.g., toxicological
studies); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">research activities, which relate to the mechanism of action of the compound; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory activities, which relate to interactions with regulatory authorities for the compound;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pharmacovigilance activities, which relate to studies for the safety and tolerability of the compound; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">chemistry, manufacturing and control activities, which relate to the manufacturing of drug substance and drug
product. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development expenses may vary significantly in the future based on factors, such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and scope of <FONT STYLE="white-space:nowrap">non-clinical</FONT> and Investigational New Drug
Application (&#147;IND&#148;)-enabling studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">per patient trial costs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of trials required for approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of sites included in the trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the countries in which the trials are conducted; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the length of time required to enroll eligible patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients that participate in the trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">drop-out</FONT> or discontinuation rates of patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential additional safety monitoring requested by regulatory agencies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the duration of patient participation in the trials and <FONT STYLE="white-space:nowrap">follow-up;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost and timing of manufacturing our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the phase of development of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy and safety profile of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we establish additional collaboration or license agreements; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether we choose to partner any of our drug candidates and the terms of such partnership. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these variables with respect to the development of any of our drug candidates could significantly change the
costs and timing associated with the development of that drug candidate. We may never succeed in obtaining regulatory approval for any of our drug candidates. We may obtain unexpected results from our
<FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and future clinical trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses primarily comprise personnel-related expenses, including salaries, benefits and share-based compensation
expenses, for personnel other than employees engaged in research and development activities. General and administrative expenses also include fees for professional services, mainly related to audit and legal services, consulting costs,
communications and travel costs, allocated expenses for facility costs, including rent, utilities and maintenance, directors&#146; attendance fees, and insurance costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our general and administrative expenses will increase in the future as we increase our headcount to support our continued research
activities and the development of our product candidates, potential commercialization efforts and increased costs associated with being a public company in the United States. These increases will likely include additional costs related to the hiring
of new personnel, including higher stock-based compensation expenses, and fees to outside consultants, as well as other expenses. We also anticipate that we will incur significantly increased accounting, audit, legal, regulatory, compliance and
director and officer insurance costs as well as investor and public relations expenses associated with operating as a public company both in France and in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financial Income/(Loss) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial
income/(loss) includes the amortized cost of the conditional advances, convertible notes, <FONT STYLE="white-space:nowrap">non-convertible</FONT> bonds, royalty certificates, fair value adjustments on financial instruments, and other financial
income and expenses such as the unwinding effect of CRO advances. We expect to incur additional financial expenses related to financing agreements or similar transactions that we may enter into to finance our further development. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of Years Ended December 31, 2022 and 2021 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth our results of operations for the years ended December 31, 2022 and 2021. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>(In thousands of euros)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>2021</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>2022</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>%&nbsp;Change</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Other operating income</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&#128;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I> 11,961</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&#128;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I> 4,583</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(62</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)%&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,961</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,583</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(62</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Research and development expenses</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(47,781</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(48,295</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>1</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>General and administrative expenses</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(5,580</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(7,492</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>34</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Goodwill impairment loss</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&#8194;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(13,632</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&#8194;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(53,361</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(69,419</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(41,400</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(64,836</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>57</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Financial expenses</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(3,561</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(7,022</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>97</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Financial income</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>2,509</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>11,118</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>343</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,052</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,096</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(489</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss before tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(42,452</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(60,740</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>43</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Income Tax</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&#8194;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&#8194;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&#8194;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(42,452</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(60,740</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>43</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Total Operating Income </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2022, our total operating income was &#128;4.6&nbsp;million, as compared to &#128;12.0&nbsp;million for the
year ended December 31, 2021, a decrease of &#128;7.4&nbsp;million, or 62%, as detailed below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Operating Income </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our other operating income for the years ended December 31, 2022 and 2021. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(In thousands of euros)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CIR (Research Tax Credits)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right"> 4,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">4,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsidies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>-Income recognized from Bpifrance to finance <FONT STYLE="white-space:nowrap">COVID-19</FONT>
project </I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>7,722</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>29</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(100</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)%&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total other operating income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,962</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,583</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(62</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2022, our other operating income was &#128;4.6&nbsp;million, as compared to
&#128;12.0&nbsp;million for the year ended December 31, 2021, a decrease of &#128;7.4&nbsp;million, or 62%. This decrease was primarily due to a 100% decrease in subsidies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research Tax Credits </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year
ended December 31, 2022, we recognized research tax credits for our research and development projects of &#128;4.5&nbsp;million, as compared to &#128;4.2&nbsp;million for the year ended December 31, 2021, an increase of &#128;0.3&nbsp;million, or
6%. This increase was primarily due to a slight increase in research and development expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Subsidies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2022, our subsidy income was &#128;29,000, as compared to &#128;7.7&nbsp;million for the year ended
December&nbsp;31 2021. This decrease was primarily due to there being no new subsidy entitlement in 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31,
2021, we recorded a &#128;7.7&nbsp;million subsidies income, mainly composed by subsidies received from Bpifrance for the obefazimod <FONT STYLE="white-space:nowrap">COVID-19</FONT> Program. This subsidy was initially recorded as a conditional
advance in 2020 and as subsidy in 2021, following the waiver received from Bpifrance in April 2021 after the termination of trial in March 2021. As a result, we terminated our related financing agreement with Bpifrance in March 2021, recording in
2021 an income of &#128;4.5&nbsp;million, corresponding to the carrying amount of the advance at this date, as a result of Bpifrance&#146;s agreement to waive the conditions of the advance. In addition, for the year ended December 31, 2021, we
recorded income of &#128;3.3&nbsp;million reflecting additional payments received from Bpifrance to reimburse additional expenses incurred until the termination date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Total Operating Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the
year ended December 31, 2022, our total operating expenses were &#128;69.4&nbsp;million, as compared to &#128;53.4&nbsp;million for the year ended December 31, 2021, an increase of &#128;16.1&nbsp;million, or 30%. This increase was primarily due to
an increase in goodwill impairment loss and in general and administrative expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our research and development expenses by drug candidate and therapeutic indication for the years ended December
31, 2022 and 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(In thousands of euros)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Obefazimod</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>43,979</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>45,024</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Ulcerative Colitis</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>20,684</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>38,555</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>86</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Crohn&#146;s Disease</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>136</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>1</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(100</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)%&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Rheumatoid Arthritis</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>2,422</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>848</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(65</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)%&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Covid-19</FONT></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>1,171</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(768</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(166</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)%&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Obefazimod Other Indication</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>433</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>68</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(84</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)%&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Transversal activities</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>19,132</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>6,321</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(67</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)%&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ABX196</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,198</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>693</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(42</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)%&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ABX711</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>287</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B><I></I></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B><I>&#151;</I></B><B>&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B><I></I></B><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Others</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,604</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,291</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(12</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Research and development expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>47,781</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>48,295</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2022, our research and development expenses were &#128;48.3&nbsp;million, as
compared to &#128;47.8&nbsp;million for the year ended December 31, 2021, an increase of &#128;0.5&nbsp;million, or 1%. This increase was primarily due to the &#128;17.9&nbsp;million, or 86%, increase in obefazimod for UC expenses, as we completed
our Phase 2b clinical trial in early 2022 and initiated our Phase 3 clinical trial in the first half of 2022, with the first patient in the United States enrolled in October 2022, as well as an increase of &#128;0.3&nbsp;million related to
commencing development of our novel drug candidate ABX711. This increase was offset by a decrease of &#128;12.8&nbsp;million in transversal activities following the completion of our existing studies and no new studies on these projects began in
2022, a decrease of &#128;1.9&nbsp;million in <FONT STYLE="white-space:nowrap">COVID-19</FONT> research expenses and a decrease of &#128;1.6&nbsp;million in expenses related to our rheumatoid arthritis clinical trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2022, our general and administrative expenses were &#128;7.5&nbsp;million, as compared to
&#128;5.6&nbsp;million for the year ended December 31, 2021, an increase of &#128;1.9&nbsp;million, or 34%. This increase was primarily due to an increase in other general and administrative expenses, as well as increases in consulting, and
professional fees. The &#128;2.2&nbsp;million, or 181%, increase in other general and administrative expenses in 2022 was primarily due to increased expenses related to financial and legal consulting fees. These increases were partially offset by a
decrease in personnel costs, mainly due to a reversal of share-based compensation expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Goodwill Impairment Loss </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2022, we recorded a goodwill impairment loss of &#128;13.6&nbsp;million, as compared to no goodwill impairment
loss for the year ended December 31, 2021. The goodwill impairment loss was primarily related to an impairment test conducted with respect to the ABX196 cash-generating unit as a result of significant external changes in the hepatocellular carcinoma
treatment landscape, which are expected to require a new, lengthy, heavy and risky internal development process (use of a combination of compounds). As such, while we considered the option of entering into a licensing partnership to fund the
completion of the clinical development of ABX196, we made the decision to freeze the development program for ABX196 in the treatment of hepatocellular cancer, which led to full impairment of ABX196 goodwill. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Income (Loss) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the
year ended December 31, 2022, our net operating loss was &#128;64.8&nbsp;million, as compared to a net operating loss of &#128;41.4&nbsp;million for the year ended December 31, 2021, an increase of &#128;23.4&nbsp;million, or 57%. This increase was
primarily due to an increase in goodwill impairment charges, a decrease in other operating income, as well as an increase in general and administrative expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financial Income (Loss) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the
year ended December 31, 2022, our net financial income was &#128;4.1&nbsp;million, as compared to a net financial loss of &#128;1.1&nbsp;million for the year ended December 31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2022, our net financial income was mainly a result of a &#128;9.4&nbsp;million decrease in the fair value of
derivatives (mainly due to the decrease in our share price over the period) and a &#128;1.4&nbsp;million decrease in other liabilities at fair value through profit or loss (mainly in Prosynergia <FONT STYLE="white-space:nowrap">earn-out</FONT>
liability), which was partially offset by an increase in interest expenses of &#128;3.7&nbsp;million in relation to the Kreos bonds and &#128;2.6&nbsp;million in relation to our OCEANE bonds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2021, our net financial loss was mainly a result of interest expenses of &#128;2.3&nbsp;million in relation to
the Kreos bonds and &#128;1.1&nbsp;million in relation to our OCEANE bonds, partially offset by a &#128;2.4&nbsp;million decrease in the fair value of derivatives. The decrease in the fair value of derivatives is mainly due to the decrease in our
share price over the period. See &#147;&#151;Liquidity and Capital Resources.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Income Taxes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each of the years ended December 31, 2022 and 2021, our income tax charge was zero. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended
December 31, 2022, our net loss for the period was &#128;60.7&nbsp;million, as compared to &#128;42.5&nbsp;million for the year ended December 31, 2021, an increase of &#128;18.3&nbsp;million, or 43%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the <FONT STYLE="white-space:nowrap">Six-Month</FONT> Periods Ended June&nbsp;30, 2023
and 2022 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our results of operations for the <FONT STYLE="white-space:nowrap">six-month</FONT> period
ended June&nbsp;30, 2023 and 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(In thousands of euros)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2022&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2023&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Other operating income</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,284</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,255</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)%&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Sales and marketing expenses</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&#8194;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(155</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&#8194;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Research and development expenses</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(15,107</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(32,622</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>116</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>General and administrative expenses</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(2,223</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(6,758</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>204</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Goodwill impairment loss</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(10,986</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&#8194;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&#8194;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(28,317</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(39,535</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>40</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(26,033</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(37,280</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>43</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Financial expenses</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(2,346</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(15,030</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>541</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Financial income</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>7,195</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>357</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(95</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)%&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,849</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(14,673</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(403</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)%&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss before tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(21,183</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(51,953</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>145</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Income tax</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&#8194;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&#8194;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&#8194;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(21,183</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(51,953</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>145</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Total Operating Income </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2023, our total operating income was
&#128;2.3&nbsp;million, as compared to &#128;2.3&nbsp;million for the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2022; there was no significant variation during the period, as detailed below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Operating Income </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table sets forth our other operating income for the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2023 and 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(Amounts in thousands of euros)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2022&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2023&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CIR (Research Tax Credit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsidies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>18</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(88</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)%&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total other operating income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,284</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,255</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research Tax Credits </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2023, we recognized research tax credits for our research
and development projects of &#128;2.2&nbsp;million, as compared to &#128;2.2&nbsp;million for the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2022. There was no significant variation during the period due to the
maximum amount of eligible outsourced research and development expenses being capped (similar to June&nbsp;30, 2022) and internal research and development costs being stable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Total Operating Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the <FONT
STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2023, our total operating expenses were &#128;39.5&nbsp;million, as compared to &#128;28.3&nbsp;million for the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended
June&nbsp;30, 2022, an increase of &#128;11.2&nbsp;million, or 40%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
This increase was primarily due to an increase in research and development expenses by &#128;17.5&nbsp;million and general and administrative expenses by &#128;4.5&nbsp;million, partially offset
by the absence of goodwill impairment loss as of June&nbsp;30, 2023 (compared to &#128;11.0&nbsp;million as of June&nbsp;30, 2022). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sales and
Marketing Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2023, our total sales and
marketing expenses were &#128;0.2&nbsp;million. We did not incur any sales and marketing expenses in 2022. These expenses consist of the newly hired employees within the Sales and Marketing department, including our Chief Commercial Officer in 2023.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our research and development expenses by drug candidate and therapeutic indication for the <FONT
STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2023 and 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(In thousands of euros)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2022&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2023&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Obefazimod</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13,398</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30,915</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>131</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Ulcerative Colitis</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>9,335</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>26,196</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>181</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Crohn&#146;s Disease</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>0</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&#8194;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(100</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)%&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Rheumatoid Arthritis</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>514</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>382</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(26</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)%&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Covid-19</FONT></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(723</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>5</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(101</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)%&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Obefazimod Others Indication</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>34</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>68</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>99</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Transversal activities</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>4,238</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>4,263</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>1</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ABX196</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>358</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>46</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(87</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)%&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ABX711</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>561</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Others</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,351</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(19</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)%&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Research and Development expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15,107</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32,622</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>116</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2023, our research and
development expenses were &#128;32.6&nbsp;million, as compared to &#128;15.1&nbsp;million for the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2022, an increase of &#128;17.5&nbsp;million, or 116%. This increase was
primarily due to a &#128;17.5&nbsp;million, or 131%, increase in obefazimod clinical expenses, driven by the progression of our Phase 3 clinical trials. In addition, we incurred additional expenses of &#128;0.6&nbsp;million related to the
development initiation of our novel drug candidate ABX711 in the second half of 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2023, our general and administrative expenses were
&#128;6.8&nbsp;million, as compared to &#128;2.2&nbsp;million for the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2022, an increase of &#128;4.5&nbsp;million, or 204%. This increase was primarily due to an increase
in personnel costs, resulting from management changes that occurred during the period and the reversal of share-based compensation expenses incurred in 2021 that was recorded in the first half of 2022. The increase was also due to an increase in
consulting and professional fees related to recruitment and legal activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Goodwill Impairment Loss </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We did not record any goodwill impairment loss for the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2022, we recorded a goodwill impairment loss of
&#128;11.0&nbsp;million. This impairment loss relates to an impairment test conducted in the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2022 on the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ABX196 cash generating unit as a result of significant external changes in the hepatocellular carcinoma treatment landscape. These changes were expected to require a new, lengthy and risky
internal development process (involving use of a combination of compounds). For additional information see Note 3.1 to our unaudited interim condensed consolidated financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operating Income (Loss) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the <FONT
STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2023, our operating loss was &#128;37.3&nbsp;million, as compared to a loss of &#128;26.0&nbsp;million for the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended
June&nbsp;30, 2022, an increased loss of &#128;11.2&nbsp;million, or 43%, primarily as the result of an increase of &#128;17.5&nbsp;million in research and development expenses and an increase of &#128;4.5&nbsp;million in general and administrative
expenses. These increases were partially offset by the absence of goodwill impairment recorded over the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2023, as compared to the &#128;11.0&nbsp;million loss recorded over
the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Income (Loss) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2023, we recorded net financial loss of
&#128;14.7&nbsp;million, as compared to a net financial income of &#128;4.8&nbsp;million for the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2022, a decrease of &#128;19.5&nbsp;million, or 403%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2023, our financial expenses were &#128;15.0&nbsp;million
and were primarily related to royalty certificates (&#128;7.3 million). These expenses result from our reassessment of the probability of future cash flows related to the certificates. This change reflects the higher probability to reach the
objectives of our development and commercialization plans, following the recent changes in management and governance, as well as our Phase 2b <FONT STYLE="white-space:nowrap">two-year</FONT> open-label maintenance trial for UC. Our financial
expenses were also due to an increase in the fair value of the convertible option related to OCEANE bonds by &#128;4.2&nbsp;million and the Kreos Tranche A BSA and Kreos Tranche B BSA&#146;s fair values by an aggregate amount of
&#128;1.4&nbsp;million (as a result of a significant change in market conditions and an increase in our share price), partially offset by our financial income of &#128;0.4&nbsp;million which was mainly the result of the effect of unwinding the
discount related to the long-term CRO advances amounting to &#128;0.3&nbsp;million. For additional information see Note 21 to our unaudited interim condensed consolidated financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2022, our financial expenses were &#128;2.3&nbsp;million
and were primarily related to interests related to the bonds issued under the First KC Agreement and the Second KC Agreement, for an aggregate amount of &#128;0.9&nbsp;million, and interests related to the OCEANE bonds for &#128;1.3&nbsp;million.
They were offset by our financial income, amounting to &#128;7.2&nbsp;million. Our financial income primarily resulted from decreases in the fair values of the Kreos Tranche A BSA, Kreos Tranche B BSA and the convertible option related to
convertible bonds issued in July 2021 and the <FONT STYLE="white-space:nowrap">earn-out</FONT> liability related to the acquisition of Prosynergia, amounting to respectively &#128;1.6&nbsp;million, &#128;1.0&nbsp;million, &#128;3.3&nbsp;million and
&#128;1.3&nbsp;million, as a result of the significant change in market conditions and a decrease in our share price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Income Taxes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each of the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2023 and 2022, our income tax charge was zero.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Net Loss </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the <FONT
STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2023, our net loss for the period was &#128;52.0&nbsp;million, as compared to a net loss of &#128;21.2&nbsp;million for the <FONT STYLE="white-space:nowrap">six-month</FONT>
period ended June&nbsp;30, 2022, an increase of &#128;30.8&nbsp;million, or 145% as a result of the significant increases in operating expenses (in an amount of &#128;11.2 million), mostly driven by our research and development expenses, and
increases in financial expenses (in the amount of &#128;12.7 million) previously described. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sources of Liquidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
incurred substantial operating losses since inception and expect to continue to incur significant operating losses for the foreseeable future and may never become profitable. For the six-month periods ended June 30, 2023 and 2022 and the years ended
December 31, 2022 and 2021, we reported net losses of &#128;52.0&nbsp;million, &#128;21.2 million, &#128;60.7&nbsp;million and &#128;42.5 million, respectively. As of June 30, 2023, we carried forward accumulated tax losses of &#128;355.4 million.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, we have financed our operations through the issuance of ordinary shares with gross aggregate proceeds of &#128;333.9
million, of which &#128;130 million of gross proceeds were from offerings of our ordinary shares on Euronext Paris in February 2023, bank borrowings and structured loans for &#128;125.0 million, reimbursements of CIR in an amount of &#128;26.6
million, subsidies received from Bpifrance (including &#128;13.5&nbsp;million of subsidies and &#128;6.6 million of conditional advances) and royalty certificates in an amount of &#128;2.9&nbsp;million. As a result of (a) our existing cash and cash
equivalents of &#128;114.4 million as of June 30, 2023, (b)&nbsp;the net proceeds of the August 2023 drawdown of the first tranches of the Kreos / Claret Financing and the Heights Financing, collectively amounting to &#128;27.2 million (net of
repayments of all outstanding amounts that remained due under the First KC Agreement, the Second KC Agreement and the OCEANE bonds), (c) the available drawdowns of the second tranches of the Kreos / Claret Financing and the Heights Financing (which
tranches are not conditional on the amount of proceeds raised in this offering), collectively amounting to &#128;65 million in gross proceeds and (d) the expected reimbursement of the CIR from 2022 in the second half of 2023 amounting to
&#128;4.5&nbsp;million, we expect to be able to fund our forecasted operating cash flow requirements through the third quarter of 2024. This takes into account our assumption that R&amp;D expenditure will be substantially increased in 2023 driven by
the progression of the Phase 3 clinical trials of obefazimod, which started enrollment of patients with moderately to severely active UC in October 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect we will be able to extend our financing horizon beyond the third quarter of 2024 through additional dilutive and non-dilutive
financing, which could include a combination of capital increase, venture loans and convertible bonds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the above and the actions
we have taken, management has concluded that the substantial doubt about our ability to continue as a going concern has been alleviated beyond 12 months from issuance of the accompanying financial statements, and the accompanying financial
statements have been prepared on a going concern basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Capital Increases </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have been financed primarily by capital increases from our founders and investors, net proceeds from the initial public offering
of our ordinary shares on Euronext Paris in France in 2015, and additional <FONT STYLE="white-space:nowrap">follow-on</FONT> capital increases. We have not yet commercialized any of our drug candidates, which are in various phases of clinical
development, and we do not expect to generate revenue from sales of any products for several years, if at all. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale
of equity, debt financings or other capital sources, including potential collaborations with other companies or other strategic transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our main capital increases since inception. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(In thousands of euros)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross&nbsp;proceeds&nbsp;amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial Public Offering (Euronext) - June&nbsp;23, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">57,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital increase from issuance of ordinary shares - July 11, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital increase from issuance of ordinary shares - October 29, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">28,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital increase from issuance of ordinary shares - July 27, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">60,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital increase from issuance of ordinary shares - September 7, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">46,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital increase from issuance of ordinary shares - March&nbsp;1, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">130,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;23, 2015, we received gross proceeds of &#128;57.7&nbsp;million from the
issuance of 2,707,089 new ordinary shares at a subscription price of &#128;21.30 per share. The proceeds were primarily used for financing older research and development programs (pivotal study in Asia for ABX203 in chronic hepatitis B treatment and
the Phase 2 trial for obefazimod in HIV/AIDS treatment), which have since been terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;11, 2019, we received gross
proceeds of &#128;12.0&nbsp;million from the issuance of 1,500,000 new ordinary shares at a subscription price of &#128;8.00 per share. The proceeds were primarily used for the clinical development of obefazimod (including a Phase 2b clinical
trial), Phase 2a clinical trials for RA and the ABX196 treatment of hepatocellular cancer in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October 29, 2020, we
received gross proceeds of &#128;28.0&nbsp;million from the issuance of 1,620,370 new ordinary shares at a subscription price of &#128;17.28 per share. The proceeds were primarily used to finance the progress of obefazimod clinical trials in chronic
inflammatory diseases and for general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July 27, 2021, we received gross proceeds of &#128;60.0&nbsp;million from
the issuance of 1,964,031 ordinary shares at a subscription price of &#128;30.55 per share. The proceeds were primarily used to finance the progress of obefazimod clinical trials in chronic inflammatory diseases, for general corporate purposes,
payments with respect to, and redemption of, certain existing indebtedness, and advancement of ABX196 for the treatment of hepatocellular carcinoma. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September 7, 2022, we received gross proceeds of &#128;46.2&nbsp;million from the issuance of 5,530,000 ordinary shares at a subscription
price of &#128;8.36 per share, and the issuance of royalty certificates of &#128;2.9&nbsp;million, for a total financing of &#128;49.2&nbsp;million. See &#147;Business&#151;Key Collaborations and Partners&#151;Financing Arrangements&#151;Royalty
Certificates.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;1, 2023, we received gross proceeds of &#128;130.0&nbsp;million from the issuance of 20,000,000
ordinary shares at a subscription price of &#128;6.50 per share. The proceeds were primarily used to finance the progress of obefazimod clinical trials in chronic inflammatory diseases and for general corporate purposes (research and development
expenses and loans maturities payments). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Equity Line </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into an equity line agreement with Kepler Cheuvreux in September 2017. In accordance with the terms of this agreement, Kepler
Cheuvreux, acting as financial intermediary and guarantor, committed to subscribe for 970,000 ordinary shares, at its option in line with a schedule lasting no longer than 24 months, at an issuance price based on an average market price weighted
according to the volumes traded over the two trading days preceding each issue, less a maximum discount of 7.0%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We renewed this
financing line and entered into an agreement on September 30, 2019, with Kepler Cheuvreux, who committed to subscribe for 730,000 ordinary shares (corresponding to the number of shares unsubscribed as of September 30, 2019, and granted under the
previous agreement) under the same terms and conditions for a period of 24 months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September 24, 2021, we extended the agreement for
an additional <FONT STYLE="white-space:nowrap">12-month</FONT> period with respect to the unsubscribed shares at that date. This agreement was terminated on September 30, 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research Tax Credits </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From our inception
to June&nbsp;30, 2023, we have benefited from refunds of CIRs in a total amount of &#128;26.6&nbsp;million. In August 2021, we received CIRs of &#128;2.6&nbsp;million with respect to the year ended December 31, 2020. In October 2022, we received
CIRs of &#128;4.2&nbsp;million with respect to the year ended December 31, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bpifrance&#151;Conditional Advances and Subsidies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have received several conditional advances and subsidies from Bpifrance since our inception. Funds received from Bpifrance in the form of
conditional advances are recognized as financial liabilities, as we have a contractual obligation to reimburse Bpifrance for such conditional advances in cash based on a repayment schedule. Each award of an advance is made to help fund a specific
development milestone. Subsidies are <FONT STYLE="white-space:nowrap">non-repayable</FONT> grants, which are recognized in the financial statements when there exists reasonable assurance that we will comply with the conditions attached to the
subsidies and the subsidies will be received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the monies granted by and received from Bpifrance as of
June&nbsp;30, 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(In thousands of euros)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Contract&nbsp;status</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount&nbsp;awarded</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount&nbsp;collected</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Conditional advances</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>26,387</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,609</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Carena</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>Ongoing</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&#128;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>3,830</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&#128;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>2,187</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">RNP-VIR</FONT></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>Ongoing</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&#128;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>6,298</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&#128;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>4,032</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Ebola</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>Stopped</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&#128;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>390</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&#128;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>390</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">COVID-19</FONT></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>Stopped</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&#128;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>15,869</I></TD>
<TD NOWRAP VALIGN="bottom"><I><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&#8194;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Subsidies</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 7,475</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13,524</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Carena</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>Ongoing</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&#128;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>1,397</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&#128;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>1,187</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">RNP-VIR</FONT></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>Ongoing</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&#128;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>2,112</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&#128;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>1,123</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Ebola</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>Stopped</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&#8194;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&#8194;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">COVID-19</FONT></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>Stopped</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&#128;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>3,967</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&#128;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>11,214</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>33,862</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20,133</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Following the termination of the study in March 2021, the conditional advance of &#128;6.3&nbsp;million paid in
2020 was reclassified as a subsidy, following the waiver received from Bpifrance to repay the conditional advance. See &#147;&#151;Bpifrance &#150; <FONT STYLE="white-space:nowrap">COVID-19.&#148;</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bpifrance&#151;CARENA Contract </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part
of the development of therapeutic and diagnostic solutions targeting alternative splicing and RNA interference in the fields of virology <FONT STYLE="white-space:nowrap">(HIV-AIDS,</FONT> <FONT STYLE="white-space:nowrap">HTLV-1)</FONT> and
metabolism (obesity), SPLICOS, which we acquired in October 2014, entered into a Master Support Agreement and a conditional advance contract on December 2013 for the &#147;CARENA&#148; Strategic Industrial Innovation Project (&#147;CARENA
project&#148;), with Bpifrance. Under this contract, we are eligible to receive up to &#128;3.8&nbsp;million in conditional advances to develop a therapeutic HIV treatment program with obefazimod. As of June&nbsp;30, 2023, we had received
&#128;2.2&nbsp;million of conditional advances, of which &#128;1.2&nbsp;million was received in December 2013, &#128;1.0&nbsp;million in September 2014 and &#128;29,000 in June 2016. The repayment of these funds is spread from the date on which the
repayments are called by Bpifrance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Bpifrance&#151;RNP-VIR</FONT> Contract </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the CARENA project, focused on the clinical development of a drug molecule and demonstrating the validity of an innovative
therapeutic approach targeting viral RNPs, we entered into a Master Support Agreement with Bpifrance, as well as a beneficiary agreement dated March 21, 2017, with conditional advances for the
<FONT STYLE="white-space:nowrap">&#147;RNP-VIR&#148;</FONT> structuring research and development project for competitiveness. Under the <FONT STYLE="white-space:nowrap">RNP-VIR</FONT> contract, we are eligible to receive up to &#128;6.3&nbsp;million
in conditional advances to develop methods for the discovery of new molecules for the treatment of viral infectious diseases through the development of the &#147;Modulation of RNA biogenesis&#148; platform. As of June&nbsp;30, 2023, we had received
&#128;4.0&nbsp;million of conditional advances, of which &#128;1.8&nbsp;million was received in September 2017, &#128;0.3&nbsp;million in August 2018 and &#128;1.9&nbsp;million </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in November 2019. The repayment of these funds is spread from the date on which the repayments are called by Bpifrance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bpifrance&#151;Ebola </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <I>Bpifrance
</I>and Occitane Region joint support agreement was entered into on June&nbsp;2, 2017 and provides for conditional advances for a total amount of &#128;0.4&nbsp;million (&#128;0.1&nbsp;million from the Languedoc Roussillon Midi
Pyr&eacute;n&eacute;es Region and &#128;0.3&nbsp;million from <I>Bpifrance</I>) for the Ebola program. All funds under this contract were received. In September 2019, we terminated this program due to the imminent licensing of a competing vaccine
for this indication, as well as changes in the macroeconomic climate for public funding. The reimbursement of the conditional advance is spread over the period from September 2019 to June 2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Bpifrance&#151;COVID-19</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;22, 2020, we entered into agreements with Bpifrance setting out the conditions for aid to contribute to the financing of the
development of obefazimod as a potential therapeutic option for the treatment of <FONT STYLE="white-space:nowrap">COVID-19</FONT> patients at risk of developing a severe form of the disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This financing covered the conduct of a <FONT STYLE="white-space:nowrap">&#147;miR-AGE&#148;</FONT> international clinical trial as well as
all additional clinical, preclinical, regulatory and industrial work to enable registration and accelerated access to obefazimod in the <FONT STYLE="white-space:nowrap">COVID-19</FONT> indication. The
<FONT STYLE="white-space:nowrap">&#147;miR-AGE&#148;</FONT> clinical trial was conducted under our sole responsibility, in collaboration with the University Hospital of Nice, which was tasked with the financial and administrative coordination of the
study, with the rest of the work being borne by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The maximum amount of aid available under the framework agreement was
&#128;36.0&nbsp;million, of which &#128;19.8&nbsp;million was allocated directly to us (reflecting &#128;15.9&nbsp;million in conditional advances and &#128;4.0&nbsp;million in grants). Bpifrance&#146;s participation was paid according to the
achievement of certain phases and milestones during the development program for the <FONT STYLE="white-space:nowrap">COVID-19</FONT> Program, broken down as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">grants for a maximum total amount of &#128;20.1&nbsp;million, including &#128;4.0&nbsp;million for us (or a grant
rate of 16% of planned expenditure) and &#128;16.2&nbsp;million for the University Hospital of Nice (or a grant rate of 100% of planned expenditure); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conditional advances for a maximum total amount of &#128;15.9&nbsp;million for us (or a rate of 64% of total
planned expenditure). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2020, we had received a grant of &#128;1.6&nbsp;million and net proceeds from
the conditional advance of &#128;6.3&nbsp;million. In view of the results of the study and the recommendations of the Data and Safety Monitoring Board, we terminated the study on March 5, 2021. As Bpifrance had recorded the project as unsuccessful,
we recognized an income of &#128;4.5&nbsp;million (discounted amount) as a result of Bpifrance&#146;s agreement to waive the conditions of the advance as of June 30, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2021, we had also received an additional payment covering expenses incurred until the termination date amounting to
&#128;3.3&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Indebtedness </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Kreos /
Claret Financing Agreements </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July 24, 2018, we entered into a &#128;20 million venture loan agreement with KC (the &#147;First KC
Agreement&#148;). The financing consisted of two tranches of structured debt financing: (i) a total principal amount of &#128;10 million, comprised of (x) &#128;8 million in non-convertible bonds issued in July 2018 and (y) &#128;2 million in
convertible bonds issued in August 2018 (the &#147;First Tranche A Notes&#148;) and (ii) a total principal amount of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#128;10&nbsp;million, comprised of (x) &#128;8 million in non-convertible bonds and (y) &#128;2 million in convertible bonds, each issued in May 2019 (the &#147;First Tranche B Notes&#148;,
together with the First Tranche A Notes, the &#147;First KC Notes&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October 12, 2020, we entered into a bonds issue agreement
with KC (the &#147;Second KC Agreement&#148;), pursuant to which we issued bonds in a total principal amount of &#128;15 million, comprised of (i) a &#128;10 million tranche (the &#147;Second Tranche A Notes&#148;) and a &#128;5 million tranche (the
&#147;Second Tranche B Notes&#148;), with an option to issue an additional &#128;5 million tranche (the &#147;Second Tranche C Notes&#148; and collectively with the Second Tranche A Notes and the Second Tranche B Notes, the &#147;Second KC
Notes&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Second Tranche A Notes were issued in October 2020, and the Second Tranche B Notes were issued in November 2020. The
Second KC Notes rank pari passu with the First KC Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;20, 2023, we entered into the Framework Subscription Agreement
with KC and Claret, as the Secured Lenders. Under this Framework Subscription Agreement, we may draw up to &#128;75 million in structured debt financing in three tranches of &#128;25 million in aggregate principal amount each, as further described
below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The first tranche, with an aggregate principal amount of &#128;25 million, takes the form of senior secured convertible bonds with
warrants attached (i.e., the Kreos / Claret OCABSA). We drew the first tranche on August&nbsp;21, 2023. On the same date, we repaid all outstanding amounts that remained due under the First KC Agreement and the Second KC Agreement. The Kreos /
Claret OCABSA are convertible into ordinary shares at any time from their issuance at the request of their holders at a fixed conversion price of &#128;21.2209, subject to standard adjustments, including anti-dilution and dividend protections. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The second tranche, with an aggregate principal amount of &#128;25 million, takes the form of senior secured non-convertible bonds and may be
drawn before March 31, 2024, subject to satisfaction of customary closing conditions. The drawdown of the second tranche is subject to a maximum 10% Debt-To-Market Capitalization Ratio at the time of drawdown. The &#147;Debt-To-Market Capitalization
Ratio&#148; is calculated, on any relevant date, by dividing (i) our indebtedness (including amounts due under the Kreos / Claret Financing, but excluding amounts due under the Heights Financing), by (ii) our market capitalization calculated by
multiplying the number of our outstanding ordinary shares by the closing price of our ordinary shares on such relevant date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The third
tranche, with an aggregate principal amount of &#128;25 million, takes the form of senior secured non-convertible bonds and may be drawn before July 31, 2024, subject to satisfaction of customary closing conditions. The drawdown of the third tranche
is subject to a maximum 10% Debt-To-Market Capitalization Ratio at the time of drawdown and is conditional on our raising of a minimum of $125 million in gross proceeds through a listing on Nasdaq before June 30, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information regarding these agreements, see &#147;Business&#151;Key Collaborations and Partners&#151;Financing
Arrangements&#151;Kreos / Claret Financing Agreements.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>OCEANE Bonds </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July 30, 2021, we issued &#128;25 million 6% convertible senior unsecured and unsubordinated bonds due July 30, 2026 corresponding to
654,621 convertible bonds (the &#147;OCEANE bonds&#148;). The OCEANE bonds were exchangeable, at the option of the bondholders, for new or existing shares and bear interest at a rate of 6% per annum, payable semi-annually on January 30 and July 30
of each year, beginning January 30, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Heights Convertible Notes </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;20, 2023, we entered into the Heights Subscription Agreement with Heights. Under the Heights Subscription Agreement, we may draw
up to &#128;75 million of the Heights Convertible Notes in two tranches of &#128;35 million and &#128;40 million, respectively, as further described below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The first tranche in aggregate principal amount of &#128;35 million was drawn on August 24,
2023. On the same date, we repaid all amounts due under the OCEANE bonds. The Heights Convertible Notes are convertible into ordinary shares at any time from their issuance at the request of the holder at a fixed conversion price set at
&#128;23.7674, subject to standard adjustments, including anti-dilution and dividend protections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The second tranche in aggregate
principal amount of up to &#128;40 million may be drawn during the period from the date immediately following the three-month anniversary of the issuance of the first tranche to the first-year anniversary of the issuance of the first tranche. It may
be drawn in up to two separate closings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information regarding these agreements, see &#147;Business&#151;Key Collaborations and
Partners&#151;Financing Arrangements&#151;Heights Convertible Notes.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>State-Guaranteed Loan (Pr&ecirc;t Garantis par l&#146;Etat
(&#147;PGE&#148;)) </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2020, we obtained a <FONT STYLE="white-space:nowrap">non-dilutive</FONT> financing in the form of a
state-guaranteed loan of &#128;5.0&nbsp;million. The loan was structured with an initial maturity of 12 months at 0.25% and a five-year extension option. In March 2021, we exercised the five-year extension option with a <FONT
STYLE="white-space:nowrap">one-year</FONT> deferral of principal repayment, with the following conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a revised interest rate of 0.58% per annum, excluding insurance and state-guaranteed premium; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a state-guaranteed premium of &#128;0.1&nbsp;million to be paid by installments over the contract period starting
in June 2021. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Royalty Certificates </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the completion of the capital increase from issuance of ordinary shares on September 2, 2022, we issued royalty certificates with a
subscription price amounting to &#128;2.9&nbsp;million. The royalty certificates entitle their holders to royalties equal to 2% of the future net sales of obefazimod (worldwide and for all indications) as from the commercialization of such product.
The amount of royalties that may be paid under the royalty certificates is capped at &#128;172.0&nbsp;million in the aggregate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes in Cash Flows
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash inflows and outflows for six-month periods ended June 30, 2023 and 2022 and the years ended
December 31, 2022 and 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months&nbsp;ended<BR>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(In thousands of euros)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash flows (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,048</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,714</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash flows from (used in) investing activities </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,232</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,026</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,712</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash flows provided by (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,431</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,915</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase (decrease) in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>31,399</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(33,751</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(207</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(34,098</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>87,432</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(356</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents at the beginning of the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>29,302</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>60,701</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>107</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>60,701</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>26,950</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(56</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents at the end of the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>60,701</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>26,950</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(56</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>26,602</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>114,381</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>330</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2022, cash used in operating activities was &#128;53.9&nbsp;million, as compared to &#128;45.0&nbsp;million for
the year ended December 31, 2021, an increase of &#128;8.9&nbsp;million, or 20%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2022, cash used in operating activities mainly reflected our
net loss of &#128;60.7&nbsp;million and was primarily used for our research and development efforts (&#128;48.3 million) as a result of progression of our portfolio development (partially offset by the elimination of the amortization of intangibles
and depreciation of property and equipment on the ABX196 cash generating unit), enhanced by an increase in derivatives and liabilities fair value of &#128;10.8&nbsp;million, a decrease in trade payables of &#128;2.4&nbsp;million and offset by an
increase in interest expenses of &#128;7.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2021, cash used in operating activities mainly
reflected our net loss of &#128;42.5&nbsp;million and was primarily used for our research and development efforts (&#128;47.8 million) as a result of progression of our portfolio development and net <FONT STYLE="white-space:nowrap">non-cash</FONT>
expense of &#128;1.9&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the six-month period ended June 30, 2023, cash used in operating activities was &#128;27.6
million, as compared to &#128;24.7 million for the six-month period ended June 30, 2022, a decrease of &#128;2.9 million, or 12%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the
six-month period ended June 30, 2023, cash used in operating activities mainly reflects our net operating loss of &#128;37.3 million and was primarily used for our research and development efforts (&#128;32.6&nbsp;million) as a result of the
progression of the UC Phase 3 clinical trial and partially offset by the net increase in our working capital (&#128;9.2 million). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the
six months ended June 30, 2022, cash used in operating activities was primarily used for our research and development efforts (&#128;15.1 million) and to finance the net decrease in our working capital (&#128;8.4&nbsp;million). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cash used in
investing activities for the year ended December&nbsp;31, 2022, was mainly composed of (i)&nbsp;CRO contracts advances for clinical trials which have to be recovered at the end of the trials, amounting to &#128;12.2&nbsp;million, and by
(ii)&nbsp;the completion of the acquisition of Prosynergia in 2022 and the remaining payment of the acquisition price of &#128;2.9&nbsp;million, partially offset by (iii)&nbsp;the <FONT STYLE="white-space:nowrap">non-recurring</FONT>
&#128;3.3&nbsp;million advance repayment from University Hospital of Nice as part of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> Program clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2021, cash used in investing activities was &#128;6.2&nbsp;million, and was mainly composed by the
&#128;4.0&nbsp;million advance payment to the University Hospital of Nice as part of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> Program clinical trial, as well as our entry in 2021 of a &#128;1.4&nbsp;million loan agreement to fund the
acquisition of Prosynergia and an advance payment made with respect to the acquisition of &#128;0.3&nbsp;million. The loan was made to allow early repayment by Prosynergia of its existing indebtedness. For accounting purposes, this loan is
considered as a prepayment for the acquisition of Prosynergia&#146;s assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the six-month period ended June 30, 2023, cash used in
investing activities was &#128;1.7 million, as compared to &#128;3.0 million for the six-month period ended June 30, 2022, a decrease of &#128;1.2 million, or 42%. For the six-month period ended June 30, 2023, cash used in investing activities was
mainly due to the payment of additional long-term CRO advances amounting to &#128;1.6 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the six-month period ended June 30,
2022, cash used in investing activities was mainly due to the &#128;2.9&nbsp;million payment made for the acquisition of Prosynergia, including related costs and net of cash acquired. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financing Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended
December 31, 2022, cash from financing activities was &#128;32.2&nbsp;million, which consisted primarily of &#128;46.2&nbsp;million of net proceeds from a capital increase (including transaction costs of &#128;3.3 million), net proceeds from the
issuance of the royalty certificates in an amount of &#128;2.9&nbsp;million, partially offset by &#128;13.4&nbsp;million of repayments under the First KC Notes and the Second KC Notes and interest paid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2021, cash from financing activities was
&#128;82.7&nbsp;million, which consisted primarily of &#128;60.0&nbsp;million of net proceeds from a capital increase (including transaction costs of &#128;4.2 million), &#128;8.1&nbsp;million of net proceeds from the exercise of share warrants
(BSA) under the equity line agreement, &#128;1.5&nbsp;million of net proceeds from the exercise of other share warrants (BSA), and net proceeds from the issuance of the OCEANE bonds in an amount of &#128;24.9&nbsp;million, partially offset by
&#128;7.4&nbsp;million of repayments under the First KC Notes and the Second KC Notes and interest paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the six-month period ended
June 30, 2023, cash provided by financing activities was &#128;116.7 million, which consisted of net proceeds from a capital increase of &#128;123.3 million (including transaction costs of &#128;6.7&nbsp;million), partially offset by repayments
under the First KC Notes and the Second KC Notes (in an amount of &#128;3.7&nbsp;million), PGE (in an amount of &#128;1.3 million) and interest paid (in an amount of &#128;1.2 million). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the six-month period ended June 30, 2022, cash used in financing activities was &#128;6.4 million, which consisted primarily of repayments
under the First KC Notes and the Second KC Notes (in an amount of &#128;5.4&nbsp;million) and interest paid (in an amount of &#128;0.9 million). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material Cash Requirements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Contractual Obligations
and Loans </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth aggregate information about material contractual obligations as of June&nbsp;30, 2023 and
December&nbsp;31, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The commitment amounts in the table below are associated with contracts that are enforceable and legally binding
and that specify all significant terms, including, fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing of the actions under the contracts. Future events could cause actual payments to differ
from these estimates. All amounts except the retirement benefits in the table below are presented gross and are undiscounted. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June 30, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(In thousands of euros)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>1 year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than<BR>1 year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>1 year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than<BR>1 year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial debt obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>52,445</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>47,457</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,403</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,126</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retirements benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>610</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>594</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Off-balance</FONT> sheet obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>194,731</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>187,375</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>208,473</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>40,716</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>249,188</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>199,475</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>37,077</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>236,552</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of our business, we regularly use the services of subcontractors and enters into
research and partnership arrangements with various CROs and with public-sector partners or subcontractors, who conduct clinical trials and studies in relation to the drug candidates. <FONT STYLE="white-space:nowrap">Off-balance</FONT> sheet
obligations in the table above are commitments related to these research and partnership agreements. They are classified at less than one year maturity in the absence of a fixed schedule in contracts, in case of multiple-year contracts, such as CRO
contracts. CRO contracts include payments that are conditional to the completion of future development milestones. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our material cash
requirements in the above table do not include potential future royalty payments related to the royalty certificates, amounting to 2% of the future net sales of obefazimod (worldwide and for all indications). The amount of royalties that may be paid
under the royalty certificates is capped at &#128;172.0 million in the aggregate. Royalty payments are expected to take place before the expiry date of the certificates, which is 15 years after their issuance date (September 2, 2037). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, our contractual obligations and loans were &#128;249.2&nbsp;million, comprising financial debt obligations of
&#128;52.4&nbsp;million (in turn, comprising &#128;13.1&nbsp;million with respect to First KC Notes and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Second KC Notes, &#128;25.0&nbsp;million with respect to the OCEANE bonds, &#128;5.0&nbsp;million with respect to the PGE, &#128;6.4&nbsp;million with respect to conditional advances from
Bpifrance and &#128;2.9&nbsp;million with respect to royalty certificates), and <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet obligations of &#128;194.7&nbsp;million with respect to purchase obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2023, our contractual obligations and loans were &#128;236.6&nbsp;million comprising financial debt obligations of
&#128;47.4&nbsp;million (in turn, comprising &#128;9.4&nbsp;million with respect to First KC Notes and Second KC Notes, &#128;25.0&nbsp;million with respect to the OCEANE bonds, &#128;3.8&nbsp;million with respect to the PGE, &#128;6.3&nbsp;million
of conditional advances from Bpifrance and &#128;2.9&nbsp;million with respect to royalty certificates) and <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet obligations of &#128;187.4&nbsp;million with respect to purchase obligations. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operating Capital and Capital Expenditures Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred substantial operating losses since inception and expect to continue to incur significant operating losses for the foreseeable
future and may never become profitable. For the six-month period ended June 30, 2023, we recorded a net loss of &#128;52.0 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2023, our cash and cash equivalents were &#128;114.4 million. We believe that based on our anticipated net proceeds from this
offering, together with (a) our existing cash and cash equivalents of &#128;114.4 million as of June 30, 2023, (b) the net proceeds of the August 2023 drawdown of the first tranches of the Kreos / Claret Financing and the Heights Financing,
collectively amounting to &#128;27.2 million (net of repayments of all outstanding amounts that remained due under the First KC Agreement, the Second KC Agreement and the OCEANE bonds), (c) the anticipated net proceeds from the drawdown of the
second tranche of the Kreos / Claret Financing, amounting to &#128;25 million (which is a portion of the total available drawdown of &#128;65 million from the Kreos / Claret Financing and the Heights Financing) and (d) the expected Research Tax
Credit (CIR) reimbursements would enable us to fund our operations through the fourth quarter of 2025. Under these assumptions and based on our current clinical plan, we would have sufficient funds to finance our operations through (i) the
announcement of our top-line data from the Phase 3 ABTECT-1 and ABTECT-2 induction trials for UC and (ii) the announcement of our top-line data from the Phase 2a induction trial for CD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we further draw down on the third tranche of the Kreos / Claret Financing, amounting to &#128;25 million and the second tranche of the
Heights Financing amounting to &#128;40 million, we expect to have sufficient funds to finance our operations into the second quarter of 2026. Under these assumptions and based on our current clinical plan, we would have sufficient funds to finance
our operations through the announcement of our top-line data from the Phase 3 ABTECT maintenance trial for UC. For additional details relating to the Kreos / Claret Financing and the Heights Financing, see &#147;Business&#151;Key Collaborations and
Partners&#151;Financing Arrangements.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our present and future funding requirements will depend on many factors, including,
among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size, progress, timing, and completion of our preclinical studies and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of potential new drug candidates we identify and decide to develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs involved in filing patent applications and maintaining and enforcing patents or defending against
claims or infringements raised by third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the time and costs involved in obtaining regulatory approval for our drug candidates and any delays we may
encounter as a result of evolving regulatory requirements or adverse results with respect to any of these drug candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selling and marketing activities undertaken in connection with the anticipated commercialization of obefazimod
and any other current or future drug candidates and costs involved in the creation of an effective sales and marketing organization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of revenue, if any, we may derive either directly or in the form of milestones or royalty payments
from our existing or future partnership or collaboration agreements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the severity, duration and impact of the Russia/Ukraine war, which may continue to adversely impact our business
and clinical trials. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;Risk Factors&#151;Risks Related to our Financial Position and Need for Additional
Capital&#148; for additional risks associated with our substantial capital requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Internal Control Over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A company&#146;s internal control over financial reporting is a process designed by, or under the supervision of, a company&#146;s principal
executive and principal financial officers, or persons performing similar functions, and effected by a company&#146;s board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements in accordance with IFRS. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material
misstatement of the company&#146;s annual or interim financial statements will not be prevented or detected on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We must
maintain effective internal controls over financial reporting in order to accurately and timely report our results of operations and financial condition. In addition, as a public company listed in the United States, the Sarbanes-Oxley Act will
require, among other things, that we assess the effectiveness of our internal controls over financial reporting at the end of each fiscal year, starting with the end of the first full fiscal year after the completion of the U.S. offering. However,
our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting for so long as we are an &#147;emerging growth company,&#148; which may be up to five fiscal
years following the date of this U.S. offering. An independent assessment of the effectiveness of our internal controls could detect problems that our management&#146;s assessment might not. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management has not completed an assessment of the effectiveness of our internal controls over financial reporting, and our independent
registered public accounting firm has not conducted an audit of our internal controls over financial reporting. In conjunction with preparing our financial statements as of and for the years ended December 31, 2022 and 2021 and as of and for the
six-month period ended June 30, 2023 for this offering, material weaknesses in our internal controls over financial reporting were identified. The material weaknesses related to a lack of risk assessment as well as formal, documented and implemented
processes, controls and review procedures, specifically due to a lack of a sufficient number of professionals with an appropriate level of internal control knowledge, training and experience. These material weaknesses did not result in a material
misstatement to our financial statements included herein, however these material weaknesses could result in material inaccuracies in our financial statements and impair our ability to comply with applicable financial reporting requirements and
related regulatory filings on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a remediation plan to address these material weaknesses and strengthen
our controls in these areas. In this regard, we have started to reorganize our finance and accounting function by hiring additional experienced employees to provide more review and oversight over our financial processes. While we are working to
remediate the material weaknesses as quickly and efficiently as possible, we cannot at this time provide the expected timeline in connection with implementing our remediation plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2023, we had not yet completed remediation of these material weaknesses. These remediation measures may be time-consuming
and costly and might place significant demands on our financial and operational resources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, neither our management nor an independent registered public accounting firm has
performed an evaluation of our internal control over financial reporting in accordance with the provisions of the <FONT STYLE="white-space:nowrap">Sarbanes-Oxley</FONT> Act. Had we or our independent registered public accounting firm performed an
evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act, additional material weaknesses may have been identified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;Risk Factors&#151;Risks Related to our Financial Position and Need for Additional Capital&#151;There are material weaknesses in our
internal controls over financial reporting and if we are unable to maintain effective internal controls over financial reporting, the accuracy and timeliness of our financial reporting may be adversely affected, which could adversely affect our
business, investor confidence and the market price of our securities.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Recent Pronouncements Issued by the IASB </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A description of accounting policies and estimates along with a description of the recently-issued accounting pronouncements that may
potentially impact our financial position and results of operations is disclosed in Note 4 and 2 respectively to our financial statements as of and for the six-month period ended June&nbsp;30, 2023, appearing elsewhere in this prospectus. We did not
have to change our accounting policies or make retrospective adjustments as a result of adopting these standards, which include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IAS 1 Presentation of Financial Statements and IFRS Practice Statement 2 &#150; Disclosure of
Accounting Policies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IAS 8 &#150; Definition of Accounting Estimates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IAS 12 &#150; Deferred Tax related to Assets and Liabilities arising from a Single Transaction;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IFRS 17 &#150; Insurance Contracts and related amendments. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We did not elect for early application of the new standards, amendments and interpretations, which were issued but not mandatory as of January
1, 2023. We assessed the impacts resulting from the application of these recently issued accounting pronouncements and concluded that impacts are not material. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no standards that are issued and not yet effective that are expected to have a material impact on our financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A description of quantitative and qualitative disclosures about market risk is disclosed in Note 27 to our financial statements as of and for
the year ended December 31, 2022 appearing elsewhere in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal financial instruments we hold are cash and cash
equivalents. The purpose of holding these instruments is to finance our ongoing business activities. It is not our policy to invest in financial instruments for speculative purposes. We do not use derivative financial instruments for hedging
purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal risks to which we are exposed are liquidity risk, interest rate risk, foreign currency exchange risk and credit
risk. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidity Risk </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Liquidity risk
management aims to ensure that we dispose of sufficient liquidity and financial resources to be able to meet our present and future obligations. We prepare short-term cash forecasts and annual operating
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cash flow forecasts as part of our budget procedures. Prudent liquidity risk management involves maintaining sufficient liquidity, having access to financial resources through appropriate credit
facilities and being able to unwind market positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have required substantial amounts of cash since inception.
Developing pharmaceutical drug candidates, including conducting clinical trials, is expensive, lengthy, and risky, and we expect our research and development expenses to increase substantially in connection with our ongoing activities. Accordingly,
we will continue to require substantial additional capital to continue our clinical development activities and potentially engage in commercialization activities. See &#147;&#151;Operating Capital and Capital Expenditures Requirements.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to meet any additional financing needs, we may seek to obtain one or more dilutive or
<FONT STYLE="white-space:nowrap">non-dilutive</FONT> financings depending on market conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest Rate Risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to market risks in connection with our medium- and long-term borrowings that are subject to variable interest rates. We have not
adopted any other recurring mechanism of hedging to protect against interest rate fluctuations. We may consider in the future using a suitable policy to hedge interest rate risks in a more significant manner, if needed. Due to a significant increase
in market interest rates over the year ended December&nbsp;31, 2022, we have performed a reassessment of our exposure to interest rate risk. As of December&nbsp;31, 2022, all of our financial liabilities accounted for at amortized cost bear fixed
interest rates, except for the First KC Notes, which bear interest based on <FONT STYLE="white-space:nowrap">3-month</FONT> Euribor plus an 8% margin. Due to the <FONT STYLE="white-space:nowrap">3-month</FONT> Euribor being capped at 1% (in
accordance with contractual terms), the First Tranche A Notes being repaid in full in December 2022 and the First Tranche B Notes maturing November 2023, we have limited exposure. We believe a hypothetical 100 basis point change in interest rates
during any of the periods presented would not have had a material effect on our financial statements included elsewhere in this prospectus. Over the six-month period ended June 30, 2023, we did not identify significant changes in market conditions
that would lead us to reassess our exposure to interest rate risk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Kreos / Claret OCABSA and the Heights Convertible Notes issued in
August 2023 bear fixed annual interest rates of 9% and 6%, respectively. Therefore, the Kreos / Claret Financing and the Heights Financing do not contribute to increasing our exposure to interest rate risk. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Foreign Currency Exchange Risk </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
exposed to a risk of exchange rate fluctuations on commercial transactions performed in currencies different from our functional currency in which we record the transactions. We have not adopted any other recurring mechanism of hedging to protect
against currency fluctuations. From time to time, we may nevertheless subscribe for currency term accounts in order to cover a commitment in currency. We may consider in the future using a suitable policy to hedge exchange risks in a more
significant manner, if needed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables set forth the operating expenses we incurred in foreign currencies in
the years ended December 31, 2021 and 2022 as well as the six-month periods ended June 30, 2023 and 2022. Some figures have been rounded. Accordingly, the totals in the tables may not be the exact sums of component items. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Foreign&nbsp;currency</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Euros</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Foreign&nbsp;currency</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Euros</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Currency</B> <I>(thousands)</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Australian dollar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Israeli shekel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Japanese yen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hungarian forints</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pound sterling</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Swedish krona</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Swiss franc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States dollar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,050</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,144</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Foreign&nbsp;currency</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Euros</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Foreign&nbsp;currency</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Euros</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Currency</B> (<I>thousands</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Danish Kroner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hungarian forints</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pound sterling</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Swedish krona</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Swiss franc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States dollar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,012</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,504</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2022, the total amount of operating expenses we incurred in foreign currencies
was &#128;2.1&nbsp;million, or 3.1% of our total operating expenses of &#128;69.4&nbsp;million in that year. For the year ended December 31, 2021, the total amount of operating expenses we incurred in foreign currencies was &#128;3.0&nbsp;million,
or 5.7% of our total operating expenses of &#128;53.4&nbsp;million in that year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the six-month period ended June 30, 2023, the total
amount of operating expenses we incurred in foreign currencies was &#128;1.5 million, or 3.8% of our total operating expenses of &#128;39.5 million for the period. As of June 30, 2023, we hold no assets in foreign currencies other than advance
salary payments made to employees for $0.3 million. For the six-month period ended June 30, 2022, the total amount of operating expenses we incurred in foreign currencies was &#128;1.0 million, or 3.6% of our total operating expenses of &#128;28.3
million for the period. As of June 30, 2022, we held no assets in foreign currencies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Credit Risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The credit risk related to our cash and cash equivalents is not significant in light of the quality of our
<FONT STYLE="white-space:nowrap">co-contracting</FONT> financial institutions. As of June&nbsp;30, 2023, substantially all our cash and cash equivalents were maintained with one financial institution in France. While our deposit accounts are insured
up to the legal limit, the balances we maintain may, at times, exceed this insured limit. As of June&nbsp;30, 2023 we maintained &#128;114.3&nbsp;million in bank deposit accounts that are in excess of the legally insured limit in one legally insured
financial institution. We have not experienced any losses in such accounts and we do not believe that we are exposed to any significant credit risk related to these instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The credit risk related to our other receivables and related account is minimal. In
particular, the credit risk related to advances made to CROs is deemed insignificant due to their credit ratings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOBS Act Exemptions and Foreign
Private Issuer Status </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company&#148; as defined in the U.S. Jumpstart Our Business Startups Act
of 2012 (&#147;JOBS Act&#148;). An emerging growth company may take advantage of specified reduced reporting and other burdens that are otherwise applicable generally to public companies. These provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from the auditor attestation requirement in the assessment of our internal control over financial
reporting pursuant to the Sarbanes-Oxley Act of 2002; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with any requirement that may be adopted by the PCAOB regarding mandatory audit firm
rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to the extent that we no longer qualify as a foreign private issuer, reduced disclosure about our company&#146;s
executive compensation arrangements and exemptions from the requirements to obtain a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on executive compensation or a shareholder approval of any golden parachute arrangements.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these provisions for up to five years or such earlier time that we are no longer an emerging
growth company. We would cease to be an emerging growth company if we have more than $1.235&nbsp;billion in annual revenue, have more than $700&nbsp;million in market value of our ordinary shares held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> or issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over a three-year period. We may choose to take advantage of some but not all of these
reduced burdens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period
for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. Given that we currently
report and expect to continue to report under IFRS, as issued by the IASB, we are not able to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which
adoption of such standards is required by the IASB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have taken advantage of reduced reporting requirements in this prospectus.
Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold equity securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon consummation of the offering, we will report under the Exchange Act as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> company with
foreign private issuer status. As a result, in accordance with Nasdaq Listing Rule 5615(a)(3), we may choose to comply with home country governance requirements and certain exemptions thereunder rather than complying with certain of the corporate
governance requirements of Nasdaq. Even after we no longer qualify as an emerging growth company, as long as we qualify as a foreign private issuer under the Exchange Act, we will be exempt from certain provisions of the Exchange Act that are
applicable to U.S. domestic public companies, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations with respect
to a security registered under the Exchange Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading
activities and liability for insiders who profit from trades made in a short period of time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> containing unaudited financial and other specified information, or current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> upon the occurrence of specified significant events; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Regulation FD, which regulates selective disclosures of material information by issuers. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_13"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biotechnology company focused on developing therapeutics that harness the body&#146;s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. We are currently evaluating our lead drug candidate,
obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis (&#147;UC&#148;). We are also in the planning stages of initiating a Phase 2a clinical trial of obefazimod in patients with
Crohn&#146;s disease (&#147;CD&#148;), as well as evaluating other potential inflammatory indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We focus on indications where
existing treatments have left patients with significant unmet needs, and where we believe our investigational agents have the potential to be meaningfully differentiated from currently available therapies. The indications we target have substantial
populations and represent large commercial opportunities, pending regulatory approvals and successful commercialization. Our initial focus is on inflammatory bowel diseases (&#147;IBD&#148;), chronic conditions involving inflammation of the
gastrointestinal (&#147;GI&#148;) tract, of which the two most common forms are UC and CD. As of 2022, an aggregate of approximately 2.9&nbsp;million patients across the United States, EU4 (France, Germany, Italy and Spain), the United Kingdom and
Japan suffered from IBD, with 1.5&nbsp;million of these patients in the United States alone. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the primary goals of IBD therapy is
to achieve durable&nbsp;clinical remission while simultaneously taking into consideration a patient&#146;s quality of life and concerns regarding potential side effects. Despite a number of different therapies approved for UC and CD, the vast
majority of these therapies require chronic administration via injections or intravenous infusions, and may come with serious and concerning warnings, including, but not limited to, risks of serious infections leading to hospitalizations or death
and increased risks of various malignancies. A vast majority of IBD patients do not achieve clinical remission with existing therapies, and a significant number of patients will lose response over time, especially those patients on TNF-<FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitor therapy where anti-drug antibodies are very common. Further, despite the increased number of biosimilars, such as TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitor therapies, becoming
available for the treatment of IBD, biosimilars unfortunately do not alleviate any of the potential side&nbsp;effect concerns that often cause patients to delay, or avoid altogether, stepping up to more advanced therapies. In addition, although a
small number of oral therapies have more recently been approved for the treatment of IBD, these therapies also come with concerning potential side effects, which can discourage patients from initiating treatment with advanced therapies. Therefore,
there continues to be significant unmet need for novel oral therapies with durable efficacy, improved safety profiles and minimal preinitiation requirements for patients with moderately to severely active IBD. Moreover, we believe the IBD market has
significant growth potential driven by growing diagnosis of these diseases and increased penetration of oral treatments with improved benefit/risk profiles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our lead drug candidate, obefazimod, is differentiated from competing approaches for the treatment of IBD via its novel mechanism
of action. Obefazimod was demonstrated to specifically enhance the expression of a single <FONT STYLE="white-space:nowrap">micro-RNA,</FONT> <FONT STYLE="white-space:nowrap">miR-124,</FONT> which plays a critical role in the regulation of the
inflammatory response. In the context of inflammation, <FONT STYLE="white-space:nowrap">miR-124</FONT> is a natural regulator of the inflammatory response, controlling progression of inflammation and restoring homeostasis of the immune system,
without causing broader immunosuppression. In contrast to currently available advanced therapies, prescribed post-conventional therapies, some of which target only a single cytokine or pathway, <FONT STYLE="white-space:nowrap">miR-124</FONT>
modulates the expression of several key cytokines and pathways. Modulating multiple inflammatory pathways simultaneously may lead to more durability of efficacy results over the long-term, which is critical in lifelong conditions such as IBD,
potentially differentiating obefazimod from currently available IBD treatments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our Phase 2 clinical trials for the treatment of
moderately to severely active UC, consistent with the pharmacological effects observed in our preclinical studies, obefazimod demonstrated an onset of symptom relief by day 8 of dosing, with meaningful reductions in rectal bleeding and stool
frequency scores. In our induction </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Phase 2b clinical trial, which included 252 patients, obefazimod met the primary endpoint of a statistically significant reduction in Modified Mayo Score, a measure of disease activity relative
to placebo. In addition, we observed high rates of sustained and newly achieved clinical remission in the subsequent open-label maintenance extension trial of up to two years of treatment, of which approximately 45% of patients were previously
exposed to biologics or Janus kinase (&#147;JAK&#148;) inhibitors. Greater than 90% of patients previously exposed to advanced therapy prior to enrollment were highly refractory, having failed two advanced therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2023, we reported the results from the final analysis of our Phase 2b open-label maintenance trial, including 217 patients of which
164 patients (76%) completed the second year of once-daily oral treatment with 50 mg obefazimod. At the conclusion of the second year of treatment, 114 of the 217 patients enrolled (53%) achieved clinical remission and 158 patients (73%) achieved
clinical response. Among the 98 <FONT STYLE="white-space:nowrap">bio-refractory</FONT> patients, 66&nbsp;patients (67%) had a clinical response, 38 patients (39%) were in clinical remission, 46&nbsp;patients (47%) had endoscopic improvement and
20&nbsp;patients (20%) had endoscopic remission at week&nbsp;96. Among the 124&nbsp;patients that achieved clinical response at the end of the 8-week induction period of the double-blind study, 82 patients (66%) achieved clinical remission at week
48, mimicking the re-randomization of responders approach typically utilized in Phase 3 maintenance trials. Of the 124 patients in clinical response at week 8, 74 patients (60%) achieved clinical remission, 95 patients (77%) had clinical response,
79 patients (64%) achieved endoscopic improvement and 52 patients (42%) achieved endoscopic remission at week 96. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2023,
we reported an interim analysis of step-down dosing from 50 mg to 25 mg for the third and fifth year of open-label maintenance treatment with obefazimod in UC patients. These patients were treated with 50 mg of oral, once-daily obefazimod for
approximately four years in the Phase 2a clinical trial and approximately two years in the Phase 2b clinical trial. Patients were eligible to enroll in the trial if they had a Mayo endoscopic subscore of 0 or 1. Eligible patients were switched to 25
mg, and an interim analysis was performed at week 48 with a cut-off date of July 31, 2023. Of the 71 eligible patients, 63 completed their <FONT STYLE="white-space:nowrap">48-week</FONT> visit. Among these patients, 53 out of 63 patients (84%)
demonstrated disease control (stable or improved Modified Mayo Score). No new safety signals were detected in UC patients treated up to five years with oral, once-daily obefazimod. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obefazimod&#146;s tolerability profile indicates potentially important clinical differentiation. As of November&nbsp;30, 2022 (the last safety
data <FONT STYLE="white-space:nowrap">cut-off</FONT> date), 1,074 patients and volunteers had been treated with obefazimod, of which 209 patients were treated with 50 mg obefazimod for one year or more with no change in the observed tolerability
profile underscored by 76% of patients that remained on therapy throughout the <FONT STYLE="white-space:nowrap">two-year</FONT> open-label maintenance trial period. No new adverse safety signals were observed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We initiated our pivotal Phase 3 clinical trials of obefazimod for the treatment of moderately to severely active UC in October 2022, which
consist of two induction trials <FONT STYLE="white-space:nowrap">(ABTECT-1</FONT> and <FONT STYLE="white-space:nowrap">ABTECT-2)</FONT> and one ABTECT maintenance trial. <FONT STYLE="white-space:nowrap">Top-line</FONT> data from the <FONT
STYLE="white-space:nowrap">ABTECT-1</FONT> and <FONT STYLE="white-space:nowrap">ABTECT-2</FONT> induction trials is expected to be announced in the first quarter of 2025, and <FONT STYLE="white-space:nowrap">top-line</FONT> data from the ABTECT
maintenance trial is expected to be announced in the first quarter of 2026. We intend to (i) file an Investigational New Drug Application (&#147;IND&#148;) in the fourth quarter of 2023, (ii) initiate a Phase 2a clinical trial in patients with CD in
the first quarter of 2024 and (iii) announce Phase 2a induction trial top-line results in the second half of 2025 with the objective to demonstrate clinical response and tolerability profile consistent with that already observed in our clinical
trials for moderately to severely active UC. Based on the results from this Phase 2a clinical trial, we intend to proceed directly to a Phase 3 clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our team is comprised of industry leaders in the fields of biology, data analytics and drug development, as well as scientific experts in
chronic inflammatory diseases, including IBD. We are led by Marc de Garidel, our Chief Executive Officer, who has more than 40 years of experience in the pharmaceutical and biotechnology sector. Collectively, our team has decades of experience and a
proven track record of advancing compounds into and through clinical development and commercialization, including at the following organizations: Amgen, Arena Pharmaceuticals, AstraZeneca, BioNTech, Boehringer Ingelheim, Eli Lilly, Genentech/Roche,
Guerbet, Ipsen Pharmaceuticals, J&amp;J, Pfizer, Sanofi, Sanofi-Pasteur and Shire/Takeda. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Pipeline </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead drug candidate, obefazimod, is in clinical development for the treatment of moderately to severely active UC. We are continuing to
develop obefazimod for the treatment of CD and are evaluating additional potential inflammatory indications to pursue, subject to the availability of necessary resources and funding. In parallel, we are in the process of generating <FONT
STYLE="white-space:nowrap">follow-on</FONT> compounds based on the <FONT STYLE="white-space:nowrap">miR-124</FONT> platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The chart
below sets forth details relating to the current stages of development of our lead drug candidate: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g00r08.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Decision subject to results of the Phase 3 monotherapy induction trials. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>IBD Overview and Limitations of Existing Treatments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IBD, such as UC and CD, is a chronic life-long immune-mediated inflammatory condition of the GI tract with many contributing factors, including
genetic, environmental and immunologic. UC and CD are the two most common forms of IBD and are characterized by dysregulation of lymphocytes contributing to inflammation. Both UC and CD are chronic, relapsing, remitting, inflammatory conditions of
the GI tract that begin most commonly during adolescence and young adulthood. UC involves the innermost lining of the large intestine, and symptoms include abdominal pain and diarrhea, frequently with blood and mucus. CD can affect the entire
thickness of the bowel wall and all parts of the GI tract from mouth to anus. CD symptoms include abdominal pain, diarrhea and other more systemic symptoms, such as weight loss, nutritional deficiencies and fever. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IBD, as of 2022, affected approximately 1.5&nbsp;million patients in the United States alone. As of 2022, the prevalence of UC and CD in the
United States were estimated at approximately 0.9&nbsp;million and 0.6&nbsp;million patients, respectively. The prevalence of IBD in the EU4 and the United Kingdom is estimated at 1.2&nbsp;million with approximately 0.7&nbsp;million patients with UC
and 0.5&nbsp;million patients with CD. As of 2022, an aggregate of approximately 2.9&nbsp;million patients across the United States, EU4, the United Kingdom and Japan suffered from IBD. This figure is expected to grow to approximately 3.0 million
patients by 2028. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the primary goals of IBD therapy is to achieve durable&nbsp;clinical remission while simultaneously taking into
consideration a patient&#146;s quality of life and concerns regarding potential side effects. Despite a number of different therapies approved for UC and CD, the vast majority of these therapies require chronic administration via injections or
intravenous infusions, and may come with serious and concerning warnings, including, but not limited to, risks of serious infections leading to hospitalizations or death and increased risks of various malignancies. A vast majority of IBD patients do
not achieve clinical remission with existing therapies, and a significant number of patients will lose response over time, especially those patients on TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitor therapy where anti-drug antibodies
are very common. Further, despite the increased number of biosimilars, such as TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitor therapies, becoming available for the treatment of IBD, biosimilars unfortunately do not alleviate any of the
potential side&nbsp;effect concerns that often cause patients to delay, or avoid altogether, stepping </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
up to more advanced therapies. In addition, although a small number of oral therapies have more recently been approved for the treatment of IBD, these therapies also come with concerning
potential side effects, which can also discourage patients from initiating treatment with advanced therapies. Therefore, there continues to be significant unmet need for novel oral therapies with durable efficacy, improved safety profiles and
minimal preinitiation requirements for patients with moderately to severely active IBD. Moreover, we believe the IBD market has significant growth potential driven by growing diagnosis of these diseases and increased penetration of oral treatments
with improved benefit/risk profiles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2022, pharmaceutical sales in IBD were $16.3&nbsp;billion in the United States and
$7.4&nbsp;billion in the rest of the world, totaling $23.7&nbsp;billion worldwide. In 2028, pharmaceutical sales in IBD are estimated to be $17.5&nbsp;billion and $26.8&nbsp;billion in the United States and worldwide, respectively. Worldwide sales
in the UC market were $7.4&nbsp;billion in 2022 and are estimated to be $10.2&nbsp;billion in 2028, while in the CD market worldwide sales reached $16.3&nbsp;billion in 2022 and are estimated to be $16.6&nbsp;billion in 2028. We believe the IBD
market has significant growth potential driven by growing diagnosis of these diseases and increased penetration of oral treatments with improved benefit/risk profiles. We believe the potential for oral agents to gain significant market share is
supported by physician and patient preference for the convenience of oral administration over injectable agents, increasing demand for therapies with long-term efficacy profiles and the opportunity for potent and well-tolerated oral agents to expand
the overall segment of the moderately to severely active UC population undergoing treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medical treatment of IBD is typically
divided into two types of therapy: induction and maintenance. Induction therapy is used to reduce inflammation quickly (in three months or less) and maintenance therapy is used to sustain that reduction. Patients with IBD are classified by the
activity of their disease as either mild to moderately active or moderately to severely active based on the level of symptoms experienced, inflammatory biomarkers and severity of disease on endoscopy. The current standard of care for the treatment
of patients with&nbsp;moderately to severely active&nbsp;IBD is to reduce inflammation with anti-inflammatory agents. Patients with mild to moderately active IBD are treated with <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;conventional
therapies&#148; which are anti-inflammatory treatments that include: aminosalicylates (e.g., <FONT STYLE="white-space:nowrap">5-ASAs),</FONT> immunosuppressants or immunomodulators (e.g., <FONT STYLE="white-space:nowrap">6-mercaptopurine,</FONT>
methotrexate and azathioprine) and corticosteroids. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the widespread use of conventional therapies to treat mild to moderately
active IBD, due to the progressive and lifelong nature of both UC and CD, for many patients the severity of their disease progresses in activity and are considered moderately to severely active. This requires patients and their physicians to
consider using more targeted therapies typically termed &#147;advanced therapies.&#148; The majority of advanced therapies require chronic parenteral administration including
<FONT STYLE="white-space:nowrap">TNF-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitors (e.g., infliximab, adalimumab and golimumab), Interleukin <FONT STYLE="white-space:nowrap">(&#147;IL&#148;)-12/23</FONT> inhibitor (ustekinumab),
anti-integrin antibodies (vedolizumab) or <FONT STYLE="white-space:nowrap">IL-23</FONT> inhibitors (mirikizumab). There are also two classes of oral treatments including JAK inhibitors (e.g., tofacitinib, filgotinib and upadacitinib) and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sphingosine-1-phosphate</FONT></FONT> (&#147;S1P&#148;) receptor agonists (ozanimod). Although these therapies have demonstrated efficacy in UC and/or CD, the majority of IBD patients do
not achieve clinical remission, and a significant number of patients lose response over time, especially those treated with TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitor therapies where anti-drug antibodies are common. Due to
mechanisms of action that are poorly understood, with each line of advanced therapy that is exhausted, patients become less likely to respond to the next advanced therapy utilized in the sequence of care. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the advanced therapy classes are associated with notable side effect and safety tradeoffs that must be considered before initiating
treatment. For instance: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U><FONT STYLE="white-space:nowrap">TNF-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitors</U>:
Boxed warnings for increased risk of serious infections leading to hospitalizations or death and various forms of malignancies are noted in the United States prescribing information with similar warnings in the European Medicines Agency
(&#147;EMA&#148;) summary of product characteristics (&#147;SmPCs&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U><FONT STYLE="white-space:nowrap">IL-12/23</FONT> inhibitors</U>: Warnings in label for serious infections,
tuberculosis, malignancies and posterior reversible encephalopathy syndrome (PRES). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Anti-integrin antibodies</U>: Warnings in label for potential risk of Progressive Multifocal
Leukoencephalopathy (&#147;PML&#148;), gut specificity of vedolizumab may be connected with exacerbating or causing extraintestinal manifestations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U><FONT STYLE="white-space:nowrap">IL-23</FONT> inhibitors</U>: Warnings in the EU for severe infections and
risk of hepatic enzyme elevations (mirikizumab not approved in the United States). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>JAK inhibitors</U>: Boxed warnings for increased risk of serious infections leading to hospitalization or
death, higher rates of <FONT STYLE="white-space:nowrap">all-cause</FONT> mortality, malignancies, cardiovascular death, myocardial infarction, stroke and thrombosis appear in the United States prescribing information with similar warnings in the EU.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>S1P receptor agonists</U>: Warnings in label for infections, bradyarrhythmia and atrioventricular conduction
delays, liver injury and macular edema. These warnings result in multiple preinitiation requirements prior to initiating therapy. Risk of PML also exists. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients and physicians must take into consideration the lifelong burden of chronic parenteral administration for injectable agents and the
potential safety warnings for all therapies when deciding which treatment, if any, to initiate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart depicts the current
UC treatment landscape: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g00a32.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For patients who do not or no longer respond to treatment, or experience complications, surgical treatment
may be necessary. Approximately 50% to 80% of CD patients and 10% to 30% of UC patients require surgery over their lifetime. In light of the above, we believe that there is significant unmet medical need in the UC treatment paradigm due to imperfect
existing therapies with unfavorable clinical characteristics and limited efficacy that frequently wanes over time. A general patient preference for oral agents over injectables suggests a potential untapped market opportunity available for
efficacious, well-tolerated oral therapies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strengths </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the following strengths will allow us to advance our proprietary drug candidates through clinical trials, while building upon our
advanced position in the development of therapeutics for IBD and other chronic inflammatory diseases: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our focus on indications of high unmet need and substantial commercial potential, with an initial focus on
IBD.</B> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We focus on indications where existing treatments have left patients with significant unmet
needs, and where we believe our investigational agents have the potential to be meaningfully differentiated from currently available therapies. The indications we target have substantial populations and represent large commercial opportunities,
pending regulatory approvals and successful commercialization. Our initial focus is on IBD, chronic conditions involving inflammation of the GI tract, of which the two most common forms are UC and CD. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We believe the IBD market has significant growth potential driven by growing diagnosis of these diseases and increased penetration of oral
treatments with improved benefit/risk profiles. We believe the need for differentiated treatment options is high, in particular for patients with moderate and severe forms of IBD, for whom available therapies often have limited efficacy and
durability while carrying significant safety and tolerability challenges. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>We believe we are market leaders in leveraging <FONT STYLE="white-space:nowrap">micro-RNA</FONT> biology to
target inflammation.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We believe our lead drug candidate, obefazimod, is differentiated from competing approaches for
the treatment of IBD via its novel mechanism of action. Obefazimod was demonstrated to specifically enhance the expression of a single <FONT STYLE="white-space:nowrap">micro-RNA,</FONT> <FONT STYLE="white-space:nowrap">miR-124,</FONT> which plays a
critical role in the regulation of the inflammatory response. In the context of inflammation, <FONT STYLE="white-space:nowrap">miR-124</FONT> is a natural regulator of the inflammatory response, controlling progression of inflammation and restoring
homeostasis of the immune system, without causing broader immunosuppression. In contrast to currently available advanced therapies, prescribed post-conventional therapies, some of which target only a single cytokine or pathway, <FONT
STYLE="white-space:nowrap">miR-124</FONT> modulates the expression of several key cytokines and pathways. Modulating multiple inflammatory pathways simultaneously may lead to more durability of efficacy results over the long-term, which is critical
in lifelong conditions such as IBD, potentially differentiating obefazimod from currently available IBD treatments. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Robust data generated from our Phase 2 clinical trials of obefazimod for the treatment of moderately to
severely active UC. </B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In our Phase 2 clinical trials for the treatment of moderately to severely active UC,
consistent with the pharmacological effects observed in our preclinical studies, obefazimod demonstrated an onset of symptom relief by day 8 of dosing, with meaningful reductions in rectal bleeding and stool frequency scores. In our induction Phase
2b clinical trial, which included 252 patients, obefazimod met the primary endpoint of a statistically significant reduction in Modified Mayo Score, a measure of disease activity relative to placebo. In addition, we observed high rates of sustained
and newly achieved clinical remission in the subsequent open-label maintenance extension trial of up to two years of treatment, of which approximately 45% of patients were previously exposed to biologics or JAK inhibitors. Greater than 90% of
patients previously exposed to advanced therapy prior to enrollment were highly refractory, having failed at least two advanced therapies. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our lead drug candidate, obefazimod, has been well-tolerated in our clinical trials to date. </B>
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Obefazimod&#146;s tolerability profile indicates potentially important clinical differentiation. Many existing therapies
for IBD have been limited by safety and tolerability concerns, including increased risks of serious infections or various malignancies, sometimes requiring warning labels. By contrast, as of November&nbsp;30, 2022 (the last safety data <FONT
STYLE="white-space:nowrap">cut-off</FONT> date), the tolerability profile of obefazimod is supported by more than 1,074 patients and volunteers that had been treated with obefazimod, of which 209 patients were treated with 50 mg obefazimod for one
year or more with no change in the observed tolerability profile. In addition, to date, the entire obefazimod safety database presents no death or malignancies and no reported clinically significant changes in laboratory parameters, such as liver
function, hemoglobin levels and white blood cell counts. The most common treatment emergent adverse event (&#147;TEAE&#148;) reported has been mild to moderate headache, which has been transient and manageable with or without <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> medications. Furthermore, at present, no increased rate of opportunistic infections or malignancies compared with placebo have been observed across all
clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
trials. We conduct an annual analysis of clinical safety data from our ongoing clinical trials using an annual <FONT STYLE="white-space:nowrap">cut-off</FONT> date of November&nbsp;30 with the
intention to provide additional safety data in January of the following year. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Compelling and differentiating clinical characteristics position obefazimod as a potential first-line advanced
therapy for moderately to severely active UC.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Therapies currently available to patients with UC in the first-line
setting are limited to older, broad immunosuppressive agents with safety, tolerability and efficacy challenges. Advanced therapies, which include biologic agents such as TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitors, <FONT
STYLE="white-space:nowrap">IL-12/23</FONT> inhibitors or <FONT STYLE="white-space:nowrap">IL-23</FONT> inhibitors, carry significant safety and tolerability challenges and their administration, as injectable agents, is not convenient to patients.
Newer oral molecules, such as JAK inhibitors and S1P receptor agonists, while addressing convenient route of administration for patients, also present safety and tolerability challenges. Comparatively, obefazimod is being developed as a once-daily,
oral medication which, combined with its observed tolerability to date, would represent a meaningfully differentiated clinical profile from existing therapies. We believe this may position obefazimod as a potential first-line advanced therapy choice
for both prescribers and patients, if approved. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our experienced team is comprised of global industry leaders in the development of therapeutics for chronic
inflammatory diseases.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We believe that the breadth of experience and accomplishments of our management team, board
of directors and scientific advisory board, combined with our broad network of established relationships with leaders in the industry and medical community, provide us with fresh insights into drug development and commercialization, and have allowed
us to bring together top researchers to build interdisciplinary research and development teams. We are led by Marc de Garidel, our Chief Executive Officer, who has more than 40 years of experience in the pharmaceutical and biotechnology sector and
successfully led the sales of CinCor Pharma to AstraZeneca in 2023 and Corvidia Therapeutics to Novo Nordisk in 2020. Collectively, our team has decades of experience and a proven track record of advancing compounds into and through clinical
development and commercialization, including at the following organizations: Amgen, Arena Pharmaceuticals, AstraZeneca, BioNTech, Boehringer Ingelheim, Eli Lilly, Genentech/Roche, Guerbet, Ipsen Pharmaceuticals, J&amp;J, Pfizer, Sanofi,
Sanofi-Pasteur and Shire/Takeda. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary goal is to develop and commercialize obefazimod for the treatment of inflammatory diseases, starting with moderately to severely
active UC. We have already generated compelling data in moderately to severely active UC from our Phase 2a and 2b clinical trials, which we believe provides us with potential readthrough into a broader set of inflammatory diseases. We focus on
indications with high unmet needs with substantial commercial potential. To achieve our goal, we are pursuing the following key elements of our strategy: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Advance obefazimod through pivotal clinical trials and establish obefazimod as a potential first-line advanced
therapy for IBD.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We believe that the strength of the data we have generated in our Phase 2 clinical trials,
specifically the potential to demonstrate rapid onset of action and durability of safety and efficacy results (as evidenced by a clinical remission rate of 53%, clinical response rate of 73% and no new adverse safety signals observed from our
two-year Phase 2b open-label maintenance trial), if supported by the results of our Phase 3 clinical trials, uniquely positions obefazimod as a potential first-line advanced therapy choice for moderately to severely active UC, if approved. We
believe our data, if supported by the results of our Phase 3 clinical trials, well-positions obefazimod as a potential first-line advanced therapy choice for moderately to severely active UC, if approved. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Based on the positive clinical data generated in our UC trials, preclinical studies in dextran sulfate sodium (&#147;DSS&#148;) mouse model
which provide support for pursuing further development in CD, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
underlying biological and mechanistic rationale, we plan to initiate a Phase 2a clinical trial in patients with CD in the first quarter of 2024 to potentially demonstrate outcomes consistent with
those observed in our Phase 2 clinical trials for moderately to severely active UC. CD causes long-lasting inflammation and ulcers in the digestive tract, with fibrosis and stricturing, playing a key role in disease progression. It differs from UC
in that it affects the entire thickness of the bowel wall and all parts of the digestive tract from mouth to anus. However, CD shares many of the underlying pathophysiological processes and clinical manifestations of UC, and, as a result, the
current treatment paradigm of CD is similar to UC, as described further below. In addition, we believe that obefazimod&#146;s clinical profile observed to-date lends itself to potential combinations with existing or new therapies, which we are
exploring. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Disrupt the IBD landscape in the near-term with our Phase 3 data beginning in 2025.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Currently available therapies have limited efficacy and durability that wanes over time, have extensive pre-initiation requirements, carry
significant safety and tolerability challenges (such as black box safety warnings), and most of them are injectable biologics. We believe the potential for oral agents to gain significant market share is supported by physician and patient preference
for the convenience of oral administration over injectable agents, increasing demand for therapies with long-term efficacy profiles and the opportunity for potent and well-tolerated oral agents to expand the overall segment of the moderately to
severely active UC population undergoing treatment. We believe obefazimod&#146;s novel mechanism of action that modulates multiple inflammatory pathways simultaneously offers a potentially differentiated oral treatment option that may lead to more
durability of efficacy results as we observed in our Phase 2 clinical trials. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Leverage library of <FONT STYLE="white-space:nowrap">miR-124</FONT> enhancers to expand our pipeline.</B>
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We are currently prioritizing development of IBD treatments including for moderately to severely active UC and CD, but
are evaluating other additional indications that have similar immunologic characteristics. Based on the mechanistic concept of obefazimod, we have launched a research and development program to generate new potential drug candidates to strengthen
our intellectual property portfolio on the miR-124 platform and to identify additional drug candidates from our proprietary small molecule library that includes additional miR-124 enhancers. Our strategy is to conduct
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> studies with obefazimod to show that enhanced expression of <FONT STYLE="white-space:nowrap">miR-124</FONT> demonstrates disease-modifying effects in
other inflammatory conditions where there is unmet medical need, similar to our Phase 2a clinical trial in patients with rheumatoid arthritis (&#147;RA&#148;), where we saw encouraging
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data supporting obefazimod&#146;s potential role in addressing inflammatory conditions beyond IBD, to fully explore its potential. To further our
strategy, our first follow-on drug candidate is expected to be selected and enter preclinical development in 2024. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Opportunistically evaluate strategic partnerships to maximize the value of obefazimod and our therapeutic
pipeline.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We have discovered and are developing obefazimod as an innovative medicinal product and we currently hold
its worldwide rights. We intend to retain worldwide development and commercialization rights for obefazimod. For certain geographies, we may opportunistically enter into strategic partnerships to accelerate development activities in order to realize
the commercial potential of obefazimod as well as other assets in our pipeline. In connection with any potential strategic partnership, we plan to pursue and receive upfront funding, milestone payments and future royalties for these agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Team </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our team is comprised of
industry leaders in the fields of biology, data analytics and drug development, as well as scientific experts in chronic inflammatory diseases including IBD, with 34 full-time employees as of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
June&nbsp;30, 2023. Collectively, our team has decades of experience and a proven track record of advancing compounds into and through clinical development and commercialization. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Marc de Garidel, our Chief Executive Officer, has more than 40 years of experience in the pharmaceutical and
biotechnology sector, including 12 years of experience as Chief Executive Officer of pharmaceutical and biotechnology companies. Between July 2021 and April 2023, he served as Chief Executive Officer of CinCor Pharma and led its successful sale for
up to $1.8&nbsp;billion, subject to the achievement of certain milestones, to AstraZeneca in February 2023. From April 2018 until August 2020, he was Chief Executive Officer of Corvidia Therapeutics and led its sale to Novo Nordisk for
$2.1&nbsp;billion in total consideration. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Didier Blondel, our Chief Financial Officer and Board Secretary, was previously Chief Financial Officer at Sanofi
Pasteur MSD, a Lyon-based joint venture between Sanofi and Merck. Over the past 20 years, he has held a wide variety of senior finance positions at Sanofi in both Commercial Operations and Research and Development, including as Global Research and
Development Chief Financial Officer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sheldon Sloan, MD, M Bioethics, our Chief Medical Officer, has over 30 years of experience in academia and the
biopharmaceutical industry, with an extensive track record in the field of gastroenterology and IBD. Prior to joining us, Dr.&nbsp;Sloan worked for Arena Pharmaceuticals and, after its acquisition, for Pfizer, where he was Program Lead for
Etrasimod. Before joining Arena Pharmaceuticals, he held different leadership positions at Johnson and Johnson in Medical Affairs, Research and Development, and Science Policy, including Global Medical Affairs Leader for IBD, leading the global
launch strategy and execution for CD and UC for Stelara. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Michael Ferguson, MBA, our Chief Commercial Officer, has over 22 years of experience in the biopharmaceutical
industry, with an extensive track record in the field of gastroenterology and IBD. He has spent the last 16 years of his career in large pharmaceutical and biotech companies, including 13&nbsp;years in leading commercial positions at Shire/Takeda,
followed by Arena Pharmaceuticals, where he served as Vice President Global Commercial Marketing and Planning and specifically as Global Commercial Lead for Etrasimod across all GI Indications. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pierre Courteille, Pharmacist, MBA, our Chief Business Officer, has more than 25 years of experience in
marketing, sales and business development within the pharmaceutical industry. He has extensive commercial launch and marketing experience from prior roles as Senior Vice President of Sales and Marketing for Guerbet and Chief Executive Officer of
MEDEX, a medical device company owned by Guerbet, and Marketing Manager at Sanofi Pasteur Japan&#146;s joint-venture with Daiichi Sankyo. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Didier Scherrer, Ph.D., our Chief Scientific Officer, has extensive experience in the development of a portfolio
of therapeutics in oncology, viral diseases and autoimmune / inflammatory&nbsp;diseases. Prior to joining our company in March 2009, he performed a combined role of Chief Executive Officer and Scientific Director at Splicos. He also has experience
from prior roles as Associate Director (Capability Pathways&#151;Discovery Enabling Capabilities and Sciences) of the Research Department of AstraZeneca and as Head of Research at LFB Biotechnologies. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our management team also consists of other top industry veterans such as Paul Gineste, PharmD, our VP of Clinical
Operations and formerly International Clinical Trials Manager at Boehringer Ingelheim; J&eacute;r&ocirc;me Denis, Ph.D., our VP of Process Development&nbsp;&amp; Manufacturing and formerly Executive Head of Development&nbsp;&amp; Associate Director
of Vaccine Development at Imaxio; and Mary Mantock, MSc, our VP of Regulatory Affairs and formerly Executive Director, RA, Global Development for immune-oncology at Astellas. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is led by our Chairman and Chief Executive Officer, Marc de Garidel. Additional board members include: Corinna zur
Bonsen-Thomas, Co-founder and Chief Executive Officer of RetInSight and former General Counsel at Baxter International; Carol Brosgart, MD, Clinical Professor of Medicine, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Epidemiology and Biostatistics at the University of California, San Francisco; Kinam Hong MD, MBA, CFA, Partner at the Crossover Fund of Sofinnova; Troy Ignelzi, CFO of Karuna Therapeutics; June
Lee, MD, Venture Partner at 5AM Ventures; Paolo Rampulla, representing Sant&#233; Holdings SRL; and Philippe Pouletty, MD, our founder and Managing Partner at Truffle Capital, representing Truffle Capital. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Programs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead drug candidate,
obefazimod, is in clinical development for the treatment of moderately to severely active UC. We are continuing to develop obefazimod for the treatment of CD and are evaluating additional potential inflammatory indications to pursue, subject to the
availability of necessary resources and funding. In parallel, we are in the process of generating <FONT STYLE="white-space:nowrap">follow-on</FONT> compounds based on the <FONT STYLE="white-space:nowrap">miR-124</FONT> platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The chart below sets forth details relating to the current stages of development of our lead drug candidate: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g00r08.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Decision subject to results of the Phase 3 monotherapy induction trials. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Lead Drug Candidate for the Treatment of Inflammatory Diseases: Obefazimod </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obefazimod is an oral small molecule drug candidate in clinical development for the treatment of moderately to severely active UC. We believe
that obefazimod is the only small molecule drug candidate in clinical development with a mechanism of action that was demonstrated to specifically enhance the expression of a single <FONT STYLE="white-space:nowrap">micro-RNA,</FONT> <FONT
STYLE="white-space:nowrap">miR-124,</FONT> which plays a critical role in the regulation of the inflammatory response. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our induction
Phase 2b clinical trial, which included 252 patients, obefazimod met the primary endpoint of a statistically significant reduction in Modified Mayo Score, a measure of disease activity relative to placebo. We have observed an onset of symptom relief
by day 8 of dosing, with meaningful reductions in rectal bleeding and stool frequency scores, consistent with the pharmacological effects observed in our preclinical studies, and high rates of sustained and newly achieved clinical remission in the
subsequent open-label maintenance extension trial of up to two years of treatment, of which approximately 45% of patients were previously exposed to biologics or JAK inhibitors. In April 2023, we reported the results from the final analysis of our
Phase 2b open-label maintenance trial, including 217 patients of which 164 patients (76%) completed the second year of once-daily oral treatment with 50 mg obefazimod. At the conclusion of the second year of treatment, 114 of the 217 patients
enrolled (53%) achieved clinical remission and 158 patients (73%) achieved clinical response. Among the 98 <FONT STYLE="white-space:nowrap">bio-refractory</FONT> patients, 66 patients (67%) had a clinical response, 38 patients (39%) were in clinical
remission, 46 patients (47%) had endoscopic improvement and 20 patients (20%) had endoscopic remission at week 96. Among the 124 patients that achieved clinical response at the end of the 8-week induction period of the double-blind study, 82
patients (66%) achieved clinical remission at week 48, mimicking the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">re-randomization</FONT> of responders approach typically utilized in Phase 3 maintenance trials. Of the 124 patients in clinical response at week 8, 74 patients
(60%) achieved clinical remission, 95 patients (77%) had clinical response, 79 patients (64%) achieved endoscopic improvement and 52 patients (42%) achieved endoscopic remission at week 96. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2023, we reported an interim analysis of step-down dosing from 50 mg to 25 mg for the third and fifth year of open-label
maintenance treatment with obefazimod in UC patients. These patients were treated with 50 mg of oral, once-daily obefazimod for approximately four years in the Phase 2a clinical trial and approximately two years in the Phase 2b clinical trial.
Patients were eligible to enroll in the trial if they had a Mayo endoscopic subscore of 0 or 1. Eligible patients were switched to 25 mg, and an interim analysis was performed at week 48 with a cut-off date of July 31, 2023. Of the 71 eligible
patients, 63 completed their 48-week visit. Among these patients, 53 out of 63 patients (84%) demonstrated disease control (stable or improved Modified Mayo Score). No new safety signals were detected in UC patients treated up to five years with
oral, once-daily obefazimod. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, obefazimod&#146;s tolerability profile indicates potentially important clinical
differentiation. As of November&nbsp;30, 2022 (the last safety data <FONT STYLE="white-space:nowrap">cut-off</FONT> date), 1,074 patients and volunteers had been treated with obefazimod, of which 209 patients were treated with 50 mg obefazimod for
one year or more with no change in the observed tolerability profile underscored by 76% of patients that remained on therapy throughout the <FONT STYLE="white-space:nowrap">two-year</FONT> open-label maintenance trial period. No new adverse safety
signals were observed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We initiated our pivotal Phase 3 clinical trials of obefazimod for the treatment of moderately to severely active
UC in consultation with international regulators, including the U.S. Food and Drug Administration (the &#147;FDA&#148;), the EMA, the Pharmaceuticals and Medical Devices Agency (&#147;PMDA&#148;) and the China Center for Drug Evaluation
(&#147;CDE&#148;). These pivotal Phase 3 clinical trials consist of two induction trials <FONT STYLE="white-space:nowrap">(ABTECT-1</FONT> and <FONT STYLE="white-space:nowrap">ABTECT-2)</FONT> and one ABTECT maintenance trial in doses of 25 mg and
50 mg across 36 countries in North America, Latin America, Europe and Asia Pacific, involving 1,200 moderately to severely active UC patients in over 600 sites. Each of the trials will be randomized, double-blind and placebo-controlled, using
independent and central review of video-taped endoscopies with the primary endpoint of clinical remission according to the Modified Mayo Score assessed at week 8 (induction) and at week 44 (maintenance), as recommended by the FDA. Enrollment of the
first patient under this program occurred on October&nbsp;11, 2022. <FONT STYLE="white-space:nowrap">Top-line</FONT> data from the <FONT STYLE="white-space:nowrap">ABTECT-1</FONT> and <FONT STYLE="white-space:nowrap">ABTECT-2</FONT> induction trials
is expected to be announced in the first quarter of 2025, and <FONT STYLE="white-space:nowrap">top-line</FONT> data from the ABTECT maintenance trial is expected to be announced in the first quarter of 2026. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, the obefazimod safety database is supported by more than 1,000 subjects treated with obefazimod across different indications,
including UC patients, some of whom are in their fifth year of continuous daily dosing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Summary of Obefazimod&#146;s Mechanism of Action
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our lead drug candidate, obefazimod, is differentiated from competing approaches for the treatment of IBD via its novel
mechanism of action. Obefazimod was demonstrated to specifically enhance the expression of a single <FONT STYLE="white-space:nowrap">micro-RNA,</FONT> <FONT STYLE="white-space:nowrap">miR-124,</FONT> which plays a critical role in the regulation of
the inflammatory response. In the context of inflammation, <FONT STYLE="white-space:nowrap">miR-124</FONT> is a natural regulator of the inflammatory response, controlling progression of inflammation and restoring homeostasis of the immune system,
without causing broader immunosuppression. Once expressed, <FONT STYLE="white-space:nowrap">micro-RNA</FONT> interact with specific mRNA targets and decrease their translation into proteins to regulate specific pathways. By binding to the cap
binding complex, a complex playing a role in cellular RNA biogenesis, obefazimod enhances the selective splicing of a single long <FONT STYLE="white-space:nowrap">non-coding</FONT> RNA to generate the anti-inflammatory
<FONT STYLE="white-space:nowrap">micro-RNA,</FONT> <FONT STYLE="white-space:nowrap">miR-124,</FONT> in immune cells. Importantly, obefazimod does not impact the splicing of cellular messenger RNA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By targeting key inflammatory mRNA players such as STAT3 and MCP1, miR-124, a known anti-inflammatory micro-RNA, regulates inflammation by
decreasing macrophages and downregulating the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
translation of <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokines and chemokines, such as TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>,
<FONT STYLE="white-space:nowrap">IL-6,</FONT> <FONT STYLE="white-space:nowrap">MCP-1</FONT> and <FONT STYLE="white-space:nowrap">IL-17,</FONT> as well as Th17+ cells, to control overactive immune stimulation seen in chronic inflammatory diseases.
This downregulation thereby regulates the inflammatory process and suggests broad potential as a novel anti-inflammatory therapeutic agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following charts provide schematics of obefazimod&#146;s mechanism of action at both a protein-level (direct downregulation) and
cellular-level (indirect downregulation): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g00a36.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g40x42.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a DSS mouse model, we observed that administration of DSS enhances the expression of pro-inflammatory
cytokines in colonic tissue and Th17 cells in lymph nodes and that the treatment of these mice with obefazimod reduced the level of pro-inflammatory cytokines and Th17 cells back to their normal level. Interestingly, when we treated healthy mice
with obefazimod, we did not observe any effect on Th17 cells in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
lymph node and on cytokine levels in the colonic tissue, which we believe illustrates that regulation via enhanced expression of miR-124 has an effect only when these pathways are dysregulated,
as shown below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g40x90.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Laboratory analysis of the Phase 2b clinical trial at week 8 showed a highly statistically significant
enhancement of expression of <FONT STYLE="white-space:nowrap">miR-124</FONT> in rectal tissue in patients treated with obefazimod, compared to baseline. The median increases were <FONT STYLE="white-space:nowrap">13-fold</FONT> for the 25 mg group, <FONT
STYLE="white-space:nowrap">25-fold</FONT> for the 50 mg group and <FONT STYLE="white-space:nowrap">25-fold</FONT> for the 100 mg group, while no enhanced expression was observed in the placebo group <FONT STYLE="white-space:nowrap">(1.02-fold</FONT>
increase), indicative of the positive pharmacological effect of obefazimod. Downstream effects of enhancement of expression of <FONT STYLE="white-space:nowrap">miR-124</FONT> have been demonstrated by the reduction in
<FONT STYLE="white-space:nowrap">IL-17</FONT> and <FONT STYLE="white-space:nowrap">Il-23</FONT> levels in the blood and rectal biopsies of patients treated with obefazimod. The following charts depict those results: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g00a42.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g609070g00b42.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In contrast to currently available advanced therapies, prescribed post-conventional therapies, some of
which target only a single cytokine or pathway, <FONT STYLE="white-space:nowrap">miR-124</FONT> modulates the expression of several key cytokines and pathways. Modulating multiple inflammatory pathways simultaneously may lead to more durability of
efficacy results over the long-term, which is critical in lifelong conditions such as IBD, potentially differentiating obefazimod from currently available IBD treatments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Obefazimod in UC </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>UC Overview </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">UC, one of the most common forms of IBD, is a chronic inflammatory disease of the large intestine or colon, that affects the lining of the
colon and causes small sores or ulcers. UC is the result of several factors that are not yet well understood. Abnormal inflammatory response, genetics, microbiome and environmental factors all contribute to UC. UC can occur at any age, though most
people are diagnosed aged 20 to 30, and men and women are equally likely to be affected. UC can affect people of any racial or ethnic group. UC symptoms can vary, depending on the severity of inflammation and where it occurs. Signs and symptoms may
include diarrhea, rectal bleeding, abdominal pain and cramping, weight loss, fatigue and fever, substantially impacting the quality of life of patients with this debilitating disease. There were an estimated 4.1&nbsp;million prevalent cases of UC
globally in 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the 12 months ended May 2023, we estimate that there were approximately 776,000 patients treated for UC in the
United States. Of those patients, approximately 594,000 patients received conventional therapies; approximately 285,000 patients were maintained on conventional therapy, approximately 193,000 patients received steroids only and approximately 116,000
patients could not be controlled with conventional therapies. The remaining 182,000 patients received some form of advanced therapies, which we believe represented approximately $5.3 billion of sales in the United States; approximately 43,000
patients were new to advanced therapy, approximately 51,000 patients received suboptimal results or recently switched from other forms of therapy and approximately 88,000 patients were maintained on advanced therapy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Existing Therapies and Their Limitations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current UC treatment approach is influenced by multiple factors, including disease severity, previous response to treatment, side effects
and <FONT STYLE="white-space:nowrap">co-morbidities.</FONT> Both existing conventional therapies as well as advanced therapies, including approved products and drug candidates in development, face significant room for improvement in efficacy, safety
and tolerability, and convenience from dosing and route of administration standpoints as discussed below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conventional Therapies for UC </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aminosalicylates <FONT STYLE="white-space:nowrap">(5-ASAs)</FONT> are used as a first-line therapy in mildly to moderately active UC.
Corticosteroids are used primarily during induction therapy and are effective for reducing symptoms, but do not address mucosal healing which limit their ability to modify and improve the underlying cause of disease. In addition, there are safety
considerations with extended corticosteroid use, including lowered quality of life, bone loss, weight gain and cardiovascular complications. As a result, corticosteroids are used primarily as a bridge to manage symptoms until immunomodulators or
biologic agents become effective and enable mucosal healing. Oral immunosuppressants (e.g. azathioprine, <FONT STYLE="white-space:nowrap">6-mercatopurine</FONT> and methotrexate) have not been effective as induction agents and are generally used for
steroid-sparing or as an adjunctive therapy for reducing immunogenicity against biologic agents. Oral immunosuppressants are also associated with known toxicities such as drops in white blood cell counts and increased risk for infection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the above insufficiencies of these conventional therapies, patients suffering from mild UC may evolve towards moderate and severe forms
requiring the use of advanced therapies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advanced Therapies for UC </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Advanced therapies for UC include biological agents as well as emerging oral molecules. Biological agents such as TNF-<FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitors (including infliximab, adalimumab and golimumab), <FONT STYLE="white-space:nowrap">IL-12/23</FONT> inhibitors (such as ustekinumab) or <FONT STYLE="white-space:nowrap">IL-23</FONT> inhibitors,
which specifically block certain inflammatory factors involved in UC. Biological agents also include <FONT STYLE="white-space:nowrap">gut-specific</FONT> anti-integrin antibodies (such as vedolizumab and natalizumab). New oral molecules acting on
certain pathways of the inflammation include JAK inhibitors (including tofacitinib and upadacitinib) &#150; or, on the trafficking of inflammatory cells such as S1P receptor agonists (e.g., ozanimod). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, these therapies often only have moderate efficacy that may wane over time, as patients stop responding or do not respond at all to
these treatments and thus require new therapeutic management options. For patients who do not or no longer respond to treatment, or experience complications, surgical treatment may be necessary. Approximately 10% to 30% of UC patients require
surgery over their lifetime. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitors and JAK inhibitors and
newer biological agents, including anti-integrin antibodies, <FONT STYLE="white-space:nowrap">IL-12/23</FONT> inhibitors and <FONT STYLE="white-space:nowrap">IL-23</FONT> inhibitors, have generally improved the care of moderate to severely active
IBD (JAK inhibitors specifically in UC), these are all anti-inflammatory agents with safety and tolerability concerns. These include increased risks for cancers, infections and blood clots due to their systemic impact and resulting effects on the
immune system outside of the GI tract. In addition, prolonged treatment with biological therapies can lead to anti-drug antibody development by patients&#146; immune systems which may lead to gradual waning of therapeutic efficacy and patients
needing to switch to other biological agents. Furthermore, biological agents require injections or intravenous infusions, resulting in patient inconvenience and burden, which often negatively impacts patient compliance. Injections can also lead to
injection-related events such as sciatica, neuralgia, neuropathic pain and peripheral neuropathy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2021, the FDA published
strict warnings about increased risk of serious heart-related events, cancer, blood clots and death for JAK inhibitors that treat certain chronic inflammatory conditions (including UC). In January 2023, the EMA stated recommendations to minimize the
risk of serious side effects with JAK inhibitors used to treat several chronic inflammatory disorders, noting that these side effects include cardiovascular conditions, blood clots, cancer and serious infections which were adopted by the European
Commission in March 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recently, there have been efforts to develop drug candidates targeting novel mechanisms, such as S1P receptor
agonists and TL1A inhibitors. S1P agonists, while offering convenient oral dosing, have not achieved meaningful commercial adoption. Ozanimod and other S1P agonists work by blocking capacity of lymphocytes to egress from lymph nodes, thereby
reducing the number of lymphocytes in peripheral blood, which can lead to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
increased susceptibility to infections. Furthermore, Ozanimod, in its UC Study 1 which assessed efficacy during the induction period, achieved 18% clinical remission in all patients at week 10,
with only 10% of patients with prior exposure to TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitors showing clinical remission. TL1A inhibitors have garnered interest from those seeking newer targets and agents with differentiated
clinical profile. While Merck-Prometheus and <FONT STYLE="white-space:nowrap">Pfizer-Roivant</FONT> have generated promising early Phase 2 data in both biologics-experienced and <FONT STYLE="white-space:nowrap">biologics-na&iuml;ve</FONT> patients,
neither have initiated Phase 3 clinical trials and do not have long-term safety and efficacy data beyond 56 weeks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In summary, we believe
that there is significant unmet medical need in the UC treatment paradigm due to imperfect existing therapies with unfavorable clinical characteristics and limited efficacy that frequently wanes over time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obefazimod is being developed as a once-daily, oral medication which, combined with its observed tolerability to date, would represent a
meaningfully differentiated clinical profile from existing therapies. We believe this may position obefazimod as a potential first-line advanced therapy choice for both prescribers and patients, if approved. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Market Opportunity: UC </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
estimated market opportunity for UC was approximately $7.4&nbsp;billion in worldwide sales in 2022 and is expected to reach $10.2&nbsp;billion in worldwide sales in 2028. In 2022, there were 4.1&nbsp;million prevalent cases of UC worldwide. In the
United States, EU4, the United Kingdom and Japan, there were 2.0&nbsp;million prevalent cases of UC, of which 1.3&nbsp;million of these cases in G7 countries were treated with <FONT STYLE="white-space:nowrap">5-ASAs</FONT> or advanced therapies. In
addition, approximately 76% of patients suffering from UC in the United States were covered by commercial insurance, with approximately 20% and 3% covered by Medicare and Medicaid, respectively. The UC market has significant growth potential driven
by increasing incidence of the disease as well as the development of innovative oral therapeutics. We believe the potential for oral agents to gain significant market share is supported by physician and patient preference for the convenience of oral
administration over injectable agents, increasing demand for therapies with long-term efficacy profiles and the opportunity for potent and well-tolerated oral agents to expand the overall segment of the moderately to severely active UC population
undergoing treatment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clinical Trial Results of Obefazimod in Moderately to Severely Active UC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of November&nbsp;30, 2022 (the last safety data <FONT STYLE="white-space:nowrap">cut-off</FONT> date), 1,074 patients and volunteers had
been treated with obefazimod, of which 209 patients were treated with 50 mg obefazimod for one year or more with no change in the observed tolerability profile. At present, no increased rate of opportunistic infections or malignancies compared with
placebo have been observed across all clinical trials. We are conducting Phase 3 clinical trials in moderately to severely active UC in the United States, Europe, Asia Pacific and Latin America. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Phase 2a Clinical Trial with Obefazimod for the Treatment of Moderately to Severely Active UC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The induction Phase 2a clinical trial was a randomized trial of an 8-week placebo-controlled, double-blind induction phase followed by an
open-label long term extension trial. It was completed in September 2018. This <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial enrolled 32 adult patients who had been diagnosed with moderately
to severely active UC for at least 12 weeks and who failed or were intolerant to conventional treatments (50%) or biologics (50%). Patients who completed the induction phase were eligible to continue in the open-label extension trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the induction phase, patients were randomized <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">two-to-one</FONT></FONT> to
a once-daily orally-administered 50 mg dose of obefazimod or placebo for eight weeks. In the long-term extension, all patients received a once-daily orally-administered 50 mg dose of obefazimod. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This double-blind, placebo-controlled trial follows a standard study design in this indication for which a dose response as well as placebo
effect can be frequently observed. The 50 mg daily dose was selected on the basis of the safety data accumulated for this dose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trial design of our Phase 2a clinical trial for obefazimod in patients with moderately
to severely active UC is depicted below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g56a56.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of Primary Endpoints of Induction Phase 2a Clinical Trial with Obefazimod for the Treatment of UC </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary endpoint in the induction Phase 2a clinical trial was safety, assessed as the rate of TEAEs. The primary endpoint in the induction
phase, evaluation of safety and tolerability of obefazimod, was met. The most frequently reported adverse events reported in the 50 mg group were GI disorders and headache. GI disorders were experienced by 35% of subjects in the obefazimod group and
22% of subjects in the placebo group. These included abdominal pain, abdominal pain upper, anal fissure, anorectal discomfort, dyspepsia and nausea for the obefazimod group and abdominal pain and diarrhea for the placebo group. Headache was
experienced by 17% of subjects in the obefazimod group and 0% in the placebo group. Headaches occurred early and were transient (lasting only a few days), mainly mild or moderate (grade 1 or 2) and manageable with or without <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> medications. No serious adverse events related to treatment were observed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides an overall summary of TEAEs by treatment group: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g59g59.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">AE = adverse event; TEAE = treatment-emergent adverse event </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of Secondary Endpoints of Induction Phase 2a Clinical Trial with Obefazimod for the Treatment of
UC </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table depicts secondary efficacy endpoints of our Phase 2a clinical trial with obefazimod in moderately to severely
active UC at week 8: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g60a60.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">POC Study was not powered for efficacy </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">ITT = <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Intent-to-treat;</FONT></FONT> PP = Per Protocol </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The secondary endpoints in the induction Phase 2a clinical trial included the proportion of patients achieving clinical remission at week 8 as
compared to placebo, change from baseline to week 8 in total Modified Mayo Score (which is based on stool frequency, rectal bleeding, physician global assessment and endoscopic subscore), rate of endoscopic improvement, clinical response rate, as
well as <FONT STYLE="white-space:nowrap">miR-124</FONT> expression in the rectal tissue of the patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of Additional <FONT
STYLE="white-space:nowrap">Follow-Up</FONT> Data from Long Term Extension Portion of Phase 2a Clinical Trial with Obefazimod for the Treatment of Moderately to Severely Active UC </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the long-term extension, the primary objective was long term safety of obefazimod. Additional efficacy endpoints included clinical and
endoscopic rates of response and remission. Overall, 32 patients were enrolled in the induction phase, 23 patients were randomized to obefazimod, and nine patients were randomized to placebo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of the 29 patients who completed the induction phase (20 patients for obefazimod and nine patients for placebo), 22 patients continued their
treatment into the long-term extension. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2019, we announced the <FONT STYLE="white-space:nowrap">12-month</FONT> data from this
Phase 2a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial. This open-label maintenance trial was conducted in 22 patients, of which 19 completed the first year of treatment. At 12&nbsp;months, an
endoscopy was performed in 16 of the 19 patients to evaluate the rate of clinical remission, and 12 of the 16 evaluable patients (75%) were observed to achieve clinical remission. Obefazimod was also observed to maintain enhanced expression of <FONT
STYLE="white-space:nowrap">miR-124</FONT> throughout the 12 months of the trial. At month&nbsp;12, mean change in Mayo Score was observed at -2.6 points compared to the maintenance baseline. Median fecal calprotectin decreased from 153.1&nbsp;<FONT
STYLE="FONT-FAMILY:SYMBOL">&#109;</FONT>g/g (baseline) to 27.9&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#109;</FONT>g/g and 31.6&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#109;</FONT>g/g at week&nbsp;52 and month&nbsp;24, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table depicts secondary efficacy endpoints of our Phase&nbsp;2a clinical trial with obefazimod in moderately to severely active
UC at 24 and 48 months: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g00a15.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Phase 2b Clinical Trial with Obefazimod for the Treatment of UC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of Induction Phase 2b Clinical Trial with Obefazimod for the Treatment of UC </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The induction Phase 2b clinical trial for the treatment of moderately to severely active UC was conducted in 252 patients enrolled at 130 trial
sites across 15 European countries, Canada and the United States. It was completed in April 2021. The trial was a randomized, double-blind and placebo-controlled <FONT STYLE="white-space:nowrap">16-week</FONT> induction trial with a primary efficacy
endpoint at week 8 involving four treatment groups (receiving an oral once-daily 25 mg, 50 mg or 100 mg dose of obefazimod or placebo). Endoscopies were read centrally and blinded, by independent reviewers. Electronic patient diaries were used to
enhance the reliability of the collection of stool frequency, rectal bleedings, and other patient reported outcomes-all efficacy endpoints were set according to FDA guidance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart depicts the design of our Phase 2b clinical trial with obefazimod in moderately to severely active UC: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g00r47.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between August&nbsp;13, 2019 and April&nbsp;16, 2021, 252 patients were randomly allocated to obefazimod
100 mg (n=64), obefazimod 50 mg (n=63), obefazimod 25 mg (n=61) or placebo (n=64). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Baseline characteristics were well-balanced among the
treatment groups, indicating a moderately to severely active UC population. At screening, 49% of patients had an inadequate response, loss of response, or intolerance to TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitors, vedolizumab,
other biologics and/or JAK inhibitors treatments, while the other patients were refractory to conventional treatments only. Enrolled patients suffered from longstanding UC with an overall mean disease duration of 8.05 years and 71% of the patients
had a severe disease profile (baseline Modified Mayo Score of 7 to 9 points). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table depicts the baseline characteristics of our Phase 2b clinical trial:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g47p47.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Percentages based on number of patients with previous exposure to biologics/JAK inhibitors
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of Primary Endpoints of Induction Phase 2b Clinical Trial with Obefazimod for the Treatment of UC </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Modified Mayo Score</U>: In the full analysis set (&#147;FAS&#148;), corresponding to an ITT analysis, the primary endpoint was met at week
8 (statistically significant reduction of Modified Mayo Score) with <FONT STYLE="white-space:nowrap">-2.9</FONT> (95% CI <FONT STYLE="white-space:nowrap">-3.4</FONT> to <FONT STYLE="white-space:nowrap">-2.5)</FONT> for the obefazimod 100 mg group, <FONT
STYLE="white-space:nowrap">-3.2</FONT> <FONT STYLE="white-space:nowrap">(-3.7</FONT> to <FONT STYLE="white-space:nowrap">-2.7)</FONT> for the obefazimod 50 mg group, <FONT STYLE="white-space:nowrap">-3.1</FONT>
<FONT STYLE="white-space:nowrap">(-3.6</FONT> to <FONT STYLE="white-space:nowrap">-2.6)</FONT> for the obefazimod 25 mg group, and <FONT STYLE="white-space:nowrap">-1.9</FONT> <FONT STYLE="white-space:nowrap">(-2.4</FONT> to <FONT
STYLE="white-space:nowrap">-1.5)</FONT> for placebo group. The magnitude of the difference in Modified Mayo Score from baseline was significantly greater in all three obefazimod groups compared with placebo (p=0.0039 for obefazimod 100 mg vs
placebo, p=0.0003 for obefazimod 50 mg vs placebo, and p=0.0010 for obefazimod 25 mg vs placebo). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Clinical Response, Clinical
Remission and Endoscopic Improvement</U>: Furthermore, rates of clinical response and clinical remission at week 8 in the FAS were higher in the three obefazimod dosage groups than with placebo. The subgroup of patients who were refractory to one or
more second line therapies showed results that were consistent with the overall analysis for clinical response and clinical remission at week 8. Rates of endoscopic improvement at week 8 were also higher in the obefazimod dosage groups than in the
placebo group in the FAS. Change in fecal calprotectin from baseline in the FAS was greater in all obefazimod groups than with placebo. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables depict the changes of the primary endpoint from baseline in Modified
Mayo Score at week 8: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g01b48.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">ANCOVA model for change from baseline MMS at week 8 which includes baseline MMS as a covariate and treatment,
previous exposure to biological drugs or JAK inhibitors as fixed effects and a random error term. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">p-values are based on nonparametric ANCOVA using ranked data. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">MMS is the sum of assessment scores <FONT STYLE="white-space:nowrap">(0-3)</FONT> of mucosal appearance on
endoscopy, stool frequency, and rectal bleeding. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">n = number of patients in the category with data available for baseline and week 8 visit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables depict the secondary efficacy endpoint results at week 8: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g01a49.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Clinical remission (per Modified Mayo Score) is defined as stool frequency subscore (SFS) &#8804;1, rectal
bleeding subscore (RBS) of 0 and endoscopic subscore &#8804;1. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Clinical response (per Adapted Mayo Score) is defined as a decrease from baseline in the Modified Mayo Score
&#8805;2 points and &#8805;30&nbsp;percent from baseline, plus a decrease in RBS &#8805;1 or an absolute RBS &#8804;1. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Endoscopic improvement is defined as endoscopic subscore &#8804;1 without friability. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">n = number of patients that met the respective endpoint. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">N = number of patients in the relevant analysis set. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Delta = arithmetic difference rounded to nearest full percentage. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also conducted sub-group analyses of biologics / JAK-na&iuml;ve and biologics /
JAK-experienced patients, the results of which are displayed below: </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g01b49.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Trial not powered for statistical significance for sub-group analysis. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">n = Number of patients in the category with data available for baseline and week 8 visit. </P></TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">MMS is the sum of assessment scores (0-3) of mucosal appearance on endoscopy, stool frequency, and rectal
bleeding. </P></TD></TR></TABLE> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g01a50.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Trial not powered for statistical significance for sub-group analysis. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Endoscopic improvement is defined as endoscopic subscore &#8804;1 without friability. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">n = number of patients that met the respective endpoint. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">N = number of patients in the relevant analysis set. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Delta = arithmetic difference rounded to nearest full percentage. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of Maintenance Phase 2b Clinical Trial with Obefazimod for the Treatment of UC </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of the 222 patients who completed the <FONT STYLE="white-space:nowrap">16-week</FONT> Phase 2b induction trial, 217 patients (98%) enrolled in
the subsequent open-label maintenance trial to evaluate the induction Phase 2b clinical trial long-term safety and efficacy profile of obefazimod for up to two years, irrespective of treatments or treatment outcome during the induction phase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At week 48, of those 217 patients who received a 50 mg once-daily oral dosing with obefazimod, 178 patients (82%) had clinical response, 119
patients (55%) were in clinical remission, 133 patients (61%) had endoscopic improvement and 72 patients (33%) had endoscopic remission. Moreover, 38 patients were in sustained clinical remission and 107 patients showed sustained clinical response.
A total of 71 patients exhibited de novo clinical response and 81 patients exhibited de novo clinical remission. Among the 98 bio-refractory patients, 66 patients (67%) had a clinical response, 38 patients (39%) were in clinical remission, 46
patients (47%) had endoscopic improvement and 20 patients (20%) had endoscopic remission at week 96. These results demonstrate the long-term clinical response of obefazimod in patients who were refractory to conventional treatments, as well as
patients who were previously exposed to treatment with biologics and/or JAK inhibitors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At week 96, of the 49 patients who were in
clinical remission at the end of the induction phase, 33 patients (67%) remained in clinical remission. Of the 168 patients who were not in clinical remission at the end of the induction phase, 81 patients (48%) exhibited de novo clinical remission.
Furthermore, the clinical remission rate for patients who did not show at least a clinical response at the end of the 8-week induction phase was 43% (40&nbsp;patients). Of the patients included in the maintenance trial, 164 patients (75%) completed
two years of once-daily oral dosing with 50 mg obefazimod. Thirty patients dropped out during the first year of treatment. Six&nbsp;patients did not qualify for the second year due to non-response after the first year of treatment, and
17&nbsp;patients dropped out during the second year. These patients were all considered as treatment failures in the intent-to-treat analysis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart depicts clinical results of our long-term extension Phase 2b clinical trial at weeks 48 and 96: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g67a67.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Number of patients that met the respective endpoint. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Number of patients in the relative analysis set. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Sustained clinical remission/response or endoscopic remission/improvement means a clinical remission or clinical response or endoscopic remission or endoscopic
improvement in the subpopulation of patients with clinical remission or clinical response or endoscopic remission or endoscopic improvement at maintenance trial entry (i.e., at week 8 of induction trial). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">De novo clinical remission/response or endoscopic remission/improvement means a clinical remission or
clinical response or endoscopic remission or endoscopic improvement in the subpopulation of patients without clinical remission or clinical response or endoscopic remission or endoscopic improvement at maintenance trial entry (i.e. at week 8 of
induction trial). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">* For week 48, with respect to six subjects, endoscopic data were missing at week 8 of the induction trial and were not included in this
analysis. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">* For week 96, drop outs were considered as treatment failures in the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">intent-to-treat</FONT></FONT> analysis (30 patients dropped out during the first year; six patients did not qualify for the second year of treatment due to <FONT
STYLE="white-space:nowrap">non-response</FONT> after the first year and 17 patients dropped out during the second year). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of all 217
patients who entered the Phase 2b open-label maintenance trial, regardless of their status at the end of the 8-week induction period, 119 patients (55%) achieved clinical remission at week 48 and 114 patients (53%) achieved clinical remission at
week 96. Among the 124 patients who achieved clinical response at the end of the 8-week induction period of the double-blind study, 82 patients (66%) achieved clinical remission at week 48, mimicking the re-randomization of responders approach
typically utilized in Phase 3 maintenance trials, and 74 patients (60%) achieved clinical remission at week 96. This comparison is shown below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g52a52.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">217/222 eligible patients enrolled into open label maintenance study. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Irrespective of patient outcome at the end of the 8-week induction phase. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">n = Number of patients that met the respective endpoint. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">N = Number of patients in the relevant analysis set. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">124 patents achieved clinical response at end of 8-week induction phase. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">From week 48 to week 96, 19 patients began experiencing symptoms of UC again (i.e., were not in clinical
remission anymore), and 14&nbsp;patients achieved clinical remission. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The below table depicts the types of adverse
events observed from our Phase 2b clinical trial: </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g52b52.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the induction and the maintenance treatments of the Phase 2b clinical trial, the
safety and tolerability profile observed was consistent with previous findings and no new adverse safety signals were observed. As of November&nbsp;30, 2022 (the last safety data <FONT STYLE="white-space:nowrap">cut-off</FONT> date), 1,074 patients
and volunteers had been treated with obefazimod, of which 209 patients were treated with 50 mg obefazimod for one year or more with no change in the observed tolerability profile. At present, no increased rate of opportunistic infections or
malignancies compared with placebo have been observed across all clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of Phase 2 Open-Label Trial to Evaluate Long-Term Safety
and Efficacy of Obefazimod at 25 mg </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2023, we reported an interim analysis of step-down dosing from 50 mg to 25 mg for
the third and fifth year of open-label maintenance treatment with obefazimod in UC patients. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g01b53.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These patients were treated with 50 mg of oral, once-daily obefazimod for approximately four years in the
Phase 2a clinical trial and approximately two years in the Phase 2b clinical trial. Patients were eligible to enroll in the trial if they had a Mayo endoscopic subscore of 0 or 1. Eligible patients were switched to 25 mg, and an interim analysis was
performed at week 48 with a cut-off date of July 31, 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g53p53.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">ABX464-108 Interim Analysis Outputs as of July 31, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">n = Number of patients that met the respective endpoint. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">N = Number of patients in the relevant analysis set. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of the 71 eligible patients, 63 completed their 48-week visit. Among these patients, 53 out
of 63 patients (84%) demonstrated disease control (stable or improved Modified Mayo Score). No new safety signals were detected in UC patients treated up to five years with oral, once-daily obefazimod. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 3 Clinical Trials and Regulatory Pathway in UC </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are working with IQVIA, a global premier contract research organization, to conduct the Phase 3 clinical trials with obefazimod in
moderately to severely active UC, following consultations with regulatory agencies, including FDA, EMA, CDE and PMDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These pivotal Phase
3 clinical trials consist of two induction trials <FONT STYLE="white-space:nowrap">(ABTECT-1</FONT> and <FONT STYLE="white-space:nowrap">ABTECT-2)</FONT> and the subsequent ABTECT maintenance trial investigating obefazimod at doses of 25 mg and 50
mg across 36&nbsp;countries in North America, Latin America, Europe and Asia Pacific, involving 1,200 moderately to severely active UC patients in over 600 sites. Each of the trials will be randomized, double-blind and placebo-controlled, using
independent and central review of the video-taped endoscopies with the primary endpoint of clinical remission according to the Modified Mayo Score assessed at week 8 (induction) and at the end of the 44-week maintenance trial (total 52 weeks), as
recommended by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Modified Mayo Score evaluates UC disease activity, based on three parameters: stool frequency, rectal
bleeding and endoscopic evaluation. Each parameter of the score ranges from zero (normal or inactive disease) to three (severe activity). The patient rates stool frequency score (&#147;SFS&#148;) and rectal bleeding score (&#147;RBS&#148;) daily.
The endoscopy subscore is evaluated by a central reader (who is blinded to any clinical information about the patient) from an endoscopy that is performed at the trial site. The inclusion criteria based on FDA guidance for moderately to severely
active UC is active disease defined by a Modified Mayo Score &#8805; 5 with (RBS) &#8805; 1 and endoscopy subscore of 2 or 3 (confirmed by central reader). The primary endpoint for induction and maintenance is clinical remission defined as SFS of 0
or 1 and not greater than baseline and RBS = 0 and endoscopy subscore of 0 or 1. At week 8, secondary endpoints include endoscopic improvement, clinical response, symptomatic remission and histologic-endoscopic mucosal improvement
(&#147;HEMI&#148;). At week 44 of the maintenance trial, secondary endpoints include endoscopic improvement, symptomatic remission, corticosteroid-free clinical remission, sustained clinical remission, HEMI and endoscopic remission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart depicts the design of our Phase 3 clinical trial with obefazimod in moderately to severely active UC: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g00m54.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enrollment of the first patient under this program in the United States occurred on October&nbsp;11, 2022. <FONT
STYLE="white-space:nowrap">Top-line</FONT> data from the <FONT STYLE="white-space:nowrap">ABTECT-1</FONT> and <FONT STYLE="white-space:nowrap">ABTECT-2</FONT> induction trials is expected to be announced in the first quarter of 2025, and <FONT
STYLE="white-space:nowrap">top-line</FONT> data from the ABTECT maintenance trial is expected to be announced in the first quarter of 2026. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart depicts our recently completed and expected upcoming milestones for our
Phase 3 clinical trials of obefazimod for moderately to severely active UC: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g00m55.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Additional Clinical Trials Completed with
Obefazimod </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, four Phase 1 clinical trials have recently been completed to assess the tolerability and safety profile of
obefazimod: (i)&nbsp;a Phase 1 heart rhythm (QT interval) trial, for which we enrolled 120 healthy volunteers; (ii)&nbsp;a Phase 1 clinical trial of drug-drug interactions, for the purposes of providing further information on any possible
interactions of obefazimod with other drugs, for which we enrolled 60 healthy volunteers; (iii)&nbsp;a Phase 1 absorption, distribution, metabolism and excretion trial for the purposes of generating additional data to further evaluate the safety
profile of obefazimod, for which we enrolled 12 healthy volunteers; and (iv)&nbsp;a Phase 1 clinical trial conducted in Japanese subjects to further evaluate pharmacokinetics and tolerability of obefazimod in this population, for which we enrolled
48 healthy volunteers. The results of these Phase 1 clinical trials provide supportive data for our further clinical development and New Drug Application (&#147;NDA&#148;) submission. Furthermore, additional Phase 1 clinical trials to support NDA
submission are planned. While we have decided not to pursue additional clinical work in RA at this point, we have completed a Phase 2a clinical trial in patients with RA, where we saw encouraging <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data supporting obefazimod&#146;s potential role in addressing inflammatory conditions beyond IBD. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Obefazimod in CD </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>CD Overview </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CD is a chronic inflammatory condition that can affect the GI tract from mouth to anus but typically affects the colon and last section of the
ileum (terminal ileum). Although considered in the same category of IBD as UC, the inflammation occurs across the bowel wall which leads to different complications including stricture and fistula formation. CD affects about 3.2 per 1,000 people in
Europe, North America&nbsp;and the United Kingdom. Collectively, we estimate there are approximately 1.1&nbsp;million CD patients in G7 countries. Of these patients, approximately 0.5&nbsp;million patients (or approximately 44%) are estimated to be
diagnosed with moderately to severely active CD, with approximately 0.6&nbsp;million patients (or approximately 56%) diagnosed with mildly to moderately active CD.&nbsp;While this disease is diagnosed at any age, onset is more common among
adolescents and young adults.&nbsp;Patients typically present with abdominal pain, diarrhea, fatigue and weight loss.&nbsp;In cases of bowel obstruction, patients will also experience bloating and vomiting.&nbsp;The likelihood of having surgery
mostly due to bowel obstruction within the lifetime of a CD patient is approximately 80%.&nbsp;Besides bowel complications, patients can experience extra-intestinal manifestations (&#147;EIMs&#148;), which impact the skin, eye and joints
primarily.&nbsp;The prevalence rate of EIMs is approximately 24% in all IBD patients, 27% in UC patients, but as high as 35% in CD patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Existing Therapies and Their Limitations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to existing UC treatments, patients may receive oral immunosuppressants, such as azathioprine and methotrexate as well as short courses
of corticosteroids.&nbsp;In cases of moderately to severely active CD, the options for advanced therapy include very commonly prescribed TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitors, anti-integrin antibodies, <FONT
STYLE="white-space:nowrap">IL-12/23</FONT> inhibitors, <FONT STYLE="white-space:nowrap">IL-23</FONT> inhibitors and JAK inhibitors.&nbsp;Therapies such as <FONT STYLE="white-space:nowrap">TNF-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>
inhibitors, <FONT STYLE="white-space:nowrap">IL-12/23</FONT> inhibitors or <FONT STYLE="white-space:nowrap">IL-23</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inhibitors are injectable agents, representing a significant commercial disadvantage due to patients&#146; and prescribers&#146; preference for the convenience of oral therapies.&nbsp;JAK
inhibitors are accompanied by safety warnings due to increased risk of adverse events such as infection, cancer or blood clots. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Induction
remission rates for these existing therapies are less than 50% and maintenance remission rates often decrease over time. There remains unmet needs for more effective and durable therapy, including those with more convenient delivery methods (as
there are no approved oral therapies for first-line use in the United&nbsp;States), durable efficacy, treatment of patients who have failed biologic agents, improved mucosal healing, improved treatment for fistulizing CD and improved corticosteroid
free remission. We believe obefazimod&#146;s differentiated clinical profile, including dosing as a once-daily, oral therapy as well as its demonstrated tolerability and durability to date, position it favorably as a potential first-line advanced
therapy option for patients and prescribers, if approved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Market Opportunity: CD </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated market opportunity for CD was approximately $16.3&nbsp;billion in worldwide sales in 2022 and is expected to reach
$16.6&nbsp;billion in worldwide sales in 2028. In 2022, approximately $11.4&nbsp;billion of sales came from the United States and all moderately to severely active CD sales came exclusively from injectable products. Similar to the UC market, we
believe oral agents represent a significant commercial opportunity, particularly if such therapeutics can provide long-term safety and efficacy profiles comparable to injectable agents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Proposed Obefazimod CD Development Program </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the pathophysiological and clinical similarities of CD and UC, we plan to initiate a Phase 2a clinical trial in patients with CD in the
first quarter of 2024 to potentially demonstrate outcomes consistent with those observed in our Phase 2 clinical trials for moderately to severely active UC. We believe the preclinical and Phase 1 data generated in our UC clinical trials are
sufficient for completion of these equivalent trials in CD. We intend to (i)&nbsp;file an IND in the fourth quarter of 2023, (ii)&nbsp;initiate a Phase 2a clinical trial in patients with CD in the first quarter of 2024 and (iii) announce Phase 2a
induction trial top-line results in the second half of 2025 with the objective to demonstrate clinical response and tolerability profile consistent with that already observed in our clinical trials for moderately to severely active UC. Based on the
results from this Phase 2a clinical trial, we intend to proceed directly to a Phase 3 clinical trial. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart depicts
the design of our Phase 2a clinical trial with obefazimod in CD: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g00m56.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Potential Combination Therapy for the Treatment of IBD with Obefazimod as the Cornerstone </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the development of various advanced targeted therapies for IBD over the past 20 years, a single agent with transformational efficacy
remains elusive. Although cross-trial efficacy comparisons must be interpreted with caution, induction of clinical remission rates have currently reached a placebo-adjusted </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
therapeutic ceiling up to 30%. Improved efficacy of combination therapy with thiopurines and TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitors has been well described (SONIC and <FONT
STYLE="white-space:nowrap">UC-SUCCESS)</FONT> but did not breach the aforementioned efficacy ceiling. Emerging data utilizing dual advanced targeted therapy affecting complementary mechanisms of action indicate a potential path to higher efficacy
rates. The first trial utilizing this strategy (VEGA) randomized patients to three parallel treatment groups: (1) dual combination therapy with guselkumab <FONT STYLE="white-space:nowrap">(IL-23</FONT> inhibitor) plus golimumab (TNF-<FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitor); (2) guselkumab alone; or (3)&nbsp;golimumab alone. At the end of the <FONT STYLE="white-space:nowrap">12-week</FONT> induction period, a greater proportion of patients randomized to dual
combination therapy achieved clinical remission (approximately 47%) compared to either monotherapy treatment arms (guselkumab at approximately 25%; golimumab at approximately 24%). Importantly, adverse events, serious adverse events and infection
rates were comparable among treatment groups. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe synergistic improvements that may be achieved with advanced combination therapy
should be balanced with patient adherence to multiple biologic injections and safety considerations associated with immune suppression. Several of obefazimod&#146;s attributes make it a potentially attractive candidate to pair with other advanced
treatments. First, the oral route of administration is preferred by a majority of patients, potentially resulting in higher levels of medication adherence. Further, obefazimod&#146;s proposed mechanism of action harnesses the body&#146;s natural
regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases. The novel mechanism of action of obefazimod potentially lends itself as complementary to other oral or injectable agents with the potential
of improving the induction and remission efficacy over monotherapy. We believe the current clinical results we have observed with obefazimod including a lack of signals for malignancy, opportunistic or serious infection risk up to 96 weeks of
treatment support development as an agent to be used in potential combination therapy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Follow-On</FONT> Compounds
Program </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the mechanistic concept of obefazimod, a research and development program is currently ongoing to generate new
potential drug candidates to strengthen our intellectual property portfolio on the <FONT STYLE="white-space:nowrap">miR-124</FONT> platform. The first <FONT STYLE="white-space:nowrap">follow-on</FONT> drug candidate is expected to be selected and
enter preclinical development in 2024. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing and Supply </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obefazimod </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead compound,
obefazimod, is manufactured using commercially available, widely used raw materials and common chemical engineering and synthetic processes. Obefazimod is formulated as an oral solid capsule. We have successfully
<FONT STYLE="white-space:nowrap">scaled-up</FONT> active pharmaceutical ingredients and drug product processes, and we have a large supply of active pharmaceutical ingredients and capsules available for clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We outsource all manufacturing operations and rely on European third-party CMOs to supply clinical trials and finalize the development of
obefazimod. These operations are designed to be in compliance with the standards imposed by Good Manufacturing Practice (&#147;GMP&#148;). We believe our outsourcing strategy and internal organization allow us to focus our resources on the
development of different drug candidates and the management of third parties, without investing in expensive manufacturing facilities and equipment. All third parties are assessed under our quality system and agreements are in place to compel
compliance and we maintain agreements with manufacturers which include confidentiality and intellectual property provisions to protect proprietary rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are in the process of further optimizing and scaling up our supply chain for obefazimod to ensure capacity for our expected commercial
supply, if the FDA or foreign regulatory authority approved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our incorporation in 2013, the majority of our resources have been allocated to research and development activities. We are conducting
development activities to expand the commercial potential of our drug </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates, in particular obefazimod. In the years ended December&nbsp;31, 2021 and 2022, we incurred &#128;47.8&nbsp;million and &#128;48.3&nbsp;million, respectively, of research and
development expenses, or 89.5% and 69.6% respectively, of our total operating expenses. Our research and development expenses consist primarily of the following items: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">personnel expenses, including salaries, benefits, and share-based compensation expenses, for employees engaged in
research and development activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">sub-contracting,</FONT> collaboration and consultant expenses that primarily
include the cost of third-party contractors such as CROs who conduct our preclinical studies and clinical trials, and research related to our proprietary platforms, as well as investigative sites and consultants that conduct our preclinical studies
and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred under agreements with CMOs, including manufacturing
<FONT STYLE="white-space:nowrap">scale-up</FONT> expenses and the cost of acquiring and manufacturing preclinical study and clinical trial materials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses relating to preclinical studies and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses relating to regulatory affairs; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses relating to the implementation of our quality assurance system. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2022, our total operating expenses were &#128;69.4&nbsp;million, as compared to &#128;53.4&nbsp;million
for the year ended December&nbsp;31, 2021, an increase of &#128;16.1&nbsp;million, or 30%. This increase was primarily due to an increase in goodwill impairment loss and in general and administrative expenses while research and development expenses
remained at a consistent level. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We compete with companies that have drugs on the market or are developing drug candidates for chronic inflammatory disease. The biotechnology
and pharmaceutical industries are highly competitive and subject to significant and rapid technological change, as researchers learn more about chronic inflammatory diseases and develop new technologies and treatments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant competitive factors in our industry include: (i)&nbsp;product efficacy and safety; (ii)&nbsp;quality and breadth of an
organization&#146;s technology; (iii)&nbsp;skill of an organization&#146;s employees and its ability to recruit and retain key employees; (iv)&nbsp;timing and scope of regulatory approvals; (v)&nbsp;government reimbursement rates for, and the
average selling price of, pharmaceutical products; (vi)&nbsp;the availability of raw materials and qualified manufacturing capacity; (vii)&nbsp;manufacturing costs; intellectual property and patent rights and their protection; and (viii)&nbsp;sales
and marketing capabilities. Given the intense competition in our industry, we cannot assure you that even if we are able to successfully develop any products, that they will have a higher benefit-risk profile or better cost effectiveness compared to
products developed or introduced by our competitors. Our competitors in the chronic inflammatory disease field are primarily large pharmaceuticals companies including, but not limited to, AbbVie, Pfizer, Eli Lilly, Takeda and Johnson&nbsp;&amp;
Johnson. Several lines of research are being developed to improve the treatment of IBD. Many companies are working to develop new, more effective and better tolerated treatments with more practical formulations, especially small molecules
administered orally, better accepted than monoclonal antibodies that require administration by injection or intravenous infusions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
molecules in development have various mechanisms of action and are primarily: (i)&nbsp;TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitors; <FONT STYLE="white-space:nowrap">(ii)&nbsp;IL-12/23</FONT> inhibitors; (iii)&nbsp;anti-integrin
anti-bodies; <FONT STYLE="white-space:nowrap">(iv)&nbsp;IL-23</FONT> inhibitors; (v)&nbsp;JAK inhibitors; (vi)&nbsp;S1P receptor agonists; or (vii)&nbsp;TL1A inhibitors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> treatment class, Remicade<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>
(Janssen) was first approved by the FDA in 1998. In 2012, the European Commission approved AbbVie&#146;s Humira<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> for the treatment of pediatric patients aged six to 17 years with severe active
CD who have an inadequate response, are intolerant or have contraindications to conventional therapy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">IL-12/23</FONT> inhibitors entered the UC market in 2019 as
ustekinumab (Johnson&nbsp;&amp; Johnson&#146;s Stelara<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>). In 2021, AbbVie filed an authorization application with FDA and EMA for Risankizumab <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">(Anti-IL-23&#151;Skyrizi</FONT></FONT><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>) for the treatment of moderately to severely active CD and a Phase 3 clinical trial in patients with UC is underway. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Etrolizumab, a selective <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-alpha-4/beta-7</FONT></FONT> monoclonal
antibody developed by Roche/Genentech, recently failed in Phase 3 for CD after failing in Phase 3 in UC in 2020. The anti-integrin class is currently represented by vedolizumab/Entyvio<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and
natalizumab/Tysabri<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. We are also aware of Morphic Therapeutic&#146;s <FONT STYLE="white-space:nowrap">MORF-057</FONT> and Protagonist Therapeutics/Johnson&nbsp;&amp; Johnson&#146;s <FONT
STYLE="white-space:nowrap">PN-943</FONT> currently in development. The anti-integrin drugs work by preventing the leukocytes to move from the blood vessels to sites of inflammation. They block the action of integrin on the surface of circulating
immune cells and endothelial cell adhesion molecules, thereby inhibiting the interactions between leukocytes and intestinal blood vessels. Natalizumab and vedolizumab block
<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT><FONT STYLE="white-space:nowrap">4-integrin</FONT> and <FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT><FONT STYLE="white-space:nowrap">4&szlig;7-integrin</FONT> respectively. These drugs are injectable
(Humanized mAb). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2021, Eli Lilly reported that mirikizumab
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(Anti-IL-23)</FONT></FONT> generated data in a Phase 3 maintenance trial in patients with UC that led to the submission of an authorization request to regulatory agencies. Phase 3
clinical trials in CD are also underway with mirikizumab. All these drugs are injectable (Humanized mAb). <FONT STYLE="white-space:nowrap">IL-23</FONT> is a regulator of <FONT STYLE="white-space:nowrap">T-helper</FONT>
<FONT STYLE="white-space:nowrap">(Th)-17</FONT> cell. <FONT STYLE="white-space:nowrap">IL-23</FONT> prevents regulatory <FONT STYLE="white-space:nowrap">T-cell</FONT> response in the intestine, and therefore increases inflammation in the gut.
Anti-interleukins targeting the <FONT STYLE="white-space:nowrap">IL-23</FONT> have been shown to be effective for induction and maintenance of remission in patients with moderate-severe UC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The JAK correspond to four intracellular tyrosine kinases: JAK1, JAK2, JAK3 and tyrosine kinase 2. Inhibition of the <FONT
STYLE="white-space:nowrap">JAK-STAT</FONT> signal channel makes it possible to block the production of <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokines, including <FONT STYLE="white-space:nowrap">TNF-</FONT><FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>, to block other pathways of inflammation and to regulate innate and adaptive immunity. Thus, several cytokines and several inflammation pathways are blocked simultaneously, unlike <FONT
STYLE="white-space:nowrap">TNF-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitors, which only have a single target. In September 2021, FDA published a black box warning, requiring pharmaceutical companies to provide a warning for
increased risk of serious cardiac events, cancer, blood clots and death linked to JAK inhibitor treatments used for the treatment of certain IBD, including UC. Consequently, these treatments are only accessible to patients who do not respond to any
other available treatment and who have certain well-defined conditions. In the JAK inhibitor class, to our knowledge the following products are authorized or in advanced development: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pfizer&#146;s tofacitinib (Xeljanz<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>) is a <FONT
STYLE="white-space:nowrap">non-selective</FONT> JAK inhibitor. It obtained marketing approval in UC in June 2018. In September 2021, the FDA concluded that there was a high risk of serious side effects following a randomized clinical trial conducted
to assess the safety of tofacitinib. Consequently, the molecule will be used as a third line treatment in patients who meet specific criteria. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Gilead and Galapagos&#146; filgotinib (Jyseleca<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>) is a
selective JAK1 inhibitor. Since November 2021, filgotinib has been approved for the treatment of UC in the European Union (the &#147;EU&#148;). Authorization requests have also been submitted to the UK Medicines and Healthcare products Regulatory
Agency (&#147;MHRA&#148;) and the Japanese PMDA for the treatment of moderately to severely active UC. A Phase 3 clinical trial in patients with CD is also underway. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">AbbVie&#146;s upadacitinib (Rinvoq<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>), which is also a
selective JAK1 inhibitor, was approved by the FDA in March 2022 for the treatment of moderately to severely active UC. EMA authorization for the treatment of moderately to severely active UC was granted in July 2022. A Phase 3 clinical trial in
patients with CD is currently underway. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">S1P receptor agonists allow sequestration of activated lymphocytes in lymph
nodes and thus reduce their circulation in the GI tract. Ozanimod (Zeposia<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>) is a S1P receptor modulator that is selective for the S1P1 and S1P5 receptors. It was approved by the FDA and EMA
for the treatment of moderately to severely active UC in 2021. Phase 3 clinical trials are currently being conducted to assess the efficacy of ozanimod in CD. <FONT STYLE="white-space:nowrap">Top-line</FONT> results of a Phase 3 induction trial of
ARENA Pharmaceuticals&#146; Etrasimod for the treatment of UC were announced in March 2022 and the primary endpoint, as well as the key secondary endpoints were reached; a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Phase 2/3 clinical trial is currently being conducted in CD. In addition, in October 2023, Ventyx Biosciences announced results from its Phase 2 clinical trial of VTX002 in UC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also aware of other types of treatments currently under various stages of development, such as NImmune Biopharma&#146;s omilancor (a
Lanthionine Synthetase <FONT STYLE="white-space:nowrap">C-Like</FONT> 2 activator) as well as tyrosine kinase 2 inhibitors from Bristol Myers Squibb&#146;s Sotyktu (deucravacitinib &#150; approved in the EU) and Ventyx Biosciences&#146; VTX 958.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, TL1A inhibitors have garnered interest from those seeking newer targets and agents with differentiated clinical profile.
While PRA023 (Merck-Prometheus) and <FONT STYLE="white-space:nowrap">RVT-3101</FONT> <FONT STYLE="white-space:nowrap">(Pfizer-Roivant)</FONT> have generated promising early Phase 2 data in both biologics-experienced and <FONT
STYLE="white-space:nowrap">biologics-na&iuml;ve</FONT> patients, neither have initiated Phase 3 clinical trials and do not have long-term safety and efficacy data beyond 56 weeks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our competitors may also succeed in obtaining European Commission, FDA or other regulatory approvals for their drug candidates more rapidly
than us, which could place us at a significant competitive disadvantage. Market acceptance of our drug candidates will depend on a number of factors, including: (i)&nbsp;potential advantages over existing or alternative therapies or tests;
(ii)&nbsp;the actual or perceived safety of similar classes of products; (iii)&nbsp;the effectiveness of our sales, marketing, and distribution capabilities; and (iv)&nbsp;the scope of any approval provided by the FDA or foreign regulatory
authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that we will face intense and increasing competition as new drugs and therapies enter the market and advanced
technologies become available. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Companies operating in the pharmaceutical industry are subject to increased scrutiny by the competent authorities and must deal with an
ever-changing and increasingly restrictive legal and regulatory environment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development of drugs involves several stages: research
and development, preclinical tests, clinical trials, authorization, manufacturing and commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of these stages are subject
to specific requirements that impose substantial and onerous constraints, compliance with which is ensured by various national, regional (in the EU, the EMA) or federal (in the United States, the FDA) authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with these regulations may be subject to fines, to the suspension or withdrawal of the authorizations and certifications
required to perform pharmaceutical activities, to the seizure or withdrawal of products from the market, or to partial or total suspension of their manufacturing. Regulatory authorities may also withdraw marketing authorizations (&#147;MAs&#148;)
previously granted or reject MA applications (&#147;MAAs&#148;) and initiate legal proceedings, and their outcome remains uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the regulatory constraints may differ from a country to another, development of therapeutic products for human use must comply with
requirements shared by all developed countries. The steps to be completed before obtaining an MA in the EU and in the United States are generally as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conduct of preclinical laboratory tests and studies in animals, in accordance with Good Laboratory Practice
(&#147;GLP&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conduct of clinical trials in humans to demonstrate the safety and efficacy of the product for each considered
indication, in accordance with Good Clinical Practice (&#147;GCP&#148;), if necessary after authorization by a competent authority and an ethics committee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparation and submission of an MAA to the competent authority, in order to market the product;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inspection by the competent authority of the manufacturing facilities in which the product and/or its ingredients
are manufactured to assess compliance with Good Manufacturing Practices (&#147;GMP&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inspection by the competent authority of establishments distributing medicinal products in order to assess their
compliance with Good Distribution Practice (&#147;GDP&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if needed, commitment by the applicant to comply with <FONT STYLE="white-space:nowrap">post-MA</FONT>
requirements. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to these regulatory constraints, the development and approval process of a drug candidate for
commercialization, which varies according to its nature, complexity and novelty, usually extends over several years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>EU Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical Studies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within all EU Member
States, preclinical studies include laboratory evaluation of the composition, purity and stability of the active pharmaceutical ingredient and the formulated product, as well as studies to evaluate the tolerance (toxicological studies), activity and
behavior of the product candidate in vitro and in animals (in vivo). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conduct of preclinical studies is subject to legal and
regulatory provisions. <FONT STYLE="white-space:nowrap">Non-clinical</FONT> studies are performed to demonstrate the health or environmental safety of new chemical or biological substances. <FONT STYLE="white-space:nowrap">Non-clinical</FONT>
(pharmaco-toxicological) studies must be conducted in compliance with GLP, as set forth in EU Directive 2004/10/EC (unless otherwise justified for certain particular medicinal products &#150; e.g., radio-pharmaceutical precursors for radio-labelling
purposes). In particular, <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies, both in vitro and in vivo, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of
rules and criteria for a quality system for the organizational process and the conditions for <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies. These GLP standards reflect the Organization for Economic
<FONT STYLE="white-space:nowrap">Co-operation</FONT> and Development requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical studies are a prerequisite for the
initiation of clinical trials in humans: all the results of these trials are submitted to the regulatory authorities at the same time as the application to initiate clinical trials. However, while preclinical tests must be performed prior to
conducting clinical trials in humans, certain long-term preclinical tests, such as tests on reproductive toxicity and carcinogenicity, may continue after the submission of an application to initiate clinical trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Trials in Humans </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The various
phases of clinical trials in the EU are subject to significant regulatory controls. They must be conducted in accordance with EU and national regulations, the standards adopted by the International Conference on Harmonization (&#147;ICH&#148;) and
GCP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Directive no. 2001/20/EC on the conduct of clinical trials sought to harmonize the regulatory framework for clinical trials in the
EU, setting out common rules for the monitoring and authorization of clinical trials in the EU. To reduce disparities between the transpositions by the Member States, Regulation 536/2014 on clinical trials on medicinal products for human use and
repealing Directive 2001/20/EC, was adopted on April&nbsp;16, 2014. This regulation aims to further harmonize and streamline the clinical trial authorization process, simplify adverse event reporting procedures, improve the supervision of clinical
trials, and increase the transparency of clinical trials. This regulation became applicable on January&nbsp;31, 2022. However, it provides for a three-year transition period (i.e., clinical trials for which an application was submitted in accordance
with Directive no. 2001/20/EC before January&nbsp;31, 2022, will continue to be subject to the Directive provisions for a period of three years). Furthermore, sponsors having submitted a clinical trial under the Directive until January&nbsp;31, 2023
may remain governed by the Directive until January&nbsp;31, 2025. By that date, all ongoing trials will become fully subject to the provisions of the Regulation 536/2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the clinical trials regulation, the sponsor may submit its application for a clinical
trial authorization to one or several Member States, in which case the evaluation of Part I of the dossier (scientific part) is carried out according to a coordinated procedure. In this framework, the sponsor must submit a single application for
authorization via the portal associated with the EU database (&#147;CTIS&#148;), comprising a common scientific part evaluated jointly by all the EU Member States in which the trial will be carried out (with one of the Member States concerned acting
as rapporteur Member State) and a national part covering the ethical aspects of the trial, evaluated independently by each Member State. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conclusion of the rapporteur Member State with regard to Part I of the assessment report is deemed to be the conclusion of all Member
States concerned. However, the Member States concerned may disagree with this conclusion for a number of limited reasons, for example when they consider that participation in the clinical trial would lead to a subject receiving a treatment inferior
to that of normal clinical practice on their territory. The Member State concerned may then refuse the clinical trial on its territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A
&#147;single&#148; decision covering the conclusions of the Part I and Part II evaluations is issued by each of the Member States concerned and is notified to the sponsor on the dedicated European portal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sponsor of a clinical trial conducted in the EU notifies through the EudraVigilance database without delay and at the latest within the
deadlines set by the clinical trials regulation, of all relevant information on suspected serious and unexpected adverse reactions to the investigational medicinal product. If the competent bodies concerned consider that the adverse effects outweigh
the benefits for the participants, they may require the immediate suspension or early termination of the trial at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
the sponsor must submit through CTIS once a year, for the duration of the clinical trial, an Annual Safety Report (ASR) for each investigational drug used in the clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, the EU framework applicable to clinical trials has also been significantly strengthened with Regulation (EU) 2016/679 of the European
Parliament and of the Council of April&nbsp;27, 2016, on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation,
&#147;GDPR&#148;), which entered into force on May&nbsp;25, 2018. This regulation has significantly increased EU citizens&#146; rights by giving them more control over their personal data. Thus, depending on the type of personal data processing
carried out during clinical trials and the nature of such trials, it might be necessary to carry out formalities by the local Data Protection Authority, in addition to seeking formal informed consent which must be obtained from each clinical trial
subject. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Responsibility of the Sponsor and Insurance Obligation of the Sponsor </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, the sponsor shall indemnify the subject of the trial in case of damage arising as a consequence of the research, unless he proves
that the damage does not result from his fault or the fault of any other person intervening in the trial. In the EU, Member States generally require a sponsor to have an insurance covering its civil liability and the liability of any person
intervening in the research. In addition, any breach to the provisions concerning clinical trials may lead to significant administrative, criminal and/or reputational penalties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Marketing Approval </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within the EU,
marketing of medicinal products is governed by EU regulations (including but not limited to Directive 2001/83/EC and Regulation 726/2004/EU). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;26, 2023, the European Commission issued proposals for a revision of the current legal framework. Although the proposal is
subject to adoption by EU institutions, which become effective upon adoption, this new framework, which in particular aims at granting timely access to patients for safe, effective and affordable medicines and at enhancing supply of medicines, may
significantly amend general principles described above, notably timelines and market exclusivity periods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, medicinal product candidates can only be commercialized after obtaining an MA. To
obtain regulatory approval of a product candidate under EU regulatory systems, we must submit an MAA. The process for doing this depends, among other things, on the nature of the medicinal product. There are two types of MAs: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Centralized MAs&#148; are granted by the European Commission through the centralized procedure based on the
opinion of the Committee for Medicinal Products for Human Use (&#147;CHMP&#148;) of the EMA. The MA issued under this procedure is valid in all EU Member States. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The centralized procedure is compulsory for some types of medicinal products such as biotechnology products,
designated orphan medicinal products, products containing a new active substance indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes or autoimmune and viral diseases, advanced therapy medicinal products (such as gene
therapy, somatic cell therapy and tissue engineered products). The centralized procedure is optional for products containing a new active substance that has not yet been authorized in the EU or for products which present a significant therapeutic,
scientific or technical innovation or are of interest for the public health in the EU. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;National MAs&#148; are issued at a national level by the competent authorities of the concerned Member
States. They are valid only on their territory. National MAs can be issued for products that do not fall within the mandatory scope of the centralized procedure. Medicinal products which have not received a national MA in any of the Member States,
may be authorized through the decentralized procedure. This procedure enables the simultaneous issuance of national MAs in several EU countries. Under the decentralized procedure, an identical dossier is submitted to the competent authorities of
each of the Member States in which an MA is sought. One of these Member States is designated by the applicant to act as the Reference Member State (&#147;RMS&#148;). The competent authority of the RMS drafts an assessment report and prepares an
SmPC, a package leaflet and a draft labelling, which are sent to the other Member States involved in the procedure, known as the Concerned Member States (&#147;CMS&#148;), for approval. If the CMS do not raise any objections based on a potential
serious risk to public health, regarding the assessment, the SmPC, the labelling or the packaging proposed by the RMS, a national MA is granted for the product in all Member States involved in the procedure (i.e., in the RMS and the CMS). Where a
product has already been authorized for marketing in an EU Member State, this national MA can be recognized in another member state through the mutual recognition procedure. In this procedure, the Member State which issued the initial MA, known as
the RMS, must prepare an assessment report on the medicinal product or update any existing report. This report is sent to the CMS, together with the approved SmPC and the labelling and package leaflet. Unless an objection based on a potential
serious risk to public health is raised, the CMS issue(s) a national MA for the product, the terms of which are identical to the MA granted by the RMS. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending on the procedure used, the EMA or the national competent authority(ies) must, before granting a MA, make an assessment of the
benefit/risk ratio of the product based on scientific criteria of quality, safety of use and efficacy. Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the EMA is 210 days, excluding clock stops. In exceptional
cases, the CHMP might perform an accelerated review of an MAA in no more than 150 days (not including clock stops). Innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a
number of expedited development and review programs, such as the Priority Medicines (&#147;PRIME&#148;) scheme, which provides incentives similar to the breakthrough therapy designation in the U.S. In March 2016, the EMA launched an initiative, the
PRIME scheme, a voluntary scheme aimed at enhancing the EMA&#146;s support for the development of medicines that target unmet medical needs. It is based on increased interaction and early dialogue with companies developing promising medicines, to
optimize their product development plans and speed up their evaluation to help them reach patients earlier. Product developers that benefit from PRIME designation can expect to be eligible for accelerated assessment but this is not guaranteed. Many
benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and
accelerated MAA assessment once a dossier has been submitted. Importantly, a dedicated contact and rapporteur from the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
CHMP is appointed early in the PRIME scheme facilitating increased understanding of the product at EMA&#146;s committee level. An initial meeting initiates these relationships and includes a team
of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, in the EU, a
conditional MA may be granted by the European Commission for a period of one year and is renewable annually. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A conditional MA is granted
in the absence of sufficient clinical data to obtain an ordinary MA if the following requirements are met: (i)&nbsp;the medicinal product is intended to treat, prevent or diagnose a fatal or seriously debilitating disease, (ii)&nbsp;it fulfils to an
unmet medical need, (iii)&nbsp;its benefit/risk ratio is, on the basis of the available data, positive, (iv)&nbsp;it is likely that the applicant will be able to provide the required comprehensive <FONT STYLE="white-space:nowrap">post-MA</FONT>
clinical data and (v)&nbsp;in terms of public health, the benefits of the product&#146;s immediate availability to patients outweigh the risks inherent to the lack of sufficient clinical data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The granting of a conditional MA is accompanied by specific obligations, in particular relating to the completion of clinical trials, the
performance of new studies and the collection of pharmacovigilance data in order to confirm the benefit/risk ratio of the product. Once the pending studies are provided, it can become a &#147;standard&#148; MA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAs may also be granted under exceptional circumstances to medicinal products for which a complete evaluation file cannot be provided when the
product&#146;s indication is too rarely encountered and reasonably prevents the provision of comprehensive evidence, when the current state of scientific knowledge prevents the provision of such data or when the collection of the necessary data
would be unethical. This MA is close to the conditional MA as it is reserved to medicinal products to be approved for severe diseases or unmet medical needs and the applicant does not hold the complete data set legally required for the grant of a
MA. However, unlike the conditional MA, the applicant does not have to provide the missing data and will never have to. Although the MA &#147;under exceptional circumstances&#148; is granted definitively, the risk-benefit balance of the medicinal
product is reviewed annually and the MA is withdrawn in case the risk-benefit ratio is no longer favorable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, despite the granting
of a MA, both the MA holder and the competent authorities may decide to withdraw (voluntarily or compulsorily) a product from the market or a MA, when it appears that the product presents more risks than benefits for the patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Data and Marketing Exclusivity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
EU, new products authorized for marketing (<I>i.e.</I>, reference products) generally receive eight years of data exclusivity and an additional two years of market exclusivity upon MA. If granted, the data exclusivity period prevents generic and
biosimilar applicants from relying on the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar MA in the EU during a period of eight years from the date on which the
reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until ten years have elapsed from the initial MA of the reference
product in the EU. The overall <FONT STYLE="white-space:nowrap">ten-year</FONT> market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the MA holder obtains an authorization for
one or more new therapeutic indications, which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will
be considered by the EU&#146;s regulatory authorities to be a new chemical or biological entity, and products may not qualify for data exclusivity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pediatric Development </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, MAAs
for new medicinal products must include the results of studies conducted in the pediatric population, in compliance with a Pediatric Investigation Plan (&#147;PIP&#148;) agreed with the EMA&#146;s Pediatric
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Committee (&#147;PDCO&#148;). The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the medicinal product for which MA is being sought. The PDCO
can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial
data can be waived by the PDCO when these data is not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when
the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained in all the EU member states and study results are included in the product information, even when negative, the
product is eligible for six months&#146; supplementary protection certificate extension (if any is in effect at the time of approval) or, in the case of orphan pharmaceutical products, a <FONT STYLE="white-space:nowrap">two-year</FONT> extension of
the orphan market exclusivity is granted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Manufacturing and Distribution-related Requirements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To ensure patients&#146; safety, the manufacturing, distribution and import of active pharmaceutical ingredients and finished products into the
EU are also subject to extensive requirements and both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the European Commission and/or the competent regulatory authorities of the Member
States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medicines (including their active substances) must be manufactured in accordance with GMP requirements. These regulations govern
manufacturing processes and procedures, and notably provide for requirements relating to the implementation of quality systems to control and ensure the quality of materials and products. Manufacturing activities must be performed only within
companies holding valid licenses from the competent regulatory authorities of the Member States which is issued following an inspection of the concerned facilities. In addition, routine inspections are conducted on a regularly basis to ensure that
compliance is maintained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Distributors must also comply with very strict requirements, including good distribution practices
(&#147;GDP&#148;). These regulations provide for strict requirements including the implementation of an effective quality system and adequate procedures to ensure the quality of the products all over the distribution chain and efficiently respond to
claims, recalls, and risks of falsification, or the use of appropriate facilities, equipment and personnel. Similarly to manufacturing, distribution activities are subject to a prior approval from the competent regulatory authorities of the Member
States which is issued following an inspection of the concerned facilities which aims at ensuring that the establishment complies with the applicable regulations. Routine inspections are also conducted on a regularly basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, the import of active pharmaceutical ingredients and medicines into the EU must also be authorized in advance, in order to ensure that
the products are manufactured and distributed in accordance with standards at least equivalent to those existing for the EU market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with the above requirements may be sanctioned by the suspension or withdrawal of the manufacturing/distribution/import
authorization, civil, criminal or administrative penalties, or the withdrawal of the concerned active ingredients and finished products from the market. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Post-Approval Requirements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Pharmacovigilance
Requirements</U></I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MA holder must establish and maintain a pharmacovigilance system and designate a Qualified Person Responsible for
Pharmacovigilance (&#147;QPPV&#148;) who is responsible for the establishment and maintenance of that system, and oversees the safety profiles of medicinal products and any emerging safety concerns. The main obligations of the QPPV include prompt
reporting of suspected serious adverse reactions and submission of periodic pharmacovigilance update reports (&#147;PSURs&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All new MAA must include a risk management plan (&#147;RMP&#148;) describing the risk
management system that the company will put in place and setting out measures to prevent or minimize the risks associated with the medicinal product. The regulatory authorities may also issue an MA subject to the fulfillment of specific obligations.
These risk reduction measures or post-authorization obligations may consist, in particular, of reinforced safety monitoring, more frequent submission of PSURs, the conduct of additional clinical trials or the performance of post- authorization
safety studies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Advertising Requirements</U></I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, the advertising and promotion of medicinal products is also subject to laws concerning promotion of medicinal products, interactions
with physicians, misleading and comparative advertising and unfair commercial practices. The general principles applicable to the advertising of medicines, which is broadly defined as any form of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">door-to-door</FONT></FONT> information, canvassing activity or inducement designed to promote the prescription, supply, sale or consumption of medicinal products, are established by EU directives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any advertising or promotion of a medicinal product must comply with its approved SmPC. Consequently, any promotion of <FONT
STYLE="white-space:nowrap">off-label</FONT> promotion is prohibited. Indeed, the advertising must encourage the rational use of medicines by presenting them objectively without exaggeration and thus, must not be misleading. <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Direct-to-consumer</FONT></FONT> advertising of prescription medicines is also prohibited in the EU. Although general requirements for advertising and promotion of medicinal products are
established under EU directives, the details are governed by regulations in each Member State and can differ from one country to another. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending on the Member States, advertising-related regulatory requirements may be sanctioned notably by fines, suspension or withdrawal of
regulatory authorizations, medicinal products recalls, medicinal products seizures, operating restrictions and even criminal and/or civil prosecution and significant fines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aforementioned EU rules are generally applicable in the European Economic Area (&#147;EEA&#148;) which consists of the 27 EU member states
plus Norway, Liechtenstein and Iceland. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Coverage and Reimbursement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, pricing and reimbursement systems widely vary from one country to another and remain exclusively the responsibility of the Member
States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Thus, Member States may restrict the range of medicines for which their national health insurance system provides reimbursement
and to control the price of medicines for human use, provided that time limits for review of a reimbursement application provided in Directive 89/105/EEC of 21&nbsp;December 1988 must be complied with. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some Member States use a system of positive and negative lists, whereby medicines can only be marketed after a reimbursement price has been
agreed. Others may require additional studies comparing the cost-effectiveness of a medicinal product to existing therapies in order to obtain approval for reimbursement or pricing. Finally, Member States can agree to a set price or, instead, allow
companies to set their own prices while having their profits monitored and controlled (e.g., control of the quantity of prescriptions). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the last few years, many EU Member States have increased the amount of rebates applied to medicinal products, and these efforts may
continue as Member States exercise greater control over their healthcare spending due to often large debts. The downward pressure on healthcare costs in general, including medicinal products subject to mandatory prescription, has become
considerable. Changing political, economic and regulatory conditions can complicate price negotiations. This price negotiation can continue after reimbursement has been achieved and is generally subject to periodic reviews. Finally, reference prices
used by various EU Member States and parallel trade (i.e., arbitrage by distributors between low and high price Member States) may also lead to further price reductions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;13, 2021, Regulation No 2021/2282 on Health Technology Assessment
(&#147;HTA&#148;) amending Directive 2011/24/EU, was adopted. While the Regulation entered into force in January 2022 it will only begin to apply from January 2025 onwards, with preparatory and implementation-related steps to take place in the
interim. Once the Regulation becomes applicable, it will have a phased implementation depending on the concerned products. This regulation intends to boost cooperation among EU Member States in assessing health technologies, including new medicinal
products, and providing the basis for cooperation at the EU level for joint clinical assessments in these areas. The regulation will permit EU Member States to use common HTA tools, methodologies, and procedures across the EU, working together in
four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of
emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU Member States will continue to be responsible for assessing
<FONT STYLE="white-space:nowrap">non-clinical</FONT> (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Healthcare Laws </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Relationships
between the pharmaceutical industry and healthcare professionals are subject to national restrictions and regulations in order to avoid any incentive to prescribe drugs that is not justified by the patient&#146;s state of health and profile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, in France, relations between companies producing and/or marketing health products or providing services associated with these
products, regardless of their nationality and/or the location of their registered office, and healthcare professionals practicing in France are governed by the &#147;anti-gift&#148; and &#147;transparency&#148; laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose is to ensure that healthcare professionals, in their choice of a medicinal product, equipment or service, are guided solely by
medical information and considerations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By way of principle, under the French anti-gift law, persons providing health services,
manufacturing or marketing healthcare products are prohibited from promising or offering advantages, in cash or in kind, either directly or indirectly, to healthcare professionals practicing in France, students intending to enter such professions or
associations of these individuals, including learned societies and national professional councils. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The list of benefits that do that do
not qualify as &#147;advantages&#148; under the anti-kickback regulation is very limited and includes, for example, benefits that relate to the exercise of the beneficiary&#146;s profession and of negligible value, which may not exceed the amounts
provided for by a Ministerial Order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By way of exception, above-mentioned health stakeholders may provide advantages to the healthcare
professionals/associations mentioned above, subject to the conclusion of a written agreement and to a prior declaration to or approval from the authority to which the concerned beneficiary belongs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This exception is however limited to specific situations mainly including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The remuneration, compensation and expenses for research activities, research promotion, scientific evaluation,
consultancy, provision of services or commercial promotion, provided that the remuneration is proportionate to the service provided and that the compensation or expenses do not exceed the costs actually incurred by the persons concerned;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Donations and gifts, in cash or in kind, exclusively intended to finance research activities, the promotion of
research or scientific evaluation; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Hospitality offered during events of an exclusively professional or scientific nature, or during events promoting
healthcare products or services, provided that this hospitality is of a reasonable level, strictly limited to the main purpose of the event and to healthcare professionals (excluding students); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When failing to comply with these regulations, in addition to a significant risk to their
reputation, the companies and professionals concerned may be subject to significant criminal penalties and, in the case of the latter, disciplinary penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The French transparency provision, for its part, provides citizens with access to certain information on a website so that they can more
objectively assess the relationships between health actors (i.e., a broad list including healthcare professionals, associations of healthcare professionals, students, associations of users of the health system, health establishments, academic
institutions, foundations, learned societies and societies or advisory bodies involved in the health product or health services sector, etc.) and companies producing or marketing health products or providing services associated with these products.
Under the terms of this regulation, the companies concerned must disclose the main information relating to their relationships with healthcare professionals, such as compensation or benefits paid, and agreements entered into. Companies that
knowingly fails to disclose such information may be subject to criminal penalties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>UK Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the end of the Brexit transition period on January&nbsp;1, 2021, Great Britain (&#147;GB&#148;) (England, Scotland and Wales) has not
been directly subject to EU laws. However, under the terms of the Ireland/Northern Ireland Protocol, EU laws have generally applied to Northern Ireland. On February&nbsp;27, 2023, the UK government and the European Commission reached a political
agreement on the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;Windsor Framework&#148; which is intended to revise the Ireland/Northern Ireland Protocol in order to address some of the perceived shortcomings in its operation. The agreement
was adopted at the Withdrawal Agreement Joint Committee on March&nbsp;24, 2023. If the changes are adopted in the form proposed, medicinal products to be placed on the market in the UK will be authorized solely in accordance with UK laws. Northern
Ireland would be reintegrated back into a <FONT STYLE="white-space:nowrap">UK-only</FONT> regulatory environment under the authority of the MHRA with respect to all medicinal products. The implementation of the Windsor Framework would occur in
various stages, with new arrangements relating to the supply of medicines into Northern Ireland anticipated to take effect in 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
EU laws that have been transposed into United Kingdom (&#147;UK&#148;) law through secondary legislation remain applicable in Great Britain. However, new EU legislation that was either adopted or entered into application after Brexit such as the EU
CTR is not applicable in Great Britain. The UK regulatory framework in relation to clinical trials is derived from previously existing EU legislation (as implemented into UK law, through secondary legislation). On January&nbsp;17, 2022, the UK MHRA
launched an 8-week consultation on reframing the UK legislation for clinical trials. The consultation closed on March&nbsp;14, 2022, and aims to streamline clinical trial approvals, enable innovation, enhance clinical trials transparency, enable
greater risk proportionality and promote patient and public involvement in clinical trials. The outcome of the consultation is being closely watched and will determine whether the UK chooses to align with the (EU) CTR or diverge from it. Under the
terms of the Ireland/Northern Ireland Protocol, provisions of the EU CTR which relate to the manufacture and import of investigational medicinal products and auxiliary medicinal products currently apply in Northern Ireland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2021, the MHRA has been the sole regulatory of medicines and medical devices in GB and for medicinal products that are
not authorized through the centralized procedure in Northern Ireland. The MHRA has introduced changes to national licensing procedures, including procedures to prioritize access to new medicines that will benefit patients, including a <FONT
STYLE="white-space:nowrap">150-day</FONT> assessment and a rolling review procedure. All existing EU MAs for centrally authorized products were automatically converted or grandfathered into UK MAs, effective in GB (only), free of charge on
January&nbsp;1, 2021, unless the MA holder <FONT STYLE="white-space:nowrap">opted-out.</FONT> In order to use the centralized procedure to obtain an MA that will be valid throughout the EEA, companies must be established in the EEA. Therefore, since
Brexit, companies established in the UK can no longer use the EU centralized procedure for authorization of medicinal products intended to be marketed in the UK. In order to obtain a UK MA to commercialize products in the UK, an applicant must be
established in the UK and must follow one of the UK national authorization procedures or one of the remaining post-Brexit international cooperation procedures to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obtain an MA to commercialize products in the UK. Until December&nbsp;31, 2023, the MHRA may rely on a decision taken by the European Commission on the approval of a new (centralized procedure)
MA when reviewing an application for authorization of a medicinal product to be supplied in GB. Depending on the nature and intended therapeutic purpose of the medicinal product, the MHRA may, alternatively, use its own decentralized or mutual
recognition procedures which enable the MHRA to have regard to MAs approved in EU Member States, Iceland, Liechtenstein, Norway) when granting an MA in the UK or GB. From the first quarter of 2024, a new international recognition framework should be
in place with an aim to extend the countries whose assessments the MHRA will take into account. The UK government will need to adopt new legislation to introduce this route. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no <FONT STYLE="white-space:nowrap">pre-MA</FONT> orphan designation procedure. Applications for orphan designation are made at the
same time as an application for MA and the MHRA will review applications for orphan designation in parallel to the corresponding MA application. The criteria are essentially the same, but have been tailored for the market (i.e., the prevalence of
the condition in GB, rather than the EU, must not be more than five in 10,000). Should an orphan designation be granted, the period or market exclusivity will be set from the date of first approval of the product in GB. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Government Regulation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, (&#147;FDCA&#148;) and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state,
and local statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process, or after approval,
may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#146;s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold on a clinical trial, issuance of warning letters, product
recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process required by the FDA before a drug may be marketed in the United States generally involves the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Completion of preclinical laboratory studies, animal studies and formulation studies in compliance with the
FDA&#146;s GLP regulations, and other applicable regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Submission to the FDA of an IND which must become effective before human clinical trials may begin;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approval by the Institutional Review Board (&#147;IRB&#148;) or ethics committee, at each clinical site before
each trial may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Performance of adequate and well-controlled human clinical trials, in accordance with GCP requirements to
establish the safety and effectiveness of the proposed drug product for each indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Submission to the FDA of an NDA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Satisfactory completion of an FDA advisory committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is
produced to assess compliance with current good manufacturing practice (&#147;cGMP&#148;) requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#146;s identity, strength, quality and purity, and of
potential inspection of selected clinical investigation sites to assess compliance with GCPs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the NDA. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical Studies and INDs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential
safety and efficacy. An IND sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some
preclinical studies may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials
and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical
trials to commence. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Trials </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational drug to human patients under the supervision of qualified investigators in
accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols
detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to
the FDA as part of the IND. In addition, the IRB(s) competent for the institution(s) participating in the clinical trial must review and approve the plan for any clinical trial before it commences. Information about certain clinical trials must be
submitted within specific timeframes to the National Institutes of Health for public dissemination on their www.clinicaltrials.gov website. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the IND is active, progress reports detailing the results of the clinical trials and nonclinical studies performed since the last
progress report, among other information, must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies
suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction
compared to that listed in the protocol or investigator brochure. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an
unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug has been associated with unexpected serious
harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether
a trial may move forward at designated check points based on access to certain data from the trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of FDA approval, human
clinical trials are generally conducted in three sequential phases that may overlap or be combined: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 1:</I> The drug candidate is initially introduced into healthy human subjects and tested for safety,
dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 2:</I> The drug candidate is administered to a limited patient population with a specified disease or
condition to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the drug candidate for specific targeted diseases and to determine dosage tolerance and appropriate dosage. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 3:</I> The drug candidate is administered to an expanded patient population to further evaluate dosage,
to provide substantial evidence of efficacy and to further test for safety, generally at multiple </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk-benefit ratio of the drug candidate and provide an adequate basis for product
labeling. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Post-approval trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing
approval. These trials are used to, among other things, gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a
condition of approval of an NDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies usually complete additional animal studies and must also
develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with GMPs. The manufacturing process must be capable of
consistently producing quality batches of the drug candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected
and tested, and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Marketing Approval </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming successful
completion of the required clinical testing, the results of the preclinical studies and clinical trials, together with detailed information relating to the product&#146;s chemistry, manufacture, controls and proposed labeling, among other things,
are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act
guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#147;filing&#148; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date
the NDA is submitted to FDA because the FDA has approximately two months to make a &#147;filing&#148; decision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the
Pediatric Research Equity Act of 2003, as amended and reauthorized, certain NDAs or supplements to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric
subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or
all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA also may require submission of a Risk Evaluation and Mitigation Strategy (&#147;REMS&#148;) plan to ensure that the benefits of the
drug outweigh its risks. The REMS plan could include Medication Guides (FDA approved patient labeling to be provided to patients when the drug is dispensed), physician communication plans, assessment plans, or Elements to Assure Safe Use, such as
restricted distribution methods, patient registries, or other risk minimization tools. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA conducts a preliminary review of all NDAs
within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this
event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an <FONT
STYLE="white-space:nowrap">in-depth</FONT> substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets
standards designed to assure the product&#146;s continued safety, quality and purity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may refer an application for a novel drug
to an Advisory Committee. An Advisory Committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under
what conditions. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
FDA is not bound by the recommendations of an Advisory Committee, but it considers such recommendations carefully when making decisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an NDA, the FDA typically will inspect the facility or facilities where the commercial product would be manufactured. The FDA
will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally,
before approving an NDA, the FDA may inspect one or more clinical trial sites to verify the clinical data submitted in the NDA, and to assure compliance with GCP requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After evaluating the NDA and all related information, including the Advisory Committee recommendation, if any, and inspection reports
regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing
information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form, and describes the specific deficiencies in the NDA
identified by the FDA and may require additional clinical data, such as an additional clinical trial or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a CRL is issued, the
sponsor must resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications,
warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#146;s safety after approval, require testing and surveillance programs to
monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product.
The FDA may at any time prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After initial approval, some types of changes to the approved product, such as adding new indications,
manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Post-Approval
Requirements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the
FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, the submission of advertising and promotion, and reporting of adverse experiences with the product. After approval,
most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual program user fee requirements for any marketed products, as well as new
application fees for certain supplemental applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may impose a number of post-approval requirements as a condition of
approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register
their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and
often require prior FDA approval before being implemented. FDA regulations also require manufacturers to investigate and correct of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any
third-party </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP
compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is
not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to
comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other
restrictions under a REMS program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other potential consequences include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market
or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Fines, warning letters or holds on post-approval clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of
product approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Product seizure or detention, or refusal to permit the import or export of products; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted
only for the approved indications and in accordance with the provisions of the approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of unapproved uses
<FONT STYLE="white-space:nowrap">(&#147;off-label&#148;</FONT> uses), and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant liability. Physicians may prescribe
legally available products for uses that are not described in the product&#146;s labeling and that differ from those tested by us and approved by the FDA. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA
does, however, restrict manufacturer&#146;s communications on the subject of <FONT STYLE="white-space:nowrap">off-label</FONT> use of their products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Marketing Exclusivity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market exclusivity
provisions under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of <FONT STYLE="white-space:nowrap">non-patent</FONT> data exclusivity within the United States to the first
applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of
the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application (&#147;ANDA&#148;), or an NDA submitted under Section&nbsp;505(b)(2) (&#147;505(b)(2) NDA&#148;) submitted by another company
for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to
all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or <FONT STYLE="white-space:nowrap">non-infringement</FONT> to one of the patents listed with the FDA
by the innovator NDA holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an
existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or
strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for
drugs containing the active agent for the original indication or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct, or obtain
a right of reference to, all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an
additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor
to undertake the described clinical trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Coverage and Reimbursement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of our drug candidates, if approved, will depend, in part, on the extent to which such products will be covered by third-party payors,
such as government health care programs, commercial insurance and managed healthcare organizations. These third-party payors determine which medications they will cover and establish reimbursement levels. In addition, these third-party payors are
increasingly limiting coverage or reducing reimbursements for medical products and services. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement
for products can differ significantly from payor to payor. In addition, the U.S. government and state legislatures have continued implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for
substitution of generic products. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their
prescription drugs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products. As a result, adoption of price controls and cost-containment
measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. Decreases in third-party reimbursement for our drug candidates or a decision by a third-party
payor to not cover our drug candidates could reduce physician usage of our drug candidates, once approved, and have a material adverse effect on our sales, results of operations and financial condition. Additionally, we or our collaborators may
develop companion diagnostic tests for use with our drug candidates. We or our collaborators will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we seek for our drug
candidates, once approved. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Healthcare Laws </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will also be
subject to other healthcare regulation and enforcement by the U.S. federal government and the states in which we will conduct our business once our drug candidates are approved. Failure to comply with these laws, where applicable, can result in the
imposition of significant administrative, civil, and criminal penalties. The laws that may affect our ability to operate in the United States include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal healthcare programs&#146; Anti-Kickback Statute, which prohibits, among other things, persons from
knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which
payment may be made under federal healthcare programs such as the Medicare and Medicaid programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Federal false claims act laws, including the civil False Claims Act, which prohibit, among other things,
individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal health care fraud statutes, which created additional federal criminal statutes that impose criminal
and civil liability for, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or knowingly and willingly falsifying, concealing or covering up a material fact or making false statements relating
to healthcare matters; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Physician Payments Sunshine Act, which requires manufacturers of drugs, devices, biologics, and medical
supplies to report annually to the Centers for Medicare&nbsp;&amp; Medicaid Services, information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors),
other health care professionals (such as physicians assistants and nurse practitioners), and teaching hospitals, as well as and ownership and investment interests held by physicians and their immediate family members; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The U.S. federal Health Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;), which created
additional federal criminal statutes that impose criminal and civil liability for, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or knowingly and willingly falsifying, concealing or
covering up a material fact or making false statements relating to healthcare matters; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#147;HITECH&#148;),
which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, many states have similar laws and regulations, such as anti-kickback and false claims laws that may be broader in scope and may
apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. Further, certain states enacted laws that require: pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary
compliance guidelines and the relevant compliance guidance promulgated by the federal government; drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing
expenditures; the reporting of information related to drug pricing; the registration of pharmaceutical sales representatives. Certain states have also enacted legislation to govern the privacy and security of health information, many of which differ
from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. Additionally, to the extent that our product is sold in a foreign country, we may be subject to similar foreign laws. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Healthcare Reform </U></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The enactment
of the Affordable Care Act (&#147;ACA&#148;) has substantially changed healthcare financing and delivery by both governmental and private insurers, and significantly impacted the pharmaceutical industry. The ACA, among other things, established an
annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents, revised the methodology by which rebates owed by manufacturers to the state and federal government for covered
outpatient drugs under the Medicaid Drug Rebate Program are calculated, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate program to utilization of
prescriptions of individuals enrolled in Medicaid managed care organizations, and provided incentives to programs that increase the federal government&#146;s comparative effectiveness research. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been judicial and congressional challenges to certain aspects of the ACA. Most recently, on June&nbsp;17,
2021, the United States Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the individual mandate was repealed by Congress. In addition, there have been a number of health reform
initiatives by the Biden administration that have impacted the ACA. For example, on August&nbsp;16, 2022, President Biden signed the Inflation Reduction Act of 2022 (&#147;IRA&#148;), into law, which among other things, extends enhanced subsidies
for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#147;donut hole&#148; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cost through a newly established manufacturer discount program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted since the ACA was enacted. For example, on August&nbsp;2, 2011, the Budget Control
Act of 2011 was signed into law which among other things, led to aggregate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reductions in Medicare payments to providers. These reductions went into effect on April&nbsp;1, 2013, and, due to subsequent legislative amendments, will remain in effect until 2032, except for
a temporary suspension from May&nbsp;1, 2020, through March&nbsp;31, 2022, due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products.
For example, there have been several congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform
government program reimbursement methodologies for drug products. For example, on March 11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a
drug&#146;s average manufacturer price, beginning January 1, 2024. In addition, the IRA, among other things, (1)&nbsp;directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2)&nbsp;imposes rebates
under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions took effect progressively starting in fiscal year 2023, although the Medicare drug price negotiation program is currently subject to
litigation. Further, the Biden administration released an additional executive order on October&nbsp;14, 2022, directing HHS to submit a report within 90 days on how the Center for Medicare and Medicaid Innovation (&#147;CMMI&#148;) can be further
leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. In response, on February 14, 2023, HHS released a report outlining three new models for testing by the CMMI which will be evaluated on their ability to
lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. At the state level, legislatures are increasingly passing legislation and
implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency
measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that additional U.S.
federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our drug candidates or
additional pricing pressures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success will depend upon our ability to obtain and maintain patents and other intellectual property for our drug candidates in the United
States and internationally, including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">composition-of-matter,</FONT></FONT> pharmaceutical composition, synthesis process, method of manufacture and method of treatment, as well as
patent and other intellectual property and proprietary protection for our novel discoveries and other important technology inventions and <FONT STYLE="white-space:nowrap">know-how.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of our strategies is also to file new patents that could extend obefazimod&#146;s intellectual property protection in the United States to
2039 and to generate new intellectual property through the protection of potential <FONT STYLE="white-space:nowrap">follow-on</FONT> compounds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patents, we rely upon unpatented trade secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> and continuing technological
innovation to develop and maintain our competitive position. We protect our proprietary information, in part, using confidentiality agreements with our commercial partners, collaborators, employees and consultants and invention assignment agreements
with our employees. We also have confidentiality agreements or invention assignment agreements with our commercial partners and selected consultants. Despite these measures, any of our intellectual property and proprietary rights could be
challenged, invalidated, circumvented, infringed or misappropriated, or such intellectual property and proprietary rights may not be sufficient to permit us to take advantage of current market trends or otherwise to provide competitive advantages.
In addition, such confidentiality agreements and invention assignment agreements can be breached and we may not have adequate remedies for any such breach. For more information, please see &#147;Risk Factors&#151;Risks Related to Intellectual
Property.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the legal term of the patents in the countries
in which they are obtained. In most countries in which we are seeking patent protection for our drug candidates, the patent term is 20 years from the earliest date of filing a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent
application. In the United States, the term of a patent may be lengthened by a patent term adjustment, which provides for term extension in the case of administrative delays at the United States Patent and Trademark Office in granting a patent, or
may be shortened if a patent is terminally disclaimed over another patent with an earlier expiration date. Furthermore, in the United States, the term of a patent covering an FDA approved drug may be eligible for patent term extension
(&#147;PTE&#148;) under the Hatch-Waxman Amendments as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years beyond the expiration of the patent but cannot extend the term
of a patent beyond a total of 14 years from the date of product approval. Only one patent covering a single FDA-approved product among those eligible for an extension may be extended. In the future, if any of our drug candidates receives FDA
approval, we expect to apply for a PTE, if available, to extend the term of a patent covering such approved drug product. We also expect to seek PTEs in any jurisdictions where they are available, however, there is no guarantee that the applicable
authorities, including the FDA, will agree with our assessment of whether such an extension should be granted, and even if granted, the length of such an extension. See &#147;Risk Factors&#151;Risks Related to Intellectual Property &#151; Our
ability to commercialize our drug candidates may decrease if we are unable to protect our intellectual property rights or if these rights are insufficient for our purposes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patents </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All the patents and
patent applications covering obefazimod are <FONT STYLE="white-space:nowrap">co-owned</FONT> with the French National Centre for Scientific Research (the &#147;CNRS&#148;), the University of Montpellier, and the Institut Curie, except U.S. patent
10,464,903 and U.S. patent 10,745,357, as described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Obefazimod </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2023, the principal patent rights related to obefazimod, include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. patent 10,017,498, which is directed to the composition of matter of obefazimod generically and specifically
and to a pharmaceutical composition comprising it. This patent is also granted in Europe and several other countries (Australia, Brazil, Canada, China, Hong Kong, Cuba, India, Japan, South Korea, Mexico, Russia, South Africa) and has an expiry date
of 2030, not including patent term adjustment or any potential PTE. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. patent 10,975,063, which is directed specifically to obefazimod (composition of matter), free base and salts
of obefazimod, a pharmaceutical composition comprising it, a process for preparing it and a method for treating HIV infection. This patent has an expiry date of 2030, not including patent term adjustment or any potential PTE. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. patent 10,435,370, which is directed to methods of treating inflammatory diseases including UC and CD by
obefazimod generically and specifically. This patent is also granted in Europe and several other countries. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. continuation patent 11,649,211 is directed to the method of treating inflammatory diseases including UC and
CD by obefazimod specifically. Divisional U.S. patents protect methods of treating additional inflammatory diseases (U.S. patent 10,981,874 and U.S. patent 11,649,210). These patents have an expiry date of 2035, not including patent term adjustment
or any potential PTE. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. patent 10,464,903 and U.S. patent 10,745,357, which are directed to a synthesis process for manufacturing
obefazimod and derivatives thereof, a polymorphic form of the free base of obefazimod and crystalline forms of various salts of obefazimod. These patents have an expiry date of 2037, not including patent term adjustment or any potential PTE. A
corresponding European patent has also been granted. These patents are solely owned by us. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Further indications are also protected by other patents: U.S. patent 9,827,237, which is directed to the method
of treating Human Leukemia virus infection. This patent is also granted in Europe and several other countries and has an expiry date of 2034. U.S. patent 9,145,367, which is directed to the method of treating AIDS by obefazimod generically and
specifically. This patent is also granted in Europe and several other countries and has an expiry date of 2030. U.S. patent 9,108,919, which is directed to the method of treating cancer by obefazimod generically and specifically. This patent is also
granted in Europe and several other countries and has an expiry date of 2030. Another patent application directed to a method of treating cancer has been filed worldwide in 2019. U.S. patent 10,806,729 which is directed to the method of treating HIV
resistant patients by obefazimod generically and specifically. This patent is also granted in Europe and other countries and has an expiry date of 2036. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. patent applications 17/416,856 and 17/416,679, which are respectively directed to the method of treating
other inflammatory diseases and cancer by obefazimod generically and specifically or its N-glucuronide metabolite have been filed in 2019, as well as counterpart applications in other countries. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. patent application 17/913,063, which is directed to the method of treating Coronaviridae infection by
obefazimod generically and specifically or its N-glucuronide metabolite has been filed in 2021, as well as counterpart applications in other countries. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. patent application 17/796,834, which is directed to the amorphous solid dispersion (ASD) of obefazimod, its
method of preparation, pharmaceutical composition and method of treating inflammatory disease, cancer and viral diseases therewith has been filed in 2021, as well as counterpart applications in other countries. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. patent application 17/793,133, which is directed to co-crystals and salts of obefazimod, pharmaceutical
composition and method of treating inflammatory disease, cancer and viral diseases therewith has been filed in 2021, as well as counterpart applications in other countries. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">PCT international patent application PCT/EP2022/057628, which is directed to a synthesis process for
manufacturing obefazimod and derivatives thereof and was filed in 2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Two PCT international patent applications were filed under PCT/EP2023/050641 and PCT/EP2023/051424 in 2023
directed to combinations products with obefazimod respectively with etrasimod and Rinvoq. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trademarks and Domain Names
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own a number of trademarks and domain names, including our logo and the URL for our website, as well as a number of websites
including the name &#147;abivax&#148; or &#147;obefazimod.&#148; &#147;Abivax&#148; is a registered trademark of our company in Canada, China, Cuba, the EU, France, India, South Africa and the United Kingdom. We also hold pending applications for
the &#147;Abivax&#148; trademark in Australia, Brazil, Canada, Cuba, India, Japan, Mexico, South Africa, South Korea and the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key
Collaborations and Partners </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financing Arrangements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Kreos / Claret Financing Agreements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
August&nbsp;20, 2023, we entered into the Framework Subscription Agreement with KC and Claret, as the Secured Lenders. Under this Framework Subscription Agreement, we may draw up to &#128;75 million in structured debt financing in three tranches of
&#128;25 million in aggregate principal amount each, as further described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The first tranche, with an aggregate principal amount of
&#128;25 million, takes the form of senior secured convertible bonds with warrants attached, which we refer to as the Kreos / Claret OCABSA. We drew the first tranche on August 21, 2023. On the same date, we repaid all outstanding amounts that
remained due under the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
First KC Agreement and the Second KC Agreement. The Kreos / Claret OCABSA are convertible into ordinary shares at any time from their issuance at the request of their holders at a fixed
conversion price of &#128;21.2209, subject to standard adjustments, including anti-dilution and dividend protections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The second tranche,
with an aggregate principal amount of &#128;25&nbsp;million, takes the form of senior secured <FONT STYLE="white-space:nowrap">non-convertible</FONT> bonds and may be drawn before March 31, 2024, subject to satisfaction of customary closing
conditions. The drawdown of the second tranche is subject to a maximum 10% Debt-To-Market Capitalization Ratio at the time of drawdown. The &#147;Debt-To-Market Capitalization Ratio&#148; is calculated, on any relevant date, by dividing (i) our
indebtedness (including amounts due under the Kreos / Claret Financing, but excluding amounts due under the Heights Financing), by (ii) our market capitalization calculated by multiplying the number of our outstanding ordinary shares by the closing
price of our ordinary shares on such relevant date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The third tranche, with an aggregate principal amount of &#128;25 million, takes the
form of senior secured non-convertible bonds and may be drawn before July 31, 2024, subject to satisfaction of customary closing conditions. The drawdown of the third tranche is subject to a maximum 10% Debt-To-Market Capitalization Ratio at the
time of drawdown and is conditional on our raising of a minimum of $125 million in gross proceeds through a listing on Nasdaq before June 30, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest on the Kreos / Claret OCABSA accrues annually at a rate of 9% payable in quarterly installments. The Kreos / Claret OCABSA&#146;s
maturity date is March 31, 2027 and the final repayment date is January 1, 2027. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A variable interest rate of 7.5% plus European Central
Bank Base Rate (subject to a minimum interest rate of 2.5% and a maximum interest rate of 4%) applies to each of the second and third tranches. These two tranches will be repaid monthly through March 31, 2027, after a deferred repayment of the
principal (i) until October 1, 2024, for the second tranche, or February 1, 2025, if the conditions to draw the third tranche are met, and (ii)&nbsp;until February 1, 2025, for the third tranche. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Kreos / Claret Financing provides for certain restrictive covenants (subject to customary exceptions), which include, among other things,
restrictions on the incurrence of indebtedness, cross-default, the distribution of dividends and the grant of security interests. As security for the Kreos / Claret Financing, the Secured Lenders benefit from the grant of first-ranking collateral on
our principal tangible and intangible assets, including pledges over our business (<I>fonds de commerce</I>) as a going concern and intellectual property rights in our lead drug candidate, as well as pledges over our bank accounts and receivables.
Such securities apply to all tranches of the Kreos / Claret Financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the Kreos / Claret Financing, we have issued warrants
to the Secured Lenders for a global subscription price of &#128;1.00, giving them the right to subscribe to up to 214,198 new ordinary shares at an exercise price of &#128;18.6744. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the conditions for the drawdown of the third tranche of the Kreos / Claret Financing are met, we will issue additional warrants to KC and
Claret for a global subscription price of &#128;1.00 unless we expressly decline the third tranche within 14 days of the conditions being met. The exercise price of the additional warrants to be issued will be equal to 110% of the 15-day volume
weighted average price (&#147;VWAP&#148;) of our ordinary shares prior to the date on which their issuance is decided. The number of warrants to be issued will be calculated by dividing &#128;4 million by the aforementioned exercise price. Of these
additional warrants, 50% will be exercisable upon issuance and the remaining 50% shall only be exercisable if we draw the third tranche of the Kreos / Claret Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants issued to the Secured Lenders can be exercised over a period of seven years from their issuance date or up until the date of the
successful closing of a tender offer for our ordinary shares, whichever is earlier. At the time of exercise of the warrants, the holders of the warrants are eligible to sell part of their warrants to us in accordance with a put option agreement to
allow for a cashless exercise of the warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Kreos / Claret OCABSA, the non-convertible bonds and the warrants issued in the
framework of the Kreos / Claret Financing will not be listed on any market. The agreements relating to the Kreos / Claret Financing are governed by French law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Prior KC Agreements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;24,
2018, we entered into the First KC Agreement for &#128;20&nbsp;million venture loan agreement with KC. The financing consists of two tranches of structured debt financing: (i)&nbsp;a total principal amount of First Tranche A Notes of
&#128;10&nbsp;million, comprised of (x) &#128;8&nbsp;million in non-convertible bonds issued in July 2018 and (y) &#128;2&nbsp;million in convertible bonds issued in August 2018 and (ii)&nbsp;a total principal amount of First Tranche B Notes of
&#128;10&nbsp;million, comprised of (x) &#128;8&nbsp;million in non-convertible bonds and (y) &#128;2&nbsp;million in convertible bonds, each issued in May 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;12, 2020, we entered into the Second KC Agreement for bonds issue agreement with KC, pursuant to which we issued bonds in a
total principal amount of Second Tranche A Notes of &#128;15&nbsp;million, comprised of (i)&nbsp;a &#128;10&nbsp;million tranche and Second Tranche B Notes of &#128;5&nbsp;million, with an option to issue Second Tranche C Notes of an additional
&#128;5&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August 21, 2023, we repaid all outstanding amounts that remained due under the First KC Agreement and the Second
KC Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Heights Convertible Notes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;20, 2023, we entered into the Heights Subscription Agreement with Heights. Under the Heights Subscription Agreement, we may draw
up to &#128;75 million of the Heights Convertible Notes in two tranches of &#128;35&nbsp;million and &#128;40 million, respectively, as further described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The first tranche in aggregate principal amount of &#128;35 million was drawn on August 24, 2023. On the same date, we repaid all amounts due
under the OCEANE bonds. The Heights Convertible Notes are convertible into ordinary shares at any time from their issuance at the request of the holder at a fixed conversion price set at &#128;23.7674, subject to standard adjustments, including
anti-dilution and dividend protections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The second tranche in aggregate principal amount of up to &#128;40 million may be drawn during
the period from the date immediately following the three-month anniversary of the issuance of the first tranche to the first-year anniversary of the issuance of the first tranche. It may be drawn in up to two separate closings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount available for drawdown under the second tranche will be determined based on our market capitalization (based on seven (7) of the
ten (10) trading days immediately preceding such drawdown) (&#147;Average Market Capitalization&#148;) and the average daily valued traded of our ordinary shares (&#147;ADVT&#148;) over the <FONT STYLE="white-space:nowrap">three-month</FONT> period
preceding the drawdown, as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Average Market</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Capitalization</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>ADVT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Maximum Cumulated Amount<BR>Outstanding
Under Both First and<BR>Second Tranches of the Heights<BR>Financing</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">At least &#128;700,000,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">At least &#128;900,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#128;45,000,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">At least &#128;850,000,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">At least &#128;1,250,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#128;55,000,000</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">At least &#128;1,000,000,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">At least &#128;1,500,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#128;65,000,000</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest on the Heights Convertible Notes accrues annually at a rate of 6% payable in quarterly installments
in cash or, at our option, in ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Heights Convertible Notes will be repaid through sixteen quarterly installment
payments, beginning three months after their issuance date (corresponding, for the first tranche, to a final repayment date on August&nbsp;24, 2027). Installments are payable in cash or, at our option, in ordinary shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any interest or installment payments in shares will be made on the basis of a share price
equal to 90% of the Market Price of our ordinary shares at the time of payment. &#147;Market Price&#148; refers to the arithmetic average of the daily VWAP for our ordinary shares on the two (2) days with the lowest daily VWAPs out of the five (5)
trading days immediately preceding the applicable date, but in no event greater than the VWAP of our ordinary shares on the applicable date. The Market Price may not be higher than the applicable conversion price. Issuances of ordinary shares may
not be made at a price lower than a 15% discount to the 15-day VWAP at the time of the decision to issue the Heights Convertible Notes (i.e., &#128;14.4303 per ordinary share for the first tranche). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the occurrence of certain events (including a change of control of Abivax, a free float event or a delisting of our ordinary shares on
Euronext Paris), any noteholder will have the option to require us to redeem all, and no less than all, of its Heights Convertible Notes at par plus accrued but unpaid interest. In the event that our ordinary shares are targeted by a public offer
(in cash or in securities, in cash and securities, etc.) which may result in a change of control or filed following a change of control, upon conversion of the Heights Convertible Notes, we shall (i) deliver new ordinary shares at the conversion
price, and (ii) pay a cash amount equal to the sum of the remaining coupons scheduled until the maturity date, and any accrued interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms and conditions of the Heights Convertible Notes include a standard negative pledge providing that any security granted in favor of
other borrowed debt or debt instruments should also be granted in favor of the Heights Convertible Notes on an equal basis (with the exception of the securities issued pursuant to the Kreos&nbsp;/ Claret Financing, as described above). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Heights Financing is a senior, unsecured financing. The convertible bonds of the Heights Financing will not be listed on any market. The
agreements relating to the Heights Financing are governed by French law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>OCEANE Bonds </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;30, 2021, we issued &#128;25&nbsp;million 6% convertible senior unsecured and unsubordinated bonds due July&nbsp;30, 2026
corresponding to 654,621 OCEANE bonds. The OCEANE bonds were exchangeable, at the option of the bondholders, for new or existing shares and bear interest at a rate of 6% per annum, payable semi-annually on January&nbsp;30 and July&nbsp;30 of each
year, beginning January&nbsp;30, 2022. On August&nbsp;24, 2023, we repaid all amounts due under the OCEANE bonds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Royalty Certificates </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;31, 2022, we issued &#128;2.9&nbsp;million in royalty certificates (the &#147;Royalty Certificates&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms and conditions of the Royalty Certificates provide holders with the right to royalties equal to 2% of the future net sales of
obefazimod (worldwide and for all indications) following its commercialization. The amount of royalties that may be paid under the Royalty Certificates is capped at &#128;172&nbsp;million (the &#147;Royalty Cap&#148;). The Royalty Certificates do
not provide for any dividend rights, coupon payments or any other additional financial rights other than the right to royalties. In particular, the Royalty Certificates do not grant any financial rights in respect of any other products that may be
developed by us beyond obefazimod. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Royalty Certificates have a term of 15 years and do not provide for an accelerated repayment in
case of a change of control. We may at any time repay the Royalty Certificates in full by paying an amount equal to the Royalty Cap minus any royalties paid prior to such reimbursement. The Royalty Certificates are subject to a <FONT
STYLE="white-space:nowrap">one-year</FONT> <FONT STYLE="white-space:nowrap">lock-up,</FONT> after which they will become freely transferable by each holder thereof in whole, but not in part. The Royalty Certificates are not listed nor assigned an
ISIN. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share Purchase Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Prosynergia S.&agrave;.r.L. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
April&nbsp;1, 2022, we entered into a share purchase agreement pursuant to which we acquired 100% of the capital and voting rights of Prosynergia S.&agrave;.r.L, a Luxembourg biotech company, registered in the Luxembourg Trade and Companies Register
under no. B257479, with registered offices located at 241 route de Longwy &#150; 1941 Luxembourg City, Luxembourg for consideration of &#128;3.25&nbsp;million (the &#147;Prosynergia Agreement&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December 1, 2021, we granted a loan to Prosynergia, for &#128;1,400,000. On December 12, 2022, we completed a merger with Prosynergia
through a <I>Transmission Universelle du Patrimoine</I> (&#147;TUP&#148;) and all of Prosynergia&#146;s assets and liabilities were transferred to us. Following the merger, Prosynergia was dissolved. See Note 4.15 to our audited financial statements
as of and for the years ended December 31, 2021 and 2022 included elsewhere in this prospectus for further detail. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration, Research and
Development Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>IQVIA Master Services Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;17, 2018, we entered into a master services agreement with IQVIA Ltd (&#147;IQVIA&#148;) for the provision of clinical trial
services, research and other services for individual clinical trials on human beings (the &#147;IQVIA Master Services Agreement&#148;), as amended on September&nbsp;9, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the IQVIA Master Services Agreement and underlying Work Order, IQVIA agreed to perform certain services on our behalf as we
request, subject to IQVIA&#146;s acceptance of the services and related budget in the applicable Work Order, including, but not limited to, strategic planning, expert consultation, clinical trial services, statistical programming and analysis, data
processing, data management, regulatory, project management, pharmacovigilance, central laboratory services, clinical pharmacology services, electrocardiogram services and device services. In consideration therefore, we agreed to pay IQVIA an agreed
set of fees based on our requests, as set forth in the applicable Work Order. We have the right to terminate the IQVIA Master Services Agreement or requested work without cause and at any time upon 45 days&#146; written notice. We and IQVIA each
have the right to terminate the IQVIA Master Services Agreement in the event of a breach by the other party, if such breach has not been substantially cured within the <FONT STYLE="white-space:nowrap">30-day</FONT> period. We have the right to
terminate the IQVIA Master Services Agreement and/or any Work Order with immediate effect by written notice and without any liability whatsoever in case IQVIA becomes debarred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the IQVIA Master Services Agreement and a study specific Work Order executed with IQVIA, IQVIA is responsible for coordinating our
Phase 3 clinical trial for obefazimod in moderately to severely active UC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, &#128;12.2&nbsp;million in
undiscounted advance payments to IQVIA had been paid in connection with the IQVIA agreement. Such amounts are to be recovered at the end of the relevant studies (i.e., between April 2025 and July 2026). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Evotec Drug Discovery Services Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;1, 2017, we entered into a drug discovery services agreement with Evotec International GmbH (&#147;Evotec&#148;), pursuant to
which Evotec provides drug discovery services to us, in order to have optimized leads obtained for various viral indications for further developments within the context of a global collaborative program and to any further development programs under
which we would require the assistance of Evotec in the provision of services (the &#147;Evotec Drug Discovery Services Agreement&#148;). Under the Evotec Drug Discovery Services Agreement, Evotec must provide its services in accordance with common
industry standard of current established practices by suitably qualified staff, using equipment in an agreed premises, under allocated timelines agreed between the parties and in compliance with all relevant legislation. Evotec may not subcontract
its obligations to us other than to an affiliate without our express prior written consent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration for services provided, we are required to pay Evotec an agreed set of fees
as agreed in the relevant project description relating to such services. As of June&nbsp;30, 2023, we have paid &#128;7.6 million to Evotec, and no amounts were received as of such date. The total maximum amount that could be payable by us to Evotec
under work orders in effect as of end of August 2023 is &#128;0.9 million. To the extent additional projects are completed under the agreement, additional amounts may be payable to Evotec, but they are not determinable as of the date of this
prospectus. We own, and Evotec assigns to us to the extent permissible under applicable law, all intellectual property rights conceived, discovered, invented or made by Evotec in connection with the provision of drug discovery services. No milestone
payments or royalties are payable pursuant to the Evotec Drug Discovery Services Agreement. No drug candidate has currently been discovered pursuant to this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the right to terminate Evotec Drug Discovery Services Agreement or any project without cause at any time upon 60 days&#146; written
notice. We and Evotec each have the right to terminate any ongoing project upon 20 days&#146; written notice for a breach by the other party, if such breach has not been remedied within the <FONT STYLE="white-space:nowrap">20-day</FONT> period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delpharm Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;24,
2016, we entered into a manufacturing agreement with Delpharm Lille S.A.S. (&#147;Delpharm&#148;), pursuant to which Delpharm produces batches of capsules containing obefazimod required to carry out clinical trials (the &#147;Delpharm
Agreement&#148;). The Delpharm Agreement renews automatically for successive periods of one year until either party notifies the other of its intention not to renew the agreement. The agreement is still in effect on the date hereof. Either party may
terminate the agreement upon serious breach or a serious <FONT STYLE="white-space:nowrap">non-execution</FONT> of the agreement by the other party. Abivax may also terminate the Delpharm Agreement at any time, subject to certain reimbursement
obligations to Delpharm. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Seqens Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;11, 2016, we entered into a clinical batch development and production agreement with &#147;Produits Chimiques Auxiliaires et de
Synth&egrave;se&#148; (&#147;Seqens&#148;), under which Seqens provides services relating to the development and production of active ingredients, including obefazimod (the &#147;Seqens Agreement&#148;). The Seqens Agreement was amended on
March&nbsp;2, 2021, in connection with our UC Phase 3 clinical trials. In accordance with the Seqens Agreement, in consideration for services provided, we are required to pay Seqens an agreed set of fees as agreed in the relevant Work Order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Seqens Agreement remains in full force and effect until the earlier of (i)&nbsp;the execution of an agreement for the commercial
manufacturing by Seqens of obefazimod under Phase IV, such agreement to be negotiated between Seqens and us in good faith, (ii)&nbsp;the failure to reach such a Phase IV agreement or (iii)&nbsp;the failure to obtain all marketing approval by the FDA
and other relevant regulators in Europe. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the Seqens Agreement, either party may terminate the agreement in the event of the
other party&#146;s failure to perform one or more of its obligations. This termination shall only become effective one month after the issuance by the complaining party of a registered letter with acknowledgement of receipt setting out the reasons
for the complaint, unless within this period the defaulting party has fulfilled its obligations or has provided proof of an impediment due to force majeure. The termination may take effect without delay by simple written notification in case of
fraud or intentional fault by the party in default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the Seqens Agreement, we have the right to postpone or terminate any
pending work at any time upon 30 days prior written notice, subject to payment to Seqens of the sums due in proportion to the actual progress of the work on the day of receipt by Seqens of its notification, as well as any costs incurred prior to
such receipt by Seqens that would be <FONT STYLE="white-space:nowrap">non-revocable</FONT> and not subject to reallocation within a reasonable time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>State-Guaranteed Loan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;11, 2020, we obtained <FONT STYLE="white-space:nowrap">non-dilutive</FONT> financing from Soci&eacute;t&eacute;
G&eacute;n&eacute;rale in the form of a &#128;5&nbsp;million State-guaranteed loan (the &#147;State-guaranteed loan&#148;). The State-guaranteed loan had an initial duration of 12&nbsp;months (subject to a five-year extension option) and accrues
interest at a rate of 0.25% with repayment of principal falling due in June 2021. The State-guaranteed loan was immediately made available to us in June 2020. In March 2021, we entered into an amendment to the State-guaranteed loan, which extended
the repayment date of the State- guaranteed loan by five years until June 2026 with a <FONT STYLE="white-space:nowrap">one-year</FONT> deferral of principal repayment, with the following conditions: (i)&nbsp;a revised interest rate of 0.58% per
annum, excluding insurance and State-guaranteed premium; and (ii)&nbsp;a State-guaranteed premium of &#128;0.1&nbsp;million to be paid by instalments over the contract period starting in June 2021. The State-guaranteed loan includes certain
customary covenants and prepayment provisions, as well as a negative covenant restricting the disposal of assets representing more than 50% of the gross value of our fixed assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Royalties Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;18, 2008, we entered into an agreement with (i)&nbsp;the CNRS, (ii)&nbsp;the University of Montpellier, and (iii)&nbsp;the Institut Curie, which sets out financial conditions under which we can use any intellectual property rights and
research results derived from certain research collaboration programs we had with the CNRS, the University of Montpellier, and the Institut Curie and which have now been terminated (the &#147;Royalties Agreement&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Royalties Agreement, the CNRS and the Institut Curie are entitled to receive milestone payments, as well as royalty payments
on global net sales of products using the intellectual property rights and research results jointly developed with them (including obefazimod) (each, a &#147;Qualifying Product&#148;). The amounts of the milestone payments for each Qualifying
Product are limited and not material compared to the amount of the expected royalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case we commercialize directly a Qualifying
Product (either (i)&nbsp;implementing the jointly developed patents and the jointly developed <FONT STYLE="white-space:nowrap">know-how</FONT> or (ii)&nbsp;only implementing the jointly developed <FONT STYLE="white-space:nowrap">know-how),</FONT>
royalties due under the Royalties Agreement are in the low single-digit percentages subject to an annual minimum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event we
commercialize a Qualifying Product by way of a license granted to a third-party, we may elect (i)&nbsp;to pay royalties calculated in the same manner as if we were commercializing the Qualifying Product directly, or (ii) to pay royalties (high
single-digit to low double-digit percentages) calculated based on the revenues we receive under the license granted to the third-party. We must notify the CNRS regarding which royalty amount we elect to pay at the same time that the third-party
grants the license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, the Royalties Agreement does not include any cap on the total payments which may be due
by us under such Royalties Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Royalties Agreement survives until the expiration of the underlying intellectual property
rights (without any termination rights to either party). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We sublease approximately 765 m&sup2; of office space and three parking spaces at <FONT STYLE="white-space:nowrap">7-11</FONT> boulevard
Haussmann, 75009 Paris, France, for our headquarters and other administrative functions. The sublease agreement has been entered into for a period of three years expiring on June&nbsp;21, 2025. Unless terminated by either party, it will be
automatically renewed for additional successive periods of one year. The sublease of these facilities may, subject to certain restrictions provided by law, be terminated by us or by the lessor from June&nbsp;30, 2024, subject to nine months&#146;
prior </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
written notice. Furthermore, the sublease will automatically terminate in the event of the early termination of the head lease (which expires on June&nbsp;30, 2027). We believe that our
facilities are sufficient to meet our current needs and that suitable additional space will be available in the future on commercially reasonable terms, if required. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees and Human Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
of June&nbsp;30, 2023, we had 34 full-time employees, consisting of 18 employees within the research and development department, six employees within the commercial, marketing and market access department, and 10&nbsp;employees within the general
administrative department. Our employees based in France are subject to the national collective bargaining agreement for the pharmaceutical industry (the <I>convention collective nationale de l&#146;industrie pharmaceutique</I>). We believe that we
maintain good relations with our employees. A majority of our future planned hires are expected to be residing in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
of June&nbsp;30, 2023, 25 full-time employees were based in France and nine full-time employees were based in the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time,</FONT></FONT> we may be a party to legal,
administrative or arbitration proceedings arising in the ordinary course of our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, we are not a
party to any material legal, administrative or arbitration proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, financial condition, results of operations or cash
flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of
management resources and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_14"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing, Management and Supervisory Bodies and Executive management </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table sets forth the name, age and position of each of our executive officers and directors as of August 31, 2023. The business address of our executive officers and directors is our principal executive offices located at <FONT
STYLE="white-space:nowrap">7-11</FONT> boulevard Haussmann, 75009 Paris, France. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="50%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position(s)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc de Garidel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer and Director, Chairman of the Board</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Didier Blondel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer and Board Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sheldon Sloan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Medical Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Ferguson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Commercial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pierre Courteille</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Business Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Didier Scherrer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Scientific Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Directors*</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June Lee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Independent Director, Chair of the Appointments and Compensation Committee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Troy Ignelzi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Independent Director, Chair of the Audit Committee</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol L. Brosgart</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Independent Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corinna zur Bonsen-Thomas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Independent Director, Member of the Audit Committee and the Appointments and Compensation Committee</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kinam Hong (Sofinnova Partners)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director, Member of the Audit Committee and the Appointments and Compensation Committee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paolo Rampulla (Sant&eacute; Holdings SRL)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philippe Pouletty (Truffle Capital)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director, Member of the Appointments and Compensation Committee</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Independence criteria assessed in accordance with the definition provided in the Middlenext Code of
Corporate Governance </I></P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Marc de Garidel</B> has been our Chief Executive Officer and Chairman of the Board since May 5, 2023 and has more than 40 years of
experience in the pharmaceutical and biotechnology sector, including 12 years of experience as Chief Executive Officer of pharmaceutical and biotechnology companies. Between July 2021 and April 2023, he served as Chief Executive Officer of CinCor
Pharma and led its successful sale for up to $1.8&nbsp;billion, subject to the achievement of certain milestones, to AstraZeneca in February 2023. Between September 2020 and May 2021, Mr.&nbsp;de Garidel served as Chief Executive Officer of
AZTherapies. From April&nbsp;2018 until August 2020, he was Chief Executive Officer of Corvidia Therapeutics and led its sale to Novo Nordisk for $2.1 billion in total consideration. Mr. de Garidel was the Chief Executive Officer of Ipsen between
November 2010 and July 2016, overseeing the development of its U.S. presence. Prior to that, he worked for Amgen and Eli Lilly in jobs of increasing responsibilities and in various markets, including the United States and Europe. Mr. de Garidel has
served as chairman of the board of directors of Ipsen since 2010 and has been a member of the board of directors of Claris Bio since 2020. He holds a degree in Civil Engineering from the Ecole des Travaux Publics in Paris, a Master&#146;s degree in
International Management from Thunderbird Global School Management and an executive MBA from Harvard Business School. We believe that Mr. de Garidel is qualified </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to serve on our Board because of his experience as an executive and member of the boards of companies in the life sciences industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Didier Blondel</B> has been our Chief Financial Officer and Board Secretary since January 2017. From January 2012 to December 2016, he was
Chief Financial Officer at Sanofi Pasteur MSD, a Lyon-based joint-venture between Sanofi and Merck and a European leader in human vaccines. Prior to that, over a <FONT STYLE="white-space:nowrap">20-year</FONT> period, Mr.&nbsp;Blondel held a wide
range of senior finance positions at Sanofi, in Commercial Operations and then research and development, where he became global research and development Chief Financial Officer. He started his career as an auditor at PricewaterhouseCoopers, after
graduating with a Master&#146;s degree in Business and Administration from the Commercial Institute of Nancy, a leading French business school. Mr.&nbsp;Blondel also holds a Master&#146;s degree in Finance and Accounting from Nancy II University, as
well as a Graduate Diploma in Finance and Accounting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Sheldon Sloan</B> has been our Chief Medical Officer since March 2023. He has
over 30 years of experience in academia and the biopharmaceutical industry, with an extensive track record in the field of gastroenterology and IBD. From March 2022 to January 2023, Dr. Sloan was Program Lead for etrasimod UC at Pfizer. From
November 2019 to March 2022, Dr. Sloan worked for Arena Pharmaceuticals. Between September 1997 and October 2019, Dr. Sloan held different leadership positions at Johnson and Johnson in Medical Affairs, Research and Development, and Science Policy,
including Global Medical Affairs Leader for IBD, leading the global launch strategy and execution for CD and UC for Stelara. He holds a Doctor of Medicine from Rush Medical College, Chicago and a Master of Bioethics from the University of
Pennsylvania. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Michael Ferguson</B> has been our Chief Commercial Officer since April 2023. He has over 22 years of experience in the
biopharmaceutical industry, with an extensive track record in the field of Gastroenterology (GI) and IBD. From August 2019 through May 2022, Mr. Ferguson served as Vice President Global Commercial Marketing and Planning and specifically as Global
Commercial Lead for etrasimod across all GI Indications at Arena Pharmaceuticals. From March 2007 to August 2019, he held various leading commercial leadership positions at Shire/Takeda. Mr. Ferguson holds both a B.S. and an MBA in Finance from the
Pennsylvania State University as well as a post graduate degree in Pharmaceutical Marketing from St. Joseph&#146;s University, Philadelphia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Pierre Courteille</B> has been our Chief Business Officer since May 2023. Prior to this appointment, he served as our Chief Commercial
Officer and Vice President Business Development. Mr. Courteille has over 25 years of experience in marketing, sales and business development within the pharmaceutical industry (13 years based in Japan). Prior to joining us in April 2015, he was
Senior VP sales and marketing for Guerbet as well as Chief Executive Officer of MEDEX (medical devices company owned by Guerbet) from 2012. From 2009, Mr.&nbsp;Courteille served as VP Sales for Asia, Latin America and EMEA and met the ambitious
objective of optimizing commercial performance across these three regions. As President of Guerbet Japan and VP for Guerbet Asia, Mr.&nbsp;Courteille has successfully managed the roll-out of its Japanese subsidiary and led the development of other
branches in Asia. Mr. Courteille holds a pharmacy degree and MBA (with Honors) from The University of Chicago Booth School of Business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Didier Scherrer</B> has been our Chief Scientific Officer since August 2023. Prior to this appointment, he served as our Vice President of
Research and Development. Mr. Scherrer has extensive experience in the development of a portfolio of therapeutics in oncology, viral diseases and autoimmune / inflammatory&nbsp;diseases. Prior to joining our company in March 2009, he performed a
combined role of Chief Executive Officer and Scientific Director at Splicos from September 2009. He also has experience from prior roles as Associate Director (Capability Pathways &#150; Discovery Enabling Capabilities and Sciences) of the Research
Department of AstraZeneca and as Head of Research at LFB Biotechnologies. Mr. Scherrer has a Ph.D. in Molecular Pharmacology from Universit&#233; Louis Pasteur (Strasbourg I). He completed his post-doctoral studies at Harvard Medical School and then
at the Stanford University School of Medicine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>June Lee</B> has been one of our independent directors since July 2023. Dr. Lee has served as a venture partner at 5AM Venture Management,
LLC since July 2022. Dr. Lee was most recently Founder and Chief Executive Officer of Esker Therapeutics until September 2021. Dr. Lee previously served as the Executive Vice President and Chief Development Officer of MyoKardia, Inc. from January
2019 to June 2020, and was the Chief Operating Officer from February 2017 until January 2019, and the Chief Development Officer from October 2017 to January 2019. From April 2011 until February 2017, Dr. Lee served on the faculty of the University
of California, San Francisco, or UCSF, where she was director of the Catalyst program at the Clinical and Translational Science Institute and a professor in the School of Medicine, and was responsible for overall strategy and operations for enabling
and supporting translational research at the university. Catalyst is an internal UCSF accelerator for therapeutics, devices, diagnostics, and digital health technologies. Prior to UCSF, Dr. Lee was a disease area lead, early clinical development, at
Genentech, Inc. from 2006 to 2011, where she was responsible for all strategy and activities as well as management of staff, budget, and resource allocation in the early clinical development group in multiple therapeutic areas. Dr. Lee served as a
Medical Director in the clinical development group at Genentech, Inc. from 2004 to 2006, where she was responsible for clinical activities for licensed product of the company. She currently serves on Johns Hopkins University Center for Therapeutic
Translation&#146;s Advisory Board, serves on the board of directors of Tenaya Therapeutics Inc, Eledon Pharmaceuticals Inc. and GenEdit, is a member of the Scientific Advisory Board for Foresite Labs, and previously served as a member of the board
of directors of CinCor Pharma, Inc. Dr. Lee holds a B.A. in chemistry from Johns Hopkins University and an M.D. from the University of California, Davis. We believe that Dr.&nbsp;Lee is qualified to serve on our Board because of her experience as an
investor and member of the boards of companies in the life sciences industry. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Troy Ignelzi</B> has been one of our independent
directors since July 2023. Mr. Ignelzi has served as the Chief Financial Officer of Karuna Therapeutics, Inc. since March 2019. Prior to that, Mr. Ignelzi was the Chief Financial Officer of scPharmaceuticals Inc. from March 2016 to February 2019,
and provided consulting services to scPharmaceuticals Inc. in February and March 2016. Mr. Ignelzi previously served as Chief Financial Officer and as a member of the executive leadership teams at Juventas Therapeutics Inc., a privately held
biotechnology company, from October 2014 to February 2016. From October 2013 to October 2014, Mr. Ignelzi served as Senior Vice President&#151;Operations and Business Development of Pharmalex GmbH. Prior to Pharmalex, Mr. Ignelzi was Vice
President&#151;Business Development at Esperion Therapeutics, Inc., a public pharmaceutical company, from January 2009 to September 2013. Mr. Ignelzi served as Vice President, Business Development &amp; Strategic Planning at Insys Therapeutics,
Inc., a specialty pharmaceutical company, from February 2007 to February 2009. Previously, Mr. Ignelzi had served as a specialty senior sales representative at Eli Lilly from February 2002 to August 2005. Mr. Ignelzi currently serves as a member of
the board of directors of Vedanta Biosciences, Inc. and previously served as a member of the board of directors of CinCor Pharma, Inc. Mr. Ignelzi has a B.S. in accounting from Ferris State University. We believe that Mr. Ignelzi is qualified to
serve on our Board because of his experience as an executive and member of the boards of companies in the life sciences industry. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Carol L. Brosgart</B> has been one of our independent directors since January 2018. She has held several executive management positions,
notably those of Chief Medical Officer at Alios (now J&amp;J), from February 2011 to August 2011, and Senior Vice President and Medical Director at the Children&#146;s Hospital and Research Center in Oakland, California from December 2009 to January
2011. She held several executive management positions at Gilead Sciences (Vice President Clinical Research, Vice President Medical Affairs, Vice President Public Health and Strategy) between 1998 and 2009. She has served as a member of the board of
directors of Galmed Pharmaceuticals, a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases, since 2017, and Enochian Biosciences, a biotechnology company committed to developing advanced allogenic
cell and gene therapies, since 2020. Dr. Brosgart also serves as a director on the board of Mirum Pharmaceuticals, a clinical stage drug development biopharmaceutical company for rare liver diseases, since 2021. Dr.&nbsp;Brosgart is the chair of the
scientific advisory board at Hepion Pharmaceuticals, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
formerly ContraVir, a biotech company operating in the area of NASH, HBV, HCV and HDV in the field of HBV cures. She is also a consultant at Dynavax and several biotech companies working in the
fields of liver diseases and infectious diseases. In addition, Dr.&nbsp;Brosgart currently sits on the board of the Hepatitis B Foundation, the Management Committee of the National Viral Hepatitis Roundtable, the Executive Committee of the Forum for
Collaborative Research and the Management Committee of the HBV Cure Forum. She is also a clinical professor of medicine, biostatistics and epidemiology in the Global Health Sciences Department of the University of California, San Francisco.
Dr.&nbsp;Brosgart holds a degree in Community Medicine from UC Berkeley and earned a Doctor of Medicine from UC San Francisco. We believe that Dr.&nbsp;Brosgart is qualified to serve on our Board because of her extensive experience as an executive
and as a member of the boards of companies in the life sciences industry and her medical background. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Corinn</B><B>a</B><B>
</B><B>zu</B><B>r</B><B> </B><B>Bonsen-Thoma</B><B>s</B><B> </B>served as our Chair between August 2022 and May 2023 and has been one of our independent directors since June 2017. Since April 2020, Ms. zur Bonsen-Thomas has held the position of
Managing Director and Chief Executive Officer of RetInSight GmbH, a company which she co-founded in April&nbsp;2020 and specializes in ophthalmic imaging. Ms. zur Bonsen-Thomas was General Counsel for Smart Reporting GmbH from February 2017 to
December 2022. From 1999 to 2015, she served as a member of the Supervisory Board of Baxter AG, an Austrian company. She has more than thirty years of international professional experience in the pharmaceutical, biopharmaceutical, medical and
biotechnology industries. Ms. zur Bonsen-Thomas received her First Law State Examination from Ludwig Maximilian Universitaet and her Second Law State Examination from the Bavarian Ministry of Justice. We believe that Ms. zur Bonsen-Thomas is
qualified to serve on our Board because of her extensive professional experience in the life sciences industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Kinam Hong </B>has
served as the permanent representative of Sofinnova Partners on our Board since September 2019. He has served as the partner responsible for Sofinnova&#146;s strategy of crossover and growth investment in late development stage companies at
Sofinnova Partners since January 2017. He has served as the permanent representative of Sofinnova Partners on the board of directors of CytoImmune Therapeutics, Inc. since July 2021 and as an observer then board member of Limflow SA since April
2018. Prior to Sofinnova Partners, Dr. Hong spent ten years as an investor and research analyst covering the biotechnology sector. Dr. Hong co-led the Exane Equinox Fund, a global healthcare fund investing in public biotech companies. He also worked
at Citigroup investment research where he focused on small- and midcap biotechnology companies. Before his investment career, Dr. Hong worked in new product development at Sanofi, a multinational pharmaceutical company, where he held positions in
business development and strategic/new product marketing. Dr. Hong is a doctor and scientist who holds a Bachelor of Science degrees in molecular biology/biochemistry and a Doctor of Medicine from the University of Florida. He also holds a Chartered
Financial Analyst and a Master of Business Administration from INSEAD, France. We believe that Dr. Hong is qualified to serve on our Board because of his extensive experience as an investor and as a member of the boards of companies in the life
sciences industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Paolo Rampulla </B><B></B>has served as the permanent representative of Sant&#233; Holdings SRL on our Board since
September 2023. Dr. Rampulla is a trained economist, qualified tax advisor (<I>dottore commercialista</I>) and chartered auditor (<I>revisore legale</I>). Dr. Rampulla has served as a member of the board of Carmat SA since September 2023. Dr.
Rampulla holds a Master in Tax Law from Ipsoa School of Economics, Milan, Italy, and a degree in Economics from the University Luigi Bocconi, Milan, Italy. Dr. Rampulla is a partner at ADVANT-NCTM, where he has practiced law since 2003 and regularly
advises clients in M&amp;A and international tax matters in the healthcare and med-tech industries. We believe that Dr. Rampulla is qualified to serve on our Board because of his experience as an advisor to companies in the life sciences industry.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Philippe</B><B> </B><B>Pouletty,</B><B> </B><B>MD </B>has served as a director since December 2013 and is our founder, as well as
founder or co-founder of Carbios, Carmat, Vexim, Symetis, Affluent Medical, SpikImm and more than a dozen other biotechnology and medical technology companies of Truffle Capital, several being listed or were acquired. He was the Chairman of France
Biotech from 2001 to 2006 and from 2007 to 2009, the French association of biotech companies and Vice-Chairman of Europabio from 2002 to 2006, the European federation of biotechnologies. Dr. Pouletty is a member of the board of directors or the
chairman of several biotechnology and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
medical device companies in Europe. Dr. Pouletty, acting as permanent representative of Truffle Capital, has served as director of Pharnext SA, from April 2016 to October 2021, Carmat SA, from
April 2021 to July 2021, and Deinove SA, from 2009 to 2021. Dr. Pouletty holds a Doctor of Medicine from Universit&#233; Paris VI and was a Post-doctoral fellow at Stanford University and is a permanent member of the hall of fame of inventors of
Stanford University. We believe that Dr. Pouletty is qualified to serve on our Board because of his extensive experience as founder and member of the boards of companies in the life sciences industry, his medical background and his experience as an
executive of several biotechnology organizations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Family Relationships </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of our executive officers or directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board of Directors </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to
French law and our <FONT STYLE="white-space:nowrap">by-laws,</FONT> our Board must be comprised of between three and 18 members, without prejudice to the derogation established by law in the event of a merger. As of the date of this prospectus, our
Board is comprised of eight directors. The number of directors of each gender may not be less than 40% under French law. In case a board of directors comprises up to eight members, the difference between the number of directors of each gender may
not exceed two. Any appointment made in violation of this limit that is not remedied within six months of this appointment will be null and void and payment of directors&#146; compensation will be suspended. Within these limits, the number of
directors is determined by our shareholders. Our directors are appointed for four-year renewable terms, in accordance with our <FONT STYLE="white-space:nowrap">by-laws</FONT> and the chairperson is appointed for the duration of his term as director.
In accordance with French law, our <FONT STYLE="white-space:nowrap">by-laws</FONT> also provide that our directors may be removed with or without cause by the holders of at least a majority of the voting rights of the shareholders present,
represented by a proxy or voting by mail at the relevant ordinary shareholders&#146; meeting, and that any vacancy on our Board be filled by a vote of a majority of our directors then in office provided that there has been no shareholders meeting
since such death or resignation. Directors chosen or appointed to fill a vacancy shall be elected by the Board for the remaining duration of the current term of the replaced director. The appointment must then be ratified at the next
shareholders&#146; meeting. In the event that the Board would be composed of less than three directors as a result of a vacancy, the remaining directors shall immediately convene a shareholders&#146; meeting to elect one or several new directors so
there are at least three directors serving on the Board, in accordance with French law. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Current&nbsp;Position</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Year&nbsp;of&nbsp;Initial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Appointment</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Term&nbsp;Expiration</B><br><B>Year<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc de Garidel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Chairman</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2023&nbsp;(as&nbsp;Director), 2023&nbsp;(as&nbsp;Chairman)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corinna zur Bonsen-Thomas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Director</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June Lee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Director</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Troy Ignelzi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Director</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sant&eacute; Holdings SRL<BR>(permanent representative to the Board: Paolo Rampulla)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Director</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Truffle Capital<BR>(permanent representative to the Board: Philippe Pouletty)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Director</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol L. Brosgart</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Director</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sofinnova Partners (permanent representative to the Board: Kinam Hong)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Director</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(1)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>The mandates expire at the annual shareholders&#146; meeting approving the financial statements closed on
December&nbsp;31 of the previous year. </I></P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director Independence </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a foreign private issuer, under the listing requirements and rules of Nasdaq, we are not required to have independent directors on our
Board, except to the extent that our audit committee is required to be consistent with independence requirements, subject to certain <FONT STYLE="white-space:nowrap">phase-in</FONT> schedules. In determining whether a director is an independent
director, our Board considers the relationships that each <FONT STYLE="white-space:nowrap">non-employee</FONT> director has with the Board and all other facts and circumstances that our Board deems relevant in determining the director&#146;s
independence, including the number of ordinary shares beneficially owned by the director and his or her affiliated entities, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
currently have four independent directors (as defined by the Middlenext Code of Corporate Governance), including June Lee, Troy Ignelzi, Corinna zur Bonsen-Thomas and Carol L. Brosgart. The Middlenext Code sets out the five following criteria
justifying the independence of directors, characterized by the absence of any significant financial, contractual or family relationship likely to affect their independence of judgment: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">they must not be a salaried employee or corporate officer of us or our group and must not have held such a
position within the last five years; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">they must not be in a significant business relationship with us or our group (e.g., client, supplier, competitor,
provider, creditor, banker, etc.) within the last two years; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">they must not be a reference shareholder or hold a significant number of voting rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">they must not have close relationships or family ties with any of our corporate officer or reference shareholder;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">they must not have been our auditor within the last six years. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-voting</FONT> Board Members </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our <FONT STYLE="white-space:nowrap">by-laws,</FONT> the General Meeting or the Board may appoint
<FONT STYLE="white-space:nowrap">non-voting</FONT> board members. To date, no <FONT STYLE="white-space:nowrap">non-voting</FONT> directors have been appointed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conflicts of Interest Among the Management and Supervisory Bodies and Executive Management </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Chairperson and Chief Executive Officer, our Chief Financial Officer and Board Secretary and our directors are direct or indirect
shareholders or holders of securities giving access to our share capital. See &#147;Compensation and Benefits&#151;Compensation of Chief Executive Officer.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are agreements between related parties, as described in &#147;Certain Relationships and Related Person Transactions.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Practices </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Corporate Governance Practices
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a French <I>soci&eacute;t&eacute; anonyme </I>(limited liability company) listed on Euronext Paris, we are subject to
various corporate governance requirements under French law. In particular, we refer to the Code of Corporate Governance for small and <FONT STYLE="white-space:nowrap">medium-sized</FONT> firms as published in September 2021 by Middlenext, as amended
from time to time. In addition, as a foreign private issuer listed on the Nasdaq Global Market, we will be subject to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Nasdaq&#146;s corporate governance listing standards. Nasdaq&#146;s listing standards provide that foreign private issuers are permitted to follow home country governance practices in lieu of
Nasdaq rules, with certain exceptions. We intend to rely on certain exemptions for foreign private issuers and follow French corporate governance practices in lieu of Nasdaq corporate governance rules, which would require that (i)&nbsp;a majority of
our Board consists of independent directors and (ii)&nbsp;the audit committee be composed of entirely independent directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a foreign
private issuer, we are required to comply with Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> of the Exchange Act, relating to audit committee composition and responsibilities. Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> provides that the
audit committee must have direct responsibility for the nomination, compensation and choice of our auditors, as well as control over the performance of their duties, management of complaints made and selection of consultants. However, if the laws of
the foreign private issuer&#146;s home country require that any such matter be approved by the Board or the shareholders, the audit committee&#146;s responsibilities or powers with respect to such matter may instead be advisory. Under French law,
the audit committee may only have an advisory role and appointment of our statutory auditors, in particular, must be decided by our shareholders at our annual meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Nasdaq rules require that a listed company specify that the quorum for any meeting of the holders of common stock (or ordinary
shares) be at least 33<SUP STYLE="font-size:75%; vertical-align:top">1</SUP>/<SUB STYLE="font-size:75%; vertical-align:bottom">3</SUB><SUB STYLE="font-size:75%; vertical-align:bottom"></SUB>&nbsp;% of the outstanding shares of the company&#146;s
common voting stock. Consistent with French Law, our <FONT STYLE="white-space:nowrap">by-laws</FONT> provide that, for ordinary shareholders&#146; meetings to be quorate, <FONT STYLE="white-space:nowrap">one-fifth</FONT> of the holders of shares
entitled to voting rights must be present in person or vote by mail or by proxy or by authorized intermediary or by any means of telecommunication permitting their identification. An extraordinary shareholders&#146; meeting is quorate if <FONT
STYLE="white-space:nowrap">one-fourth</FONT> of the holders of shares entitled to voting rights are present or vote by mail or by proxy or by authorized intermediary or by any means of telecommunication. As an exception, an extraordinary
shareholders&#146; meeting deciding upon a share capital increase by capitalization of reserves, profits or share premium as the same quorum requirement as an ordinary shareholders&#146; meeting. If the requirements for a quorum are not satisfied,
the meeting is adjourned. When an adjourned ordinary shareholders&#146; meeting is resumed, there is no quorum requirement. When an adjourned extraordinary shareholders&#146; meeting is resumed, there is a quorum of
<FONT STYLE="white-space:nowrap">one-fifth</FONT> of the holders of shares entitled to voting rights. If a quorum is not present, the reconvened extraordinary shareholders&#146; meeting may be adjourned for a maximum of two months. No deliberation
by the shareholders may take place without a quorum. For special meetings of holders of a certain class of shares, the quorum requirement is <FONT STYLE="white-space:nowrap">one-third</FONT> of the certain class of shares entitled to voting rights
for the meeting convened on the first call, notice and <FONT STYLE="white-space:nowrap">one-fifth</FONT> of the holders of shares entitled to voting rights, should the meeting be reconvened. See &#147;Description of Share
Capital&#151;Shareholders&#146; Meetings and Voting Rights (Article 22 of the <FONT STYLE="white-space:nowrap">By-Laws)&#151;Quorum.&#148;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board consists of eight members and the composition of our Board is described further below in this section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules of procedure of our Board set the principles guiding the composition of the Board. The most recent version of this document was
adopted by our Board in April 2021. We have established an audit committee, appointment and compensation committee and scientific committee, as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board has established two permanent, specialized committees to assist the Board in its work: the audit committee and the appointments and
compensation committee, as well as one ad hoc committee, the scientific committee. Subject to available exemptions the composition and functioning of all of our committees will comply with applicable requirements of the French Commercial Code, the
Exchange Act, the Nasdaq Global Market and SEC rules and regulations.<B><I> </I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with French law, committees of our
Board only have an advisory role and can only make recommendations to our Board. As a result, decisions will be made by our Board taking into account <FONT STYLE="white-space:nowrap">non-binding</FONT> recommendations of the relevant Board
committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Audit Committee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mission and Responsibilities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit
committee monitors issues relating to the elaboration and control of accounting and financial information as provided for by French law and by our <FONT STYLE="white-space:nowrap">by-laws</FONT> and by the rules of procedure of the Board. It then
formulates recommendations to the Board in its task of permanent control of our management. It also issues recommendations in relation to the proposed statutory auditors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee is responsible for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitoring the preparation and development of accounting and financial information and, where appropriate,
formulating recommendations in this respect to ensure its accuracy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the efficiency of the internal control and risk management systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ensuring proper legal oversight of the preparation of the annual financial statements and financial statements by
the statutory auditors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selecting and ensuring the independence of the statutory auditors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee is also responsible for approving: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">non-audit</FONT> services provided by the statutory auditors (including the
permitted level of fees); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all budgets for statutory audits and other engagements provided by the statutory auditors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee further controls the services provided by the auditors in relation to what is permitted by law or regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee is responsible for formulating recommendations regarding the statutory auditors proposed for nomination by the General
Meeting of Shareholders and/or during the renewal of their term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within this context, the audit committee may examine our annual
financial statements in the form that they are presented to the Board, hear the opinions of the statutory auditors and the finance director and receive communications in relation to their analysis work and their conclusions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee may use external experts at our expense, after approval of the chairperson of the Board or the audit committee or of the
Chief Executive Officer, and render any expert reports to the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee may hear any director and carry out any internal
or external audit on any subject it considers relevant to its mission. The chairperson of the audit committee shall inform the Board in advance. In particular, the audit committee has the power to interview the persons involved in the preparation of
the accounts or in their control (administrative and financial director and the main managers of the financial department). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Composition and
Compensation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee and chairperson of the audit committee are appointed by the Board from members of the Board,
excluding executive directors, with finance or accounting skills and at least one member must be independent in accordance with the provisions of the Middlenext Code. Members of the audit committee are appointed for a fixed period of time, which may
not exceed the duration of their terms of office as director and may be revoked by the Board at any time and without reason. Appointments are renewable without limitation. The audit committee is composed of at least two members and members receive
no compensation other than attendance fees. Their duties on the audit committee may be taken into account in determining the allocation of such attendance fees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current members of the audit committee are Troy Ignelzi, Corinna zur Bonsen-Thomas and
Kinam Hong (representing Sofinnova Partners). The current chairperson of the audit committee is Mr. Ignelzi. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The committee may invite any
person, internal or external to us, to take part in its meetings and its work. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board has determined that each of the members of our
audit committee is independent within the meaning of the applicable listing rules and the independence requirements contemplated by Rule <FONT STYLE="white-space:nowrap">10A-3.</FONT> Committee members must be competent in financial or accounting
matters and at least one member must be independent in accordance with the provisions of the Middlenext Code. Our Board has further determined that Mr. Ignelzi is an &#147;audit committee financial expert&#148; as defined by SEC rules and
regulations and that Mr. Ignelzi qualifies as financially sophisticated under the applicable exchange listing rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conditions of Functioning
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee meets when the chairperson of the audit committee, at least two members of the audit committee, the chairperson of
the Board or the Chief Executive Officer deems useful and at least twice per year, particularly before publication of the financial statements. The committee may be convened by any means 24&nbsp;hours before the meeting by the chairperson of the
audit committee or of the Board or any individual to whom one of them shall have delegated the necessary authority. The committee meets at the registered office or in any other place specified in the notice of the meeting. It may also meet by video
conference or by any means of telecommunication as specified in the internal regulation of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To deliberate validly, at least
half of the members of the committee must be present. At meetings, one member of the audit committee may be represented by another audit committee member and the audit committee&#146;s recommendations are adopted by simple majority. Upon completion
of each meeting, if the members deem it necessary, meeting minutes may be prepared. The chairperson of the audit committee regularly reports to the Board on the committee&#146;s work and immediately report any difficulty encountered. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Appointments and Compensation Committee </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mission and
Responsibilities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The appointments and compensation committee makes recommendations to the Board in relation to the nomination of, and
compensation for, executive directors and the operational and functional management, and with regard to appointments and compensation policy and internal profit sharing. In particular, the appointments and compensation committee: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provides recommendations and proposals to the Board concerning the appointment, in particular in the research of
a balanced representation of men and women on the Board, compensation, retirement and provident scheme, supplementary pension benefits, benefits in kind, various financial rights of our managers and executive officers, the allocation of share
warrants (BSA), founder&#146;s share warrants (BCE), free shares (AGA), share subscription or share purchase options, for the benefit of our employees, managers or consultants and, where applicable, its subsidiaries, in accordance with legal
provisions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">defines the methods for determining the variable portion of the compensation of corporate officers and monitors
its application; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">proposes a general policy for awarding share warrants (BSA), founder&#146;s share warrants (BCE), free shares
(AGA) and options to subscribe or purchase shares, and determines the frequency thereof, depending on the categories of beneficiaries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">examines the system of for the allocation of directors&#146; fees among the members of the Board, particularly
according to their participation in our committees; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expresses its opinion to senior management about the compensation of the principal senior executives.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The appointments and compensation committee is also involved in discussing each independent
director&#146;s qualifications upon his or her nomination and during the exercise of his or her term of office, as applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Composition and
Compensation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The appointments and compensation committee is composed of at least two members. The chairperson of the compensation
committee and the committee&#146;s members are appointed by the Board from members of the Board. Members are appointed for a fixed period of time, which may not exceed, as applicable, the duration of their term of office as director and may be
revoked by the Board at any time and without reason. Their appointments shall be renewable without limitation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The chairperson of the
Board, if not a member of the appointments and compensation committee, may be invited to participate in the appointments and compensation committee&#146;s meetings. The appointments and compensation committee shall invite him/her to present its
proposals. He/she shall not have the right to vote and shall not be present during the deliberations relating to his/her own situation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current members of the appointments and compensation committee are June Lee, Philippe Pouletty (representing Truffle Capital), Corinna zur
Bonsen-Thomas and Kinam Hong (representing Sofinnova Partners). The current chairperson of the appointments and compensation committee is Dr. Lee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The appointments and compensation committee may invite any person, internal or external to us, to take part in its meetings and its work. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Appointments and compensation committee members shall receive no compensation other than attendance fees. Their duties on the compensation
committee may be taken into consideration in determining the allocation of such attendance fees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conditions of Functioning </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The appointments and compensation committee meets when the chairperson of the appointments and compensation committee, at least two members of
the appointments and compensation committee, the chairperson of the Board or the Chief Executive Officer deems useful and at least once a year. The appointments and compensation committee may be convened by any means, 24 hours before the meeting, by
the chairperson of the appointments and compensation committee or of the Board, or any individual to whom one of them shall have delegated the authority necessary for the convocation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The committee meets at the registered office or in any other place specified in the notice of the meeting. It may also meet by video
conference or by any means of telecommunication, as specified in the internal regulation of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To deliberate validly, at least
half of the members of the committee must be present. A member of the appointments and compensation committee may be represented by another appointments and compensation committee member and the appointments and compensation committee&#146;s
recommendations are adopted by simple majority. Upon completion of each meeting, if the members deem it necessary, meeting minutes may be prepared. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The appointments and compensation committee chairperson reports regularly to the Board on the appointments and compensation committee&#146;s
work and shall immediately report any difficulty encountered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Scientific Committee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mission and Responsibilities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
scientific committee was created by a decision by the Board on September&nbsp;27, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The role of the scientific committee is to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">examine specific scientific questions submitted to it; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make recommendations for determining the general guidelines to be adopted in the scientific field; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make recommendations for defining our priorities in the field of research and development and the means for
achieving such objectives. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The committee meets at least once a year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It works in collaboration with the Chief Executive Officer, who may request its opinion on subjects related to its mission. At the request of
the Board, the chairperson of the scientific committee reports on the committee&#146;s work to the Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Composition </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The scientific committee is composed of at least four members appointed by the Board upon proposal of the Chief Executive Officer. The members
of the scientific committee do not have to be members of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current members of the scientific committee are Prof. Ian
McGowan, MD, PhD, (Chairman); Prof. Christian Br&eacute;chot; Prof. Christoph Huber; Prof. J&uuml;rgen Rockstroh; Prof. Christian Trepo; Prof. Lawrence R. Stanberry; Prof. Luc Teyton; and Claude Bertrand. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The composition of the scientific committee is currently under review in light of our needs for the continued development of our clinical
programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have adopted a Code of Business Conduct and Ethics policy in connection with the offering. Under this policy, our employees and
members of our Board have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest. In considering related-party transactions, our Board will take into account
the relevant available facts and circumstances including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the benefits and perceived benefits to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the opportunity costs of alternative transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the materiality and character of the related party&#146;s interest; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the actual or apparent conflict of interest of the related party; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">and the terms available to or from, as the case may be, unrelated third parties or to or from employees
generally. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The policy requires that, in determining whether to approve, ratify or reject a related-party transaction,
our Board must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our shareholders, as our Board determines in the good faith exercise of its discretion. All of the
transactions referred to above were entered into prior to the adoption of the written related-party transaction policy but all were approved by our Board to the extent required by, and in compliance with, French law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation and Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation of Chief Executive Officer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets out the compensation awarded to our Chief Executive Officer in the applicable period: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2021&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(&#128;)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(&#128;)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Marc de Garidel&#151;Chief Executive Officer and Chairman from May 5, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Fixed compensation</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Variable annual compensation</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:6.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:6.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Variable multi-year compensation</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Exceptional variable compensation</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Remuneration allocated due to mandate as director</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Benefits in kind</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>N/A</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>N/A</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Hartmut Ehrlich&#151;Chief Executive Officer until May 5, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Fixed compensation</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>303,685</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>321,906</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Variable annual
compensation<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>144,250</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>193,144</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Variable multi-year compensation</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&#8194;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&#8194;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Exceptional variable compensation</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>43,384</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&#8194;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Remuneration allocated due to mandate as director</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&#8194;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&#8194;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Benefits in kind</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>8,880</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>8,880</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>500,199</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>523,930</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Variable compensation paid for the financial year corresponds to the amount due for the previous year.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate compensation paid and benefits in-kind granted by us to our current executive officers and directors,
including share-based compensation, for the year ended December 31, 2022 and 2021 were &#128;1.0 million and &#128;0.9 million, respectively. For both years, we did not allocate any amounts to be set aside or accrued to provide pension, retirement
or similar benefits to our directors or executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets out the compensation awarded to our directors in the applicable period: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2021&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2022&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(&#128;)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(&#128;)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corinna zur Bonsen-Thomas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joy Amundson<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Jacques Bertrand<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sant&eacute; Holdings SRL<BR>(permanent representative to the Board: Paolo Rampulla)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Truffle Capital<BR>(permanent representative to the Board: Christian Pierret)<SUP
STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol L. Brosgart</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sofinnova Partners (permanent representative to the Board: Kinam Hong)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June Lee<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Troy Ignelzi<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philippe Pouletty<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>85,350</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>80,065</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of July 2023, Ms. Amundson resigned from our Board, and Dr. Lee was appointed to our Board.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of July 2023, Mr. Bertrand resigned from our Board, and Mr. Ignelzi was appointed to our Board.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On May 5, 2023, Dr. Pouletty resigned from his personal office as director and became Truffle Capital&#146;s
representative to the Board in replacement of Mr. Pierret. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the general meeting of shareholders held on June&nbsp;9,
2022, our shareholders approved a package of attendance fees and the compensation policy applicable to the chairperson of the Board and the Chief Executive Officer. For the fiscal year ended June&nbsp;30, 2023, none of the amounts set aside or
accrued to provide pension, retirement or similar benefits to our employees was attributable to our executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table sets forth the AGAs allocated to the chairperson and chief executive officer: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Chairperson&nbsp;&amp; CEO</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Allocation date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Type&nbsp;of&nbsp;AGAs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number&nbsp;of&nbsp;AGAs</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>allocated</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Subscription&nbsp;price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Acquisition period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc de Garidel</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">July-11-2023</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Free&nbsp;Shares&nbsp;2023-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,382,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Minimum&nbsp;of&nbsp;1&nbsp;year&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(*)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,382,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(*)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Acquisition Periods shall be as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For 212,738 Free Shares 2023-1: the Acquisition Period shall end on the first (1st) anniversary of the allocation
date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For 638,214 Free Shares 2023-1: the Free Shares 2023-1 shall progressively be definitively acquired on a monthly
basis over a period of three (3) years starting after the first (1st) anniversary of the allocation date (i.e. 17,728 Free Shares 2023-1 per month except for the last month of the three-year period where 17,734 Free Shares 2023-1 shall be acquired).
The duration of the Acquisition Period of these Free Shares 2023-1 shall be calculated accordingly; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For 212,738 Free Shares 2023-1: the Acquisition Period shall end on the latest date between (i)&nbsp;the first
(1st) anniversary of the allocation date, and (ii)&nbsp;the date on which a specific performance condition is fulfilled (condition&nbsp;1); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For 106,369 Free Shares 2023-1: the Acquisition Period shall end on the latest date between (i)&nbsp;the first
(1st) anniversary of the allocation date, and (ii)&nbsp;the date on which a specific performance condition is fulfilled (condition&nbsp;2); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For 106,369 Free Shares 2023-1: the Acquisition Period shall end on the latest date between (i)&nbsp;the first
(1st) anniversary of the allocation date, and (ii)&nbsp;the date on which a specific performance condition is fulfilled (condition&nbsp;3); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For 106,368 Free Shares 2023-1: the Acquisition Period shall end on the first (1st)&nbsp;anniversary of the
allocation date subject to the completion, prior to such date, of a specific performance condition (condition&nbsp;4). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>History of
Awards of Share Warrants (BSA), Founder&#146;s Share Warrants (BCE) and Free Shares (AGA) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The history of the award of BSAs, BCEs
and AGAs is set forth in the Section &#147;Description of Share Capital.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions or Allocations to Pay Pensions, Retirement or Other
Benefits for Directors and Management </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the fiscal year ended December&nbsp;31, 2022, none of the amounts set aside or accrued
to provide pension, retirement or similar benefits to our employees was attributable to our administrative, supervisory or management bodies. We have not set aside any provisions to pay pensions, retirement and other benefits for corporate
directors. The directors&#146; compensation does not include any profit-sharing plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Functioning of Governing and Management Bodies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Company Management </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a French
limited liability company with a board of directors (<I>soci&eacute;t&eacute; anonyme &agrave; conseil d&#146;administration</I>). Since May 5, 2023, our Board has been chaired by our Chief Executive Officer, Mr. de Garidel, who represents us <I><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT></I> third parties in his capacity as Chief Executive Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All members of the Board may serve for a maximum of four years, expiring at the end of the shareholders&#146; meeting called to approve the
financial statements from the previous year and held during the year in which the term expires. Members of the Board may be <FONT STYLE="white-space:nowrap">re-elected.</FONT> They may be dismissed at any time by a decision of the ordinary general
meeting of shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the fiscal year ended December&nbsp;31, 2022, the Board met 18 times. The average attendance rate of the
Directors was approximately 98%. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Agreements with our Directors and Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a discussion of our agreements with certain of our directors and executive officers, see &#147;Certain Relationships and Related Person
Transactions.&#148; Except for the arrangements described in such section, there are no arrangements or understandings between us and any of our other executive officers or directors that provide for benefits upon termination of their employment,
other than as required by applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Liability and Indemnification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, provisions of <FONT STYLE="white-space:nowrap">by-laws</FONT> that limit the liability of directors are prohibited. However,
French law allows <I>soci&eacute;t&eacute;s anonyme </I>to contract for and maintain liability insurance against civil liabilities incurred by any of their directors and officers involved in a third-party action, provided that they acted in good
faith and within their capacities as directors or officers of Abivax SA. Criminal liability cannot be indemnified under French law, whether directly by us or through liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain liability insurance for our directors and officers, including insurance against liability under the Securities Act and we intend
to enter into agreements with our directors and executive officers to provide contractual indemnification. With certain exceptions and subject to limitations on indemnification under French law, these agreements will provide for indemnification for
damages and expenses including, among other things, attorneys&#146; fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding arising out of his or her actions in that capacity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These agreements may discourage shareholders from bringing a lawsuit against our directors and executive officers for breach of their
fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and executive officers, even though such an action, if successful, might otherwise benefit us and our shareholders.
Furthermore, a shareholder&#146;s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these insurance agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors may, through their relationships with their employers or
partnerships, be insured and/or indemnified against certain liabilities in their capacity as members of our Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any underwriting
agreement we enter into in connection with the sale of ordinary shares (including in the form of ADSs) being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who
control us within the meaning of the Securities Act against certain liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2023, we had 34 full-time employees, consisting of 18 within the research and development department and 16 within the
general administrative department. Our employees based in France are subject to the national collective bargaining agreement for the pharmaceutical industry (the <I>convention collective nationale de l&#146;industrie pharmaceutique</I>). We believe
that we maintain good relations with our employees. As of June&nbsp;30, 2023, 25 full-time employees were based in France and nine full-time employees were based in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on skilled, experienced and innovative employees to conduct the operations of our company. We are committed to building an
outstanding, committed team and we focus on a culture that values a focus on scientific innovation, inclusion, collaboration and equity. We focus on recruiting, retaining and developing employees from a diverse range of backgrounds to conduct our
research, development, clinical, commercial, marketing and market access activities. We recognize that recruiting, motivating and retaining talented employees is vital to our success. The principal purposes of our equity and cash incentive plans are
to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase shareholder value and the success of our company by motivating such individuals to perform to the best of their
abilities and achieve our objectives. We aim to create an equitable, inclusive and empowering environment in which our employees can grow and advance their careers, with the overall goal of developing, expanding and retaining our workforce to
support our current pipeline and future business goals. Employees are encouraged to attend scientific, clinical and technological meetings and conferences and have access to broad resources they need to be successful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_15"></A>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2021, we have engaged in the following transactions with our directors, executive officers and holders of more than 5%
of our outstanding voting securities and their affiliates, which we refer to as to our related parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intra-Group Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;1, 2022, we acquired 100% of the share capital of Prosynergia S.&agrave;.r.L, a Luxembourg biotech company pursuant to the terms
of a share purchase agreement entered into on November&nbsp;15, 2021 (the &#147;Prosynergia SPA&#148;). On December&nbsp;1, 2021, we granted a loan to Prosynergia, for &#128;1,400,000. On December 12, 2022, we completed a merger with Prosynergia
through a <I>Transmission Universelle du Patrimoine</I> (&#147;TUP&#148;) and all of Prosynergia&#146;s assets and liabilities were transferred to us. Following the merger, Prosynergia was dissolved. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Arrangements with our Directors and Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuances of Securities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We issued
(i) 1,964,031 ordinary shares in a private placement on July&nbsp;27, 2021; (ii)&nbsp;5,530,000 ordinary shares in a private placement on September&nbsp;7, 2022; and (iii)&nbsp;20,000,000 ordinary shares in a private placement on February 23, 2023.
The following table summarizes the ordinary shares acquired in connection with these offerings by our executive officers, directors and holders of more than 5% of our outstanding voting securities. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Entities&nbsp;affiliated<BR>with<BR>Truffle&nbsp;Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Sofinnova</B><br><B>Crossover</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TCG<BR>Crossover</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Entities<BR>affiliated</B><br><B>With<BR>Venrock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deep<BR>Track<BR>Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Invus</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Private placement in 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Number of ordinary shares purchased (#)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">467,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Purchase price per share (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Private placement in 2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Number of ordinary shares purchased (#)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">584,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,688,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,463,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,126,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">371,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Purchase price per share (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Private placement in 2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Number of ordinary shares purchased (#)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,535,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,150,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Purchase price per share (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 197,000 ordinary shares subscribed by FCPI BioMedTech, which is controlled by Truffle Capital
(&#147;Truffle Capital&#148; and together the &#147;Truffle Entities&#148;), itself controlled at 39.66% (of the share capital) respectively by Dr.&nbsp;Philippe Pouletty, a member of our Board, and Mr.&nbsp;Bernard-Louis Roques. The principal
business address of the Truffle Entities is 5 rue de la Baume, 75008, Paris, France. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 1,039,900 ordinary shares subscribed by Venrock Healthcare Capital Partners EG, L.P.
(&#147;VHCP EG&#148;), (ii) 384,623 ordinary shares subscribed by Venrock Healthcare Capital, Partners III, L.P. (&#147;VHCP III&#148;), and (iii) 38,477 ordinary shares subscribed by VHCP <FONT STYLE="white-space:nowrap">Co-Investment</FONT>
Holdings III, LLC </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
(&#147;VHCP <FONT STYLE="white-space:nowrap">Co-Investment&#148;).</FONT> VHCP EG, VHCP III and VHCP <FONT STYLE="white-space:nowrap">Co-Investment</FONT> are controlled by Venrock
(&#147;Venrock&#148; and together the &#147;Venrock Entities&#148;). Venrock Entities are controlled by Dr.&nbsp;Bong Koh and Nimish Shah. The principal business address of the Venrock Entities is 7, Bryant Park, 23rd Floor, <FONT
STYLE="white-space:nowrap">New-York,</FONT> NY 10018, United States. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 817,420 ordinary shares subscribed by VHCP EG, (ii) 302,335 ordinary shares subscribed by VHCP
III, and (iii) 30,245 ordinary shares subscribed by VHCP Co-Investment. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We further issued 374 ordinary shares on
November&nbsp;9, 2020 to the benefit of Mr.&nbsp;Didier Blondel, our Chief Financial Officer and Board Secretary. Following his exercise of 374 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-1,</FONT></FONT> he holds 374
ordinary shares at an issue price per share equal to &#128;6.39. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We further issued royalty certificates on September 7, 2022 to each of
FCPI BioMedTech, Deep Track Biotechnology Master Fund, Ltd., Sofinnova Crossover I SLP, TCG Crossover Fund I, L.P., Invus Public Equities, L.P., and VHCP III. The terms and conditions of these royalty certificates are further detailed in an exhibit
to this registration statement for the global offering of which this prospectus forms a part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director and Executive Officer Compensation
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are parties to employment agreements and other compensation arrangements, including equity compensation arrangements, with our
directors and executive officers in the ordinary course of business. See &#147;Compensation and Benefits&#151;Compensation of Chief Executive Officer&#148; for information regarding compensation of the Directors and Executive Officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into employment agreements with each of our executive officers, except for our Chief Executive Officer, who is a corporate
officer (mandataire social) with whom we have entered into a management contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Chief Executive Officer has been appointed for a
term lasting until the end of the Board meeting following the general meeting of shareholders held to approve the financial statements for the year ending December 31, 2026. He has also been appointed as Chairman of the Board for a term lasting
until the end of the Board meeting following the general meeting of shareholders held to approve the financial statements for the year ending December 31, 2024. In case of termination of the Chief Executive Officer as a result of
(i)&nbsp;non-renewal, (ii) revocation except for gross negligence or willful misconduct and/or (iii) resignation justified by invalidity or health issues or Mr. de Garidel&#146;s definitive retirement (a &#147;Qualifying Departure&#148;), Mr. de
Garidel shall be entitled to a severance payment equal to 12 months of the higher of either (i) the monthly average fixed remuneration and variable remuneration received by Mr. de Garidel during the 12-month period preceding the effective date of
the Qualifying Departure, or (ii) the monthly average fixed remuneration received by Mr. de Garidel during the 12-month period preceding the effective date of the Qualifying Departure plus 1/12th of the variable remuneration for the financial year
immediately preceding the date of the Qualifying Departure, irrespective of the date of payment of that variable remuneration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
February 2023, we entered into an offer letter with Dr. Sloan. Dr. Sloan may terminate his employment with us without good reason (as defined in his offer letter), and we may terminate his employment with us without cause (as defined in his offer
letter) upon four months of notice. If Dr. Sloan&#146;s employment is terminated by us without cause or Dr. Sloan resigns with good reason (as defined in his offer letter), then he will be entitled to receive severance pay in an amount equal to (i)
six months of his then-current base compensation, (ii) prorated portion of the variable compensation and (iii) any premiums for healthcare plans provided by us (including any eligible COBRA coverage) for the earlier of a period of six months from
the date of termination and the date on which Dr. Sloan becomes eligible to receive such benefits with a new employer. The offer letter also includes a non-competition provision lasting during and for six months following his employment with us.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2023, we entered into an offer letter with Mr. Ferguson. Mr. Ferguson may terminate his employment with us without good reason
(as defined in his offer letter), and we may terminate his employment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with us without cause (as defined in his offer letter) upon four months of notice. If Mr. Ferguson&#146;s employment is terminated by us without cause or Mr. Ferguson resigns with good reason (as
defined in his offer letter), then he will be entitled to receive severance pay in an amount equal to (i) six months of his then-current base compensation, (ii) prorated portion of the variable compensation and (iii) any premiums for healthcare
plans provided by us (including any eligible COBRA coverage) for the earlier of a period of six months from the date of termination and the date on which Mr. Ferguson becomes eligible to receive such benefits with a new employer. The offer letter
also includes a non-competition provision lasting during and for six months following his employment with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of our executive
officers has agreed to maintain the confidentiality of any confidential information, both during and after the employment/management agreement expires or is earlier terminated. In addition, they are subject to loyalty and confidentiality obligations
and certain of them are bound by a non-solicitation covenant that prohibits such executive officer from soliciting our customers, or soliciting or hiring our executive employees and those of our employees working in the same team as our executive
officer, during his or her employment/office and for one year after the termination of his or her employment/office. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2021, we have not granted any share warrants (BSA) or founder&#146;s share warrants (BCE) to employees, consultants or
directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual Property Assignment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July 7, 2021, we entered into an intellectual property assignment agreement with Hartmut Ehrlich, who served as our Chief Executive Officer
until May 5, 2023. The purpose of this agreement is to transfer to us all the intellectual property rights held by Dr. Hartmut Ehrlich on certain patents of which he is a <FONT STYLE="white-space:nowrap">co-inventor.</FONT> No compensation has been
paid in respect of this transfer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Free Shares (attributions gratuites d&#146;actions) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December 31, 2022, Dr. Hartmut Ehrlich received long-term remuneration in the form of a grant of free shares. As of June
30, 2023, all of these free shares have become null and void, as the performance conditions applicable to such free shares have not been met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We further entered into a transition protocol with Dr. Hartmut Ehrlich, our previous Chief Executive Officer, according to which he was
granted by a Board decision on July 11, 2023 100,000 free shares that are subject to the achievement of specific performance conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, pursuant to a Board decision on July 11, 2023, we have allocated a total number of 1,382,796 free shares (AGA) to Mr. Marc de
Garidel, as our current Chief Executive Officer, to which performance conditions and presence conditions apply. In particular, 106,369 out of these 1,382,796 free shares (AGA) are subject to an additional vesting condition of the successful
completion of this offering raising at least $100&nbsp;million in gross proceeds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September 28, 2023, certain of our officers and
employees were allocated 985,750 free shares (AGA) in the aggregate, the vesting of which is subject to certain conditions. Subject to remaining employed with us, each such officer or employee&#146;s free shares (AGA) will be vested as follows: (i)
50% at the end of a two-year period from the allocation date, (ii) 25% at the end of a three-year period from the allocation date and (iii) 25% at the end of a four-year period from the allocation date. Of the 985,750 free shares (AGA), 254,250 free
shares (AGA) are subject to an additional vesting condition of the successful completion of this offering raising at least $200&nbsp;million in gross proceeds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transition Protocol </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In light of Dr. Hartmut Ehrlich&#146;s upcoming retirement and in order to ensure a smooth transition with our new Chief Executive Officer and
protect our interests, the Board approved, during its meeting on April 18, 2023, the entering into a transition protocol with Dr. Hartmut Ehrlich which provides that Dr. Hartmut Ehrlich will: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be entitled to the payment of a departure indemnity equal to &#128;1,209,825; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">agree to be bound by a non-compete undertaking for a duration of twelve months following the termination of his
role as Chief Executive Officer (not compensated); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">remain our employee on a part-time basis until December 31, 2023 in a capacity as advisor to the new Chief
Executive Officer against payment of a total compensation of &#128;100,000; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be eligible to receive up to 100,000 free shares depending on the achievement of specific performance conditions.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into this transition protocol on April 18, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The payment of Dr. Hartmut Ehrlich&#146;s departure indemnity will be subject to shareholders&#146; approval pursuant to Article L. 22-10-34
of the French Commercial Code. The entering into the transition protocol is subject to the procedure applicable to related-party agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related
Person Transaction Policy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We comply with French law regarding approval of transactions with related parties. In particular, in
accordance with article <FONT STYLE="white-space:nowrap">L.225-38</FONT> and seq. of the French Commercial Code, transactions with our general managers, directors, shareholders holding more than 10% of the voting rights of the company and any
company controlling a shareholder holding more than 10% of our voting rights, other than transactions in the ordinary course of business and at arm&#146;s length, are (i)&nbsp;subject to a prior approval by the Board, (ii)&nbsp;reported to the
statutory auditors who must then prepare a report on such transaction, and (iii)&nbsp;ratified by the our shareholders at the annual general meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have adopted a related-party transaction policy that sets forth our procedures for the identification, review, consideration
and approval or ratification of related-party transactions. For purposes of our policy only, a related-party transaction is defined as (1)&nbsp;any individual or series of financial transactions, arrangements or relationships (including any
indebtedness or guarantee of indebtedness), in which we and any related parties are, were or will be participants, or otherwise have a direct or indirect interest, or (2)&nbsp;any agreement or similar transaction under French law which falls within
the scope of Article L. <FONT STYLE="white-space:nowrap">225-38</FONT> of the French Commercial Code. For purposes of this policy, a related party is any person who is or at any time since the beginning of the our last fiscal year was, a director,
director nominee, executive officer, beneficial owner of more than 5% of any class of our voting securities or any immediate family member(s) of the foregoing persons, or any firm, corporation or other entity in which any of the foregoing persons is
employed or is a partner or principal or in a similar position or in which such person has more than a 5% beneficial ownership interest. Under the policy, related-party transactions must be reported to us by the relevant related parties. If a
transaction has been identified as a related-party transaction, management must present information regarding the related-party transaction to our Board for review, consideration and approval or ratification. Regarding certain transactions, our
Board may appoint an independent expert whenever the signing of a related person transaction is likely to have a material impact on our balance sheet or results. In this case, this expert review will be mentioned in the special report of the
statutory auditors and disclosed to the public subject, as the case may be, to any information likely to adversely affect trade secret. Our Board may also seek the opinion of the audit committee and/or of the independent statutory auditors if there
is any doubt about the qualification of a related person transaction subject to his evaluation. When submitted to our Board&#146;s review, the persons who have a direct or indirect interest in the transaction shall not participate in its review.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_16"></A>PRINCIPAL SHAREHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table and accompanying footnotes set forth information with respect to the beneficial ownership of our ordinary shares as of
September&nbsp;30, 2023 for: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each beneficial owner, known by us, of more than 5% of our outstanding ordinary shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors and executive officers individually; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our directors and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities
to persons who possess sole or shared voting power or investment power with respect to those securities and include ordinary shares that can be acquired within 60 days of September&nbsp;30, 2023. The percentage ownership information shown in the
table prior to the global offering is based upon 42,569,216 ordinary shares outstanding as of September&nbsp;30, 2023 (excluding 11,152 treasury shares issued by us as of September 30,&nbsp;2023). The percentage ownership information shown in the
table after the global offering is based upon ordinary shares outstanding (excluding 11,152 treasury shares issued by us as of September&nbsp;30, 2023), assuming the sale of ordinary shares (which may be in the form of ADSs) by us in the global
offering and no exercise of the underwriters&#146; option to purchase additional ADSs and/or ordinary shares. The percentage ownership information shown in the table after the global offering if the underwriters&#146; option to purchase additional
ADSs and/or ordinary shares is exercised in full is based upon ordinary shares outstanding (excluding 11,152 treasury shares issued by us as of September&nbsp;30, 2023), assuming the sale of ordinary shares (which may be in the form of ADSs) by us
in the global offering and the exercise in full of the underwriters&#146; option to purchase additional ADSs and/or ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, the table below does not reflect any ordinary shares that may be purchased in the global offering, all of the
shares reflected in the table are ordinary shares and all persons listed below have sole voting and investment power with respect to the shares beneficially owned by them, subject to applicable community property laws. The information is not
necessarily indicative of beneficial ownership for any other purpose. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In computing the number of ordinary shares beneficially owned
by a person and the percentage ownership of that person, we deemed outstanding ordinary shares subject to options and warrants held by that person that are immediately exercisable or exercisable within 60 days of September&nbsp;30, 2023. We did not
deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. Beneficial ownership representing less than 1% is denoted with an asterisk (*). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in the table below is based on information known to us or ascertained by us
from public filings made by the shareholders (which may be in the form of ADSs). Except as otherwise indicated in the table below, addresses of the directors, executive officers and named beneficial owners are in care of Abivax SA, <FONT
STYLE="white-space:nowrap">7-11&nbsp;boulevard</FONT> Haussmann, 75009 Paris, France. Our major shareholders do not have any special voting rights. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Ordinary</B><br><B>Shares</B><br><B>Beneficially</B><br><B>Owned&nbsp;
Before</B><br><B>Global</B><br><B>Offering</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of</B><br><B>Ordinary</B><br><B>Shares&nbsp;Beneficially</B><br><B>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of</B><br><B>Voting Power+</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before</B><br><B>Global</B><br><B>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After</B><br><B>Global</B><br><B>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before</B><br><B>Global</B><br><B>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After</B><br><B>Global</B><br><B>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% Shareholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TCG Crossover(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,956,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.64</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.09</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.98</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.26</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities managed by Truffle Capital(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,677,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.64</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.79</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.93</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sofinnova Crossover(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,064,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.55</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.64</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.58</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.41</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Invus(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,034,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.48</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.59</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.91</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deep Track Capital(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,675,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.28</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.37</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.39</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.92</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Venrock(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,613,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.14</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.27</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.26</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.82</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc de Garidel(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Didier Blondel(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pierre Courteille(9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Didier Scherrer(10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sheldon Sloan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Ferguson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June Lee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Troy Ignelzi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol L. Brosgart(11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corinna zur Bonsen-Thomas(12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kinam Hong (representing Sofinnova Partners)(13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,064,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.55</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.64</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.58</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.41</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paolo Rampulla (representing Sant&#233; Holdings SRL)(14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.97</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.37</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.90</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.11</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philippe Pouletty (representing Truffle Capital)(15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,952,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.63</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.09</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.90</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.73</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All directors and officers as a group (13&nbsp;persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,096,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.72</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.49</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33.73</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.54</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than 1%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">A double voting right is attached to each registered ordinary share (except treasury share) that is held in the
name of the same shareholder for at least two years. For additional information, see &#147;Description of Share Capital&#151;Attendance and Voting at Shareholders&#146; Meetings.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">These securities are held by TCG Crossover Fund I, L.P. (&#147;TCG Crossover I&#148;). TCG Crossover GP I, LLC
(&#147;TCG Crossover GP I&#148;) is the general partner of TCG Crossover I. Chen Yu is the sole managing member of TCG Crossover GP I and holds voting and dispositive power with respect to the securities held by TCG Crossover I. The principal
business address of each of TCG Crossover GP I, TCG Crossover I and Dr. Yu is 705 High St., Palo Alto, CA 94301, United States. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 2,213,333 ordinary shares held by FCPR Truffle Capital II (&#147;Truffle Capital II&#148;),
(ii)&nbsp;1,164,858 ordinary shares held by FCPI UFF Innovation 7 (&#147;UFF Innovation&nbsp;7&#148;), (iii)&nbsp;119,000 ordinary shares held by FCPI UFF Innovation 15 (&#147;UFF Innovation&nbsp;15&#148;), (iv)&nbsp;171,600 ordinary shares held by
FCPI Fortune 4 (&#147;FCPI Fortune 4&#148;), (v) 91,973 ordinary shares held by FCPI Fortune 3&nbsp;(&#147;FCPI Fortune 3&#148;), (vi)&nbsp;157,100 ordinary shares held by FCPI UFF Innovation 12 (&#147;UFF Innovation 12&#148;), (vii)&nbsp;193,900
ordinary shares held by FCPI UFF Innovation 8 (&#147;UFF Innovation 8&#148;), (viii)&nbsp;103,400 ordinary shares held by FCPI UFF Innovation 14 (&#147;UFF Innovation 14&#148;), (ix)&nbsp;84,983 ordinary shares held by FCPI Truffle Fortune 5
(&#147;FCPI Fortune 5&#148;), (x)&nbsp;54,120 ordinary shares held by FCPI UFF Innovation&nbsp;16 (&#147;UFF Innovation 16&#148;), (xi)&nbsp;28,263 ordinary shares held by FCPI Truffle Fortune 6 (&#147;FCPI Fortune&nbsp;6&#148;), (xii)&nbsp;23,493
ordinary shares held by FCPI UFF Innovation 17 (&#147;UFF Innovation 17&#148;), (xiii)&nbsp;16,394 ordinary shares held by FCPI Truffle Innocroissance 2015 (&#147;Truffle Innocroissance 2015&#148;), (xiv)&nbsp;36,400 ordinary shares held by Truffle
Developpement (&#147;Truffle Developpement&#148;), (xv)&nbsp;21,252 ordinary shares held by FCPI Truffle Innocroissance 2018 (&#147;Truffle Innocroissance 2018&#148;) and (xvi) 197,000 ordinary shares held by FCPI BioMedTech
(&#147;BioMedTech&#148;). Truffle Capital II, UFF Innovation 7, UFF Innovation 15, FCPI Fortune 4, FCPI Fortune 3, UFF Innovation 12, UFF Innovation 8, UFF Innovation 14, FCPI Fortune 5, UFF Innovation 16, FCPI Fortune 6, UFF Innovation 17, Truffle
Innocroissance 2015, Truffle Developpement, Truffle Innocroissance 2018 and BioMedTech are managed by Truffle Capital (&#147;Truffle Capital&#148; and together the &#147;Truffle Entities&#148;), itself controlled at 36.85% (of the share capital)
respectively by Dr.&nbsp;Philippe&nbsp;Pouletty, a member of our Board, and Mr.&nbsp;Bernard-Louis Roques. The principal business address of the Truffle Entities is 5 rue de la Baume, 75008, Paris, France. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of 4,064,739 ordinary shares held by Sofinnova Crossover I SLP (&#147;Sofinnova Crossover&#148;).
Sofinnova Crossover is controlled by Sofinnova Partners (&#147;Sofinnova Partners&#148; and together the &#147;Sofinnova Entities&#148;). Each of Antoine Papiernik, Cedric Moreau, Kinam Hong, a member of our Board, Joseph Anderson and Jacques
Theurillat is a member of the investment committee of Sofinnova Crossover and may be deemed to have shared voting and investment control over the shares held by Sofinnova Crossover. Each of such individuals disclaims beneficial ownership of such
shares except to the extent of their pecuniary interest therein. The principal business address of the Sofinnova Entities is 7-11&nbsp;boulevard Haussmann, 75009 Paris, France. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of 4,034,364 ordinary shares directly held by Invus Public Equities, L.P. (&#147;Invus PE&#148;). Invus
Public Equities Advisors, LLC (&#147;Invus PE Advisors&#148;), controls Invus PE, as its general partner and accordingly, may be deemed to beneficially own the ordinary shares held by Invus PE. The Geneva branch of Artal International S.C.A.
(&#147;Artal International&#148;), controls Invus PE Advisors, as its managing member and accordingly, may be deemed to beneficially own the ordinary shares held by Invus PE. Artal International Management S.A. (&#147;Artal International
Management&#148;), as the managing partner of Artal International, controls Artal International and accordingly, may be deemed to beneficially own the ordinary shares that Artal International may be deemed to beneficially own. Artal Group S.A.
(&#147;Artal Group&#148;), as the sole stockholder of Artal International Management, controls Artal International Management and accordingly, may be deemed to beneficially own the ordinary shares that Artal International Management may be deemed to
beneficially own. Westend S.A. (&#147;Westend&#148;), as the parent company of Artal Group, controls Artal Group and accordingly, may be deemed to beneficially own the ordinary shares that Artal Group may be deemed to beneficially own. Stichting
Administratiekantoor Westend (the &#147;Stichting&#148;), as majority shareholder of Westend, controls Westend and accordingly, may be deemed to beneficially own the ordinary shares that Westend may be deemed to beneficially own. Mr. Amaury
Wittouck, as the sole member of the board of Stichting, controls the Stichting and accordingly, may be deemed to beneficially own the ordinary shares that the Stichting may be deemed to beneficially own. The principal business address for Invus PE
and Invus PE Advisors is 750 Lexington Avenue, 30th Floor, New York, NY 10022. The principal business address for Artal International, Artal International Management, Artal Group, Westend and Mr. Wittouck is Valley Park, 44, Rue de la Vall&#233;e,
L-2661, Luxembourg. The principal business address for the Stichting is Claude Debussylaan, 46, 1082 MD Amsterdam, the Netherlands. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of 2,675,238 ordinary shares held by Deep Track Biotechnology Master Fund, Ltd. (&#147;Deep Track
Fund&#148;) acting on behalf of funds it manages. Deep Track Fund is controlled by Deep Track Capital GP, LLC. The latter is controlled by Mr.&nbsp;David Kroin who is also its managing member. The principal business address of the Deep Track
Entities is 200 Greenwich Avenue 3rd Floor, Greenwich, CT 06830, United States. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of (i)&nbsp;1,857,320 ordinary shares held by Venrock Healthcare Capital Partners EG, L.P. (&#147;VHCP
EG&#148;), (ii)&nbsp;686,958 ordinary shares held by Venrock Healthcare Capital, Partners III, L.P. (&#147;VHCP III&#148;) and (iii) 68,722 ordinary shares held by VHCP <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Holdings III, LLC
(&#147;VHCP Co-Investment&#148;). VHCP Management III, LLC (&#147;VHCPM&#148;) is the sole general partner of VHCP III and the sole manager of VHCP Co-Investment. VHCP Management EG, LLC (&#147;VHCPM EG&#148;) is the sole general partner of VHCP EG.
Dr. Bong Koh and Nimish Shah are the voting members of VHCPM and VHCPM EG. The principal business address of the Venrock Entities is 7 Bryant Park, 23rd Floor, New York, NY 10018, United States. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of 38,145 ordinary shares held as of September&nbsp;30, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 374 ordinary shares held as of September&nbsp;30, 2023 and (b) up to 67,000 ordinary shares
issuable upon the exercise of options and warrants that are immediately exercisable or exercisable within 60 days of September&nbsp;30, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) one ordinary share held as of September&nbsp;30, 2023 and (b) up to 67,373 ordinary shares
issuable upon the exercise of options and warrants that are immediately exercisable or exercisable within 60 days of September&nbsp;30, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of 35,773 ordinary shares held as of September&nbsp;30, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of up to 16,400 ordinary shares issuable upon the exercise of options and warrants that are immediately
exercisable or exercisable within 60 days of September&nbsp;30, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of up to 16,400 ordinary shares issuable upon the exercise of options and warrants that are immediately
exercisable or exercisable within 60 days of September&nbsp;30, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of 4,064,739 ordinary shares held by Sofinnova Crossover, as described in footnote 4 above. Kinam Hong,
a member of our Board, is a member of the investment committee of Sofinnova Crossover and may be deemed to have shared voting and investment control over the shares held by Sofinnova Crossover, as described in footnote 4 above.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 741,541 ordinary shares held as of September&nbsp;30, 2023 and (b) up to 96,924 ordinary shares
issuable upon the exercise of options and warrants that are immediately exercisable or exercisable within 60 days of September&nbsp;30, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 275,000 ordinary shares held as of September&nbsp;30, 2023 and (b) 4,677,069 ordinary shares
held by the Truffle Entities, as described in footnote 1 above. Dr.&nbsp;Philippe&nbsp;Pouletty, a member of our Board, controls Truffle Capital and may be deemed to have shared voting and investment control over the shares held by the Truffle
Entities, as described in footnote 1 above. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_17"></A>DESCRIPTION OF SHARE CAPITAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated as a
<I>soci&eacute;t&eacute; anonyme</I> (limited liability company), on December&nbsp;4, 2013 and registered at the Paris Trade and Company Register on December&nbsp;27, 2013 for a period of 99 years until December&nbsp;22, 2112, subject to extension
or early dissolution, under the number 799&nbsp;363&nbsp;718. Our corporate purpose in France and abroad includes the research, development and marketing of therapeutic and prophylactic vaccines and small therapeutic molecules that primarily have
applications in the anti-infective field, as set forth in Article 4 of our by-laws. We may participate, by any means, directly or indirectly in any operations that may be related to our purpose through the creation of new companies, contribution,
subscription or purchase of company securities or rights, merger or otherwise, creation, acquisition, leasing, management lease of any businesses or establishments. Our principal executive offices are located at
<FONT STYLE="white-space:nowrap">7-11&nbsp;boulevard</FONT> Haussmann, 75009&nbsp;Paris, France, and our telephone number is +33&nbsp;(0)&nbsp;1&nbsp;53&nbsp;83&nbsp;08&nbsp;41. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of our <FONT STYLE="white-space:nowrap">by-laws</FONT> and share capital does not purport to be complete and is
qualified in its entirety by reference to our <FONT STYLE="white-space:nowrap">by-laws</FONT> as of the date of this prospectus. Copies of our <FONT STYLE="white-space:nowrap">by-laws</FONT> may be obtained from the Trade and Company Registry
(<I>Greffe du Registre du Commerce et des Soci&eacute;t&eacute;s</I>) of Paris, France or our corporate headquarters and are filed as an exhibit to this registration statement for the global offering of which this prospectus forms a part. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Capital </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share Capital History </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2023, our share capital amounted to &#128;425,475.68 and is divided into 42,547,568 ordinary shares of &#128;0.01<B> </B>par
value each after taking into account: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER&nbsp;OF</B><br><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PAR&nbsp;VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AMOUNT&nbsp;OF&nbsp;PAID</B><br><B>UP CAPITAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(&#128;)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(&#128;)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,547,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">425,475.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>42,547,568</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.01</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>425,475.68</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the shares are fully subscribed and paid. As of the date of this prospectus, we have not issued
securities that do not represent our share capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below shows the changes in our share capital over the last three fiscal
years. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Type of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">operation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Prior Share<br>Capital (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Premium (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<br>shares<br>created</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total<br>number of<br>shares after<br>issuance</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nominal<br>value&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Share<br>capital after<br>transaction&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Issue&nbsp;price<br>per&nbsp;share&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">07/01/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,019.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,203,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,032.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">11/01/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,032.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,219,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,196.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">16/01/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,196.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,222,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,226.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">17/01/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,226.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,222,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,226.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">22/01/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,226.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,224,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,240.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Type of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">operation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Prior Share<br>Capital (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Premium (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<br>shares<br>created</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total<br>number of<br>shares after<br>issuance</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nominal<br>value&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Share<br>capital after<br>transaction&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Issue&nbsp;price<br>per&nbsp;share&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">11/02/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,240.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,225,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,256.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">17/03/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-7</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,256.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,228,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,282.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">29/07/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-7</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,282.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,230,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,308.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">30/10/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Conversion of convertible bonds</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,308.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,995,356.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">464,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,695,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,951.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">02/11/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Capital increase through issue of new shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,951.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,983,789.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,620,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,315,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,155.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">09/11/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,155.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,386.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,315,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,159.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">30/11/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,159.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,316,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,166.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">02/12/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,166.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,623.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,318,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,183.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">08/12/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,183.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,320,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,202.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">04/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,202.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,321,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,212.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">05/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,212.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,322,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,220.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">05/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,220.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,324,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,240.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">05/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,240.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,325,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,253.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">07/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,253.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,327,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,273.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">08/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,273.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,343,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,437.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">11/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,437.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,343,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,437.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">12/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,437.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,344,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,447.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">22/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,447.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,346,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,462.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">28/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,462.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,347,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,472.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">28/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,472.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">523,343.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,394,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,942.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">01/02/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,942.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,397,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,972.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">02/02/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,972.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,400,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,002.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">09/02/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,002.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,404,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,042.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">22/02/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,042.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,406,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,062.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">02/03/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,062.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,408,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,085.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Type of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">operation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Prior Share<br>Capital (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Premium (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<br>shares<br>created</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total<br>number of<br>shares after<br>issuance</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nominal<br>value&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Share<br>capital after<br>transaction&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Issue&nbsp;price<br>per&nbsp;share&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">02/03/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,085.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,810.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,411,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,113.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">03/03/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,113.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,895.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,411,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,117.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">25/05/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,117.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,998,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,531,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,317.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">26/05/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,317.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,249,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,581,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,817.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">31/05/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,817.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">519,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,601,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,017.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">02/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-4</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,017.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,601,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,017.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">03/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,017.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">573,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,623,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,237.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">15/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,237.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,626,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,262.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">24/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,262.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">549,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,646,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,462.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">25/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,462.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,651,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,512.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">29/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,512.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">288,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,661,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,612.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">30/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,612.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">282,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,671,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,712.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">01/07/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,712.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,673,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,732.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">02/07/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,732.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">539,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,693,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,932.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">05/07/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,932.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">944,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,728,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,282.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">22/07/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Capital increase through issuance of new shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,282.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,981,506.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,964,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.692.268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,922.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">06/09/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,922.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,731.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,693,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,933.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">09/09/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,933.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,327.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,696,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,963.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">09/09/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,963.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,696,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,967.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">10/09/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,967.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,292.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,706,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,067.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">20/09/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,067.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,282.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,709,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,097.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">18/10/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,097.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,710,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,107.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">20/10/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,107.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,245.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,713,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,137.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">20/10/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,137.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,005.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,717,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,171.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">25/10/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,171.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,718,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,181.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Type of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">operation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Prior Share<br>Capital (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Premium (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<br>shares<br>created</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total<br>number of<br>shares after<br>issuance</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nominal<br>value&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Share<br>capital after<br>transaction&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Issue&nbsp;price<br>per&nbsp;share&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">25/10/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,181.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,719,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,191.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">30/11/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-2</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,191.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,740,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,401.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">21/12/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-2</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,401.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214,048.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,764,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,640.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">08/03/2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,640.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,444.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,764,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167.643,85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">30/05/2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167.643,85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,783,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,831.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">07/09/2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Capital increase through issue of new shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,831.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,175,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,530,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,313,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223,131.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">20/01/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap">BCE-2014-4</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223,131.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,331,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223,315.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">27/02/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Capital increase through issue of new shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223,315.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,331,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423,315.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">10/05/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap">BSA-2014-3</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423,315.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,347,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423,479.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">06/06/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of BSA-2018-KREOS-A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423,479.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">488,786.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,415,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424,158.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">06/06/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of BSA-2018-KREOS-b</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424,158.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338,830.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,447,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424,475.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">19/06/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap">BCE-2014-2</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424,475.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,547,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425,475.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">12/09/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of BSA-2014-3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425,475.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,563,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425,639.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">14/09/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of BSA-2014-3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425,639.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,580,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425,803.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; Meetings and Voting Rights (Articles 12, 22, 23, 24, 25 and 26 of the <FONT
STYLE="white-space:nowrap">By-Laws)</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the French Commercial Code (<I>Code de Commerce</I>), there are three types of shareholders&#146; meetings: ordinary,
extraordinary and special. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ordinary shareholders&#146; meetings are required to elect, replace or remove directors, appoint independent
statutory auditors, approve the annual financial statements, approve share repurchase programs, declare dividends or authorizing dividends to be paid in shares and approve regulated agreements. In addition, pursuant to AMF recommendation, French
listed companies may be required to conduct a consultation of the Ordinary Shareholders Meeting prior to the disposal of the majority of their assets, under certain conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Extraordinary shareholders&#146; meetings are required for approval of matters such as amendments to our
<FONT STYLE="white-space:nowrap">by-laws,</FONT> including amendments required in connection with extraordinary corporate actions (i.e., changing our name, corporate purpose or registered office, increasing or decreasing our share capital and
creating a new class of equity securities (ordinary or preferred shares)). Shareholders&#146; rights may be modified as allowed by French law. Only the extraordinary shareholders&#146; meeting is authorized to amend any and all provisions of our <FONT
STYLE="white-space:nowrap">by-laws.</FONT> It may not, however, increase shareholder commitments without the prior approval of each shareholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Special meetings of holders of a certain category of shares or of securities giving access to our share capital are required for any
modification of the rights relating to such categories of shares. The resolutions of the shareholders&#146; meeting modifying these rights are effective only after they have been approved by the relevant special meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Special Voting Rights of Warrant Holders </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, the holders of warrants of the same class (<I>i.e.,</I> warrants that were issued at the same time and with the same rights),
including founder&#146;s share warrants (BCEs), are entitled to vote as a separate class at a general meeting of that class of warrant holders under certain circumstances, principally in connection with any proposed modification of the terms and
conditions of the class of warrants or any proposed issuance of preferred shares or any modification of the rights of any outstanding class or series of preferred shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shareholders&#146; Meetings </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
Board convenes an annual ordinary shareholders&#146; meeting for the approval of the annual financial statements. This meeting is held within six months of the end of each fiscal year. This period may be extended by an order of the President of the
French Commercial Court (<I>Tribunal de Commerce</I>) at the request of the Board. The Board may also convene an ordinary or extraordinary shareholders&#146; meeting upon proper notice at any time during the year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Board fails to convene a shareholders&#146; meeting at the shareholders&#146; request, our statutory auditors may call the meeting. In
the event of bankruptcy, the liquidator or court-appointed agent may also call a shareholders&#146; meeting. In addition, any of the following may request the President of the French Commercial Court to appoint an agent to convene the
shareholders&#146; meeting: one or several shareholders holding at least 5% of our share capital, any interested party in cases of urgency, the workers council in cases of urgency or duly qualified associations of shareholders who have held their
shares in registered form for at least two years and who together hold a minimum number of the voting rights of our share capital. Shareholders holding a majority of the share capital or voting may also convene a shareholders&#146; meeting after the
filing of a public offer or sale of a controlling interest in our share capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholders&#146; meetings shall be chaired by the
chairperson of the Board or, in his or her absence, by a Deputy chairperson or by a director elected for this purpose. Failing that, the meeting itself shall elect a chairperson. Vote counting shall be performed by the two members of the meeting who
are present and accept such duties, who represent, either on their own behalf or as proxies, the greatest number of votes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice of
Shareholders&#146; Meeting </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to French law requirements in relation to notice of shareholders&#146; meetings and
announce shareholders&#146; meetings at least 35 days in advance by means of a preliminary notice published in the <I>Bulletin des annonces l&eacute;gales obligatoires</I> (BALO), as well as on our website at least 21&nbsp;days prior to the meeting.
At least 15 days prior to the date set for a shareholders&#146; meeting, or ten days if it is a second call, we must publish a final notice in accordance with French law requirements. In addition to the particulars relative to us, the final notice
indicates, notably, the meeting&#146;s agenda and the draft resolutions that will be presented. The requests for recording of issues or draft resolutions on the agenda must be addressed to the company under the conditions provided for in the current
legislation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, shareholders can only take action at shareholders&#146; meetings on matters listed on the agenda for the
meeting. As an exception to this rule, shareholders may take action, among other things, with respect to the dismissal of directors, even if these actions have not been included on the agenda. The Board must submit properly proposed resolutions to a
vote of the shareholders. When a shareholder submits a blank proxy form without naming a representative, his vote is deemed to be in favor of the resolutions (or amendments) proposed or recommended by the Board and against all others. As of the date
of the publication of the final notice of a meeting but no later than four business days before the shareholders&#146; meeting, any shareholder may submit written questions to the Board relating to the agenda for the meeting. The Board must respond
to these questions during the meeting. A common answer can be given to several questions if they have the same content or bear on the same topic. The answer to a written question is deemed to have been given insofar as it is published on our website
in a section devoted to questions and answers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Agenda and Conduct of Annual Shareholders&#146; Meetings. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agenda of the shareholders&#146; meeting shall appear in the notice to convene the meeting and is set by the author of the notice. The
shareholders&#146; meeting may only deliberate on the items on the agenda except for the removal of directors and the appointment of their successors which may be put to vote by any shareholder during any shareholders&#146; meeting. Pursuant to
French law and our current share capital, one or more shareholders representing 5% of our share capital may request the inclusion of items or proposed resolutions on the agenda. Such request must be received at the latest on the 25th day preceding
the date of the shareholders&#146; meeting, and in any event no later than the 20th day following the date of the convening notice to the shareholders&#146; meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Attendance and Voting at Shareholders&#146; Meetings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ownership of one share implies, <I>ipso jure</I>, adherence to our <FONT STYLE="white-space:nowrap">by-laws</FONT> and the decision of the
shareholders&#146; meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The voting rights attached to equity or dividend shares are proportional to the percentage of the share
capital they represent. Each share entitles the holder to one vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, a double voting right compared to that conferred to other
shares with regard to the percentage of share capital they represent is allocated to all fully <FONT STYLE="white-space:nowrap">paid-up</FONT> ordinary shares with proof of being held in registered form by the same owner for at least two
(2)&nbsp;years. Under French law, treasury shares or ordinary shares held by entities controlled by us are not entitled to voting rights and do not count for quorum purposes. Purchasers of ADSs or ordinary shares in this global offering, in the open
market following the completion of this global offering or in subsequent offerings will be unlikely to meet the requirements to have double voting rights attach to any ordinary shares held by them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to participate in any general meeting, shareholders are required to have their shares registered under the conditions and time limits
provided for the applicable laws before such general meeting in their name or in the name of an intermediary registered on their behalf, either in the registered shares shareholder account or in the bearer shares shareholder account. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Proxies and Votes by Mail or Videoconference </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, all shareholders who have properly registered and fully paid their shares or duly presented a certificate from their accredited
intermediary may participate in shareholders&#146; meetings. Shareholders may participate in shareholders&#146; meetings either in person, by proxy or by mail or, if provided for by the <FONT STYLE="white-space:nowrap">by-laws,</FONT> by
videoconference or by any means of telecommunications in accordance with applicable regulations, if the Board provides for such possibility when convening the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proxies are sent to any shareholder upon request. In order to be counted, such proxies must be received at our registered office, or at any
other address indicated on the notice convening the meeting, prior to the date of the meeting. A shareholder may grant proxies to his or her spouse, civil partner, to another shareholder or to any other person (individual or legal) of his/her/its
choice. A shareholder that is a corporation may grant proxies to a legal representative. A shareholder who is a <FONT STYLE="white-space:nowrap">non-resident</FONT> of France may be represented at a shareholders&#146; meeting by an intermediary
registered under the conditions set forth by French law. Alternatively, the shareholder may send a blank proxy to us without nominating a representative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to votes by mail, we will send shareholders a voting form. The completed form must be returned to us at least three days prior to
the date of the shareholders&#146; meeting. The final date for returning votes by mail is disclosed in the notice of meeting published in accordance with French law requirements. Under our <FONT STYLE="white-space:nowrap">by-laws,</FONT>
shareholders&#146; meetings by means of telecommunications permitting their identification are possible if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Board so determines in the preliminary or final notice of the meeting. Shareholders voting by proxy, mail, authorized intermediary or, if provided for in the preliminary or final notice of
the meeting by any means of telecommunications permitting them to be identified, will be considered to be present at the meeting for the computation of the quorum and the majority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A shareholder who has voted by correspondence will no longer be able to participate directly in the meeting or to be represented. In the case
of returning the proxy form and the voting by correspondence form, the proxy form is taken into account, subject to the votes cast in the voting by correspondence form. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Quorum </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For an ordinary
shareholders&#146; meeting to be quorate, <FONT STYLE="white-space:nowrap">one-fifth</FONT> of the holders of shares entitled to voting rights must be present in person or vote by mail or by proxy or by authorized intermediary or by any means of
telecommunication permitting their identification. An extraordinary shareholders&#146; meeting is quorate if <FONT STYLE="white-space:nowrap">one-fourth</FONT> of the holders of shares entitled to voting rights are present or vote by mail or by
proxy or by authorized intermediary or by any means of telecommunication. As an exception, an extraordinary shareholders&#146; meeting deciding upon a share capital increase by capitalization of reserves, profits or share premium has the same quorum
requirement as an ordinary shareholders&#146; meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the requirements for a quorum are not satisfied, the meeting is adjourned. When
an adjourned ordinary shareholders&#146; meeting is resumed, there is no quorum requirement. Extraordinary shareholders&#146; meetings require a quorum of <FONT STYLE="white-space:nowrap">one-fifth</FONT> of the holders of shares entitled to voting
rights. If a quorum is not present, the reconvened meeting may be adjourned for a maximum of two months. No deliberation by the shareholders may take place without a quorum. For special meetings of holders of a certain class of shares, the quorum
requirement is <FONT STYLE="white-space:nowrap">one-third</FONT> of the certain class of shares entitled to voting rights for the meeting convened on the first call. Should the special meeting be reconvened, the quorum requirement is <FONT
STYLE="white-space:nowrap">one-fifth</FONT> of the certain class of shares entitled to voting rights for the meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Majority </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A simple majority of shareholders may pass a resolution at either an ordinary shareholders&#146; meeting or an extraordinary shareholders&#146;
meeting deciding upon a share capital increase by capitalization of reserves, profits or share premium. At any other extraordinary shareholders&#146; meeting, a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of the shareholder votes
cast is required. A unanimous shareholder vote is required to increase shareholders&#146; liabilities. Abstention from voting by those present either in person or by means of telecommunications if provided for by the
<FONT STYLE="white-space:nowrap">by-laws,</FONT> or those represented by proxy or voting by mail is counted as a vote against the resolution submitted to a shareholder vote. In general, each shareholder is entitled to one vote per share at any
shareholders&#146; meeting. Under the French Commercial Code, shares of a company held by it or by entities controlled directly or indirectly by that company are not entitled to voting rights and do not count for quorum or majority purposes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financial Statements and Other Communications with Shareholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the annual ordinary shareholders&#146; meeting, we must provide or make available to any shareholder a set of documents
including, among other things, our annual report, the annual and consolidated accounts, the statutory auditors&#146; reports and a draft of the meeting&#146;s resolutions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The chairperson of the Board is required to deliver a special report to the annual ordinary shareholders&#146; meeting regarding the
composition of the Board, the representation of men and women in its composition, the status of the preparation and organization of the work of the Board, the status of the internal control procedures that we have implemented, including those in
connection with the treatment of the accounting and financial statements and principles and rules that it establishes to determine management compensation and benefits. French law requires that a special report be provided annually to the ordinary
shareholders&#146; meeting regarding stock options authorized and/or granted by the company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rights, Preferences and Restrictions Attaching to Ordinary Shares (Articles&nbsp;7, 11, 30, 31 and 32 of
the <FONT STYLE="white-space:nowrap">By-Laws)</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We only distribute dividends out of our &#147;distributable profits,&#148; plus any amounts filed in its reserves that the shareholders decide
to make available for distribution, other than those reserves that are specifically required by French law or our <FONT STYLE="white-space:nowrap">by-laws.</FONT> &#147;Distributable profits&#148; consist of our net profit in each fiscal year, as
increased or reduced by any profit or loss carried forward from prior years, less any contributions to the reserve accounts pursuant to French law or our <FONT STYLE="white-space:nowrap">by-laws.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Reserve </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law,
we are required to allocate 5% of our net income for each fiscal year, after reduction for losses carried forward from previous years, if any, to a legal reserve fund until the amount in the legal reserve is equal to 10% of the aggregate nominal
value of the share capital. The legal reserve subject to this requirement may only be used to offset losses when other reserves cannot be used and, in particular, may not be distributed to shareholders until our liquidation. As of December&nbsp;31,
2022, our legal reserve was &#128;0. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Approval of Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholders may decide in an ordinary shareholders&#146; meeting, upon proposal of the Board, to allocate all or part of the distributable
profits to special or general reserves, to carry them forward to the following fiscal year as retained earnings, or to allocate them to the shareholders as dividends. Dividends may be paid in cash or as shares upon the option of the shareholders if
such option is granted at the annual ordinary shareholders&#146; meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we have earned distributable profits since the end of the
preceding fiscal year, as reflected in an interim income statement certified by its auditors, the Board may distribute interim dividends to the extent of the distributable profits for the period covered by the interim income statement before
approval of the annual financial statements. Subject to French law, the Board may declare interim dividends paid in cash without obtaining shareholder approval. For interim dividends paid in shares, prior authorization by an ordinary
shareholders&#146; meeting is required. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Distribution of Dividends and Timing of Payment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In principle, dividends are distributed to shareholders pro rata according to their respective shareholdings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Timing of Payment </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, we
must pay any dividends within nine months of the end of our fiscal year, unless otherwise authorized by an order of the President of the French Commercial Court. Dividends on shares that are not claimed within five years of the date of declared
payment revert to the French State. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of interim dividends, distributions are made to shareholders on the date set by our Board
during the meeting in which the distribution of interim dividends is approved. The actual dividend payment date is decided by the shareholders at an annual shareholders&#146; meeting or by our Board in the absence of such a decision by the
shareholders. Shareholders that own shares on the actual payment date are entitled to the dividend. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholders may be granted an option
to receive dividends in cash or in shares, in accordance with legal conditions. The conditions for payment of dividends in cash shall be set at the shareholders&#146; meeting or, failing this, by the Board. </P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Increases in Share Capital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our share capital may only be increased by obtaining the approval of the shareholders at an extraordinary shareholders&#146; meeting upon the
recommendation of the Board. The decision to increase share capital through increases in the nominal value of existing shares requires unanimous approval at an extraordinary shareholders&#146; meeting. The decision to increase share capital through
the capitalization of reserves, profits and/or share premiums must be submitted to an extraordinary shareholders&#146; meeting applying the quorum and majority requirements applicable to ordinary shareholders&#146; meetings. In the case of an
increase in share capital in connection with the payment of a share dividend the voting and quorum procedures of an ordinary shareholders&#146; meetings apply. All other share capital increases require the approval of an extraordinary
shareholders&#146; meeting. See &#147;Description of Share Capital&#151;Shareholders&#146; Meetings and Voting Rights (Articles 6, 12 and 22 of the <FONT STYLE="white-space:nowrap">By-Laws)&#148;</FONT> above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Increases in our share capital may be effected by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issuing additional shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increasing the par value of existing shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">creating a new class of equity securities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exercising the rights attached to securities giving access to the share capital. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Increases in share capital by issuing additional securities may be effected through one or a combination of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in consideration for cash; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in consideration for assets contributed in kind; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through an exchange offer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by conversion of previously issued debt instruments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by capitalization of profits, reserves or share premium; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain conditions, by way of offset against debt incurred by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to certain conditions, shareholders may delegate the authority (<I>d&eacute;l&eacute;gation de comp&eacute;tence</I>) or the powers
(<I>d&eacute;l&eacute;gation de pouvoirs</I>) to carry out certain increases in our share capital to the Board following approval at an extraordinary shareholders&#146; meeting. The Board may further
<FONT STYLE="white-space:nowrap">sub-delegate</FONT> this right to the Chief Executive Officer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reduction in Share Capital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, any reduction in our share capital requires approval of the shareholders at an extraordinary shareholders&#146; meeting. The
share capital may be reduced either by decreasing the nominal value of the outstanding shares or by reducing the number of outstanding shares. The number of outstanding shares may be reduced by the repurchase and cancellation of the shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of each class of shares must be treated equally unless each affected shareholder agrees otherwise. As a general matter, reductions of
capital occur pro rata among all shareholders, except (i)&nbsp;in the case of a share buyback program, or a public tender offer to repurchase shares, where such a reduction occurs pro rata only among tendering shareholders and (ii)&nbsp;in the case
where all shareholders unanimously consent to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-pro-rata</FONT></FONT> reduction. In any case, we must not own more than 10% of our outstanding share capital. The extraordinary
shareholders&#146; meeting may authorize the <FONT STYLE="white-space:nowrap">buy-back</FONT> program for a period not exceeding 18 months. In addition, we may not cancel more than 10% of our outstanding share capital over any <FONT
STYLE="white-space:nowrap">24-month</FONT> period. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferential Subscription Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to French law, existing shareholders have preferential subscription rights to these securities on a pro rata basis if we issue
certain kinds of additional securities. These preferential subscription rights require us to give priority treatment to existing shareholders. The rights entitle the individual or entity that holds them to subscribe to an issue of any securities
that may increase our share capital by means of a cash payment or a settling of cash debts. Pursuant to legislation, which entered into force on October&nbsp;1, 2016, subscription rights are transferable during a period starting two days prior the
opening of the subscription period (or, if such day is not a business day, the preceding trading day) and ending two days prior the closing of the subscription period (or, if such day is not a business day, the preceding trading day). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of the shares entitled to vote at an extraordinary shareholders&#146; meeting
may vote to waive preferential subscription rights with respect to any particular offering or a portion of that offering. French law requires that the Board and our statutory auditors present reports that specifically address any proposal to waive
preferential subscription rights. In the event of a waiver, the issue of securities must be completed within the period prescribed by French law. The shareholders may also decide at an extraordinary shareholders&#146; meeting to give existing
shareholders a <FONT STYLE="white-space:nowrap">non-transferable</FONT> priority right to subscribe to such new securities during a limited period of time. Shareholders also may notify us that they wish to waive their own preferential subscription
rights with respect to any particular offering if they so choose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a share capital increase without preferential
subscription rights to existing shareholders, French law requires that the capital increase be made at a price equal to or exceeding the weighted-average market price of the shares in the three trading days preceding the setting of the price (such
weighted-average-market price may be reduced by a maximum discount of 5%). However, within the limit of 10% of the share capital per year, the extraordinary shareholders&#146; meeting may authorize the Board to set the issuing price in accordance
with terms established by the extraordinary shareholders&#146; meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Holding and Transfer of Shares (Articles 10 and 11 of the <FONT
STYLE="white-space:nowrap">By-Laws)</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Form of Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">by-laws</FONT> provide that the shares once fully paid may be held in registered or bearer form at the
option of the shareholder, subject to applicable laws. Shares not fully paid must be nominal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Holding of Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with French law, shareholders&#146; ownership rights are represented by book entries instead of share certificates. Shares issued
are registered in individual accounts opened by us or any authorized intermediary, in the name of each shareholder and kept according to the terms and conditions laid down by the legal and regulatory provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any owner of our shares may elect to have its shares held in registered form and registered in its name in an account currently maintained by
Uptevia, 12 place des Etats-Unis, CS 40083, 92549 Montrouge Cedex, France for and on our behalf or held in bearer form and recorded in its name in an account maintained by an accredited financial intermediary, such as a French broker, bank or other
authorized financial institution. Any shareholder may, at its expense, change from one form of holding to the other. Both methods are operated through Euroclear. In addition, according to French law, shares held by any
<FONT STYLE="white-space:nowrap">non-French</FONT> resident may be held on the shareholder&#146;s behalf in a collective account or in several individual accounts by an intermediary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When our shares are held in bearer form by a beneficial owner who is not a resident of France, Euroclear may agree to issue, upon our request,
a bearer depository receipt with respect to such shares for use only outside France. In this case, the name of the holder is deleted from the accredited financial intermediary&#146;s books. Title to the shares represented by a bearer depository
receipt will pass upon delivery of the relevant receipt outside France. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with applicable laws, we may request the information referred to in <FONT
STYLE="white-space:nowrap">Article&nbsp;L.228-2</FONT> of the French Commercial Code at any time from the central depository responsible for holding our shares. Thus, we are at any time entitled to request the name and year of birth or, in the case
of a legal entity, the name and the year of incorporation, nationality and address of the holders of our shares or other securities granting immediate or future voting rights, held in bearer form, and the number of shares or other securities so held
and, if applicable, the restrictions relating to such securities. Furthermore, under French law, any intermediary who acts on behalf of one or more persons who are not domiciled in France must declare that it is acting as an intermediary. We may
also request the identity of the shareholders on whose behalf it is acting. Consequently, the owner of shares recorded in a collective account or in several individual accounts by an intermediary will be represented in the shareholders&#146;
meetings by this intermediary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transfer of Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">by-laws</FONT> do not contain any restrictions relating to the transfer of shares. Shares are freely
negotiable, subject to applicable legal and regulatory provisions. French and European law provide for standstill obligations and prohibition of insider trading. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidation Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are liquidated,
any assets remaining after payment of our debts, liquidation expenses and all of our remaining obligations will be distributed first to repay in full the nominal value of our shares (up to the amount of the
<FONT STYLE="white-space:nowrap">paid-up</FONT> and <FONT STYLE="white-space:nowrap">non-liquidated</FONT> share capital). Any surplus will be distributed pro rata among shareholders in proportion to the nominal value of their shareholdings, taking
into account, where applicable, the rights attached to shares of different classes. Shareholders shall only bear losses up to the amount of their contributions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Disclosure Requirements for Holdings Exceeding Certain Thresholds </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Declaration of Crossing of Ownership Thresholds (Article 11.2 of the <FONT STYLE="white-space:nowrap">By-laws)</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to certain disclosure requirements under French law. Any individual or entity, acting alone or in concert with others, that
acquires, either directly or indirectly, shares representing more than 5%, 10%, 15%, 20%, 25%, 30%, 33<SUP STYLE="font-size:75%; vertical-align:top">&nbsp;1</SUP>/<SUB STYLE="font-size:75%; vertical-align:bottom">3</SUB>%, 50%, 66<SUP
STYLE="font-size:75%; vertical-align:top">&nbsp;2</SUP>/<SUB STYLE="font-size:75%; vertical-align:bottom">3</SUB>%, 90% or 95% of our outstanding share capital or voting rights or that increases or decreases its shareholding or voting rights above
or below any of those percentage thresholds, must notify us and the French Market Authority (<I>Autorit&eacute; des March&eacute;s </I><I>Financiers</I>) (&#147;AMF&#148;), within four trading days of the date on which such threshold was crossed.
French law and AMF regulations impose additional reporting requirements on persons who acquire more than 10%, 15%, 20% or 25% of the outstanding shares or voting rights of a listed company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a shareholder fails to comply with the notification requirements under French law, the shares or voting rights in excess of the relevant
threshold will be deprived of voting rights until the end of a <FONT STYLE="white-space:nowrap">two-year</FONT> period following the date on which the owner of such shares has complied with the notification requirements. They may also be suspended
for up to five years and may be subject to criminal fines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">by-laws</FONT> provide that any
shareholder, acting alone or in concert, who comes into possession, in any manner whatsoever, either directly or indirectly, of a number of shares representing 2% of our share capital and/or voting rights must, by registered letter with
acknowledgment of receipt sent to the registered office, or any other equivalent means for the shareholders or security holders residing outside of France, within five trading days of crossing such threshold, notify us of the total number of shares
and voting rights he or she owns and the number of securities he or she owns that give access to the capital and voting rights attached thereto. This disclosure requirement shall apply, under the conditions above, each time a new threshold of 2% of
capital and/or voting rights is met or exceeded, for whatever reason, including beyond the legal threshold of 5%. If the shares have not been reported under the above conditions, the shares exceeding the fraction that should have been
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reported are denied the right to vote in shareholders&#146; meetings, if at a shareholders&#146; meeting, the failure to report was recorded and if one or more shareholders holding together not
less than 5% of capital or voting rights so request at that meeting. The denial of voting rights applies to any shareholders&#146; meeting to be held until the expiration of a period of two years from the date of regularization of the reporting.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to publish the total number of voting rights and shares composing the share capital (if such numbers vary from the
numbers previously published) on a monthly basis. The AMF makes this information public. We are subject to AMF regulations regarding public tender offers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, and subject to certain exemptions, any shareholder crossing, alone or acting in concert, the 30% threshold shall file a mandatory
public tender offer with the AMF. Also, any shareholder holding directly or indirectly a number between 30% and 50% of the capital or voting rights and who, in less than 12 consecutive months, increases his/her/its holding of capital or voting
rights by at least 1% of the company&#146;s capital or voting rights, shall file a mandatory public tender offer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Treasury Shares and Purchases of our
Own Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not permitted to hold more than 10% of our share capital in treasury shares or to have more than 10% of our share
capital to be held for us by our subsidiaries. Treasury shares are not entitled to dividends, voting rights or preferential subscription rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Repurchase and Redemption of Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, we may acquire our own shares. Such acquisition may be challenged on the ground of market abuse regulations. However, EU
Market Abuse Regulation 596/2014 of April&nbsp;16, 2014 (&#147;MAR&#148;) provides for safe harbor exemptions when the acquisition is made for the following purposes only: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to decrease our share capital, provided that such a decision is not driven by losses and that a purchase offer is
made to all shareholders on a&nbsp;pro rata&nbsp;basis, with the approval of the shareholders at an extraordinary meeting. In this case, the shares repurchased must be cancelled within one month from the expiry of the purchase offer;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to meet obligations arising from debt securities that are exchangeable into equity instruments;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide shares for distribution to employees or managers under a profit-sharing, free share or share option
plan. In this case the shares repurchased must be distributed within 12 months from their repurchase failing which they must be cancelled; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under a <FONT STYLE="white-space:nowrap">buy-back</FONT> program to be authorized by the shareholders in
accordance with the provisions of Article <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L.&nbsp;22-10-62</FONT></FONT> of the French Commercial Code and in accordance with the general regulations of, and market practices accepted
by the AMF. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All other purposes, and especially share <FONT STYLE="white-space:nowrap">buy-backs</FONT> made for
external growth operations in pursuance of Article L. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">22-10-62</FONT></FONT> of the French Commercial Code, while not forbidden, must be pursued in strict compliance of market
manipulation and insider dealing rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under MAR and in accordance with the general regulations (<I>r&eacute;glement
g&eacute;n&eacute;ral</I>) of the AMF, or the General Regulations, a corporation shall report to the competent authority of the trading value on which the shares have been admitted to trading or are traded, no later than by the end of the seventh
daily market session following the date of the execution of the transaction, all the transactions relating to the <FONT STYLE="white-space:nowrap">buy-back</FONT> program, in a detailed form and in an aggregated form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No such repurchase of shares may result in us holding, directly or through a person acting on our behalf, more than 10% of our issued share
capital. Shares repurchased by us continue to be deemed &#147;issued&#148; under French law but are not entitled to dividends or voting rights so long as we hold them directly or indirectly, and we may not exercise the preferential subscription
rights attached to them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ownership of Shares by <FONT STYLE="white-space:nowrap">Non-French</FONT> Persons </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EU and <FONT STYLE="white-space:nowrap">non-EU</FONT> residents are required to file an administrative notice (<I>d&eacute;claration administrative</I>) with
the French authorities in connection with certain direct or indirect investments in us, including through ownership of ADSs, on the date a binding purchase agreement is executed or a tender offer is made public. Under existing administrative rulings
the following transactions qualify as foreign investments in us that require the filing of an administrative notice: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction carried out on our capital by a <FONT STYLE="white-space:nowrap">non-French</FONT> resident
provided that after the transaction the cumulative amount of the capital or the voting rights held by <FONT STYLE="white-space:nowrap">non-French</FONT> residents exceeds 1/3 of our capital or voting rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction mentioned above by a corporation incorporated under French law whose capital or voting rights are
held for more than 33.33% by <FONT STYLE="white-space:nowrap">non-French</FONT> residents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction carried out abroad resulting in a change of the controlling shareholder of a corporation
incorporated under a foreign law that holds a shareholding or voting rights in us if our capital or voting rights are held for more than 33.33% by <FONT STYLE="white-space:nowrap">non-French</FONT> residents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loans and guarantees granted by the acquirer to us in amounts evidencing control over our financing; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent licenses granted by an acquirer or management or technical assistance agreements with such acquirer that
place us in a dependent position <I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT></I> such party or its group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-French</FONT> residents must file a declaration for statistical purposes with the Bank of France
(<I>Banque de France</I>) within twenty working days following the date of certain direct foreign investments in us, including any purchase of our ADSs. In particular, such filings are required in connection with investments exceeding
&#128;15,000,000 that lead to the acquisition of at least 10% of our company&#146;s share capital or voting rights or cross such 10% threshold. Violation of this filing requirement may be sanctioned by five years of imprisonment and a fine up to
twice the amount of the relevant investment. This amount may be increased fivefold if the violation is made by a legal entity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Marketable Securities
that are Convertible, Exchangeable or Associated with a Share Warrant </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2023, we had issued several types of
founder&#146;s share warrants (BCE) as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Founder&#146;s Share Warrants (BCE) Plans: </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:6pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:5.5pt; font-family:Times New Roman; "><B>Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2014-1</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2014-2</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B><br><B><FONT STYLE="white-space:nowrap">2014-3</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2014-4</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2014-5</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2014-6</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2014-7</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2015-9</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B>(G)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2015-9</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B>(S)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2015-9</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B>(D)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2015-9</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B>(C)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2016-1</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2017-1</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2017-2</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B>BCE</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2017-3</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2017-4</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2017-5</FONT></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman"><B>Expiration date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">11/03/</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">2024</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">11/03/</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">2024</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:6pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">11/03/<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">2024</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:6pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/ 2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">11/03/</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">2024</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Null and void</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Null&nbsp;and void</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Null&nbsp;and void</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Null&nbsp;and void</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Null&nbsp;and void</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/11/2026</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23/01/2027</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20/11/2027</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20/11/2027</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20/11/2027</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20/11/2027</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman"><B>Subscription or purchase price (&#128;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman"><B>Exercise price per&nbsp;share&nbsp;(&#128;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.79</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.79</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.79</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.79</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.39</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman"><B>Exercise conditions</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Note&nbsp;(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Note&nbsp;(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">Achievement of objectives</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">Note (3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">Achievement of objectives</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">Note (4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">Achievement of objectives</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">Note (5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Note (6)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">Achievement of objectives</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">Note (7)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">Achievement of objectives Note (8)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">Achievement of objectives</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">Note (9)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">Achievement of objectives Note (10)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">Achievement of objectives Note (11)</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman"><B>Number of shares subscribed</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,400</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,800</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,700</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,006</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,426</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top" COLSPAN="15"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman"><B>Beneficiaries </B>(remaining number of shares that can be subscribed)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman"><B>Marc de Garidel</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman"><B>Other</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,495</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,373</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,374</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman"><B>Cumulative number of cancelled or lapsed BCEs</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,650</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,687</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,374</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,687</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,374</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,499</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,500</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,635</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman"><B>BCEs outstanding as of 30/06/2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">0</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">0</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,495</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">112,500</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,373</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,374</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman"><B>BCEs exercisable at 30/06/2023*</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">0</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">0</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,495</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">112,500</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,373</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,374</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-2</FONT></FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>BCE <FONT STYLE="white-space:nowrap">2018-3</FONT></B></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-4</FONT></FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-5</FONT></FONT></B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Expiration date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15/03/2028</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21/05/2028</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20/11/2028</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14/05/2028</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14/05/2028</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Subscription or purchase price (&#128;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Exercise price per share (&#128;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Terms of exercise</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Note (12)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Achievement of objectives Note (13)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right">Achievement of objectives</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="right">Note (14)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right">Achievement of objectives</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="right">Note (15)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Note (16)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Number of shares subscribed</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,930</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,916</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,843</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,750</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" COLSPAN="11"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Beneficiaries </B>(number of shares that can be subscribed)</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Marc de Garidel</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Others</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,980</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,844</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,843</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Cumulative number of cancelled or lapsed BCEs</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,090</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,458</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,250</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>BCEs outstanding at June 30, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,980</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,844</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,843</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>BCEs exercisable at June&nbsp;30, 2023*</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,980</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,844</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,843</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(*)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>The number of shares to which the exercise of the BSAs and BCEs entitles the holder has been multiplied by
100 for all BSAs and BCEs issued prior to the division by 100 of the nominal value of the shares, decided by our general meeting on February 20, 2015. According to the exercise conditions provided in the notes below and assuming that performance
objectives have been achieved.</I> </P></TD></TR></TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Service condition fully fulfilled on the date hereof. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Service condition fully fulfilled on the date hereof. BCE 2014-2 has a warrant to share ratio of 1:100.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">BCE 2014-4 has a warrant to share ratio of 1:100. 246 BCE-2014-4 are exercisable subject to a service condition,
which is fully fulfilled on the date hereof. 369 BCE-2014-4 are exercisable exclusively in the event of the achievement of qualitative and/or quantitative objectives <FONT STYLE="white-space:nowrap">(non-market</FONT> conditions), as set by the
Board on September&nbsp;8, 2014. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">197 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2014-6</FONT></FONT> are exercisable
subject to a service condition, which is fully fulfilled on the date hereof. 328 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2014-6</FONT></FONT> are exercisable exclusively in the event of the achievement of qualitative
and/or quantitative objectives <FONT STYLE="white-space:nowrap">(non-market</FONT> conditions), as set by the Board on September&nbsp;8, 2014 and revised on November&nbsp;20, 2017. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">50% of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2014-7</FONT></FONT> granted to
each beneficiary are exercisable subject to a presence condition, which is fully fulfilled on the date hereof. 50% of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2014-7</FONT></FONT> are exercisable exclusively in the
event of the achievement of qualitative and/or quantitative objectives <FONT STYLE="white-space:nowrap">(non-market</FONT> conditions), as set by the Board on September&nbsp;8, 2014. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Service condition fully fulfilled on the date hereof. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">33,687 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-1</FONT></FONT> are
exercisable subject to a service condition, which is fully fulfilled on the date hereof, 16,844 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-1</FONT></FONT> are exercisable exclusively in the event of achievement of the
qualitative objectives <FONT STYLE="white-space:nowrap">(non-market</FONT> conditions) set by the Board, and 16,843 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-1</FONT></FONT> are exercisable exclusively in the event
of achievement of the quantitative targets (market conditions) set by the Board. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><B></B>75,000 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-2</FONT></FONT> are
exercisable subject to a service condition, which is fully fulfilled on the date hereof: and <B></B>75,000 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-2</FONT></FONT> are exercisable exclusively in the event of the
achievement of qualitative objectives <FONT STYLE="white-space:nowrap">(non-market</FONT> conditions) set by the Board. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><B></B>50,531 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-3</FONT></FONT> are
exercisable subject to a service condition, which is fully fulfilled on the date hereof, and <B></B>50,530 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-3</FONT></FONT> are exercisable exclusively in the event of the
achievement of qualitative objectives <FONT STYLE="white-space:nowrap">(non-market</FONT> conditions) set by the Board. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><B></B>33,687 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-4</FONT></FONT> are
exercisable subject to a service condition, which is fully fulfilled on the date hereof, and <B></B>33,687 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-4</FONT></FONT> are exercisable exclusively in the event of the
achievement of qualitative objectives <FONT STYLE="white-space:nowrap">(non-market</FONT> conditions) set by the Board. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">16,843 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-5</FONT></FONT> are
exercisable subject to a service condition, which is fully fulfilled on the date hereof, and 16,844 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-5</FONT></FONT> are exercisable exclusively in the event of the
achievement of qualitative objectives <FONT STYLE="white-space:nowrap">(non-market</FONT> conditions) set by the Board. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Service condition fully fulfilled on the date hereof. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">33,686 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-2</FONT></FONT> are
exercisable subject to a service condition, which is fully fulfilled on the date hereof, and <B></B>33,686 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-2</FONT></FONT> are exercisable exclusively in case of achievement
of qualitative objectives <FONT STYLE="white-space:nowrap">(non-market</FONT> conditions) set by the Board. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">16,843 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT> are
exercisable subject to a service condition, which is fully fulfilled on the date hereof, and 16,844 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT> are exercisable exclusively in the event of the
achievement of qualitative objectives <FONT STYLE="white-space:nowrap">(non-market</FONT> conditions) set by the Board. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">8,422 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-4</FONT></FONT> are exercisable
subject to a service condition, which is fully fulfilled on the date hereof, and 8,421 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-4</FONT></FONT> are exercisable exclusively in the event of the achievement of
qualitative objectives <FONT STYLE="white-space:nowrap">(non-market</FONT> conditions) set by the Board. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Service condition fully fulfilled on the date hereof. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>General note</U>: all of our BCE plans provide for specific cases of acceleration resulting in the exercise of said BCEs in the event of the occurrence of
specific events and in particular in the event of a change of control of us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2023, we had issued several types of share warrants (BSA) as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share Warrants (BSA) Plans: </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:6pt; font-family:Times New Roman; "><B>Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-&nbsp;1</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-&nbsp;2</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-&nbsp;3</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014&nbsp;-4</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-&nbsp;5</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-&nbsp;6</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-&nbsp;7</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2015-&nbsp;9</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">BSA-2015</FONT></B><br><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">-&nbsp;11-&nbsp;
Sant&eacute;</FONT></FONT></B><br><B>Holdings</B><br><B>SRL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2015-&nbsp;12</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2017-&nbsp;1</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2018-&nbsp;1</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2018-&nbsp;2</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Date of general meeting</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20/02/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20/02/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20/02/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23/06/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23/06/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23/06/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Date of Board meeting</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21/02/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21/02/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21/02/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21/02/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21/02/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21/02/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21/02/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14/09/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">04/12/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">04/12/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18/09/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22/01/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14/05/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Date of decision of the Chief Executive Officer</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" COLSPAN="52"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Total number of shares that may be subscribed or purchased (<SUP
STYLE="font-size:75%; vertical-align:top">*</SUP>)&nbsp;:</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:7pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Sant&eacute; Holding SRL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Corinna zur Bonsen-Thomas</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Carol L. Brosgart</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Others</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(*)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">The number of shares to which the exercise of the BSAs and BCEs entitles the holder has been multiplied by 100
for all BSAs and BCEs issued prior to the division by 100 of the nominal value of the shares, decided by our general meeting on February&nbsp;20, 2015. Consequently, BSA 2014-3, BSA 2014-4 and BSA 2014-5 have a warrant to share ratio of 1:100.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:6pt; font-family:Times New Roman; "><B>Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-</FONT></FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-</FONT></FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-</FONT></FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-4</FONT></FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-&nbsp;2014-5</FONT></FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BSA-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2014-6</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BSA-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2014-7</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BSA-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2015-9</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BSA-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2015-11-</FONT></FONT><BR>Sant&eacute;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Holding</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>SRL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BSA-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2015-12</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BSA-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2017-1</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BSA-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2018-1</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BSA-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2018-2</FONT></B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Starting date for exercising options</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">According to&nbsp;the achievement of criteria (see Terms of exercise)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">According to the achievement of criteria (see Terms of exercise)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">According to the achievement of criteria (see Terms of exercise)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">According to&nbsp;the achievement of criteria (see Terms of exercise)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">According to&nbsp;the achievement of criteria (see Terms of exercise)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14/09/2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/12/2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">04/12/2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18/09/2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22/01/2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14/05/2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Expiry date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14/09/2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">04/12/2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">04/12/2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18/09/2027</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22/01/2028</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14/05/2028</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="13" ALIGN="center"><B>or at the end of a period of 90 days following the date on which the beneficiary ceases<BR>to work for us</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="11" ALIGN="center"><B>or at the end of 90 days following the expiration of the<BR>beneficiary&#146;s mandate</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Subscription or purchase price&nbsp;(&#128;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.07</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.78</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.78</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.29</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.90</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.73</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Exercise price per share&nbsp;(&#128;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.73</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.79</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.79</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.57</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.05</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.60</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Terms of exercise</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Note (1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="right">Achievement of objectives</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="right">Note (2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="right">Achievement of objectives</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="right">Note (3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Note (4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Note (5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Note (6)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Note (7)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Note (8)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Number of shares subscribed</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,400</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,800</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,340</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,200</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,100</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Cumulative number of BSA or BCE cancelled or lapsed</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,274</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,600</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,800</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>BSAs as of June 30, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">842</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,924</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>BSA potentially exercisable as of June&nbsp;30 2023,*</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">842</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,924</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(*)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">The number of shares to which the exercise of the BSAs and BCEs entitles the holder has been multiplied by 100
for all BSAs and BCEs issued prior to the division by 100 of the nominal value of the shares, decided by our general meeting on February 20, 2015. According to the exercise conditions provided in the notes below and assuming that the objectives have
been achieved. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Progressive vesting in time fully vested on the date hereof. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">263 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-4</FONT></FONT> are exercisable
at any time as from March&nbsp;11, 2014. 1,052 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-4</FONT></FONT> are exercisable exclusively in the event of the achievement of qualitative and/or quantitative objectives <FONT
STYLE="white-space:nowrap">(non-market</FONT> conditions), as set by the Board on September&nbsp;8, 2014. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Exercisable by their beneficiary according to the exercise conditions set by the Board on September&nbsp;8,
2014. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Progressive vesting in time fully vested on the date hereof. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Progressive vesting in time fully vested on the date hereof. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Progressive vesting in time fully vested on the date hereof. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Progressive vesting in time fully vested on the date hereof. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Progressive vesting in time fully vested on the date hereof. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Differences in Corporate Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The laws applicable to French<I></I><I>&nbsp;soci&eacute;t&eacute;s anonymes</I><I></I>&nbsp;(limited liability companies) differ from laws
applicable to U.S. corporations and their shareholders. Set forth below is a summary of certain differences between the provisions of the French Commercial Code applicable to us and the Delaware General Corporation Law relating to shareholders&#146;
rights and protections. This summary is not intended to be a complete discussion of the respective rights, and it is qualified in its entirety by reference to Delaware law and French law. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>FRANCE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DELAWARE</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Number of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under&nbsp;French&nbsp;law,&nbsp;a<I>&nbsp;soci&eacute;t&eacute;&nbsp;anonyme</I><I></I>&nbsp;must have at least three and may have up to 18 directors. The number of directors is fixed by or in the manner provided in the <FONT
STYLE="white-space:nowrap">by-laws.</FONT> The number of directors of each gender may not be less than 40%. In case a board of directors comprises up to eight members, the difference between the number of directors of each gender may not exceed two.
Any appointment made in violation of this limit that is not remedied within six months of this appointment will be null and void and payment of directors&#146; compensation will be suspended.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, a corporation must have at least one director and the number of directors shall be fixed by or in the manner provided in the <FONT STYLE="white-space:nowrap">by-laws</FONT> (unless specified in the certificate of
incorporation of the corporation).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Director Qualifications</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under French law, a corporation may prescribe qualifications for directors under its <FONT STYLE="white-space:nowrap">by-laws.</FONT> In addition, under French law, members of a board of directors may be legal entities, and such
legal entities must designate an individual to represent them and to act on their behalf at meetings of the board of directors.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, a corporation may prescribe qualifications for directors under its certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Removal of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under French law, directors may be removed from office, with or without cause, at any shareholders&#146; meeting without notice or justification, by a simple majority vote of the shareholders present and voting at the meeting in
person or by proxy.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, unless otherwise provided in the certificate of incorporation, directors may be removed from office, with or without cause, by a majority stockholder vote, though in the case of a corporation whose board is
classified, shareholders may effect such removal only for cause.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Vacancies on the board of directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under&nbsp;French&nbsp;law,&nbsp;vacancies&nbsp;on&nbsp;the board of directors resulting from death or a resignation, provided that at least three directors remain in office, may be filled by a majority of the remaining directors
pending ratification by the shareholders by the next shareholders&#146; meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, vacancies on a corporation&#146;s board of directors, including those caused by an increase in the number of directors, unless otherwise provided in the certificate of incorporation, may be filled by the board of
directors or other governing body.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>FRANCE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DELAWARE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Annual Shareholders&#146; Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under French law, the annual shareholders&#146; meeting shall be held at such place, on such date and at such time as decided each year by the board of directors and notified to the shareholders in the convening notice of the annual
meeting, within six months after the close of the relevant fiscal year unless such period is extended by court order.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, the annual meeting of stockholders shall be held at such place, on such date and at such time as may be designated from time to time by the board of directors or as provided in the certificate of incorporation or
by the <FONT STYLE="white-space:nowrap">by-laws.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shareholders&#146; Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under French law, shareholders&#146; meetings may be called by the board of directors or, failing that, by the statutory auditors, or by a court appointed agent or liquidator in certain circumstances, or by the majority shareholder
in capital or voting rights following a public tender offer or exchange offer or the transfer of a controlling block on the date decided by the board of directors or the relevant person.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, special meetings of the stockholders may be called by the board of directors or by such person or persons as may be authorized by the certificate of incorporation or by the
<FONT STYLE="white-space:nowrap">by-laws.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Notice of Shareholders&#146; Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">A meeting notice (<I>avis de r&eacute;union</I>) is published in the <I>Bulletin des annonces l&eacute;gales obligatoires </I>(&#147;BALO&#148;), at least 35 days prior to a meeting and made available on the website of the company
at least 21&nbsp;days prior to the meeting. Additionally, a convening notice (<I>avis de convocation</I>) is published at least 15&nbsp;days prior to the date of the meeting, in a legal announcement bulletin of the registered office department and
in the BALO. Further, the holders of registered shares (<I>actions nominatives</I>) for at least a month at the time of the convening notice shall be summoned individually, by regular letter (or by registered letter if they request it and include an
advance of expenses) sent to their last known address. This notice may also be transmitted by electronic means of telecommunication, in lieu of any such mailing, to any shareholder requesting it beforehand by registered letter with acknowledgment of
receipt in accordance with legal and regulatory requirements, specifying his <FONT STYLE="white-space:nowrap">e-mail</FONT> address.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, unless otherwise provided in the certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws,</FONT> written notice of any meeting of the stockholders must be given to each stockholder entitled to
vote at the meeting not less than ten nor more than 60 days before the date of the meeting and shall specify the place, date, hour, means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person
and vote, the record date for voting if it is different from the record date determining notice and, in the case of a special meeting, purpose or purposes of the meeting.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The meeting notice must also indicate the conditions under which the shareholders may vote by correspondence, the places and conditions in which they can obtain voting forms, and as the case may be, the <FONT
STYLE="white-space:nowrap">e-mail</FONT> address to which they may send written questions.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>FRANCE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DELAWARE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Proxy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Each shareholder has the right to attend the meetings and participate in the discussions (i)&nbsp;personally, (ii) by granting proxy to any individual or legal entity of his choosing, (iii)&nbsp;by sending a proxy to the company
without indication of the mandate (in which case such proxy shall be cast in favor of the resolutions supported by the board of directors), (iv) by voting by correspondence or (v)&nbsp;by videoconference or another means of telecommunication
allowing identification in accordance with applicable laws. The proxy is only valid for a single meeting or for successive meetings convened with the same agenda. It can also be granted for two meetings, one ordinary the other extraordinary, held on
the same day or within a period of 15 days.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, at any meeting of stockholders, a stockholder may designate another person to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy
provides for a longer period.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shareholder Action by Written Consent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under French law, shareholders&#146; action by written consent is not permitted in a<I>&nbsp;soci&eacute;t&eacute; anonyme.</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, a corporation&#146;s certificate of incorporation (i)&nbsp;may permit stockholders to act by written consent if such action is signed by all stockholders, (ii)&nbsp;may permit stockholders to act by written
consent signed by stockholders having the minimum number of votes that would be necessary to take such action at a meeting or (iii)&nbsp;may prohibit actions by written consent.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Preferential Subscription Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under French law, in case of issuance of additional shares or other securities for cash or <FONT STYLE="white-space:nowrap">set-off</FONT> against cash debts, the existing shareholders have preferential subscription rights to these
securities on a pro rata basis unless such rights are waived by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes held by</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, unless otherwise provided in a corporation&#146;s certificate of incorporation, a stockholder does not, by operation of law, possess preemptive rights to subscribe to additional issuances of the
corporation&#146;s stock.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the shareholders present at the extraordinary meeting deciding or authorizing the capital increase, voting in person or represented by proxy or voting by mail. In case such rights are not waived by the extraordinary general meeting,
each shareholder may individually either exercise, assign or not exercise its preferential subscription rights.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>FRANCE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DELAWARE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sources of Dividends</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under French law, dividends may only be paid by a French<I>&nbsp;soci&eacute;t&eacute; anonyme</I>&nbsp;out of &#147;distributable
profits,&#148; plus any distributable reserves and &#147;distributable premium&#148; that the shareholders decide to make available for distribution, other than those reserves that are specifically required
<FONT STYLE="white-space:nowrap">by-law.</FONT> &#147;Distributable profits&#148; consist of the unconsolidated net profits of the relevant corporation for each fiscal year, as increased or reduced by any profit or loss carried forward from prior
years, minus the amounts to be set aside to the statutory reserve (at least 5% of the profit until the reserve has reached 10% of the amount of the share capital) and to the reserve set forth in the company&#146;s
<FONT STYLE="white-space:nowrap">by-laws</FONT> (if any).</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Distributable
premium&#148; refers to the contribution paid by the shareholders in addition to the par value of their shares for their subscription that the shareholders decide to make available for distribution.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Except in the case of a share capital reduction, no distribution can be made to the
shareholders when the net equity is, or would become, lower than the amount of the share capital plus the reserves which cannot be distributed in accordance with the law or the <FONT STYLE="white-space:nowrap">by-laws.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, dividends may be paid by a Delaware corporation either out of (i)&nbsp;surplus, as defined in and computed in accordance with Delaware law, or (ii)&nbsp;in case there is no surplus, out of its net profits for the
fiscal year in which the dividend is declared and/or the preceding fiscal year, except when the capital is diminished by depreciation in the value of its property, or by losses or otherwise, to an amount less than the aggregate amount of capital
represented by issued and outstanding stock having a preference on the distribution of assets.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Repurchase of Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under French law, a corporation may acquire its own shares. Such acquisition may be challenged on the ground of market abuse regulations.
However, MAR provides for safe harbor exemptions when the acquisition is made for the following purposes only:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;to&nbsp;decrease&nbsp;its&nbsp;share&nbsp;capital, provided that such decision is not driven by
losses and that a purchase offer is made to all shareholders on a pro rata basis, with the approval of the shareholders at the extraordinary general meeting deciding the capital reduction; or to meet obligations arising from debt securities, that
are exchangeable into equity instruments.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Delaware law, a corporation may generally redeem or repurchase shares of its stock unless the capital of the corporation is impaired or
such redemption or repurchase would impair the capital of the corporation.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">No such
repurchase of shares may result in the company holding, directly or through a person acting on its behalf, more than 10% of its issued share capital.</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>FRANCE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DELAWARE</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;with a view to distributing within one year of their repurchase the relevant
shares to employees or managers under a profit-sharing, free share or share option plan; or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;under a <FONT STYLE="white-space:nowrap">buy-back</FONT> program to be authorized by the
shareholders in accordance with the provisions of Article L. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">22-10-62</FONT></FONT> of the French Commercial Code and in accordance with the general regulations of the AMF.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All other purposes, and especially share
<FONT STYLE="white-space:nowrap">buy-backs</FONT> for external growth operations by virtue of Article L. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">22-10-62</FONT></FONT> of the French Commercial Code, while not forbidden,
must be pursued in strict compliance of market manipulations and insider dealing rules.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No such repurchase of shares may result in the company holding, directly or through a person acting on its behalf, more than 10% of its issued share
capital.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under MAR and in accordance with the General Regulations, a corporation
shall report to the competent authority of the trading venue on which the shares have been admitted to trading or are traded, no later than by the end of the seventh daily market session following the date of the execution of the transaction, all
the transactions relating to the <FONT STYLE="white-space:nowrap">buy-back</FONT> program, in a detailed form and in an aggregated form.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Liability of Directors and Officers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under French law, the <FONT STYLE="white-space:nowrap">by-laws</FONT> may not include any provisions limiting the liability of directors.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Delaware law, a corporation&#146;s certificate of incorporation may include a provision eliminating or limiting the personal liability
of a director to the corporation and its stockholders for damages arising from a breach of fiduciary duty as a director. However, no provision can limit the liability of a director for:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;any breach of the
director&#146;s duty of loyalty to the corporation or its stockholders;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;acts or omissions not in good faith or that involve intentional misconduct or a knowing violation
of law;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;intentional or
negligent payment of unlawful dividends or stock purchases or redemptions; or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;any transaction from which the director derives an improper personal
benefit.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>FRANCE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DELAWARE</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Voting Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">French law provides that, unless otherwise provided in the <FONT STYLE="white-space:nowrap">by-laws,</FONT> each shareholder is entitled to one vote for each share of share capital held by such shareholder. Further, pursuant to the
introduction of Law <FONT STYLE="white-space:nowrap">No.&nbsp;2014-384</FONT> dated March&nbsp;29, 2014 (<I>Loi Florange</I>), shares registered for more than two years in the name of the same shareholder are automatically be granted double voting
rights from 2016, unless the <FONT STYLE="white-space:nowrap">by-laws</FONT> expressly reject this measure.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware law provides that, unless otherwise provided in the certificate of incorporation, each stockholder is entitled to one vote for each share of capital stock held by such stockholder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shareholder Vote on Certain Transactions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, under French law, completion of a merger, dissolution or sale or exchange of all or substantially all of a corporation&#146;s
assets (<I>apport partiel d&#146;actifs</I>) requires:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the approval of the board of directors; and</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;approval by a <FONT
STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes held by the shareholders present, represented by proxy or voting by mail at the relevant meeting or, in the case of a merger with a <FONT STYLE="white-space:nowrap">non-EU</FONT>
company, approval of all shareholders of the corporation.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, under Delaware law, unless the certificate of incorporation pro</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">vides for the vote of a larger portion of shares, completion of a merger, consolidation, sale, lease or exchange of all or substantially all of a
corporation&#146;s assets or dissolution requires:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the approval of the board of directors; and</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;approval by the vote of the
holders of a majority of the outstanding stock or, if the certificate of incorporation provides for more or less than one vote per share, a majority of the votes of the outstanding stock of a corporation entitled to vote on the matter.</P></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dissent or Dissenters Appraisal Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">French law does not provide for any such right but provides that a merger is subject to shareholders&#146; approval by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority vote, as stated above.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, a holder of shares of any class or series has the right, in specified circumstances, to dissent from a merger or consolidation by demanding payment in cash for the stockholder&#146;s shares equal to the fair
value of those shares, as determined by the Delaware Chancery Court in an action timely brought by the corporation or a dissenting stockholder. Delaware law grants these appraisal rights only in the case of mergers or consolidations and not in the
case of a sale or transfer of assets or a purchase of</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">assets for shares. Further, no appraisal rights are available for shares of any class or series that is listed on a national securities
exchange or held of record by more than 2,000 stockholders, unless the agreement of merger or consolidation requires the holders to accept for their shares anything other than:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;shares of stock of the surviving
corporation;</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>FRANCE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DELAWARE</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;shares of another corporation that are either listed on a national securities
exchange or held of record by more than 2,000 stockholders;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;cash in lieu of fractional shares of the stock described in the two preceding bullet points;
or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;any combination of the
above.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In addition, appraisal rights are not available to holders of shares of the
surviving corporation in specified mergers that do not require the vote of the stockholders of the surviving corporation.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Standard of Conduct for Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">French law does not contain specific provisions setting forth the standard of conduct of a director. However, directors have a duty to act without self-interest, on a well-informed basis, and not to take any decision against a
corporation&#146;s corporate interest (<I>int&eacute;r&ecirc;t social</I>).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware law does not contain specific provisions setting forth the standard of conduct of a director. The scope of the fiduciary duties of directors is generally determined by the courts of the State of Delaware. In general,
directors have a duty to act without self-interest, on a well-informed basis and in a manner they reasonably believe to be in the best interest of the stockholders.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shareholder Suits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">French law provides that a shareholder, or a group of shareholders, may initiate a legal action to seek indemnification from the directors of
a corporation in the corporation&#146;s interest if it fails to bring such legal action itself. If so, any damages awarded by the court are paid to the corporation and any legal fees relating to such action are borne by the relevant shareholder or
the group of shareholders.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The plaintiff must remain a shareholder through the
duration of the legal action.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no other case where shareholders may initiate a derivative action to enforce a right of a corporation.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">A shareholder may alternatively or cumulatively bring individual legal action against
the directors, provided he has suffered distinct damages from those suffered by the corporation. In this case, any damages awarded by the court are paid to the relevant shareholder.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Delaware law, a stockholder may initiate a derivative action to enforce a right of a corporation if the corporation fails to enforce
the right itself. The complaint must:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff
complains or that the plaintiff&#146;s shares thereafter devolved on the plaintiff by operation of law; and</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;allege with particularity the efforts made by the plaintiff to obtain the action the plaintiff
desires from the directors and the reasons for the plaintiff&#146;s failure to obtain the action; or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;state the reasons for not making the effort.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Additionally, the plaintiff
must remain a stockholder through the duration of the derivative suit. The action will not be dismissed or compromised without the approval of the Delaware Court of Chancery.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>FRANCE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DELAWARE</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amendment of Certificate of Incorporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unlike companies incorporated under Delaware law, the organizational documents, which comprise both a certificate of incorporation and <FONT
STYLE="white-space:nowrap">by-laws,</FONT> companies incorporated under French law only have <FONT STYLE="white-space:nowrap">by-laws</FONT> (<I>statuts</I>) as organizational documents.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">As indicated in the paragraph below, only the extraordinary shareholders&#146; meeting
is authorized under French law to adopt or amend the <FONT STYLE="white-space:nowrap">by-laws.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Delaware law, generally a corporation may amend its certificate of incorporation if:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;its board of directors has
adopted a resolution setting forth the amendment proposed and declared its advisability; and</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the amendment is adopted by the affirmative votes of a majority (or greater percentage as may be
specified by the corporation) of the outstanding shares entitled to vote on the amendment and a majority (or greater percentage as may be specified by the corporation) of the outstanding shares of each class or series of stock, if any, entitled to
vote on the amendment as a class or series.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amendment of <FONT STYLE="white-space:nowrap">by-laws</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under French law, only the extraordinary shareholders&#146; meeting is authorized to adopt or amend the <FONT STYLE="white-space:nowrap">by-laws</FONT> <FONT STYLE="white-space:nowrap">(two-thirds</FONT> majority). The extraordinary
shareholders&#146; meeting may authorize the board of directors to amend the <FONT STYLE="white-space:nowrap">by-laws</FONT> to comply with legal provisions, subject to the ratification of such amendments by the next extraordinary shareholders&#146;
meeting. The board of directors is authorized to amend the <FONT STYLE="white-space:nowrap">by-laws</FONT> as a result of a decision to relocate the company&#146;s registered office in France, subject to ratification by the next ordinary
shareholders&#146; meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, the stockholders entitled to vote have the power to adopt, amend or repeal <FONT STYLE="white-space:nowrap">by-laws.</FONT> A corporation may also confer, in its certificate of incorporation, that power upon the
board of directors.</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied to list our ADSs on the Nasdaq Global Market under the symbol &#147;ABVX.&#148; Our ordinary shares are currently listed on
Euronext Paris under the symbol &#147;ABVX.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_18"></A>LIMITATIONS AFFECTING SHAREHOLDERS OF A FRENCH COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ownership of ADSs by <FONT STYLE="white-space:nowrap">Non-French</FONT> Residents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the French Commercial Code nor our <FONT STYLE="white-space:nowrap">by-laws</FONT> currently impose any restrictions on the right of <FONT
STYLE="white-space:nowrap">non-French</FONT> residents or <FONT STYLE="white-space:nowrap">non-French</FONT> shareholders to own and vote shares. However, <FONT STYLE="white-space:nowrap">non-French</FONT> residents must file a declaration for
statistical purposes with the Bank of France (<I>Banque de France</I>) within 20 working days following the date of certain direct foreign investments in us, including any purchase of our ADSs. In particular, such filings are required in connection
with investments exceeding &#128;15,000,000 that lead to the acquisition of at least 10% of our share capital or voting rights or cross such 10% threshold. Violation of this filing requirement may be sanctioned by five years of imprisonment and a
fine of up to twice the amount of the relevant investment. This amount may be increased fivefold if the violation is made by a legal entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, any investment: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)
by (a)&nbsp;any <FONT STYLE="white-space:nowrap">non-French</FONT> citizen, (b)&nbsp;any French citizen not residing in France, (c)&nbsp;any <FONT STYLE="white-space:nowrap">non-French</FONT> entity or (d)&nbsp;any French entity controlled by one of
the aforementioned persons or entities; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) that will result in the relevant investor (a)&nbsp;acquiring control of an entity registered
in France, (b)&nbsp;acquiring all or part of a business line of an entity registered in France, or (c)&nbsp;for <FONT STYLE="white-space:nowrap">non-EU</FONT> or <FONT STYLE="white-space:nowrap">non-EEA</FONT> investors crossing, directly or
indirectly, alone or in concert, a 25% threshold of voting rights in an entity registered in France; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) developing activities in
certain strategic industries related to (a)&nbsp;activity likely to prejudice national defense interests, participating in the exercise of official authority or are likely to prejudice public policy and public security (including weapons, <FONT
STYLE="white-space:nowrap">double-use</FONT> items, IT systems, cryptology, date capturing devices, gambling, toxic agents or storage of data), (b) activities relating to essential infrastructure, goods or services (including energy, water,
transportation, space, telecom, public health, farm products or media), and (c)&nbsp;research and development activity related to critical technologies (including cybersecurity, artificial intelligence, robotics, additive manufacturing,
semiconductors, quantum technologies, energy storage or biotechnology) or <FONT STYLE="white-space:nowrap">dual-use</FONT> items, is subject to the prior authorization of the French Ministry of Economy, which authorization may be conditioned on
certain undertakings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Decree (<I>d&eacute;cret</I>) No.&nbsp;2020 892 dated July&nbsp;22, 2020, as amended on December&nbsp;28, 2020
by the Decree No.&nbsp;2020-1729 on December&nbsp;22, 2021 by the Decree No.&nbsp;2021-1758, and lastly on December 23, 2022 by the Decree <I>(d&#233;cret)</I> n&deg; 2022-1622 has implemented a 10% threshold of the voting rights for the non-EU/EEA
investments made (i)&nbsp;in an entity incorporated under the laws of France and (ii)&nbsp;whose shares are admitted to trading on a regulated market, in addition to the 25% above-mentioned threshold. Set to expire on December 31, 2023, this 10%
threshold could become permanent. The transactions falling within the scope of the Decree <I>(d&#233;cret)</I> No. 2020-892, as amended, benefit from a &#147;fast-track procedure&#148; pursuant to which the investor is exempt from the authorization
request provided for in Article R. 151-5 of the Monetary and Financial Code, provided that the investment project has been the subject of prior notification to the French Minister of Economy and that the transaction is carried out within six months
following the notification. Unless the French Minister of Economy objects, the authorization is granted at the end of a period of ten working days following notification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the absence of such authorization, the relevant investment shall be deemed null and void. The relevant investor may be found criminally
liable and may be sanctioned with a fine not to exceed the greater of the following amounts: (i)&nbsp;twice the amount of the relevant investment, (ii) 10% of the annual turnover before tax of the target company or (iii) &#128;5&nbsp;million (for a
company) or &#128;1&nbsp;million (for a natural person). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Exchange Controls </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under current French foreign exchange control regulations there are no limitations on the amount of cash payments that we may remit to
residents of foreign countries. Laws and regulations concerning foreign exchange controls do, however, require that all payments or transfers of funds made by a French resident to a <FONT STYLE="white-space:nowrap">non-resident</FONT> such as
dividend payments be handled by an accredited intermediary. All registered banks and substantially all credit institutions in France are accredited intermediaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_19"></A>DESCRIPTION OF AMERICAN DEPOSITARY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Citibank, N.A. has agreed to act as the depositary bank for the American Depositary Shares. Citibank&#146;s depositary offices are located at
388 Greenwich Street, New York, New York 10013. American Depositary Shares are frequently referred to as &#147;ADSs&#148; and represent ownership interests in securities that are on deposit with the depositary bank. ADSs may be<B> </B>represented by
certificates that are commonly known as &#147;American Depositary Receipts&#148; or &#147;ADRs.&#148; The depositary bank typically appoints a custodian to safekeep the securities on deposit. In this case, the custodian is Citibank Europe plc
located at 1 North Wall Quay, Dublin 1, Ireland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will appoint Citibank as depositary bank pursuant to a deposit agreement. A copy of
the deposit agreement is on file with the SEC under cover of a Registration Statement on Form <FONT STYLE="white-space:nowrap">F-6.</FONT> You may obtain a copy of the deposit agreement from the SEC&#146;s Public Reference Room at 100 F Street,
N.E., Washington, D.C. 20549 and from the SEC&#146;s website (www.sec.gov). Please refer to Registration Number <FONT STYLE="white-space:nowrap">333-&#8195;</FONT> when retrieving such copy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are providing you with a summary description of the material terms of the ADSs and of your material rights as an owner of ADSs. Please
remember that summaries by their nature lack the precision of the information summarized and that the rights and obligations of an owner of ADSs will be determined by reference to the terms of the deposit agreement and not by this summary. We urge
you to review the deposit agreement in its entirety. The portions of this summary description that are italicized describe matters that may be relevant to the ownership of ADSs but that may not be contained in the deposit agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each ADS represents the right to receive, and to exercise the beneficial ownership interests in, one ordinary share that is on deposit with
the depositary bank and/or custodian. An ADS also represents the right to receive, and to exercise the beneficial interests in, any other property received by the depositary bank or the custodian on behalf of the owner of the ADS but that has not
been distributed to the owners of ADSs because of legal restrictions or practical considerations. We and the depositary bank may agree to change the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-Share</FONT></FONT> ratio
by amending the deposit agreement. This amendment may give rise to, or change, the depositary fees payable by ADS owners. The custodian, the depositary bank and their respective nominees will hold all deposited property for the benefit of the
holders and beneficial owners of ADSs. The deposited property does not constitute the proprietary assets of the depositary bank, the custodian or their nominees. <B></B>Beneficial ownership in the deposited property will under the terms of the
deposit agreement be vested in the beneficial owners of the ADSs. The depositary bank, the custodian and their respective nominees will be the record holders of the deposited property represented by the ADSs for the benefit of the holders and
beneficial owners of the corresponding ADSs. <B></B>A beneficial owner of ADSs may or may not be the holder of ADSs. Beneficial owners of ADSs will be able to receive, and to exercise beneficial ownership interests in, the deposited property only
through the registered holders of the ADSs, the registered holders of the ADSs (on behalf of the applicable ADS owners) only through the depositary bank, and the depositary bank (on behalf of the owners of the corresponding ADSs) directly, or
indirectly, through the custodian or their respective nominees, in each case upon the terms of the deposit agreement.<B></B><B>&nbsp;</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you become an owner of ADSs, you will become a party to the deposit agreement and therefore will be bound to its terms and to the terms of
any ADR that represents your ADSs. The deposit agreement and the ADR specify our rights and obligations as well as your rights and obligations as an owner of ADSs and those of the depositary bank. As an ADS holder you appoint the depositary bank to
act on your behalf in certain circumstances. The deposit agreement and the ADRs are governed by New York law. However, our obligations to the holders of ordinary shares will continue to be governed by the laws of France, which may be different from
the laws in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, applicable laws and regulations may require you to satisfy reporting requirements and obtain
regulatory approvals in certain circumstances. You are solely responsible for complying with such reporting requirements and obtaining such approvals. Neither the depositary bank, the custodian, us or any of their or our respective agents or
affiliates shall be required to take any actions whatsoever on your behalf to satisfy such reporting requirements or obtain such regulatory approvals under applicable laws and regulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>As an owner of ADSs, we will not treat you as one of our shareholders and you will not
have direct shareholder rights. The depositary bank will hold on your behalf the shareholder rights attached to the ordinary shares underlying your ADSs. As an owner of ADSs you will be able to exercise the shareholders rights for the ordinary
shares represented by your ADSs through the depositary bank only to the extent contemplated in the deposit agreement. To exercise any shareholder rights not contemplated in the deposit agreement you will, as an ADS owner, need to arrange for the
cancellation of your ADSs and become a direct shareholder.&#8195; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manner in which you own the ADSs (e.g., in a brokerage account
vs. as registered holder, or as holder of certificated vs. uncertificated ADSs) may affect your rights and obligations, and the manner in which, and extent to which, the depositary bank&#146;s services are made available to you. As an owner of ADSs,
you may hold your ADSs either by means of an ADR registered in your name, through a brokerage or safekeeping account, or through an account established by the depositary bank in your name reflecting the registration of uncertificated ADSs directly
on the books of the depositary bank (commonly referred to as the &#147;direct registration system&#148; or &#147;DRS&#148;). The direct registration system reflects the uncertificated (book-entry) registration of ownership of ADSs by the depositary
bank. Under the direct registration system, ownership of ADSs is evidenced by periodic statements issued by the depositary bank to the holders of the ADSs. The direct registration system includes automated transfers between the depositary bank and
The Depository Trust Company (&#147;DTC&#148;), the central book-entry clearing and settlement system for equity securities in the United States. If you decide to hold your ADSs through your brokerage or safekeeping account, you must rely on the
procedures of your broker or bank to assert your rights as ADS owner. Banks and brokers typically hold securities such as the ADSs through clearing and settlement systems such as DTC. The procedures of such clearing and settlement systems may limit
your ability to exercise your rights as an owner of ADSs. Please consult with your broker or bank if you have any questions concerning these limitations and procedures. All ADSs held through DTC will be registered in the name of a nominee of DTC.
This summary description assumes you have opted to own the ADSs directly by means of an ADS registered in your name and, as such, we will refer to you as the &#147;holder.&#148; When we refer to &#147;you,&#148; we assume the reader owns ADSs and
will own ADSs at the relevant time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration of the ordinary shares in the name of the depositary bank or the custodian shall, to
the maximum extent permitted by applicable law, vest in the depositary bank or the custodian the record ownership in the applicable ordinary shares with the beneficial ownership rights and interests in such ordinary shares being at all times vested
with the beneficial owners of the ADSs representing the ordinary shares. The depositary bank or the custodian shall at all times be entitled to exercise the beneficial ownership rights in all deposited property, in each case only on behalf of the
holders and beneficial owners of the ADSs representing the deposited property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends and Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a holder of ADSs, you generally have the right to receive the distributions we make on the securities deposited with the custodian. Your
receipt of these distributions may be limited, however, by practical considerations and legal limitations. Holders of ADSs will receive such distributions under the terms of the deposit agreement in proportion to the number of ADSs held as of the
specified record date, after deduction of the applicable fees, taxes and expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions of Cash </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we make a cash distribution for the securities on deposit with the custodian, we will deposit the funds with the custodian. Upon
receipt of confirmation of the deposit of the requisite funds, the depositary bank will arrange for the funds received in a currency other than U.S. dollars to be converted into U.S. dollars and for the distribution of the U.S. dollars to the
holders, subject to the laws and regulations of France. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conversion into U.S. dollars will take place only if practicable and if the
U.S. dollars are transferable to the United States. The depositary bank will apply the same method for distributing the proceeds of the sale of any property (such as undistributed rights) held by the custodian in respect of securities on deposit.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of cash will be made net of the fees, expenses, taxes and governmental
charges payable by holders under the terms of the deposit agreement. The depositary bank will hold any cash amounts it is unable to distribute in a <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing account for the benefit of the
applicable holders and beneficial owners of ADSs until the distribution can be effected or the funds that the depositary bank holds must be escheated as unclaimed property in accordance with the laws of the relevant states of the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions of Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we make
a free distribution of ordinary shares for the securities on deposit with the custodian, we will deposit the applicable number of ordinary shares with the custodian. Upon receipt of confirmation of such deposit, the depositary bank will
<U>either</U> distribute to holders new ADSs representing the ordinary shares deposited <U>or</U> modify the <FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT> shares ratio, in which case each ADS you hold will represent rights and interests in
the additional ordinary shares so deposited. Only whole new ADSs will be distributed. Fractional entitlements will be sold and the proceeds of such sale will be distributed as in the case of a cash distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of new ADSs or the modification of the <FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT> shares ratio upon a
distribution of ordinary shares will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. In order to pay such taxes or governmental charges, the depositary bank may sell all
or a portion of the new ordinary shares so distributed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No such distribution of new ADSs will be made if it would violate a law
(<I>e.g.</I>, the U.S. securities laws) or if it is not operationally practicable. If the depositary bank does not distribute new ADSs as described above, it may sell the ordinary shares received upon the terms described in the deposit agreement and
will distribute the proceeds of the sale as in the case of a distribution of cash. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions of Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we intend to distribute rights to subscribe for additional ordinary shares, we will give prior notice to the depositary bank and we
will assist the depositary bank in determining whether it is lawful and reasonably practicable to distribute rights to subscribe for additional ADSs to holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will establish procedures to distribute rights to subscribe for additional ADSs to holders and to enable such holders to
exercise such rights if it is lawful and reasonably practicable to make the rights available to holders of ADSs, and if we provide all of the documentation contemplated in the deposit agreement (such as opinions to address the lawfulness of the
transaction). You may have to pay fees, expenses, taxes and other governmental charges to subscribe for the new ADSs upon the exercise of your rights. The depositary bank is not obligated to establish procedures to facilitate the distribution and
exercise by holders of rights to subscribe for new ordinary shares other than in the form of ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will <I>not</I>
distribute the rights to you if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We do not timely request that the rights be distributed to you or we request that the rights not be distributed
to you; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We fail to deliver satisfactory documents to the depositary bank; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It is not reasonably practicable to distribute the rights. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will sell the rights that are not exercised or not distributed if such sale is lawful and reasonably practicable. The
proceeds of such sale will be distributed to holders as in the case of a cash distribution. If the depositary bank is unable to sell the rights, it will allow the rights to lapse. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Elective Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we intend to distribute a dividend payable at the election of shareholders either in cash or in additional shares, we will give prior
notice thereof to the depositary bank and will indicate whether we wish the elective distribution to be made available to you. In such case, we will assist the depositary bank in determining whether such distribution is lawful and reasonably
practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will make the election available to you only if it is reasonably practicable and if we have provided all
of the documentation contemplated in the deposit agreement. In such case, the depositary bank will establish procedures to enable you to elect to receive either cash or additional ADSs, in each case as described in the deposit agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the election is not made available to you, you will receive either cash or additional ADSs, depending on what a shareholder in France would
receive upon failing to make an election, as more fully described in the deposit agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we intend to distribute property other than cash, ordinary shares or rights to subscribe for additional ordinary shares, we will
notify the depositary bank in advance and will indicate whether we wish such distribution to be made to you. If so, we will assist the depositary bank in determining whether such distribution to holders is lawful and reasonably practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If it is reasonably practicable to distribute such property to you and if we provide to the depositary bank all of the documentation
contemplated in the deposit agreement, the depositary bank will distribute the property to the holders in a manner it deems practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution will be made net of fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit
agreement. In order to pay such taxes and governmental charges, the depositary bank may sell all or a portion of the property received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will <I>not</I> distribute the property to you and will sell the property if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We do not request that the property be distributed to you or if we request that the property not be distributed
to you; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We do not deliver satisfactory documents to the depositary bank; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The depositary bank determines that all or a portion of the distribution to you is not reasonably practicable.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The proceeds of such a sale will be distributed to holders as in the case of a cash distribution.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we decide to redeem any of the securities on deposit with the custodian, we will notify the depositary bank in advance. If it is
practicable and if we provide all of the documentation contemplated in the deposit agreement, the depositary bank will provide notice of the redemption to the holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The custodian will be instructed to surrender the shares being redeemed against payment of the applicable redemption price. The depositary
bank will convert into U.S. dollars upon the terms of the deposit agreement the redemption funds received in a currency other than U.S. dollars and will establish procedures to enable holders to receive the net proceeds from the redemption upon
surrender of their ADSs to the depositary bank. You may have to pay fees, expenses, taxes and other governmental charges upon the redemption of your ADSs. If less than all ADSs are being redeemed, the ADSs to be retired will be selected by lot or on
a <I>pro rata</I> basis, as the depositary bank may determine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Changes Affecting Ordinary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ordinary shares held on deposit for your ADSs may change from time to time. For example, there may be a change in nominal or par value, <FONT
STYLE="white-space:nowrap">split-up,</FONT> cancellation, consolidation or any other reclassification of such ordinary shares or a recapitalization, reorganization, merger, consolidation or sale of our assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any such change were to occur, your ADSs would, to the extent permitted by law and the deposit agreement, represent the right to receive
the property received or exchanged in respect of the ordinary shares held on deposit. The depositary bank may in such circumstances deliver new ADSs to you, amend the deposit agreement, the ADRs and the applicable Registration Statement(s) on Form <FONT
STYLE="white-space:nowrap">F-6,</FONT> call for the exchange of your existing ADSs for new ADSs and take any other actions that are appropriate to reflect as to the ADSs the change affecting the Shares. If the depositary bank may not lawfully
distribute such property to you, the depositary bank may sell such property and distribute the net proceeds to you as in the case of a cash distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuance of ADSs upon Deposit of Ordinary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of the offering, the ordinary shares being offered pursuant to the prospectus will be deposited by us with the
custodian.&nbsp;Upon receipt of confirmation of such deposit, the depositary bank will issue ADSs to the underwriters named in the prospectus. After the completion of the offering, the ordinary shares that are being offered for sale pursuant to the
prospectus will be deposited by us with the custodian. Upon receipt of confirmation of such deposit, the depositary bank will issue ADSs to the underwriters named in the prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the closing of the offer, the depositary bank may create ADSs on your behalf if you or your broker deposit ordinary shares with the
custodian. The depositary bank will deliver these ADSs to the person you indicate only after you pay any applicable issuance fees and any charges and taxes payable for the transfer of the ordinary shares to the custodian. Your ability to deposit
ordinary shares and receive ADSs may be limited by U.S. and French legal considerations applicable at the time of deposit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance
of ADSs may be delayed until the depositary bank or the custodian receives confirmation that all required approvals have been given and that the ordinary shares have been duly transferred to the custodian. The depositary bank will only issue ADSs in
whole numbers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When you make a deposit of ordinary shares, you will be responsible for transferring good and valid title to the
depositary bank. As such, you will be deemed to represent and warrant that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The ordinary shares are duly authorized, validly issued, fully
paid, <FONT STYLE="white-space:nowrap">non-assessable</FONT> and legally obtained. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All preemptive (and similar) rights, if any, with
respect to such ordinary shares have been validly waived or exercised. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">You are duly authorized to deposit the ordinary shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The ordinary shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge, mortgage or adverse claim,
and are not, and the ADSs issuable upon such deposit will not be, &#147;restricted securities&#148; (as defined in the deposit agreement). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The ordinary shares presented for deposit have not been stripped of any rights or entitlements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of the representations or warranties are incorrect in any way, we and the depositary bank may, at your cost and expense, take any and
all actions necessary to correct the consequences of the misrepresentations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">229 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer, Combination and Split Up of ADRs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an ADR holder, you will be entitled to transfer, combine or split up your ADRs and the ADSs evidenced thereby. For transfers of ADRs, you
will have to surrender the ADRs to be transferred to the depositary bank and also must: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">ensure that the surrendered ADR is properly
endorsed or otherwise in proper form for transfer; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">provide such proof of identity and genuineness of signatures as the depositary bank
deems appropriate; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">provide any transfer stamps required by the State of New York or the United States; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">pay all applicable fees, charges, expenses, taxes and other government charges payable by ADR holders pursuant to the terms of the deposit
agreement, upon the transfer of ADRs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To have your ADRs either combined or split up, you must surrender the ADRs in question to the
depositary bank with your request to have them combined or split up, and you must pay all applicable fees, charges and expenses payable by ADR holders, pursuant to the terms of the deposit agreement, upon a combination or split up of ADRs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Withdrawal of Ordinary Shares Upon Cancellation of ADSs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a holder, you will be entitled to present your ADSs to the depositary bank for cancellation and then receive the corresponding number of
underlying ordinary shares at the custodian&#146;s offices. Your ability to withdraw the ordinary shares held in respect of the ADSs may be limited by U.S. and French law considerations applicable at the time of withdrawal. In order to withdraw the
ordinary shares represented by your ADSs, you will be required to pay to the depositary bank the fees for cancellation of ADSs and any charges and taxes payable upon the transfer of the ordinary shares. You assume the risk for delivery of all funds
and securities upon withdrawal. Once canceled, the ADSs will not have any rights under the deposit agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold ADSs registered
in your name, the depositary bank may ask you to provide proof of identity and genuineness of any signature and such other documents as the depositary bank may deem appropriate before it will cancel your ADSs. The withdrawal of the ordinary shares
represented by your ADSs may be delayed until the depositary bank receives satisfactory evidence of compliance with all applicable laws and regulations. Please keep in mind that the depositary bank will only accept ADSs for cancellation that
represent a whole number of securities on deposit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You will have the right to withdraw the securities represented by your ADSs at any
time except for: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Temporary delays that may arise because (i)&nbsp;the transfer books for the ordinary shares or ADSs are closed, or
(ii)&nbsp;ordinary shares are immobilized on account of a shareholders&#146; meeting or a payment of dividends. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Obligations to pay fees,
taxes and similar charges. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Restrictions imposed because of laws or regulations applicable to ADSs or the withdrawal of securities on
deposit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The deposit agreement may not be modified to impair your right to withdraw the securities represented by your ADSs except to
comply with mandatory provisions of law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a holder, you generally have the right under the deposit agreement to instruct the depositary bank to exercise the voting rights for the
ordinary shares represented by your ADSs. The voting rights of holders of ordinary shares are described in the section of this prospectus entitled &#147;Description of Share Capital.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">230 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our request, the depositary bank will distribute to you any notice of shareholders&#146;
meeting received from us together with information explaining how to instruct the depositary bank to exercise the voting rights of the securities represented by ADSs. In lieu of distributing such materials, the depositary bank may distribute to
holders of ADSs instructions on how to retrieve such materials upon request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the depositary bank timely receives voting instructions
from a holder of ADSs, it will endeavor to vote the securities (in person or by proxy) represented by the holder&#146;s ADSs in accordance with such voting instructions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities for which no voting instructions have been received will not be voted (except as otherwise contemplated in the deposit agreement).
<B></B>Please note that the ability of the depositary bank to carry out voting instructions may be limited by practical and legal limitations and the terms of the securities on deposit. We cannot assure you that you will receive voting materials in
time to enable you to return voting instructions to the depositary bank in a timely manner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fees and Charges </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an ADS holder, you will be required to pay the following fees under the terms of the deposit agreement: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Service</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fees</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Issuance of ADSs (e.g., an issuance of ADS upon a deposit of ordinary shares, upon a change in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS(s)-to-ordinary</FONT></FONT> share ratio, or for any other
reason), excluding ADS issuances as a result of distributions of ordinary shares)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS issued</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cancellation of ADSs (e.g., a cancellation of ADSs for delivery of deposited property, upon a change in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS(s)-to-ordinary</FONT></FONT> share ratio, or for any
other reason)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS cancelled</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Distribution of cash dividends or other cash distributions (e.g., upon a sale of rights and other entitlements)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Distribution of ADSs pursuant to (i)&nbsp;share dividends or other free share distributions, or (ii)&nbsp;exercise of rights to purchase additional ADSs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Distribution of securities other than ADSs or rights to purchase additional ADSs (e.g., upon a <FONT STYLE="white-space:nowrap">spin-off)</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ADS Services</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held on the applicable record date(s) established by the depositary bank</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Registration of ADS transfers (e.g., upon a registration of the transfer of registered ownership of ADSs, upon a transfer of ADSs into DTC and <I>vice versa</I>, or for any other reason)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS (or fraction thereof) transferred</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Conversion of ADSs of one series for ADSs of another series (e.g., upon conversion of Partial Entitlement ADSs for Full Entitlement ADSs, or upon conversion of Restricted ADSs (each as defined in the Deposit Agreement) into freely
transferable ADSs, and <I>vice versa</I>).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS (or fraction thereof) converted</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an ADS holder you will also be responsible to pay certain charges such as: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">taxes (including applicable interest and penalties) and other governmental charges; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">231 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">the registration fees as may from time to time be in effect for the registration of ordinary
shares on the share register and applicable to transfers of ordinary shares to or from the name of the custodian, the depositary bank or any nominees upon the making of deposits and withdrawals, respectively; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">certain cable, telex and facsimile transmission and delivery expenses; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">the fees, expenses, spreads, taxes and other charges of the depositary bank and/or service providers (which may be a division, branch or
affiliate of the depositary bank) in the conversion of foreign currency; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">the reasonable and customary <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by the depositary bank in connection with compliance with exchange control regulations and other regulatory requirements applicable to ordinary shares, ADSs and ADRs; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">the fees, charges, costs and expenses incurred by the depositary bank, the custodian, or any nominee in connection with the ADR program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ADS fees and charges for (i)&nbsp;the issuance of ADSs, and (ii)&nbsp;the cancellation of ADSs are charged to the person for whom the ADSs are
issued (in the case of ADS issuances) and to the person for whom ADSs are cancelled (in the case of ADS cancellations). In the case of ADSs issued by the depositary bank into DTC, the ADS issuance and cancellation fees and charges may be deducted
from distributions made through DTC, and may be charged to the DTC participant(s) receiving the ADSs being issued or the DTC participant(s) holding the ADSs being cancelled, as the case may be, on behalf of the beneficial owner(s) and will be
charged by the DTC participant(s) to the account of the applicable beneficial owner(s) in accordance with the procedures and practices of the DTC participants as in effect at the time. ADS fees and charges in respect of distributions and the ADS
service fee are charged to the holders as of the applicable ADS record date. In the case of distributions of cash, the amount of the applicable ADS fees and charges is deducted from the funds being distributed. In the case of (i)&nbsp;distributions
other than cash and (ii)&nbsp;the ADS service fee, holders as of the ADS record date will be invoiced for the amount of the ADS fees and charges and such ADS fees and charges may be deducted from distributions made to holders of ADSs. For ADSs held
through DTC, the ADS fees and charges for distributions other than cash and the ADS service fee may be deducted from distributions made through DTC, and may be charged to the DTC participants in accordance with the procedures and practices
prescribed by DTC and the DTC participants in turn charge the amount of such ADS fees and charges to the beneficial owners for whom they hold ADSs. In the case of (i)&nbsp;registration of ADS transfers, the ADS transfer fee will be payable by the
ADS Holder whose ADSs are being transferred or by the person to whom the ADSs are transferred, and (ii)&nbsp;conversion of ADSs of one series for ADSs of another series, the ADS conversion fee will be payable by the Holder whose ADSs are converted
or by the person to whom the converted ADSs are delivered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of refusal to pay the depositary bank fees, the depositary bank
may, under the terms of the deposit agreement, refuse the requested service until payment is received or may set off the amount of the depositary bank fees from any distribution to be made to the ADS holder. Certain depositary fees and charges (such
as the ADS services fee) may become payable shortly after the closing of the ADS offering. Note that the fees and charges you may be required to pay may vary over time and may be changed by us and by the depositary bank. You will receive prior
notice of such changes. The depositary bank may reimburse us for certain expenses incurred by us in respect of the ADR program, by making available a portion of the ADS fees charged in respect of the ADR program or otherwise, upon such terms and
conditions as we and the depositary bank agree from time to time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendments and Termination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may agree with the depositary bank to modify the deposit agreement at any time without your consent. We undertake to give holders 30
days&#146; prior notice of any modifications that would materially prejudice any of their substantial rights under the deposit agreement. We will not consider to be materially prejudicial to your substantial rights any modifications or supplements
that are reasonably necessary for the ADSs to be registered under the Securities Act or to be eligible for book-entry settlement, in each case without imposing or increasing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">232 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the fees and charges you are required to pay. In addition, we may not be able to provide you with prior notice of any modifications or supplements that are required to accommodate compliance with
applicable provisions of law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You will be bound by the modifications to the deposit agreement if you continue to hold your ADSs after the
modifications to the deposit agreement become effective. The deposit agreement cannot be amended to prevent you from withdrawing the ordinary shares represented by your ADSs (except as permitted by law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the right to direct the depositary bank to terminate the deposit agreement. Similarly, the depositary bank may in certain
circumstances on its own initiative terminate the deposit agreement. In either case, the depositary bank must give notice to the holders at least 30 days before termination. Until termination, your rights under the deposit agreement will be
unaffected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After termination, the depositary bank will continue to collect distributions received (but will not distribute any such
property until you request the cancellation of your ADSs) and may sell the securities held on deposit. After the sale, the depositary bank will hold the proceeds from such sale and any other funds then held for the holders of ADSs in a <FONT
STYLE="white-space:nowrap">non-interest</FONT> bearing account. At that point, the depositary bank will have no further obligations to holders other than to account for the funds then held for the holders of ADSs still outstanding (after deduction
of applicable fees, taxes and expenses). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with any termination of the deposit agreement, the depositary bank may make
available to owners of ADSs a means to withdraw the ordinary shares represented by ADSs and to direct the depositary of such ordinary shares into an unsponsored American depositary share program established by the depositary bank. The ability to
receive unsponsored American depositary shares upon termination of the deposit agreement would be subject to satisfaction of certain U.S. regulatory requirements applicable to the creation of unsponsored American depositary shares and the payment of
applicable depositary fees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Books of Depositary </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will maintain ADS holder records at its depositary office. You may inspect such records at such office during regular
business hours but solely for the purpose of communicating with other holders in the interest of business matters relating to the ADSs and the deposit agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will maintain in New York facilities to record and process the issuance, cancellation, combination, <FONT
STYLE="white-space:nowrap">split-up</FONT> and transfer of ADSs. These facilities may be closed from time to time, to the extent not prohibited by law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Obligations and Liabilities </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The deposit agreement limits our obligations and the depositary bank&#146;s obligations to you. Please note the
following: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank are obligated only to take the actions specifically stated in the deposit agreement
without negligence or bad faith. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The depositary bank disclaims any liability for any failure to carry out voting instructions, for any manner in
which a vote is cast or for the effect of any vote, provided it acts in good faith and in accordance with the terms of the deposit agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The depositary bank disclaims any liability for any failure to determine the lawfulness or practicality of any
action, for the content of any document forwarded to you on our behalf or for the accuracy of any </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">233 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
translation of such a document, for the investment risks associated with investing in ordinary shares, for the validity or worth of the ordinary shares, for any tax consequences that result from
the ownership of ADSs, for the credit-worthiness of any third party, for allowing any rights to lapse under the terms of the deposit agreement, for the timeliness of any of our notices or for our failure to give notice. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank will not be obligated to perform any act that is inconsistent with the terms of the
deposit agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank disclaim any liability if we or the depositary bank are prevented or forbidden from or
subject to any civil or criminal penalty or restraint on account of, or delayed in, doing or performing any act or thing required by the terms of the deposit agreement, by reason of any provision, present or future of any law or regulation, or by
reason of present or future provision of any provision of our <FONT STYLE="white-space:nowrap">by-laws,</FONT> or any provision of or governing the securities on deposit, or by reason of any act of God or war or other circumstances beyond our
control. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank disclaim any liability by reason of any exercise of, or failure to exercise, any
discretion provided for in the deposit agreement or in our <FONT STYLE="white-space:nowrap">by-laws</FONT> or in any provisions of or governing the securities on deposit. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank further disclaim any liability for any action or inaction in reliance on the advice or
information received from legal counsel, accountants, any person presenting Shares for deposit, any holder of ADSs or authorized representatives thereof, or any other person believed by either of us in good faith to be competent to give such advice
or information. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank also disclaim liability for the inability by a holder to benefit from any
distribution, offering, right or other benefit that is made available to holders of ordinary shares but is not, under the terms of the deposit agreement, made available to you. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank may rely without any liability upon any written notice, request or other document
believed to be genuine and to have been signed or presented by the proper parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank also disclaim liability for any consequential or punitive damages for any breach of
the terms of the deposit agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No disclaimer of any Securities Act liability is intended by any provision of the deposit agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nothing in the deposit agreement gives rise to a partnership or joint venture, or establishes a fiduciary
relationship, among us, the depositary bank and you as ADS holder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nothing in the deposit agreement precludes Citibank (or its affiliates) from engaging in transactions in which
parties adverse to us or the ADS owners have interests, and nothing in the deposit agreement obligates Citibank to disclose those transactions, or any information obtained in the course of those transactions, to us or to the ADS owners, or to
account for any payment received as part of those transactions. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>As the above limitations relate to our obligations
and the depositary&#146;s obligations to you under the deposit agreement, we believe that, as a matter of construction of the clause, such limitations would likely to continue to apply to ADS holders who withdraw the ordinary shares from the ADS
facility with respect to obligations or liabilities incurred under the deposit agreement before the cancellation of the ADSs and the withdrawal of the ordinary shares, and such limitations would most likely not apply to ADS holders who withdraw the
ordinary shares from the ADS facility with respect to obligations or liabilities incurred after the cancellation of the ADSs and the withdrawal of the ordinary shares and not under the deposit agreement. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>In any event, you will not be deemed, by agreeing to the terms of the deposit agreement, to have waived our or the depositary&#146;s
compliance with U.S. federal securities laws and the rules and regulations promulgated </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">234 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
thereunder. In fact, you cannot waive our or the depositary&#146;s compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You will be responsible for the
taxes and other governmental charges payable on the ADSs and the securities represented by the ADSs. We, the depositary bank and the custodian may deduct from any distribution the taxes and governmental charges payable by holders and may sell any
and all property on deposit to pay the taxes and governmental charges payable by holders. You will be liable for any deficiency if the sale proceeds do not cover the taxes that are due. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank may refuse to issue ADSs, to deliver, transfer, split and combine ADRs or to release securities on deposit until all taxes
and charges are paid by the applicable holder. The depositary bank and the custodian may take reasonable administrative actions to obtain tax refunds and reduced tax withholding for any distributions on your behalf. However, you may be required to
provide to the depositary bank and to the custodian proof of taxpayer status and residence and such other information as the depositary bank and the custodian may require to fulfill legal obligations. You are required to indemnify us, the depositary
bank and the custodian for any claims with respect to taxes based on any tax benefit obtained for you. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Currency Conversion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will arrange for the conversion of all foreign currency received into U.S. dollars if such conversion is practical, and it
will distribute the U.S. dollars in accordance with the terms of the deposit agreement. You may have to pay fees and expenses incurred in converting foreign currency, such as fees and expenses incurred in complying with currency exchange controls
and other governmental requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the conversion of foreign currency is not practical or lawful, or if any required approvals are
denied or not obtainable at a reasonable cost or within a reasonable period, the depositary bank may take the following actions in its discretion: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Convert the foreign currency to the extent practical and lawful and distribute the U.S. dollars to the holders for whom the conversion and
distribution is lawful and practical. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Distribute the foreign currency to holders for whom the distribution is lawful and practical. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Hold the foreign currency (without liability for interest) for the applicable holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law/Waiver of Jury Trial </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
deposit agreement, the ADRs and the ADSs will be interpreted in accordance with the laws of the State of New York. The rights of holders of ordinary shares (including ordinary shares represented by ADSs) are governed by the laws of France. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an owner of ADSs, you irrevocably agree that any legal action arising out of the Deposit Agreement, the ADSs or the ADRs involving us or
the Depositary may only be instituted in a state or federal court in the city of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>AS A PARTY TO THE DEPOSIT AGREEMENT, YOU
IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, YOUR RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF THE DEPOSIT AGREEMENT OR THE ADRs AGAINST US AND/OR THE DEPOSITARY BANK. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">235 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The deposit agreement provides that, to the extent permitted by law, ADS holders waive the
right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our ordinary shares, the ADSs or the deposit agreement, including any claim under U.S. federal securities laws. If we or the depositary
opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable in the facts and circumstances of that case in accordance with applicable case law. However, you will not be deemed, by agreeing to the
terms of the deposit agreement, to have waived our or the depositary&#146;s compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">236 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_20"></A>ORDINARY SHARES AND ADSs ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the global offering, no public market existed in the United States for our ordinary shares or the ADSs. Future sales of ADSs in the
public market after the global offering, and the availability of ADSs for future sale, could adversely affect the market price of the ADSs prevailing from time to time. As described below, a significant number of currently outstanding ordinary
shares will not be available for sale shortly after the global offering due to contractual restrictions on transfers of ordinary shares. Accordingly, sales of substantial amounts of the ADSs or the ordinary shares, or the perception that these sales
could occur, could adversely affect prevailing market prices for the ADSs and could impair our future ability to raise equity capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the number of ordinary shares outstanding on June&nbsp;30, 2023, upon completion of the global offering, 61,223,068 ordinary shares
(including ordinary shares represented by ADSs) will be outstanding, assuming no outstanding options or warrants are exercised. All of the ADSs sold in the global offering will be freely tradable without restrictions or further registration under
the Securities Act, except for any ADSs sold to our &#147;affiliates,&#148; as that term is defined under Rule 144 under the Securities Act. The remaining ordinary shares held by existing shareholders are &#147;restricted securities,&#148; as that
term is defined in Rule&nbsp;144 under the Securities Act. Restricted securities may be sold in the public market only if registered or if their resale qualifies for exemption from registration described below under Rule 144 or 701 under the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, of the options, convertible bonds and warrants to purchase 1,464,227 ordinary shares outstanding as of
June&nbsp;30, 2023 and assuming no outstanding options, convertible bonds or warrants are exercised and no exercise of the underwriters&#146; option to purchase 2,801,325 additional ADSs and/or ordinary shares, options and warrants exercisable for
1,200,130 ordinary shares will be vested and eligible for sale 90 days after the date of this prospectus subject to French law, as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below and the provisions of Rules 144 and 701 under the
Securities Act and French law, and assuming no exercise of the underwriters&#146; option to purchase 2,801,325 additional ADSs and/or ordinary shares, these restricted securities will be available for sale in the public market as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approximately 51,195,545 ordinary shares (including ordinary shares represented by ADSs and any securities that
may be sold to our affiliates in this offering) will be eligible for immediate sale on the date of this prospectus; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">10,027,523 ordinary&nbsp;shares (including ordinary shares represented by ADSs and excluding any securities that
may be sold to our affiliates in this offering) will be eligible for sale upon the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements 90 days after the date of this prospectus, provided that shares held by our affiliates
will remain subject to volume, manner of sale and other resale limitations set forth in Rule 144 of the Securities Act, as described below and subject to French law, both as described above. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>French Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, and notably
under the General Regulation issued by the French Financial Market Authority (<I>R&eacute;glement G&eacute;n&eacute;ral de l&#146;AMF</I>), as well as under EU Market Abuse Regulation 596/2014 of April&nbsp;16, 2014 (MAR), any person that holds
inside information shall, until such information is made public, refrain from (i)&nbsp;carrying out any transactions relating to securities issued by the company, (ii)&nbsp;recommending that another person engage in insider dealing or inducing
another person to engage in insider dealing, and (iii)&nbsp;unlawfully disclosing inside information outside of the normal exercise of an employment, a profession or duties. The use of inside information by cancelling or amending an order concerning
a financial instrument to which the information relates where the order was placed before the person concerned possessed the inside information, shall also be considered to be insider dealing. These rules apply to all persons who hold inside
information as a result of (1)&nbsp;their status as board member, executive officer, manager, employee of the company, third parties acting on behalf of the company and having access to privileged information as party of their professional relations
with the company during the preparation or the completion of a particular transaction, such as investor </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">237 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
services providers, lawyers or public relations agencies, (2)&nbsp;their holding of securities in the share capital of the company, and/or (3)&nbsp;their access to information because of their
employment, profession or duties or their participation in the preparation of a financial transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under MAR and the General
Regulation of the French Financial Market Authority, it is also prohibited for a person to engage or attempt to engage in market manipulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prohibited transactions include all transactions related to securities (shares, securities convertible, options and warrants), and in
particular, (i)&nbsp;transfer of securities, (ii)&nbsp;exercise of options, warrants (including founder&#146;s share warrants (BCE) or share warrants (BSA)), exercise of any securities giving access to the capital, (iii)&nbsp;transfer of free shares
(AGA) and (iv)&nbsp;acquisition of securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, a person who has beneficially owned our ordinary shares that are restricted shares for at least six months would be entitled to
sell such securities, provided that (i)&nbsp;such person is not deemed to have been one of our affiliates at the time of, or at any time during the 90 days preceding, a sale and (ii)&nbsp;we are subject to the Exchange Act periodic reporting
requirements for at least 90 days before the sale. Persons who have beneficially owned our ordinary shares that are restricted shares for at least six months but who are its affiliates at the time of, or any time during the 90 days preceding, a
sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of either of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of our ordinary shares then outstanding, which will equal approximately 612,230 ordinary shares
immediately after the global offering, assuming no exercise of the underwriter&#146;s option to purchase 2,801,325 additional ADSs and/or ordinary shares; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of the ADSs on the Nasdaq Global Market during the four calendar weeks
preceding the filing of a notice on Form 144 with respect to the sale, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, in each case, that we are subject to the Exchange Act
periodic reporting requirements for at least 90 days before the sale. Such sales both by affiliates and by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> must also comply with the manner of sale, current public information and notice
provisions of Rule 144 to the extent applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rule 701 under the Securities Act, as in effect on the date of this prospectus, permits resales of shares in reliance upon Rule 144 but without
compliance with certain restrictions of Rule 144, including the holding period requirement. Most of our employees, executive officers or directors who purchased shares under a written compensatory plan or contract may be entitled to rely on the
resale provisions of Rule 701, but all holders of Rule 701 shares are required to wait until 90 days after the date of this prospectus before selling their shares subject also to French law, as described above. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, all Rule 701 shares are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements as described below and in the section of
this prospectus titled &#147;Underwriters&#148; and will not become eligible for sale until the expiration of the restrictions set forth in those agreements. In addition, any Rule 701 shares held by employees who are French tax residents and who
were granted share options prior to September 28, 2012, may be subject to an additional holding period under the terms of the applicable share option plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulation S </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulation S provides
generally that sales made in offshore transactions are not subject to the registration or prospectus-delivery requirements of the Securities Act. Accordingly, restricted securities may be sold in offshore transactions in compliance with Regulation
S. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">238 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of our security holders possess registration rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, our officers, directors and certain of our existing shareholders have agreed, among other things and subject to certain exceptions, with
the underwriters not to nor publicly disclose the intention to, during the period ending 90 days after the date of this prospectus, directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any
option or contract to sell, grant any option, right or warrant for the sale of, enter into any hedging, swap or any other agreement or otherwise transfer or dispose of any ordinary shares, ADSs or any securities convertible into, exercisable or
exchangeable for our ordinary shares or ADSs, except with the prior written consent of the representatives of the underwriters. See &#147;Underwriters.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not expect any release of ordinary shares or ADSs subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements prior to the
expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period. Upon the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, substantially all of the ordinary shares (which may be in the form of ADSs) subject to such <FONT
STYLE="white-space:nowrap">lock-up</FONT> restrictions will become eligible for sale, subject to the limitations described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Morgan
Stanley &amp; Co. LLC and Leerink Partners LLC, in their sole discretion, may release the securities subject to the lock-up agreements described above in whole or in part at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">239 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_21"></A>MATERIAL UNITED STATES FEDERAL INCOME AND FRENCH TAX
CONSIDERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The summary set forth below describes certain French and U.S. federal income tax consequences relating to the
purchase, ownership and disposition of the ADSs to U.S. Holders (as defined below) as of the date hereof. This summary does not represent a detailed description of the tax consequences applicable to a U.S. Holder that is subject to special treatment
under the U.S. federal tax laws, including, without limitation: </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">traders in securities who use a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of tax accounting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dealers in securities or currencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding ADSs as part of a hedging transaction, &#147;straddle,&#148; wash sale, conversion transaction or
integrated transaction or persons entering into a constructive sale with respect to the ADSs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts, grantor trusts or other trusts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons whose &#147;functional currency&#148; for U.S. federal income tax purposes is not the U.S. dollar;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expatriates of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax exempt entities, including &#147;individual retirement accounts&#148; and &#147;Roth IRAs&#148;;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">entities or arrangements classified as partnerships or other pass-through entities for U.S. federal income tax
purposes (and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that received ADSs as compensation for the performance of services; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that own or are deemed to own ten percent or more of our shares (by vote or value); and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding ADSs in connection with a trade or business, permanent establishment, or fixed base outside the
United States. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This summary is for general information only. Prospective Investors considering the purchase,
ownership or disposition of the ADSs are advised to consult their own tax advisers concerning the French and U.S. federal income tax consequences in light of their particular facts and circumstances, as well as any consequences arising under the
laws of any other taxing jurisdiction. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>French Income Tax Considerations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following describes the material French income tax consequences to U.S. Holders (as defined below) of purchasing, owning and disposing of
our ADSs and, unless otherwise noted, this discussion is the opinion of Dechert, our French tax counsel, insofar as it relates to matters of French tax law and legal conclusions with respect to those matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion does not purport to be a complete analysis or listing of all potential tax effects of the acquisition, ownership or
disposition of our ADSs to any particular investor, and does not discuss tax considerations that arise from rules of general application or that are generally assumed to be known by investors. All of the following is subject to change. Such changes
could apply retroactively and could affect the consequences described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2011, France introduced a comprehensive set of new tax
rules applicable to French assets that are held by or in foreign trusts. These rules, among other things, provide for the inclusion of trust assets in the settlor&#146;s net assets for purpose of applying the former French wealth tax (replaced by
the French real estate wealth tax as from January&nbsp;1, 2018), for the application of French gift and death duties to French assets held in trust, for a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">240 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
specific tax on capital on the French assets of foreign trusts not already subject to the former French wealth tax (replaced by the French real estate wealth tax as from January&nbsp;1, 2018) and
for a number of French tax reporting and disclosure obligations. The following discussion does not address the French tax consequences applicable to ADSs held in trusts. If ADSs are held in trust, the grantor, trustee and beneficiary are urged to
consult their own tax adviser regarding the specific tax consequences of acquiring, owning and disposing of ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The description of the
French income tax and real estate wealth tax consequences set forth below is based on the Convention Between the Government of the United States of America and the Government of the French Republic for the Avoidance of Double Taxation and the
Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital of August&nbsp;31, 1994 which came into force on December&nbsp;30, 1995 (as amended by any subsequent protocols, including the protocol of January&nbsp;13, 2009), or the Treaty
and the tax guidelines issued by the French tax authorities in force as of the date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this
discussion, the term &#147;U.S. Holder&#148; means a beneficial owner of ADSs that is (or is treated as), for U.S. federal income tax purposes: (1)&nbsp;an individual who is a U.S. citizen or resident, (2)&nbsp;a corporation or other entity that is
treated as a corporation for U.S. federal income tax purposes, created or organized in or under the laws of the United States or any state thereof, including the District of Colombia, (3)&nbsp;otherwise subject to U.S. federal income taxation or
(4)&nbsp;a trust, if a court within the United States is able to exercise primary supervision over its administration and one or more U.S. persons have the authority to control all of the substantial decisions of such trust or has a valid election
in effect under applicable U.S. Treasury Regulations to be treated as a United States person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership (or any other entity
treated as partnership for U.S. federal income tax purposes) holds ADSs, the tax treatment of the partnership and a partner in such partnership generally will depend upon the status of the partner and the activities of the partnership. If a U.S.
Holder is a partnership or a partner in a partnership that holds ADSs, such holder is urged to consult its own tax adviser regarding the specific tax consequences of acquiring, owning and disposing of securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion applies only to investors that hold our ADSs as capital assets that have the U.S. dollar as their functional currency, that
are entitled to Treaty benefits under the &#147;Limitation on Benefits&#148; provision contained in the Treaty, and whose ownership of the ADSs is not effectively connected to a permanent establishment or a fixed base in France. Certain U.S. Holders
(including, but not limited to, U.S. expatriates, partnerships or other entities classified as partnerships for U.S. federal income tax purposes, banks, insurance companies, regulated investment companies,
<FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations, financial institutions, persons subject to the alternative minimum tax, persons who acquired the securities pursuant to the exercise of employee share options or otherwise as
compensation, persons that own (directly, indirectly or by attribution) 5% or more of our voting stock or 5% or more of our outstanding share capital, dealers in securities or currencies, persons that elect to mark their securities to market for
U.S. federal income tax purposes and persons holding securities as a position in a synthetic security, straddle or conversion transaction) may be subject to special rules not discussed below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. Holders are urged to consult their own tax advisers regarding the tax consequences of the purchase, ownership and disposition of
securities in light of their particular circumstances, especially with regard to the &#147;Limitations on Benefits&#148; provision. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Estate and Gift
Taxes and Transfer Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, a transfer of securities by gift or by reason of death of a U.S. Holder that would otherwise be
subject to French gift or inheritance tax, respectively, will not be subject to such French tax by reason of the Convention between the Government of the United States of America and the Government of the French Republic for the Avoidance of Double
Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Estates, Inheritances and Gifts, dated November&nbsp;24, 1978, unless (i)&nbsp;the donor or the transferor is domiciled in France at the time of making the gift or at the time of
his or her death, or (ii)&nbsp;the securities were used in, or held for use in, the conduct of a business through a permanent establishment or a fixed base in France. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">241 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Transactions Tax </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Article 235 ter ZD of the French Tax Code (<I>Code g&eacute;n&eacute;ral des imp&ocirc;ts</I>) (the &#147;FTC&#148;), purchases of
certain securities issued by a French company, including ordinary shares (which may be in the form of ADSs), which are listed on a regulated market of the EU or an exchange market formally acknowledged by the Minister of Economy, after consultation
opinion from the AMF (in each case within the meaning of the French Monetary and Financial Code (the &#147;FMFC&#148;)) are subject in France to a 0.3% tax on financial transactions (the &#147;TFT&#148;), provided <I>inter alia</I> that the
issuer&#146;s market capitalization exceeds &#128;1&nbsp;billion as of December&nbsp;1 of the year preceding the taxation year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Nasdaq Global Market, on which ADSs will be listed, is not currently acknowledged by the French Minister of Economy, but it may change in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, a list of French relevant companies whose market capitalization exceeds &#128;1&nbsp;billion as of December&nbsp;1 of the year
preceding the taxation year is published annually by the French State. The last version of such list was dated December&nbsp;21, 2022 <FONT STYLE="white-space:nowrap">(BOI-ANNX-000467).</FONT> It did not include Abivax SA as its market
capitalization did not exceed &#128;1.0&nbsp;billion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the global offering, purchases of our ADSs may thus be subject to the TFT if
(1)&nbsp;Abivax SA&#146;s market capitalization exceeds &#128;1.0&nbsp;billion, and (2)&nbsp;the Nasdaq Global Market is acknowledged by the French Minister of Economy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Duties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case where
the TFT is not applicable, (1)&nbsp;transfers of shares issued by a French company which are listed on a regulated or organized market within the meaning of the FMFC are subject to uncapped registration duties at the rate of 0.1% if the transfer is
evidenced by a written statement (&#147;acte&#148;) executed either in France or outside France, whereas (2)&nbsp;transfers of shares issued by a French company which are not listed on a regulated or organized market within the meaning of the FMFC
are subject to uncapped registration duties at the rate of 0.1% notwithstanding the existence of a written statement. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As ordinary
shares of Abivax SA are listed on Euronext Paris, which is a regulated market within the meaning of the FMFC, their transfer should be subject to uncapped registration duties at the rate of 0.1% only if such transfer is evidenced by a written
agreement. Although the official guidelines published by the French tax authorities are silent on this point <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(BOI-ENR-DMTOM-40-10-10-12/09/2012),</FONT></FONT></FONT></FONT></FONT></FONT> ADSs should remain outside of the scope of the aforementioned 0.1% registration duties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Real Estate Wealth Tax </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since
January&nbsp;1, 2018, the French wealth tax (<I>imp&ocirc;t de solidarit&eacute; sur la fortune</I>) has been repealed and replaced by the French real estate wealth tax (<I>imp&ocirc;t sur la fortune immobili&egrave;re</I>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The scope of such new tax is narrowed to real estate assets (and certain assets deemed to be real estate assets) or rights, held directly or
indirectly through one or more legal entities and whose net taxable assets amount at least to &#128;1,300,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Broadly, subject to
provisions of double tax treaties and to certain exceptions, individuals who are not residents of France for tax purposes within the meaning of Article 4 B of the FTC, are subject to real estate wealth tax (<I>imp&ocirc;t sur la fortune
immobili&egrave;re</I>) in France in respect of the portion of the value of their shares of our company representing real estate assets (Article 965, 2&deg; of the FTC). Some exceptions are provided by the FTC. For instance, any participations
representing less than 10% of the share capital of an operating company and shares representing real estate for the professional use of the company considered shall not fall within the scope of the French real estate wealth tax (<I>imp&ocirc;t sur
la fortune immobili&egrave;re</I>). Under the Treaty (the provisions of which should be applicable to this new real estate wealth tax (<I>imp&ocirc;t sur la fortune immobili&egrave;re</I>) in France), the French real estate wealth tax
(<I>imp&ocirc;t sur la fortune immobili&egrave;re</I>) will however generally not apply to securities held by an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">242 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
eligible U.S. Holder who is a U.S. resident, as defined pursuant to the provisions of the Treaty, provided that such (i) U.S. Holder (a)&nbsp;does not own directly or indirectly more than 25% of
the issuer&#146;s financial rights and (b)&nbsp;that the ADSs do not form part of the business property of a permanent establishment or fixed base in France and (ii) that the issuer&#146;s assets do not consist in at least 50 percent of real
property located in France, or that the issuer&#146;s shares do not derive at least 50 percent of their value, directly or indirectly, from real property located in France. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. Holders are advised to consult their own tax advisor regarding the specific tax consequences which may apply to their particular
situation with respect to such French real estate wealth tax (<I>imp&ocirc;t sur la fortune immobili&egrave;re</I>). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Taxation of Dividends </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends paid by a French corporation to <FONT STYLE="white-space:nowrap">non-residents</FONT> of France are generally subject to French
withholding tax at a rate of currently (i) 25% for dividends paid to legal persons which are not French tax residents, and (ii) 12.8% for dividends paid to individuals who are not French tax residents. Dividends paid by a French corporation in a <FONT
STYLE="white-space:nowrap">non-cooperative</FONT> State or territory, as defined in Article <FONT STYLE="white-space:nowrap">238-0</FONT> A of the FTC, other than those states or territories mentioned in 2&deg; of 2 bis of the same Article 238-0 A
will generally be subject to French withholding tax at a rate of 75%. However, eligible U.S. Holders entitled to Treaty benefits under the &#147;Limitation on Benefits&#148; provision contained in the Treaty who are U.S. residents, as defined
pursuant to the provisions of the Treaty, will not be subject to this 12.8%, 25% or 75% withholding tax rate, but may be subject to the withholding tax at a reduced rate (as described below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Treaty, the rate of French withholding tax on dividends paid to an eligible U.S. Holder who is a U.S. resident as defined pursuant
to the provisions of the Treaty and the beneficial owner of these dividends, and whose ownership of the ordinary shares (which may be in the form of ADSs) is not effectively connected with a permanent establishment or fixed base that such U.S.
Holder has in France, is generally reduced to 15%, or to 5% if such U.S. Holder is a corporation and owns directly or indirectly at least 10% of the share capital of the issuer; such U.S. Holder may claim a refund from the French tax authorities of
the amount withheld in excess of the Treaty rates of 15% or 5%, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For U.S. Holders that are not individuals but are U.S. residents,
as defined pursuant to the provisions of the Treaty, the requirements for eligibility for Treaty benefits, including the reduced 5% or 15% withholding tax rates contained in the &#147;Limitation on Benefits&#148; provision of the Treaty, are
complicated, and certain technical changes were made to these requirements by the protocol of January&nbsp;13, 2009. U.S. Holders are advised to consult their own tax advisers regarding their eligibility for Treaty benefits in light of their own
particular circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends paid to an eligible U.S. Holder may immediately be subject to the reduced rates of 5% or 15% provided
that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such holder establishes before the date of payment that it is a U.S. resident under the Treaty by completing and
providing the depositary with a treaty form (Form 5000) in accordance with French guidelines <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(BOI-INT-DG-20-20-20-20-12/09/2012);</FONT></FONT></FONT></FONT></FONT></FONT></FONT> or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary or other financial institution managing the securities account in the U.S. of such U.S. Holder
provides the French paying agent with a document listing certain information about the U.S. Holder and its ordinary shares or ADSs and a certificate <FONT STYLE="white-space:nowrap">(BOI-LETTRE-000138-28/07/2014)</FONT> whereby the financial
institution managing the U.S. Holder&#146;s securities account in the United States takes full responsibility for the accuracy of the information provided in the document. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Otherwise, dividends paid to a U.S. Holder, if such U.S. Holder is a legal person, will be subject to French withholding tax at the rate of
25%, or 75% if paid in a <FONT STYLE="white-space:nowrap">non-cooperative</FONT> State or territory (as defined in Article 238-0 A of the FTC, but other than those states or territories mentioned in 2&deg; of 2 bis of the same Article 238-0 A), and
then reduced at a later date to 5% or 15%, provided that such holder duly completes and provides the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">243 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
French tax authorities with the treaty forms Form 5000 and Form 5001 before December&nbsp;31 of the second calendar year following the year during which the dividend is paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain qualifying pension funds and certain other <FONT STYLE="white-space:nowrap">tax-exempt</FONT> entities are subject to the same general
filing requirements as other U.S. Holders except that they may have to supply additional documentation evidencing their entitlement to these benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the withholding tax rate applicable under French domestic law to U.S. Holders who are individuals does not exceed the cap provided in
the Treaty (i.e., 15%), the 12.8% rate shall apply, without any reduction provided under the Treaty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Besides, please note that pursuant
to Article 235 <I>quater</I> of the FTC (introduced by the French finance bill No.&nbsp;2019-1479 for 2020) and under certain conditions, a corporate U.S. Holder which is in a tax loss position for the fiscal year during which the dividend is
received may be entitled to a deferral regime, and obtain a withholding tax refund. The tax deferral ends in respect of the first financial year during which this U.S. Holder is in a profit making position, as well as in the cases set out in Article
235 <I>quater</I> of the FTC. Finance Bill for 2022 extended the deadline to claim the refund (December 31 of the second year following the year of payment instead of three months after the end of the fiscal year following the payment of the income)
and clarify the order in which the deferred taxes become due (the forfeiture of the deferral applies in priority to the oldest withholding taxes). Also, pursuant to newly introduced Article 235 <I>quinquies</I> of the FTC and under certain
conditions, a corporate U.S. Holder may be entitled to a refund of a fraction of the withholding tax, up to the difference between the withholding tax paid (on a gross basis) and the withholding tax based on the dividend net of the expenses incurred
for the acquisition and conservation directly related to the income, provided (i)&nbsp;that these expenses would have been tax deductible had the U.S. Holder been established in France, and (ii)&nbsp;that the tax rules in the United States do not
allow the U.S. Holder to offset the withholding tax. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax on Sale or Other Disposition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under the Treaty, a U.S. Holder who is a U.S. resident for purposes of the Treaty will not be subject to French tax on any capital
gain from the redemption (other than redemption proceeds characterized as dividends under French domestic tax law or administrative guidelines), sale or exchange of ADSs unless the ADSs form part of the business property of a permanent establishment
or fixed base that the U.S. Holder has in France. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Special rules apply to U.S. Holders who are residents of more than one country. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material U.S. Federal Income Tax Considerations for U.S. Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a description of the material U.S. federal income tax consequences to the U.S. Holders described below of acquiring, owning
and disposing of the ADSs. It is not a comprehensive description of all tax considerations that may be relevant to a particular person&#146;s decision to acquire securities. This discussion applies only to a U.S. Holder that is an initial purchaser
of the ADSs pursuant to the global offering and that will hold such ADSs as &#147;capital assets&#148; (generally, property held for investment) under the U.S. Internal Revenue Code of 1986, as amended (the &#147;Code&#148;). In addition, it does
not describe all of the tax considerations that may be relevant in light of a U.S. Holder&#146;s particular circumstances, including U.S. federal estate, gift, Medicare contribution tax on net investment income, and alternative minimum tax
considerations, the special tax accounting rules under Section&nbsp;451(b) of the Code, any state, local, or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax considerations, and tax considerations applicable to U.S. Holders subject to special
rules, including, without limitation:<I> </I> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">traders in securities who use a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of tax accounting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dealers in securities or currencies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">244 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding ADSs as part of a hedging transaction, &#147;straddle,&#148; wash sale, conversion transaction or
integrated transaction or persons entering into a constructive sale with respect to the ADSs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts, grantor trusts or other trusts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons whose &#147;functional currency&#148; for U.S. federal income tax purposes is not the U.S. dollar;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expatriates of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax exempt entities, including &#147;individual retirement accounts&#148; and &#147;Roth IRAs&#148;;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">entities or arrangements classified as partnerships or other pass-through entities for U.S. federal income tax
purposes (and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that received ADSs as compensation for the performance of services; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that own or are deemed to own ten percent or more of our shares (by vote or value); and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding ADSs in connection with a trade or business, permanent establishment, or fixed base outside the
United States. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an entity or arrangement that is classified as a partnership for U.S. federal income tax purposes
holds the ADSs, the U.S. federal income tax treatment of a partner in that partnership will generally depend on the status of the partner and the activities of the partnership. Partnerships holding the ADSs and partners in such partnerships are
encouraged to consult their own tax advisers as to the particular U.S. federal income tax consequences of acquiring, owning, and disposing of the ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This description is based on the Code, existing, proposed and temporary U.S. Treasury Regulations promulgated thereunder and administrative
and judicial interpretations thereof, in each case as in effect and available on the date hereof. All of the foregoing is subject to change, which change could apply retroactively, and to differing interpretations, all of which could affect the tax
considerations described below. No rulings have been sought from the U.S. Internal Revenue Service (the &#147;IRS&#148;), regarding the matters discussed herein and there can be no assurance that the IRS will not take a contrary position concerning
the tax consequences of the acquisition, ownership and disposition of the ADSs or that such a position would not be sustained. U.S. Holders should consult their own tax advisers concerning the U.S. federal, state, local and <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of acquiring, owning, and disposing of the ADSs in their particular circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used for purposes of this section &#147;&#151;Material U.S. Federal Income Tax Considerations for U.S. Holders&#148;, &#147;U.S.
Holder&#148; is a holder who, for U.S. federal income tax purposes, is a beneficial owner of the ADSs that is an initial purchaser of the ADSs pursuant to the global offering and is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United
States, any state therein or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate whose income is eligible for inclusion in gross income for U.S. federal income tax purposes, regardless
of its source; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust, if (A)&nbsp;a U.S. court is able to exercise primary supervision over the trust&#146;s administration
and one or more United States persons (as such term is defined under the Code) have authority to control all substantial decisions of the trust, or (B)&nbsp;the trust has a valid election in place under applicable U.S. Treasury regulations to treat
the trust as a United States person (as such term is defined under the Code). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discussion below assumes that the
representations contained in the depositary agreement are true and that the obligations in the deposit agreement and any related agreement will be complied with in accordance with its terms. For U.S. federal income tax purposes, it is generally
expected that a U.S. Holder of ADSs will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">245 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treated as the beneficial owner of the underlying ordinary shares represented by the ADSs. The remainder of this discussion assumes that a U.S. Holder of our ADSs will be treated in this manner.
Accordingly, deposits or withdrawals of ADSs for ordinary shares will generally not be subject to U.S. federal income tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>U.S.
Holders are encouraged to consult their own tax advisers concerning the U.S. federal, state, local and foreign tax consequences of acquiring, owning and disposing of the ADSs in their particular circumstances. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxation of Distributions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject
to the passive foreign investment company (&#147;PFIC&#148;) rules described below, distributions paid on the ADSs, other than certain pro rata distributions of the ADSs, will generally be treated as dividends to the extent paid out of our current
or accumulated earnings and profits (as determined under U.S. federal income tax principles). We do not maintain calculations of our earnings and profits under U.S. federal income tax principles, and so we expect that distributions generally will be
reported to U.S. Holders as dividends. Subject to applicable limitations, dividends paid by a &#147;qualified foreign corporation&#148; are eligible for taxation at a preferential capital gains rate rather than the marginal tax rates generally
applicable to ordinary income provided that certain requirements are met. However, if we are a PFIC (or treated as a PFIC with respect to the U.S. Holder) for the taxable year in which the dividend is paid or the preceding taxable year (see
discussion below under &#147;Passive Foreign Investment Company Rules&#148;), we will not be treated as a qualified foreign corporation, and therefore the preferential capital gains tax rate described above will not apply. Each U.S. Holder is
advised to consult its tax advisors regarding the availability of the preferential tax rate on dividends with regard to its particular circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation (other than a corporation classified as a PFIC for the taxable year in which
the dividend is paid or the preceding taxable year) generally will be considered to be a qualified foreign corporation if: (i)&nbsp;if it is eligible for the benefits of a comprehensive tax treaty with the United States, which the Secretary of
Treasury of the United States determines is satisfactory for purposes of this provision, and which includes an exchange of information provision; or (ii)&nbsp;with respect to any dividend it pays on shares that are readily tradable on an established
securities market in the United States. We believe that we qualify as a resident of France for the purposes of, and are eligible for the benefits of, the income tax treaty between France and the United States, which the IRS has determined is
satisfactory for purposes of the qualified dividend rules, and that it includes an exchange of information provision, although there can be no assurance in this regard. Further, our ADSs will generally be considered to be readily tradable on an
established securities marked in the United States if they are listed on the Nasdaq Global Market, which we anticipate the ADSs will be. Therefore, subject to the discussion below under &#147;Passive Foreign Investment Company Rules,&#148; if the
income tax treaty between France and the United States is applicable, or if the ADSs are readily tradable on an established securities market in the United States, dividends paid on the ADSs will generally be &#147;qualified dividend income&#148; in
the hands of individual U.S. Holders, provided that certain conditions are met, including conditions relating to the holding period and the absence of certain risk reduction transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. Holder must include the gross amount of a dividend without reduction for amounts withheld by us in respect of French income taxes (see
&#147;Material United States Federal Income and French Tax Considerations&#151;Certain French Considerations&#148;), even though the U.S. Holder did not in fact receive the amount associated with the withheld French tax.<I> </I>The amount of the
dividend will be treated as foreign-source dividend income to U.S. Holders and will not be eligible for the dividends-received deduction generally available to U.S. corporations under the Code. Dividends will generally be included in a U.S.
Holder&#146;s income on the date of the U.S. Holder&#146;s receipt (or deemed receipt) of the dividend. The amount of any distribution of property other than cash (and excluding certain pro rata distributions of ordinary shares or ADSs or rights to
acquire ordinary shares or ADSs) will be the fair market value of such property on the date of the distribution. The amount of any dividend income paid in euros will be the U.S. dollar amount calculated by reference to the exchange rate in effect on
the date of actual or constructive receipt, regardless of whether the payment is in fact converted into U.S. dollars. If the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">246 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dividend is converted into U.S. dollars on the date of receipt, a U.S. Holder should not be required to recognize foreign currency gain or loss in respect of the dividend income. A U.S. Holder
may have foreign currency gain or loss if the dividend is converted into U.S. dollars after the date of receipt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to applicable
limitations, some of which vary depending upon the U.S. Holder&#146;s particular circumstances, French income taxes withheld from dividends on the ADSs at a rate not exceeding the rate provided by the income tax treaty between France and the United
States will generally be creditable against the U.S. Holder&#146;s U.S. federal income tax liability. Dividend distributions with respect to the ADSs generally will be treated as &#145;&#145;passive category&#146;&#146; income from sources outside
the United States for purposes of determining a U.S. Holder&#146;s U.S. foreign tax credit limitation. The rules governing foreign tax credits are complex and U.S. Holders should consult their tax advisers regarding the creditability of foreign
taxes in their particular circumstances. In lieu of claiming a foreign tax credit, U.S. Holders may, at their election, deduct foreign taxes, including any French income tax, in computing their taxable income, subject to generally applicable
limitations under U.S. law. An election to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sale or Other Taxable Disposition of the ADSs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. Holder will generally recognize gain or loss for U.S. federal income tax purposes upon the sale, exchange or other taxable disposition
of the ADSs in an amount equal to the difference between the U.S. dollar value of the amount realized from such sale or exchange and the U.S. Holder&#146;s tax basis for those ADSs. Subject to the PFIC rules described below, this gain or loss will
generally be a capital gain or loss. The adjusted tax basis in an ADS generally will be equal to the cost of such ADS. Capital gain from the sale, exchange or other taxable disposition of ADSs of a
<FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder is generally eligible for a preferential rate of taxation applicable to capital gains, if the <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder&#146;s holding period
determined at the time of such sale, exchange or other taxable disposition for such ADSs exceeds one year (<I>i.e.,</I> such gain is long-term taxable gain). The deductibility of capital losses for U.S. federal income tax purposes is subject to
limitations under the Code. Any such gain or loss that a U.S. Holder recognizes generally will be treated as U.S. source income or loss for foreign tax credit limitation purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a cash basis taxpayer, units of foreign currency paid or received are translated into U.S. dollars at the spot rate on the settlement date
of the purchase or sale. In that case, no foreign currency exchange gain or loss will result from currency fluctuations between the trade date and the settlement date of such a purchase or sale. An accrual basis taxpayer, however, may elect the same
treatment required of cash basis taxpayers with respect to purchases and sales of the ADSs that are traded on an established securities market, provided the election is applied consistently from year to year. Such election may not be changed without
the consent of the IRS. For an accrual basis taxpayer who does not make such an election, units of foreign currency paid or received are translated into U.S. dollars at the spot rate on the trade date of the purchase or sale. Such an accrual basis
taxpayer may recognize exchange gain or loss based on currency fluctuations between the trade date and the settlement date. Any foreign currency gain or loss a U.S. Holder realizes will be U.S. source ordinary income or loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Passive Foreign Investment Company Rules </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Code, we will be a PFIC for any taxable year in which, after the application of certain
<FONT STYLE="white-space:nowrap">&#147;look-through&#148;</FONT> rules with respect to subsidiaries, either (i) 75% or more of our gross income consists of &#147;passive income,&#148; (&#147;income test&#148;) or (ii) 50% or more of the average
quarterly value of our assets (generally determined on the basis of a weighted quarterly average) consist of assets that produce, or are held for the production of, &#147;passive income.&#148; Passive income generally includes dividends, interest,
and gains from the sale or exchange of investment property and rents or royalties other than rents or royalties which are received from unrelated parties in connection with the active conduct of a trade or business. Passive assets include, among
others, cash and assets readily convertible into cash, while our goodwill and other unbooked intangibles associated with active business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">247 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
activities may generally be treated as non-passive assets. In addition, for purposes of the above calculations, a non-U.S. corporation that owns, directly or indirectly, at least 25% by value of
the equity interests of another corporation is treated as if it held its proportionate share of the assets of the other corporation, and received directly its proportionate share of the income of the other corporation. If a corporation is treated as
a PFIC with respect to a U.S. Holder for any taxable year, the corporation will continue to be treated as a PFIC with respect to that U.S. Holder in all succeeding taxable years, regardless of whether the corporation continues to meet the PFIC
requirements in such years, unless certain elections are made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our analysis of our financial statements, activities and relevant
market and shareholder data, we do not believe that we were a PFIC for the taxable year ended December 31, 2022. Whether we are a PFIC for any taxable year will depend on the composition of our income and the composition, nature and value of our
assets from time to time (including the value or our goodwill, which may be determined by reference to the value of our ADSs, which could fluctuate considerably). We currently do not generate product revenues and therefore we may be a PFIC for any
taxable year in which we do not generate sufficient amounts of non-passive income to offset our passive financing income. As a result, there can be no assurance that we will not be treated as a PFIC for the current or any future taxable year and our
U.S. counsel expresses no opinion with respect to our PFIC status for any prior, current or future taxable year. Even if we determine that we are not a PFIC for a taxable year, there can be no assurance that the IRS, will agree with our conclusion
and that the IRS would not successfully challenge our position. If we are a PFIC for any year during which a U.S. Holder holds the ADSs, unless certain elections have been made by the U.S. Holder, we generally will continue to be treated as a PFIC
with respect to such U.S. Holder for all succeeding years during which the U.S. Holder holds the ADSs, even if we cease to meet the threshold requirements for PFIC status. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are a PFIC for any taxable year during which a U.S. Holder holds the ADSs, the U.S. Holder may be subject to adverse tax consequences,
regardless of whether we remain a PFIC. Generally, gain recognized upon a disposition (including, under certain circumstances, a pledge) of the ADSs by the U.S. Holder would be allocated ratably over the U.S. Holder&#146;s holding period for such
ADSs. The amounts allocated to the taxable year of disposition and to years before we became a PFIC <FONT STYLE="white-space:nowrap">(&#147;pre-PFIC</FONT> Years&#148;) would be taxed as ordinary income. The amount allocated to each other taxable
years would be subject to tax at the highest rate in effect for that taxable year for individuals or corporations, as appropriate, and would be subject to an interest charge on the resulting tax deemed deferred with respect to each such other
taxable year. Further, to the extent that any distribution received by a U.S. Holder on its ADSs exceeds 125% of the average of the annual distributions on such ADSs received by the U.S. Holder during the (i)&nbsp;preceding three years or
(ii)&nbsp;the U.S. Holder&#146;s holding period, whichever is shorter, that distribution would be subject to taxation in the same manner described immediately above with respect to gain on disposition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Alternatively, if we are a PFIC and if the ADSs are &#147;regularly traded&#148; on a &#147;qualified exchange,&#148; a U.S. Holder could make
a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election that would result in tax treatment different from the general tax treatment described in the preceding paragraph. The ADSs would be treated as
&#147;regularly traded&#148; in any calendar year in which more than a <I>de minimis </I>quantity of the ADSs are traded on a qualified exchange, including the Nasdaq Global Market, on at least 15 days during each calendar quarter. The ADSs are
listed on the Nasdaq Global Market, and we expect, although no assurance can be given, that they will be regularly traded on the Nasdaq Global Market. U.S. Holders should consult with their own tax advisors regarding potential availability of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a U.S. Holder makes the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election, the U.S. Holder generally will recognize as ordinary income any excess of the fair market value of the ADSs at the end of each taxable year over their
adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the ADSs over their fair market value at the end of the taxable year (but only to the extent of the net amount of income previously
included as a result of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election). If a U.S. Holder makes the election, the U.S. Holder&#146;s tax basis in the ADSs will be adjusted to reflect these
income or loss amounts. Any gain recognized on the sale or other disposition of ADSs in a year when we are a PFIC will be treated as ordinary income and any loss will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">248 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treated as an ordinary loss (but only to the extent of the net amount of income previously included as a result of the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election). If a U.S. Holder makes a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election in respect of
a corporation classified as a PFIC and such corporation ceases to be classified as a PFIC, the holder will not be required to take into account the gain or loss described above during any period that such corporation is not classified as a PFIC.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A timely election to treat a PFIC as a qualified electing fund under Section&nbsp;1295 of the Code (&#147;QEF Election&#148;) would
result in alternative treatment. If a U.S. Holder makes a QEF Election for the first tax year of such U.S. Holder&#146;s holding period in which we are classified as a PFIC, then such U.S. Holder generally would not be subject to the PFIC
rules&nbsp;described above.&nbsp;Instead, a U.S. Holder that makes a timely and effective QEF Election will currently include in gross income such U.S. Holder&#146;s (a) pro rata share of our ordinary earnings as ordinary income and (b)&nbsp;pro
rata share of our net capital gain as long-term capital gain, regardless of whether we have made any distributions of such earnings or gain. The U.S. Holder&#146;s basis in its ADSs would be increased to reflect the amount of such income
inclusions.&nbsp;Generally, for this purpose, &#147;ordinary earnings&#148; are the excess of our (a) &#147;earnings and profits&#148; over (b)&nbsp;net capital gain, and &#147;net capital gain&#148; is the excess of our (a)&nbsp;net long-term
capital gain over (b)&nbsp;net short-term capital loss.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. Holder that has made such a timely and effective QEF Election generally may
receive a distribution <FONT STYLE="white-space:nowrap">tax-free</FONT> as a return of capital to the extent that such distribution represents &#147;earnings and profits&#148; that were previously included in income by the U.S. Holder because of
such QEF Election and such distribution&nbsp;will reduce such U.S. holder&#146;s adjusted tax basis in our ADSs to reflect the amount allowed as a tax free distribution because of such QEF Election.&nbsp;A U.S. Holder that makes a QEF Election would
generally recognize capital gain or loss on the sale, exchange or other taxable disposition of its ADSs<B>.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, a U.S. Holder
will only be able to make a QEF Election if we provide such U.S. Holder with certain tax information annually, and we may determine not to provide such information. Furthermore, if the IRS determines that we were a PFIC for a year with respect to
which we had determined that we were not (or believed we were not) a PFIC, it might be too late for a U.S. Holder to make a timely QEF Election, unless the U.S. Holder qualifies under the applicable Treasury Regulations to make a retroactive (late)
election. U.S. Holders should consult their own tax advisors regarding the making of any such QEF Election. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if we are a PFIC
or, with respect to particular U.S. Holders, are treated as a PFIC for the taxable year in which we paid a dividend or for the prior taxable year, the preferential rates discussed above with respect to dividends paid to certain <FONT
STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders would not apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a U.S. Holder owns ADSs during any year in which we are
a PFIC, the holder generally must file an IRS Form 8621, or such other form as is required by the U.S. Treasury Department, generally with the holder&#146;s federal income tax return for that year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. Holders should consult their tax advisers regarding whether we are or may become a PFIC and the potential application of the PFIC rules.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information Reporting and Backup Withholding </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments of distributions and sales proceeds that are made within the United States or through certain U.S.-related financial intermediaries
generally are subject to information reporting, and may be subject to backup withholding, unless (i)&nbsp;the U.S. Holder is a corporation or other exempt recipient or (ii)&nbsp;in the case of backup withholding, the U.S. Holder provides a correct
taxpayer identification number and certifies that it is not subject to backup withholding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax.
The amount of any backup withholding from a payment to a U.S. Holder will be allowed as a credit against the holder&#146;s U.S. federal income tax liability and may entitle it to a refund, provided that the required information is timely furnished
to the IRS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">249 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information With Respect to Foreign Financial Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain U.S. Holders who are individuals may be required to report information relating to their ownership of an interest in certain foreign
financial assets, including stock of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> person, generally on Form 8938, subject to exceptions (including an exception for stock held through a U.S. financial institution). In addition, certain U.S.
Holders may be required to file a FinCEN Form 114 (Report of Foreign Bank and Financial Accounts) with the U.S. Treasury Department each year to report their interest in the ADSs. U.S. Holders should consult their tax advisers regarding their
reporting obligations with respect to the ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The above description is not intended to constitute a complete analysis of all tax
consequences relating to acquisition, ownership and disposition of the ADSs. You should consult your tax advisor concerning the tax consequences of your particular situation. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">250 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_22"></A>UNDERWRITERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus, the underwriters named below,
for whom Morgan Stanley &amp; Co. LLC and Leerink Partners LLC are acting as representatives, have severally agreed to purchase, and we have agreed to sell to them, severally, the number of ADSs (including underlying ordinary shares) and ordinary
shares indicated below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>ADSs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Ordinary<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Morgan Stanley &amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bryan Garnier Securities SAS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bryan Garnier &amp; Co Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LifeSci Capital LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The closings of the U.S. offering and the European private placement will occur simultaneously. The total
number of ordinary shares (including in the form of ADSs) in the U.S. offering and European private placement is subject to reallocation between these offerings, as permitted under applicable laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and the representatives are collectively referred to as the &#147;underwriters&#148; and the &#147;representatives,&#148;
respectively. The underwriters are offering the ADSs and ordinary shares subject to their acceptance of the ADSs and ordinary shares from us and subject to prior sale. The underwriting agreement provides that the obligations of the several
underwriters to pay for and accept delivery of the ADSs and ordinary shares offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriters are obligated to take and
pay for all of the ADSs and ordinary shares offered by this prospectus if any such ADSs and ordinary shares are taken. However, the underwriters are not required to take or pay for the ADSs and/or ordinary shares covered by the underwriters&#146;
over-allotment option described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters initially propose to offer part of the ADSs and ordinary shares directly to the
public at the offering price listed on the cover page of this prospectus and part to certain dealers at a price that represents a concession not in excess of $ &#8195;&#8195;&#8195;&#8195;per ADS and &#128; &#8195;&#8195;&#8195;&#8195;&#8195;per
ordinary share under the public offering price. After the initial offering of the ADSs and ordinary shares, the offering price and other selling terms may from time to time be varied by the representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase up to 2,801,325
additional ADSs and/or ordinary shares at the public offering price listed on the cover page of this prospectus, less underwriting commissions. The underwriters may exercise this option solely for the purpose of covering over-allotments, if any,
made in connection with the offering of the ADSs and ordinary shares offered by this prospectus. To the extent the option is exercised, each underwriter will become obligated, subject to certain conditions, to purchase about the same percentage of
the additional ADSs and/or ordinary shares as the number listed next to the underwriter&#146;s name in the preceding table bears to the total number of ADSs and/or ordinary shares listed next to the names of all underwriters in the preceding table.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">251 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the per ADS, per ordinary share and total public offering
price, underwriting commissions, and proceeds before expenses to us. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase up to an additional 2,801,325 ADSs and/or ordinary shares. </P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per ADS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Ordinary Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No<BR>Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full<BR>Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No<BR>Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full<BR>Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No<BR>Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full<BR>Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting commissions to be paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes an exchange rate of $&#8195;&#8195;&#8195; per euro, the exchange rate on &#8195;&#8195;&#8195;, 2023,
as reported by the European Central Bank. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated offering expenses payable by us, exclusive of the underwriting
commissions, are approximately $7.0 million. We have agreed to reimburse the underwriters for expenses relating to clearance of this offering with the Financial Industry Regulatory Authority up to $45,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters have informed us that they do not intend sales to discretionary accounts to exceed 5% of the total number of ADSs and
ordinary shares offered by them. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of the underwriters are expected to make offers and sales both inside and outside the United
States through their respective selling agents. Any offers or sales in the United States will be conducted by broker-dealers registered with the SEC. Bryan, Garnier &amp; Co will not effect any offers or sales of any ADSs in the United States unless
it is through one or more U.S. registered broker-dealers as permitted by the regulations of FINRA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have requested that
the underwriters make issuer directed allocations in the aggregate of &#8195;&#8195;&#8195; to certain investors. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied to
list our ADSs on the Nasdaq Global Market under the symbol &#147;ABVX.&#148; Our ordinary shares are listed on Euronext Paris under the symbol &#147;ABVX.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and all directors and executive officers and certain of our shareholders have agreed that, without the prior written consent of Morgan
Stanley &amp; Co. LLC and Leerink Partners LLC on behalf of the underwriters, we and they will not, and will not publicly disclose an intention to, during the period ending 90 days after the date of this prospectus (the &#147;restricted
period&#148;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any ADSs, ordinary shares, or any securities convertible into or exercisable or exchangeable for ADSs or ordinary shares
(such other securities, including any received upon grant or vesting pursuant to a free share plan, &#147;derivative securities&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">file any registration statement with the SEC relating to the offering of any ADSs, ordinary shares or
derivative securities; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">enter into any hedging, swap or other arrangement that transfers to another, in whole or in part, any of the
economic consequences of ownership of ADSs, ordinary shares or derivative securities, whether any such transaction described above is to be settled by delivery of ADSs, ordinary shares or derivative securities, in cash or otherwise.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we and each such person agrees that, without the prior written consent of Morgan Stanley &amp; Co. LLC and
Leerink Partners LLC on behalf of the underwriters, we or such other person will not, during the restricted period, make any demand for, or exercise any right with respect to, the registration of any ADSs, ordinary shares or derivative securities.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">252 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to us, the restrictions described above do not apply to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the sale of the ADSs and ordinary shares offered by this prospectus to the underwriters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the issuance of ADSs or ordinary shares upon the exercise of an option or warrant or the conversion of a
security outstanding on the date of this prospectus and described herein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the issuance of ADSs, ordinary shares, share options, free shares or warrants pursuant to existing shareholder
authorizations described in this prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the facilitating of the establishment of a trading plan on behalf of any of our shareholders, officers or
directors pursuant to Rule 10b5-1 under the Exchange Act (&#147;10b5-1 trading plan&#148;) for the transfer of ADSs or ordinary shares or of the amendment of an existing 10b5-1 trading plan, provided that (i) such 10b5-1 trading plan does not
provide for the transfer of ADSs or ordinary shares during the restricted period and (ii) no public announcement or filing under the Exchange Act or otherwise is required of or voluntarily made by or on behalf of the applicable individual or us
regarding the establishment or amendment of such 10b5-1 trading plan; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the entry into any agreement providing for the issuance by us of ADSs, ordinary shares or derivative securities
in connection with (i) the acquisition by us of the securities, business, technology, property or other assets of another person or entity, or pursuant to an employee benefit plan assumed by us in connection with such acquisition, or (ii) joint
ventures, commercial relationships or other strategic transactions, and in each case, the issuance of any such securities pursuant to any such agreement; provided, however, that the aggregate number of ADSs, ordinary shares or derivative securities
that we may sell or issue or agree to sell or issue shall not exceed 5% of the total number of ordinary shares (including in the form of ADSs) issued and outstanding immediately following the completion of this offering; and provided, further, that
we must cause each recipient of such securities to execute and deliver to the representatives, on or prior to the issuance of such securities, a lock-up agreement substantially in the form attached to the underwriting agreement with respect to the
remainder of the restricted period and enter stop transfer instructions with our transfer agent and registrar for such securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, with respect to our directors and executive officers and certain of our shareholders, the restrictions described above are
subject to specified exceptions, including, without limitation and subject in certain cases to various conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transactions relating to ADSs, ordinary shares or derivative securities acquired in this offering or in open
market transactions after the completion of this offering; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers of ADSs, ordinary shares or derivative securities (i) as a <I>bona fide</I> gift; (ii) to any trust
for the direct or indirect benefit of such person; (iii) as a distribution or other transfer by a corporation to its shareholders or former shareholder or to any wholly-owned subsidiary of such corporation; (iv) to such person&#146;s affiliates or
to any investment fund or other entity controlled or managed by such person; (v)&nbsp;pursuant to a qualified domestic relations order or in connection with a divorce settlement or (vi) by will or intestate succession or intestate distribution upon
the death of such person; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">surrender of ordinary shares to the depositary or the depositary&#146;s custodian for the purpose of receiving
an equivalent number of ADSs in lieu of such ordinary shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers of ADSs, ordinary shares or derivative securities to the company in satisfaction of any tax
withholding obligation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers or sales of up to 1,000,000 ADSs or ordinary shares (in the aggregate for all of our directors,
officers and affiliates) used for the primary purpose of satisfying any withholding tax or other governmental withholding or payment obligations pursuant to equity awards granted under a share incentive plan or other equity award plan that is
described in this prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers of ADSs, ordinary shares or derivative securities to us pursuant to any contractual arrangement that
provides for the repurchase of the ADSs, ordinary shares or derivative securities held by such person </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">253 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
in connection with the termination of such person&#146;s services to us or such person&#146;s failure to meet certain conditions set out upon receipt of such ADSs, ordinary shares or derivative
securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the exercise or exchange by such person of any option or warrant to acquire any ADSs or ordinary shares or
option to purchase ADSs or ordinary shares, in each case for cash or on a &#147;cashless&#148; or &#147;net exercise&#148; basis, pursuant to any share option, share bonus or other share plan or arrangement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the transfer of ADSs, ordinary shares or derivative securities upon the completion of a bona fide third-party
tender offer, merger, consolidation or other similar transaction that is approved by our Board, made to all holders of our securities and involves a change of control of us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the establishment of a 10b5-1 trading plan for the transfer of ADSs or ordinary shares or the amendment of an
existing 10b5-1 trading plan, provided that such 10b5-1 trading plan does not provide for the transfer of ADSs or ordinary shares during the restricted period; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sales by one of our shareholders of up to 265,000 ordinary shares in the aggregate pursuant to certain
regulatory obligations imposed by the AMF. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Morgan Stanley &amp; Co. LLC and Leerink Partners LLC, in their sole
discretion, may release the ADSs, ordinary shares and derivative securities subject to the lock-up agreements described above in whole or in part at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to facilitate the offering of the ADSs and ordinary shares, the underwriters may engage in transactions that stabilize, maintain or
otherwise affect the price of the ADSs and/or ordinary shares. Specifically, the underwriters may sell more ADSs and ordinary shares than they are obligated to purchase under the underwriting agreement, creating a short position. A short sale is
covered if the short position is no greater than the number of ADSs and ordinary shares available for purchase by the underwriters under the over-allotment option. The underwriters can close out a covered short sale by exercising the over-allotment
option or purchasing ADSs and/or ordinary shares in the open market. In determining the source of ADSs and/or ordinary shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of ADSs and/or
ordinary shares compared to the price available under the over-allotment option. The underwriters may also sell ADSs and ordinary shares in excess of the over-allotment option, creating a naked short position. The underwriters must close out any
naked short position by purchasing ADSs and/or ordinary shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the ADSs and/or ordinary
shares in the open market after pricing that could adversely affect investors who purchase in this offering. As an additional means of facilitating this offering, the underwriters may bid for, and purchase, ADSs and ordinary shares in the open
market to stabilize the price of the ADSs and ordinary shares. These activities may raise or maintain the market price of the ADSs and ordinary shares above independent market levels or prevent or retard a decline in the market price of the ADSs and
ordinary shares. The underwriters are not required to engage in these activities and may end any of these activities at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and
the underwriters have agreed to indemnify each other against certain liabilities, including liabilities under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A
prospectus in electronic format may be made available on websites maintained by one or more underwriters, or selling group members, if any, participating in this offering. The representatives may agree to allocate a number of ADSs and/or ordinary
shares to underwriters for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to underwriters that may make Internet distributions on the same basis as other allocations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include
securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Certain of the underwriters and their respective affiliates
have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees and expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">254 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their various business activities, the underwriters
and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the
accounts of their customers and may at any time hold long and short positions in such securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and their respective affiliates
may also make investment recommendations or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such securities
and instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pricing of the Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our ordinary shares are traded on Euronext Paris, prior to this offering, there has been no public market for our ADSs or ordinary shares
in the United States. The offering price for our ADSs in U.S. dollars and the corresponding offering price for our ordinary shares in euros was determined through negotiations between us and the representatives, and by reference to the prevailing
market prices of our ordinary shares on Euronext Paris after taking into account market conditions and other factors. However, in accordance with French law and the shareholders&#146; resolutions applicable to this offering, such prices will not be
lower than 10% below the volume-weighted average price of our ordinary shares on Euronext Paris for the three trading days preceding the appropriate reference date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Australia</I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and
Investments Commission in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001, or the Corporations Act, and does not purport to include
the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
offer in Australia of the securities may only be made to persons, or the Exempt Investors, who are &#147;sophisticated investors&#148; (within the meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the
meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations Act so that it is lawful to offer the securities without disclosure to investors under Chapter 6D of the
Corporations Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of
12 months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or
otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring securities must observe such Australian on-sale restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains general information only and does not take into account the investment objectives, financial situation or particular
needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate for their
needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area (each, a &#147;Relevant State&#148;), no securities have been offered or will be
offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the securities which has been approved by the competent authority in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">255 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation,
except that offers of the securities may be made to the public in that Relevant State at any time under the following exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined under the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus
Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>provided</I> that no such offer of the securities shall require us or any of our representatives to publish a prospectus pursuant to
Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes
of this provision, the expression an &#147;offer to the public&#148; in relation to the securities in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to
be offered so as to enable an investor to decide to purchase any securities, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person in a Relevant State who receives any communication in respect of, or who acquires any securities under, the offering contemplated
hereby will be deemed to have represented, warranted and agreed to and with each of the underwriters and their affiliates and to us that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) it is a qualified investor within the meaning of the Prospectus Regulation; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) in the case of any securities acquired by it as a financial intermediary, as that term is used in Article 5 of the Prospectus Regulation,
(i) the securities acquired by it in the offering have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any Relevant State other than qualified investors, as
that term is defined in the Prospectus Regulation, or have been acquired in other circumstances falling within the points (a) to (d) of Article 1(4) of the Prospectus Regulation and the prior consent of the representative has been given to the offer
or resale; or (ii) where the securities have been acquired by it on behalf of persons in any Relevant State other than qualified investors, the offer of those securities to it is not treated under the Prospectus Regulation as having been made to
such persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, the underwriters and their affiliates, and others will rely upon the truth and accuracy of the foregoing
representation, acknowledgement and agreement. Notwithstanding the above, a person who is not a qualified investor and who has notified the representative of such fact in writing may, with the prior consent of the representative, be permitted to
acquire securities in the offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>MiFID II Product Governance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Solely for the purposes of each manufacturer&#146;s product approval process, the target market assessment in respect of ordinary shares has
led to the conclusion that: (i)&nbsp;the target market for the ordinary shares is eligible counterparties, professional clients and retail clients, each as defined in Directive 2014/65/EU, as amended (&#147;MiFID II&#148;); and (ii)&nbsp;all
channels for distribution of the ordinary shares to eligible counterparties, professional clients and retail clients are appropriate. Any person subsequently offering, selling or recommending the ordinary shares, or a distributor, should take into
consideration the manufacturers&#146; target market assessment; however, a distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the ordinary shares (by either adopting or refining the
manufacturers&#146; target market assessment) and determining appropriate distribution channels. For the avoidance of doubt, even if the target market includes retail clients, it has been decided that the ordinary shares will only be offered to
persons who meet the criteria of eligible counterparties and professional clients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">256 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>UK MiFIR Product Governance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Solely for the purposes of each manufacturer&#146;s product approval process, the target market assessment in respect of the securities has led
to the conclusion that: (i)&nbsp;the target market for the securities is retail clients, as defined in point (8)&nbsp;of article 2 of Regulation (EU) No.&nbsp;2017/565 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act
2018 (&#147;EUWA&#148;), and eligible counterparties, as defined in the Financial Conduct Authority (&#147;FCA&#148;) Handbook Conduct of Business Sourcebook (&#147;COBS&#148;) and professional clients, as defined in Regulation (EU) No 600/2014 as
it forms part of domestic law by virtue of the EUWA (&#147;UK MiFIR&#148;); and (ii)&nbsp;all channels for distribution of the securities are appropriate. Any person subsequently offering, selling or recommending the securities (a
&#147;distributor&#148;) should take into consideration the manufacturers&#146; target market assessment; however, a distributor subject to the FCA Handbook Product Intervention and Product Governance Sourcebook (the &#147;UK MiFIR Product
Governance Rules&#148;) is responsible for undertaking its own target market assessment in respect of the securities (by either adopting or refining the manufacturer&#146;s target market assessment) and determining appropriate distribution channels.
For the avoidance of doubt, even if the target market includes retail clients, it has been decided that the securities will only be offered to persons who meet the criteria of eligible counterparties and professional clients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United Kingdom </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus
and any other material in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this prospectus relates is available only to, and will be engaged in only
with persons who are (i) persons having professional experience in matters relating to investments who fall within the definition of investment professionals in Article 19(5) of the FPO; or (ii) high net worth entities falling within Article
49(2)(a) to (d) of the FPO; (iii) outside the UK; or (iv) persons to whom an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the FSMA) in connection with the issue or sale of any securities may
otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as &#147;Relevant Persons&#148;). The securities are only available in the UK to, and any invitation, offer or agreement to purchase or
otherwise acquire the securities will be engaged in only with, the Relevant Persons. This prospectus and its contents are confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any
other person in the UK. Any person in the UK that is not a Relevant Person should not act or rely on this prospectus or any of its contents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No securities have been offered or will be offered pursuant to the offering to the public in the UK prior to the publication of a prospectus
in relation to the securities which has been approved by the Financial Conduct Authority in the UK in accordance with the UK Prospectus Regulation and the FSMA, except that offers of the securities may be made to the public in the UK at any time:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK
Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Section&nbsp;86 of the FSMA, provided that no such offer of
securities shall require us or any of our representatives to publish a prospectus pursuant to Section&nbsp;85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to the securities in the UK means the
communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase or subscribe for any securities, and the expression &#147;UK Prospectus
Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">257 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person in the UK who acquires any securities in the offer or to whom any offer is made
will be deemed to have represented, acknowledged and agreed to and with us, the underwriters and their affiliates that it meets the criteria outlined in this section. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>France </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities have not
been and will not be offered or sold to the public in the Republic of France, and no offering of this prospectus or any marketing materials relating to securities may be made available or distributed in any way that would constitute, directly or
indirectly, an offer to the public in the Republic of France (except for public offerings defined in Article <FONT STYLE="white-space:nowrap">L.411-2</FONT> 1&deg; of the French Monetary and Financial Code). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may only be offered or sold in France pursuant to article L. <FONT STYLE="white-space:nowrap">411-2</FONT> 1&deg; of the French
Monetary and Financial&nbsp;Code to qualified investors (<I>investisseurs qualifi&eacute;s</I>) (as such term is defined in Article 2(e) of the Prospectus Regulation) acting for their own account, and in accordance with articles L. <FONT
STYLE="white-space:nowrap">411-1,</FONT> L. <FONT STYLE="white-space:nowrap">411-2</FONT> and D. <FONT STYLE="white-space:nowrap">411-2</FONT> to <FONT STYLE="white-space:nowrap">D.411-4</FONT> of the French Monetary and Financial&nbsp;Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prospective investors are informed that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither this prospectus nor any other offering materials relating to the securities described in this prospectus
has been submitted for clearance to the French financial markets authority (<I>Autorit&eacute; des march&eacute;s financiers);</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither this prospectus, nor any offering material relating to the securities has been or will be released,
issued, distributed or caused to be released, issued or distributed to the public in France or used in connection with any offer for subscription or sale of the securities to the public in France within the meaning of article L. 411-1 of the French
Monetary and Financial Code (other than public offerings defined in Article <FONT STYLE="white-space:nowrap">L.411-2</FONT> 1&deg; of the French Monetary and Financial&nbsp;Code); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">individuals or entities referred to in article L. <FONT STYLE="white-space:nowrap">411-2</FONT> 1&deg; of the
French Monetary and Financial Code may participate in the offering, as provided under articles <FONT STYLE="white-space:nowrap">D.411-4</FONT> of the French Monetary and Financial&nbsp;Code; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the direct and indirect distribution or sale to the public of the securities acquired by them may only be made in
compliance with articles L. <FONT STYLE="white-space:nowrap">411-1,</FONT> L. <FONT STYLE="white-space:nowrap">411-2</FONT> 1&deg;, L. <FONT STYLE="white-space:nowrap">412-1</FONT> and L. <FONT STYLE="white-space:nowrap">621-8</FONT> to L. <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">621-8-2</FONT></FONT> of the French Monetary and Financial Code. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Canada </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may be sold
in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National <FONT STYLE="white-space:nowrap">Instrument&nbsp;45-106&nbsp;Prospectus</FONT> Exemptions or subsection 73.3(1)
of the Securities Act (Ontario), and are permitted clients, as defined in National <FONT STYLE="white-space:nowrap">Instrument&nbsp;31-103&nbsp;Registration</FONT> Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the
securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this
prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s
province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National <FONT STYLE="white-space:nowrap">Instrument&nbsp;33-105&nbsp;Underwriting</FONT> Conflicts <FONT
STYLE="white-space:nowrap">(NI&nbsp;33-105),&nbsp;the</FONT> underwriters are not required to comply with the disclosure requirements of <FONT STYLE="white-space:nowrap">NI&nbsp;33-105&nbsp;regarding</FONT> underwriter conflicts of interest in
connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">258 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dubai International Financial Centre </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority, or the
DFSA. This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or
verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The securities to which this prospectus
relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the contents of this prospectus you should
consult an authorized financial advisor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hong Kong </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (i)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (ii)&nbsp;in other circumstances which do not result in the document being a
&#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32)&nbsp;of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation
or document relating to our securities has been or may be issued or has been or may be in the possession of any person for the purposes of issuance, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be
accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to our securities which are or are intended to be disposed of only to persons outside Hong Kong or only to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance and any rules made under that Ordinance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Israel </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Israeli Securities Law, and has not been
filed with or approved by the Israel Securities Authority. In Israel, this prospectus is being distributed only to, and is directed only at, and any offer of the securities hereunder is directed only at, (i) a limited number of persons in accordance
with the Israeli Securities Law and (ii) investors listed in the first addendum to the Israeli Securities Law, or the Addendum, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers,
investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50 million and &#147;qualified individuals,&#148; each as defined in the Addendum (as it may be amended from time
to time), collectively referred to as qualified investors (in each case, purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors are
required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Japan
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No registration pursuant to Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948, as
amended), or the FIEL, has been made or will be made with respect to the solicitation of the application for the acquisition of the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, the securities have not been, directly or indirectly, offered or sold and will not be, directly or indirectly, offered or sold in
Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan) or to others for re-offering or re-sale, directly
or indirectly, in Japan or to, or for the benefit of, any resident of Japan except pursuant to an exemption from the registration requirements, and otherwise in compliance with, the FIEL and the other applicable laws and regulations of Japan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">259 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For Qualified Institutional Investors, or QII </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph 2, Article 4 of the FIEL) in
relation to the securities constitutes either a &#147;QII only private placement&#148; or a &#147;QII only secondary distribution&#148; (each as described in Paragraph 1, Article 23-13 of the FIEL). Disclosure regarding any such solicitation, as is
otherwise prescribed in Paragraph 1, Article 4 of the FIEL, has not been made in relation to the securities. The securities may only be transferred to QIIs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For Non-QII Investors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please note that
the solicitation for newly-issued or secondary securities (each as described in Paragraph 2, Article 4 of the FIEL) in relation to the securities constitutes either a &#147;small number private placement&#148; or a &#147;small number private
secondary distribution&#148; (each as is described in Paragraph 4, Article 23-13 of the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article 4 of the FIEL, has not been made in relation to the
securities. The securities may only be transferred en bloc without subdivision to a single investor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Singapore </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of the securities may not be circulated or distributed, nor may the securities be offered or sold, or be made the subject of an invitation for
subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA, (ii)&nbsp;to a
relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the
conditions of, any other applicable provision of the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the securities are subscribed or purchased under Section&nbsp;275 of the
SFA by a relevant person which is (a) a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more
individuals, each of whom is an accredited investor; or (b) a trust (where the trustee is not an accredited investor ) the sole purpose of which is to hold investments and each beneficiary of the trust is an individual who is an accredited investor,
securities (as defined in Section 239(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired
the securities pursuant to an offer made under Section&nbsp;275 of the SFA except: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) to an institutional investor or to a relevant
person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; (ii) where no consideration is or will be given for the transfer; (iii) where the
transfer is by operation of law; (iv) as specified in Section 276(7) of the SFA; or (v) as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations 2018.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Solely for the purposes of its obligations pursuant to Section 309B of the SFA, we have determined, and hereby notify all relevant
persons (as defined in the CMP Regulations 2018), that the shares are &#147;prescribed capital markets products&#148; (as defined in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA 04-N12: Notice on the Sale
of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Switzerland </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is not intended to constitute an offer or solicitation to purchase or invest in our securities. Our securities may not be
publicly offered, directly or indirectly, in Switzerland within the meaning of the Swiss </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">260 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Financial Services Act, or the FinSA, and no application has or will be made to admit our securities to trading on any trading venue (exchange or multilateral trading facility) in Switzerland.
Neither this prospectus nor any other offering or marketing material relating to our securities constitutes a prospectus pursuant to the FinSA, and neither this prospectus nor any other offering or marketing material relating to our securities may
be publicly distributed or otherwise made publicly available in Switzerland. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">261 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_23"></A>EXPENSES RELATING TO THE GLOBAL OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the costs and expenses, other than underwriting commissions, payable in connection with the sale of ordinary
shares (which may be in the form of ADSs) in the global offering. All amounts are estimated except the SEC registration fee, the Nasdaq initial listing fee and the FINRA filing fee. Except as otherwise noted, all the expenses below will be paid by
us. Some figures have been rounded. Accordingly, the totals in the table may not be the exact sums of component items.</P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>EXPENSES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq initial listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,209,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,812,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">420,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,029,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">262 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_24"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of our ordinary shares (which may be in the form of ADSs) and certain other matters of French law will be passed upon for us by
Dechert (Paris) LLP. Certain matters of U.S. federal and New York state law will be passed upon for us by Cooley LLP, New York, New York. Latham &amp; Watkins LLP, New York, New York, with respect to U.S. federal law, and Gide Loyrette Nouel
A.A.R.P.I., with respect to French law, are acting as counsel for the underwriters in connection with the global offering. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_25">
</A>EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements as of December&nbsp;31, 2021 and December&nbsp;31, 2022 and for each of the two years in the
period ended December&nbsp;31, 2022 included in this prospectus have been so included in reliance on the report of PricewaterhouseCoopers Audit, an independent registered public accounting firm, given on the authority of said firm as experts in
auditing and accounting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offices of PricewaterhouseCoopers Audit are located at 63, rue de Villiers, 92200 <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Neuilly-sur-Seine,</FONT></FONT> France. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_25a"></A>DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act, may be permitted to our directors, officers or persons
controlling us, we have been advised that it is the SEC&#146;s opinion that such indemnification is against public policy as expressed in such act and is, therefore, unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">263 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_26"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the Securities and Exchange Commission a registration statement (including amendments and exhibits to the registration
statement) on Form <FONT STYLE="white-space:nowrap">F-1</FONT> under the Securities Act. A related registration statement on Form <FONT STYLE="white-space:nowrap">F-6</FONT> will be filed with the Securities and Exchange Commission to register the
ADSs. This prospectus, which is part of the registration statement, does not contain all of the information set forth in the registration statement and the exhibits and schedules to the registration statement. For further information, we refer you
to the registration statement and the exhibits and schedules filed as part of the registration statement. If a document has been filed as an exhibit to the registration statement, we refer you to the copy of the document that has been filed. Each
statement in this prospectus relating to a document filed as an exhibit is qualified in all respects by the filed exhibit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon
completion of the U.S. offering, we will become subject to the informational requirements of the Exchange Act. Accordingly, we will be required to file reports and other information with the SEC, including annual reports on <FONT
STYLE="white-space:nowrap">Form&nbsp;20-F</FONT> and reports on Form <FONT STYLE="white-space:nowrap">6-K.</FONT> The SEC maintains a website that contains reports and other information about issuers, like us, that file electronically with the SEC.
The address of that website is www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a foreign private issuer, we are exempt under the Exchange Act from, among other things,
the rules prescribing the furnishing and content of proxy statements, and our directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&nbsp;16 of the Exchange Act. In
addition, we will not be required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will send the transfer agent a copy of all notices of shareholders&#146; meetings and other reports, communications and information that
are made generally available to shareholders. The transfer agent has agreed to mail to all shareholders a notice containing the information (or a summary of the information) contained in any notice of a meeting of our shareholders received by the
transfer agent and will make available to all shareholders such notices and all such other reports and communications received by the transfer agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a corporate website at www.abivax.com. The reference to our website is an inactive textual reference only and information
contained in, or that can be accessed through, our website or any other website cited in this prospectus is not part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">264 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A><A NAME="toc609070_27"></A>INDEX TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial Statements as of and for the Years Ended December&nbsp;31, 2021 and 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin609070_2">Report of Independent Registered Public Accounting Firm </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin609070_3">Statements of Financial Position as of December&nbsp;31, 2021 and 2022
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin609070_4">Statements of Income (Loss) for the Years Ended December&nbsp;
31, 2021 and 2022</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin609070_5">Statements of Comprehensive Income (Loss) for the Years Ended December 31, 2021
 and 2022</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin609070_6">Statements of Changes in Shareholders&#146; Equity for the Years Ended December&nbsp;31,
 2021 and 2022</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin609070_7">Statements of Cash Flows for the Years Ended December&nbsp;
31, 2021 and 2022</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin609070_8">Notes to the Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial Statements as of and for the Six-Month Periods Ended June&nbsp;30, 2022 and
2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin609070_9">Unaudited Interim Condensed Consolidated Statements of Financial Position as of
 December&nbsp;31, 2022 and June&nbsp;30, 2023</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin609070_10">Unaudited Interim Condensed Consolidated Statements of Income (Loss) for the
 Periods Ended June&nbsp;30, 2022 and 2023 </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin609070_11">Unaudited Interim Condensed Consolidated Statements of Comprehensive Income (Loss)
 for the Periods Ended June&nbsp;30, 2022 and 2023</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin609070_12">Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders&#146;
 Equity for the Periods Ended June&nbsp;30, 2022 and 2023</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin609070_13">Unaudited Interim Condensed Consolidated Statements of Cash Flows for the Periods
 Ended June&nbsp;30, 2022 and 2023</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin609070_14">Notes to the Unaudited Interim Condensed Consolidated Financial Statements
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin609070_2"></A>Report of Independent Registered Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Directors and Shareholders </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Opinion on
the Financial Statements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying statements of financial position of Abivax SA (the &#147;Company&#148;) as of December
31, 2022 and 2021, and the related statements of income (loss) and comprehensive income (loss), of changes in shareholders&#146; equity and of cash flows for each of the two years in the period ended December 31, 2022, including the related notes
(collectively referred to as the &#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its
operations and its cash flows for each of the two years in the period ended December 31, 2022 in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board and International Financial
Reporting Standards as adopted by the European Union. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis for Opinion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits of these
financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to
error or fraud. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting
principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Emphasis of Matter </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed in Note 2. Basis
of preparation to the financial statements, the Company will need to continue to rely on additional capital from investors or lenders to meet its forecasted operating cash flow requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers Audit </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neuilly-sur-Seine, France </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July 28, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor
since 2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin609070_3"></A>ABIVAX SA STATEMENTS OF FINANCIAL POSITION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands of euros) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of<BR>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of</B><br><B>December&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>6</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>7</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>8</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>9</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables and assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>10</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables and assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>10</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>11</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LIABILITIES AND SHAREHOLDERS&#146; EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Premiums related to share capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,361</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(82,770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>13</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retirement benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>16</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provisions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible loan notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15.1&nbsp;&amp;&nbsp;15.3</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15.1 &amp; 15.3</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15.5</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>22</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible loan notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15.3</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15.5</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>17.1</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax and employee-related payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>17.2</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL LIABILITIES AND SHAREHOLDERS&#146; EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I><A NAME="fin609070_4"></A>ABIVAX SA STATEMENTS OF INCOME (LOSS) </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands of euros, except per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Year ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Year ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>18</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>19.1</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,781</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>19.2</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,580</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,492</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill impairment loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>6</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,632</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,361</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,561</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,022</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial gain (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>21</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,052</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss before tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>22</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss for the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss per share (&#128;/share)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of outstanding shares used for computing basic/diluted loss per
share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,455,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,092,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic / diluted loss per share (&#128;/share)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>23</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2.75</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3.18</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin609070_5"></A>ABIVAX SA STATEMENTS OF COMPREHENSIVE INCOME (LOSS) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands of euros) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Year ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Year ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss for the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(42,452</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(60,740</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Items that will not be reclassified to profit or loss</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>169</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>235</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Actuarial gains and losses on retirement benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>16</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Items that will be reclassified to profit or loss</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>169</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>235</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(42,283</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(60,506</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin609070_6"></A>ABIVAX SA STATEMENTS OF CHANGES IN SHAREHOLDERS&#146; EQUITY
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands of euros, except share date) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(In thousands of euros, except<BR>number of shares)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER&nbsp;OF<BR>SHARES<BR>ISSUED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SHARE<BR>CAPITAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PREMIUMS<BR>RELATED&nbsp;TO<BR>SHARE<BR>CAPITAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RESERVES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NET&nbsp;LOSS</B><br><B>FOR&nbsp;THE&nbsp;YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL<BR>SHAREHOLDER&#146;S<BR>EQUITY</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>As of January&nbsp;1, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,320,271</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>143</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>42,073</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,851</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(37,633</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,733</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total comprehensive loss for the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>169</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(42,452</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(42,283</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Appropriation of 2020 net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,633</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Capital increase from issuance of ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,964,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Transaction costs related to capital increase</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,090</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,090</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercises of share warrants under the Equity line agreement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">312,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercises of share warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Shares based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Transaction on treasury shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,764,051</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>168</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>107,578</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(39,361</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(42,452</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>25,934</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total comprehensive loss for the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>235</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(60,740</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(60,506</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Appropriation of 2021 net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Capital increase from issuance of ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,530,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Transaction costs related to capital increase</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercises of share warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Shares based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,164</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,164</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Transaction on treasury shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>22,313,185</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>223</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>150,476</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(82,771</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(60,740</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,189</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin609070_7"></A>ABIVAX SA STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Amounts in thousands of euros) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(In thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Cash flows used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Ajustments for:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Elimination of amortization of intangibles and depreciation of property, plant and
equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Elimination of Impairment loss of goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>6</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Elimination of retirement benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>16</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Elimination of share-based compensation expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>14</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,164</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">(-) Net gain on sale of treasury shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(108</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest expenses and other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>21</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">(-) Financial income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Effect of unwinding the discount related to conditional advances</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Decrease/(increase) in derivatives and liabilities fair value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,817</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Redemption of Covid 19 conditional advances</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>17</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Others</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Cash flows used in operating activities before change in working capital
requirements</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(44,381</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(51,933</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Decrease / (increase) in other receivables and related accounts</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,977</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Increase / (decrease) in trade payables</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Increase / (decrease) in tax and social security liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Increase / (decrease) in deferred income and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Changes in working capital requirements</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(667</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,002</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Cash flows used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(45,048</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(53,936</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Cash flows used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Acquisitions of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Acquisitions of property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Advances related to CRO contracts</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>9</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,187</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Repayment / (disbursement) of the advance made to the Nice CHU</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>10</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Payments for the acquisition of Prosynergia, incl. acquisition related costs, net of cash
acquired&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(1) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>4.15&nbsp;&amp;&nbsp;10</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,913</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Increase in deposits</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>9</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Decrease in deposits</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>9</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest received</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Cash flows used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,232</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(12,026</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Cash flows provided by (used in) financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Capital increases</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>13</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Transaction costs related to capital increase</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Warrants subscription</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Repayments of KREOS <SUP STYLE="font-size:75%; vertical-align:top">(2) </SUP>1&amp;2 bond
loans</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,537</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net proceeds from the royalty certificates</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net proceeds from OCEANE issuance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net proceeds from sale of treasury shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Repayments of conditional advances</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(90</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Payments of the lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(301</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,908</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,015</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Cash flows provided by (used in) financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>82,679</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32,211</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Increase (decrease) in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>31,399</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(33,751</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash and cash equivalents at the beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash and cash equivalents at the end of the year</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Increase (decrease) in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>31,399</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(33,751</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Prosynergia SARL (or &#147;Prosynergia&#148;) </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Kreos Capital V UK Ltd (or &#147;Kreos&#148;) </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin609070_8"></A>ABIVAX SA NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 1. The Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 1.1. Information on the
Company and its business </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABIVAX SA (the &#147;Company&#148;) is a <I>Soci&eacute;t&eacute; anonyme </I>incorporated under the laws of France on
December 4, 2013. Its registered office is located at <FONT STYLE="white-space:nowrap">7-11</FONT> Boulevard Haussmann&#151;75009 Paris, France. The Company is developing innovative therapeutic approaches (drugs and immunotherapies) to modulate the
body&#146;s natural immune system to treat patients with chronic inflammatory diseases, viral infections, and cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has incurred losses
since its inception and had shareholders&#146; equity of &#128;7,189&nbsp;thousand as of December 31, 2022. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its drug
candidates which are currently under development. Substantial additional financing will be needed by the Company to fund its operations and to commercially develop its drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s future operations are highly dependent on a combination of factors, including: (i)&nbsp;the success of its research and development
activities; (ii)&nbsp;regulatory approval and market acceptance of its proposed future products; (iii)&nbsp;the timely and successful completion of additional financing and (iv)&nbsp;the development of competitive therapies by other biotechnology
and pharmaceutical companies. As a result, the Company is, and expects to continue to be, in the short to <FONT STYLE="white-space:nowrap">mid-term,</FONT> financed through the issuance of new equity or debt instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is focusing its efforts on the following points: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continuation of the clinical development program for obefazimod, with priority given to the treatment of chronic
inflammatory diseases. The specific order of priority is as follows: chronic inflammatory bowel disease (&#147;IBD&#148;), starting with ulcerative colitis (&#147;UC&#148;), followed by Crohn&#146;s disease, and other indications.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continuation of other therapeutic indicators of obefazimod according to the relevance of scientific data and
research into potential derivative molecules of obefazimod. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Research into new molecules aimed at treating chronic inflammatory diseases and major viral infections
(&#147;Modulation of RNA Biogenesis&#148; platform). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2022, due to the lack of progress made in
the negotiation of a development partnership, the Company made the decision to freeze the development program for ABX196 in the treatment of hepatocellular cancer (see Note 3.2.Significant events for year ended December&nbsp;31, 2022). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 1.2. Date of authorization of issuance </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
financial statements and related notes (the &#147;financial statements&#148;) have been prepared under the responsibility of management of the Company and were approved and authorized for issuance by the Company&#146;s board of directors on April
18, 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2. Basis of preparation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except for
share data and per share amounts, the financial statements are presented in thousands of euros. Amounts are rounded up or down the nearest whole number for the calculation of certain financial data and other information contained in these accounts.
Accordingly, the total amounts presented in certain tables may not be the exact sum of the preceding figures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Statement of compliance </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of the Company as of and for the years ended December 31, 2021 and 2022 have been prepared in accordance with both International
Financial Reporting Standards (&#147;IFRS&#148;) as issued by the International Accounting Standard Board (&#147;IASB&#148;) and IFRS as adopted by the European Union (&#147;EU&#148;) regulation n&deg;1606/2002 of July 19, 2002. The term
&#147;IFRS&#148; refers collectively to International Accounting Standards (&#147;IAS&#148;) and IFRS as well as the interpretations issued by the Standing Interpretations Committee (&#147;SIC&#148;) and the International Financial Reporting
Interpretations Committee (&#147;IFRIC&#148;), whose application is mandatory for the year ended December 31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preparation of the financial
statements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of the Company were prepared on a historical cost basis, with the exception of certain asset and liability
categories and in accordance with the provisions set out in IFRS such as employee benefits measured using the projected unit credit method, borrowings measured at amortized cost and derivative financial instruments measured at fair value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Going concern </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has incurred substantial
operating losses since inception, and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. For the year ended December 31, 2022, the Company had a net loss of &#128;60.7 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since inception, the Company has financed its operations through the issuance of ordinary shares with gross aggregate proceeds of &#128;336.8 million, of
which &#128;130 million of gross proceeds were from offerings of its ordinary shares on Euronext Paris in February 2023, bank borrowings and structured loans for &#128;65.0 million to date, reimbursements of Research Tax Credits (Cr&eacute;dit
d&#146;Imp&ocirc;t Recherche (&#147;CIR&#148;)) in an aggregate amount of &#128;26.6 million, and subsidies received from Banque Publique d&#146;Investissement (&#147;Bpifrance&#148;) (including &#128;13.5 million of subsidies and &#128;6.6 million
of conditional advances to date). As a result of the level of available cash and cash equivalent of &#128;27.0 million as of December 31, 2022, the February 2023 capital increase amounting to &#128;123.3 million in net proceeds and the reimbursement
of the 2022 Research Tax Credit in 2023, and under the assumption that R&amp;D needs are being substantially increased in 2023, as the Company continues to make progress on its lead drug candidate obefazimod, which has started enrollment of patients
in its UC Phase 3 clinical trials in October 2022, the Company expects, as of the date of issuance of these financial statements, it will be able to fund its forecasted operating cash flow requirements throughout the second quarter of 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expects it will be able to extend its financing horizon beyond the second quarter of 2024 through additional dilutive and non-dilutive financing,
which could include a combination of capital increase, venture loans and convertible bonds. Based on the above and the actions the Company has taken, management has concluded that the substantial doubt about its ability to continue as a going
concern has been alleviated beyond 12 months from issuance of these financial statements, and these financial statements have been prepared on a going concern basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Impact of the Ukraine/Russia Hostilities on the Company </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2022, Russia invaded Ukraine. The conflict has already had major implications for the global economy and the rate of inflation, particularly in
relation to the supply of energy, raw materials and food products. It has also caused intense volatility on the financial markets, something that is still ongoing at the reporting date and has pushed down stock market prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given these developments, the Company has decided not to include Ukraine, Russia and Belarus in its global Phase 3 program for obefazimod in UC. However, the
global scale of this conflict cannot be predicted at this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stage. The Company, therefore, cannot rule out an adverse impact of this conflict on its business, including in terms of access to raw materials, logistics, the performance of clinical studies
and in relation to any future financing the Company may seek. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 2b maintenance trial of obefazimod in moderately to severely active UC is the
Company&#146;s only clinical trial currently in progress in Ukraine. The Company has, however, terminated a few trial sites since the Russia/Ukraine war began. The <FONT STYLE="white-space:nowrap">12-month</FONT> assessment was carried out in all
the Ukrainian patients before the war broke out and these patients are therefore included in the <FONT STYLE="white-space:nowrap">one-year</FONT> maintenance results that were reported on April&nbsp;6, 2022. Ukrainian patients who completed the <FONT
STYLE="white-space:nowrap">two-year</FONT> Phase 2b maintenance trial have been transitioned to the long-term safety and efficacy trial that is still <FONT STYLE="white-space:nowrap">on-going.</FONT> None of these sites are located in the Crimea
Region of Ukraine, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, or the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic. The Company is also evaluating the possibility to
include a few Ukrainian sites in the western part of Ukraine in the ABTECT Phase 3 clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Together with its CROs, the Company is making
considerable efforts to ensure the <FONT STYLE="white-space:nowrap">follow-up</FONT> of patients who are unable to come to the study centers. Monitoring takes place through a remote monitoring system that was established and used successfully during
the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>New, revised or amended Standards and Interpretations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company applied the following amendments to IFRS that are effective as of December 31, 2022: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendment to IFRS 16
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Leases&#151;COVID-19-Related</FONT></FONT> Rent Concessions beyond 30&nbsp;June 2021, whose application is for annual reporting periods beginning on or after April&nbsp;1, 2021;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IFRS 3 Business Combinations &#150; Reference to the Conceptual Framework, whose application is for
annual reporting periods beginning on or after January&nbsp;1, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IAS 16 &#150; Property, Plant and Equipment &#150; Proceeds before Intended Use, whose application
is for annual reporting periods beginning on or after January&nbsp;1, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IAS 37 Provisions, Contingent Liabilities and Contingent Assets &#150; Onerous
Contracts&nbsp;&#150;&nbsp;Cost of Fulfilling a Contract, whose application is for annual reporting periods beginning on or after January&nbsp;1, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual Improvements to IFRS Standards 2018-2020 &#150; Amendments to IFRS 1 First-time Adoption of International
Financial Reporting Standards, IFRS 9 Financial Instruments, IFRS 16 Leases, and IAS&nbsp;41 Agriculture, whose application is for annual reporting periods beginning on or after January&nbsp;1, 2022. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>New standards, amendments and interpretations issued by IASB but not yet mandatory for financial years starting from January 1, 2022 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company did not elect for early application of the following new standards, amendments and interpretations, which were issued but not mandatory as of
December&nbsp;31, 2022: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IAS 1 Presentation of Financial Statements and IFRS Practice Statement 2 &#150; Disclosure of
Accounting Policies, whose application is for annual reporting periods beginning on or after January&nbsp;1, 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IAS 8 &#150; Definition of Accounting Estimates, whose application is for annual reporting periods
beginning on or after January&nbsp;1, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IAS 12 &#150; Deferred Tax related to Assets and Liabilities arising from a Single Transaction,
whose application is for annual reporting periods beginning on or after January&nbsp;1, 2023; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IAS 1 Presentation of Financial Statements &#150; Classification of Liabilities as Current or <FONT
STYLE="white-space:nowrap">Non-current,</FONT> whose application is for annual reporting periods beginning on or after January&nbsp;1, 2024; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IFRS 16 Leases: Lease Liability in a Sale and Leaseback, whose application is for annual reporting
periods beginning on or after January&nbsp;1, 2024 (not yet approved by the UE). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company assessed the impacts resulting from the
application of these issued accounting pronouncements and concluded that impacts are not material. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3. Significant events for the years ended
December 31, 2021 and 2022 and subsequent events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 3.1. For the year ended December 31, 2021 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Share capital issuance and unsecured senior convertible bonds exchangeable for new or existing shares (or &#147;OCEANE&#148;) issuance&#151;July 2021
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company received a gross proceed of &#128;85.0&nbsp;million on<I> </I>July 30, 2021 through (i)&nbsp;the issuance of 1,964,031 ordinary shares
with a subscription price of &#128;30.55 per share, and (ii)&nbsp;the issuance of &#128;25,000&nbsp;thousand in OCEANE, maturing on July 30, 2026. The proceeds of the transaction mainly serve to finance the progress of ABX464 clinical trials in
chronic inflammatory. Note 15.3, &#147;OCEANE&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">COVID-19</FONT> BPI subsidies &#150; March 2021 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March 5, 2021, the Company announced the interruption of the phase 2b/3 miR-AGE <FONT STYLE="white-space:nowrap">Covid-19</FONT> clinical trial due to lack
of efficacy. As the Company terminated its financing agreement with Bpifrance in March 2021, Bpifrance made an additional payment of &#128;3.3&nbsp;million in October 2021 to reimburse additional expenses incurred by the Company and agreed to waive
the conditional advance of &#128;6.3&nbsp;million. See Note 15.5, &#147;Conditional Advances&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 3.2. For the year ended December 31, 2022
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Acquisition of Prosynergia SARL &#150; April 2022 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April 1, 2022, the Company acquired 100% of the share capital of Prosynergia SARL (or &#147;Prosynergia&#148;), a Luxembourg biotech company, in order to
strengthen its portfolio. The terms of the share purchase acquisition (or the &#147;Prosynergia SPA&#148;) entered on November 15, 2021 included an early payment of &#128;325&nbsp;thousand made on November 25, 2021 (see Note 10), an additional
payment of &#128;2,925&nbsp;thousand made on April 1, 2022, and possible <FONT STYLE="white-space:nowrap">earn-out</FONT> payments for a maximum additional amount of &#128;4,000&nbsp;thousand based on the potential evolution of the Company&#146;s
market capitalization, a listing of the Company&#146;s shares on Nasdaq or a M&amp;A transaction incurred before March 31, 2023. In addition, the Company granted a loan of &#128;1,400&nbsp;thousand to Prosynergia on December 1, 2021, which term was
at least on December 31, 2025 or at an earlier date in the event of a breach in the Prosynergia SPA (see Note 10, &#147;Other receivables and assets&#148;). Such prepayment was repayable in cash only in the event the transaction is not completed.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Considering that Prosynergia only owned patent rights but did not enter into any employee contract, research agreement, collaboration agreement or <FONT
STYLE="white-space:nowrap">out-licensed</FONT> agreement, it does not meet the definition of a business under IFRS 3. Consequently, the acquisition cost of this group of assets was allocated between the identifiable assets and liabilities acquired,
pro rata to their respective fair values as of April 1, 2022, without recognition of goodwill. Also, the &#128;1,400&nbsp;thousand loan granted to Prosynergia in December 2021 was included in the acquisition cost to be allocated, as it is considered
a prepayment for the acquisition of the group of assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Merger with Prosynergia &#150; December 2022 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;12, 2022, the Company completed the merger with Prosynergia under the French legal procedure called &#147;Transmission Universelle de
Patrimoine<I>&#148;</I> (universal transfer of assets and liabilities). All of Prosynergia&#146;s assets and liabilities were transferred to the Company and Prosynergia was dissolved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Impairment of ABX196 cash-generating unit </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the first half of 2022, management took into account significant external changes in the hepatocellular carcinoma (HC) treatment landscape. These changes
are expected to require a new, lengthy, heavy and risky internal development process (use of a combination of compounds). In this context, entering into a licensing partnership to fund the completion of the clinical development of ABX196 is the
option being considered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, due to the lack of progress made in the negotiation of a development partnership, the Company made the decision to
freeze the development program for ABX196 in the treatment of hepatocellular cancer. This decision led to the full impairment of the ABX196 goodwill, i.e. an impairment loss of &#128;13,586&nbsp;thousand related to Wittycell&#146;s goodwill and
&#128;45&nbsp;thousand related to licenses. As of December&nbsp;31, 2022, the value in use and the fair value less costs to sell of the ABX196 cash-generating unit (&#147;CGU&#148;) are nil. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Forfeiture of AGA plans </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AGAs granted in September 2021
were subject to vesting conditions including the completion of a M&amp;A transaction on or prior to July 31, 2022. As the <FONT STYLE="white-space:nowrap">non-market</FONT> performance vesting conditions were not satisfied, the Company recognized a
reversal of related compensation expense of &#128;1,026&nbsp;thousand and accrual for social taxes of &#128;205&nbsp;thousand in the financial statements for the period ended December&nbsp;31, 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Repayment of the advance made to Nice CHU &#150; August 2022 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#128;4,000&nbsp;thousand advance made to Nice CHU was reimbursed in August 2022 for an amount of &#128;3,302&nbsp;thousand. The remaining amount of
&#128;698&nbsp;thousand was settled by way of compensation with a payable due to the Nice CHU related to the recharge of third-party services expenses that had been invoiced to the Nice CHU as part of the miR-AGE project (see Note 10, &#147;Other
receivables and assets&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Change in governance &#150; August 2022 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;16, 2022, the Company announced a transition in the chairmanship of its Board of Directors. Philippe Pouletty, the Company&#146;s founder and
Chairman of the Board of Directors since the Company was created in 2013, informed the Board of Directors of his decision to resign as Chairman with immediate effect. However, after many years of successfully leading the Board of Directors,
Mr.&nbsp;Pouletty will continue to support the Company&#146;s development as a member of the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pending the appointment of a new,
permanent independent Chair, Ms.&nbsp;Corinna zur Bonsen-Thomas, an independent member of the Board of Directors of the Company, carried out the role of interim Chair (see Note 3.3. Subsequent events). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Company completed &#128;49.2&nbsp;million cross-over financing with <FONT STYLE="white-space:nowrap">top-tier</FONT> US and European investors &#150;
September 2022 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September 2, 2022, the Company announced oversubscribed financing of around &#128;49.2&nbsp;million, led by TCGX with the
participation of Venrock Healthcare Capital Partners, Deep Track Capital, Sofinnova Partners, Invus and Truffle Capital, <FONT STYLE="white-space:nowrap">top-tier</FONT> investors specializing in the biotechnology sector. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financing consists of two transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a reserved capital increase of a gross amount of approximately &#128;46.2&nbsp;million through the issuance of
5,530,000 new shares with a nominal value of &#128;0.01 per share, representing 33% of its current share capital, at a subscription price of &#128;8.36 per share; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an issue of royalty certificates with a subscription price amounting to &#128;2.9&nbsp;million. The royalty
certificates give right to their holders to royalties equal to 2% of the future net sales of obefazimod </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
(worldwide and for all indications) as from the commercialization of such product. The amount of royalties that may be paid under the royalty certificates is capped at &#128;172&nbsp;million.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proceeds of the financing will primarily be used to fund the advancement of Phase 3 clinical trials for obefazimod in ulcerative
colitis, expanding the Company&#146;s cash runway to the end of Q1 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Related transaction costs amounted to &#128;3.3&nbsp;million and were deducted
from the share premiums. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Royalty certificates are recorded as financial liabilities at amortized cost (see Note 15.8). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Company announces first US patient enrollment in global Phase 3 program with obefazimod in UC&nbsp;&#150;&nbsp;October 2022 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;11, 2022, the Company announced that the first patient was enrolled in the US into its global Phase 3 clinical program with product candidate
obefazimod for the treatment of moderately to severely active UC. IQVIA, a global premier contract research organization, is responsible for coordinating the Company&#146;s Phase 3 clinical trial for obefazimod in UC. As of December&nbsp;31, 2022,
the undiscounted amount of the advance payments made by the Company in relation to the IQVIA agreement is &#128;12,187&nbsp;thousand. They were recorded at inception at their fair value (discounted amount) and subsequently measured at amortized cost
calculated using the effective interest rate method. As of December&nbsp;31, 2022, their carrying amount is &#128;10,471&nbsp;thousand. The repayment dates of these advances are scheduled between April 2025 and July 2026 (see Note 9). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 3.3. Subsequent events </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Company
announces successful oversubscribed &#128;130.0&nbsp;million cross-over financing at market price with <FONT STYLE="white-space:nowrap">top-tier</FONT> US and European Biotech investors &#150; February 2023 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;22, 2023, the Company announced the successful pricing of an oversubscribed &#128;130.0&nbsp;million financing with high-quality US and
European biotech specialist investors, led by TCGX, with participation from existing investors Invus, Deep Track Capital, Sofinnova Partners, Venrock Healthcare Capital Partners, as well as from new investors Great Point Partners, LLC, Deerfield
Management Company, Commodore Capital, Samsara BioCapital, Boxer Capital and others, by way of a reserved capital increase of &#128;130&nbsp;million through the issuance of 20,000,000 newly-issued ordinary shares with a nominal value of &#128;0.01
per share, representing 89.6% of its current share capital, at a subscription price of &#128;6.50 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Related transaction costs amounted to
&#128;6.7&nbsp;million and were deducted from the share premiums. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Change in governance and management &#150; February-July 2023 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;5, 2023, the Company announced the appointment of Marc de Garidel as Chief Executive Officer (&#147;CEO&#148;) and Interim Board Chair, effective
May&nbsp;5, 2023. Corinna zur Bonsen-Thomas will step down as acting Chair, a position she has held since August 2022, and will remain a Board Member. Prof. Hartmut J. Ehrlich, M.D., will retire from the CEO position, which he has held since the
Company&#146;s founding in 2013, and will stay on as a strategic advisor until the transition is complete. The Company expects to appoint a long-term Board Chair in 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;17, 2023, and April&nbsp;18, 2023, the Company respectively announced the appointments of Dr.&nbsp;Sheldon Sloan, M.D., M. Bioethics as new
Chief Medical Officer and Michael Ferguson as new Chief Commercial Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;11, 2023, the Company announced the appointments of June Lee,
M.D. and Troy Ignelzi as new independent members of the Company&#146;s Board of Directors, replacing Joy Amundson and Jean-Jacques Bertrand. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Creation of Abivax LLC &#150; March 2023 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;25, 2023, Abivax LLC (or &#147;the Subsidiary&#148;), was incorporated as a<I> </I>Limited Liability Company<I> </I>under the laws of Delaware.
As of the issuance of the financial statements, the Company has full ownership over the Subsidiary. The Subsidiary will host the Group&#146;s operations in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash less exercise of the Kreos A&amp;B BSA &#150; May 2023 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;24, 2023, Kreos Capital V UK Ltd (or &#147;Kreos&#148;) opted for the cash less exercise option of the share warrants they held (as defined in Note
15.1), implemented through the repurchase by the Company of 43,070 tranche A share warrants (&#147;Kreos A BSA&#148;) and 43,070 tranche B share warrants (&#147;Kreos B BSA&#148;) and the issuance of respectively 67,887 and 31&nbsp;696 ordinary
shares, as a result of the exercise by Kreos of the oustanding Kreos A&nbsp;&amp; B BSA. The operation resulted in the derecognition of the derivative financial liabilities corresponding to the Kreos A&nbsp;&amp; B BSA, amounting to
&#128;424&nbsp;thousand as of December&nbsp;31, 2022, and in a capital increase including share premiums of &#128;829&nbsp;thousand. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4.
Accounting principles </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.1. Goodwill </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following initial recognition, goodwill is stated at cost less any accumulated impairment losses (see Note 4.4). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In respect of business combinations prior to January 1, 2020, in accordance with IFRS 1 exemption, goodwill is included on the basis of its deemed cost, which
represents the amount recorded under the prior basis of accounting, French GAAP, (&#147;Previous GAAP&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.2. Intangible assets
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to IAS 38&#151;<I>Intangible Assets</I>, intangible assets acquired are recognized as assets on the statements of financial position at
their acquisition cost. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Licenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments for
separately acquired research and development are capitalized within &#147;Other intangible assets&#148; provided that they meet the definition of an intangible asset: a resource that is (i)&nbsp;controlled by the Company, (ii) expected to provide
future economic benefits for the Company and (iii)&nbsp;identifiable (i.e., it is either separable or arises from contractual or legal rights). In accordance with paragraph 25 of IAS 38&#151;<I>Intangible Assets</I>, the recognition criterion
relating to the likelihood of future economic benefits generated by the intangible asset, is presumed to be achieved for research and development activities when they are acquired separately. In this context, amounts paid to third parties in the
form of initial payments or milestone payments relating to pharmaceutical specialties that have not yet obtained a marketing authorization are recognized as intangible assets. These rights will be amortized on a straight-line basis, after obtaining
the marketing authorization, over their useful life. Unamortized rights (before marketing authorization) are subject to impairment tests in accordance with the method defined in Note 4.4. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and development costs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to IAS 38 &#150;
<I>Intangible Assets</I>, research costs are expensed in the period during which they are incurred. Development costs are only recognized as intangible assets if the following criteria are met: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is technically feasible to complete the development of the project; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is the Company&#146;s intention to complete the project and to utilize it; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it has capacity to utilize the intangible asset; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there is proof of the probability of future economic benefits associated with the asset </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there is availability of the technical, financial and other resources for completing the project; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there is a reliable evaluation of the development expenses. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initial measurement of the asset is the sum of expenses incurred starting on the date on which the development project meets the above criteria. Because
of the risks and uncertainties related to regulatory authorizations and to the research and development process, the Company believes that the six criteria stipulated by IAS 38 have not been fulfilled to date and the application of this principle
has resulted in all development costs being expensed as incurred in all periods presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other intangible assets </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other intangible assets mainly consist of acquired software. Costs related to the acquisition of software licenses are recognized as assets based on the costs
incurred to acquire and set up the related software. Other intangible assets are amortized using the straight-line method over a period of one year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.3. Property, plant and equipment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant
to IAS 16 &#150; <I>Property, Plant and Equipment</I>, property, plant and equipment are recognized at their acquisition cost (purchase price and directly attributable costs) or at their production cost by the Company, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property, plant and equipment are depreciated using the straight-line method over the estimated useful life of the asset. The principal useful lives applied
are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>DEPRECIATION PERIOD</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Buildings</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Office fixtures and fittings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&#8201;&#8201;&#8201;&#8199;&#8199;&#8199;&#8199;&#8199;3&nbsp;years&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Equipment</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Industrial materials and equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5 to 10 years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Technical facilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5 to 10 years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Furniture and computer equipment:</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Office equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5 to 10 years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">IT equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#8199;&#8199;&#8201;<FONT STYLE="font-size:4pt">&#8201;</FONT>&#8199;&#8199;3 years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Furniture</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#8201;&#8199;&#8199;&#8199;10&nbsp;years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Office fixtures and fittings estimated useful lives correspond to the Headquarters residual estimated lease
term. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The useful lives of property, plant and equipment as well as any residual values are reviewed at each <FONT
STYLE="white-space:nowrap">year-end</FONT> and, in the event of a significant change, the depreciation schedule is revised prospectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.4.
Impairment of goodwill, intangible assets, property and plant and equipment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill and intangible assets not yet available for use are not
amortized and are tested for impairment annually. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Company assesses at the end of each reporting period whether there is an indication
that intangible assets and property, plant and equipment may be impaired. Pursuant to IAS 36&#151;<I>Impairment of Assets</I>, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
criteria for assessing indication of loss in value may notably include performance levels lower than forecast, a significant change in market data or the regulatory environment, or obsolescence
or physical damage of the asset not included in the amortization/depreciation schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purpose of impairment testing, goodwill and intangible
assets not yet available for use are allocated to each of the Company&#146;s CGUs expected to benefit from synergies arising from the business combination or from the use of the intangible assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An impairment loss is recognized when the carrying amount of a CGU, including the goodwill, exceeds the recoverable amount of the CGU. The recoverable amount
of a CGU is the higher of the CGU&#146;s fair value less cost to sell and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">value-in-use.</FONT></FONT> The total impairment loss of a CGU is allocated first to reduce the carrying
amount of goodwill allocated to the CGU and then to the other assets of the CGU <FONT STYLE="white-space:nowrap">pro-rata</FONT> on the basis of the carrying amount of each asset in the CGU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An impairment loss on goodwill is not reversed in a subsequent period. Impairment losses on intangible assets and property, plant and equipment shall be
reversed subsequently if the impairment loss no longer exists or has decreased. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.5. Financial assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financial assets at amortized cost </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other financial assets
(advances, loans and deposits granted to third parties) and other receivables are <FONT STYLE="white-space:nowrap">non-derivative</FONT> financial assets with fixed or determinable payments that are not listed on an active market. They are initially
recognized at fair value plus transaction costs that are directly attributable to the acquisition or issue of the financial asset. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IFRS 9 &#150;
<I>Financial Instruments </I>requires an entity to recognize a loss allowance for expected credit losses on a financial asset at amortized cost at each statement of financial position date. The amount of the loss allowance for expected credit losses
equal to: (i)&nbsp;the 12&#151;month expected credit losses or (ii)&nbsp;the full lifetime expected credit losses. The latter applies if credit risk has increased significantly since initial recognition of the financial instrument. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash and cash equivalents </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company classifies
investments as cash equivalents in the statements of financial position and statements of cash flows when they meet the conditions of IAS 7&#151;<I>Statement of Cash Flows, </I>i.e., when they are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">held in order to face short-term cash commitments; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short term and highly liquid assets at acquisition date, readily convertible into known amount of cash and not
exposed to any material risk of change in value. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.6. Share capital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary shares are classified in shareholders&#146; equity. Costs associated with the issuance of new shares are directly accounted for in shareholders&#146;
equity in diminution of issuance premium. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s own shares bought in the context of a brokering/liquidity agreement entered with an
independent broker are presented as a reduction of shareholders&#146; equity until their cancellation, their reissuance or their disposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.7. Share-based payments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since its inception, the Company has established several plans for compensation settled in equity instruments in the form of founders&#146; share subscription
warrants (&#147;bons de souscription de parts de cr&eacute;ateur d&#146;entreprise&#148; or &#147;BCE&#148;), share subscription warrants (&#147;Bons de souscription d&#146;actions,&#148; or &#147;BSA&#148;) and free shares (&#147;Attributions
gratuites d&#146;actions,&#148; or &#147;AGA&#148;), granted to its employees, corporate officers and scientific consultants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to IFRS
2&#151;<I>Share-based Payment, </I>these awards are measured at their fair value on the date of grant. The values of the equity instruments are determined using the option pricing model (in particular, a Black and Scholes model for the BCE and BSA
plans and a Monte-Carlo simulation for the AGA plan) based on the value of the underlying equity instrument at grant date, the volatility observed in a sample of comparable listed companies and the estimated life of the related equity instruments.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes the fair value of these awards as a share-based compensation expense over the period in which the related services are received,
i.e. over the vesting period, with a corresponding increase in shareholders&#146; equity. Share-based compensation is recognized by installments in consistency with their graded vesting schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and
<FONT STYLE="white-space:nowrap">non-market</FONT> performance conditions are expected to be met, such that the amount ultimately recognized is based on the number of awards that meet the related service and
<FONT STYLE="white-space:nowrap">non-market</FONT> performance conditions at the vesting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For share-based payment awards with market vesting
conditions, the grant-date fair value of the share-based payment is measured to reflect such conditions and there is no <FONT STYLE="white-space:nowrap">true-up</FONT> for differences between expected and actual outcome. The measurement of the fair
value of BSA, BCE and AGA incorporates the market-based vesting conditions as described in Note 4.16 &#147;Use of estimates and judgments&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.8. Financial liabilities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to IFRS
9 &#150; <I>Financial Instruments, </I>borrowings and other financial liabilities (excluding derivative financial instruments) are measured at amortized cost. Financial liabilities that are due within one year are presented as current financial
liabilities in the statements of financial position. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financial liabilities at amortized cost </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Borrowings and Other financial liabilities (conditional advances and royalty certificates), other than derivatives instruments, are initially recognized at
fair value and subsequently measured at amortized cost calculated using the effective interest rate (&#147;EIR&#148;) method. The transaction costs that are directly attributable to the issue of the financial liability reduce that financial
liability. These expenses are then amortized over the lifetime of the liability, on the basis of the EIR. The EIR is the rate that exactly discounts estimated future cash payments through the expected life of the financial liability to the amortized
cost of a financial liability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Royalty certificates </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Royalty certificates meet the definition of financial liabilities. The Company concluded that they do not include embedded derivatives related to the
variability of royalties that are based on future net sales. In addition, the Company concluded that the prepayment options were separate derivative instruments as their redemption price did not reimburse holders for an amount up to the approximate
present value of lost interest for the remaining term of the host contracts. However, their value at inception and subsequent dates is nil and has no impact on the financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Royalty certificates are initially measured at fair value (refer to note 15.8 for valuation model applied).
They are subsequently measured at amortized cost calculated using the EIR method. The EIR is calculated based on future cash flows, estimated on the basis of development and commercialization plans and budgets approved by the Board of Directors of
the Company. If there is a change in the timing or amount of estimated cash flows, then the gross carrying amount of the amortized cost of the financial liability is adjusted in the period of change to reflect the revised actual and estimated cash
flows, with a corresponding income or expense being recognized in profit or loss. The revised gross carrying amount of the amortized cost of the financial liability is calculated by discounting the future revised estimated cash flows at the original
EIR. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conditional advances and State guaranteed loan &#150; &#147;PGE&#148; </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounting treatment for conditional advances and PGE is set forth in Note 4.9. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Leases </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounting treatment for lease liabilities is set
forth in Note 4.12. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financial liabilities measured at fair value through profit or loss </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BSA attached to Kreos 1 bonds, the conversion option of OCEANE and certain prepayment options of bonds are derivatives instruments. Derivatives are recognized
initially at fair value at the date the derivative contract is entered into and are subsequently remeasured to their fair value at each reporting date. The resulting gain or loss from change in the fair value is recognized in profit or loss
immediately, as financial expenses or income. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Hybrid instruments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OCEANE bonds are hybrid instruments. A &#147;hybrid contract&#148; is a contract that includes both a <FONT STYLE="white-space:nowrap">non-derivative</FONT>
host contract and one or more embedded derivatives. Embedded derivatives are required to be separated from the host contract (bifurcated) if: the economic characteristics and risks of the embedded derivative are not closely related to those of the
host, a separate instrument with the same terms as the embedded derivative would meet the definition of a derivative, and the hybrid contract is not measured at fair value through profit or loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Separable embedded derivatives are required to be measured at fair value, with all changes in fair value recognized in profit or loss. The initial bifurcation
of a separable embedded derivative does not result in any gain or loss being recognized. Because the embedded derivative component is measured at fair value on initial recognition, the carrying amount of the host contract on initial recognition is
the difference between the carrying amount of the hybrid instrument and the fair value of the embedded derivative. If the fair values of the hybrid instrument and host contract are more reliably measurable than that of the derivative component -
e.g. because of the availability of quoted market prices - then it may be acceptable to use those values to determine the fair value of the derivative on initial recognition indirectly - i.e. as a residual amount. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fair value measurement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When measuring the fair value of
an asset or a liability, the Company uses market observable data as far as possible. Fair values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">level 1: fair value calculated using quoted prices in an active market for identical assets and liabilities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">level 2: fair value calculated using valuation techniques based on observable market data such as prices for
assets and liabilities or similar parameters quoted in an active market; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">level 3: fair value calculated using valuation techniques based in whole or in part on unobservable inputs such
as prices in an inactive market or a valuation based on multiples of unlisted securities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 12 Financial assets and liabilities,
Note 15 Financial liabilities and Derivative instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.9. Research tax credit, subsidies and conditional advances </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research tax credit </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company benefits from the
provisions of Articles 244c of the French General Tax Code relating to the French research tax credit (&#147;<I>Cr&eacute;dit d&#146;Imp&ocirc;t Recherche</I>&#148; or &#147;CIR&#148;). The CIR is granted to companies in order to encourage them to
conduct technical and scientific research. Companies that prove that they have expenditures which meet the required criteria (research expenditures located in France or, since January 1, 2005, within the European Union or in another state that is a
party to the Agreement on the European Economic Area and has concluded a tax treaty with France that contains an administrative assistance clause) receive a tax credit that can be used for the payment of the corporate tax due for the fiscal year in
which the expenditures were made and the next three fiscal years, or as applicable, companies may receive cash reimbursement for any excess portion at the three-year period following the fiscal year of the expenditures. Only those companies meeting
the EU definition of a small or <FONT STYLE="white-space:nowrap">medium-sized</FONT> entity (&#147;SME&#148;) are eligible for payment in cash of their research tax credit (to the extent not used to offset corporate tax payables) in the year
following the request for reimbursement. The expenditures taken into account for the calculation of the CIR involve only research expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CIR is
presented under &#147;Other operating income&#148; in the statements of income (loss) as it is accounted for as a government grant as defined in IAS 20 &#150; <I>Accounting for Government Grants and Disclosure of Government Assistanc</I>e, and as
&#147;Other receivables and related accounts&#148; in the statement of financial position until its payment is received. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Subsidies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsidies are <FONT STYLE="white-space:nowrap">non-repayable</FONT> grants received by the Company and recognized in the financial statements when there exists
reasonable assurance that the Company will comply with the conditions attached to the subsidies and the subsidies will be received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsidies that are
upfront payments are presented as deferred income and recognized through &#147;Other operating income&#148; for the amount of the expenses incurred as part of the research program to which the subsidy relates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A subsidy that is to be received either as compensation for expenses or for losses already incurred, or for immediate financial support of the Company without
associated future costs, is recognized in the Statements of income (loss) as &#147;Other operating income&#148; when there exists reasonable assurance that the subsidies will be received. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conditional advances and PGE </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company receives
conditional advances to finance at below market interest rate research and development projects. Due to the innovative nature of its drug candidate development programs, the Company has benefited from certain sources of financial assistance from
Bpifrance. Bpifrance provides financial assistance and support to emerging French enterprises to facilitate the development and commercialization of innovative technologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Funds received from Bpifrance in the form of conditional advances are recognized as financial liabilities, as the Company has a contractual obligation to
reimburse Bpifrance for such conditional advances in cash based on a repayment schedule. Each award of an advance is made to help fund a specific development milestone. More </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
details on conditional advances are provided in Note 15.5. Receipts or reimbursements of conditional advances are reflected as financing transactions in the statements of cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The difference between the present value of the advance at market rate (i.e., present value of contractual cash flows including principal and interest,
discounted using a market rate as effective interest rate in accordance with IFRS 9) and the amount received as cash from the Bpifrance constitutes a subsidy within the meaning of IAS 20. Considering that these advances do not finance fixed assets,
these subsidies are presented as &#147;Deferred income&#148; in the statement of financial position and recognized in the statement of net income (loss) as &#147;Other operating income&#147; on a systematic basis over the periods in which the
Company recognizes as expenses the related costs for which the grants are intended to compensate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The incremental interest expense resulting from the
difference between (a)&nbsp;the market interest rate and the (b)&nbsp;below-market rate is spread over the contractual period until the last repayment and recognized in the statement of income (loss) accordingly, using the EIR method. In the event
of a change in estimate of contractual cash flows due under the conditional advances, the Company recalculates the book value of the debt resulting from the discounting of the anticipated new future cash flows at the initial EIR. The adjustment is
recognized in the statements of income (loss) for the period during which the modification is recognized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the statements of financial position, these
conditional advances are recorded in &#147;Other financial liabilities&#148; as current or <FONT STYLE="white-space:nowrap">non-current</FONT> portion depending on their maturity. In the event Bpifrance waived the repayment of the advance, the
corresponding liability is derecognized and treated as a subsidy in the statements of income (loss). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The benefit resulting from the low interest of PGE
loans is also recognized as a subsidy corresponding to the difference between the present value of the PGE at market rate and the amount received as cash. The accounting treatment is therefore similar to the above-mentioned accounting treatment for
conditional advances. PGE are recorded in &#147;Borrowings&#148; as current or <FONT STYLE="white-space:nowrap">non-current</FONT> portion depending on their maturity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.10. Employee benefits </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s
employees in France benefit from retirement benefits provided under French law, which consist in the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compensation paid by the Company to employees upon their retirement (a defined benefit plan); and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payments of retirement pensions by the social security agencies, which are financed by the contributions made by
the Company and employees. As they meet the definition of a defined contribution plan, the liabilities are presented as Tax and employee-related payables in the statement of financial position. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with IAS 19 &#150; <I>Employee Benefits</I>, the liability with respect to defined benefit plans is estimated by using the projected credit unit
method. According to this method, the cost of the retirement benefit is recognized in the statements of income (loss). The retirement benefit commitments are valued at the current value of the estimated future payments, discounted using the market
rate for high quality corporate bonds with a term and currency that correspond to that estimated for the payment of the benefits. The Company applied the decision of the IFRS IC, published on May&nbsp;24, 2021, that concluded that, in the case that
no rights were acquired in the event of departure before retirement age and that the rights were capped after a certain number of years of seniority (&#147;30 years&#148;), the commitment would only be recognized for the last 30 years of the
employee&#146;s career within the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The difference between the amount of the provision at the beginning of a period and at the close of that
period is recognized through operating expenses for the portion representing the costs of services rendered and financial expenses for the net interest costs, and through other comprehensive income (loss) for the portion representing the actuarial
gains and losses due to changes in assumptions and experience adjustments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.11. Provisions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provisions correspond to commitments resulting from litigation and various risks to which the Company may face in the context of its operations. In accordance
with IAS 37 &#150; <I>Provisions, Contingent Liabilities and</I> <I>Contingent Assets, </I>a provision is recorded when the Company has an obligation to a third party resulting from a past event that will likely result in an outflow of resources to
the third party, and for which future cash outflows may be estimated reliably. The amount recorded as a provision is an estimate of the expenditure required to settle the obligation, discounted where necessary at year end. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.12. Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As lessee, the Company assesses
whether a contract contains a lease at inception of a contract and upon the modification of a contract. The Company elected to allocate the consideration in the contract to the lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components
on the basis of the relative standalone price. The Company recognizes a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and a corresponding lease liability for all arrangements in which it is a
lessee, except for leases with a term of 12 months or less (short-term leases) and <FONT STYLE="white-space:nowrap">low-value</FONT> leases (value of the underlying asset below &#128;5.0 thousand). For these short-term and <FONT
STYLE="white-space:nowrap">low-value</FONT> leases, the Company recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The lease liability is initially measured at the present value of the future lease payments as from the commencement date of the lease to the end of the lease
term. The lease terms used by the Company reflect the <FONT STYLE="white-space:nowrap">non-cancellable</FONT> terms of each contract, plus any extension or termination options that the Company is reasonably certain to exercise or not exercise for
all of the leases periods covered by the extension options. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the Company incremental borrowing rate for the asset subject to the lease in
the respective markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company remeasures the lease liability (and makes a corresponding adjustment to the related <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset) whenever there is a change to the lease terms or expected payments under the lease, or a modification that is not accounted for as a separate lease. The portion of the lease payments
attributable to the repayment of lease liabilities and the portion attributable to payment of interests are recognized in cash flows used in financing activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets are initially recognized on the balance sheet at cost,
which comprises the amount of the initial measurement of the corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease incentives received and any initial direct costs incurred
by the Company, and expected costs for obligations to dismantle and remove <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets when they are no longer used. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets are depreciated on a straight-line basis from the
commencement date of the lease over the shorter of the useful life of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset or the end of the lease term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets are assessed for impairment whenever there is an
indication that the balance sheet carrying amount may not be recoverable using cash flow projections. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.13. Translation of transactions
denominated in foreign currency </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to IAS 21 &#150; <I>The Effects of Changes in Foreign Exchange Rates</I>, transactions performed by the
Company in currencies other than their functional currency, which is the Euro, are translated at the prevailing exchange rate on the transaction date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trade receivables and payables and liabilities denominated in a currency other than the functional currency are translated at the <FONT
STYLE="white-space:nowrap">period-end</FONT> exchange rate. Unrealized gains and losses arising on translation are recognized in net financial income / (loss). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.14. Current and deferred tax </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the French tax authorities,
using tax rates and tax laws enacted or substantively enacted at the end of the reporting period in accordance with IAS 12 &#150; Income Tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The income
tax charge for the period comprises current tax due and the deferred tax charge. The tax expense is recognized in the statement of income (loss) unless it relates to items recorded in other comprehensive income (loss) or directly in equity, in which
case the tax is also recorded in other comprehensive income (loss) or directly in equity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Current taxes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The current tax expense is calculated based on taxable profit for the period, using tax rates enacted or substantively enacted at the statement of financial
position date. Considering the level of tax loss of the Company, no current tax expense is recognized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Deferred taxes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred taxes are recognized when there are temporary differences between the carrying amount of assets and liabilities in the Company&#146;s financial
statements and the corresponding tax basis used to calculate taxable profit. Deferred taxes are not recognized if they arise from the initial recognition of an asset or liability in a transaction other than a business combination which, at the time
of the transaction, does not affect either the accounting or the taxable profit (tax loss). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Deferred tax assets </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred tax assets are recognized for all deductible temporary differences, unused tax losses and unused tax credits to the extent that it is probable that
the temporary difference will reverse in the foreseeable future and that taxable profit will be available against which the deductible temporary difference, unused tax losses or unused tax credits can be utilized. See Note 4.16. Use of judgments and
estimates and Note 22. Income tax. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.15. Accounting of Prosynergia acquisition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From April 1, 2022 up until the merger completed on December&nbsp;12, 2022, the Company owned a 100% ownership interest of Prosynergia and as such, controlled
Prosynergia. The Company had power over Prosynergia, was exposed or had rights to variable returns from its involvement with the entity and had the ability to affect those returns through its power over the entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of Prosynergia were therefore included in the consolidated financial statements of the Company from the date control was obtained,
i.e. April 1, 2022. Prosynergia was merged into the Company in December&nbsp;12, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Considering that Prosynergia only owned patent rights but did not
enter into any employee contract, research agreement, collaboration agreement or <FONT STYLE="white-space:nowrap">out-licensed</FONT> agreement, it did not meet the definition of a business under IFRS 3. Consequently, the acquisition cost of this
group of assets was allocated between the identifiable assets and liabilities acquired, pro rata to their respective fair values as of April 1, 2022, without recognition of goodwill. For this purpose, the following approach was applied: first
measurement of any identifiable asset or liability initially measured at an amount other than cost in accordance with the applicable standards, deduction from the cost of the group of assets of the amounts allocated to these assets and liabilities,
and then allocation of the residual cost of acquisition to the remaining identifiable assets and liabilities based on their relative fair values at the date of acquisition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also, the &#128;1,400&nbsp;thousand loan granted to Prosynergia in December 2021 was included in the
acquisition cost to be allocated, since, in substance, it was considered as a prepayment for the acquisition of the group of assets, which is repayable in cash in the event of <FONT STYLE="white-space:nowrap">non-completion</FONT> of the
transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The potential <FONT STYLE="white-space:nowrap">earn-out</FONT> payment to be paid in the first half of 2023 was measured at fair value on
April 1, 2022, for an amount of &#128;1,446&nbsp;thousand, and included in the acquisition cost. This earn out is triggered in the event the Company&#146;s market capitalization is in excess of &#128;300&nbsp;million (evaluated at certain specified
record dates), a listing of the Company&#146;s shares on Nasdaq or a merger and acquisition transaction prior to March 31, 2023. The amount of the <FONT STYLE="white-space:nowrap">earn-out</FONT> is equal to 1% of the difference between the
Company&#146;s market capitalization and &#128;300&nbsp;million, subject to a maximum amount of &#128;4.0&nbsp;million. It is, as the case may be, payable in the first half of 2023. No amount will be payable in the event the Company&#146;s market
capitalization is lower than &#128;300&nbsp;million. The related financial liability is subsequently remeasured to its fair value at each reporting date. The gain or loss arising from the change in the fair value is recognized in profit of loss
immediately. As of December&nbsp;31, 2022, the fair value of the <FONT STYLE="white-space:nowrap">earn-out</FONT> liability is nil (see Note 15.7). The remeasurement results in a financial income of &#128;1,446&nbsp;thousand over the year ended
December&nbsp;31, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The allocation of the acquisition cost is as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(Amounts in thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount&nbsp;allocated&nbsp;as<BR>of&nbsp;April&nbsp;1,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash prepayment made in 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loan granted to Prosynergia in 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash payment made in 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition fees (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Earn-out</FONT> measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total acquisition cost allocated</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,562</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,571</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(9</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total net assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,562</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Of which &#128;451&nbsp;thousand were disbursed in 2021 and &#128;15&nbsp;thousand in 2022. Acquired cash
amounts to &#128;41&nbsp;thousand. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The acquisition cost was mainly allocated to Prosynergia&#146;s patents US 10,464,903 (filed on
March 20, 2017 and granted on November 5, 2019), EP3 429 998 (filed on March 20, 2017 and granted on September 1, 2021) and continuation US 10,745,357 (filed on November 1, 2019 and granted on August&nbsp;18, 2020). All patents will expire in 2037.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These patents cover alternative synthesis process for obefazimod and a family of close chemical analogues. They also cover alternative forms of
obefazimod (salts thereof and crystalline forms of said salts), the pharmaceutical composition comprising them, that could be of interest to the Company for future development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.16. Use of judgments and estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
order to prepare financial statements in accordance with IFRS, estimates, judgments and assumptions were made by the Company&#146;s management which could affect the reported amounts of assets, liabilities, contingent liabilities, income and
expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These estimates are based on the assumption of going concern and are prepared in accordance with information available at the date the
financial statements were prepared. They are reviewed on an ongoing basis using past experience and various other factors considered to be reasonable as the basis to measure the carrying amount of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assets and liabilities. Estimates may be revised due to changes in the underlying circumstances or subsequent to new information. Actual results may differ significantly from these estimates in
line with assumptions or different conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This note provides an overview of the areas that involved a higher degree of judgement or complexity, and
of items which are more likely to be materially adjusted due to changes in estimates and assumptions. Detailed information about each of these estimates and judgements is included in other notes together with information about the basis of
calculation for each affected line item in the financial statements. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recognition and measurement of impairment of CGUs. The main assumptions used for the impairment test include
(a)&nbsp;the amount of cash flows that are set on the basis of the development and commercialization plans and budgets approved by Board of Directors, (b)&nbsp;assumptions related to the achievement of the clinical trials and the launch of the
commercialization, (c)&nbsp;the discount rate, (d) assumptions on risk related to the development and (e)&nbsp;for the commercialization, selling price and volume of sales. The sensitivity analysis in respect of the recoverable amount of the CGUs is
presented in Note 6. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">measurement of share-based compensation granted to employees, corporate officers and scientific consultants, such
as BCE, BSA and AGA, which is based on actuarial models; these models require the use by the Company of certain calculation assumptions such as the estimated vesting, the occurrence dates of a change of control or a M&amp;A transaction dates, the
expected volatility and maturity of the underlying equity instrument (see Note 4.7 and Note 14), </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fair value measurements at inception and after of derivative financial instruments resulting from (i)&nbsp;the
warrants issued concomitantly with the issuance of the straight and convertible bonds to Kreos on July 24, 2018 (or &#147;Kreos 1&#148;), (ii) the prepayment option attached to the straight and convertible bonds issued to Kreos on October 2 2020 (or
&#147;Kreos 2&#148;), and (iii)&nbsp;the prepayment option attached to the issuance of bond convertible into new or existing shares in July 30, 2021 (or &#147;OCEANE&#148;) (see Notes 15), </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fair value measurements of financial liabilities at inception (see Note 15), </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">amortized cost measurement of royalty certificates, based on the following assumptions: (a)&nbsp;future cash
flows, estimated on the basis of development and commercialization plans and budgets approved by the Board of Directors and (b)&nbsp;the discount rate. The sensitivity analysis in respect of the measurement of royalty certificates is presented in
Note 15. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fair value measurements of the call option resulting from the equity line contracts entered into on September 30,
2019 (or &#147;Equity lines&#148;) (see Note 13.2), </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CIR based on internal and external expenses which meet the required criteria incurred by the Company during the
year (see Note 4.9), </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recognition of deferred tax assets: availability of future taxable profit against which deductible temporary
differences and tax losses carried forward can be utilized and whether sufficient evidence exists (see Note 22). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The main critical
judgments made by the Company&#146;s management impact the following item: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the occurrence dates of a change of control or a M&amp;A transaction dates used for the measurement of
share-based compensation (see Note 4.7). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5. Segment information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The assessment of the Company&#146;s performance and the decisions about resources to be allocated are made by the chief operating decision maker, based on the
management reporting system of the Company. The Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
identified the Chief Executive Officer of the Company as &#147;Chief operating decision maker&#148;. The Chief operating decision maker reviews on an aggregated basis the incurred expenses for
allocating and evaluating performance of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company operates in a single operating segment: R&amp;D of pharmaceutical products in order to
market them in the future. All operations, assets, liabilities and losses of the Company are located in France. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6. Goodwill and impairment test
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill relates to the acquisition of Splicos SAS and Wittycel SAS occurred in 2014 (i.e., prior the transition date to IFRS), which were merged into
the Company in the same year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill from Splicos SAS and Wittycel SAS acquisition corresponds to the &#147;Modulation of RNA biogenesis /
splicing&#148; technological platform and the &#147;iNKT agonists&#148; technological platform, respectively, from which derived the lead drug candidates of the Company: ABX464 and ABX196, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IFRS 3 was not applied to acquisitions of subsidiaries deemed to be a business within the meaning of IFRS, carried out before the IFRS transition date, i.e.,
January&nbsp;1 2020. Due to the application of this exemption, the previous accounting for business combinations in accordance with French GAAP remains unchanged (no identified Intellectual Property, Research&nbsp;&amp; Development
(&#147;IPR&amp;D&#148;) assets are recognized in the statement of financial position). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carrying amounts of the goodwill resulting from Splicos SAS
and Wittycel SAS acquisitions were, as of December&nbsp;31, 2021, &#128;18,419&nbsp;thousand and &#128;13,586&nbsp;thousand, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance
with IAS 36, goodwill is allocated to CGUs at a level corresponding to the lead drug candidates. Thus, goodwill from Splicos SAS and Wittycel SAS are allocated to ABX464 CGU and ABX196 CGU, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill impairment tests are undertaken annually or more frequently if events or changes in circumstances indicate a potential impairment, in accordance with
IAS 36. The carrying amount of goodwill is compared to the recoverable amount, which is the higher value in use and the fair value less costs to sell. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As
of December 31, 2021 and 2022, the recoverable amount used for the impairment test of each CGU was the value in use. This value in use was based on a net present value calculation, using the following assumptions as of December 31, 2021 and 2022:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cash flows are set on the basis of the development and commercialization plans and budgets approved by Board of
Directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A discount rate (or &#147;WACC&#148;) of 14% as of December 31, 2022 and 13.5% as of December 31, 2021,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A risk of development is taken into consideration by applying probabilities of success (or &#147;POS&#148;) of
reaching future phases of development to cash flows related to the commercialization phase. Those average probabilities of success of R&amp;D projects are based on public sources (INFORMA databases). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the commercialization phase, selling price and sales volume are estimated on the basis of the potential
market and the observed performances of comparable drugs currently on the market. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The impairment tests resulted in no impairment
charges as of December 31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the first half of 2022, management took into account significant external changes in the hepatocellular carcinoma
(HC) treatment landscape. These changes were expected to require a new, lengthy, heavy and risky </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
internal development process (use of a combination of compounds). For this purpose, entering into a licensing partnership to fund the completion of the clinical development of ABX196 was being
considered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of this change in circumstances, an impairment test of ABX196 CGU was performed in accordance with IAS 36, resulting into an
impairment loss of &#128;10,986&nbsp;thousand of Wittycell&#146;s goodwill, based on a fair value of &#128;2,600&nbsp;thousand, recorded in the interim financial statements as of June&nbsp;30, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, due to the lack of progress made in the negotiation of a development partnership, the Company made the decision to freeze the
development program for ABX196 in the treatment of hepatocellular cancer. In this context, the impairment test carried out as of December&nbsp;31, 2022 resulted in the full impairment of the goodwill resulting from the acquisition of Wittycell SAS
and other assets included in the ABX196 CGU, i.e. an impairment loss of &#128;13,632&nbsp;thousand as of December&nbsp;31, 2022 (&#128;13,586&nbsp;thousand related to goodwill and &#128;45&nbsp;thousand related to other assets &#150; see Note 7).
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Sensitivity testing as of December&nbsp;31, 2022 and December&nbsp;31, 2021: </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has conducted an analysis of the sensitivity of the impairment tests to changes in the key assumptions used to determine the recoverable amount of
the CGUs to which goodwill is allocated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regarding ABX464, as the product is currently in development, a clinical trial failure or a failure to obtain a
marketing approval could result in an impairment. The results of the impairment test indicate a headroom level that is high enough so that any reasonably possible change in any of the key assumptions (except clinical failure) would not lead to any
impairment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regarding ABX196: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as of December&nbsp;31, 2022, as above-mentioned, the net book value of the CGU was brought to zero after
recording an impairment of &#128;13,632&nbsp;thousand. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as of December 31, 2021, an increase in WACC of 3.7 percentage points, or a reduction in sales of 22%, or a
reduction in POS per phase of 10%, would result in the recoverable value being equal to the net book value. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7. Intangible
assets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intangible assets are mainly comprised of the intellectual property underlying: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The exclusive license agreement with the Scripps Research Institute, University of Chicago and Brigham Young
University for which the Company paid a milestone of &#128;45&nbsp;thousand in September 2019 as a result of an IND filling of ABX196. The value in use and the fair value less costs to sell of the ABX196 CGU being nil as of December&nbsp;31, 2022, a
&#128;45&nbsp;thousand impairment was recorded during the period (see Note 6). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The collaboration and license agreement with the CNRS, Montpellier 2 university and the Curie for which the
Company paid a milestone of &#128;40&nbsp;thousand in September 2019 as a result of the entry in phase 2 of ABX464. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Patents acquired through the acquisition of Prosynergia of &#128;6,529&nbsp;thousand (cf. Note 4). The patents
are not yet amortized, similarly to licenses. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Licenses and patents recognized as Intangible assets as of December 31, 2021 and 2022 are not amortized
while they are not operating in a manner intended by the management. As a consequence, and in accordance with IAS 36, those assets were subject to an annual impairment test as of December 31, 2021 and 2022, which did not result in the need for an
impairment to be recognized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LICENCES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SOFTWARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PATENTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>GROSS VALUES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of January&nbsp;1, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>85</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>110</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>85</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>110</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>120</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,529</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,673</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LICENCES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SOFTWARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PATENTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>AMORTIZATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of January&nbsp;1, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(12</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(12</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(17</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(17</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(45</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(21</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(66</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LICENCES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SOFTWARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PATENTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NET BOOK VALUES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of January&nbsp;1, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 8. Property, plant and equipment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables present movements in property, plant and equipment including the right of use of assets (or &#147;ROU&#148;) as of December 31, 2021 and
2022: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BUILDINGS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EQUIPMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FURNITURE</B><br><B>AND<BR>COMPUTER<BR>EQUIPMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B><B><I>OF&nbsp;WHICH<BR></I></B><B></B><B><I>ROU</I></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>GROSS VALUES</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of January 1st, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>593</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>447</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>194</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,234</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I></I><B><I></I></B><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I></I><B><I>636</I></B><I></I></TD>
<TD NOWRAP VALIGN="bottom"><I></I><B><I></I></B><I>&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>62</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposal</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(16</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>593</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>402</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>235</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,230</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I></I><B><I></I></B><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I></I><B><I>682</I></B><I></I></TD>
<TD NOWRAP VALIGN="bottom"><I></I><B><I></I></B><I>&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>1,472</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposal</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(593</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(597</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(593</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,618</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>438</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>344</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,400</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I></I><B><I></I></B><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I></I><B><I>1,561</I></B><I></I></TD>
<TD NOWRAP VALIGN="bottom"><I></I><B><I></I></B><I>&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BUILDINGS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EQUIPMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FURNITURE<BR>AND<BR>COMPUTER<BR>EQUIPMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B><B><I>OF&nbsp;WHICH<BR></I></B><B></B><B><I>ROU</I></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>DEPRECIATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of January 1st, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(222</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(368</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(151</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(741</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I></I><B><I></I></B><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I></I><B><I>(243</I></B><I></I></TD>
<TD NOWRAP VALIGN="bottom"><I></I><B><I>)</I></B><I>&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(222</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(297</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(244</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>16</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(445</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(346</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(134</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(925</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I></I><B><I></I></B><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I></I><B><I>(470</I></B><I></I></TD>
<TD NOWRAP VALIGN="bottom"><I></I><B><I>)</I></B><I>&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(407</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(481</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(414</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>593</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(259</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(378</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(171</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(808</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I></I><B><I></I></B><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I></I><B><I>(290</I></B><I></I></TD>
<TD NOWRAP VALIGN="bottom"><I></I><B><I>)</I></B><I>&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BUILDINGS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EQUIPMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FURNITURE<BR>AND<BR>COMPUTER<BR>EQUIPMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B><B><I>OF&nbsp;WHICH<BR></I></B><B></B><B><I>ROU</I></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NET BOOK VALUES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of January 1st, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>394</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>212</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>1,270</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Right of use assets relate to buildings, vehicles and furniture. The net book value of right of use assets related to buildings
amounted to &#128;147&nbsp;thousand and &#128;1,224&nbsp;thousand as of December 31, 2021 and 2022, respectively. Acquisitions over the year ended December&nbsp;31, 2022 mainly include the right of use asset related to the new Headquarters entered
into in July 2022 (see Note 15.6), as well as office fittings and IT equipment. Disposals over the period mainly include the right of use assets related to the former headquarters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 9. Other financial assets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other financial assets
break down as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>OTHER FINANCIAL ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Advances related to CRO contracts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits paid under the liquidity agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits paid on Kreos 1 and 2 bond loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposit paid under the Headquarters lease agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,342</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,708</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advances related to CRO contracts </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Advances amounting to &#128;12,187&nbsp;thousand were made during the year ended December&nbsp;31, 2022. These advances are related to CRO/CMO contracts for
clinical studies and are to be recovered at the end of the studies after final reconciliation with pass-through costs, which are being invoiced and paid as studies are carried out. These long-term advances were measured at fair value on initial
recognition, using discount rates ranging from 0.19% to 7.16%, and are subsequently measured at amortized cost. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At inception, a prepaid expenses asset
was recognized for the difference between the advances&#146; nominal value and fair value, and spread over the term of the advances, at the rate of recognition of the related R&amp;D expenses (see Note 10). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 10. Other receivables and assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other receivables and related accounts break down as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>OTHER RECEIVABLES AND ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses - non current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> other receivables and
assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,037</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research tax credit (&#147;CIR&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VAT receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Advance made to the Nice CHU</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Advance payment for the acquisition of Prosynergia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses - current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Credit notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current other receivables and assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,784</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,231</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total other receivables and assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,784</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,268</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research tax credit (&#147;CIR&#148;) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CIR is recognized as Other Operating Income (see note 4.9) in the year to which the eligible research expense relates. The Company received the payment of
the CIR for 2021 tax year in the amount of &#128;4,204&nbsp;thousand in 2022 and expects to receive the CIR for 2022 tax year of &#128;4,448&nbsp;thousand in 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>VAT Receivables </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Value-added tax (&#147;VAT&#148;)
receivables relate primarily to the deductible VAT and VAT refunds claimed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advance to be received </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;20, 2021, the Company amended the research agreement entered with the University Hospital Center of Nice (or &#147;Nice CHU&#148;) on
September&nbsp;25, 2020, which consisted in the conduct of a study to test whether ABX464 could prevent the development of severe <FONT STYLE="white-space:nowrap">Covid-19</FONT> disease in the participants. The Company agreed to advance amount of
&#128;4,000&nbsp;thousand to Nice CHU corresponding to the expenses recharged by its third parties for the year ended December&nbsp;31, 2021. An amount of &#128;3,302&nbsp;thousand was reimbursed in August 2022. The remaining &#128;698&nbsp;thousand
amount was settled by way of compensation with a payable due to the Nice CHU related to the recharge of third-party services expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advance payment
for the acquisition of Prosynergia </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the context of the acquisition of Prosynergia, the Company made an initial payment of the acquisition price of
&#128;325&nbsp;thousand on November 25, 2021 (see Note 3.3). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December 1, 2021, the Company signed a loan agreement with Prosynergia for
&#128;1,400&nbsp;thousand. Prosynergia committed to reimburse the loan at the end of the contract, on December 31, 2025. The purpose of the loan was to allow early repayment by Prosynergia of all its existing indebtedness and was a suspensive
condition for the acquisition of Prosynergia shares provided by the Share purchase agreement entered with the shareholder of Prosynergia on November 15, 2021. For accounting purposes, this loan was considered as a prepayment for the acquisition of
the group of assets, which was repayable in cash only in the event the acquisition is not completed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, there is no more loan
recognized following the merger of the Company and Prosynergia on December&nbsp;12, 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Prepaid expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prepaid expenses as of December 31, 2021 include costs related to the acquisition of Prosynergia for &#128;451&nbsp;thousand. During the year ended
December&nbsp;31, 2022, these costs were then included in the acquisition price of Prosynergia which was allocated to acquired patents (see Notes 3.3 and 4.15). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prepaid expenses as of December&nbsp;31, 2022 include prepaid expenses related to CRO contracts for amount of &#128;1,714&nbsp;thousand (see Note 9). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 11. Cash and cash equivalents </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash
equivalents break down as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CASH AND CASH EQUIVALENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents (short-term investments)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash (bank accounts)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>60,701</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>26,950</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 12. Financial assets and liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value
hierarchy. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" NOWRAP><B></B><I>(In thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AMOUNT</B><br><B>RECOGNIZED&nbsp;IN<BR>THE&nbsp;STATEMENT<BR>OF FINANCIAL<BR>POSITION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FAIR<BR>VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ASSETS/ LIABILITIES<BR>AT FAIR VALUE<BR>THROUGH PROFIT<BR>AND LOSS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ASSETS AT<BR>AMORTIZED<BR>COST</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LIABILITIES<BR>AT&nbsp;AMORTIZED<BR>COST</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other financial assets (2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other receivables and assets&nbsp;(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents&nbsp;(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>76,827</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>76,827</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>76,827</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Financial <FONT STYLE="white-space:nowrap">liabilities&#151;non-current</FONT> portion
(4,&nbsp;Note&nbsp;15)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Financial liabilities&#151;current portion (3, Note 15)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Trade payables and other current liabilities (3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Tax, employee-related payables (5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>81,323</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>83,664</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,932</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>73,732</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" NOWRAP><B></B><I>(In thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AMOUNT</B><br><B>RECOGNIZED&nbsp;IN<BR>THE&nbsp;STATEMENT<BR>OF&nbsp;FINANCIAL<BR>POSITION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FAIR<BR>VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ASSETS/ LIABILITIES<BR>AT FAIR VALUE<BR>THROUGH PROFIT<BR>AND LOSS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ASSETS AT<BR>AMORTIZED<BR>COST</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LIABILITIES<BR>AT&nbsp;AMORTIZED<BR>COST</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other financial assets (2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other receivables and assets&nbsp;(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents&nbsp;(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>48,926</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>48,488</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>48,488</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" NOWRAP><I>(In thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AMOUNT</B><br><B>RECOGNIZED&nbsp;IN<BR>THE&nbsp;STATEMENT<BR>OF&nbsp;FINANCIAL<BR>POSITION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FAIR<BR>VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ASSETS/ LIABILITIES<BR>AT FAIR VALUE<BR>THROUGH PROFIT<BR>AND LOSS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ASSETS AT<BR>AMORTIZED<BR>COST</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LIABILITIES<BR>AT&nbsp;AMORTIZED<BR>COST</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Financial <FONT STYLE="white-space:nowrap">liabilities&#151;non-current</FONT> portion
(4,&nbsp;Note&nbsp;15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Financial liabilities&#151;current portion (3,&nbsp;Note&nbsp;15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Trade payables and other current liabilities&nbsp;(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Tax, employee-related payables&nbsp;(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>66,620</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>58,424</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>566</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>57,858</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The fair value of cash and cash equivalents is determined based on Level&nbsp;1 fair value measurements and
corresponds to the market value of the assets. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The carrying amount of financial assets measured at amortized cost was deemed to be a reasonable estimation of
fair value, except for the long-term advances made to CROs, whose fair value is determined based on Level&nbsp;3 fair value measurement and is estimated based on future cash-flows discounted at market rates, using credit spreads ranging from 16 bp
to 476 bp as of December&nbsp;31, 2022. As of December&nbsp;31, 2022, an increase in the credit spread by +100 bp would result in a decrease in the advances fair value by &#128;240&nbsp;thousand. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The carrying amount of short-term financial liabilities measured at amortized cost was deemed to be a
reasonable estimation of fair value. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The fair values of Kreos BSA A&amp;B, OCEANE conversion option and royalty certificates are based on
Level&nbsp;3 fair value measurements and are estimated based on models and assumptions detailed in note 15. The fair value of other long-term financial liabilities is determined based on Level&nbsp;3 fair value measurements and is estimated based on
future cash-flows discounted at market rates, using the following assumptions: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the debt components of Kreos 1&amp;2 bonds, a credit spread of 1,058 bp as of December 31, 2021 and 1,475 bp
as of December&nbsp;31, 2022. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As of December 31, 2021 and 2022, an increase in the credit spread by +100 bp would result
in a decrease in the Kreos 1&amp;2 bonds fair value by &#128;209&nbsp;thousand and &#128;68&nbsp;thousand, respectively. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the debt component of OCEANE bonds, a credit spread similar to that detailed in note 15.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As of December 31, 2021, and 2022, an increase in the credit spread by +100 bp would result in a decrease in the OCEANE
debt component fair value by &#128;648&nbsp;thousand and &#128;476&nbsp;thousand, respectively. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the conditional advances and the PGE loan, a credit spread of 850 bp as of December 31, 2021 and 1,475 bp as
of December&nbsp;31, 2022. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">An increase in the credit spread by +100 bp would result in the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of December 31, 2021 and 2022, a decrease in the PGE loan fair value by &#128;102&nbsp;thousand and
&#128;55&nbsp;thousand, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of December 31, 2021 and 2022, a decrease in the <FONT STYLE="white-space:nowrap">RNP-VIR</FONT> conditional
advance fair value by &#128;61&nbsp;thousand and &#128;31&nbsp;thousand, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of December 31, 2021 and 2022, a decrease in the CARENA conditional advance fair value by
&#128;58&nbsp;thousand and &#128;37&nbsp;thousand respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of December 31, 2021 and 2022, a decrease in the Ebola conditional advance fair value by &#128;3&nbsp;thousand
and &#128;1&nbsp;thousand, respectively. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of December 31, 2021, a decrease in the <FONT STYLE="white-space:nowrap">Covid-19</FONT> conditional advance
fair value by &#128;161&nbsp;thousand. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Social security and other tax payables are excluded from the tax and employee-related payables, as this
analysis is required only for financial instruments. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 13. Shareholders&#146; equity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 13.1. Share capital issued </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
manages its capital to ensure that the Company will be able to continue as a going concern while maximizing the return to shareholders through the optimization of the debt and equity balance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2021, the Company&#146;s share capital amounted to &#128;168&nbsp;thousand divided into 16,764,051 ordinary shares issued with a par value
of &#128;0.01 each, fully paid up, after taking into account the various capital increases that took place since the inception (see Note 13.3). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
December 31, 2022, the Company&#146;s share capital amounted to &#128;223&nbsp;thousand divided into 22,313,185 ordinary shares issued with a par value of &#128;0.01 each, fully paid up, after taking into account the various capital increases that
took place since the inception (see Note 13.3). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share capital does not include BCEs, BSAs, and AGAs that have been granted to certain investors or
natural persons, both employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> of the Company, but not yet exercised or acquired. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Treasury
shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company held 8,600 and 12,000 of its own shares as of December 31, 2021 and 2022, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of outstanding ordinary shares (excluding treasury shares held by the Company) was 16,755,451 and 22,301,185 as of December 31, 2021 and 2022,
respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 13.2. Equity line instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Equity line agreement with Kepler Cheuvreux </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
entered into an equity line agreement with Kepler Cheuvreux in September 2019. In accordance with the terms of this agreement, Kepler Cheuvreux, acting as financial intermediary and guarantor of the transaction, committed to subscribe for 730,000
shares, at its own initiative, following a schedule lasting no longer than 24 months, at an issuance price based on an average market price weighted according to the volumes traded over the two trading days preceding each issue, less a maximum
discount of 7.0%. On September 24, 2021, the Company extended the agreement for an additional period of 12 months for the unsubscribed shares at that date. On October&nbsp;1, 2022, the agreement ended and the 300,000 outstanding BSAs lapsed. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>NUMBER OF<BR>BSAs<BR>OUTSTANDING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>MAXIMUM<BR>NUMBER<BR>OF&nbsp;SHARES<BR>TO&nbsp;BE<BR>ISSUED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>NUMBER&nbsp;OF<BR>BSAs<BR>EXERCISED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>NUMBER<BR>OF&nbsp;BSAs<BR>LAPSED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>NUMBER OF<BR>BSAs<BR>OUTSTANDING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>MAXIMUM<BR>NUMBER&nbsp;OF<BR>SHARES<BR>TO&nbsp;BE<BR>ISSUED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>FOR THE YEAR ENDED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS OF DECEMBER&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DECEMBER&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS OF DECEMBER&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BSAs granted under the Equity line agrement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(300,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Considering that the Company could terminate or suspend the Equity line agreement by buying back the BSAs or increasing the
minimum exercise price and that Kepler Cheuvreux was committed to subscribe the shares if the conditions are met, the BSAs granted to Kepler Cheuvreux under the Equity line agreements were <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet
commitments rather than derivative instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 13.3. Change in share capital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The increases in the share capital for the year ended December 31, 2021 relate to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The completion of a capital increase of &#128;59,982&nbsp;thousand on July 27, 2021 by issuing 1,964,031 ordinary
shares with a par value of &#128;0.01 per share and a subscription price of &#128;30.55 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The exercises of 167,749 share warrants for the year ended December 31, 2021 (see note 14), resulting in a
capital increase of &#128;1,522&nbsp;thousand by issuing 167,749 ordinary shares with a par value of &#128;0.01 per share and an average subscription price of &#128;8,49 per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The exercises of 312,000 share warrants under the Equity line agreement for the year ended December 31, 2021 (see
note 13.2), resulting in a capital increase of &#128;8,094&nbsp;thousand, net of commissions, by issuing 312,000 ordinary shares with a par value of &#128;0.01 per share and an average subscription price of &#128;27,13 per share;
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Incremental costs directly attributable to the issue of new shares were classified as a deduction of shareholders&#146; equity and
amounted to &#128;4,153&nbsp;thousand for the year the year ended December 31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The increases in the share capital for the year ended December 31,
2022 relate to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The completion of a capital increase of &#128;46,231&nbsp;thousand on September&nbsp;7, 2022 by issuing 5,530,000
ordinary shares with a par value of &#128;0.01 per share and a subscription price of &#128;8.36 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The exercises of 522 share warrants for the year ended December 31, 2022 (see Note 14), resulting in a capital
increase of &#128;3&nbsp;thousand by issuing 19,134 ordinary shares with a par value of &#128;0.01 per share and an average subscription price of &#128;0.14 per share; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Incremental costs directly attributable to the issue of new shares were classified as a deduction of shareholders&#146; equity and amounted to
&#128;3,280&nbsp;thousand for the period ended December&nbsp;31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Distribution of dividends </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company did not distribute any dividends for any of the periods presented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 14. Share-based payments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has granted
BCEs, BSAs and AGAs. These plans qualify as &#147;equity settled&#148; under IFRS 2. The Company does not have any obligation to purchase these instruments in the event of departure or if a specific event does not occur. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Valuation methods of BCEs, BSAs and AGAs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value
of share-based awards was determined at grant date using the Black Scholes model for the BCEs and BSAs and the Monte-Carlo simulation for AGAs plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
assumptions used to estimate the fair value of the instruments are presented below and include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expected maturity of the options </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expected volatility based on the historical market share price available; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expected dividends based on management best estimate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Risk-free interest rate based on French OAT rates measured at grant dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Share price offered in case of change of control (only for the market condition applicable on the free-share
plan) is based on Monte-Carlo simulations and taking into account a change of control premium based on the management best estimate. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>BCEs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables summarize the data relating to BCEs as well as the assumptions used for the measurement thereof in accordance with IFRS 2 &#150;
<I>Share-based Payment</I>: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6.5pt">
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>GRANT</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>DATE</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TYPE</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER&nbsp;OF</B><br><B>BCEs</B><br><B>ISSUED</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER&nbsp;OF</B><br><B>BCE<BR>OUTSTANDING</B><br><B>AS&nbsp;OF<BR>JANUARY</B><br><B>1, 2022</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER&nbsp;OF<BR>LAPSED</B><br><B>BCEs</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER&nbsp;OF<BR>EXERCISED</B><br><B>BCEs</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>OF&nbsp;BCEs</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>OUTSTANDING</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>OF&nbsp;BCEs</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>EXERCISABLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>MAXIMUM</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER OF<BR>SHARES TO<BR>BE ISSUED<BR>IF ALL<BR>CONDITIONS<BR>ARE MET</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS OF DECEMBER&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2014-03-11</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2014-2</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2014-03-11</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2014-4</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2016-11-07</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2017-01-23</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-1</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2017-11-20</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-2</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2017-11-20</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">BCE <FONT STYLE="white-space:nowrap">2017-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2017-11-20</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-4</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2017-11-20</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-5</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2018-03-15</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,090</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2018-05-21</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-2</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2018-05-14</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">BCE <FONT STYLE="white-space:nowrap">2018-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2018-05-14</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-4</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2018-05-14</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-5</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(334</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>Total BCEs</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>702,821</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>429,767</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,340</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(334</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>424,093</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>222,766</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>541,309</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6.5pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>TYPE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FAIR&nbsp;VALUE&nbsp;OF<BR>THE&nbsp;UNDERLYING<BR>SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FAIR&nbsp;VALUE<BR>OF THE BCE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BCE&nbsp;PRICE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>STRIKE&nbsp;PRICE<BR>PER SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EXPECTED<BR>TERM</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EXPECTED<BR>MATURITY</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>VOLATILITY</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RISK&nbsp;FREE<BR>RATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2014-4</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.54&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.77%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.96 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[2.77&#128;-3.15&#128;]</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[5.5-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">[-0.1%-0.18%]</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-1</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.95 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[2.38&#128;-2.72&#128;]</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.39 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[5.5-7.05</FONT></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[0.11%-0.44%]</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-2</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.22&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[4.01&#128;-4.56&#128;]</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[5.5-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">[-0.14%-0.1%]</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BCE&nbsp;2017-3</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.22&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[3.83&#128;-4.56&#128;]</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[5.04-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">[-0.21%-0.1%]</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-4</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.22&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[4.01&#128;-4.43&#128;]</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[5.5-6.64</FONT></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">[-0.14%-0.04%]</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-5</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.22&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[3.92&#128;-4.43&#128;]</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[5.26-6.64</FONT></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">[-0.18%-0.04%]</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.00 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[3.81&#128;-4.28&#128;]</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[5.5-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[0.14%-0.37%]</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-2</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.00 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[2.31&#128;-3.11&#128;]</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[5-8.06</FONT></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[0.05%-0.53%]</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BCE <FONT STYLE="white-space:nowrap">2018-3</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.03&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">[2.75&#128;-3.11&#128;]</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10&nbsp;years</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">[5-6.4</FONT></TD>
<TD NOWRAP VALIGN="top">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">[0.08%-0.3%]</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-4</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.03&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">[2.75&#128;-3.11&#128;]</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10&nbsp;years</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">[5-6.4</FONT></TD>
<TD NOWRAP VALIGN="top">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">[0.08%-0.3%]</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-5</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.03&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">[2.88&#128;-3.26&#128;]</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10&nbsp;years</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">[5.5-7</FONT></TD>
<TD NOWRAP VALIGN="top">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">[0.16%-0.39%]</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BCEs include a service condition under which the beneficiary must still be an employee, a corporate officer or a
scientific consultant of the Company at the time of vesting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise rights for most of the BCEs are vested annually and have the following vesting
terms: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">25% of the award vests on the first anniversary of the date of grant for all currently issued BCEs; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the remaining 75% of the award, the BCEs vest 1/48th per month over four years from the anniversary date of
the grant. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Most of the BCEs plans (all BCEs plans except BCE <FONT STYLE="white-space:nowrap">2014-2</FONT> fully vested as of January
1, 2020) include or partially include <FONT STYLE="white-space:nowrap">non-market</FONT> performance conditions (obtaining financing of &#128;100&nbsp;million, positive results on clinic studies, signature of informed consent in a clinical phase,
signing a license agreement, FDA authorization). The level of achievement of the <FONT STYLE="white-space:nowrap">non-market</FONT> performance conditions are taken into account in determining the number of BCEs allocated initially and reassessed at
each closing date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of a change of control or a M&amp;A transaction, all the BCEs will become immediately exercisable. A change of control is
defined as a new investor/company holding directly or indirectly more than 50% of the share capital or voting rights. As such the probable vesting date of each plan corresponds to the weighted average of probable change of control dates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For BCE <FONT STYLE="white-space:nowrap">2014-4,</FONT> BCE <FONT STYLE="white-space:nowrap">2016-1,</FONT>
BCE <FONT STYLE="white-space:nowrap">2017-1,</FONT> the vesting terms have been modified by the Board of Directors on February 14, 2020 to provide for the possible exercise of the instruments, even if the associated performance and/ or conditions
included in the graded vesting schedule are not met, in case of change of control. Since this modification affects a vesting condition other than a market condition, the modified vesting condition was taken into account by adjusting the number of
equity instruments that eventually vest. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>BSAs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following tables summarize the data relating to BSAs in accordance with IFRS 2 &#150; <I>Share-based Payment</I>: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>GRANT&nbsp;DATE</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TYPE</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER<BR>OF BSAs<BR>ISSUED</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER OF<BR>BCAs<BR>OUTSTANDING<BR>AS OF<BR>JANUARY 1,<BR>2022</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER&nbsp;OF<BR>LAPSED<BR>BSAs</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER<BR>OF<BR>EXERCISED<BR>BSAs</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>NUMBER OF<BR>BSAs<BR>OUTSTANDING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>NUMBER OF<BR>BSAs<BR>EXERCISABLE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>MAXIMUM<BR>NUMBER OF<BR>SHARES TO<BR>BE ISSUED IF<BR>ALL<BR>CONDITIONS<BR>ARE MET</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>AS OF DECEMBER&nbsp;31, 2022</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2014-03-11</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-3</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2015-12-04</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2015-11</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2015-12-04</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2015-12</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2017-09-18</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2017-1</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2018-01-22</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2018-1</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2014-03-11</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-4</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2014-03-11</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-5</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>Total BSAs</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>247,798</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>148,105</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(188</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>147,917</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>147,917</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>325,384</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BSAs include a service condition under which the beneficiary must still be an employee, a corporate officer or a
scientific consultant of the Company at the time of vesting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise rights for most of the BSAs are vested annually and have the following vesting
terms: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">25% of the award vests on the first anniversary of the date of grant for all currently issued BSAs; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the remaining 75% of the award, the BSAs vest 1/48th per month over four years from the anniversary date of
the grant. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of the BSAs plans include or partially include <FONT STYLE="white-space:nowrap">non-market</FONT> performance conditions
(positive results on clinic studies, signature of informed consent in a clinical phase, signing a license agreement, FDA authorization). The level of achievement of the <FONT STYLE="white-space:nowrap">non-market</FONT> performance conditions are
taken into account in determining the number of BSAs allocated initially and reassessed at each closing date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of a change of control or a
M&amp;A transaction, all the BSAs will become immediately exercisable. A change of control is defined as a new investor/company holding directly or indirectly more than 50% of the share capital or voting rights. As such the probable vesting date of
each plan corresponds to the weighted average of probable change of control dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For BSA <FONT STYLE="white-space:nowrap">2014-5,</FONT> the vesting
terms have been modified by the Board of Directors of February 14, 2020 to provide for the possible exercise of the instruments, even if the associated performance and/or conditions included in the graded vesting schedule are not met, in case of
change of control. Since this modification affects a vesting condition other than a market condition, the modified vesting condition was taken into account by adjusting the number of equity instruments that eventually vest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>AGAs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables summarize the data relating to AGAs as well as the assumptions used for the measurement thereof in accordance with IFRS 2 &#150;
<I>Share-based Payment</I>: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; "><B>GRANT&nbsp;DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TYPE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER&nbsp;OF<BR>AGAs&nbsp;ISSUED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER&nbsp;OF&nbsp;AGAs<BR>OUTSTANDING&nbsp;AS<BR>OF&nbsp;JANUARY&nbsp;1,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER&nbsp;OF<BR>LAPSED&nbsp;AGAs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER&nbsp;OF<BR>EXERCISED&nbsp;AGAs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER&nbsp;OF&nbsp;AGAs<BR>OUTSTANDING&nbsp;AS<BR>OF&nbsp;DECEMBER&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2021-09-21</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">AGA&nbsp;2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>155,000</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(155,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>Total&nbsp;AGAs</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>155,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>155,000</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(155,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; "><B>TYPE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FAIR&nbsp;VALUE&nbsp;OF<BR>THE&nbsp;UNDERLYING<BR>SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FAIR&nbsp;VALUE<BR>OF&nbsp;THE&nbsp;AGA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA<BR>PRICE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>STRIKE&nbsp;PRICE<BR>PER&nbsp;SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EXPECTED<BR>TERM</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DURATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>VOLATILITY</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RISK&nbsp;FREE<BR>RATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGA 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31.60&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.92&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">n.a.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">n.a.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AGAs granted in September 2021 are subject to a vesting service condition of one year following the grant date. The number of
shares that will be finally vested under this plan will depend on the following conditions: if a M&amp;A transaction is completed on or prior to July 31, 2022 and the price per ordinary share of the Company retained in the framework of the M&amp;A
transaction is at least equal to &#128;100 per share (or lower than &#128;100 per share) then 100% (or 75%) of the shares initially granted will be vested. The AGAs are forfeited if a M&amp;A transaction is not completed on or prior to July 31,
2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These conditions qualify as both a <FONT STYLE="white-space:nowrap">non-market</FONT> performance condition (occurrence or not of a M&amp;A
transaction before July 31, 2022) and a market condition (number of shares depending on the share price offered in case of a M&amp;A transaction before July 31, 2022) under IFRS 2 principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The level of achievement of the market condition is directly included in the unit fair value of the free shares and the probability of a M&amp;A transaction
before July 31, 2022 is included in the estimation of the number of shares that will be finally vested by the beneficiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31,
2021, considering that it was probable that an M&amp;A transaction would occur before July&nbsp;31, 2022, 100% of the shares originally granted were included in the calculation of share based payment expenses. In addition, the Company recognized an
accrual for social taxes related to the AGA 2021 plan of &#128;205&nbsp;thousand as of December&nbsp;31, 2021.The total share-based compensation expense amounted to &#128;828&nbsp;thousand (&#128;389&nbsp;thousand in research and development and
&#128;440&nbsp;thousand in general and administrative, respectively). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the period ended December&nbsp;31, 2022, the AGAs were all forfeited since
no M&amp;A transaction was completed on or prior to July 31, 2022. This resulted in a reversal of the related compensation expense of &#128;1,026&nbsp;thousand and the reversal of the accrual for social taxes of &#128;205&nbsp;thousand that was
recorded as of December 31, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Breakdown of the compensation expenses accounted for the year ended December&nbsp;31, 2021 and 2022 </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B><U>TYPE</U></B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EXPENSES&nbsp;RELATED<BR>TO&nbsp;THE&nbsp;YEAR&nbsp;ENDED</B><br><B>DECEMBER&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EXPENSES&nbsp;RELATED<BR>TO&nbsp;THE&nbsp;YEAR&nbsp;ENDED</B><br><B>DECEMBER&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><I>(in thousands of euros)</I></P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BCEs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSAs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGAs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1&nbsp;026</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Social taxes related to AGAs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1&nbsp;032</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1&nbsp;369</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 15. Financial liabilities </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>FINANCIAL LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kreos 1 &amp; 2 bond loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PGE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Borrowings</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,458</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,127</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oceane</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Convertible loan notes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18,191</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19,332</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kreos A&nbsp;&amp; B BSA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oceane conversion option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Derivative instruments</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,932</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>566</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conditional advances BPI</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalties certificates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,659</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,549</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> financial liabilities</B></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>50,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>35,573</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kreos 1 &amp; 2 bond loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PGE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Borrowing</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,608</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,077</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conditional advances BPI</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prosynergia <FONT STYLE="white-space:nowrap">earn-out</FONT> liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,112</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,521</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oceane</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Convertible loan notes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>625</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>625</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,224</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>61,585</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>49,797</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.1. Structured debt financing with Kreos subscribed in July 2018 &#150; &#147;Kreos 1&#148; </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 24, 2018, the Company entered into a Venture Loan Agreement, a Straight Bonds Issue Agreement and a Convertible Bonds Issue Agreement with Kreos
Capital V (UK) Ltd., (or &#147;Kreos&#148;), which provided for up to &#128;20,000&nbsp;thousand in financing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the agreements,
Kreos agreed to subscribe for &#128;16,000&nbsp;thousand in <FONT STYLE="white-space:nowrap">non-convertible</FONT> bonds and &#128;4,000&nbsp;thousand in convertible bonds, to be issued by the Company in two tranches of &#128;10,000&nbsp;thousand
each. The tranches were issued in July 2018 and May 2019, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The convertible bonds were convertible into new ordinary shares of the Company at
any time from their issuance and at the discretion of their holders. In October 2020, Kreos required the conversion of all the convertible bonds they held (2,000,000 for Tranche A and 2,000,000 for Tranche B) and 464,309 shares were issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each tranche bears an 8% annual interest rate, plus <FONT STYLE="white-space:nowrap">3-month</FONT> Euribor, including a floor at 8% and a cap at 9%, and must
be repaid in 54 monthly installments, after a deferred repayment of the nominal value to 12 months for the first tranche (&#147;Tranche A&#148;) and 6 months for the second tranche (&#147;Tranche B&#148;). In addition, each tranche
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
bears exit fees of 9% of the total drawdown amount (i.e. &#128;900&nbsp;thousand per tranche), payable upon the last monthly installment (exit fees remain payable in full in case of early
redemption). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the agreements, the Company has the right, at any time but with no less than 30 days prior notice to Kreos, to
prepay or purchase the <FONT STYLE="white-space:nowrap">non-convertible</FONT> and convertible bonds, exclusively in full. The prepayment will be equal to (i)&nbsp;the principal amount outstanding, plus (ii)&nbsp;exit fees of 9% of the total draw
down amount and (iii)&nbsp;the sum of all interest repayments which would have been paid throughout the remainder of the term of the relevant tranche discounted by 4% per annum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreements do not contain any financial covenants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
connection with each tranche, the Company issued 110,957 tranche A share warrants (or &#147;Kreos A BSA&#148;) and 74,766 tranche B share warrants (or &#147;Kreos B BSA&#148;), each, for a global subscription price of &#128;1. Each Kreos A BSA and
Kreos B BSA gives rights to one new ordinary share at an exercise price of &#128;7.21 less a discount and &#128;10.70 less a discount, respectively. Both Kreos A BSA and Kreos B BSA are freely transferrable among financial institutions and are
exercisable over a <FONT STYLE="white-space:nowrap">10-year</FONT> period from the issue date. In addition, the Company granted to the holders of the Kreos A BSA and the Kreos B BSA the option to sell to the Company, upon each exercise of all or
parts of the Kreos A BSA, at the put price defined in the agreement, a proportion of the number of the warrants, for the sole purpose of implementing a cash less exercise of the Kreos A BSA and Kreos B BSA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Accounting treatment </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Kreos 1 financing package is
issued at market conditions: the net issuance proceeds reflect the fair value of the instruments at inception. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The straight bond tranches are split
between i) a debt component (then measured at amortized cost), and ii) a premium corresponding to the initial fair value of attached BSA (then remeasured at fair value through profit and loss). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BSA attached to all tranches (both straight and convertible) do not meet the &#147;fixed for fixed&#148; criteria (non cash settlement option which may
result in exchanging a variable number of shares, for a variable price), and are accounted for as standalone derivative instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The issuer
prepayment options meet the definition of a separate derivative. However, their value at inception and subsequent dates is nil as per Schoenbucher model, and has no impact on the financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Measurement of Kreos A BSA&nbsp;&amp; Kreos B BSA </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Kreos A BSA and Kreos B BSA are measured at fair value using a Black-Scholes valuation model. The main data and assumptions are the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Kreos A BSA - July 31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;and&nbsp;for&nbsp;the&nbsp;year<BR>December&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;and&nbsp;for&nbsp;the&nbsp;year<BR>December&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of outstanding Kreos A BSA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary share price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">28.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">6.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Residual maturity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.6&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.6&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.98</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fair value of issued Kreos A BSA (in thousands&nbsp;of&nbsp;&#128;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,478</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>275</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Change in fair value of Kreos A BSA for the year
(in&nbsp;thousands&nbsp;of&nbsp;&#128;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(699</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,203</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Kreos B BSA - June 1, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;and&nbsp;for&nbsp;the&nbsp;year<BR>December&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;and&nbsp;for&nbsp;the&nbsp;year<BR>December&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of outstanding <B>Kreos B BSA </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary share price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">28.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">6.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Residual maturity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.4&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.4&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.96</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fair value of issued Kreos B BSA (in thousands of &#128;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,525</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>149</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Change in fair value of Kreos B BSA for the year
(in&nbsp;thousands&nbsp;of&nbsp;&#128;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(494</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,376</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2021, using the same assumption with an increase of +1% volatility, &#128;+1share price and +1% risk-free
rate would result in an increase of Kreos A&amp;B BSA fair value of &#128;16&nbsp;thousand, &#128;176&nbsp;thousand, and &#128;69&nbsp;thousand respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2022, using the same assumption with an increase of +1% volatility, &#128;+1share price and +1% risk-free rate would result in an increase
of Kreos A&amp;B BSA fair value of &#128;6&nbsp;thousand, &#128;78&nbsp;thousand, and &#128;12&nbsp;thousand, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.2. Structured
debt financing with Kreos subscribed in October 2020 &#150; &#147;Kreos 2&#148; </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October 13, 2020, the Company obtained a straight bond loan of
&#128;15,000&nbsp;thousand from Kreos corresponding to two tranches of &#128;10,000&nbsp;thousand (&#147;Tranche A&#148;) and &#128;5,000&nbsp;thousand (&#147;Tranche B&#148;), with an option for an additional &#128;5,000&nbsp;thousand. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tranches A and B were paid in October and November 2020, respectively, with the following conditions. Each tranche bears an 8% annual interest rate, plus <FONT
STYLE="white-space:nowrap">3-month</FONT> Euribor, for the first 12 monthly installments, after which the annual interest rate is increased to a fixed rate of 9.75% for the following 36 monthly installments. Each tranche is to be repaid in 36
monthly installments starting from October 2021 and November 2021, for the tranche A and B, respectively. The agreements do not contain any financial covenants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, each tranche bears exit fees of 4% of the total drawdown amount (i.e. &#128;400&nbsp;thousand &#128;200&nbsp;thousand for Tranche A&nbsp;&amp; B,
respectively), payable upon the last monthly installment (exit fees remain payable, in full or partially, in case of early redemption). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the
terms of the agreements, the Company has the right, at any time but with no less than 30 days prior notice to Kreos, to prepay or purchase the <FONT STYLE="white-space:nowrap">non-convertible</FONT> exclusively in whole. The prepayment will be equal
to (i)&nbsp;the principal amount outstanding, plus (ii)&nbsp;exit fees of 2% of the outstanding amount in the event of prepayment occurring between the 18th and the 30th installment or exit fees of 4% of the outstanding amount in the event of
prepayment occurring after the 30th installment and (iii)&nbsp;the sum of all interest repayments which would have been paid throughout the remainder of the term of the relevant tranche discounted by 4% per annum. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Accounting treatment </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Kreos 2 straight bonds were
initially measured at fair value, which corresponds to the net cash proceeds, and subsequently measured at amortized cost. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the prepayment
option is a separate derivative instrument as the redemption price does not reimburse Kreos for an amount up to the approximate present value of lost interest for the remaining term of the host </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contract. However, its fair value at inception and subsequent dates is nil as per Schoenbucher model, and has no impact on the financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.3. OCEANE </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company received a gross
proceed of &#128;85,000&nbsp;thousand on July 30, 2021 through (i)&nbsp;the issuance of 1,964,031 shares with a subscription price of &#128;30.55 per share (see Note 13.3 (changes in share capital)) for gross amount of &#128;60,000&nbsp;thousand,
and (ii)&nbsp;the issuance of &#128;25,000&nbsp;thousand in OCEANE, maturing on July 30, 2026. The proceeds of the transaction mainly serve to finance the progress of ABX464 clinical trials in chronic inflammatory diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The OCEANE bears a 6% interest rate per year, payable semi-annually January 30, and July, 31 from January 31, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The OCEANE shall be convertible into new ordinary shares and/or exchanged for existing ordinary shares of the Company at any time from their issuance and at
the discretion of their holders. The conversion ratio is one ordinary share of the company per OCEANE, representing a conversion price set to &#128;&nbsp;38.19 per ordinary share. This conversion price will be updated (decrease only) 18 months, 24
months, 36 months after OCEANE issuance date to match the volume weighted average price of the thirty trading days that precedes the update subjected to the following floor threshold. The floor threshold for the
<FONT STYLE="white-space:nowrap">18-month</FONT> update matches 85% initial conversion price (&#128;32.462 per ordinary share). The floor threshold for the <FONT STYLE="white-space:nowrap">24-month</FONT> update matches 70% initial conversion price
(&#128;26.733 per ordinary share). The floor threshold for the <FONT STYLE="white-space:nowrap">36-month</FONT> update matches 68% initial conversion price (&#128;25.969 per ordinary share). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OCEANE terms and conditions anticipate a conversion ratio adjustment in order to preserve the rights of OCEANE holders with the following achievements made by
the company: issuance of new shares with the preemptive subscription right, attribution of free shares or securities for the benefit of all the shareholders, number of share multiplication, shares consolidation, increase of the nominal value by
incorporation of reserves, profits or bonuses, distribution of dividends, premiums or reserves, mergers, scission, repurchase of shares above market value, capital reduction, creation of preferred shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Accounting treatment and measurement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the conversion
ratio is adjusted 18 months, 24 months, and 36 months after the issuance date of the OCEANE bond with the weighted average price of the shares and is subject to a floor and a cap, the conversion does not result in the delivery of a fixed number of
shares. Consequently, the OCEANE bond is recorded as an hybrid instrument which includes i) a debt host contract accounted for at amortized cost, and ii) a conversion option which is a standalone derivative accounted for at fair value through profit
and loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At inception, the net cash proceeds reflect the OCEANE initial fair value. The fair value of the bifurcated option at inception has been
measured with a Monte Carlo model using a Longstaff Schwartz algorithm, with a 53% share price volatility, a 1 400 bp credit spread assumption and a &#128;31.50 share price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of July 30, 2021, the issuance price of &#128;&nbsp;25,000&nbsp;thousand has been split between i) a financial liability for &#128;17,839&nbsp;thousand,
and ii) a financial derivative for &#128;7,161&nbsp;thousand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2021, the fair value of the conversion option amounts to
&#128;5,929&nbsp;thousand, based on the same valuation model, a credit spread assumption of 1,400 bp, a share price of &#128;28.55, and a price volatility of 77%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2021, using the same assumptions, an increase of +1% volatility, &#128;+1 share price and +1% risk free rate would result in an increase of
the OCEANE conversion option fair value of &#128;114&nbsp;thousand, &#128;337&nbsp;thousand, and &#128;243&nbsp;thousand, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2022, the fair value of conversion option amounts to &#128;142&nbsp;thousand, based on
the same valuation model, a credit spread assumption of 1,475 bp, a share price of &#128;6.18, and a price volatility of 44%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2022,
using the same assumptions, an increase of +1% volatility, &#128;+1 share price and +1% risk free rate would result in an increase of the OCEANE conversion option fair value of &#128;17&nbsp;thousand, &#128;97&nbsp;thousand, and
&#128;15&nbsp;thousand respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.4. State guaranteed loan &#150; &#147;PGE&#148; </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2020, the Company subscribed to a PGE from Soci&eacute;t&eacute; G&eacute;n&eacute;rale with an initial maturity of 12 months at 0.25% and a five-year
extension option. In March 2021, the company exercised the five-year extension option with a <FONT STYLE="white-space:nowrap">one-year</FONT> deferral of the principal repayment, with the following conditions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Rate: 0.58% per annum excluding insurance and state guaranteed premium, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">State guaranteed premium of &#128;138&nbsp;thousand to be paid by installments over the contract period starting
in June 2021, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Reimbursement by yearly installments from June 2021 to June 2026. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The benefit resulting from the low interest nature of the award as a subsidy was recognized as other income during the period ended December&nbsp;31, 2020 for
an amount of &#128;377&nbsp;thousand. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.5. Conditional advances </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>(In thousands of euros)</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>CONDITIONAL ADVANCES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B>&#8195;2021&#8195;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B>&#8195;2022&#8195;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RNP VIR &#150; Bpifrance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CARENA &#150; Bpifrance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EBOLA &#150; Bpifrance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">COVID-19</FONT> &#150; Bpifrance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total conditional advances</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,770</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,783</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>RNP-VIR &#150; Bpifrance </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the <FONT STYLE="white-space:nowrap">RNP-VIR</FONT> contract, the Company was eligible to receive up to &#128;6.3&nbsp;million in conditional advances to
further develop methods for the discovery of new molecules for the treatment of viral infectious diseases through the development of the &#147;Modulation of RNA biogenesis&#148; platform. As of December 31, 2022, the Company had received
&#128;4,032&nbsp;thousand, of which &#128;1,756&nbsp;thousand was received in September 2017, &#128;346&nbsp;thousand in August&nbsp;2018 and &#128;1,930&nbsp;thousand in November 2019. The repayment of these funds is spread from the date on which
the repayments are called by BPI. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 25.2. Commitments under BPI conditional advances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>CARENA &#150; Bpifrance </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the CARENA agreement, the
Company was eligible to receive up to &#128;3,840&nbsp;thousand to develop a therapeutic HIV treatment program with ABX464. As of December 31, 2022, the Company received &#128;2,187&nbsp;thousand, of which &#128;1,150&nbsp;thousand was received in
December 2013, &#128;1,008&nbsp;thousand in September 2014 and &#128;29&nbsp;thousand received in June 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The repayment of the advance is spread from the date on which the repayments are called by BPI. An
additional repayment is provided for based on the income the Company generates through this research and development program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 25.2. Commitments
under BPI conditional advances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>EBOLA &#150; Bpifrance </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Bpifrance and Occitanie region joint aid agreement, the Company received a total of &#128;390&nbsp;thousand (&#128;300&nbsp;thousand as of December
31, 2017 and &#128;90&nbsp;thousand as of December 31, 2019). The reimbursement is spread from 2019 to June 2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">COVID-19</FONT> &#150; Bpifrance </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2020, Bpifrance granted the Company with a conditional advance of up to a total of &#128;15,869&nbsp;thousand under the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> agreement to complete the miR-AGE study to demonstrate the efficacy and safety of ABX464 for the treatment of <FONT STYLE="white-space:nowrap">COVID-19</FONT> patients at risk of developing severe
forms of the disease thanks to an anti- inflammatory and antiviral effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the project failed, the repayment of these funds were to be spread over
five years from March 31, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the Company had received a grant of &#128;1,587&nbsp;thousand and a repayable advance of
&#128;6,348&nbsp;thousand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In view of the study results and the recommendations of the Data and Safety Monitoring Board, the Company terminated the study
on March&nbsp;5, 2021. As Bpifrance had recorded the project as a failure, the repayable advance of &#128;6,348&nbsp;thousand paid in 2020 was recognized as a grant. As of December&nbsp;31, 2021, the Company had also received the remainder of the
grant, amounting to &#128;3,279&nbsp;thousand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A valuation of conditional advances was made using a market rate of 8% per year as of May&nbsp;31, 2020
(see&nbsp;Note&nbsp;18). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.6. Lease liability </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>(amounts in thousands of euros)</I></P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt"><B>LEASE AGREEMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LEASE&nbsp;LIABILITY</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>400</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(+) Increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(-) Decrease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&#8195;&#8195;&#8195;&#8195;214</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(+) Increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(-) Decrease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(305</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,384</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lease liabilities mainly relate the Company&#146;s headquarter and to a lesser extent to vehicles, parking lots and printers
(Note 8). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The lease for the Company&#146;s corporate headquarters in Paris, France at 5 Rue de la Baume, 75008 Paris ended in August 2022. A new lease
for premises at <FONT STYLE="white-space:nowrap">7-11</FONT> Boulevard Haussmann, 75009 Paris started in July 2022. It has a three-year duration, with a tacit renewal option for approximately two years and the possibility to break the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contract one year before the end. Per Management, renewal and termination options are not reasonably certain due to the forecasted development of the Company, which may lead the Company to
relocate at the end of the initial term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2021 and December&nbsp;31, 2022, the lease liability of the headquarter represented 92%
and 97% of the total lease liability, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lease expenses related to contracts for which a lease liability and right of use asset is recognized
under IFRS 16 were &#128;250&nbsp;thousand and &#128;424&nbsp;thousand for the years ended December 31, 2021 and 2022, respectively. They were recognized for (i) &#128;244&nbsp;thousand and &#128;414&nbsp;thousand as Depreciation expenses and (ii)
&#128;5&nbsp;thousand and &#128;10&nbsp;thousand as Interest expenses, for the years ended December 31, 2021 and 2022, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lease expenses
related to short-term lease contracts and low value assets that are not included in the valuation of the lease liability amount to &#128;25&nbsp;thousand and &#128;331&nbsp;thousand for the years ended December 31, 2021 and 2022, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.7 Prosynergia <FONT STYLE="white-space:nowrap">earn-out</FONT> liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Prosynergia <FONT STYLE="white-space:nowrap">earn-out</FONT> liability is measured at fair value using a Black-Scholes valuation model. The main data and
assumptions are the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Prosynergia <FONT STYLE="white-space:nowrap">earn-out</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;April&nbsp;1,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;and&nbsp;for&nbsp;the<BR>period ended<BR>December&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0,27</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,28</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Market capitalization (in thousands of &#128;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">403&nbsp;118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135&nbsp;952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary share price (&#128;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Time to maturity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25&nbsp;year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,01</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fair value of the <FONT STYLE="white-space:nowrap">earn-out</FONT> liability (in thousands
of &#128;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1&nbsp;446</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of April 1, 2022, using the same assumption with an increase of +1% volatility, &#128;+1 share price and +1% risk free rate
would result in an increase of the <FONT STYLE="white-space:nowrap">earn-out</FONT> liability fair value by &#128;12&nbsp;thousand, &#128;132&nbsp;thousand and &#128;17&nbsp;thousand, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, the fair value of the <FONT STYLE="white-space:nowrap">earn-out</FONT> liability is approximately &#128;0. Using the same
assumption with an increase of +1% volatility, &#128;+1 share price and +1% risk free rate would result in an increase of the <FONT STYLE="white-space:nowrap">earn-out</FONT> liability fair value by an amount less than &#128;1&nbsp;thousand. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.8 Royalty certificates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September 2,
2022, the Company completed a financing of &#128;49,162&nbsp;thousand, consisting of two transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a reserved capital increase of a gross amount of &#128;46,231&nbsp;thousand through the issuance of 5,530,000 new
shares with a nominal value of &#128;0.01 per share at a subscription price of &#128;8.36 per share; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an issue of royalty certificates with a subscription price amounting to &#128;2,931&nbsp;thousand. The royalty
certificates give right to their holders to royalties equal to 2% of the future net sales of obefazimod (worldwide and for all indications) as from the commercialization of such product. The amount of royalties that may be paid under the royalty
certificates is capped at &#128;172,000&nbsp;thousand. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Related transaction costs amounted to &#128;3,280&nbsp;thousand and are recorded
in equity, since entirely related to the reserved capital increase. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, following a change in the estimate of future royalty cash flows, the
certificates&#146; amortized cost was remeasured at &#128;3,287&nbsp;thousand, using the original EIR calculated at the date of issuance. The change in estimate resulted in a decrease in the related interest expense by &#128;100&nbsp;thousand over
the period ended December&nbsp;31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fair value as of December&nbsp;31, 2022 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At this date, the fair value of the royalty certificates, calculated using the same model as their initial measurement, amounts to &#128;3,307&nbsp;thousand.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the Royalty Certificates is based on NPV of royalties, which depend on assumptions made by the Company with regards to the probability
of success of its studies (&#147;POS&#148;), the commercialization budget of obefazimod (&#147;peak penetration&#148;) and the discount rate. In addition, royalty projections have been adjusted to reflect any difference between the company&#146;s
value derived from management projections and the company&#146;s market capitalization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sensitivity analysis to key assumptions is presented below:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Fair&nbsp;value&nbsp;of&nbsp;royalty<BR>certificates&nbsp;(in&nbsp;thousands<BR>of&nbsp;euros)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">POS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-5&nbsp;points</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">+5&nbsp;points</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Fair&nbsp;value&nbsp;of&nbsp;royalty<BR>certificates&nbsp;(in&nbsp;thousands<BR>of&nbsp;euros)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peak penetration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-5%&nbsp;(worst&nbsp;case&nbsp;scenario)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">+5%&nbsp;(best&nbsp;case scenario)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Fair&nbsp;value&nbsp;of&nbsp;royalty<BR>certificates&nbsp;(in&nbsp;thousands<BR>of&nbsp;euros)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount Rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-1&nbsp;point</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">+1&nbsp;point</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.9. Change in financial liabilities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in financial liabilities, excluding derivative instruments, are presented below as of December 31, 2021 and December 31, 2022: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>(Amounts&nbsp;in&nbsp;thousands&nbsp;of&nbsp;euros)</I></P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt"><B>FINANCIAL LIABILITIES</B><br><B>(excluding derivatives instruments)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Kreos&nbsp;1&nbsp;&amp;&nbsp;2<BR>bond loans</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Oceane</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Conditional<BR>advances<BR>BPI</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Lease<BR>liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Prosynergia<BR><FONT STYLE="white-space:nowrap">earn-out</FONT><BR>liability</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty<BR>certificates</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>26&nbsp;233</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4&nbsp;623</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11&nbsp;193</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>400</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>42&nbsp;449</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds <SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25&nbsp;000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25&nbsp;000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5&nbsp;537</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5&nbsp;856</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> changes: interest expense and other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> changes : classification of the conversion option
as a derivative instrument</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7&nbsp;161</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7&nbsp;161</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> changes : subsidies</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4&nbsp;459</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4&nbsp;367</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non cash changes: additional leases</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21&nbsp;110</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18&nbsp;816</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4&nbsp;742</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6&nbsp;770</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>214</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>51&nbsp;653</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>(Amounts&nbsp;in&nbsp;thousands&nbsp;of&nbsp;euros)</I></P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt"><B>FINANCIAL LIABILITIES</B><br><B>(excluding derivatives instruments)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Kreos&nbsp;1&nbsp;&amp;&nbsp;2<BR>bond loans</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Oceane</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Conditional<BR>advances<BR>BPI</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Lease<BR>liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Prosynergia<BR><FONT STYLE="white-space:nowrap">earn-out</FONT><BR>liability</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty<BR>certificates</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2&nbsp;931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2&nbsp;931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9&nbsp;410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(90</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(305</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9&nbsp;806</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2&nbsp;456</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1&nbsp;496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4&nbsp;006</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> changes: interest expense and other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3 738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2&nbsp;636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6&nbsp;983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> changes: recognition of <FONT
STYLE="white-space:nowrap">earn-out</FONT> liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> changes: fair value remeasurement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1&nbsp;446</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1&nbsp;446</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non cash changes: additional leases</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12&nbsp;982</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19&nbsp;957</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4&nbsp;838</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6&nbsp;783</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1&nbsp;384</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3&nbsp;287</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>49&nbsp;231</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Excluding issuance fees of &#128;87&nbsp;thousand for the year ended December 31, 2021. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.10. Change in derivative instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in derivative instruments, are presented below as of December 31, 2021 and December&nbsp;31, 2022 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>(In thousands of euros)</I></P> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt"><B>FINANCIAL
INSTRUMENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Kreos&nbsp;A&nbsp;BSA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Kreos&nbsp;B&nbsp;BSA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>OCEANE<BR>conversion<BR>option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of January&nbsp;1, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3&nbsp;177</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2&nbsp;019</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5&nbsp;196</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(+) Increase in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7 161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7 161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(-) Decrease in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(699</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(494</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1&nbsp;231</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2&nbsp;425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2&nbsp;478</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1&nbsp;525</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5&nbsp;929</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9&nbsp;932</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(+) Increase in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(-) Decrease in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2&nbsp;203</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1&nbsp;376</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5&nbsp;787</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9&nbsp;366</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>275</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>149</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>142</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>566</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.11. Breakdown of financial liabilities by maturity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The maturities of financial liabilities are presented below as of December 31, 2021 and December&nbsp;31, 2022: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>(In thousands of euros)</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>CURRENT AND <FONT STYLE="white-space:nowrap">NON-CURRENT</FONT> FINANCIAL<BR>LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>LESS&nbsp;THAN</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>FROM&nbsp;1&nbsp;TO</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>LONGER&nbsp;THAN</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>GROSS&nbsp;AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1&nbsp;YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>5&nbsp;YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>5&nbsp;YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kreos 1 &amp; 2 bond loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oc&eacute;ane</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PGE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conditional advances BPI</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>61,585</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>46,237</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,003</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Of which current portion</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>11,345</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Of which <FONT STYLE="white-space:nowrap">non-current</FONT> portion</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>50,240</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>(In thousands of euros)</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>CURRENT AND <FONT STYLE="white-space:nowrap">NON-CURRENT</FONT> FINANCIAL<BR>LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>LESS&nbsp;THAN</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>FROM&nbsp;1&nbsp;TO</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>LONGER&nbsp;THAN</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>GROSS&nbsp;AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1&nbsp;YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>5 YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>5 YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kreos 1 &amp; 2 bond loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oceane</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PGE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conditional advances BPI</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty certificates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>49,797</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,224</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>35,150</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>424</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Of which current portion</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>14,224</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Of which <FONT STYLE="white-space:nowrap">non-current</FONT> portion</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>35,573</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 16. Retirement benefit obligations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Retirement benefit obligations include the liability for the defined benefit plan, measured based on the provisions stipulated under the applicable collective
agreements, i.e. the French pharmaceutical industry&#146;s collective agreement. This commitment only applies to employees subject to French law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
main actuarial assumptions used to measure the retirement benefit obligations are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>AS OF DECEMBER&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>ACTUARIAL ASSUMPTIONS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2022</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Retirement age</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center">65&nbsp;years for key management / 63 years for other employees</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Collective agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center">Pharmaceutical industry</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Discount Rate (IBoxx Corporates AA)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.90%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3.65%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Mortality rate table</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center">INSEE 2016-2018</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Salary increase rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center">3% for key management / 2.55% for other employees</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Turnover rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Decreasing&nbsp;from&nbsp;5,80%&nbsp;at&nbsp;20&nbsp;years-old&nbsp;to&nbsp;0,05%&nbsp;from&nbsp;55&nbsp;
years-old</FONT></FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Employee contribution rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center">45%</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in the projected benefit obligation for the periods presented were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RETIREMENT&nbsp;BENEFIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(In thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>OBLIGATIONS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of January&nbsp;1, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>745</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefits paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Actuarial gains and losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>693</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefits paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Actuarial gains and losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>610</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 17. Payables and other current liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 17.1. Trade payables and other current liabilities </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(In thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>TRADE PAYABLES AND OTHER CURRENT LIABILITIES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued invoices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Trade payables and other current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18,558</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15,475</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No discount was applied to payables and related accounts maturity does not exceed one year. As a result, fair value
approximates the carrying amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The decrease in trade payable and other current liabilities is mainly due to the end of the research collaboration
agreement with the CNRS (French National Centre for Scientific Research) and the University of Montpellier. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 17.2. Tax and employee-related
payables </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tax and employee-related payables are presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(In thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>TAX AND EMPLOYEE-RELATED PAYABLES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee-related payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Social security and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other tax and related payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Tax and employee-relates payables</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,200</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,300</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 18. Operating income </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(In thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>OPERATING INCOME</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research tax credit (&#147;CIR&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsidies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,962</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,583</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating income is composed as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research tax credit (&#147;CIR&#148;) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
carries out research and development projects. As such, it has benefited from a research tax credit for the years ended December 31, 2021 and 2022 for an amount of &#128;4.2&nbsp;million and &#128;4.5&nbsp;million, respectively (see Note 4.9). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Subsidies: </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsidy income primarily relates to Bpifrance
agreement to finance the <FONT STYLE="white-space:nowrap">&#147;COVID-19&#148;</FONT> project. This financing was granted under the French Future Investments Project. This study was conducted with the participation of the University Hospital of
Nice, which directly manages part of the financing of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> clinical trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2021, the Company recognized as a subsidy: (i) &#128;4,459&nbsp;thousand
corresponding to the conditional advance received in June 2020 (discounted amount) which had been waived by Bpifrance in April 2021 (See Note 15.5, &#147;Conditional advances&#148;), and (ii)&nbsp;an additional payment of &#128;3,279 thousand
received in October 2021 to reimburse additional expenses incurred until the termination date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 19. Operating expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 19.1. Research and development </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and
development expenses break down as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(amounts in thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>PERIOD&nbsp;ENDED&nbsp;DECEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>RESEARCH AND DEVELOPMENT EXPENSES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Sub-contracting,</FONT> studies and research</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consulting and professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intellectual property fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Research and development expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>47,781</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>48,295</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of the following items: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">personnel expenses, including salaries, benefits, and share-based compensation expenses, for employees engaged in
research and development activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">sub-contracting,</FONT> collaboration and consultant expenses that primarily
include the cost of third-party contractors such as CROs who conduct our <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and clinical trials, and research related to our proprietary platforms, as well as investigative sites and
consultants that conduct our preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred under agreements with contract manufacturing organizations (&#147;CMOs&#148;), including
manufacturing <FONT STYLE="white-space:nowrap">scale-up</FONT> expenses and the cost of acquiring and manufacturing preclinical study and clinical trial materials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses relating to preclinical studies and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses relating to regulatory affairs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allocated expenses for facility costs, including rent, utilities and maintenance; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses relating to the implementation of our quality assurance system. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2022, research and development expenses were &#128;48,295&nbsp;thousand, as compared to &#128;47,781&nbsp;thousand for the
year ended December 31, 2021. This increase was primarily due to the &#128;20,841&nbsp;thousand increase in UC expenses, following the strong progress of obefazimod in this indication since 2021, as the Company completed the Phase 2b clinical trial
in early 2022 and initiated Phase 3 clinical trial in the first half of 2022. This increase is offset by a decrease by &#128;13,943&nbsp;thousand in transversal activities, as the Company completed existing studies, a decrease by
&#128;2,021&nbsp;thousand in Crohn&#146;s Disease research expenses and a decrease by &#128;2,834&nbsp;thousand in Rheumatoid Arthritis expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 19.2. General and administrative </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses break down as follows; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(amounts in thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>PERIOD&nbsp;ENDED&nbsp;DECEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>GENERAL AND ADMINISTRATIVE EXPENSES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consulting and professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>General and administrative expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,580</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,492</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of personnel-related expenses, including salaries, benefits and
share-based compensation expenses, for personnel other than employees engaged in research and development activities. General and administrative expenses also include fees for professional services, mainly related to audit and legal services,
consulting costs, communications and travel costs, allocated expenses for facility costs, including rent, utilities and maintenance, directors&#146; attendance fees, and insurance costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2022, general and administrative expenses were &#128;7,492&nbsp;thousand, as compared to &#128;5,580&nbsp;thousand for
the year ended December&nbsp;31, 2021. This increase was primarily driven by other general expenses, as well as an increase in consulting and professional fees. The &#128;2,233&nbsp;thousand increase in other general and administrative expenses in
2022 was primarily related to financial and legal consulting fees. These increases are partially offset by a decrease in personnel costs, mainly due to a reversal of share-based compensation expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Principal audit fees and services: </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(In thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statutory Auditor, certification of individual financial statements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other procedures required by law</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>166</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>840</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 20. Employees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company&#146;s average workforce during the years ended December 31, 2021 and 2022 was as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>HEADCOUNTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Key management</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other employees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>27</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 21. Financial gain or loss </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(In thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>FINANCIAL GAIN OR LOSS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on Kreos 1 &amp; 2 straight bond loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,344</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on convertible loan notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,064</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on conditional advances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(145</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on royalty certificates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(356</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3,561</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(7,022</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease/(increase) in derivatives fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease/(increase) in other liabilities at fair value through profit and loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,509</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,118</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial gain (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,052</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,096</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended the year ended December 31, 2021, the fair values of the Kreos A BSA, the Kreos B BSA and the convertible
option related to the OCEANE bond decreased by &#128;639&nbsp;thousand, &#128;427&nbsp;thousand and &#128;1,231&nbsp;thousand, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year
ended the year ended December 31, 2022, the fair values of the Kreos A BSA, the Kreos B BSA and the convertible option related to the OCEANE bond decreased by &#128;2,203&nbsp;thousand, &#128;1,376&nbsp;thousand and &#128;5,787&nbsp;thousand,
respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 22. Income tax </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The income tax
rate applicable to the Company is the French corporate income tax rate, i.e. 26.5% and 25% for the years ended December 31, 2021 and 2022, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Reconciliation between theoretical and effective tax rate </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros, except percentage)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statutory French tax rates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Nominal income tax using statutory French tax rate</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,250</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15,185</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CIR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs related to capital increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease / (increase) in derivatives fair value and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-recognition</FONT> of deferred tax assets related to tax
losses and temporary differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(192</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Effective income tax (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Deferred taxes balances by nature </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>DEFERRED TAX ASSETS BY NATURE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retirement benefit obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty certificates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kreos 1 &amp; 2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax losses carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred tax assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>61,743</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>77,558</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsidies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kreos 1 &amp; 2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oceane</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred tax liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>680</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,427</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred tax assets, net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>61,063</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>76,130</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrecognized deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61,063</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(76,130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total deferred taxes, net recognized in the statement of financial position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company incurred tax losses in the years ended December 31, 2021 and 2022. As the recoverability of these tax losses is
not considered probable in subsequent periods due to the uncertainties inherent in the Company&#146;s business, the Company has not recognized deferred tax assets beyond deferred tax liabilities arising within the same taxable entity under the same
taxable regime and with consistent timing of reversal, after considering, if applicable, limitations in the use of deductible tax losses carried forward from prior periods applicable under tax law in France. The amount of accumulated tax loss carry
forwards is related to the Company and amounts to &#128;232,167&nbsp;thousand and &#128;308,829&nbsp;thousand as of December 31, 2021 and 2022, respectively, and do not have any expiration date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 23. Income (loss) per share </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic losses per share
is calculated by dividing income (loss) attributable to equity holders of the Company by the weighted-average number of outstanding ordinary shares for the year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Diluted losses per share are calculated by adjusting the weighted average number of ordinary outstanding shares to assume conversion of all dilutive potential
ordinary shares. All existing instruments giving deferred rights to capital (e.g., BCEs or BSAs) have an antidilutive effect. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros, except share data)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>BASIC AND DILUTED LOSS PER SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of outstanding shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,455,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,092,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic and diluted loss per share (&#128;/share)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2.75</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3.18</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Potentially dilutive instruments (BCEs, BSAs, AGAs, Equity lines, BSA Kreos 1, OCEANE) have been excluded from the computation
of diluted weighted-average shares outstanding, because such instruments had an antidilutive impact due to the losses reported. As of December 31, 2021 and 2022, the number potentially dilutive instruments were 1,873,216 and 1,707,037 respectively,
giving rights to a maximum number of shares to be issued of 2,186,551 and 1,707,037 respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 24. Related parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate compensation of the members of the Company&#146;s Board of Directors and to the Chief Executive Officer includes the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>FOR&nbsp;THE&nbsp;YEAR&nbsp;ENDED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros) </I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>COMPENSATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed compensation owed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Variable compensation owed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contributions <FONT STYLE="white-space:nowrap">in-kind</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service cost related to post-employment defined-benefit plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attendance fees&#151;board of directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>738</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>427</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2021 and 2022, the liability related to post-employment defined benefit obligations (corresponding to
the legal retirement benefits obligations) for members of the Company&#146;s Board of Directors and Chief Executive Officer amounts to respectively &#128;141&nbsp;thousand and &#128;149&nbsp;thousand. No other post-employment benefits are granted.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other arrangements with our Directors and Executive Officers </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company entered into an intellectual property assignment agreement with CEO Hartmut Ehrlich on July 7, 2021. The purpose of this agreement is to transfer
to the Company all the intellectual property rights held by Hartmut Ehrlich on certain patents of which he is a <FONT STYLE="white-space:nowrap">co-inventor.</FONT> No compensation has been paid in respect of this transfer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 25. <FONT STYLE="white-space:nowrap">Off-balance</FONT> sheet commitments given </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 25.1. Commitments under collaboration, research, service provision and licensing agreements granted by the Company </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration, research and development, and licensing agreements, and licensing options related to the &#147;Modulation of RNA biogenesis&#148; platform.
</I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Exclusive licensing agreement with the CNRS, the University of Montpellier and the Institut Curie</I></B>
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">On December 4, 2008, the French National Centre for Scientific Research (CNRS), the University of Montpellier and the
Institut Curie granted the Company four exclusive licenses. These licenses cover the use of their technology and products by the Company in the field of human and veterinary health relating to the use of synthetic products modifying mRNA splicing,
for research, diagnosis, prevention and treatment of any possible indication. The licensing agreement includes low single-digit royalties based on future net sales to be paid by the Company. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Framework agreement for research collaboration to create a cooperative laboratory (ended
December</I></B><B><I></I></B><B><I>&nbsp;31, 2021)</I></B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">On December 11, 2008, the Company, the CNRS (French National
Centre for Scientific Research) and the University of Montpellier entered into a research collaboration agreement for a duration of two years in order to conduct a common research program in the fields of screening and development of <FONT
STYLE="white-space:nowrap">anti-HIV</FONT> and antiviral compounds, anti-cancer and anti-metastasis compounds and compounds targeting certain genetic diseases. The term and content of research programs have been changed by successive amendments in
force until December 31, 2021. Each party retains ownership of its previously acquired intellectual property rights. The parties are <FONT STYLE="white-space:nowrap">co-owners</FONT> of the research results. Since
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
this agreement ended on December 31, 2021, a hosting agreement was signed with CNRS in 2022, and renewed up until December&nbsp;31, 2023, so that the Company can continue its research program at
the CNRS center for the year 2023. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Collaboration agreement with the CNRS, the University of Montpellier, the Company and Evotec</I></B>
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In support of the development of the cooperative laboratory, the CNRS, the University of Montpellier, the Company and
Evotec International GmbH have entered into a collaboration agreement on the development of the &#147;Modulation of RNA biogenesis&#148; platform, effective October 19, 2018. The molecules generated in the framework of this collaboration are the
property of the Company, the University of Montpellier and the CNRS under the same terms and conditions as the research collaboration agreement on the creation of the cooperative laboratory. The agreement ended on December 31, 2021. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Research collaboration contract with the CNRS, the University of Montpellier and the Institut Curie</I></B>
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Concomitantly with the research collaboration framework contract relating to the creation of a cooperative laboratory
the parties have signed a financial agreement defining the financial terms for the exploitation of patents. This contract was signed on 15&nbsp;April 2009 for a duration of one year and was subsequently renewed up until March 31, 2022, In December
2022, Abivax and the Institut Curie concluded a new contract for a duration of one year, renewable by amendment, granting Abivax access to some of the Institute&#146;s equipment and consumables. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Research and development contract with license option with the CNRS, the University of Montpellier and
Theradiag</I></B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The CNRS, the University of Montpellier, the Company and Theradiag have set up a collaborative project
called CARENA, which has been in operation since February 8, 2013. Its purpose is to conduct joint research and development programs in the fields of obesity, HIV and <FONT STYLE="white-space:nowrap">HTLV-1,</FONT> in connection with the funding
obtained through the Bpifrance CARENA project. On February 18, 2015, Bpifrance accepted the reorganization of the &#147;CARENA&#148; project proposed by the Company, following the abandonment of the obesity project. At this time, Theradiag is no
longer involved in the collaborative project. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Under the terms of the collaborative project, the Company will have the exclusive and global
exploitation rights to the proprietary results of the CNRS and to those of the University of Montpellier as well as a share of the common results of which the CNRS and the University of Montpellier are
<FONT STYLE="white-space:nowrap">co-owners.</FONT> Furthermore, Theradiag granted the Company an exclusive and global license option for exploitation of its own results as well as a share of the common results of which it will be a <FONT
STYLE="white-space:nowrap">co-owner.</FONT> This option may be exercised by the Company throughout the duration of the contract and within a period of two years after its expiration or cancellation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exclusive licensing contract with &#147;The Scripps Research Institute, University of Chicago and Brigham Young University&#148; with the &#147;Immune
Stimulation&#148; platform (ABX196 product) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On 11&nbsp;November 2006, The Scripps Research Institute (La Jolla, California, USA), in agreement with
the University of Chicago (Chicago, Illinois, USA) and Brigham Young University (Provo, Utah, USA), granted the Company an exclusive license in the field of human and veterinary health on its technology and products relating to the use of iNKT
agonists for research, diagnosis, prevention and treatment of all possible indications. In consideration for the licensing rights granted to it under the agreement, the Company must: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay The Scripps Research Institute milestones at different stages of clinical and regulatory development of the
first product (the milestones amount to $50&nbsp;thousand at IND filing, paid in September 2019 and capitalized, $300&nbsp;thousand at Phase 3 and $500&nbsp;thousand at IND approval) and low single-digit royalties for vaccines, diagnostic tests and
therapeutic products, according to the amount of net sales, and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">give The Scripps Research Institute, University of Chicago and Brigham Young University an equitable interest in
the Company (as of the date of these financial statements, these three academic institutions hold 0.41% of the Company&#146;s undiluted capital). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The contract shall be terminated at the expiry of the last licensed patent in force in the last country and/or ten years after the last marketing of the
product, service or process derived from the <FONT STYLE="white-space:nowrap">know-how</FONT> or the licensed equipment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 25.2. Commitments
under BPI conditional advances </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bpifrance CARENA contract </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the development of therapeutic and diagnostic solutions targeting alternative splicing and RNA interference in the fields of virology <FONT
STYLE="white-space:nowrap">(HIV-AIDS,</FONT> <FONT STYLE="white-space:nowrap">HTLV-1)</FONT> and metabolism (obesity), SPLICOS (absorbed by the Company on 31&nbsp;October 2014) has entered into a Master Support Agreement with Bpifrance as well as a
conditional advance contract in the name of the &#147;CARENA&#148; Strategic Industrial Innovation Project dated December 16, 2013. The Company, acting as project leader for the CARENA project, is associated as part of a consortium contract with
Theradiag, a company specializing in in vitro diagnostics and the development of theranostic tests for monitoring biotherapies, as well as at the CNRS and the University of Montpellier. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CARENA project aims to develop the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HIV-AIDS</FONT></FONT> therapeutic program with
the compound ABX464 up to the Phase 2b study, as well as a companion test set up by Theradiag simultaneously with the clinical development. Beyond the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HIV-AIDS</FONT></FONT>
program, the CARENA project should extend its pharmacological investigations to another retrovirus that could be combated by the same approach: <FONT STYLE="white-space:nowrap">HTLV-1.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is committed to reimbursing the received conditional advances up to &#128;3,840&nbsp;thousand. The Company will also have to pay an annuity of 50%
of the proceeds from the sale of the intellectual property rights resulting from the project, as well as the sale of the prototypes, preproduction and models produced under the project; The sum due to BPI under this provision will be deducted from
the repayment of the conditional advances. In addition, if the advance is repaid under the conditions outlined above, the Company will pay to Bpifrance, over a period of five consecutive years after the date on which the repayment schedule ends and
provided that the Company has reached cumulative <FONT STYLE="white-space:nowrap">pre-tax</FONT> revenue greater than or equal to &#128;50&nbsp;million, an amount equal to 1.20% of the annual revenue generated from the sale of the products developed
as part of the project. This supplementary payment amount is capped at &#128;6,800&nbsp;thousand. The total period, including fixed payments and incentive payments, is limited to 15 years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bpifrance <FONT STYLE="white-space:nowrap">RNP-VIR</FONT> contract </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In pursuit of the CARENA project, focused on the clinical development of a drug molecule and demonstrating the validity of an innovative therapeutic approach
targeting viral RNPs, the Company has entered into a Master Support Agreement with Bpifrance as well as a beneficiary agreement with conditional advance for the <FONT STYLE="white-space:nowrap">&#147;RNP-VIR&#148;</FONT> structuring research and
development project for competitiveness dated December 16, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">RNP-VIR</FONT> project will further the discovery
of new molecules aimed at the treatment of multiple infectious diseases by the development of the antiviral technology platform. The Company, acting as project leader of the <FONT STYLE="white-space:nowrap">RNP-VIR</FONT> project, is associated in a
consortium contract with the CNRS and the University of Montpellier. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is committed to reimburse the received conditional advances up to
&#128;6,576&nbsp;thousand. If applicable, the Company will also have to pay an annuity of 50% of the proceeds from the sale of the intellectual property rights resulting from the project, as well as the sale of the prototypes, preproduction and
models produced under the project. The sum due to Bpifrance under this provision will be deducted from the last payment (and if needed from the previous payments). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the advance is repaid under the conditions outlined above, the Company will pay to Bpifrance, over a
period of five consecutive years following the date on which the repayment schedule ends and provided that the company has reached cumulative <FONT STYLE="white-space:nowrap">pre-tax</FONT> revenue greater than or equal to &#128;25&nbsp;million, an
amount equal to 3% of the annual revenue generated from the sale of products developed as part of the project. The supplementary payments amount is capped at &#128;5,500&nbsp;thousand. The total period, including fixed payments and incentive
payments, is limited to 15 years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bpifrance Ebola </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bpifrance and Occitanie Region joint support agreement granted on June 2, 2017 consists of conditional advances to the Company for a total amount of up to
&#128;390&nbsp;thousand, based on the success of the program (respectively &#128;130&nbsp;thousand from the Languedoc Roussillon Midi Pyr&eacute;n&eacute;es Region and &#128;260&nbsp;thousand from Bpifrance). In September 2019, the Company decided
to terminate this program, due to the existence of a vaccine in the process of being licensed for this indication as well as changes in the macroeconomic climate for public funding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The reimbursement of the conditional advance is spread until June 2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 25.3. Pledge assets to Kreos </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the
KREOS 1 &amp; 2 bonds, Kreos benefits from first-rate collateral on the Company&#146;s principal tangible and intangible assets, including its commercial fund, intellectual property rights in its principal drug candidates, as well as a pledge of the
Company&#146;s bank accounts and claims. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 25.4. Other commitments related to research and partnership arrangements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the ordinary course of business, the Company regularly uses the services of subcontractors and enters into research and partnership arrangements with
various contract research organizations, or CROs, and with public- sector partners or subcontractors, who conduct clinical trials and studies in relation to the drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At December 31, 2022, the Company&#146;s commitments amounted to &#128;194,731&nbsp;thousand. The cost of services performed by CROs is recognized as an
operating expense as incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 25.5. Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The lease for the Company&#146;s corporate headquarters in Paris, France at 5 Rue de la Baume, 75008 Paris ended in August 2022. A new lease for premises at <FONT
STYLE="white-space:nowrap">7-11</FONT> Boulevard Haussmann, 75009 Paris started in July 2022. It has a three-year duration, with a tacit renewal option for approximately two years and the possibility to break the contract one year before the end.
Per Management, renewal and termination options are not reasonably certain. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 25.6. Commitments related to Prosynergia acquisition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company entered into a share purchase acquisition on November 15, 2021 for the acquisition of all the shares of Prosynergia (Note 3.3). The acquisition was
completed on April 1, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The acquisition price included an early payment of &#128;325&nbsp;thousand made on November 25, 2021, an additional payment
of &#128;2,925&nbsp;thousand made on April 1, 2022, and possible <FONT STYLE="white-space:nowrap">earn-out</FONT> payments for a maximum additional amount of &#128;4,000&nbsp;thousand based on the potential evolution of the Company&#146;s market
capitalization, a listing of the Company&#146;s shares on Nasdaq or a M&amp;A transaction incurred before March 31, 2023. The accounting treatment related to the possible <FONT STYLE="white-space:nowrap">earn-out</FONT> payment is set forth in Note
4.15. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 26. <FONT STYLE="white-space:nowrap">Off-balance</FONT> sheet commitments received and contingent
assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The maximum amounts receivable by the Company after December 31, 2022 under the <FONT STYLE="white-space:nowrap">&#147;RNP-VIR&#148;</FONT>
and &#147;CARENA&#148; and innovation agreements entered into with Bpifrance, subject to the provision of evidence to support the forecast expenses and the achievement of scientific milestones, are &#128;3,255&nbsp;thousand and
&#128;1,853&nbsp;thousand, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kepler Cheuvreux&#146;s commitments under Equity line agreements: see Note 13.2. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 27. Management and assessment of financial risks </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal financial instruments held by the Company are cash and cash equivalents. The purpose of holding these instruments is to finance the ongoing
business activities of the Company. It is not the Company&#146;s policy to invest in financial instruments for speculative purposes. The Company does not use derivative financial instruments for hedging purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal risks to which the Company is exposed to are liquidity risk, interest rate risk, foreign currency exchange risk, credit risk and fair value
risk. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidity risk </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Liquidity risk management aims
to ensure that the Company disposes of sufficient liquidity and financial resources to be able to meet present and future obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
prepares short-term cash forecasts and annual operating cash flow forecasts as part of its budget procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prudent liquidity risk management involves
maintaining sufficient liquidity, having access to financial resources through appropriate credit facilities and being able to unwind market positions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s operations have consumed substantial amounts of cash since inception. Developing pharmaceutical drug candidates, including conducting
clinical trials, is expensive, lengthy and risky, and the Company expects its research and development expenses to increase substantially in connection with its ongoing activities. Accordingly, the Company will continue to require substantial
additional capital to continue its clinical development activities and potentially engage in commercialization activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of issuance of
these financial statements, the Company expects it will be able to fund its forecasted operating cash flow requirements throughout the second quarter of 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expects it will be able to extend its financing horizon beyond the second quarter of 2024 through additional dilutive and non-dilutive financing,
which could include a combination of capital increase, venture loans and convertible bonds. Based on the above and the actions the Company has taken, management has concluded that the substantial doubt about its ability to continue as a going
concern has been alleviated beyond 12 months from issuance of these financial statements, and these financial statements have been prepared on a going concern basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest rate risk </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is exposed to market
risks in connection with its medium and long-term borrowings subject to variable interest rates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to a significant increase in market interest rates over the year ended December&nbsp;31, 2022, the Group
has performed a reassessment of its exposure to interest rate risk. As of December&nbsp;31, 2022, all the Group&#146;s financial liabilities accounted for at amortized cost bear fixed interest rates, except for KREOS 1 bonds, which interest rate is
based on <FONT STYLE="white-space:nowrap">3-month</FONT> Euribor plus an 8% margin. The <FONT STYLE="white-space:nowrap">3-month</FONT> Euribor being capped at 1% as per contractual terms, the A tranche being repaid in full in December 2022 and the
terms of the B tranche loan being November 2023, the Group has limited exposure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Foreign currency risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is exposed to a risk of exchange rates fluctuations on commercial transactions performed in currencies different from the functional currency of
the Company entity recording the transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At this stage, the Company has not adopted any other recurring mechanism of hedging to protect its
activity against currency fluctuations. From time to time, the Company may nevertheless subscribe currency term accounts in order to cover a commitment in currency as described above. The Company may consider in the future using a suitable policy to
hedge exchange risks in a more significant manner if needed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Credit risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The credit risk related to the Company&#146;s cash and cash equivalents is not significant in light of the quality of the
<FONT STYLE="white-space:nowrap">co-contracting</FONT> financial institutions. As of December&nbsp;31, 2022, substantially all of the Company&#146;s cash and cash equivalents were maintained with one financial institution in France. While the
Company&#146;s deposit accounts are insured up to the legal limit, the maintained balances may, at times, exceed this insured limit. As of December&nbsp;31, 2022 the Company maintained &#128;26,844&nbsp;thousand in bank deposit accounts that are in
excess of the legally insured limit in one legally insured financial institution. The Company has not experienced any losses in such accounts and does not believe that it is exposed to any significant credit risk related to these instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The credit risk related to the Company&#146;s other receivables and related account is minimal. In particular, the credit risk related to advances made to
CROs (see Note 9) is deemed insignificant due to their credit ratings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin609070_9"></A>ABIVAX SA UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF
FINANCIAL POSITION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands of euros) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS&nbsp;OF&nbsp;JUNE&nbsp;30,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>6</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>7</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>8</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>9</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables and assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>10</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>39,363</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>40,711</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables and assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>10</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>11</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>36,181</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>130,370</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>75,544</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>171,081</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LIABILITIES AND SHAREHOLDERS&#146; EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Premiums related to share capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(82,770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(143,366</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>13</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,189</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>80,489</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retirement benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>16</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provisions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible loan notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty certificates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>36,223</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>44,381</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible loan notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>17.1</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax and employee-related payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>17.2</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32,132</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>46,211</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL LIABILITIES AND SHAREHOLDERS&#146; EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>75,544</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>171,081</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin609070_10"></A>ABIVAX SA UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(LOSS) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands of euros, except per share amounts) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FOR&nbsp;THE&nbsp;SIX&nbsp;MONTHS&nbsp;ENDED&nbsp;JUNE&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2023&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>18</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>19.1</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(155</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>19.2</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,107</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,622</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>19.3</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,758</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill impairment loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>6</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,986</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,317</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,535</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(26,033</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(37,280</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,346</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,030</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial gain (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>21</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,673</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss before tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(21,183</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(51,953</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>22</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(21,183</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(51,953</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss per share (&#128;/share)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of outstanding shares used for computing basic/diluted loss per
share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,759,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,903,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic / diluted loss per share (&#128;/share)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>23</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1.26</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1.45</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin609070_11"></A>ABIVAX SA UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF
COMPREHENSIVE INCOME (LOSS) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands of euros) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FOR&nbsp;THE&nbsp;SIX&nbsp;MONTHS&nbsp;ENDED&nbsp;JUNE&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2023&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(21,183</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(51,953</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Items that will not be reclassified to profit or loss</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>138</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>79</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Actuarial gains and losses on retirement benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>16</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Items that are or may be reclassified subsequently to profit or loss</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&#8194;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>3</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>138</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>82</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive income (loss) for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(21,045</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(51,871</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin609070_12"></A>ABIVAX SA UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF
CHANGES IN SHAREHOLDERS&#146; EQUITY </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands of euros) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B></B><I>(In thousands of euros, except<BR>number of shares)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER<BR>OF<BR>SHARES<BR>ISSUED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SHARE<BR>CAPITAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PREMIUMS<BR>RELATED<BR>TO SHARE<BR>CAPITAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TRANSLATION<BR>RESERVE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RETAINED<BR>EARNINGS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NET&nbsp;LOSS<BR>FOR THE<BR>YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL<BR>SHAREHOLDER&#146;S<BR>EQUITY</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of January&nbsp;1, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,764,051</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>168</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>107,578</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(39,361</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(42,452</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>25,934</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for the period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>138</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(21,183</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(21,045</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Appropriation of 2021 net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercises of share warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,221</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,221</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transactions on treasury shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of June&nbsp;30, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,783,185</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>168</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>107,581</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(82,911</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(21,183</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,655</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of January&nbsp;1, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>22,313,185</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>223</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>150,476</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(82,771</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(60,740</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,188</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for the period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>79</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(51,953</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(51,871</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Appropriation of 2022 net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital increase from issuance of ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs related to capital increase</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercises of the Kreos share warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercises of other share warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transactions on treasury shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of June&nbsp;30, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>42,547,568</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>425</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>275,383</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(143,369</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(51,953</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>80,489</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin609070_13"></A>ABIVAX SA UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH
FLOWS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands of euros) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FOR&nbsp;THE&nbsp;SIX&nbsp;MONTHS&nbsp;ENDED&nbsp;JUNE&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(Amounts in thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2023&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for the period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments for:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elimination of amortization of intangibles and depreciation of property, plant and
equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elimination of Impairment loss of goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>6</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elimination of retirement benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>16</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elimination of share-based compensation expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>14</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,426</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expenses and other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>21</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(339</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase/(decrease) in derivatives and liabilities fair value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,180</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(79</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows used in operating activities before change in working capital
requirements</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(16,340</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(36,818</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease / (increase) in other receivables and related accounts</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,194</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,417</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase / (decrease) in trade payables</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,058</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase / (decrease) in tax and social security liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(112</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase / (decrease) in deferred income and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Changes in working capital requirements</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,374</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,219</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(24,714</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(27,599</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisitions of property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(148</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Advance made to CROs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>10</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments for the acquisition of Prosynergia <SUP STYLE="font-size:75%; vertical-align:top">(1)
</SUP>, incl. related costs, net of cash acquired</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>4.16&nbsp;&amp;&nbsp;10</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,898</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>9</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,953</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,712</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows provided by (used in) financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital increases</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>13</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs related to capital increase</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants subscription</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayments of KREOS <SUP STYLE="font-size:75%; vertical-align:top">(2) </SUP>1&amp;2 bond
loans</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,379</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,727</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of PGE</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net proceeds from sale of treasury shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayments of conditional advances</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments of the lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(882</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows provided by (used in) financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,431</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>116,742</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Increase (decrease) in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(34,098</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>87,432</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at the beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at the end of the year</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Increase (decrease) in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(34,098</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>87,432</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Prosynergia SARL (or &#147;Prosynergia&#148;) </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Kreos Capital V UK Ltd (or &#147;Kreos&#148;) </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes form an integral part of these unaudited condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin609070_14"></A>ABIVAX SA NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 1. The Group </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 1.1. Information on the Group and its business </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABIVAX SA (the &#147;Company&#148;) is a <I>soci&eacute;t&eacute; anonyme </I>incorporated under the laws of France on December&nbsp;4, 2013. Its registered
office is located at <FONT STYLE="white-space:nowrap">7-11</FONT> Boulevard Haussmann&#151;75009 Paris, France. The Company is developing therapeutics that harness the body&#146;s natural regulatory mechanisms to modulate the inflammatory response
in patients with chronic inflammatory diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These unaudited interim condensed consolidated financial statements (&#147;interim financial
statements&#148;) as of and for the six months ended June&nbsp;30, 2023 comprise the Company and ABIVAX LLC (the &#147;Subsidiary&#148;), the United States subsidiary of ABIVAX SA, created on March&nbsp;20, 2023 under the laws of the State of
Delaware (together referred to as the &#147;Group&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These unaudited comparative interim condensed consolidated financial statements as of and for
the six months ended June&nbsp;30, 2022 comprise the Company and Prosynergia SARL (&#147;Prosynergia&#148;), a Luxembourg biotech company, acquired on April 1, 2022. The financial statements of Prosynergia were included in the consolidated financial
statements of the Company from the date control was obtained (i.e., April&nbsp;1, 2022) until December&nbsp;12, 2022, which is the date on which Prosynergia was merged into the Company under the French legal procedure called &#147;Transmission
Universelle de Patrimoine<I>&#148;</I> (universal transfer of assets and liabilities). On this date, all of Prosynergia&#146;s assets and liabilities were transferred to the Company and Prosynergia was dissolved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group has incurred losses since its inception and had shareholders&#146; equity of &#128;80,489&nbsp;thousand as of June&nbsp;30, 2023. The Group
anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its drug candidates which are currently under development. Substantial additional financing will be needed by the Group to fund its
operations and to commercially develop its drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group&#146;s future operations are highly dependent on a combination of factors,
including: (i)&nbsp;the success of its research and development activities; (ii)&nbsp;regulatory approval and market acceptance of its proposed future products; (iii)&nbsp;the timely and successful completion of additional financing and
(iv)&nbsp;the development of competitive therapies by other biotechnology and pharmaceutical companies. As a result, the Group is, and expects to continue to be, in the short to <FONT STYLE="white-space:nowrap">mid-term,</FONT> financed through the
issuance of new equity or debt instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group is focusing its efforts on the following points: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continuation of the clinical development program for obefazimod, with priority given to the treatment of chronic
inflammatory diseases. The specific order of priority is as follows: chronic inflammatory bowel disease (&#147;IBD&#148;), starting with moderately to severely active ulcerative colitis (&#147;UC&#148;), followed by Crohn&#146;s disease, and other
indications. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continuation of other therapeutic indications of obefazimod according to the relevance of scientific data and
research into potential derivative molecules of obefazimod. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Research into new molecules aimed at treating chronic inflammatory diseases
<FONT STYLE="white-space:nowrap">(miR-124</FONT> platform). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 1.2. Date of authorization of issuance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The interim financial statements and related notes (the &#147;financial statements&#148;) have been prepared under the responsibility of management of the
Group and were approved and authorized for issuance by the Group&#146;s board of directors on September&nbsp;19, 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2. Basis of preparation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except for share data and per share amounts, the unaudited interim condensed consolidated financial statements are presented in thousands of euros. Amounts are
rounded up or down the nearest whole number for the calculation of certain financial data and other information contained in these accounts. Accordingly, the total amounts presented in certain tables may not be the exact sum of the preceding
figures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Statement of compliance </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These unaudited
interim condensed consolidated financial statements as of June&nbsp;30, 2023 and for the <FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2023 and 2022 have been prepared in accordance with IAS 34 &#147;Interim Financial
Reporting&#148; as issued by IASB and as adopted by the European Union (EU) and should be read in conjunction with the latest Group&#146;s annual financial statements for the year ended December 31, 2021 and 2022 of the Group. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">They do not include all the information required for a complete set of financial statements prepared under IFRS. They do, however, include selected notes
explaining significant events and transactions in order to understand the changes in the Group&#146;s financial position and performance since the last annual financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accounting policies used to prepare these unaudited interim condensed financial statements are identical to those applied by the Group as of
December&nbsp;31, 2022, except for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">texts whose application is compulsory as from January 1, 2023; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the specific provisions of IAS 34 used in the preparation of the interim financial statements.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The new texts that are mandatory as of January 1, 2023 are the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IAS 1 Presentation of Financial Statements and IFRS Practice Statement 2 &#150; Disclosure of
Accounting Policies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IAS 8 &#150; Definition of Accounting Estimates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IAS 12 &#150; Deferred Tax related to Assets and Liabilities arising from a Single Transaction;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IFRS 17 &#150; Insurance Contracts and related amendments. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These new texts have no material impact on the unaudited interim condensed consolidated financial statements as of June&nbsp;30, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The standards and interpretations not yet mandatory as of June&nbsp;30, 2023 are the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IAS 12 &#150; International Tax Reform &#150; Pillar Two Model Rules, whose application is for
annual reporting periods beginning on or after January&nbsp;1, 2023 (not yet approved by the EU); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IAS 1 &#150; Presentation of Financial Statements &#150; Classification of Liabilities as Current
or <FONT STYLE="white-space:nowrap">Non-current,</FONT> whose application is for annual reporting periods beginning on or after January&nbsp;1, 2024 (not yet approved by the EU); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IAS 1 &#150; <FONT STYLE="white-space:nowrap">Non-current</FONT> Liabilities with Covenants, whose
application is for annual reporting periods beginning on or after January&nbsp;1, 2024 (not yet approved by the EU); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IFRS 16 &#150; Leases: Lease Liability in a Sale and Leaseback, whose application is for annual
reporting periods beginning on or after January&nbsp;1, 2024 (not yet approved by the EU); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IAS 7 and IFRS 7 &#150; Supplier Finance Arrangements, whose application is for annual reporting
periods beginning on or after January&nbsp;1, 2024 (not yet approved by the EU); </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These texts have not been early adopted. The expected
impacts are not considered significant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preparation of the financial statements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The interim financial statements of the Group were prepared on a historical cost basis, with the exception of certain asset and liability categories and in
accordance with the provisions set out under IFRS such as employee benefits measured using the projected unit credit method, borrowings measured at amortized cost and derivative financial instruments measured at fair value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Going concern </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group has incurred substantial
operating losses since inception, and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. For the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2023,
the Group had a net loss of &#128;52.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since inception, the Group has financed its operations through the issuance of ordinary shares with
gross aggregate proceeds of &#128;333.9&nbsp;million, of which &#128;130&nbsp;million of gross proceeds were from offerings of its ordinary shares on Euronext Paris in February 2023, bank borrowings and structured loans for &#128;125.0&nbsp;million,
reimbursements of Research Tax Credits (Cr&eacute;dit d&#146;Imp&ocirc;t Recherche (&#147;CIR&#148;)) in an aggregate amount of &#128;26.6&nbsp;million, subsidies received from Banque Publique d&#146;Investissement (&#147;Bpifrance&#148;) (including
&#128;13.5&nbsp;million of subsidies and &#128;6.6&nbsp;million of conditional advances) and royalty certificates in an amount of &#128;2.9&nbsp;million. As a result of (a)&nbsp;the Group&#146;s existing cash and cash equivalents of
&#128;114.4&nbsp;million as of June&nbsp;30, 2023, (b) the net proceeds of the August 2023 drawdown of the first tranches of the Kreos / Claret Financing and the Heights Financing, collectively amounting to &#128;27.2&nbsp;million (net of repayments
of all outstanding amounts that remained due under the First KC Agreement, the Second KC Agreement and the OCEANE bonds), (c) the available drawdowns of the second tranches of the Kreos / Claret Financing and the Heights Financing (which tranches
are not conditional on amount raised in this offering), collectively amounting to &#128;65&nbsp;million in gross proceeds and (d)&nbsp;the expected reimbursement of the CIR from 2022 in the second half of 2023 amounting to &#128;4.5&nbsp;million,
the Group expects, as of the date of issuance of these financial statements, to be able to fund its forecasted operating cash flow requirements through the third quarter of 2024. This takes into account the Group&#146;s assumption that R&amp;D
expenditure will be substantially increased in 2023 driven by the progression of the Phase 3 clinical trials of obefazimod, which started enrollment of patients with moderately to severely active UC in October 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group expects it will be able to extend its financing horizon beyond the third quarter of 2024 through additional dilutive and <FONT
STYLE="white-space:nowrap">non-dilutive</FONT> financing, which could include a combination of capital increase, venture loans and convertible bonds. Based on the above and the actions the Group has taken, management has concluded that the
substantial doubt about its ability to continue as a going concern has been alleviated beyond 12 months from issuance of these financial statements, and these financial statements have been prepared on a going concern basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Impact of the Ukraine/Russia Hostilities on the Group </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
February 2022, Russia invaded Ukraine. The conflict has already had major implications for the global economy and the rate of inflation, particularly in relation to the supply of energy, raw materials and food products. It has also caused intense
volatility on the financial markets, something that is still ongoing at the reporting date and has pushed down stock market prices around the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given these developments, the Group has decided not to include Russia and Belarus in its global Phase 3 program for obefazimod in UC. However, the global
scale of this conflict cannot be predicted at this stage. The Group, therefore, cannot rule out an adverse impact of this conflict on its business, including in terms of access to raw materials, logistics, the performance of clinical studies and in
relation to any future financing the Group may seek. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 2b maintenance trial of obefazimod in moderately to severely active UC is the Group&#146;s
only clinical trial currently in progress in Ukraine. The Group has, however, terminated a few trial sites since the Russia/</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Ukraine war began. The <FONT STYLE="white-space:nowrap">12-month</FONT> assessment was carried out in all the Ukrainian patients before the war broke out and these patients are therefore included
in the <FONT STYLE="white-space:nowrap">one-year</FONT> maintenance results that were reported on April&nbsp;6, 2022. Ukrainian patients who completed the <FONT STYLE="white-space:nowrap">two-year</FONT> Phase 2b maintenance trial have been
transitioned to the long-term safety and efficacy trial that is still <FONT STYLE="white-space:nowrap">on-going.</FONT> None of these sites are located in the Crimea Region of Ukraine, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk
People&#146;s Republic, or the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic. The Group is also evaluating the possibility to include a few Ukrainian sites in the western part of Ukraine in the ABTECT Phase 3
clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Together with its CROs, the Group is making considerable efforts to ensure the <FONT STYLE="white-space:nowrap">follow-up</FONT> of
patients who are unable to come to the study centers. Monitoring takes place through a remote monitoring system that was established and used successfully during the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3. Significant events for the periods ended December&nbsp;31, 2022, June&nbsp;30, 2023 and subsequent events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 3.1. For the period ended December&nbsp;31, 2022 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Acquisition of Prosynergia SARL &#150; April 2022 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
April&nbsp;1, 2022, the Company acquired 100% of the share capital of Prosynergia SARL (or &#147;Prosynergia&#148;), a Luxembourg biotech company, in order to strengthen its portfolio. The terms of the share purchase acquisition (or the
&#147;Prosynergia SPA&#148;) entered on November&nbsp;15, 2021 included an early payment of &#128;325&nbsp;thousand made on November&nbsp;25, 2021, an additional payment of &#128;2,925&nbsp;thousand made on April&nbsp;1, 2022, and possible <FONT
STYLE="white-space:nowrap">earn-out</FONT> payments for a maximum additional amount of &#128;4,000&nbsp;thousand based on the potential evolution of the Company&#146;s market capitalization, a listing of the Company&#146;s shares on Nasdaq or an
M&amp;A transaction incurred before March&nbsp;31, 2023. In addition, the Company granted a loan of &#128;1,400&nbsp;thousand to Prosynergia on December&nbsp;1, 2021, which term was at least on December&nbsp;31, 2025 or at an earlier date in the
event of a breach in the Prosynergia SPA. Such prepayment was repayable in cash only in the event the transaction is not completed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Considering that
Prosynergia only owned patent rights but did not enter into any employee contract, research agreement, collaboration agreement or <FONT STYLE="white-space:nowrap">out-licensed</FONT> agreement, it does not meet the definition of a business under
IFRS 3. Consequently, the acquisition cost of this group of assets was allocated between the identifiable assets and liabilities acquired, pro rata to their respective fair values as of April&nbsp;1, 2022, without recognition of goodwill. Also, the
&#128;1,400&nbsp;thousand loan granted to Prosynergia in December 2021 was included in the acquisition cost to be allocated, as it is considered a prepayment for the acquisition of the group of assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Merger with Prosynergia &#150; December 2022 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
December&nbsp;12, 2022, the Company completed the merger with Prosynergia under the French legal procedure called &#147;Transmission Universelle de Patrimoine<I>&#148;</I> (universal transfer of assets and liabilities). All of Prosynergia&#146;s
assets and liabilities were transferred to the Company and Prosynergia was dissolved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Impairment of goodwill </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the first half of 2022, management took into account significant external changes in the hepatocellular carcinoma (HC) treatment landscape. These changes
were expected to require a new, lengthy, heavy and risky internal development process (use of a combination of compounds). In this context, entering into a licensing partnership to fund the completion of the clinical development of ABX196 was the
option being considered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of this change in circumstances, an impairment test of the ABX196 Cash Generating Unit (&#147;CGU&#148;) was
performed and resulted in an impairment loss of &#128;10,986&nbsp;thousand of the goodwill allocated to such CGU during the period ended June&nbsp;30, 2022. As a consequence, the goodwill net carrying amount decreased from &#128;13,586&nbsp;thousand
as of December&nbsp;31, 2021 to &#128;2,600&nbsp;thousand as of June&nbsp;30, 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Then, during the second half of 2022, due to the lack of progress made in the negotiation of a development
partnership, the Group made the decision to freeze the development program for ABX196 in the treatment of hepatocellular cancer. This decision led to the full impairment of the ABX196 goodwill, i.e., an impairment loss of &#128;13,586&nbsp;thousand
related to Wittycell&#146;s goodwill and &#128;45&nbsp;thousand related to licenses. As of December&nbsp;31, 2022, the value in use and the fair value less costs to sell of the ABX196 cash-generating unit (&#147;CGU&#148;) are nil. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Forfeiture of AGA plans </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AGAs granted in September 2021
were subject to vesting conditions including the completion of an&#8195; M&amp;A transaction on or prior to July&nbsp;31, 2022. As the <FONT STYLE="white-space:nowrap">non-market</FONT> performance vesting conditions were not satisfied, the Group
recognized a reversal of related compensation expense of &#128;1,026&nbsp;thousand and accrual for social taxes of &#128;205&nbsp;thousand in the financial statements for the period ended December&nbsp;31, 2022 (See Note 14). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Repayment of the advance made to Nice CHU &#150; August 2022 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#128;4,000&nbsp;thousand advance made to Nice CHU was reimbursed in August 2022 for an amount of &#128;3,302&nbsp;thousand. The remaining amount of
&#128;698&nbsp;thousand was settled by way of compensation with a payable due to the Nice CHU related to the recharge of third-party services expenses that had been invoiced to the Nice CHU as part of the
<FONT STYLE="white-space:nowrap">miR-AGE</FONT> project. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Change in governance &#150; August 2022 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;16, 2022, the Group announced a transition in the chairmanship of its Board of Directors. Philippe Pouletty, the Group&#146;s founder and
Chairman of the Board of Directors since the Group was created in 2013, informed the Board of Directors of his decision to resign as Chairman with immediate effect. However, after many years of successfully leading the Board of Directors,
Mr.&nbsp;Pouletty will continue to support the Group&#146;s development as a member of the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pending the appointment of a new,
permanent independent Chair, Ms.&nbsp;Corinna zur Bonsen-Thomas, an independent member of the Board of Directors of the Group, carried out the role of interim Chair (see Note 3.2). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Group completed &#128;49.2&nbsp;million cross-over financing with <FONT STYLE="white-space:nowrap">top-tier</FONT> US and European investors &#150;
September 2022 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;2, 2022, the Group announced oversubscribed financing of around &#128;49.2&nbsp;million, led by TCGX with the
participation of <FONT STYLE="white-space:nowrap">top-tier</FONT> investors specializing in the biotechnology sector, such as Venrock Healthcare Capital Partners, Deep Track Capital, Sofinnova Partners, Invus and Truffle Capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financing consists of two transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a reserved capital increase of a gross amount of approximately &#128;46.2&nbsp;million through the issuance of
5,530,000 new shares with a nominal value of &#128;0.01 per share, representing 33% of its current share capital, at a subscription price of &#128;8.36 per share; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an issue of royalty certificates with a subscription price amounting to &#128;2.9&nbsp;million. The royalty
certificates give right to their holders to royalties equal to 2% of the future net sales of obefazimod (worldwide and for all indications) as from the commercialization of such product. The amount of royalties that may be paid under the royalty
certificates is capped at &#128;172&nbsp;million. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proceeds of the financing will primarily be used to fund the advancement of Phase
3 clinical trials for obefazimod in UC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Related transaction costs amounted to &#128;3.3&nbsp;million and were deducted from the share premiums. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Royalty certificates are recorded as financial liabilities at amortized cost (see Note 15.7). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Group announces first US patient enrollment in global Phase 3 program with obefazimod in
UC&nbsp;&#150;&nbsp;October 2022 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;11, 2022, the Group announced that the first patient was enrolled in the US into its global Phase 3
clinical program with product candidate obefazimod for the treatment of moderately to severely active UC. IQVIA, a global premier contract research organization, is responsible for coordinating the Group&#146;s Phase 3 clinical trial for obefazimod
in UC. As of December&nbsp;31, 2022, the undiscounted amount of the advance payments made by the Group in relation to the IQVIA agreement is &#128;12,187&nbsp;thousand. They were recorded at inception at their fair value (discounted amount) and
subsequently measured at amortized cost calculated using the effective interest rate method. As of December&nbsp;31, 2022, their carrying amount is &#128;10,471&nbsp;thousand. The repayment dates of these advances are scheduled between April 2025
and July 2026 (see Note 9). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 3.2. For the period ended June&nbsp;30, 2023 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Group announces successful oversubscribed &#128;130.0&nbsp;million cross-over financing at market price with
<FONT STYLE="white-space:nowrap">top-tier</FONT> US and European Biotech investors &#150; February 2023 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;22, 2023, the Group announced
the successful pricing of an oversubscribed &#128;130.0&nbsp;million financing with high-quality US and European biotech specialist investors, led by TCGX, with participation from existing investors Invus, Deep Track Capital, Sofinnova Partners,
Venrock Healthcare Capital Partners, as well as from new investors Great Point Partners, LLC, Deerfield Management Company, Commodore Capital, Samsara BioCapital, Boxer Capital and others, by way of a reserved capital increase of
&#128;130&nbsp;million through the issuance of 20,000,000 newly-issued ordinary shares with a nominal value of &#128;0.01 per share, representing 89.6% of its current share capital, at a subscription price of &#128;6.50 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Related transaction costs amounted to &#128;6.7&nbsp;million and were deducted from the share premiums. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes in governance and management &#150; February-April 2023 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;17, 2023, and April&nbsp;18, 2023, the Group respectively announced the appointments of Dr.&nbsp;Sheldon Sloan, M.D., M. Bioethics as new
Chief Medical Officer and Michael Ferguson as new Chief Commercial Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;5, 2023, the Group announced the appointment of Marc de Garidel
as Chief Executive Officer (&#147;CEO&#148;) and Interim Board Chair, effective May&nbsp;5, 2023. Corinna zur Bonsen-Thomas will step down as acting Chair, a position she has held since August 2022, and will remain a Board Member. Prof. Hartmut J.
Ehrlich, M.D., will retire from the CEO position, which he has held since the Group&#146;s founding in 2013, and will stay on as a strategic advisor until the transition is complete. The Group expects to appoint a long-term Board Chair in 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Creation of Abivax LLC &#150; March 2023 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
March&nbsp;20, 2023, Abivax LLC (or &#147;the Subsidiary&#148;) was formed as a<I> </I>limited liability company<I> </I>under the laws of the State of Delaware. As of the issuance of the financial statements, the Group has full ownership over the
Subsidiary. The Subsidiary will host the Group&#146;s operations in the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cashless exercise of the Kreos A&amp;B BSA &#150; May 2023
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;24, 2023, Kreos Capital V UK Ltd (or &#147;Kreos&#148;) opted for the cash less exercise option of the share warrants they held (as
defined in Note 15.1), implemented through the repurchase by the Group of 43,070 tranche A share warrants (&#147;Kreos A BSA&#148;) and 43,070 tranche B share warrants (&#147;Kreos B BSA&#148;) and the issuance of respectively 67,887 and 31,696
ordinary shares, as a result of the exercise by Kreos of the outstanding Kreos A&nbsp;&amp; B BSA. The accounting treatment of the operation is set forth in Note 15.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 3.3. Subsequent events </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes in governance and management &#150; July-August 2023 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;11, 2023, the Group announced the appointments of June Lee, M.D. and Troy Ignelzi as new independent members of the Group&#146;s Board of
Directors, replacing Joy Amundson and Jean-Jacques Bertrand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;23, 2023, the Group announced the appointment of Patrick Malloy as new Senior
Vice President Investor Relations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Group announces plans to conduct registered public offering in the United States &#150; August 2023 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;10, 2023, the Group announced that it planned to conduct a registered public offering of its ordinary shares, in the form of American Depositary
Shares, in the United States, subject to market and other conditions, and has confidentially submitted a draft registration statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> to the U.S. Securities and Exchange Commission. The timing,
number of securities to be offered in the proposed offering and their price have not yet been determined. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Group secures up to
&#128;150&nbsp;million from two structured debt financing transactions &#150; August 2023 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;20, 2023, the Group concurrently signed two
structured debt financing transactions for a total amount of up to &#128;150&nbsp;million consisting of (i)&nbsp;up to &#128;75&nbsp;million from Kreos Capital and Claret European Growth Capital (the &#147;Kreos / Claret Financing&#148;) together
with the issuance of warrants (&#147;the Kreos / Claret BSA&#148;) exercisable to receive ordinary shares of the Company at a fixed ratio of 1:1, for an aggregate exercise price of up to &#128;8&nbsp;million and (ii)&nbsp;up to &#128;75&nbsp;million
from a fund advised by Heights Capital Management, Inc. (the &#147;Heights Financing&#148; and together with the Kreos / Claret Financing, the &#147;Transaction&#148;). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Overall Structure of the Kreos / Claret Financing </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Kreos / Claret Financing consists of three tranches of &#128;25&nbsp;million each in aggregate principal amount. The first tranche in aggregate principal
amount of &#128;25&nbsp;million takes the form of senior secured convertible bonds with warrants attached (the &#147;Kreos / Claret OCABSA&#148;) and was drawn on August&nbsp;21, 2023. The Kreos / Claret OCABSA are convertible into ordinary shares
at any time from their issuance at the request of their holders at a fixed conversion price of &#128;21.2209, subject to standard adjustments, including anti-dilution and dividend protections. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The second tranche in aggregate principal amount of &#128;25&nbsp;million takes the form of senior secured
<FONT STYLE="white-space:nowrap">non-convertible</FONT> bonds and may be drawn before March&nbsp;31, 2024, subject to satisfaction of customary closing conditions. The drawdown of the second tranche is subject to a maximum 10% <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Debt-To-Market</FONT></FONT> Capitalization Ratio at the time of drawdown. The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;Debt-To-Market</FONT></FONT>
Capitalization Ratio&#148; is calculated, on any relevant date, by dividing (i)&nbsp;the indebtedness of the Group (including amounts due under the Kreos / Claret Financing but excluding amounts due under the Heights Financing), by (ii)&nbsp;the
market capitalization of the Group calculated by multiplying the number of outstanding ordinary shares by the closing price of the ordinary shares on such relevant date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The third tranche in aggregate principal amount of &#128;25&nbsp;million takes the form of senior secured
<FONT STYLE="white-space:nowrap">non-convertible</FONT> bonds and may be drawn before July&nbsp;31, 2024, subject to satisfaction of customary closing conditions. The drawdown of the third tranche is subject to a maximum 10% <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Debt-To-Market</FONT></FONT> Capitalization Ratio at the time of drawdown (excluding the Heights Financing) and is conditional on the Group raising a minimum of $125&nbsp;million in gross
proceeds through a listing on Nasdaq before June&nbsp;30, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As security for the Kreos / Claret Financing signed on August&nbsp;20, 2023, Kreos and
Claret benefit from the grant of first-ranking collateral on the Company&#146;s principal tangible and intangible assets, including pledges over the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company&#146;s business (<I>&#147;fonds de commerce&#148;</I>) as a going concern and intellectual property rights in the Company&#146;s lead drug candidate, as well as pledges over the
Company&#146;s bank accounts and receivables. Such securities apply to all tranches of the Kreos / Claret Financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the Kreos / Claret
Financing, both Kreos and Claret may receive, in addition to the Kreos / Claret OCABSA, warrants exercisable at a fixed ratio of 1:1, in two tranches. The first tranche of 214,198 warrants is exercisable immediately at an exercise price of
&#128;18.6744 (corresponding to a 10% premium over the <FONT STYLE="white-space:nowrap">15-day</FONT> VWAP prior to the date on which their issuance was decided). The second tranche may be issued within 14 days of the date on which the conditions to
draw the third tranche of <FONT STYLE="white-space:nowrap">non-convertible</FONT> bonds of the Kreos / Claret Financing have been met. The exercise price of the additional warrants to be issued will be equal to 110% of the <FONT
STYLE="white-space:nowrap">15-day</FONT> VWAP prior to the date on which their issuance is decided. The number of warrants to be issued will be calculated by dividing &#128;4,000,000 by the aforementioned exercise price. Of these additional
warrants, 50% will be exercisable upon issuance and the remaining 50% shall only be exercisable if the third tranche of the Kreos / Claret Financing is drawn by Abivax. The Kreos / Claret warrants can be exercised over a period of 7 years from their
issuance date or up until the date of the successful closing of a tender offer for the ordinary shares, whichever is earlier. At the time of exercise of the Kreos / Claret warrants, the holders of the warrants are eligible to sell part of their
warrants to Abivax in accordance with a put option agreement to allow for a cashless exercise. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Overall Structure of the Heights Financing </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#128;75&nbsp;million Heights Financing consists of two tranches (collectively, the &#147;Heights Convertible Notes&#148;). </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The first tranche of &#128;35&nbsp;million in aggregate principal amount is composed of 350 amortizing senior convertible notes with a nominal value of
&#128;100,000 each and a fixed conversion price of &#128;23.7674 (corresponding to a 40% premium over the <FONT STYLE="white-space:nowrap">15-day</FONT> VWAP prior to the date on which their issuance is decided, and subject to standard adjustments,
including anti-dilution and dividend protections). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The second tranche of &#128;40&nbsp;million in aggregate principal amount is composed of 400
amortizing senior convertible notes with a nominal value of &#128;100,000 each, and a conversion price (if any) that will be equal to 130% of the <FONT STYLE="white-space:nowrap">15-day</FONT> VWAP immediately preceding the date on which their
issuance will be decided. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The first tranche in aggregate principal amount of &#128;35&nbsp;million was drawn on August&nbsp;24, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The second tranche in aggregate principal amount of up to &#128;40&nbsp;million may be drawn during the period from the date immediately following the
three-month anniversary of the issuance of the first tranche to the first-year anniversary of the issuance of the first tranche. It may be drawn in up to two separate closings to provide the Group with additional flexibility to request a partial
drawdown. The amount available for drawdown under the second tranche will be determined based on the Group&#146;s Market Capitalization and the average daily valued traded of Ordinary Shares (&#147;ADVT&#148;) over the three-month period preceding
the drawdown. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Heights Financing is a senior, unsecured financing. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Use of proceeds </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The first tranches of the Kreos / Claret Financing and the Heights Financing, for &#128;25&nbsp;million and &#128;35&nbsp;million, respectively, were drawn on
August&nbsp;21, 2023, and August&nbsp;24, 2023, respectively. In addition, the Group concurrently granted to Kreos and Claret, for no additional consideration, warrants exercisable to receive ordinary shares of the Company for an aggregate exercise
price of up to &#128;4&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the Transaction, the Group is also repaying in full a total outstanding amount of
&#128;32,763&nbsp;thousand under (i)&nbsp;the <FONT STYLE="white-space:nowrap">pre-existing</FONT> debt agreements with Kreos for a total amount of &#128;7,661&nbsp;thousand and (ii)&nbsp;the <FONT STYLE="white-space:nowrap">pre-existing</FONT>
OCEANE bonds for a total amount of &#128;25,102&nbsp;thousand by way of <FONT STYLE="white-space:nowrap">set-off</FONT> with the Heights Financing, thereby fully repaying such <FONT STYLE="white-space:nowrap">pre-existing</FONT> indebtedness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The net proceeds of the drawdown of the first tranche of the Kreos / Claret Financing and of the Heights Financing which, net of the refinancing of the
existing indebtedness, amount to &#128;27,237&nbsp;thousand in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
aggregate, are expected to be allocated mainly to the development of obefazimod for the treatment of adults with moderately to severely active UC and other potential chronic inflammatory
indications, as well for working capital and general corporate purposes of the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4. Accounting principles </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group&#146;s accounting policies are the same as those described in the last annual financial statements of the Group. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of judgments and estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In preparing these
unaudited consolidated financial statements, management has made judgments and estimates that affect the application of the Group&#146;s accounting policies and the reported amounts of assets and liabilities, income and expenses. Actual values may
differ from estimated values. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The significant judgments made by management in the application of the Group&#146;s accounting policies and the key sources
of estimation uncertainty are the same as those described in the last annual financial statements of the Group. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Measurement of fair values
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A number of the Group&#146;s accounting policies require the measurement of fair values, for both financial and
<FONT STYLE="white-space:nowrap">non-financial</FONT> assets and liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When measuring the fair value of an asset or a liability, the Group uses
market observable data as far as possible. Fair values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;2: inputs other than quoted prices included in Level&nbsp;1 that are observable for the asset or
liability, either directly (i.e., prices) or indirectly (i.e., derived from prices). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;3: inputs for the asset or liability that are not based on observable market data (unobservable
inputs). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Seasonality of operations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group&#146;s operations are not subject to significant seasonality. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5. Segment information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The assessment of the
Group&#146;s performance and the decisions about resources to be allocated are made by the chief operating decision maker, based on the management reporting system of the Group. The Group identified the Chief Executive Officer of the Group as
&#147;Chief operating decision maker&#148;. The Chief operating decision maker reviews on an aggregated basis the incurred expenses for allocating and evaluating performance of the Group. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group operates in a single operating segment: R&amp;D of pharmaceutical products in order to market them in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Substantially all operations, assets, liabilities, and losses of the Group are located in France. As of June&nbsp;30, 2023, the US Subsidiary has only
incurred <FONT STYLE="white-space:nowrap">non-significant</FONT> employee-related costs and its assets and liabilities are <FONT STYLE="white-space:nowrap">non-significant.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6. Goodwill and impairment test </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill relates to the acquisition of Splicos SAS that occurred in 2014 (i.e., prior the transition date to IFRS). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill from the Splicos SAS acquisition corresponds to the &#147;Modulation of RNA biogenesis / splicing&#148; technological platform, from which derived
the lead drug candidate of the Group: ABX464. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with IAS 36, goodwill is allocated to groups of cash generating units (CGUs) at a level
corresponding to the lead drug candidates. Thus, goodwill from Splicos SAS is allocated to the ABX464 CGU. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The net carrying amount of Splicos SAS
goodwill is &#128;18,419&nbsp;thousand as of December&nbsp;31, 2022 and June&nbsp;30, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ABX464 product being currently in development, a clinical
trial failure or a failure to obtain a marketing approval could result in an impairment. As of June&nbsp;30, 2023, the Group has not identified any indication of impairment loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7. Intangible assets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intangible assets are mainly
comprised of the intellectual property underlying: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The exclusive license agreement with the Scripps Research Institute, University of Chicago and Brigham Young
University for which the Group paid a milestone of &#128;45&nbsp;thousand in September 2019 as a result of an IND filling of ABX196. The asset was fully impaired in 2022 along with the goodwill allocated to the ABX196 CGU. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The collaboration and license agreement with the CNRS, Montpellier 2 university and the Curie for which the
Group paid a &#128;40&nbsp;thousand milestone in September 2019 as a result of the entry in phase 2 of ABX464/obefazimod clinical study. Also, in January 2022, the Group was invoiced a &#128;35&nbsp;thousand milestone as a result of the entry of
phase 3 ABX464/obefazimod clinical study. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Patents acquired through the acquisition of Prosynergia of &#128;6,529&nbsp;thousand. These patents cover
alternative synthesis process for obefazimod and a family of close chemical analogues. They also cover alternative forms of obefazimod (salts thereof and crystalline forms of said salts), the pharmaceutical composition comprising them, that could be
of interest to Abivax for future development. The patents are not yet amortized, similarly to licenses. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables presents
movements in intangible assets as of June&nbsp;30, 2023 and 2022: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(amounts in thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LICENCES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SOFTWARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PATENTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>GROSS VALUES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>85</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>110</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of June&nbsp;30, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>120</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,529</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,673</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(amounts in thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LICENCES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SOFTWARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PATENTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>AMORTIZATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(17</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(17</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of June&nbsp;30, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(19</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(19</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(amounts in thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LICENCES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SOFTWARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NET BOOK VALUES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of June&nbsp;30, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(amounts in thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LICENCES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SOFTWARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PATENTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>GROSS VALUES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>120</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,529</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,673</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of June&nbsp;30, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>120</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,529</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,673</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(amounts in thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LICENCES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SOFTWARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PATENTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>AMORTIZATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(45</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(21</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(66</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of June&nbsp;30, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(45</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(23</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(69</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(amounts in thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LICENCES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SOFTWARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NET BOOK VALUES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of June&nbsp;30, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 8. Property, plant and equipment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables presents movements in property, plant and equipment including the right of use of assets (or &#147;ROU&#148;) as of June&nbsp;30, 2023 and
2022: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(amounts in thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BUILDINGS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EQUIPMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FURNITURE<BR>AND<BR>COMPUTER<BR>EQUIPMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>OF<BR>WHICH<BR>ROU</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>GROSS VALUES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>593</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>402</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>235</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,230</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>682</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of June&nbsp;30,&nbsp;2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>593</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>443</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>236</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,272</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>682</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,618</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>438</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>344</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,400</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,561</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of June&nbsp;30,&nbsp;2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,618</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>503</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>400</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,521</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,534</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(amounts in thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BUILDINGS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EQUIPMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FURNITURE<BR>AND<BR>COMPUTER<BR>EQUIPMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>OF<BR>WHICH<BR>ROU</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>DEPRECIATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(445</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(346</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(134</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(925</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(470</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(145</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of June&nbsp;30,&nbsp;2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(556</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(362</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(152</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,070</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(593</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(259</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(378</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(171</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(808</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(290</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(273</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(330</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(251</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of June&nbsp;30,&nbsp;2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(532</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(367</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(212</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,111</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(514</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(amounts in thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BUILDINGS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EQUIPMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FURNITURE<BR>AND<BR>COMPUTER<BR>EQUIPMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>OF<BR>WHICH<BR>ROU</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NET BOOK VALUES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of June&nbsp;30, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of June&nbsp;30, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Right of use assets relate to buildings, vehicles, and furniture. The net book value of right of use assets related to
buildings amounted to &#128;1,224&nbsp;thousand and &#128;978&nbsp;thousand as of December&nbsp;31, 2022 and June&nbsp;30, 2023, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 9.
Other financial assets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other financial assets break down as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(amounts in thousands of euros) </I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS&nbsp;OF<BR>DECEMBER&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS&nbsp;OF&nbsp;JUNE&nbsp;30,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>OTHER FINANCIAL ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Advances related to CRO contracts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits paid under the liquidity agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits paid on Kreos 1 and 2 bond loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposit paid under the Headquarters lease agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,708</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13,343</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advances related to CRO contracts </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Long-term advances amounting to &#128;12,187&nbsp;thousand (undiscounted amount) were made during the year ended December&nbsp;31, 2022. These advances for
clinical studies are to be recovered at the end of the studies after final reconciliation with pass-through costs, which are being invoiced and paid as studies are carried out. These long-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
term advances were measured at fair value on initial recognition, using discount rates ranging from 0.19% to 7.16%, and are subsequently measured at amortized cost. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Over the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2023, additional advances related to CRO contracts amounting to
&#128;1,620&nbsp;thousand were made (undiscounted amount). These long-term advances were measured at fair value on initial recognition, using discount rates ranging from 7.09% to 7.59%, and are subsequently measured at amortized cost. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At inception, a prepaid expenses asset was recognized for the difference between the advances&#146; nominal value and fair value, and spread over the term of
the advances, at the rate of recognition of the related R&amp;D expenses (see Note 10). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 10. Other receivables and other assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other receivables and other assets break down as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(amounts in thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS&nbsp;OF&nbsp;JUNE&nbsp;30,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>OTHER RECEIVABLES AND OTHER ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses&#151;non current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> other receivables and
assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,037</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>934</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research tax credit (&#147;CIR&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VAT receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Credit notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current other receivables and assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,231</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15,989</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other receivables and other assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,268</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,923</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>CIR </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CIR is
recognized as Other Operating Income in the year to which the eligible research expense relates. The Group received the payment of the CIR for 2021 tax year in the amount of &#128;4,204&nbsp;thousand in the second half of 2022 and expects to receive
the CIR for 2022 tax year of &#128;4,448&nbsp;thousand in the second half of 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>VAT Receivables </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Value-added tax (&#147;VAT&#148;) receivables relate primarily to the deductible VAT and VAT refunds claimed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Prepaid expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022 and
June&nbsp;30, 2023, current and <FONT STYLE="white-space:nowrap">non-current</FONT> prepaid expenses include expenses related to CRO contracts for amount of respectively &#128;1,714&nbsp;thousand and &#128;1,671&nbsp;thousand (see Note 9). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2023, current prepaid expenses also include costs related to the planned registered public offering in the United States for an amount of
&#128;1,707&nbsp;thousand (see Note 3.3). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 11. Cash and cash equivalents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents break down as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(amounts in thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS OF<BR>DECEMBER&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS&nbsp;OF&nbsp;JUNE&nbsp;30,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CASH AND CASH EQUIVALENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bank accounts (cash at hand)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>26,950</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>114,381</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 12. Financial assets and liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value
hierarchy. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>AS OF DECEMBER&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom"><I>(amounts in thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AMOUNT<BR>RECOGNIZED&nbsp;IN<BR>THE&nbsp;STATEMENT<BR>OF FINANCIAL<BR>POSITION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FAIR<BR>VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ASSETS/&nbsp;LIABILITIES<BR>AT FAIR VALUE<BR>THROUGH PROFIT<BR>AND LOSS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ASSETS AT<BR>AMORTIZED<BR>COST</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LIABILITIES<BR>AT&nbsp;AMORTIZED<BR>COST</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other financial assets (2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other receivables and assets (2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents (1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>47,889</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>47,452</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>47,452</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Financial <FONT STYLE="white-space:nowrap">liabilities&#151;non-current</FONT> portion
(4,&nbsp;Note 15)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Financial liabilities&#151;current portion (3,&nbsp;Note&nbsp;15)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Trade payables and other current liabilities&nbsp;(3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>65,272</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>58,469</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>57,903</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>AS OF JUNE&nbsp;30, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom"><I>(amounts in thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AMOUNT<BR>RECOGNIZED&nbsp;IN<BR>THE&nbsp;STATEMENT<BR>OF FINANCIAL<BR>POSITION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FAIR<BR>VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ASSETS/&nbsp;LIABILITIES<BR>AT FAIR VALUE<BR>THROUGH PROFIT<BR>AND LOSS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ASSETS AT<BR>AMORTIZED<BR>COST</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LIABILITIES<BR>AT&nbsp;AMORTIZED<BR>COST</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other financial assets (2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other receivables and assets (2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents (1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>143,713</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>143,543</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>143,543</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Financial <FONT STYLE="white-space:nowrap">liabilities&#151;non-current</FONT> portion
(4,&nbsp;Note 15)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Financial liabilities&#151;current portion (3,&nbsp;Note 15)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Trade payables and other current liabilities&nbsp;(3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>85,858</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>79,991</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>75,663</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tax and employee-related payables are <FONT STYLE="white-space:nowrap">non-financial</FONT> liabilities and
are therefore excluded from the tables above. They are presented in Note 17.2. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The fair value of cash and cash equivalents is determined based on Level&nbsp;1 fair value measurements and
corresponds to the market value of the assets. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The carrying amount of financial assets measured at amortized cost is deemed to be a reasonable estimation of
fair value, except for the long-term advances made to CROs, whose fair value is determined based on Level&nbsp;3 fair value measurement and is estimated based on future cash-flows discounted at market rates, using credit spreads ranging from 16 bp
to 476 bp as of December&nbsp;31, 2022 and 19 bp to 346 bp as of June&nbsp;30, 2023. As of December&nbsp;31, 2022 and June&nbsp;30, 2023, an increase in the credit spread by +100 bp would result in a decrease in the advances fair value by
respectively &#128;240&nbsp;thousand and &#128;234&nbsp;thousand. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The carrying amount of short-term financial liabilities measured at amortized cost is deemed to be a reasonable
estimation of fair value. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The fair values of Kreos BSA A&amp;B, OCEANE conversion option and royalty certificates are based on
Level&nbsp;3 fair value measurements and are estimated based on models and assumptions detailed in note 15. The fair value of other long-term financial liabilities is determined based on Level&nbsp;3 fair value measurements and is estimated based on
future cash-flows discounted at market rates, using the following assumptions: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the debt components of Kreos 1 &amp; 2 bonds, a credit spread of 1,475 bp as of December&nbsp;31, 2022 and
1,376 bp as of June&nbsp;30, 2023. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022 and June&nbsp;30, 2023, an increase in the credit spread
by +100 bp would result in a decrease in the Kreos 1 &amp; 2 bonds fair value by &#128;68&nbsp;thousand and &#128;34&nbsp;thousand, respectively. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the debt component of OCEANE bonds, a credit spread similar to that detailed in Note 15.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, and June&nbsp;30, 2023, an increase in the credit spread by +100 bp would result in a
decrease in the OCEANE debt component fair value by &#128;476&nbsp;thousand and &#128;447&nbsp;thousand, respectively. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the conditional advances and the PGE loan, a credit spread of 1,475 bp as of December&nbsp;31, 2022 and 1,376
bp as of June&nbsp;30, 2023. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">An increase in the credit spread by +100 bp would result in the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of December&nbsp;31, 2022 and June&nbsp;30, 2023, a decrease in the PGE loan fair value by
&#128;55&nbsp;thousand and &#128;44&nbsp;thousand, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of December&nbsp;31, 2022 and June&nbsp;30, 2023, a decrease in the
<FONT STYLE="white-space:nowrap">RNP-VIR</FONT> conditional advance fair value by &#128;31&nbsp;thousand and &#128;23&nbsp;thousand, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of December&nbsp;31, 2022 and June&nbsp;30, 2023, a decrease in the CARENA conditional advance fair value by
&#128;37&nbsp;thousand and &#128;35&nbsp;thousand respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of December&nbsp;31, 2022 and June&nbsp;30, 2023, a decrease in the Ebola conditional advance fair value by
&#128;1&nbsp;thousand and &#128;1&nbsp;thousand, respectively. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2023, the difference between the
fair value of the <FONT STYLE="white-space:nowrap">non-current</FONT> portion of financial liabilities and their carrying amount is mainly explained by the increase in market rates between their issuance dates and June&nbsp;30, 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 13. Shareholders&#146; equity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 13.1. Share capital issued </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group manages
its capital to ensure that the Group will be able to continue as a going concern while maximizing the return to shareholders through the optimization of the debt and equity balance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, the Group&#146;s share capital amounted to &#128;223&nbsp;thousand divided into 22,313,185 ordinary shares issued with a par
value of &#128;0.01 each, fully paid up, after taking into account the various capital increases that took place since the inception (see Note 13.2). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As
of June&nbsp;30, 2023, the Group&#146;s share capital amounted to &#128;425&nbsp;thousand divided into 42,547,568 ordinary shares issued with a par value of &#128;0.01 each, fully paid up. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share capital does not include founders&#146; share warrants (&#147;bons de souscription de parts de cr&eacute;ateur d&#146;entreprise&#148; or
&#147;BCE&#148;), share warrants (&#147;Bons de souscription d&#146;actions,&#148; or &#147;BSA&#148;) and free shares (&#147;Attributions gratuites d&#146;actions&#148; or &#147;AGA&#148;) that have been granted to certain investors or natural
persons, both employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> of the Group, but not yet exercised. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Treasury shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group held 12,000 and 11,487 of its own shares as of December&nbsp;31, 2022 and June&nbsp;30, 2023, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of outstanding ordinary shares (excluding treasury shares held by the Group) was 22,301,185 and 42,536,081 as of December&nbsp;31, 2022 and
June&nbsp;30, 2023, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 13.2. Change in share capital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The increase in the share capital for the period ended June&nbsp;30, 2022 relates to the exercise of 19,134 share warrants, resulting in a capital increase of
&#128;0&nbsp;thousand by issuing 19,134 ordinary shares with a par value of &#128;0.01 per share and an average subscription price of &#128;0.14 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The increase in the share capital for the period ended June&nbsp;30, 2023 relates to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the completion of a capital increase of &#128;130,000&nbsp;thousand on February&nbsp;22, 2023 by issuing
20,000,000 new ordinary shares with a par value of &#128;0.01 per share and a subscription price of &#128;6.50 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cash-less exercise of 67,887 Kreos A BSA and 31,696 Kreos B BSA, resulting in a capital increase of
&#128;1,850&nbsp;thousand by issuing 99,583 ordinary shares with a par value of &#128;0.01 per share and an average subscription price of &#128;18.57 per share, which includes the impact of the derecognition of the BSA derivative financial
liability; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exercise of 1,348 other share warrants, by issuing 134,800 ordinary shares with a par value of &#128;0.01 per
share and an average subscription price of &#128;0.01 per share (see Note 14). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Distribution of dividends </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group did not distribute any dividends for any of the periods presented. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 14. Share-based payments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group has granted BCEs, BSAs and AGAs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>BCEs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables summarize the data relating to BCEs: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6.5pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>GRANT<BR>DATE </B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>TYPE</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER<BR>OF BCEs<BR>ISSUED</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER OF<BR>BCE<BR>OUTSTANDING<BR>AS OF<BR>JANUARY&nbsp;1,<BR>2022
</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>NUMBER<BR>OF&nbsp;LAPSED<BR>BCEs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>NUMBER&nbsp;OF<BR>EXERCISED<BR>BCEs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>NUMBER OF<BR>BCEs<BR>OUTSTANDING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>NUMBER OF<BR>BCEs<BR>EXERCISABLE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>MAXIMUM<BR>NUMBER OF<BR>SHARES TO<BR>BE ISSUED<BR>IF ALL<BR>CONDITIONS<BR>ARE MET</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:6.5pt; font-family:Times New Roman; " ALIGN="center"><B>FOR&nbsp;THE
PERIOD&nbsp;ENDED<BR>JUNE&nbsp;30, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS OF JUNE&nbsp;30, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2014-03-11</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2014-2</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2016-11-07</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2014-4</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2016-11-07</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2017-01-23</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2017-11-20</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-2</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2017-11-20</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-4</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2017-11-20</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2018-03-15</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2018-05-14</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BCE <FONT STYLE="white-space:nowrap">2018-3</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2018-05-14</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-4</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2018-05-14</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(334</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Total&nbsp;BCEs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>534,386</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>429,767</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(250</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(334</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>429,183</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>227,856</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>546,399</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6.5pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>GRANT<BR>DATE</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>TYPE</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER<BR>OF BCEs<BR>ISSUED</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER OF<BR>BCE<BR>OUTSTANDING<BR>AS
OF<BR>JANUARY&nbsp;1,<BR>2023</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>NUMBER<BR>OF&nbsp;LAPSED<BR>BCEs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>NUMBER&nbsp;OF<BR>EXERCISED<BR>BCEs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>NUMBER OF<BR>BCEs<BR>OUTSTANDING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>NUMBER OF<BR>BCEs<BR>EXERCISABLE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>MAXIMUM<BR>NUMBER OF<BR>SHARES TO<BR>BE ISSUED<BR>IF ALL<BR>CONDITIONS<BR>ARE MET</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:6.5pt; font-family:Times New Roman; " ALIGN="center"><B>FOR&nbsp;THE
PERIOD&nbsp;ENDED<BR>JUNE&nbsp;30, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS OF JUNE&nbsp;30, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2014-03-11</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2014-2</FONT></FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">2,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">1,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&#8194;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">(1,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&#8194;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&#8194;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&#8194;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2014-03-11</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2014-4</FONT></FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">984</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">184</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&#8194;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">(184</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&#8194;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&#8194;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&#8194;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2016-11-07</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2017-01-23</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2017-11-20</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-2</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2017-11-20</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-4</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2017-11-20</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2018-03-15</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2018-05-14</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BCE <FONT STYLE="white-space:nowrap">2018-3</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2018-05-14</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-4</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2018-05-14</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Total&nbsp;BCEs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>534,386</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>424,093</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,184</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>422,909</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>221,582</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>422,909</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>BSAs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables summarize the data relating to BSAs as well as the assumptions used for the measurement thereof in accordance with IFRS
2&#151;<I>Share-based Payment</I>: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6.5pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>GRANT<BR>DATE </B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>TYPE</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER<BR>OF BSAs<BR>ISSUED</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER OF<BR>BCAs<BR>OUTSTANDING<BR>AS
OF<BR>JANUARY&nbsp;1,<BR>2022</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>NUMBER<BR>OF&nbsp;LAPSED<BR>BSAs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>NUMBER&nbsp;OF<BR>EXERCISED<BR>BSAs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>NUMBER OF<BR>BSAs<BR>OUTSTANDING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>NUMBER OF<BR>BSAs<BR>EXERCISABLE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>MAXIMUM<BR>NUMBER OF<BR>SHARES TO<BR>BE ISSUED<BR>IF ALL<BR>CONDITIONS<BR>ARE MET</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:6.5pt; font-family:Times New Roman; " ALIGN="center"><B>FOR THE PERIOD
ENDED<BR>JUNE&nbsp;30, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS OF JUNE&nbsp;30, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2014-03-11</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2015-12-04</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2015-11</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2015-12-04</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2015-12</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2017-09-18</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2017-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2018-01-22</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2014-03-11</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-4</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2014-03-11</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Total BSAs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>247,798</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>148,105</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(188</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>147,917</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>147,917</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>325,384</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>GRANT<BR>DATE </B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>TYPE</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER<BR>OF BSAs<BR>ISSUED</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER OF<BR>BCAs<BR>OUTSTANDING<BR>AS OF<BR>JANUARY 1,<BR>2023</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT STYLE="font-size:6.5pt"><B>NUMBER<BR>OF&nbsp;LAPSED<BR>BSAs</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT STYLE="font-size:6.5pt"><B>NUMBER&nbsp;OF<BR>EXERCISED<BR>BSAs</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT STYLE="font-size:6.5pt"><B>NUMBER OF<BR>BSAs<BR>OUTSTANDING</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT STYLE="font-size:6.5pt"><B>NUMBER OF<BR>BSAs<BR>EXERCISABLE</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT STYLE="font-size:6.5pt"><B>MAXIMUM<BR>NUMBER OF<BR>SHARES TO<BR>BE ISSUED<BR>IF ALL<BR>CONDITIONS<BR>ARE MET</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:6.5pt; font-family:Times New Roman; " ALIGN="center"><B>FOR THE PERIOD
ENDED<BR>JUNE&nbsp;30, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:6.5pt"><B>AS OF JUNE&nbsp;30, 2023</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2014-03-11</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(164</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2015-12-04</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2015-11</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2015-12-04</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2015-12</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2017-09-18</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2017-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2018-01-22</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2014-03-11</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-4</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2014-03-11</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Total BSAs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>247,798</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>147,917</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(164</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>147,753</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>147,753</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>308,984</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>AGAs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
tables summarize the data relating to AGAs as well as the assumptions used for the measurement thereof in accordance with IFRS 2&#151;<I>Share-based Payment</I>: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:6.5pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6.5pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>GRANT DATE </B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>TYPE</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER OF<BR>AGAs&nbsp;ISSUED</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER OF AGAs<BR>OUTSTANGING&nbsp;AS&nbsp;OF<BR>JANUARY&nbsp;1,
2022</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>NUMBER OF<BR>LAPSED&nbsp;AGAs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>NUMBER OF<BR>EXERCISED&nbsp;AGAs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>NUMBER&nbsp;OF&nbsp;AGAs<BR>OUTSTANDING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:6.5pt; font-family:Times New Roman; " ALIGN="center"><B>FOR THE PERIOD
ENDED<BR>JUNE&nbsp;30,&nbsp;2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS&nbsp;OF&nbsp;JUNE&nbsp;30,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2021-09-21</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AGA&nbsp;2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(155,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Total&nbsp;AGAs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>155,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>155,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(155,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AGAs granted in September 2021 are subject to a vesting service condition of one year following the grant date. The number of
shares to be vested under this plan depended on the following conditions: completion of an&#8195; M&amp;A transaction on or prior to July 31, 2022 and a price per ordinary share of the Company retained in the framework of the M&amp;A Transaction at
least equal to &#128;100 per share (or lower than &#128;100 per share). During the period ended June&nbsp;30, 2022, the AGAs were all forfeited since no M&amp;A transaction was completed on or prior to July 31, 2022. This resulted in a reversal of
the related compensation expense of &#128;1,026&nbsp;thousand and the reversal of the accrual for social taxes of &#128;205&nbsp;thousand that was recorded as of December&nbsp;31, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Breakdown of the compensation expenses accounted for the period ended June&nbsp;30, 2022 and 2023
</I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>TYPE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EXPENSES RELATED<BR>TO&nbsp;THE&nbsp;PERIOD&nbsp;ENDED<BR>JUNE&nbsp;30, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EXPENSES RELATED<BR>TO&nbsp;THE&nbsp;PERIOD&nbsp;ENDED<BR>JUNE&nbsp;30, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(in thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BCEs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSAs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGAs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,026</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Social taxes related to AGAs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,426</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>56</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the period ended June&nbsp;30, 2022, the total share-based compensation expense net of the reversal of AGA expense
resulted in an income of &#128;1,426&nbsp;thousand, including the related social taxes (&#128;828&nbsp;thousand in research and development and &#128;598&nbsp;thousand in general and administrative). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the period ended June&nbsp;30, 2023, the total share-based compensation amounted to &#128;56&nbsp;thousand (&#128;29&nbsp;thousand in research and
development and &#128;27&nbsp;thousand in general and administrative). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 15. Financial liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial liabilities break down as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(amounts in thousands of euros)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>AS OF<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>AS OF<BR>JUNE&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>FINANCIAL LIABILITIES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kreos 1 &amp; 2 bond loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PGE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Borrowings</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,127</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,068</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oceane</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Convertible loan notes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19,332</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19,964</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kreos A&nbsp;&amp; B BSA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oceane conversion option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Derivative instruments</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>566</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,328</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conditional advances Bpifrance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty certificates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,549</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,387</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> financial liabilities</B></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>35,573</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>43,747</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kreos 1 &amp; 2 bond loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PGE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Borrowings</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,077</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,031</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conditional advances Bpifrance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,521</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,012</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oceane</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Convertible loan notes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>625</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>625</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,224</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,667</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>49,797</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>56,414</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.1. Structured debt financing with Kreos subscribed in July 2018 &#150; &#147;Kreos 1&#148; and
in October 2020 <STRIKE>&#150; </STRIKE>&#147;Kreos 2&#148; </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The variation in the Kreos 1 &amp; 2 bond loans during the period ended June&nbsp;30,
2023 is primarily related to reimbursements of capital and interests. As of December&nbsp;31, 2022, the A tranche of the Kreos 1 bond loan has come to maturity and was repaid in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group granted to the holders of the Kreos A BSA and the Kreos B BSA the option to sell to the Group, upon each exercise of all or parts of the Kreos A
BSA, at the put price defined in the agreement, a proportion of the number of the warrants, for the sole purpose of implementing a cashless exercise of the Kreos A BSA and Kreos&nbsp;B BSA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;24, 2023, the holders opted for the cashless exercise option of the share warrants they held, implemented through the repurchase by the Group of
43,070 Kreos A BSA and 43,070 Kreos B BSA and the issuance by the Group of respectively 67,887 and 31,696 ordinary shares, as the result of the cashless exercise by Kreos of the outstanding 67,887 Kreos A&nbsp;&amp; 31,696 B BSA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The operation resulted in (i)&nbsp;the derecognition of the derivative financial liabilities corresponding to the Kreos A&nbsp;&amp; B BSA, amounting to
&#128;1,850&nbsp;thousand as of May&nbsp;24, 2023, (ii) an increase in shareholders&#146; equity for the same amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;21, 2023, the
outstanding Kreos 1 &amp; 2 bond loans were repaid in full, for an amount of &#128;7,661&nbsp;thousand, using the proceeds from the new Kreos / Claret Financing (see Note 3.3). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.2. OCEANE </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The OCEANE shall be convertible
into new ordinary shares and/or exchanged for existing ordinary shares of the Group at any time from their issuance and at the discretion of their holders. The initial conversion ratio is one ordinary share of the Group per OCEANE, representing a
conversion price set to &#128;&nbsp;38.19 per ordinary share initially. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the OCEANE terms and conditions, the conversion price was
updated on January&nbsp;30, 2023 and July&nbsp;30, 2023 (i.e., respectively 18 months and 24 months after OCEANE issuance) to respectively &#128;32.462 per ordinary share and &#128;26.725 per ordinary share, and the conversion ratio was adjusted to
respectively 1.176 and 1.429. The update from January&nbsp;30, 2023 was taken into account in the calculation of the fair value of the conversion option as of June&nbsp;30, 2023 (see Note 15.9). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;24, 2023, the outstanding OCEANE were repaid in full, for an amount of &#128;25,102&nbsp;thousand, using the proceeds from the new Heights
Financings (see Note 3.3). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.3. State guaranteed loan &#150; &#147;PGE&#148; </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The variation in the PGE loan over the period ended June&nbsp;30, 2023 is primarily related to the reimbursement of capital and interests. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.4. Conditional advances </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Conditional
advances as of June&nbsp;30, 2023 and December&nbsp;31, 2022 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(amounts in thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>AS OF<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>AS OF<BR>JUNE&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>CONDITIONAL ADVANCES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RNP VIR &#150; Bpifrance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CARENA &#150; Bpifrance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EBOLA &#150; Bpifrance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total conditional advances</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,783</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,780</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.5. Lease liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The variations in lease liabilities are set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(amounts in thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LEASE&nbsp;LIABILITY</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>214</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(+) Increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(-) Decrease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of June&nbsp;30, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>89</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,384</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(+) Increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(-) Decrease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of June&nbsp;30, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,114</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lease liabilities mainly relate the Group&#146;s headquarters and to a lesser extent to vehicles, parking lots and printers
(Note 8). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The lease for the Group&#146;s corporate headquarters in Paris, France at 5 Rue de la Baume, 75008 Paris ended in August 2022. A new lease for
premises at <FONT STYLE="white-space:nowrap">7-11</FONT> Boulevard Haussmann, 75009 Paris started in July 2022. It has a three-year duration, with a tacit renewal option for approximately two years and the possibility to break the contract one year
before the end. Per Management, renewal and termination options are not reasonably certain due to the forecasted development of the Group, which may lead the Group to relocate at the end of the initial term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022 and June&nbsp;30, 2023, the lease liability of the headquarters represented 97% and 96% of the total lease liability,
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lease expenses related to contracts for which a lease liability and right of use asset is recognized under IFRS 16 were
&#128;125&nbsp;thousand and &#128;263&nbsp;thousand for the six months period ended June&nbsp;30, 2022 and 2023, respectively. They were recognized for (i) &#128;124&nbsp;thousand and &#128;251&nbsp;thousand as Depreciation expenses and (ii)
&#128;1&nbsp;thousand and &#128;6&nbsp;thousand as Interest expenses, for the six months period ended June&nbsp;30, 2022 and 2023, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lease
expenses related to short-term lease contracts and low value assets are not included in the valuation of the lease liability for an amount of &#128;10&nbsp;thousand and &#128;162&nbsp;thousand for the periods ended June&nbsp;30, 2022 and 2023,
respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.6. Prosynergia <FONT STYLE="white-space:nowrap">earn-out</FONT> liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of the share purchase acquisition of Prosynergia include a possible earn out triggered in the event the Company&#146;s market capitalization is in
excess of &#128;300&nbsp;million (evaluated at certain specified record dates), a listing of the Company&#146;s shares on Nasdaq or an M&amp;A transaction prior to March&nbsp;31, 2023. The amount of the
<FONT STYLE="white-space:nowrap">earn-out</FONT> is equal to 1% of the difference between the Company&#146;s market capitalization and &#128;300&nbsp;million, subject to a maximum amount of &#128;4.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This potential <FONT STYLE="white-space:nowrap">earn-out</FONT> payment was measured at fair value on April&nbsp;1, 2022 (acquisition date), for an amount of
&#128;1,446&nbsp;thousand, and included in the acquisition cost. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2022, the fair value of the
<FONT STYLE="white-space:nowrap">earn-out</FONT> liability amounted to &#128;178&nbsp;thousand. The remeasurement resulted in a financial income of &#128;1,267&nbsp;thousand over the period ended June&nbsp;30, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, the fair value of the <FONT STYLE="white-space:nowrap">earn-out</FONT> liability was insignificant. During the first half of
2023, since its payment was not triggered by March&nbsp;31, 2023, the liability was extinguished and thus reversed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Prosynergia <FONT STYLE="white-space:nowrap">earn-out</FONT> liability is measured at fair value using a
Black-Scholes valuation model. The main data and assumptions are the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Prosynergia <FONT STYLE="white-space:nowrap">earn-out</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;April&nbsp;1,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;and&nbsp;for&nbsp;the<BR>period&nbsp;ended<BR>June&nbsp;30, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;and&nbsp;for&nbsp;the<BR>period&nbsp;ended<BR>December&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0.27</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.39</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.28</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Market capitalization (in thousands of euros)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">403,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary share price (in euros)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Time to maturity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.75&nbsp;year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25&nbsp;year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77.16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44.01</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fair value of the <FONT STYLE="white-space:nowrap">earn-out</FONT> liability (in thousands
of euros)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,446</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(178</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of April 1, 2022, using the same assumption with an increase of +1% volatility, &#128;+1 share price and +1% risk free rate
would result in an increase of the <FONT STYLE="white-space:nowrap">earn-out</FONT> liability fair value by &#128;12&nbsp;thousand, &#128;132&nbsp;thousand and &#128;17&nbsp;thousand, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2022, using the same assumption with an increase of +1% volatility, &#128;+1 share price and +1% risk free rate would result in an
increase of the <FONT STYLE="white-space:nowrap">earn-out</FONT> liability fair value by &#128;5&nbsp;thousand, &#128;58&nbsp;thousand and &#128;3&nbsp;thousand, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, the fair value of the <FONT STYLE="white-space:nowrap">earn-out</FONT> liability is approximately &#128;0. Using the same
assumption with an increase of +1% volatility, &#128;+1 share price and +1% risk free rate would result in an increase of the <FONT STYLE="white-space:nowrap">earn-out</FONT> liability fair value by an amount less than &#128;1&nbsp;thousand. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.7. Royalty certificates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Over the second
quarter of 2023, the Group reassessed its estimate of the probability of future royalty cash flows related to the royalty certificates. This change reflected the higher probability to reach the objectives of the development and commercialization
plans following the recent changes in management and governance, as well as results from its Phase 2b open-label maintenance trial in UC, as released in April 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequently, in June 2023, the Group revised the development and commercialization plans of obefazimod and reassessed its estimate of future royalty cash
flows accordingly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These changes in estimates resulted in a remeasurement of the certificates&#146; amortized costs, using the original EIR of 34%
calculated at the date of issuance, which led to an increase by &#128;6,512 of the royalty certificates liability. The expense was recorded within the interest expenses in the Statement of Profit or Loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consequently, the total interest expense (including the unwinding of discount) related to royalty certificates amounts to &#128;7,331&nbsp;thousand for the
period ended June&nbsp;30, 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fair value as of June&nbsp;30, 2023 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At this date, the fair value of the royalty certificates, calculated using the same model as their initial measurement, amounts to &#128;11,589&nbsp;thousand.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the royalty certificates is based on the NPV of royalties, which depend on assumptions made by the Group with regards to the
probability of success of its studies (&#147;POS&#148;), the commercialization budget of obefazimod (&#147;peak penetration&#148;) and the Group&#146;s WACC. In addition, royalty projections have been adjusted to reflect any difference between the
Group&#146;s value derived from management projections and the Group&#146;s market capitalization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sensitivity analysis to key assumptions is presented below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value&nbsp;of<BR>royalty&nbsp;certificates<BR>(in&nbsp;thousands&nbsp;of&nbsp;euros)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">POS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-5&nbsp;points</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-1,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">+5&nbsp;points</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair value of<BR>royalty&nbsp;certificates<BR>(in&nbsp;thousands&nbsp;of&nbsp;euros)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peak penetration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-5%&nbsp;(worst&nbsp;case&nbsp;scenario)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-1,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">+5%&nbsp;(best case scenario)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair value of<BR>royalty&nbsp;certificates<BR>(in&nbsp;thousands&nbsp;of&nbsp;euros)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WACC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-1&nbsp;point</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">+1&nbsp;point</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair value of<BR>royalty&nbsp;certificates<BR>(in&nbsp;thousands&nbsp;of&nbsp;euros)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-1&nbsp;euro</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">+1&nbsp;euro</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.8. Change in financial liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The changes in financial liabilities are set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom"><I>(Amounts in thousands of euros) </I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Kreos&nbsp;1&nbsp;&amp;&nbsp;2<BR>bond loans</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Oceane</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Conditional<BR>advances<BR>BPI</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Lease<BR>liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Prosynergia<BR><FONT STYLE="white-space:nowrap">earn-out</FONT><BR>liability</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty<BR>certificates</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>FINANCIAL&nbsp;LIABILITIES</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>(excluding derivatives instruments)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21,110</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18,816</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,742</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,770</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>214</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>51,653</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Repayments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,601</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,632</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> changes: interest expense and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> changes: recognition of <FONT
STYLE="white-space:nowrap">earn-out</FONT> liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> changes: fair value remeasurement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,267</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,267</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>As of June&nbsp;30, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,525</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19,364</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,761</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,789</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>89</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>178</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>47,707</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>As of January&nbsp;1, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,982</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19,957</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,838</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,783</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,384</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,287</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>49,231</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Repayments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,727</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,297</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(449</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> changes: interest expense and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> changes: amortized cost remeasurement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>As of June&nbsp;30, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,366</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20,589</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,619</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,780</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,114</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,618</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>52,086</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.9. Change in derivative instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The change in derivative instruments is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(amounts in thousands of euros) </I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Kreos&nbsp;A&nbsp;BSA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Kreos&nbsp;B&nbsp;BSA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>OCEANE<BR>conversion<BR>option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>DERIVATIVE FINANCIAL INSTRUMENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,478</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,525</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,929</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,932</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(+) Increase in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(-) Decrease in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,314</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,467</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of June&nbsp;30, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,261</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>589</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,615</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,465</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>275</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>149</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>142</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>566</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(+) Increase in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(-) Decrease in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(-) Repurchases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(339</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(829</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(-) Exercises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of June&nbsp;30, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,328</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,328</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Measurement of Kreos A BSA&nbsp;&amp; Kreos B BSA </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Kreos A BSA and Kreos B BSA are measured at fair value using a Black-Scholes valuation model. The main data and assumptions are the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Kreos A BSA&#151;June 1, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;and&nbsp;for&nbsp;the<BR>year&nbsp;ended<BR>December&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;May&nbsp;24,&nbsp;2023<BR>(exercise date)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of outstanding Kreos A BSA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary share price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">28.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">18.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Residual maturity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.6&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fair value of issued Kreos A BSA (in&nbsp;thousands of &#128;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>275</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,261</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Kreos B BSA&#151;June 1, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of and for the<BR>year ended<BR>December&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;May&nbsp;24,&nbsp;2023<BR>(exercise&nbsp;date)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of outstanding Kreos B BSA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary share price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">28.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">18.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Residual maturity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.4&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fair value of issued Kreos B BSA (in&nbsp;thousands of &#128;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>149</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>589</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, using the same assumptions with an increase of +1% volatility, &#128;+1share
price and +1% risk-free rate would result in an increase of Kreos A&amp;B BSA fair value of &#128;6&nbsp;thousand, &#128;78&nbsp;thousand, and &#128;12&nbsp;thousand, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;24, 2023, the holders opted for the cashless exercise option of the share warrants they held. At this date, the fair value of exercised warrants
of &#128;1,850&nbsp;thousand was reclassified from derivative financial liabilities to equity. As of this date, due to the put option being exercised by the holders, the fair value of the BSAs is deemed equal to their intrinsic value, which is equal
to the difference between the share price on May&nbsp;24, 2023 and their exercise price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Measurement of OCEANE </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022 and June&nbsp;30, 2023, the OCEANE were measured at fair value based on a Monte Carlo model using a Longstaff and Schwartz
algorithm based on the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>OCEANE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;and&nbsp;for&nbsp;the&nbsp;year<BR>December&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;and&nbsp;for&nbsp;the&nbsp;period<BR>June&nbsp;30, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.05</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.36</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Credit spread</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1475,10&nbsp;bp</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1376,20&nbsp;bp</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary share price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">6,18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">15,60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;21,&nbsp;2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;21,&nbsp;2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fair value of issued OCEANE (in&nbsp;thousands of &#128;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>142</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,328</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, using the same assumptions, an increase of +1% volatility, &#128;+1 share price and +1% risk
free rate would result in an increase of the OCEANE conversion option fair value of &#128;17&nbsp;thousand, &#128;97&nbsp;thousand, and &#128;15&nbsp;thousand respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2023, using the same assumptions, an increase of +1% volatility, &#128;+1 share price and +1% risk free rate would result in an increase
of the OCEANE conversion option fair value of &#128;75&nbsp;thousand, &#128;493&nbsp;thousand, and &#128;103&nbsp;thousand respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
August&nbsp;24, 2023, following the repayment in full of the outstanding OCEANE, for an amount of &#128;25,102&nbsp;thousand, using the proceeds from the new Kreos / Claret and Heights Financings (see Note 3.3), the derivative financial liability
related to the conversion option was derecognized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.10. Breakdown of financial liabilities by maturity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The maturities of financial liabilities are presented below as of December&nbsp;31, 2022 and June&nbsp;30, 2023: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>AS OF DECEMBER&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>CURRENT AND <FONT STYLE="white-space:nowrap">NON-CURRENT</FONT><BR>FINANCIAL&nbsp;LIABILITIES<BR>(amounts in thousands of euros)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>GROSS<BR>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LESS&nbsp;THAN&nbsp;1<BR>YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FROM&nbsp;1&nbsp;TO&nbsp;5<BR>YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LONGER&nbsp;THAN&nbsp;5<BR>YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kreos 1 &amp; 2 bond loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oceane</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PGE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conditional advances BPI</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty certificates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>49,797</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,224</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>35,150</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>424</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>AS OF JUNE&nbsp;30, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>CURRENT AND <FONT STYLE="white-space:nowrap">NON-CURRENT</FONT> FINANCIAL LIABILITIES<BR>(amounts in thousands of euros)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>GROSS<BR>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LESS&nbsp;THAN<BR>1 YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FROM&nbsp;1&nbsp;TO<BR>5 YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LONGER&nbsp;THAN&nbsp;5<BR>YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kreos 1 &amp; 2 bond loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oceane</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PGE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conditional advances BPI</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty certificates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>56,414</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,667</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>36,359</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,388</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 16. Retirement benefit obligations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Retirement benefit obligations include the liability for the defined benefit plan, measured based on the provisions stipulated under the applicable collective
agreements, i.e., the French pharmaceutical industry&#146;s collective agreement. This commitment only applies to employees subject to French law. The main actuarial assumptions used to measure the retirement benefit obligations are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>AS OF JUNE&nbsp;30,</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>ACTUARIAL ASSUMPTIONS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2023</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Retirement age</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><FONT STYLE="font-size:8pt">65&nbsp;years&nbsp;for&nbsp;key&nbsp;management&nbsp;/&nbsp;63&nbsp;years&nbsp;for&nbsp;other&nbsp;employees</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Collective agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><FONT STYLE="font-size:8pt">Pharmaceutical industry</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Discount&nbsp;Rate&nbsp;(IBoxx&nbsp;Corporates&nbsp;AA)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3.22%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3.70%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Mortality rate table</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><FONT STYLE="font-size:8pt">INSEE 2016-2018</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Salary increase rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><FONT STYLE="font-size:8pt">3% for key management / 2.55% for other employees</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Turnover rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><FONT STYLE="font-size:8pt"><FONT STYLE="white-space:nowrap">Decreasing&nbsp;from&nbsp;5.80%&nbsp;at&nbsp;20&nbsp;years-old</FONT> to 0.05% from 55
<FONT STYLE="white-space:nowrap">years-old</FONT></FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Employee contribution rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><FONT STYLE="font-size:8pt">45%</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in the projected benefit obligation for the periods presented were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><I>(amounts in thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RETIREMENT&nbsp;BENEFIT<BR>OBLIGATIONS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>693</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefits paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Actuarial gains and losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>610</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefits paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Actuarial gains and losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(79</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of June&nbsp;30, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>594</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 17. Payables and other current liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 17.1. Trade payables and other current liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trade payables and other current liabilities break down as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>(amounts in thousands of euros)</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>TRADE PAYABLES AND OTHER CURRENT LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS OF<BR>DECEMBER&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS OF<BR>JUNE&nbsp;30,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued invoices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Trade payables and other current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15,475</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>29,443</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The increase in trade payables and accrued invoices is consistent with the increase in operating expenses over the period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 17.2. Tax and employee-related payables </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tax
and employee-related payables are presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>(amounts in thousands of euros)</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>TAX
AND EMPLOYEE-RELATED PAYABLES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS OF<BR>DECEMBER&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS OF<BR>JUNE&nbsp;30,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee-related payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Social security and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other tax and related payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Tax and employee-related payables</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,300</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,979</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The increase in employee-related, social security and other payables is mainly related to the changes in management and
recruitment of additional experienced employees, including <FONT STYLE="white-space:nowrap">C-levels,</FONT> over the first half of 2023 (see Note 3.1 <I>Change in governance &#150; August 2022 </I>and Note 3.2. <I>Change in governance and
management &#150; February-July 2023</I>). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 18. Operating income </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating income is composed as below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(amounts in thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>AS&nbsp;OF&nbsp;JUNE&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>OPERATING INCOME</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research tax credit (&#147;CIR&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsidies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,284</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,255</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>CIR </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group carries
out research and development projects. As such, it has benefited from a research tax credit for the periods ended June&nbsp;30, 2022 and 2023 for an amount of &#128;2,217&nbsp;thousand and &#128;2,235&nbsp;thousand, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 19. Operating expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 19.1. Sales and marketing </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(amounts in thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>PERIOD&nbsp;ENDED&nbsp;JUNE&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>SALES AND MARKETING</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales and Marketing costs consist of the newly hired employees within the Sales and Marketing Department, including the Chief
Commercial Officer (see Note 3.2). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 19.2. Research and development </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(amounts in thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>PERIOD&nbsp;ENDED&nbsp;JUNE&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>RESEARCH AND DEVELOPMENT EXPENSES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2022&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2023&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Sub-contracting,</FONT> studies and research</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consulting and professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intellectual property fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Research and development expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15,107</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32,622</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2023, the increase in research and
development expenses by &#128;17,515&nbsp;thousand compared to June&nbsp;30, 2022, is mainly due to an increase in UC expenses, as the Group completed the Phase 2b clinical trial in early 2022 and initiated the Phase 3 clinical trial in the first
half of 2022, with the first patient in the United States enrolled in October 2022 (see Note 3.1 <I>The Group announces first US patient enrollment in global Phase 3 program with obefazimod in UC</I><I></I><I>&nbsp;&#150;</I><I></I><I>&nbsp;October
2022).</I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 19.3. General and administrative </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(amounts in thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>PERIOD&nbsp;ENDED&nbsp;JUNE&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>GENERAL AND ADMINISTRATIVE EXPENSES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consulting and professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>General and administrative expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,223</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,758</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2023, the increase in Personnel costs was
primarily the result of the changes in management that occurred during the period and the reversal of share-based compensation expenses incurred in 2021 that was recorded in the first half of 2022. The increase in Consulting and professional fees is
related to recruitment and legal fees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 20. Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group&#146;s average workforce during the periods ended June&nbsp;30, 2022 and 2023 was as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>FOR&nbsp;THE&nbsp;SIX&nbsp;MONTHS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ENDED&nbsp;JUNE&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>HEADCOUNTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2022&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2023&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Key management</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other employees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>26</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 21. Financial gain (loss) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial loss breaks down as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(amounts in thousands of euros) </I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>FOR THE SIX MONTHS<BR>ENDED JUNE&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>FINANCIAL GAIN (LOSS)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2023&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on Kreos 1 &amp; 2 straight bond loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(922</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(559</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on convertible loan notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,298</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,382</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on conditional advances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(105</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on royalty certificates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,331</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease/(increase) in derivatives fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,612</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,346</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(15,030</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease/(increase) in derivatives fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease/(increase) in other liabilities at fair value through profit and loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of unwinding the discount related to advances made to CROs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,195</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>357</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial gain (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,849</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(14,673</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the period ended June&nbsp;30, 2023, the financial loss mainly relates to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the increase in the fair value of the derivative financial liabilities, i.e. the convertible option related to
OCEANE bonds issued in July 2021 and the Kreos 1 &amp; 2 BSA, by respectively &#128;4,186&nbsp;thousand and &#128;1,426&nbsp;thousand as a result of a significant change in market conditions and an increase in the share price of the Group (see Note
15.2); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the financial expenses related to the royalty certificates of &#128;7,331&nbsp;thousand (see Note 15.7)
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the period ended June&nbsp;30, 2022, the financial gain mainly relates to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the decrease in the fair value of the derivatives: as a result of the significant change in market conditions,
the fair values of Kreos A BSA, Kreos B BSA and the convertible option related to OCEANE bonds issued in July 2021 decreased by &#128;1,601&nbsp;thousand, &#128;947&nbsp;thousand and &#128;3,314&nbsp;thousand, respectively; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the &#128;1,267&nbsp;thousand decrease in the fair value of the <FONT STYLE="white-space:nowrap">earn-out</FONT>
liability related to the acquisition of Prosynergia. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 22. Income tax </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group incurred tax losses in the current period and prior years. As the recoverability of these tax losses is not considered probable in subsequent periods
due to the uncertainties inherent in the Group&#146;s business, the Group has not recognized deferred tax assets beyond deferred tax liabilities arising within the same taxable entity under the same taxable regime and with consistent timing of
reversal, after considering, if applicable, limitations in the use of deductible tax losses carried forward from prior periods applicable under tax law in France. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 23. Income (loss) per share </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic losses per share
is calculated by dividing income (loss) attributable to equity holders of the Group by the weighted-average number of outstanding ordinary shares for the year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Diluted losses per share are calculated by adjusting the weighted average number of ordinary outstanding
shares to assume conversion of all dilutive potential ordinary shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(amounts in thousands of euros, except share data) </I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>FOR THE SIX MONTHS<BR>ENDED JUNE&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>BASIC AND DILUTED LOSS PER SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2023&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of outstanding shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,759,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,903,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic and diluted loss per share (&#128;/share)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1.26</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1.45</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since net results for the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2023 and 2022 are
losses, potentially dilutive instruments (BCEs, BSAs, AGAs, Equity lines, BSA Kreos 1, OCEANE) have been excluded from the computation of diluted weighted-average shares outstanding, because such instruments had an antidilutive impact. Consequently,
the diluted losses per share are the same as the basic losses per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 24. Related parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Over the period ended June&nbsp;30, 2023, the Group has not engaged in any transaction with its related parties, other than the compensation paid to the
members of the Company&#146;s Board of Directors and to the Chief Executive Officer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 25. <FONT STYLE="white-space:nowrap">Off-balance</FONT>
sheet commitments given </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 25.1. Commitments under collaboration, research, service provision and licensing agreements granted by the Group
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration, research and development, and licensing agreements, and licensing options related to the &#147;Modulation of RNA
biogenesis&#148; platform. </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Exclusive licensing agreement with the CNRS, the University of Montpellier and the Institut Curie</I></B>
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">On December&nbsp;4, 2008, the French National Centre for Scientific Research (CNRS), the University of Montpellier and
the Institut Curie granted the Company four exclusive licenses. These licenses cover the Company&#146;s use of their technology and products in the field of human and veterinary health relating to the use of synthetic products modifying mRNA
splicing, for research, diagnosis, prevention and treatment of any possible indication. The licensing agreement includes low single-digit royalties based on future net sales to be paid by the Company. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Fsramework agreement for research collaboration to create a cooperative laboratory (ended
December</I></B><B><I></I></B><B><I>&nbsp;31, 2021)</I></B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">On December&nbsp;11, 2008, the Company, the CNRS (French
National Centre for Scientific Research) and the University of Montpellier entered into a research collaboration agreement for a duration of two years in order to conduct a common research program in the fields of screening and development of <FONT
STYLE="white-space:nowrap">anti-HIV</FONT> and antiviral compounds, anti-cancer and anti-metastasis compounds and compounds targeting certain genetic diseases. The term and content of research programs have been changed by successive amendments in
force until December&nbsp;31, 2021. Each party retains ownership of its previously acquired intellectual property rights. The parties are <FONT STYLE="white-space:nowrap">co-owners</FONT> of the research results. Since this agreement ended on
December&nbsp;31, 2021, a hosting agreement was signed with CNRS in 2022, and renewed up until December&nbsp;31, 2023, so that the Company can continue its research program at the CNRS center for the year 2023. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Collaboration agreement with the CNRS, the University of Montpellier, the Company and Evotec</I></B>
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In support of the development of the cooperative laboratory, the CNRS, the University of Montpellier, the Company and
Evotec International GmbH have entered into a collaboration agreement on the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
development of the &#147;Modulation of RNA biogenesis&#148; platform, effective October&nbsp;19, 2018. The molecules generated in the framework of this collaboration are the property of the
Company, the University of Montpellier and the CNRS under the same terms and conditions as the research collaboration agreement on the creation of the cooperative laboratory. The agreement ended on December&nbsp;31, 2021. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Research collaboration contract with the CNRS, the University of Montpellier and the Institut Curie</I></B>
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Concomitantly with the research collaboration framework contract relating to the creation of a cooperative laboratory,
the parties have signed a financial agreement defining the financial terms for the exploitation of patents. This contract was signed on April&nbsp;15, 2009 for a duration of one year and was subsequently renewed up until March&nbsp;31, 2022. In
December 2022, Abivax and the Institut Curie concluded a new contract for a duration of one year, renewable by amendment, granting Abivax access to some of the Institute&#146;s equipment and consumables. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Research and development contract with license option with the CNRS, the University of Montpellier and
Theradiag</I></B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The CNRS, the University of Montpellier, the Company and Theradiag have set up a collaborative project
called CARENA, which has been in operation since February&nbsp;8, 2013. Its purpose is to conduct joint research and development programs in the fields of obesity, HIV and <FONT STYLE="white-space:nowrap">HTLV-1,</FONT> in connection with the
funding obtained through the Bpifrance CARENA project. On February&nbsp;18, 2015, Bpifrance accepted the reorganization of the &#147;CARENA&#148; project proposed by the Company, following the abandonment of the obesity project. At this time,
Theradiag is no longer involved in the collaborative project. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Under the terms of the collaborative project, the Company will have the
exclusive and global exploitation rights to the proprietary results of the CNRS and to those of the University of Montpellier as well as a share of the common results of which the CNRS and the University of Montpellier are <FONT
STYLE="white-space:nowrap">co-owners.</FONT> Furthermore, Theradiag granted the Company an exclusive and global license option for exploitation of its own results as well as a share of the common results of which it will be a <FONT
STYLE="white-space:nowrap">co-owner.</FONT> This option may be exercised by the Company throughout the duration of the contract and within a period of two years after its expiration or cancellation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exclusive licensing contract with &#147;The Scripps Research Institute, University of Chicago and Brigham Young University&#148; with the &#147;Immune
Stimulation&#148; platform (ABX196 product) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;11, 2006, The Scripps Research Institute (La Jolla, California, USA), in agreement with
the University of Chicago (Chicago, Illinois, USA) and Brigham Young University (Provo, Utah, USA), granted the Company an exclusive license in the field of human and veterinary health on its technology and products relating to the use of iNKT
agonists for research, diagnosis, prevention and treatment of all possible indications. In consideration for the licensing rights granted to it under the agreement, the Company must: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay The Scripps Research Institute milestones at different stages of clinical and regulatory development of the
first product (the milestones amount to $50&nbsp;thousand at IND filing, paid in September 2019 and capitalized, $300&nbsp;thousand at Phase 3 and $500&nbsp;thousand at IND approval) and low single-digit royalties for vaccines, diagnostic tests and
therapeutic products, according to the amount of net sales, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">give The Scripps Research Institute, University of Chicago and Brigham Young University an equitable interest in
the Company (as of the date of these financial statements, these three academic institutions hold 0.41% of the Company&#146;s undiluted capital). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The contract shall be terminated at the expiry of the last licensed patent in force in the last country and/or ten years after the last marketing of the
product, service or process derived from the <FONT STYLE="white-space:nowrap">know-how</FONT> or the licensed equipment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 25.2. Commitments under Bpifrance conditional advances </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bpifrance CARENA contract </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the development of
therapeutic and diagnostic solutions targeting alternative splicing and RNA interference in the fields of virology <FONT STYLE="white-space:nowrap">(HIV-AIDS,</FONT> <FONT STYLE="white-space:nowrap">HTLV-1)</FONT> and metabolism (obesity), SPLICOS
(absorbed by the Company on October&nbsp;31, 2014) has entered into a Master Support Agreement with Bpifrance as well as a conditional advance contract in the name of the &#147;CARENA&#148; Strategic Industrial Innovation Project dated
December&nbsp;16, 2013. The Company, acting as project leader for the CARENA project, is associated as part of a consortium contract with Theradiag, a company specializing in in vitro diagnostics and the development of theranostic tests for
monitoring biotherapies, as well as at the CNRS and the University of Montpellier. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CARENA project aims to develop the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HIV-AIDS</FONT></FONT> therapeutic program with the compound ABX464 up to the Phase 2b study, as well as a companion test set up by Theradiag simultaneously with the clinical
development. Beyond the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HIV-AIDS</FONT></FONT> program, the CARENA project should extend its pharmacological investigations to another retrovirus that could be combated by the
same approach: <FONT STYLE="white-space:nowrap">HTLV-1.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is committed to reimbursing the received conditional advances up to
&#128;3,840&nbsp;thousand. The Company will also have to pay an annuity of 50% of the proceeds from the sale of the intellectual property rights resulting from the project, as well as the sale of the prototypes, preproduction and models produced
under the project; the sum due to Bpifrance under this provision will be deducted from the repayment of the conditional advances. In addition, if the advance is repaid under the conditions outlined above, the Company will pay to Bpifrance, over a
period of five consecutive years after the date on which the repayment schedule ends and provided that the Company has reached cumulative <FONT STYLE="white-space:nowrap">pre-tax</FONT> revenue greater than or equal to &#128;50&nbsp;million, an
amount equal to 1.20% of the annual revenue generated from the sale of the products developed as part of the project. This supplementary payment amount is capped at &#128;6,800&nbsp;thousand. The total period, including fixed payments and incentive
payments, is limited to 15 years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bpifrance <FONT STYLE="white-space:nowrap">RNP-VIR</FONT> contract </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In pursuit of the CARENA project, focused on the clinical development of a drug molecule and demonstrating the validity of an innovative therapeutic approach
targeting viral RNPs, the Company has entered into a Master Support Agreement with Bpifrance as well as a beneficiary agreement with conditional advance for the <FONT STYLE="white-space:nowrap">&#147;RNP-VIR&#148;</FONT> structuring research and
development project for competitiveness dated December&nbsp;16, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">RNP-VIR</FONT> project will further the
discovery of new molecules aimed at the treatment of multiple infectious diseases by the development of the antiviral technology platform. The Company, acting as project leader of the <FONT STYLE="white-space:nowrap">RNP-VIR</FONT> project, is
associated in a consortium contract with the CNRS and the University of Montpellier. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is committed to reimburse the received conditional
advances up to &#128;6,576&nbsp;thousand. If applicable, the Company will also have to pay an annuity of 50% of the proceeds from the sale of the intellectual property rights resulting from the project, as well as the sale of the prototypes,
preproduction and models produced under the project. The sum due to Bpifrance under this provision will be deducted from the last payment (and if needed from the previous payments). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the advance is repaid under the conditions outlined above, the Company will pay to Bpifrance, over a period of five consecutive years following the date on
which the repayment schedule ends and provided that the Company has reached cumulative <FONT STYLE="white-space:nowrap">pre-tax</FONT> revenue greater than or equal to &#128;25&nbsp;million, an amount equal to 3% of the annual revenue generated from
the sale of products developed as part of the project. The supplementary payments amount is capped at &#128;5,500&nbsp;thousand. The total period, including fixed payments and incentive payments, is limited to 15 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bpifrance Ebola </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bpifrance and Occitanie Region joint support agreement granted on June&nbsp;2, 2017 consists of conditional advances to the Company for a total amount of
up to &#128;390&nbsp;thousand, based on the success of the program (respectively &#128;130&nbsp;thousand from the Languedoc Roussillon Midi Pyr&eacute;n&eacute;es Region and &#128;260&nbsp;thousand from Bpifrance). In September 2019, the Company
decided to terminate this program, due to the existence of a vaccine in the process of being licensed for this indication as well as changes in the macroeconomic climate for public funding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The reimbursement of the conditional advance is spread until June 2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 25.3. Pledge assets to Kreos </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the
KREOS 1 &amp; 2 bonds, Kreos benefits from first-rate collateral on the Group&#146;s principal tangible and intangible assets, including its commercial fund, intellectual property rights in its principal drug candidates, as well as a pledge of the
Group&#146;s bank accounts and claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;21, 2023, the outstanding Kreos 1 &amp; 2 bond loans were repaid in full, using the proceeds from
the new Kreos / Claret Financing (see Note 3.3). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 25.4. Other commitments related to research and partnership arrangements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the ordinary course of business, the Group regularly uses the services of subcontractors and enters into research and partnership arrangements with various
contract research organizations, or CROs, and with <FONT STYLE="white-space:nowrap">public-sector</FONT> partners or subcontractors, who conduct clinical trials and studies in relation to the drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2023, the Group&#146;s commitments amounted to &#128;187,375&nbsp;thousand. The cost of services performed by CROs is recognized as an
operating expense as incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 25.5. Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The lease for the Group&#146;s corporate headquarters in Paris, France at 5 Rue de la Baume, 75008 Paris ended in August 2022. A new lease for premises at <FONT
STYLE="white-space:nowrap">7-11</FONT> Boulevard Haussmann, 75009 Paris started in July 2022. It has a three-year duration, with a tacit renewal option for approximately two years and the possibility to break the contract one year before the end.
Per Management, renewal and termination options are not reasonably certain. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 26. <FONT STYLE="white-space:nowrap">Off-balance</FONT> sheet
commitments received and contingent assets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The maximum amounts receivable by the Group after June&nbsp;30, 2023 under the <FONT
STYLE="white-space:nowrap">&#147;RNP-VIR&#148;</FONT> and &#147;CARENA&#148; innovation agreements entered into with Bpifrance, subject to the provision of evidence to support the forecast expenses and the achievement of scientific milestones, are
&#128;3,255&nbsp;thousand and &#128;1,853&nbsp;thousand, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 27. Management and assessment of financial risks </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group is exposed to interest rate risk, credit risk, foreign currency risk and liquidity risk. The Group has not identified any significant changes in the
identified risks compared to December&nbsp;31, 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>ABIVAX SA </B></P>
<P STYLE="margin-top:110pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>18,675,500 Ordinary Shares </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>(Including Ordinary Shares in the Form of American Depositary&nbsp;Shares) </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g43a95.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>&#8195;&#8195;&#8195;, 2023 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top" NOWRAP><B>Morgan Stanley</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right"><B>Leerink Partners</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="top" NOWRAP><B>LifeSci Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right"><B>Bryan, Garnier &amp; Co</B></TD></TR>
</TABLE> <P STYLE="margin-top:85pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through and including &#8195;&#8195;&#8195;, 2023 (the 25th&nbsp;day after the date of this prospectus), all
dealers that effect transactions in these securities, whether or not participating in the global offering, may be required to deliver a prospectus. This is in addition to the dealers&#146; obligations to deliver a prospectus when acting as
underwriters and with respect to their unsold allotments or subscriptions. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&#8201;6: INDEMNIFICATION OF DIRECTORS AND OFFICERS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, provisions of <FONT STYLE="white-space:nowrap">by-laws</FONT> that limit the liability of directors are prohibited. However,
French law allows <I>soci&eacute;t&eacute;s anonyme </I>to contract for and maintain liability insurance against civil liabilities incurred by any of their directors and officers involved in a third-party action, provided that they acted in good
faith and within their capacities as directors or officers of Abivax SA. Criminal liability cannot be indemnified under French law, whether directly by Abivax SA or through liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain liability insurance for our directors and officers, including insurance against liability under the Securities Act and we intend
to enter into agreements with our directors and executive officers to provide contractual indemnification. With certain exceptions and subject to limitations on indemnification under French law, these agreements will provide for indemnification for
damages and expenses including, among other things, attorneys&#146; fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding arising out of his or her actions in that capacity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These agreements may discourage shareholders from bringing a lawsuit against our directors and executive officers for breach of their
fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and executive officers, even though such an action, if successful, might otherwise benefit us and our shareholders.
Furthermore, a shareholder&#146;s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these insurance agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors may, through their relationships with their employers or
partnerships, be insured and/or indemnified against certain liabilities in their capacity as members of our Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any underwriting
agreement we enter into in connection with the sale of ordinary shares (including in the form of ADSs) being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who
control us within the meaning of the Securities Act against certain liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&#8201;7: RECENT SALES OF UNREGISTERED SECURITIES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below is information regarding share capital issued and options and warrants granted by us since January&nbsp;1, 2020. None of the
below described transactions involving any underwriters, underwriting commissions, or any public offering in the United States. Some of the transactions described below involved directors, officers and 5% shareholders and are more fully described
under the section of the prospectus titled &#147;Certain Relationships and Related Person Transactions.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuances of Ordinary Shares
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below shows the ordinary shares issued since January&nbsp;1, 2020. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Type of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">operation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Prior Share<BR>Capital (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Premium (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<BR>shares<BR>created</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total<BR>number of<BR>shares after<BR>issuance</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nominal<BR>value&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Share<BR>capital after<BR>transaction&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Issue&nbsp;price<BR>per&nbsp;share&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">07/01/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,019.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,203,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,032.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">11/01/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,032.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,219,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,196.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">16/01/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,196.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,222,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,226.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Type of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">operation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Prior Share<BR>Capital (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Premium (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<BR>shares<BR>created</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total<BR>number of<BR>shares after<BR>issuance</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nominal<BR>value&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Share<BR>capital after<BR>transaction&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Issue&nbsp;price<BR>per&nbsp;share&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">17/01/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,226.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,222,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,226.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">22/01/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,226.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,224,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,240.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">11/02/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,240.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,225,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,256.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">17/03/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-7</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,256.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,228,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,282.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">29/07/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-7</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,282.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,230,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,308.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">30/10/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Conversion of convertible bonds</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,308.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,995,356.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">464,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,695,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,951.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">02/11/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Capital increase through issue of new shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,951.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,983,789.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,620,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,315,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,155.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">09/11/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,155.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,386.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,315,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,159.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">30/11/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,159.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,316,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,166.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">02/12/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,166.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,623.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,318,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,183.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">08/12/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,183.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,320,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,202.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">04/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise&nbsp;of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,202.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,321,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,212.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">05/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,212.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,322,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,220.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">05/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,220.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,324,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,240.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">05/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,240.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,325,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,253.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">07/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,253.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,327,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,273.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">08/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,273.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,343,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,437.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">11/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,437.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,343,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,437.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">12/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,437.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,344,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,447.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">22/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,447.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,346,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,462.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">28/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,462.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,347,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,472.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">28/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,472.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">523,343.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,394,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,942.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">01/02/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,942.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,397,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,972.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">02/02/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,972.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,400,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,002.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">09/02/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,002.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,404,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,042.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">22/02/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,042.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,406,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,062.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">02/03/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,062.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,408,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,085.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Type of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">operation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Prior Share<BR>Capital (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Premium (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<BR>shares<BR>created</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total<BR>number of<BR>shares after<BR>issuance</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nominal<BR>value&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Share<BR>capital after<BR>transaction&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Issue&nbsp;price<BR>per&nbsp;share&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">02/03/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,085.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,810.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,411,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,113.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">03/03/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,113.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,895.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,411,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,117.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">25/05/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,117.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,998,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,531,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,317.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">26/05/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,317.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,249,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,581,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,817.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">31/05/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,817.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">519,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,601,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,017.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">02/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-4</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,017.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,601,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,017.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">03/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,017.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">573,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,623,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,237.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">15/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,237.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,626,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,262.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">24/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,262.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">549,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,646,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,462.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">25/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,462.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,651,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,512.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">29/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,512.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">288,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,661,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,612.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">30/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,612.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">282,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,671,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,712.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">01/07/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,712.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,673,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,732.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">02/07/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,732.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">539,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,693,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,932.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">05/07/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,932.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">944,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,728,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,282.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">22/07/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Capital increase through issuance of new shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,282.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,981,506.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,964,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.692.268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,922.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">06/09/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,922.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,731.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,693,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,933.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">09/09/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,933.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,327.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,696,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,963.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">09/09/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,963.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,696,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,967.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">10/09/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,967.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,292.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,706,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,067.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">20/09/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,067.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,282.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,709,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,097.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">18/10/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,097.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,710,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,107.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">20/10/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,107.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,245.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,713,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,137.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">20/10/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,137.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,005.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,717,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,171.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">25/10/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,171.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,718,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,181.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">25/10/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,181.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,719,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,191.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">30/11/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-2</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,191.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,740,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,401.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Type of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">operation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Prior Share<BR>Capital (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Premium (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<BR>shares<BR>created</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total<BR>number of<BR>shares after<BR>issuance</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nominal<BR>value&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Share<BR>capital after<BR>transaction&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Issue&nbsp;price<BR>per&nbsp;share&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">21/12/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-2</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,401.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214,048.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,764,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,640.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">08/03/2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,640.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,444.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,764,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167.643,85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">30/05/2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167.643,85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,783,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,831.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">07/09/2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Capital increase through issue of new shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,831.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,175,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,530,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,313,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223,131.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">20/01/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2014-4</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223,131.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,331,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223,315.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">27/02/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Capital increase through issue of new shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223,315.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,331,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423,315.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">10/05/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423,315.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,347,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423,479.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">06/06/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2018-KREOS-A</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423,479.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">488,786.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,415,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424,158.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">06/06/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2018-KREOS-b</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424,158.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338,830.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,447,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424,475.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">19/06/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2014-2</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424,475.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,547,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425,475.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">12/09/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of BSA-2014-3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425,475.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,563,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425,639.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">14/09/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of BSA-2014-3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425,639.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,580,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425,803.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transactions described above were
exempt from registration either: (a)&nbsp;under Section&nbsp;4(a)(2) of the Securities Act in that the transactions were between an issuer and sophisticated investors and did not involve any public offering within the meaning of
Section&nbsp;4(a)(2); (b) in reliance on Rule 144A promulgated under the Securities Act in that offers, sales and issuances were made only to &#147;qualified institutional buyers&#148; (as such term is defined in Rule 144A(a)(1); or (c)&nbsp;under
Regulation S promulgated under the Securities Act in that offers, sales and issuances were not made to persons in the United States and no directed selling efforts were made in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuances of Securities Other Than Ordinary Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October 12, 2020, we entered into the Second KC Agreement, pursuant to which we issued bonds in a total principal amount of &#128;15
million, comprised of a &#128;10 million tranche and a &#128;5 million tranche. On August&nbsp;21, 2023, we repaid all outstanding amounts that remained due under such bonds, which are no longer outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July 30, 2021, we issued &#128;25 million 6% convertible senior unsecured and unsubordinated bonds due July&nbsp;30, 2026 corresponding to
654,621 OCEANE bonds. On August 24, 2023, we repaid all amounts due under the OCEANE bonds, which are no longer outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August
31, 2022, we issued &#128;2.9 million in Royalty Certificates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August 21, 2023, we issued (a) 25,000,000 convertible bonds with
warrants attached with an individual nominal value of &#128;1.00 and (b) 214,198 share warrants (BSA) to KC and Claret in connection with the Kreos / Claret Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;24, 2023, we issued 350 convertible notes due 2027 with an individual nominal value of &#128;100,000 to Heights in connection
with the Heights Financing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transactions described above were exempt from registration either: (a) under Section
4(a)(2) of the Securities Act in that the transactions were between an issuer and sophisticated investors and did not involve any public offering within the meaning of Section 4(a)(2); (b) in reliance on Rule 144A promulgated under the Securities
Act in that offers, sales and issuances were made only to &#147;qualified institutional buyers&#148; (as such term is defined in Rule 144A(a)(1)); or (c) under Regulation S promulgated under the Securities Act in that offers, sales and issuances
were not made to persons in the United States and no directed selling efforts were made in the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuances Under Our Equity Plans
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2020, an aggregate of 335,316 ordinary shares were issued upon the exercise of share warrants (BSA) and
founder&#146;s share warrants (BCE) issued under our equity incentive plans, at exercise prices from &#128;0.01 to &#128;11.14 per share, for aggregate proceeds of &#128;1,617,997.53 (including a premium of &#128;1,614,443.37). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2020, 279,262 share warrants (BSA) and founder&#146;s share warrants (BCE) issued under our equity incentive plans were
cancelled or became null and void. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also issued on September&nbsp;21, 2021, 155,000 free shares allocated to employees. However, such
free shares became void in accordance with the terms of the free share plan. We further allocated on July 11, 2023, (i)&nbsp;1,382,796 free shares to Mr. Marc de Garidel and (ii) 100,000 free shares to Dr. Hartmut Ehrlich. The issuance of these
shares is subject to the achievement of specific performance and/or service conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offers, sales and issuances of the securities
described in the preceding paragraph were exempt from registration either: (a)&nbsp;under Section&nbsp;4(a)(2) of the Securities Act in that the transactions were between an issuer and members of its senior executive management and did not involve
any public offering within the meaning of Section&nbsp;4(a)(2); (b)&nbsp;under Rule 701 promulgated under the Securities Act in that the transactions were under compensatory benefit plans and contracts relating to compensation; or (c)&nbsp;under
Regulation S promulgated under the Securities Act in that offers, sales and issuances were not made to persons in the United States and no directed selling efforts were made in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&#8201;8. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(a) Exhibits </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exhibits to the
registration statement are listed in the Exhibit Index to this registration statement and are incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following exhibits are filed herewith or incorporated herein by reference. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT<BR></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>DESCRIPTION OF
EXHIBIT</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;1.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.1+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex31.htm"><FONT STYLE="white-space:nowrap">By-laws</FONT> (<I>statuts</I>) of the registrant (English translation) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1472033/000119380523001353/e618972_ex99-a.htm">Form of Deposit Agreement (incorporated by reference to Exhibit (a) to the Form F-6 Registration Statement (File No. 333-274845), filed with
 the Commission on October 3, 2023) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1472033/000119380523001353/e618972_ex99-a.htm">Form of American Depositary Receipt (included in Exhibit 4.1) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;5.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d609070dex51.htm">Opinion of Dechert (Paris) LLP as to the validity of shares </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex101.htm">OCABSA Issue Agreement between Abivax SA and Kreos Capital VII (UK) Limited and Claret European Growth Capital Fund III SCSp dated August&nbsp;20,
 2023 </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT<BR></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>DESCRIPTION OF
EXHIBIT</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex102.htm">Subscription Agreement between Abivax SA and Kreos Capital VII (UK) Limited, Kreos Capital VII Aggregator SCSp, Claret European Specialty
 Lending Company III, S.&agrave; r.l., Claret European Growth Capital Fund III SCSp dated August&nbsp;20, 2023 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex103.htm">Tranche A-B Warrants Issue Agreement between Abivax SA and Kreos Capital VII Aggregator SCSp and Claret European Growth Capital Fund III SCSp
 dated August&nbsp;20, 2023 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex104.htm">Tranche A-B Put Option Agreement between Abivax SA and Kreos Capital VII Aggregator SCSp and Claret European Growth Capital Fund III SCSp
 dated August&nbsp;20, 2023 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex105.htm">Subscription Agreement between Abivax SA and CVI Investments, Inc. dated August&nbsp;20, 2023</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex106.htm">Intellectual Property Rights Pledge Deed between Abivax SA and Kreos Capital VII (UK) Ltd dated August&nbsp;20, 2023 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex107.htm">Terms and Conditions of the Royalty Certificates issued by Abivax SA dated August&nbsp;31, 2022 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex108.htm">Drug Discovery Services Agreement between Abivax SA and Evotec International GmbH dated September&nbsp;1, 2017 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex109.htm">Amendment No. 1 to Drug Discovery Services Agreement between Abivax SA and Evotec International GmbH dated January 1, 2022
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex1010.htm">Manufacturing Agreement between Abivax SA and Delpharm Lille S.A.S. dated November&nbsp;24, 2016 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex1011.htm">Clinical Batch and Development Production Agreement between Abivax SA and Produits Chimiques Auxiliaires et de Synth&egrave;se dated March&nbsp;11,
 2016 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex1012.htm">Amendment No. 1 to Clinical Batch and Development Production Agreement between Abivax SA and Produits Chimiques Auxiliaires et de Synth&egrave;se
 dated March&nbsp;2, 2021 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex1013.htm">State-guaranteed loan agreement between Abivax SA and Soci&#233;t&#233; General dated June&nbsp;16, 2020 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex1014.htm">Amendment No.1 to State-guaranteed loan between Abivax SA and Soci&#233;t&#233; General dated March&nbsp;15, 2021 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex1015.htm">Royalties Agreement with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie dated
 December&nbsp;18, 2008 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001956827/000119312523247378/d609070dex211.htm">List of subsidiaries of the registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d609070dex231.htm">Consent of PricewaterhouseCoopers Audit </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d609070dex51.htm">Consent of Dechert (Paris) LLP (included in Exhibit&nbsp;5.1) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1+</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1956827/000119312523247378/d609070df1.htm#sig">Power of attorney (included on signature page) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d609070dexfilingfees.htm">Filing fee table </A></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">*</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Previously filed </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment has been requested with respect to certain portions of this exhibit. Omitted portions
have been submitted separately to the Securities and Exchange Commission. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(b) Financial Statement Schedules </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All information for which provision is made in the applicable accounting regulations of the Securities and Exchange Commission is either
included in the financial statements or is not required under the related instructions or is inapplicable, and therefore has been omitted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&#8201;9. UNDERTAKINGS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement,
certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the registrant pursuant to the provisions described in Item 6 hereof, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the
Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the
registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the
matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For purposes of determining any liability under the Securities Act, the information omitted from the form of
prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of
this registration statement as of the time it was declared effective. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the purpose of determining any liability under the Securities Act, each post-effective amendment that
contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of
the requirements for filing on Form <FONT STYLE="white-space:nowrap">F-1</FONT> and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Paris, France, on October 16, 2023. </P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Abivax SA</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>By:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>/s/ Marc de Garidel</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc de Garidel</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, this amendment no. 1 to the
registration statement has been signed by the following persons in the capacities indicated on October 16, 2023. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>SIGNATURE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>TITLE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Marc de Garidel</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer and Chairman of the Board</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(<I>Principal Executive Officer</I>)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc de Garidel</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Didier Blondel</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer and Board Secretary</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(<I>Principal Financial and Accounting Officer</I>)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Didier Blondel</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corinna zur Bonsen-Thomas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"><FONT STYLE="font-size:10pt">Director, and Member of the Audit Committee and the Appointments and Compensation Committee</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Carol L.
Brosgart</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sofinnova
Partners, represented by Kinam Hong</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director and Member of the Appointments and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Compensation Committee and the Audit Committee</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Troy
Ignelzi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director and Chair of the Audit Committee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">June
Lee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director and Chair of the Appointments and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Compensation Committee</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sant&#233;
Holdings SRL, represented by Paolo Rampulla</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Truffle
Capital, represented by Philippe Pouletty</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director and Member of the Appointments and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Compensation Committee</P></TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="50%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">*By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc de Garidel</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#8194;Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Marc de Garidel</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#8194;Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attorney-in-fact</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature of Authorized U.S. Representative of Registrant </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the
undersigned, the duly authorized representative in the United States of Abivax SA has signed this registration statement on the 16th day of October, 2023. </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Marc de Garidel, Authorized Representative in the United States</TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">By:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc de Garidel</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-10 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d609070dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">October&nbsp;16, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Abivax S.A. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">7-11</FONT> boulevard Haussmann </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">75009 Paris </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">France </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are acting as special French counsel
to Abivax S.A., a <I>soci</I><I>&eacute;</I><I>t</I><I>&eacute;</I><I> anonyme</I> organized under the law of France (the &#147;<B>Company</B>&#148;), in connection with the offering and sale by the Company of (i)&nbsp;up to 18,675,500 ordinary
shares of the Company, which may be delivered in the form of American Depositary Shares (the &#147;<B>ADSs</B>&#148; ), with a par value of &#128;0.01 per ordinary share (the &#147;<B>New Shares</B>&#148;), and (ii)&nbsp;up to 2,801,325 ordinary
shares of the Company (which may be delivered in the form of ADSs) (the &#147;<B>Option Shares</B>&#148;, together with the New Shares, the &#147;<B>Offered Shares</B>&#148;), to the several underwriters (the &#147;<B>Underwriters</B>&#148;)
pursuant to the Underwriting Agreement and the Registration Statement (as these terms are defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In rendering the opinion expressed below, we
have examined and relied on originals or copies, certified or otherwise identified to our satisfaction, of such agreements, corporate records and other instruments and such documents, certificates and receipts of public officials, certificates of
officers and other representatives of the Company and others, and such other documents as we have deemed necessary or appropriate as a basis for rendering the opinion set forth below, including the following documents: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the registration statement on Form <FONT STYLE="white-space:nowrap">F-1,</FONT> as amended (Registration N<U><SUP
STYLE="font-size:75%; vertical-align:top">o</SUP></U> <FONT STYLE="white-space:nowrap">333-274780),</FONT> with respect to the Offered Shares filed by the Company with the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) under
the Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;) (such registration statement, as amended, including information deemed to be a part of such registration statement at the time of effectiveness pursuant to Rule 430A
promulgated under the Securities Act, being hereinafter referred to as the &#147;<B>Registration Statement</B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the terms and conditions of an underwriting agreement proposed to be entered into by and among the Company,
Morgan Stanley&nbsp;&amp; Co. LLC and Leerink Partners LLC (the &#147;<B>Underwriting Agreement</B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the terms and conditions of a deposit agreement proposed to be entered into by and among the Company, Citibank,
N.A., as depositary (the &#147;<B>Depositary</B>&#148;) and all Holders and Beneficial Owners of ADSs issued thereunder (the &#147;<B>Deposit Agreement</B>&#148; and, together with the Underwriting Agreement, the &#147;<B>Transaction
Documents</B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an<I> Extrait <FONT STYLE="white-space:nowrap">K-bis</FONT></I> of the Company delivered by the clerk of the
Commercial Court of Paris, dated October&nbsp;13, 2023 (the &#147;<B><FONT STYLE="white-space:nowrap">K-Bis</FONT></B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a<I> Certificat en mati&egrave;re de proc&eacute;dures collectives </I>for the Company delivered by the clerk
of the Commercial Court of Paris, dated October&nbsp;14, 2023 (the &#147;<B>Good Standing Certificate</B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an<I> Etat de Privil&egrave;ges et des Nantissements </I>(Security report (Preferential rights and Pledges)
issued by the <I>Greffe du Tribunal de Commerce </I>(Registrar of the Commercial Court) of Paris in respect of the Company dated October&nbsp;13, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a certified copy of the <FONT STYLE="white-space:nowrap">By-laws</FONT> (<I>statuts</I>) of the Company updated
as of September&nbsp;28, 2023 (the &#147;<B><FONT STYLE="white-space:nowrap">By-laws</FONT></B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the minutes of the resolutions of the shareholders&#146; meeting of the Company dated June&nbsp;5, 2023 (the
&#147;<B>Shareholders</B><B>&#146;</B><B> Resolutions</B>&#148;) authorizing the issuance of the Offered Shares under resolutions no. 15 and 19; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the minutes of the decisions of the board of directors of the Company dated October&nbsp;12, 2023 deciding on
the start of the roadshow. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(hereinafter referred to as the &#147;<B>Examined Documents</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As to the facts upon which this opinion is based, we have relied, with your consent, upon the foregoing and upon certificates of public officials and
certificates and written statements (including the representations and warranties made in the Transaction Documents) of officers, management board members, members of the board of directors, employees and representatives of, and accountants and
auditors for, the Company, and the due performance by the parties of their respective obligations set forth in the Transaction Documents, and we have assumed, in this regard, the truthfulness of such representations. We have not independently
established the facts so relied on. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to
us as original documents and the conformity to original documents of all documents submitted to us as copies. In addition, we have assumed that (i)&nbsp;all natural persons who are signatories to the Transaction Documents have the legal capacity and
competence to enter into and perform their respective obligations under the Transaction Documents; (ii)&nbsp;each of the parties to the Transaction Documents (other than the Company) is duly organized, validly existing and in good standing under the
laws of the jurisdiction of its organization; (iii)&nbsp;each of the parties to the Transaction Documents (other than the Company) has the requisite power and authority and has taken the legal action necessary to enter into and perform all of its
respective obligations thereunder and to consummate the transactions contemplated thereby; (iv)&nbsp;the Transaction Documents have been duly authorized, executed and delivered by each of the parties thereto (other than the Company); (v) that the
Company&#146;s board meetings and shareholders&#146; meeting were and will be duly convened and held, the required quorum were and will be, in each event, duly satisfied, and the directors were duly appointed and were and will be validly exercising
their term of office; (vi)&nbsp;the Company will issue and deliver the Offered Shares in the manner contemplated in the Underwriting Agreement and the issue of the Offered Shares, as a result of the offering will remain within the limits of the then
authorized but unissued amounts of ordinary shares in the resolutions of the extraordinary shareholders&#146; meeting and the Board; (vii)&nbsp;the offering restrictions contained in the Underwriting Agreement and the Registration Statement have
been and will be complied with; (viii)&nbsp;the Underwriting Agreement constitutes a valid, binding and enforceable obligation of each party thereto under all applicable laws, in particular the laws of the State of New York by which they are
expressed to be governed; (ix)&nbsp;all required authorizations of any kind (including corporate, legal, regulatory, governmental, contractual, etc.), other than with respect to the Company, have been validly and unconditionally obtained by any
appropriate means by each signatory, and were valid under the laws that govern its legal existence; (x)&nbsp;that the execution of the Transaction Documents by the Company and the performance of its obligations thereunder was serving their corporate
interests (<I>conforme &agrave; son int&eacute;r&ecirc;t social</I>); and (xi)&nbsp;that no decision, proceedings, filing or request relating to any proceedings set out in Book VI of the French Commercial code (<I>Livre VI du Code de commerce</I>)
has been taken, initiated or filed against the Company between the date of the Examined Documents and this opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have further assumed that there
has been no oral modification of, or amendment or supplement (including any express or implied waiver, however arising) to, any of the Examined Documents or any other documents or instruments used by us to form the basis of the opinion expressed
below and that such documents are in full force and effect at all times at which the Offered Shares are issued offered or sold by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
opinion is rendered by us as lawyers before the Paris Appeal Court and is furnished to you in connection with the legal matters enumerated below, speaks only as of the date hereof and is limited to the laws of France as in effect on the date hereof
as currently construed by the French <I>Conseil Constitutionnel</I>, <I>Cour de Cassation</I> and <I>Conseil d&#146;Etat</I> in their decisions as published in major legal journals. We do not express any opinion as to any laws other than French laws
as in effect on the date hereof. We express no opinion as to matters of facts. We did not establish or verify the accuracy of facts or the reasonableness of any statement or intention contained in the Examined Documents, or verify that no
substantial fact or contractual stipulation has been omitted from the Examined Documents. We express no opinion as to tax matters. We have not undertaken to advise you of any subsequent changes in French law, in the legal status of the Company or
any other fact, which hereafter may come to our attention and would be likely to affect the matters evoked herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the basis of the foregoing and such
examination of law as we have deemed necessary, and subject to the assumptions, limitations and qualifications set forth in this letter, we are of the opinion that the Offered Shares, when issued by the Company in accordance with the
Shareholders&#146; Resolutions and the decisions of the Board, pursuant to, and in accordance with, the Underwriting Agreement, upon payment of the consideration provided therein to the Company and issuance of the depositary certificates
(<I>certificats du d&eacute;positaire</I>) in respect of each of the Offered Shares, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The opinion expressed above is subject to the following qualifications: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This opinion is subject to the effect of any laws or regulations relating to bankruptcy, insolvency,
moratorium, <I>ad hoc</I> mandate (<I>mandat ad hoc</I>), conciliation, accelerated judicial safeguard (<I>proc&eacute;dure de sauvegarde acc&eacute;l&eacute;r&eacute;e</I>), judicial recovery proceedings (<I>redressement judiciaire</I>) or judicial
liquidation proceedings (<I>liquidation judiciaire</I>), <FONT STYLE="white-space:nowrap">winding-up,</FONT> or any other analogous proceedings or circumstances and, as a general rule, subject to the effect of any laws or regulations amending and/or
protecting the creditors&#146; rights. In particular, we do not express any opinion herein as to the enforceability and effectiveness of rights, obligations or recourses of any party to the Examined Documents in the event where one of the
proceedings set out in Book VI of the French Commercial code (<I>Livre VI du Code de commerce</I>) would be initiated, or any other similar proceedings would be initiated in a foreign jurisdiction. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">It should be noted that any such event affecting the Company does not necessarily give rise to immediate
formalities at the relevant Register of Commerce and Companies (<I>Registre du Commerce et des Soci&eacute;t&eacute;s</I>) and that, once such formalities have been carried out, they are not necessarily recorded immediately on the <FONT
STYLE="white-space:nowrap">K-bis</FONT> or the Good Standing Certificate, which are accordingly not conclusive as to the occurrence of any such event. It should also be noted that the opening of <I>ad hoc</I> mandate (<I>mandat ad hoc</I>) or
conciliation (<I>conciliation</I>) proceedings never appears on such document. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This opinion is subject to French courts&#146; sovereign powers of interpretation of agreements (to find out
the original intention of the parties when it has not been clearly stated) and appreciation of facts. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is addressed to you
solely for your benefit in connection with the Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is not to be transmitted to anyone else nor is it to be relied upon by anyone
else or for any other purpose or quoted or referred to in any public document (other than the Registration Statement) or filed with anyone without our prior written express consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing with the U.S. Securities and Exchange Commission of this opinion as Exhibit 5.1 to the Registration Statement and to the
reference to Dechert (Paris) LLP under the caption &#147;Legal Matters&#148; in the prospectus constituting a part of such Registration Statement. In giving such consent, we do not thereby admit that we are included in the category of persons whose
consent is required under Section&nbsp;7 of the Securities Act of 1933, as amended, or the rules and regulations of the U.S. Securities and Exchange Commission promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is governed by French law and must be construed in accordance with French law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dechert (Paris) LLP </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d609070dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use in this Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> of ABIVAX SA of our report dated<B><SUP
STYLE="font-size:75%; vertical-align:top"> </SUP></B>July&nbsp;28, 2023 relating to the financial statements of ABIVAX SA<B></B>, which appears in this Registration Statement. We also consent to the reference to us under the heading
&#147;Experts&#148; in such Registration Statement. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers Audit </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Neuilly-sur-Seine,</FONT></FONT> France </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;16, 2023 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>d609070dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Tables </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT STYLE="white-space:nowrap">F-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Abivax SA </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Table 1: Newly Registered and Carry Forward Securities </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Security<BR>Type</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Security</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Class</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Title</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Fee<BR>Calculation<BR>or Carry<BR>Forward<BR>Rule</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Amount<BR>Registered</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Proposed<BR>Maximum<BR>Offering<BR>Price Per<BR>Share</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Maximum</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Aggregate</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Offering</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Price&nbsp;(2)(3)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Fee</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Rate</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">Amount of<BR>Registration<BR>Fee&nbsp;(4)</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="17" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="17" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt">Newly Registered Securities</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fees to Be</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Ordinary Shares, par value &#128;0.01 per share<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">457(o)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$287,502,856</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$0.0001476</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$42,435.42</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="10" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Total Offering Amounts</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$287,502,856</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$42,435.42</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="10" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Total Fees Previously Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">$11,020</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="10" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Total Fee Offsets</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#151;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="10" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">Net Fee Due</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">$31,415.42</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All of the offered ordinary shares will be in the form of American Depositary Shares, or ADSs, in the offering
in the United States. Each ADS represents the right to receive one ordinary share and the ADSs may be evidenced by American Depositary Receipts, or ADRs. ADSs or ADRs issuable upon deposit of the ordinary shares registered hereby will be registered
pursuant to a separate registration statement on Form <FONT STYLE="white-space:nowrap">F-6.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes the additional ordinary shares, which may be represented by ADSs, that the registrant may issue at the
option of the underwriters. See &#147;Underwriters.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes ordinary shares that are being offered in a private placement in Europe (including France) and
countries outside of the United States but which may be resold from time to time in the United States in transactions requiring registration under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), or pursuant to an exemption
therefrom. The total number of ordinary shares in the United States offering and the private placement outside of the United States is subject to reallocation among them. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(o) under
the Securities Act. </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g609070g00a15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g00a15.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X4H_:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/F<P,&$Q-3PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @
M(" @(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE
M($YA;64Z(" @(" @(" @(" @(" @9S P83$U+F%I)B-X03M5<V5R;F%M93H@
M(" @(" @(" @(" @($1E;'1A)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @
M(" R-RU*=6PM,C R,R P-3HU,3HQ-28C>$$[15-4(%1I;64Z(" @(" @(" @
M(" @(" R-BU*=6PM,C R,R R,#HR,3HQ-28C>$$[4V-R:7!T(%9E<G-I;VXZ
M(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP
M+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X
M03OB@*(@-"!H86ER;&EN92!R=6QE<R!C:&%N9V5D('1O(# N,C4N)B-X03LF
M(WA!.^* HB Y-R!B;&%C:R!T97AT(&-H87)A8W1E<G,@8VAA;F=E9"!T;R!O
M=F5R<')I;G0N)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R
M97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @(%1I;65S+4)O
M;&0F(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@
M:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($)L86-K)B-X03L@(" @
M(" @(" @0STR,"!-/3$V(%D],38@2STP)B-X03L@(" @(" @(" @0STR-2!-
M/3(P(%D],C @2STP)B-X03L@(" @(" @(" @0STT($T],B!9/3(@2STP)B-X
M03L@(" @(" @(" @0STX.2!-/30X(%D],C,@2STS)B-X03L@(" @(" @(" @
M0STW-R!-/3(U(%D]-"!+/3 F(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z
M(" @(" @(" @(" @(" @9S P83$U+G!D9B8C>$$[57-E<FYA;64Z(" @(" @
M(" @(" @("!$96QT828C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,#<M
M4V5P+3(P,C,@,#$Z-#$Z,3 F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @
M,#8M4V5P+3(P,C,@,38Z,3$Z,3 F(WA!.U-C<FEP="!697)S:6]N.B @(" @
M(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X
M03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[XH"B
M(#$Q,"!B;&%C:R!T97AT(&-H87)A8W1E<G,@8VAA;F=E9"!T;R!O=F5R<')I
M;G0N)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@
M:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($%R:6%L350F(WA!.R @
M(" @(" @("!!<FEA;"U";VQD350F(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C
M;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @
M(" @($)L86-K)B-X03L@(" @(" @(" @0TU92R8C>$$[)B-X03LM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!
M.SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO
M9&,Z9&5S8W)I<'1I;VX^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @
M(" @(" @('AM;&YS.GAM<$=);6<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]G+VEM9R\B/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(S
M+3 Y+3 W5# Q.C0Q.C(R*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @
M(" @(" \>&UP.DUO9&EF>41A=&4^,C R,RTP.2TP-U0P,3HT,3HR,BLP-3HS
M,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR
M,#(S+3 Y+3 W5# Q.C0Q.C(Q*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @
M(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R871O<B!#4S8@
M*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z5&AU
M;6)N86EL<SX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z=VED=&@^"B @
M(" @(" @(" @(" @(" @(#QX;7!'26UG.FAE:6=H=#XU,CPO>&UP1TEM9SIH
M96EG:'0^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.F9O<FUA=#Y*4$5'
M/"]X;7!'26UG.F9O<FUA=#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G14),045S04%$+S=107-51VAV9$<Y
M>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!04%"04),04%!04%%028C>$$[05%%
M<T%!04%!44%"+RLT041K1FMB,DIL04=404%!04%!9B]B04E104)G445"055%
M0F=51D)G:T="45E*0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!341!=TU$07=1
M1$$T4$5!.$]$0DU41D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF2'=%2$)W8TY$
M03!914)!64=H55)&4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF+SA!0451
M9T%.045!07=%4B8C>$$[04%)4D%135)!9B]%06%)04%!04A!445"05%%04%!
M04%!04%!04%11D%W24=!44%(0T%K2T-W14%!9TE$05%%0D%114%!04%!04%!
M028C>$$[05%!0T%W449"9V-)0U%O3$5!04-!44U$06=10T)G8T1"04E'06Y-
M0D%G35)"04%&25))>%%614=%,D5I8UE%54UP1VA">%=X46E00B8C>$$[571(
M:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD55I(5$0P=4E)
M2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4,%I85T9L85<Q
M>&18;#E76C)H<&%M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM
M2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+5VUP-FEP<7%U
M<W)A-G9O4D%!24-!44E$0E%514)1645#04U$8E%%04%H141"0T53355%1E52
M3FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*1%)$9VAA4U5Y
M5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X<4]Z=WEG
M<"8C>$$[,"M0>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L6FUD;V%7<')B
M1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;R8C>$$[*T1L
M2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O84%!=T1!44%#
M15%-4D%$.$$Y531Q-T9867$W1EA9<3=&6%EQ-R8C>$$[1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ>#,X=W8K54\Q3"]55"]K-FU7-&9R1%AL*VMV0W,R3&A/
M>%9/=DLQ;F]&>F141%<U<$E,6B8C>$$[141).&%S,5A$9VQ4>%9U<4)V,358
M:TUG3FUY04(U;VY79% X<E(V5S R;E13=F0O=5-%261O>7 U0U%H:6EF=%5'
M+S!6<G-)>6QE-B8C>$$[6D-.8DUC>3%Q9&EQ<&(O-S!29C8V+W)X1$](,4)0
M36TW1C)+;S=28F5W=4PY63<Y,VIT4W)C<$5"66AU2D-B2T-F=%5Y1U%K1&)M
M<28C>$$[8E@Q:C53*V\S36QL4$Y*8TQY*W)Q4317;V-F-49.:SA337)J2V1I
M,$UB>3E,<U9D:7(S9DY-=V1I<G-69&ER<U9D:7)S5F1I<G-69"8C>$$[:7)S
M5F1I<G-69&ER<U9D:7)S5EDW*UE8+TM(86PO<4HO=T%N57DS1#E983AV,&PT
M5FUX8THR2W-P.&U8,G4R5FQQ;'AP:V1V2D5G:B8C>$$[3GE,:7!0,DI1;U%!
M:G-72BM753510U)B8FI*1C!N,G9N6#(P5R]%:VQT3$%I>7<S1%%F5T966&IN
M2$Y1<DAG1'1T=#!"1U9W-&)$6B8C>$$[2S9,>FI-<'AN67%Q5R\X07921B]R
M<BMV14TT9E5%.'EB<UA9<6YV;$\T,5,S=4QQ8E0P:60T-&5C;VUR5&=R<61Q
M9'E25$MC=T)!="8C>$$[0EI$-C)U5%=%>FAR9&ES3%!.2$@V>6-"2F)",7%!
M46XR1#$O;7!L1E)"-B]G;UE$;6%Y9&ER<U9E<#9T-2LX<C929%-7=7!A;F(R
M="8C>$$[>D1%2C596&(T;&I*0VAI0E=M-4=A6F=R4BMD4$QS:D]Q87!A3C9A
M.#)0<DIX-&=%;&<Q845!2V$P-F0X5F1&-3$X=5-X<$MM<5=F0R8C>$$[475)
M>5IK6&PV8W)1=%1K4E5#4TYL<C1J1E9.9E!F;%9P,V=85TQ%>7AQ<G50<D5D
M07(X=4\O2VXW1$A&5CA8;F)Y,TMR36UQ,EI#;B8C>$$[:5-:;WAV6&IT56EO
M<C!0431Q;3,Q<"]!67$W-C O9TU69#EA9G='2W4K=% T1$989E=N.$)I<G9R
M5"M!>%8S,7 O05EQ-S8P+V=-5B8C>$$[9#EA9G='2W4K=% T1$989E=N.$)I
M<G9R5"M!>%9$86I"8C9L6E,R5C5(-FQT34%*17%6<E%H:'5P0C9J2E)*0G-)
M279::B\O04-R,R8C>$$[>68X03AS0B\U2%1F.#$U6C0X*SEH-%589CAQ.3AN
M+SAS0B\U2%1F.#$T*U!0=EAW;W!8<"MK+VQB9G1.2%EY=U1M1TUZ5&5N9%-%
M3"8C>$$[17!+;'EE9$])<'5F-FI(>#4Y-BM&1E5G6#AT8GDV=7)72SA75S1A
M1U,T=EDO<F,Y9E)I:R]E=DQ6-E575#=83&]C2&EY6'=W:4Y/."8C>$$[;BM1
M9%-T179,0S-7-71:2SA*634U:7!O84@Y=G-2:#AE9F5V:%)22"]+=F9*+SA!
M>7=(+T%*2%1F.#$T*U!0=EAW;W)L+TPO04UO<28C>$$[=UE70G%P<5 S,#-5
M9C=02'@U.39J1D5++W=$9S=Y,2]Y>"\X;%IF*V%S4#5I9F4R,C<O0C-L<B]!
M2EDO*U-S=B].5U U:69E='!F3B8C>$$[66513&4K;7-*5VEJ=EE94E!.8FUE
M44]):7=13E1L+TUY:6YU4$59+VU*.38R:#$Q8CAS+U)U8FAD4V@Y2S)I:E<U
M:T8S3%)9<&=%428C>$$[2#0O<W-V154X2V1I34AJ4U)A6C)N;&YY:F57,&0Q
M87=,3F)Z2TAI;%-A47%Y;G5#1W<O;4HY-F)69CA!0C-L<B]L:B]!3U-S=B].
M5R8C>$$[4#5I9F5T=2]W9#5A+W=#5U O:W),+WI6:BM9;C-R84<X=V9L8C57
M.'=83C%C-G!A=DQ*95)#0S568FEE3DA68559>&\V<'IO;TA/;B8C>$$[2VTQ
M85I3:$HT9CA!;D@O.'1O4DE)=$Q:4%9H3G9)5G5B9T9O;5)9>7!)97!&14@P
M-S1Q<3-N-45F;#5E5T5.:&,V63!L=D%Q<D5$8R8C>$$[5&AG1FUN;BLP2$(O
M=DQY52]4-T1!<6U0>4(O3&M--5A46%@Q3V9,:F,S02]V0DMR9$@X3&@X2W5F
M.&=0>3)K4D5K,'1N16-*=# U6"8C>$$[335)4F=1845V,4E06')I<E O<3!V
M=&=6,S%A6#)X5C,Q85@R>%8S,6%8,GA6,S%A6#)X5C,Q85@R>%8S,6%8,GA6
M,S%A6#)X5C,Q828C>$$[6#)X5C,Q85@R>%8S,6%8,GA6,S%A6#)X5C,Q850R
M>%8S,6%8,GA6,S%A6#)X5FIA9FQN-5I23E173S!+1%8W86$P=F%3>4=S5GE3
M6B8C>$$[94E9:TM7<4YX-$1W=W%G-&9Y9#AL4BMO5%EC:D]J>#-)37-G5U%3
M='IL-4ER0E!J3F$P2&,T,G%E95A02VQL-68P,61/,#A-3%I76B8C>$$[;$5J
M;#)&84%,53EL54)2.'9(1E4P*W)3*S)"6&96<&9B1EAF5G!F8D989E9P9F)&
M5T\V,RM84&PO5V(R92]V3&5T+V-1=S)Z,TMS928C>$$[46IT-VA,<4Y11%9F
M-S9*5T\R.4U+<&5N-4UE4FMS8G%W:C X>#)D-'%*8S(V6$4T4C%J;T9"2% O
M25@O04E%94=+<VTP:E%O.4PP*R8C>$$[3WET>5=J:DQS6&,Q6FYK8WE/>&]!
M2W,W13=9<6I0<3!V=&=6,S%A6#)X5C4S-7 O2S-Z9'%F;E,O=T1-5VME8G!T
M2&IU-U)B94<Q:B8C>$$[4C)%8F]%*U K.%945FMQ9FAX5D-79C55+VU08D=,
M:"M91G=61&E3-%@P6"]!2')M-$5S:DXK*S(U2E9F:#AF0V="5G$X+TQ0.#%8
M=28C>$$[9$U64%!K<VQQ;$DY4T)2,$QO1FM*8TM*1S5->D925&M/<#9H5EA&
M55A.*U=(;F@Y170W2U!Z<$Y(9C)J,TIG,4)9,T1I3UI9>$9(428C>$$[4SE)
M=E10>D(X86MQ;TLS+T%#=R].5FQV5G50>D%U1B]E57-'5EA0-W170D)K+V5+
M87-P2T5!.756831Q:6(W.')F>D9M=6)I5S,O328C>$$[5R]I:FM76#!9=E1&
M161N2'!(6F=31E%B:F)F,DI"0V]D=GEK+TU75C=L8FXX=W)Y-'1*56Q33S)+
M>4E!6&I#>&QM4UE/94IQ4TLW+R8C>$$[04@T5F5T2CA+2T-A:T%!;B]B2G=+
M,U5E3TMU<5!(1EA62&II<G%J>'A6,5(T-'$V;SAC5F1594]+=7%02$985DAJ
M:7)Q:GAX5C%2-"8C>$$[-'$V;SAC5F5F,U@U9&$V=7)A<G%6;'(P;U<Y=')I
M1T-Z:V%A:7903UIT-41),49O94%+<E9E,U-M1S%3;3(O2T1Z6D)P*W-7:2MD
M3"8C>$$[:'!D5VAK:$XV,%1'84U03DI-3THY6&E0=&A354,Q57-.<4QX5F5H
M95=R1%5.4#!E2S$Q1S5&>F-R2D\O345K3$A*3SAK55%*04I%528C>$$[5$Q'
M1#,T-$944V\X8U9D565/2W5Q4$A&6%9(:FER0W9-;FMN6'(O6&(S5CE.,3)7
M,"MS,E5&;6QH52MK4%1U-#4U5TI*64%Y4E)T1B8C>$$[.6YB;7@X87%S9FHO
M04-G.#!2-E9Q9&@O:D<T;&LQ0T\S:E<W9%IF5FHY1&EA:6MW5W!+5C9D5V5V
M6$1A=E%V3&1H96%F;VQT6C-S+R8C>$$[<C-%25E-+TIN;W!C<VEC,RM*=E11
M:$]2,TY+-$943V\X8U9D565/2W9,=D\S-6<K83E$,4\K=&1-.'93-FA$83)Q
M>G=Y3$AC=C9Z;"8C>$$[;$)#=$A'67%$:U)X-3@V:71+8C164WDQ+T]J6#5$
M3S S:V96;V\P='I.141$25-Z<D@V;G!60TAD=5-J9%%"=C%P:7%T2BMB,VU+
M1"8C>$$[5&)7-V9Y5G%D>3EX571&8F\O2TU09#--15-L5VIR6# W5EAB+UA8
M<V$T<6<T9GHU=C4T-3)T+TI7<C-$,GA26FMI:F,X2D=G13=2="8C>$$[5TYA
M3V]98E4S1E0O04,X;%4P,'HX,G18=DY9=#E.:SAM87)B*W1D5SER2F-T1S-P
M4FED5TQY<WI2;T]-9DAF9G Y>%9E:EEQ-T98628C>$$[<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T97>&ER5TMU>%9G."]N=GI$839N<61V8S9'>3)L;&(S33A6
M,'9R1TYM:6Y72TQL25DQ5&DX8B8C>$$[1C)P=71$<U)V:7%7-F(K6EAN4S1S
M3E-L=69+,'-6,6$R13$S6GAH8F=,3E!%,'1)3C1U65IK:$I(=S=N64@T:%)6
M;E!L+U97,5A41B8C>$$[=D=I.4IJ3%!#4E=Q=#E8;F5(,4509$I05#5P+VMK
M67%M3TMU>%8R2W5X5FDQ.35O,2LP,38W=$1O-6PP>3)I;&Q3-VEA4FYK.4\S
M128C>$$[>7%"=T-66BM39F$X4$A:5FEU;"]M<C5X=5ID45<T.'-30T<R9VQL
M<S=I2T\V84]C9VM28T<Y23AG9FAR5')Y1DYH57%S,CAL*UEB>B8C>$$[6'1'
M1C5E5UIS<FQ:1$9,1#AD3U%65TY/86\S=VQU1$%J6F=2:7%E-'$W1E9F+U)F
M9D%R=CE&.3A69"]O=G9I<3%F<597-#EA+TA4<B8C>$$[5V<V+U)41E8S*VDK
M*TMU+S!8,WA6,RMI*RM+=2]W0D8Y.%9D+V]V=FER=CE&.3A69"]O=G9I<G8Y
M1CDX5F0O;W9V:7)V.48Y.%9D+R8C>$$[;W9V:7)V.$%29F9&6&8V3#<T<3<O
M4G9F1EAF-DPW-'$W+U)F9D97:CE5;V$Q<#-R:7)F*VDK*TMT1#9P455R5'14
M1E<O=T129F9&6"8C>$$[9C9,-S1Q-R]!15@S>%8S*VDK*TMU+S!8,WA6;V96
M2T-L861Q67$T9E9/,6%E,DMT+W=#:2LK2W4O=T)&.3A69B\Y:ST\+WAM<$=)
M;6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB;F%I;',^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12
M968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C
M95)E9B,B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B/@H@(" @(" @
M(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C8Y041#-C$Y-T(T0T5%,3$Y
M,S-&048Q13<S0T)%-3E#/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \
M>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C8Y041#-C$Y-T(T0T5%,3$Y,S-&
M048Q13<S0T)%-3E#/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP
M34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ
M-$$X-3DP1#,Q-3 X0S@\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @
M(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E
M;F1I=&EO;D-L87-S/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C8X041#-C$Y-T(T0T5%,3$Y,S-&048Q13<S0T)%
M-3E#/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C
M=6UE;G1)1#YX;7 N9&ED.C8X041#-C$Y-T(T0T5%,3$Y,S-&048Q13<S0T)%
M-3E#/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I
M9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP
M1#,Q-3 X0S@\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @
M(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I
M=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @
M(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z.&8U8F4T9#(M-34X-RTW930Q+3@U9C8M.3-F,CDU8C0W83$T
M/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M=VAE;CXR,#(S+3 W+3(W5# U.C,S.C4X*S U.C,P/"]S=$5V=#IW:&5N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!)
M;&QU<W1R871O<B R-RXS("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z
M-CE!1$,V,3DW0C1#144Q,3DS,T9!1C%%-S-#0D4U.4,\+W-T179T.FEN<W1A
M;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C,M,#DM
M,#=4,#$Z-#$Z,C(K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3
M-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @
M(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M
M+VEL;'5S=')A=&]R+S$N,"\B/@H@(" @(" @(" \:6QL=7-T<F%T;W(Z4W1A
M<G1U<%!R;V9I;&4^4')I;G0\+VEL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE
M/@H@(" @(" @(" \:6QL=7-T<F%T;W(Z0W)E871O<E-U8E1O;VP^04E2;V)I
M;CPO:6QL=7-T<F%T;W(Z0W)E871O<E-U8E1O;VP^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*
M(" @(" @(" @(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM
M<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/E1R=64\+WAM<%109SI(87-6:7-I
M8FQE3W9E<G!R:6YT/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N
M<W!A<F5N8WD^1F%L<V4\+WAM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y
M/@H@(" @(" @(" \>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@
M(" @(" @(" \>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @/'-T1&EM.G<^,S@N.3 T,3,T/"]S=$1I
M;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XW+C@P-S4S-CPO<W1$:6TZ:#X*
M(" @(" @(" @(" @/'-T1&EM.G5N:70^4&EC87,\+W-T1&EM.G5N:70^"B @
M(" @(" @(#PO>&UP5%!G.DUA>%!A9V53:7IE/@H@(" @(" @(" \>&UP5%!G
M.D9O;G1S/@H@(" @(" @(" @(" \<F1F.D)A9SX*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IF;VYT3F%M93Y!<FEA;$U4/"]S=$9N=#IF;VYT3F%M
M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^07)I86P\
M+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT1F%C93Y296=U;&%R/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N=%1Y
M<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/E9E
M<G-I;VX@-RXP,#PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/F%R:6%L
M7S$N='1F/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE
M/D%R:6%L+4)O;&1-5#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L/"]S=$9N=#IF;VYT1F%M:6QY
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^0F]L9#PO<W1&
M;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP
M93Y/<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S:6]N(#4N,#8\+W-T1FYT.G9E
M<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I
M=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F9O;G1&:6QE3F%M93YA<FEA;&)D7S N='1F/"]S=$9N=#IF;VYT
M1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI"86<^"B @(" @(" @(#PO>&UP5%!G.D9O;G1S/@H@(" @(" @
M(" \>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@
M(" @(" @(" @(" @(" \<F1F.FQI/D-Y86X\+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:3Y-86=E;G1A/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D^665L;&]W/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D^0FQA8VL\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @
M(" @(" \+WAM<%109SI0;&%T94YA;65S/@H@(" @(" @(" \>&UP5%!G.E-W
M871C:$=R;W5P<SX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \>&UP1SIG<F]U<$YA;64^1&5F875L="!3=V%T8V@@1W)O
M=7 \+WAM<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG
M<F]U<%1Y<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B @(" @(" @(" @(" @(" @
M(#QX;7!'.D-O;&]R86YT<SX*(" @(" @(" @(" @(" @(" @(" @/')D9CI3
M97$^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIS=V%T8VA.86UE/E=H:71E/"]X;7!'.G-W871C:$YA;64^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM
M;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA
M9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO
M=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0FQA
M8VL\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P
M/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE
M;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^
M,3 P+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],C @33TQ-B!9/3$V($L],#PO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z=&EN=#XQ,# N,# P,# P/"]X;7!'.G1I;G0^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C(P+C,Q,C4P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/C$U+C8R-3 P,#PO>&UP1SIM86=E;G1A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,38N
M,#$U-C P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @
M(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3(U($T]
M,C @63TR,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1I;G0^,3 P+C P,# P
M,#PO>&UP1SIT:6YT/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8WEA;CXR-"XV,#DT,# \+WAM<$<Z8WEA;CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ.2XU,S$S,#$\
M+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z>65L;&]W/C$Y+CDR,3DP,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L
M86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^0STT($T],B!9/3(@2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT:6YT
M/C$P,"XP,# P,# \+WAM<$<Z=&EN=#X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,RXU,34V,# \+WAM<$<Z8WEA
M;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XR
M+C,T,S@P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIY96QL;W<^,BXS-#,X,# \+WAM<$<Z>65L;&]W/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO
M>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIS=V%T8VA.86UE/D,].#D@33TT."!9/3(S($L],SPO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z=&EN=#XQ,# N,# P,# P/"]X;7!'.G1I;G0^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C@Y+C V,C4P
M,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM86=E;G1A/C0X+C T-C@Y.#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,C(N-C4V,S Q/"]X;7!'
M.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA
M8VL^,BXW,S0T,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3<W($T],C4@63TT($L],#PO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z=&EN=#XQ,# N,# P,# P/"]X;7!'.G1I;G0^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C<W+C,T,S<Y-CPO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/C(U+C P,# P,#PO>&UP1SIM86=E;G1A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,RXY
M,#8S,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @(" @(" @(" @/"]X;7!'.D-O;&]R86YT
M<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O
M8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B
M92!01$8@;&EB<F%R>2 Q,"XP,3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@ >@)L P$1  (1 0,1 ?_$ !X  0 !! ,! 0             &!0<("0(#
M! H!_\0 1!    4# P$& P0'!0@# 0   @,$!08  0<(5-(4$A,5DI.4"1&B
M&5/1UA87(5=8EI<V-W-VM!@B)#%"46&V)2<S5O_$ !P! 0 " P$! 0
M       ! @,$!0<&"/_$ $H1  (! @0"! @)"@4#!0     ! @,1!!(A,4%1
M!1-AD106(E5Q@934!A<R5&*BT^+P%31"<J&QLK/!T2,S-7-T4N'Q!R13@I+_
MV@ , P$  A$#$0 _ /OXH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H#XM\J&&?K0R1_OC_M[,/\
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MC?$_7QH!XZT;XGZ^- /'6C?$_7QH!XZT;XGZ^- /'6C?$_7QH!XZT;XGZ^-
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MZ9+/SS3Q]AYKE[8O=1XJ3^?1]G?VQ^V^$18-["#J3:K"M>U[7MC)9:]KVO\
M.U[7M.?G:]K_ +;7M^VUZ>/L/-<O;%[J/%2?SZ/L[^V*L_\ PI7>4O3G(I#J
MA0.SX\JS5[JYJ\9JA*W!<H%VU"U68&;A[Y4I,^9RE0.US5!XS#SAF'&#&*E+
MX<T:-.%*ET0X4Z<5&$(XQ*,(K11BO!M(I:)+1*R5DBT_@O5J3E4GCU*<VY2D
M\.[RD]VWUVK>[>[>KU/T/PIW@$?.BH-4:$$>4O"9_4M(,9J@)%+RB1*F]$X*
M AF]A'J$:)<N3I+FB&%*6N6]P$NZM1<QX\T7559]$-U53E24_#%F5.4HSE!?
M^VT4I1BY6^4XQO?*K/%>KD=/P]9'-5''P=V<XQE&,G_C:M1E)+DI2MNRC_9#
MA_B2:?Z9+/SS5_'V'FN7MB]U*^*D_GT?9W]L/LAP_P 233_3)9^>:>/L/-<O
M;%[J/%2?SZ/L[^V'V0X?XDFG^F2S\\T\?8>:Y>V+W4>*D_GT?9W]L/LAP_Q)
M-/\ 3)9^>:>/L/-<O;%[J/%2?SZ/L[^V'V0X?XDFG^F2S\\T\?8>:Y>V+W4>
M*D_GT?9W]L/LAP_Q)-/],EGYYIX^P\UR]L7NH\5)_/H^SO[8?9#A_B2:?Z9+
M/SS3Q]AYKE[8O=1XJ3^?1]G?VQ<Z-?#*)C[0G:Q9\;%5R!GC[^V/E1-A=\<,
MWY=W>7FWMV>WV?GV[_/Y?/\ 9\_E6:'_ *APC%1_),G:^OAJ6[;^:/F?5=%T
M'T=@J6$<E6=.51]8ED3SU)3MEO.ULUOE.]KZ%>^SD(_?HV_R&I_-E6^,2'FB
M7MR]T.AU_P!#ZWW1]G(1^_1M_D-3^;*?&)#S1+VY>Z#K_H?6^Z/LY"/WZ-O\
MAJ?S93XQ(>:)>W+W0=?]#ZWW1]G(1^_1M_D-3^;*?&)#S1+VY>Z#K_H?6^Z/
MLY"/WZ-O\AJ?S93XQ(>:)>W+W0=?]#ZWW1]G(1^_1M_D-3^;*?&)#S1+VY>Z
M#K_H?6^Z/LY"/WZ-O\AJ?S93XQ(>:)>W+W0=?]#ZWW2IK_A^+71.TI'#4"C6
M)V) )J:"SX(H'T#<-<M<[HB!WE7;LF"O<5RDLH0A!*,5&]W8 1=FL</A_0IR
MJSI]#.,J\U4JM8Y>744(4U-KP2V;)3A%M)745>[U'7I7M#=W?E<?_P ]@;?A
M^+6>SB%LU I$7BS8H9G&Y$%4 &J:U9A)BM$,?Z57&$A3=.6!0$L0+G$]XG,N
M(@XXL:I\/Z%7J^LZ%<^JJ1JT\V-34:D$U&:7@ELT<S<;WL[26J33K_H?6^Z4
MS[.0C]^C;_(:G\V5D^,2'FB7MR]T'7_0^M]T?9R$?OT;?Y#4_FRGQB0\T2]N
M7N@Z_P"A];[H^SD(_?HV_P AJ?S93XQ(>:)>W+W0=?\ 0^M]T?9R$?OT;?Y#
M4_FRGQB0\T2]N7N@Z_Z'UONC[.0C]^C;_(:G\V4^,2'FB7MR]T'7_0^M]T?9
MR$?OT;?Y#4_FRGQB0\T2]N7N@Z_Z'UONC[.0C]^C;_(:G\V4^,2'FB7MR]T'
M7_0^M]T?9R$?OT;?Y#4_FRGQB0\T2]N7N@Z_Z'UONF=<PF$4Q]%9%.9U(V6(
M0V),[A(91*9&Y)&=AC[&U)C%CD[.[HN-(1H$")*48>I4J#2RBBP7$(5J\Q-?
M?8Q1@_Q$=%F1XQ))A#=0$1=6.(23'43DHCD4E:'9F><NR%!%,8661M[8FZ1A
M:I[(7-&V1:1 :1QYW.,-,2.AA"54:2)RO:V]VN.U[]UG<R=@N0X=DIL='F$/
M0'UM995*H2YJBT;BBLEE$*?%D;D[5<IS1HCC1M;TWK$(U1!9J%4(FYZ%2I3#
M+.&(_'>&7(<.D,SF^/F9Z MF&.2(LIFC,%&XDC9"9JA7.48&-8I1DMZVSHB;
M5QX MJM8)+8BX%H4QHR@#"VW;L32@(! ,I8_RF5,#L?R=#)RH#/Y5BV8#0EJ
MR[,60(0K+02N,*^K3)KC7,JLTLA28GL<D&(=KIU)P?F*P6MZ]2?T H"%LN0X
M=(9G-L>L[T!;,,<IXLJF;,%&XDC9")JB7N,8,&L4(R6Y;9U1M:XX 6U6L$EL
MGN!:%,:,H P)I0$+AF0X=D&\LM#WH#S>#S1\QY*>PC<4?A,QC=D@GME'XBC2
M=4-#9<EN)8AZIN/[ZW3+#NP9V0M;UZDTH!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H"#3K)F/\ &1$:4Y E[%$B
MYG-HICB)!>5Q24^2SN</"9ABD58TU[W4N;R\.:LLLE(C*.&2E+5N2OIVU"M5
MIP(LGU 8<594.PH1/&DS)B=0<WF1RQ+E8L3VEC:>9JXL2^B0VCBF:(X8J33-
M;"4[N;+4<//*E*EE*81V<+B;.U^'X_%R?RR6QR#,*N32MT)9V1$>VI#5AQ:@
M\9J]Y=$;(RMB)&C)4+G)V>WMQ;F9E:6],J<G=W7HFQN2J5RM.08((>_YNQ+%
MI++8=()_'&J40+&1V99HQJ5O_'Q?%I"IT1#F[T46 ?0,8E3(\$D*#[@&INUN
M DY1H$AX@";/O=EZ5;^Z.W%F8\=YJ9%LBQL]K'UG;U]FQ4K61N4QFX5ETB9<
M$!*:5LK(K5$B2JTYH5:4@Y(*X[EA/N:68  @\0L\8?L[35C#/V YTQQ-(+CJ
M>I4QQZN\0F^3+,%X+&Y"<F(-3MCE(OTIC=D@%1I990GQL"L,3"6$V$!=N@%
M* 4 H!0"@% * 4 H!0%F2=0V%U.4U&%2)^SFY+2K[LQ\>"4XW)!)+1BTW%#K
M2"Z*T:'.BX3>TU-@A;P*8%0[YRDQD"PVNX6$V>_XWM?T7TOST+AFRZ.$RU%!
M!NI'Z6KXZYRU.R@+/-4VCK0Y-3.L=51A1(TJ$B[D](4B$*X].<Z&!<+M92P#
M0[C0B"QKEK#TS-4%C63%&8(NI@<P739%&I*SA=9 WNY.-G=R8\A/J:S"W.2B
MT.@[BTK@2N<G$%0Q@2!3N;H_)FQ<A6*1-GR?X_OPYER,BYDQIBB/,LHG4J2M
M33)G="P1:R%$ZR5UEKXY(%SNB9XC'HN@>9!*G,YF:W5\Z*/-;DI+8FIU>CBR
MVIM7*TX@]<0ROCB?J$*:%3%EDPW6$QS)#2<T*;JT3Q!I8J=43#)F=P #H'9M
M6*F9>0<-N4J3&X=D=G,M'9S;+JP+A4 H!0"@% * 4!A1\173Y-]4NC3-.$<;
M',H)U)TD*>XRADBHQ#'9&Y8[R1#LE@A;ZN+)4]$SSHJ'FPUS5FISTR9&^G'*
MRC$H#@W$Q=FGRY;F#6?X)K-U@P*:#=-$<6P(M1Y(T/*(RGD>2<.R?.LS;L2Z
MHHEE3+2MXE\*EKE!T6*(1&&U:O@L;627]+7MX_2!P2L*94](&BXM%QBT[W^5
M>R?&-EOQY_U+#./P_=5F1GA0V93BTT<882#XN+PB1I\ZI&M,?),X9HBLLT>&
MKB(YD=$J7$C8D*YZC*1Q">V8Z7MZ"\B(C+HF;R0AF5G;=Y+:<HVE?LORW*<Y
MZ0/B!+XNXK9U$)]D5F5)?A7.&7\4M^>(HURG/<<P=@R:QK5ECAFD0\DL[*D>
MAY3>8G)'T4FED0C65+1Q4F3R9W1+KG&B;QOIIK*S:VU\ENW9IL[<B#:E](NN
MZ>Q;"S-AS2M/L9BQYBAM<,:&(]79&5)WB:=(=2CU,U<*E$^R+J-@\9CIH<2)
M(\:U/&/L=Y>7"6.UL,CR>AQK"VIT$"<=;R3UUTLFK;_)UUYVY[W,\ Z7M2+9
MHE^*?C!@BRMJR]J&SCKEG> D39-(LW+Y VY>+,%BYZ225-(R6R)*WD_NQEAD
M+NPN+&98)CP4UW#VK"+K-!\%EOZGJ8C9Q^'KJP8\WX;38);LFBQ2Q8PP>AA,
MGC^7D:QUP)FIOS*\3[4#D"8N>1\[Q]]<C\@('5(L>I*QPW.[C-FAK4XO41Y@
MCIB%4:)4EE=[7N^&C65)+1<-^%MT[G0N^&CJ)E,Q!(I?$<A+0R[(OQ45^2 @
MU&."-O>85DB2N4DT0-"MH:\JID(HZG>QHY3'(RW(P)(-(Q7>)@WL3CWIE@<E
M9[;0LFD[-+7=6WOZ2G2315K[D6')ZV39ES"[R1ZQU\+DH]'%LMXBE#S(YA@[
M!TNC>I=*]Q*>Y,C\(R8UI,@NS6KED2D61L8M^3W(A%)X]D%R,8R0+Q%XZ6:5
MG+=/BU;9/AMH[6V(=D#1I\1MSB6C9];,/OBS*&*\7IXLI@X,S)77",8?634"
M_2>,KILN=]5T?SEB27*,8FQU=+\@8-S#J*27L@OB1EB2B',+*)S$WCKKHWRU
M>G-QMH[V\F+XW1?+)6D75VOF#^^3W#62=0N!5&MK6MDI[TZPC41%\>26<PK*
M</QLVZ9\C(WEQRI!F,$9Q^],D] 9!GF9,+_%E,I2RU#$G!P:$Z:PBZYI/*E=
MIV6]UL][\O7O>US_ /#PU]O^,92MGZ^:Y"S_  G1CHOC.&)HT:@#&HLO4AC7
M,^0Y)DI8 ]1.XTF<Y=%<<NL78%^2YLV$%3$@UY U.KBI=WE.,3FC?:RS2>W!
MI6Y\;Z<.W<^G"AC% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0&)NK?"AV78WBQ?'(0PR>?8_U$Z8)BTO:Y/'R'Z+0.
M)ZH\'Y&RXH8GY[,3*&Y,;"\>GNKPTM2TM;)OT>;FU,B=7(+8B&)3MW/]S2_>
M8Z-.$,RDYKCL348Z<R81&-<>0]6IF<Q2.##C+G"9?B3(#.W0Y R%2D>2PY 3
MRR?E01:B70A'$RX$QN+R3,#S5#9'UHF^FZO:UK/GVW6W;IPV,A-7I"PEHP))
MS[",A4'U1X9DN22OVB3@C!R]UC#$\N /V@"TP_)TDQ].'9>?V4K&W1E3(5AJ
M=(T'*21"X^A_]_V7_P#-C!%;HHU-H\@:DW:<FXSS_&\[:7LS0R=J(XA?,&3'
M*4HGTB$4V8VO-7'*61#8;X9 "&N"Q61DQ"\;8HBQL;0::C=2ES^:)NM&KIIJ
MVSVUV:7'7EKL9/X*B^H2*(,R(6B+YD@D7R1)T[5A!JSWDN/:@I=@=:1AYV/?
M<HS]P=<[SAX?L:/63VIC:67&46RI,9&0ZN(W0+;$(H^/:^*B';LTY*U]?1^V
MR]>AAJKTQ9WP)IW^(A$ILZP24WS=C2,P/"TDAT8>(W*<EZAI[!AP!CFKN>ZY
M0R"ZIYA(\X2QH<WQW<4C<K4S):NF#<<G:0DI$HM=-Q>NCU7))WTTY7[MN>\X
MH)@2BPFCL8:$L 33+!L"QAE@VL,=@6O>P+#%\Q6#:][!M?Y?._RH4.R@% *
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M@'@+OL3?,7SH!X"[[$WS%\Z > N^Q-\Q?.@'@+OL3?,7SH!X"[[$WS%\Z >
MN^Q-\Q?.@'@+OL3?,7SH!X"[[$WS%\Z > N^Q-\Q?.@'@+OL3?,7SH!X"[[$
MWS%\Z > N^Q-\Q?.@'@+OL3?,7SH!X"[[$WS%\Z > N^Q-\Q?.@'@+OL3?,7
MSH!X"[[$WS%\Z > N^Q-\Q?.@'@+OL3?,7SH!X"[[$WS%\Z > N^Q-\Q?.@'
M@+OL3?,7SH!X"[[$WS%\Z > N^Q-\Q?.@'@+OL3?,7SH!X"[[$WS%\Z > N^
MQ-\Q?.@'@+OL3?,7SH!X"[[$WS%\Z > N^Q-\Q?.@'@+OL3?,7SH!X"[[$WS
M%\Z > N^Q-\Q?.@'@+OL3?,7SH!X"[[$WS%\Z > N^Q-\Q?.@'@+OL3?,7SH
M!X"[[$WS%\Z X&1US.+&4:W"-*- (LPLRQ(RS"QAN$8!@$*X1@&&]PB"*UPB
M#>]KVO:] <_ 7?8F^8OG0#P%WV)OF+YT!P''7,SL=XVB'W8PF [=B1=@P/S[
M)@.T*_9&'YW[(K?(5OG?Y7_;>@.?@+OL3?,7SH!X"[[$WS%\Z > N^Q-\Q?.
M@'@+OL3?,7SH!X"[[$WS%\Z > N^Q-\Q?.@'@+OL3?,7SH!X"[[$WS%\Z >
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M@+++ &XAF&#%>P0  &UQ"$*]@A#:][WM:U[T!Q(/)4DDJ4QQ2A.H*+/3J"#
M&DGDF@L84<2:7<19I1H!!&68 0@# *P@WO:]KT!VT H!0'G(5I%(U):92G4&
M(S^F5@(.+-&E4]V6=TZD)8A"(/[HTHWNC;!,[LTL?9[(PWN 4*TB3N.K5)TW
M4J"DB;J#BR>H5G=KN4I'>"#WJ@[LB[HDOM&&=D78#?Y7H#T4 H!0"@% * 4
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M<6B6QR*3&%!>-G9+6"W>JDI6=M>7E6XZ<-#Z=Z&,4 H!0"@% * 4 H!0"@%
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M(0?TV)U0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M[*F>'39,ZH6E*8SLC#)F)G V,<A=DQ@;WTWU]%M>.NU^/>S:C0@4 H!0"@%
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M*5!O>=LXP0@NW:[;MMV>@N90@4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% >-Q;F]X;US2[(4;HU.B-4W.;8XI2%K>
MXMZT@:9:A7(E(#4RM&K3&F)U250680H(,&4: 98Q!N! 'W"^'90^0R3R;$^-
M)%)<<63AQY(7V"19W?(&%*:0<E##'9P:E"^+V3')4IJ>S&H0V)-3$&%]D1)=
MPA=\]]^T[Y3C&-RV9X^GR^ZU+),<WEJ1L5(1I EN\:G3(!IE4+D)2M&KZZ*O
M"UOBTG5($PD2D<EA$36W6W2H%2%<'/M_'X]+(NDTTZ<D$(>,9(< 8318WD+L
M0_/^/DF*H*GA#X^);I!)7EXBA+"!A<W5,) ANG<5J ]83=$DN6<&Z8GL";O>
M[OSN7%:(3#&!0UK&*(QAD5LD92PME5-# U-JAHAR(TDY%$VL]&D)-01E(<G3
MFI6%((IK3FD$F%)0#*!<(@B+AAJ#+WG%+B4VEM#5AEW?I)!X<Q)&MGB"&4/D
M<=XB7(CFE"W%#$N9([)YBWLR9.J3-)1LL='1:VKG=(PKV<3??MW_ 'EU:$"@
M% * 4 H!0"@% * 4 H"+'P:$JFN0,:F'Q92R2Q<J=)4SGQ]I.:Y,YKK)[+G&
M0-YB021Y7++)$ME2MQ)4J%%DR?OC!]R7V0*1DG&S!E!D:V9].<4!K#+X?.XZ
M],QR9,],,I@\A021D<FY0L2+DP0F*$ FMW2*$AZ1YCKD\,+@2<W.BLDP2G;N
M:[SPMF$\,LK]-I4SXCQBTRC)256AR-)&R!15 _3]$ON,2Y'-GA*TE.$J2K1&
M#$K3OJA>4IN,=S@#N*_S"[YL[HIAO$,#:XRR0?%>-X8RPMX=)##FB*0>,1UK
MB;^]MKHS/+Y&4#0UHTC"\.[0^/34Z.;64E6KVUX=$*L\U*X*RCA%WS(2OTQ8
M1'#G/'\9Q[$\;PZ1SB,SV:L&,HI%82WSQVC$A:)*!+,2&9C)+>F]]6L3:BE-
MC0@7/S$6H8EBZ[8N5IS@O_8O]0"@% * 4 H!0%S>@0[))[8GA0#H$.R2>V)X
M4 Z!#LDGMB>% .@0[))[8GA0#H$.R2>V)X4 Z!#LDGMB>% .@0[))[8GA0#H
M$.R2>V)X4 Z!#LDGMB>% .@0[))[8GA0#H$.R2>V)X4 Z!#LDGMB>% .@0[)
M)[8GA0#H$.R2>V)X4 Z!#LDGMB>% .@0[))[8GA0#H$.R2>V)X4 Z!#LDGMB
M>% .@0[))[8GA0#H$.R2>V)X4 Z!#LDGMB>% .@0[))[8GA0#H$.R2>V)X4
MZ!#LDGMB>% .@0[))[8GA0#H$.R2>V)X4 Z!#LDGMB>% .@0[))[8GA0#H$.
MR2>V)X4 Z!#LDGMB>% .@0[))[8GA0#H$.R2>V)X4 Z!#LDGMB>% .@0[))[
M8GA0#H$.R2>V)X4 Z!#LDGMB>% .@0[))[8GA0#H$.R2>V)X4 Z!#LDGMB>%
M .@0[))[8GA0#H$.R2>V)X4 Z!#LDGMB>% .@0[))[8GA0#H$.R2>V)X4 Z!
M#LDGMB>% .@0[))[8GA0#H$.R2>V)X4 Z!#LDGMB>% .@0[))[8GA0#H$.R2
M>V)X4 Z!#LDGMB>% .@0[))[8GA0#H$.R2>V)X4 Z!#LDGMB>% .@0[))[8G
MA0#H$.R2>V)X4 Z!#LDGMB>% .@0[))[8GA0#H$.R2>V)X4 Z!#LDGMB>% .
M@0[))[8GA0#H$.R2>V)X4 Z!#LDGMB>% .@0[))[8GA0#H$.R2>V)X4 Z!#L
MDGMB>% .@0[))[8GA0#H$.R2>V)X4 Z!#LDGMB>% .@0[))[8GA0#H$.R2>V
M)X4 Z!#LDGMB>% .@0[))[8GA0#H$.R2>V)X4 Z!#LDGMB>% .@0[))[8GA0
4#H$.R2>V)X4 Z!#LDGMB>% ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g609070g00a32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g00a32.jpg
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M 1$  A$! Q$!_\0 'P !  $$ P$! 0            8$!0<( PD* @$+_\0
M<!    8"  (""@D+# P*!@L  0(#! 4&  <($1(A"1,4%18Q596QU3(U05%7
M<767UA<8&59A=X&1M+74(B,D,S13<G26H<'P"B4G-D)8E,?1T]?Q&D=2=I/$
MQ>'DYS<X5&*8LF1S>(:2HJ>SMK?#_\0 ' $!  $% 0$               $"
M P0%!@<(_\0 8Q$  0," P0%" ,(# D)!@<  0 " P01$B$Q!1-!409A<9'1
M!Q0B@:&QP? C,E(S0G*%DK+3X146%U-58G."E)72\20E0U:3HL+#U @T1$54
M=(.$XR9C9,35XC4V=:.DL[3_V@ , P$  A$#$0 _ /?QA$PBZ]>$J(W)K1UQ
M$,]C;5:[E+.<0-WG(==S6G=.-5EG0M32\/%I&L=O*%8.<6)H*%(JW+ ]H?<G
M+\)( 9U&UFY6RS[R+]J@ B]S<$W'@MPO#25\E1_G%SZORE2GAI*^2H_SBY]7
MX1/#25\E1_G%SZOPB>&DKY*C_.+GU?A$\-)7R5'^<7/J_")X:2ODJ/\ .+GU
M?A$\-)7R5'^<7/J_")X:2ODJ/\XN?5^$3PTE?)4?YQ<^K\(GAI*^2H_SBY]7
MX1/#25\E1_G%SZOPB>&DKY*C_.+GU?A$\-)7R5'^<7/J_")X:2ODJ/\ .+GU
M?A$\-)7R5'^<7/J_")X:2ODJ/\XN?5^$3PTE?)4?YQ<^K\(GAI*^2H_SBY]7
MX1/#25\E1_G%SZOPB>&DKY*C_.+GU?A$\-)7R5'^<7/J_")X:2ODJ/\ .+GU
M?A$\-)7R5'^<7/J_")X:2ODJ/\XN?5^$3PTE?)4?YQ<^K\(GAI*^2H_SBY]7
MX1/#25\E1_G%SZOPB>&DKY*C_.+GU?A$\-)7R5'^<7/J_")X:2ODJ/\ .+GU
M?A$\-)7R5'^<7/J_")X:2ODJ/\XN?5^$3PTE?)4?YQ<^K\(GAI*^2H_SBY]7
MX1/#25\E1_G%SZOPB>&DKY*C_.+GU?A$\-)7R5'^<7/J_")X:2ODJ/\ .+GU
M?A$\-)7R5'^<7/J_")X:2ODJ/\XN?5^$3PTE?)4?YQ<^K\(GAI*^2H_SBY]7
MX1/#25\E1_G%SZOPB>&DKY*C_.+GU?A$\-)7R5'^<7/J_")X:2ODJ/\ .+GU
M?A$\-)7R5'^<7/J_")X:2ODJ/\XN?5^$3PTE?)4?YQ<^K\(GAI*^2H_SBY]7
MX1/#25\E1_G%SZOPB>&DKY*C_.+GU?A$\-)7R5'^<7/J_")X:2ODJ/\ .+GU
M?A$\-)7R5'^<7/J_")X:2ODJ/\XN?5^$3PTE?)4?YQ<^K\(GAI*^2H_SBY]7
MX1/#25\E1_G%SZOPB>&DKY*C_.+GU?A$\-)7R5'^<7/J_")X:2ODJ/\ .+GU
M?A$\-)7R5'^<7/J_")X:2ODJ/\XN?5^$3PTE?)4?YQ<^K\(GAI*^2H_SBY]7
MX1/#25\E1_G%SZOPB>&DKY*C_.+GU?A$\-)7R5'^<7/J_")X:2ODJ/\ .+GU
M?A%)Z[-+S2#U1PU1:J-'G<O117.N0Y1:MG(*=(Z*!BC^R!()>B(?J.ETAZ7(
M'+K\2/@G/J\ ?BI#A$PB81,(M0M=>VNW_OTWKTQF2=&]GQ*+)N0B81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A%U#]ELXOMN\,%*U- Z<E6]7L&TY
M.YGD+>,?'2DC$Q%*;U?ML?%-9=J^CD7$PXMB!E9!5FLX:(1QR,Q07<@X1];\
MD_1'9'2:LVM/MB)U53[+BHQ'2;R2*.66M=56DE="^.1S86TC@(P]K7NDN\.:
MW"<>HD=&&AN1=?/B +:7RSOJNAK[)CQT?XPUG\QTGZ,9[K^YMT'_ ,WJ7_35
MG_$K$W\OVS[/!/LF/'1_C#6?S'2?HQC]S;H/_F]2_P"FK/\ B4W\OVS[/!?H
M=DQXZ.8<^(:S\N?7_:.D^+^3&0?)MT(L?_9^ET_?JS_B4,\OVSW#P5V:]DJX
MX%!#I\05G-XNH86EASY^YU5H/YONYC/\G/0H:;!IA>_^6K,CS_YSUZ)OY?MG
MV>'SEZY&U[([QL'$ /OVR&Y^_"TT/<#WJV'N_P"C,&3R?=#@#;85,,OWVKZ[
M_P#2.Q76RR$7Q'._OZU*6?9#N,Q02]/>]C-U=?.'J']%<#Q>_F!)T#Z)-O;8
MM.+6SWM5R'.<\[JH2OYDY6 L/AQ]O6LQ:FXP>-G;%_J.O(7?,FTE+;,-HI%_
M)Q=83CHY)0#*O)-^9O67#GN..9).'SDC5NX=*(MU"-6ZRYDTCZ7:717HELZC
MJ*V78L3HZ:(R%D<E3CD=HR-EYPW$]V%@+B "X%Q S%0?(2 76O;@!EJ3EF/[
MQPRSBUWUQ?W&09(:0XCYG<;!9:M1TBHG5:Q1YFOS5MLCNKP;&9AK(P*B1A(2
M*#=4E@CY61A8QG)QA[*[K[IT1IFDEV)T9IF..T]@Q;,>!.]MZB>JBFCIH&U$
MSHI87W+V,)!A?&R1[HY! V9K2Y7+N/WVMK\+>'61KQM>RF$#LKCT>)O^^VW'
M#!ZC2'%SC81DYUI9+#(!VNKNHF&>U^O%?35<?S\=;H:3APGF#(SYHY(=JBL(
MJ%2U\^S>B3,.ZV:US?.13OE<VMAB;8S-DD;+,6QS,B?3RLDW3GAKA9Q&5ZKN
M)-K#*]LCEEVF^?%2)"Y=D,%6134O!U6\/%N)62ED;1IIQ7VR3.4<P;UHI8VS
MU2"[[L)AFYCG\,$CWT8N4N;MHDDJBJI@OH^B0#2*0 OD:QD;H-H-E=B8)6N$
M+FB7=NC<'MDP8'-^JXFX4@NROIQ)MP)OI[>(/)7:,OO'BZ90TAX:.%64RPAY
M8CD)W5(DB8B?ISR_P\M:@*OSIT;(4Z.DIY![:BPZ'<<9( <Y'#19(N+-1=&6
MNE:VF:'1N>PC=UOIOBG%-*R&X^G<R=S8BV'>>D]ELC="79@6X&]_7ZK]>6N>
M84WB+?QH&,Z4G+ZYBV;4EK(1<9+6+QQ).*I04MC.Q@V";U%S/Q:M:?0TF$["
M _BQC)AH^:+OA.DV6ULU+L,$"*F#BXQ$^C5 ,;-4&F;C)!;&\2->PQO+7XVN
M#@VQ(CT[$DVU.@.@^/4%*6D[QJG=(LE+(L=90)(%U"SVL#M(U2)\'^[6\T_2
M=F90CLOA76@0:2SAFY=FFXXC5)8ZX%#!?#L>Q+8A8%MA@J07!V\PX00"\?12
M7+00,#KD653;VSU]66F1MWJWQ^YM^%86QW,W^5C5JB^CX9ZR<QD/W0I//G[I
MH$2< 8$!NN@WBYIXJ804'^UBB()\U.VIXDU-2 QB.)I$C7/!!<1A !!US!Q-
M YXLSP-7S\]BYV7$#N!7ET[Q(&#JZQ9Q(?\ 9X>/^ONYKYH8P"6L#<R./#,\
M[=5D4J1WEM4Z93#<GPB(=8]R1?CY_P 0S7D6)'6BY/JX;5^W%]_DD7^@9")]
M7#:OVXOO\DB_T#")]7#:OVXOO\DB_P! PB?5PVK]N+[_ "2+_0,(KQ ;\V6P
MEV#E_/J2[$KE$'D<[9QX).FQE"@LF"B+1)9%42<^U+)*%,13HB8#I]-,Y%VM
M4?\ <TS\K%_-<;DG1O9\2H&KNWX!3C(4IA$PB81:A:Z]M=O_ 'Z;UZ8S).C>
MSXE%DW(1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+ :]_V=.[6L-)HU
M:IQ*U07%72NDW<96P,9.1+:(HDVB:F-8B%D&#L6#,3MW@2SUF'=W0*002$3A
M58  F^>ENHYW\?8HOF1RMKU\??X\N$SOBD"*C#JP>B^^@RLF%@3CK/>U4TJ\
M5"&&+5KAGU20([L2BQK$#AI+@QB2=I@^B^,5S("T>C_&]GMZM/:F?5\_)^3E
MYV^RJO.)9[JOA!5XJ(;7<-LL%-V HEKV2>/4560-]/E*>Q-CI*PS"P@J4XO2
M5F9F(%<3@JR.R('<A/H+R$VQ=*;7TV)[]KZ<>]8=5>T=[7]+_972[GT(L1,(
MF$5W9FZRB/X/C'W/YLQ'C+L/=\Y(,QRT)'SVJ6,S=9>OEXN8\_Q]?X0_#FOE
M'5E<BW5K[AW*ZS37CW>&BV2A]%[+>:Q/N%O&5X^O$%Q9K3!M@:\2?DD0.](G
M%&JZMJ3MA9AR2/>NF4.,&$H_CVZDFR:+QP Z'F9]KT#-H#9;I)Q6EN(0^95V
M L :XR"H%,:8Q-,C ^43;MDA$;W-?Z*NAIMB%@-+XAE?JO>^O#3,<URTN5NU
M M4=::UWYK]KI4@QL#5^DQ5*[@G3-=%=H\=MW3=1(B J&1*HE(('9.TEA;N$
MED%S)'Q:R.EK()()]U-3U39(7,+P6S-?<.:TM-R;!UBQP>UPNTAPN) PD$',
M$9V-ASO>WS?1;>U3B<V3!J7.6>5A%E(R6I9K5]<0J<# :[I5)KUNG5)&=F5:
MA7*BW:24FXG04DH>4+(0J\=9T6SY1S(ECF4:VY6KV%0R"GC94%[&;0BKIW5$
MTU;554U/"&Q1BIGJ7.8QL5HY8\$K7P%S UF\>]UUKCZRWD!:_'(#/PT&BF,W
MLGB4ICF.CYQ",A["A#FJ"DC$5^BKW-XT@F-/8M!L4S7FSJ?=/8J,AJFSB).7
M<=L.DV%9FNX>*R;E76-HMC5 D?$Y\D+I!4!DDU4*=KIG5#W"&.9S8FMD?+4/
MD9&+7(#@&A@$W([K6MG;+J^<^>=ZAN*'>T986MBC5H6+EF[8R<8$9KNJ1R$>
M\GI5:RN)>,9LH)!%M*6*5.K)2#A(G:IY--!F]0>14>P9-<"?8VS71&)PDD9J
M_'5SO+A%&(0R1SI27,B8T,8TGZ-Q+FEKWN<Z03ZAR TY#A[.LY#*9O.)G91T
M*PA%,(JL0K.HTNNN62M;@Y!.[MJ=K8^K3KV9Z^A$U;1%OH=_92H14D9^VB"6
M%XT:K*':,7*&O.QZ0&8O=)-(^>HE#A-(WS8SU?GEHF-D(A<U[8KO:&F0QAQ&
M;@:K@FYL!J="3J+'U'2QY=F3H64XCKI9IF+00CU)NB2UIKLBS64HD#'P<K?Z
MDSU,^J4:=XZC89=V[J]/;5FLUN(5<NFY(14T T[H176S43LV=#$Q]W!D\<4K
M"/.)'2,@F-4V9]@YX#9IG2RRO #MX-XZQ 0$FX(O;73B+=A]_#J53![UW#%R
M,@N5Z7M\A(2SZ79.JW'*MGKJ91K+%\1XS58B0R0J46OJ(H=$J:#V(,HD4IU7
MA5<.6CI2T##D&MP$2.NT,,A;A=B/[[("<R0^QO86EIN3EPO<]W(<O9VJ@1F+
M*Y923%ZBL5"9L99V3YQI6PNYUJ5^T((]J01(GW,,O()ILD2)I-U'RI"(D$Q"
MA@3L8""+>@S"TXB;-)%QF3<>B,SF<.NJK4BCVC[DH86;ODV$Y'(@W6Y-S(\A
M6!?]1R2%,1+VP%.B).9>GRY@.:F<7!N1;(#,9WXCV]N6J*8-0,5,"G(8AN1#
M]$Y1*;HJ$*<AN0@ B4Y!*<@\N1BF P<P$!S4/^L>O^[X(JG*43")A$PBY4/V
M]'_ZU/\ ^<N$7>'1_P!S3/RL7\UQN2=&]GQ*@:N[?@%.,A2F$3")A%J%KKVU
MV_\ ?IO7IC,DZ-[/B463<A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
ML$Z^?HN-T\0;).>L,BM'.M7 O"238B4#7A=4@%TR5IP6<?F=$E2?LZ7$\- =
MI?\ ZV4LF'[-R3HW+GGS4#4Y\LN79VK.V0I7GY[//7)QY6N&JU-8QVO7H&8V
MI"S,LDB8[.-D[*TU\Z@F;M8H"5%630K4X=J!^0*=[G!0'I  #[[Y"JB!E3TD
MI72L;43P[+FAA+@'R14S]H,G>QNKA$ZI@#[:;QO-8E6#9AMD,0)Y7PV[[%>;
MW/HM8281,(J]F;D(>^ _[OQ ']>>8\@^MW_%!UY_-P/=[U+69NHOW/'[_OCZ
M/3FOF&OJ/PS5QAS(]?SWK;74N]6E#J%;J#^H.9YE"\0.N]X.G#.VR%7=OV]&
MB9F*7J;1[$,>^L(ZER3!EF]KC91-_"*MR*-&"S@4W"/);5V.^LJJBJ94MA?+
ML:NV0UKJ9E0UCJR2*5M0YDKQ%*V(Q6=3R1EDH<0YX:"#>:ZP M]^'7O;3AD/
M;[%M[:..QI=(ZS1JM%O,+WZK5<AT):!VZE"3<LZKE6V#4&Z6P'T+KV-"WU-S
M&7HKEQ5FZ,$L9W$K)JSKAO,N0;<C'T0=2R0O%722[NHGE='-LTS0QMJ*FCJ'
M>9LFK7FFJ&R4A:*ASIFX901"UT3<5>,'[T\ 23?*SAG9NG5;0'@I+]??+3#C
M8CR8JEC=J6R:M<I7HT=D.#0#*-M.O7.O4Z=>HE>L+A?*96&[IS8*K!MEZFA&
M3CZ84YJ$F')D\-W1*.)M$V*HA:*>&GCGD\Q:)7OIZP5AJ:1XG'FE3.6MAJ97
M"H=)$R(9&,7K#[WR=Z5SU9Y6/.W #MXJ:M>.Z03?*R$50WT*\6?H/ =1]\6;
MN2-?JC:HO3Y@#AO66ZO:9%EK-Q6W7(Q2*MK(LX62618J1\EK9>BS, 9)5-E:
M&%N%]*",0H]H4K'83.X7:^N;,WDZ$ $%P>RK%F3;6W'E;WV4EK_&LB:3@I:T
M:^F+&\K\K2)]HY#816SU[-438>Z;E#=\GKZG2ZJT26(W&M6^X$RIN$2U>-=-
MGZ+1T:*::ZHZ.$,ECAJXXFRMJ8G#S2[6155)L^"3 UM1& _'0";$3AO.]KF%
MS<;F+GG:QUX@GJ//JT5DLG$5&7B.TM&2]*?NB:L>P*DFJ]M*"A+%$PT76(=6
M$9QT96H:)B4WK.MID-+/F,]/ BJS9O).02C>VO:&;*?3NVA)'4,::T2!@;"1
MNGR/FDWCGOFD>_"93Z#'11$ASFL876;62/1)UU U)O[!PX7Y 64@TQO8M#G+
M=.V"%FK*ZN$HPF),D9:481I)JMY"0DI"'LL-,5VW5NQP$XM("+Q)]!EF(\R!
M%(69CP<2"3S7;2V?OF0LC>R(0L=&S%$7N8"&-8^)[)(9(I&!HL6OP.!(>QUF
MEL D.((L3G^KCEUC.^MUFVI\3T?!-X95E0%6TS&-(6.%=A:2,H9)C7;!<YV*
M2B8D:TX=QZB7AB=HHHM,/R=",;*((HBLH0-/4;-+W/O/Z#G/=Z45WW?'%&[$
M\2 .ON@X ,;8N=F5(/!PMIH1P.5AKW7T68JSQ&0,+1ZN\</)>S7-D-51DH%W
M)2I6!E8&9M4@^G !]$.(^/G7Z<TD[5L"$M8'<G-'1D7,-&F:N4WFIGHGF61N
M!K(B9"UP#+^DV-K6"S@2T%I :6LP,! >X$$5_/@JV&W^$W88)O(F>UZK&M+B
M4M!W4@K*FG*XXI%;I;R$EF,%"12<D]=14 ]1:OCM0*5S-I X!$C):27P):?
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MG'DZ:*RXDPS2;.J7MJ6$R.CG=5M==V$OJ&-8?K-#7L)@8]K+G#)&QQS 5=R
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M6"9KK$FS6,-R]SL)WLCL(&%H?Z%H[%K0&N &0PFI2R-W5K L^D_\%W1V)PL
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M$@2_$@K_ *[+1DD=]9Q/;\Y(JD-.ZP .04N%Y!U!^LJ?ZW*$3ZCNL?M+A?\
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MQ '4 ?@SPN2225[Y97ODDD<7R22.<][WN-W.>]Q+G.<227.)))N2MT
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MFBFACG<QCI) Q\=342.  +6-CIJ.I>Z5]VL<UEVN:7N9;D?@%@+N()%S896
MZSFX9#,B_&P.O[?LCM72&-0<4>:F%+<R8RVO7T0B].WLC&R.ZK+0XNF%=:WM
MVT95BE7ROO+VZC%YRYQ+Z-?/)76%:8W+5C:Z;$]&ICB(GC9N7.94M>1>)\39
MFO =(8 YTL]/(V .#('M<UK*N5T-68*-\.6N8MQOV7T!S.?,@ MO'I7C=T9?
M+/49UWH(EOML1KY#8.KIFQUYE)6F+E%9G2+6VPE9?%JD^^"1JTMM&%&:C]6/
M;M?W\MK2YLXN@2$M#55"R5LV'7T\4T8V@887U)IZID<CFQ/8&5QADE;O8VX9
M64LF[=5M@IVLJH'/J&LDE,0RL)!++D"[20+@W;< V)ROGAN<CED+Y_TAQK4C
M>%N>5^(K4Y 0;.B2]V/<YI4A*V"-82H8V<@31&Q:R]B&;N^HL8NPP5DFFDD>
ML6A^^;PL,-4D[7@5VPYZ"%LCY8Y'NG9!N8P=[>4U&Z] G>A[A3ESHWQL+1+"
MUI>_>MAK;('&PR%B;WRRM?JMGD03H;VROC.N=D4KEDGX2IL]27CPID)ZKP\K
M"$%PN>!"^R,#%4M)[(DA B$I=\O-N)*1;R3^)KB]6KDQ<*%;=A5N:UQ(W[)E
MZ.21QR3&LIS$V.9['Y 2>;MD=.0TOQX&A@:TM:^432,@J(:>6.I;3TB8$@!I
M)OF!G:]K7L/7U@$M)%K\(=DNU6N6#EV5*N[BE2\'6;:>Y&8N"QG@C9W+R$).
MQZK=@\CCE@[36MD1TZUL4M5C##:PM5BKRUB2>51A8Y_:S5#>,=/ )V22P[@&
M[]]"&R&-P+FN].*6E=&Z)DPWE7%%((BV9T3?#+T38V-^HWS%KWL00;VTN%P#
MQ[RT%<;%]436B5%H%!C*X?:@OYI*0MVM9&\S>A(ZF+R!HE1_#6&.49[EF#6M
M&*(@YK\WKJUPD8O9@9-)"3D='VR0Q^;5)J*BH?**3"S##5-IV;0=,&X\+XGA
MU$S=%]VR1U,+W"*[FM;T@F[;- ]+B6DEEM+W^L0;#(@@7M=9 OG%/L"M;4U%
M366O8**C[EKMC9;E"7B>2AK'6[A=HRZV"CU:8LC=VM6*;&0=6TYNJ=O%@,SO
M O']385BMQIG,@C*N<:GV53RTE9,ZHD>Z&H=%"^"/'%+# ^".>5D9 EF=)-6
MT,<$8,%FS.EE< TL$ND(<T6 !;<W-B"02T7T&377.>8L.:O=6XQXFVZ8E-[L
MM=V6,I#B1I=<H",R[0-9+S:K2]B8*3BRURMM++*1;:GVZ64JLV=HA/3[B1K=
MO4B*P_0BXHT_1-L9\-:R@=41.J V>2HP [J"*(/D8[>RF)CS/"P31W,<89+#
MCE:7/W<B2[,>$@9 7U)-AH+G(FQRX');!:9V;&[HU1KW;,-'NXR'V+4X:WQ#
M1Z(F5&+G&:;Z.=HJF2;J+L)!FJC(1;E=HQ=.HUTT<.H^/<JJLD-=6TKJ*KJ*
M1[@Y]-,^%Y;ICC<6N!%R YI!:X N:' AKG !QK:[$T.TN+_/4=1IEJ!HLF9C
M*4PBQ=MMWWEK+2U(F[6^J]CK3YJH!A)TDI&<80,BU.8! QDG4=*N2]J$1(9R
M1LH8IC)$Y=WY.*Z:CZ54,4;B(JYE125# 39[#!)-&2-+LFBC<#J&X@/K&^%7
ML:^F>3JRSVGD;@>T$A9=24!5)-4/$HF10/B.4#!Z<^G5SBY,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$72/V
M83V&@/E+<'YMTYGT-Y"/J]*/Q)[]L+RGRE_6V-^,?=0+I/SZ"7EJFU#]N'/R
M:M^5,\P-H_<&?RK?S'K)I?NCOP#^<U=I798=3V7B2WC%,$ZAQ<.:>VU_-TMQ
M3ZAPP6#:%=D[M0C;DCZ+L:JR\1O/7[<(IE9MJ0VUG*)J\YDYRQZ,TE(,IZ#9
M1\J@O\#+ZB;IPU&IMROPSY#E=V1NO27&(F;1L>W,N\<F08M$3.9$P&D'!DD$
MR"N^,4"E,\5$HJ.C%*4!7,<0  ZL*A:GZZ]M=O\ WZ;UZ8S).C>SXE%DW(1,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(J1\@=PT722,!%A)TD#CX
MB+IB"B)A^X50I1'WPYAF/5TL5;2U-'.,4-73S4TP&ICGC=$\ \#A<;'@<U4Q
MQ8YKQJUP<.T&X5KC9!*1;BJ0.UK(J';/&QA_76;Q+D"S98.H0,41 Y#<@*LB
M=)=,3)*IF-\B[;V/5["VE4;-K&$20N)CDL0RH@<3NJB(YW9(T7U)8X.C?9['
M =3#*R>-LC#<.&8Y'B#UCVZC(JOS4JZF$6(]M6BB4Y&FRUOJ2]RFWEN3A==Q
M$56&-ELZUP/!S5@$*V5\**44[;P%;FY5[+J2$8TCXV+=.WS]NU0.H7,HXJB8
MS,AF$$8A+ZE[Y711"'>,C^EPW+VF25C&L#7N<]X:UI) 5+B!8D7-[- %S>Q.
M7J!6GDGQB<($DLA'5FEPM^5O*&MD%TV=2J+=O-4,']1%U/S[:7.C*LX+45;L
M+>T'BK=#Q3A9E"2R-):R?>"=<0NX;L;;# 733OIQ3FJ(+IIG&.HPS6CC++L=
M)62QF(/A>\!SVF<LWD8DM[R.^3;DX= ,P;9]C0;V.MC:]E<*YQ:<)VR4W;<*
M3$6BY7!9G7INKPU)A[2_MEPCC@RLU3<FDV$1)F\!ING+L).1V=#T=D6/J1[0
MV(%8@'DK%Q+LC:]*0=^^*" .E9,^=\3887#%%,,#GM^GCF#F-I7SG%-NB=[(
M&/"2,W]&]S8@ &Y&HSMH1;T@-+C(74BBN+S42- G]\0.MI5A49W9U$UZC<!B
MZ[ /KM5E:M6IZ9V3(BLNWE$JOJBL2-T/,1DV49Q@VU[/-&T>V[:"3:T_8]8:
MB/9\E2QTS*6HJ3#BED;!-O98V4K; L,U7*V# YGT;C4QESC:YG>-#2X--L0
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MA0$1  YB(!EV"">IE9!30RU$TAPQPPQOEE>X\&1L#G./4 2H)#02XAH&I)
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M;WG]?7\C.]-^S;;N6$.EJ#51>8<^IS;NK\<UF))Y'-C,N1M;:>1MFVEX7_\
M=#DJ]^_DWN/BK\W[,_NA;ETM2ZN !]YQ;.O[G7,C^/,1_DDV0T$_LGM++3*E
MY7_>?4I$SC:P:3F2,QV9DJ_-NS%;B6]EJG69?%S$'%I]WXY<?Z]68C_)9LIM
M[;2V@;<Q3<#8_P"2ZC[^I5"5Q)&$7 O;NMQZU?VW9<]NK@ CJ_7 ?$O9_?ZO
M'+?%F))Y--F,_P"L*\VURI^W]ZY7_4JA([B /;\5?VW97-KK\NEK37A1'EU
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M&NNC%&$<N-]3KWJXI<%_#ZCR[75)(.7OVFQCZ9(<L';6T#K*W_11"W99JD-
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M]I8) !4K/>$5#*>ULC_$7?Y.IDMU':/>B\EW]D^1PRUZ[&E&ECT947M^XH4
MC7%7/=47HGA^%X.T*U-.1B5)XA_$,<229&6]Q<G+._Z$G##MAU\-HZ(WQ[NU
MC79X[.P]N$]BX?I>+R;+%@Z\E7D68[^C298+MQ=F(7YKSD[!D$X3?_"]J6FK
M5.&M]$LZ%B5D:+3XS5R,38]HLZ3.1$+(PD[MZE1L?;JX#)JQFW$IMNF)MI4Q
MHU228%C4WC_KXACI:R>02.CEC+,,DCIKLA,C7.:YM/(2Q]R6X8)"6C%8WL.5
MD.&II(8RQKXWA]XV"$-?*(W-:6OFC:'ML XF=GI97&&YUPXZW1W7$Y>NZ#3"
MDFTA]=1<ZO/1-N@)%S/1&MZG&3"YX"\3%EG81 SYHL5G&)6BSUUNT*CX'3KZ
MHF@S%R]FBU'%;#A+IG,#'1N:&.FD<P8HVL8XX2+G QU_NC!('!8VT#>KEN7%
MP$8>7->PES8F!UVR.>YHN+ ![V6MNW%F%?V%,\%7M:81:A:Z]M=O_?IO7IC,
MDZ-[/B463<A$PB81,(F$3")A%@_1+ \?$['(>N.:T+K>&X'Y4'3M=V:6(]NL
MDN2QHF<%(*#:> X2+=HD H-DEBI(F,0H")%G#")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(J!G^Z)7^/I_FN-R3HWL^)10NP7-W$
M2B[!!FV5(B1$>V*F5Z1C*I$5'J(8H   <"@'6/4(\^OD%36@BYOK94.<0;"V
ME\U<JM9G$\H\3<-D4!;$1.0R)CB!@4,<H@8#B;K#H@(" A[H"'B'#FAMK7SO
MKZD:XNO>V5OBL+;6XP>'S2>R:YJ+9-X5@-@VYE2)"N0"=;M$J>5:;#V7'ZDK
M"C=Y$0[Z/ 5[K)-VLB11T12%B$GMEERLJ]'/I-O0KEB1>V7R54)\8G"PH_1C
MR\0&I>W.VT4XC%1O=<!K,FF;/.4MBS@W/?#M,Q)'ME=DZZI&QQG#Y*8(VCU$
M =/6J2I+'E\Y>(7U7>,+A6M;*M/H+B&T^[3MX54*XV6OM=CY237NX- J;(D+
M)/FDNA)SBSU!DQBW;%"1-)=NBSM22+5TU1)8\N?LU[E5DXMN%M0J1D^(G2AP
M7C3S" %V94!.M&DLDE3>ZT4PE^FJFI;8:7K" )E,=Q8(J2AT"*/V+IND2QY%
M9+I.S];[*"9-KR_4V]%KS[O9.FJ%EA[&2(D.FNGW'(GB'CLK1?MS1XW[6L)#
M=TLGK;]O9N4TBBQY*62GM;(_Q%W^3J9+=1VCWHO*U_9(BTDVW!V,1U$D_9C2
M[\6SL78*0[52&9MJ?PVKR=E;RM@N^M8:NNZM&IN[&SMDAL"FH5!U%HV?PCBC
MQ!':7=]#@#2[:#M"R@%O2(<2^L#6%K(YG/#W$,,8BD,@<68#BLN+Z5DB?9)&
MHDK#?T?1 92DONZ2%K2P7<'F6,,(QXAA7F'WW/.IKLB:-FG(65GGUE=Z_DY"
M(?T)%2U-9:=UO"%>)+U:0NNUXZ:NU1F7*_<SM_:[=#KV2#;+2$&WCV[FC1_:
M4S0-DX&N:T,;*T.$I#"UDKK'>"*G<V.1H&38XW8'6#RXB5W(5+B=IXW-<XN,
M9+3&,8+HFY8#).'21DY$O>"]OU0/HQ@[CV>LI/BBOTK'QD;"-9>,H4N2&CV+
M"+6B%)77]9D'$5.1D8RC&<?98UPY58V%J2,8+%E6[D[M-P\4</W>3LP$440<
M7.+3*W$23BM-( YI<7$L<!=A)/HD6LVP%C:1O62FP&(1N#0 W#BB8["YH#0'
M"]G#"/2O?.Z_L&9X,O:DPBZI]Z\3M:X2-6;VV[8X5[9E$=^6BNURLL'2<>K/
MV27[E49,%9-5N[2BV:;1B_D'S\S1V=%HQ6!NS=NSH-E>GZ)]&:GI9MF#9-/,
MRF!AEJ*BI>PR""FA(#Y!$'-,KR]\<<;,; Y[VXGL8'.%$CQ&TN(OP YD]?!=
M2INSR7P3&$G#I42E$1Z(&O\ ,F,!>?4!C!6R 80#D F A0$>L"EY\@]I'D+H
M+9](:R_&U#"!?L\X-NRY[5B^=G[ [SX+\^SR7W_%VJ'\O9GZ.X_<+V?_ )PU
MG]!@_3IYV?L#O/@GV>2^_P"+M4/Y>S/T=Q^X7L__ #AK/Z#!^G3SL_8'>?!5
MR'9V;TL( /#S4@Y^]?9CQ?R=^/++O(?0#,;?J^6=%#^G05?\0'L=P[BKPAV<
M:\*\N?#]5 Y\O%>I<?'S]^O_ '/Z/NYC/\BU$W_KZJ.O_0HN'_C_  58J"X7
MP@<->.5^&GSU*^-^S7W5?H\]"58O/WKQ+#R^[[0!_7W<Q'^1^C;_ -=U)RO_
M ,SB&7^G]?L[9WY^R/:KXW[,S<EO'HJL%Z^75=94?^P<Q7^2BD;<?LQ4G7_H
ML7 @?OW6IWY^SRMF=>[V9*RZ][*)*T5I8F<+IF,53M%WMU^D!D;P\<'2F;K-
M.9V60:F;UEF5..1>.E",$%2KN$6X$(NZ<J *IL63R84K+_XVJ#;+_FL8]?W4
M]9-M+*L27OZ.AX\?9P/LZUE-MV6JVKCUZ8KA?%U^%\G^'QPOXLPY/)S3,O\
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MZ#FO>XO=QKR7;5;;$YX=$UP+I'DRMA:US6N,\LC27@M:[?NW1LYKFM: ,/\
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M<R"%K@6QL N7UN3EF.L]O5KWVM=3F(W'M=FUK;)KLN]MV=207;UAHE:ILC6
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MY'V>*SJDCOI!)-!'3E-2113(DDDGMPA$TDDR@1--,A: !2$(4 *0I0 I2@
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M.;C:7,<V1K ]KL)!!O&PM<+V&(%IN".D[_@A7$Y_C<:(_DCL#]'SJOV]T?\
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M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$6.I
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MI7:I]QO%FK^>;OVJ!Z>E:A>((/UE7 J$*F9B^68 WH#-FLDJ 7/EC;'>$F3
MXO--/B:"V)S''S@PX26@-MGC:'WK+JUS(39C'E]I0UF)H:)HK&SGAP&Y$EP'
M$F^5G8;4J5JXAR1C=XZI5<4DEXEX]"':L#%*B_;M)H.]KN45OADT% =,X-RR
M.FT<IS!9M6+,>(&+<S0R8-E8RUM3-@#VMWA<,V%T9QM8*6Y&%TC77<TQF,2
M28Q$H$E?A!,,9<6$X +6<&O]$N,]AZ0800#B#RWT,)>K*YON\9FVN:S$P<5
MG;+S$J@#N"!^HC ,9:L$KRDZN2[I)@I8(R6G$EXYL@Q5%U"J.F$J4&DA&!<;
M3;.C@;,^1\N(1L=AEP R.CGWNZ!IKVB?'&0]Q< ) U[#B:\VS-6OE,;6-CL7
MN!P8R&!\8CQD2@7>QS[M &;+M=D6J3RTEO=.V(O(:+C5X$*]"+JP3YHS!F>4
MD9>GM9ADG-(SC=ZB^C&1[6^0>*M7;)LW:@F=C)JNV0DLQLV88"V1[Q+O9 )6
MN=BP,CJ'1N,9B+2U[]PTM#FN<77Q,#77NO=6[T%C6EF[82QP%L3GQ!XQAX==
MK=ZX&Q  MA<7-M827/B6!J@HIKVJ'74BVJBI2%?I$0?&L'<\BLH0UA67%M'U
M\%'"<>W(ZDY!^5L:.(\:.W'>NZ:?9&)P%7/A#W $X27-W5V ?1 7=+9I>["Q
MK"<>%S1CH$VT,KT\6; 3;$ ';RSK_2$V;'<X0"Y[K8;@D-DT[:=X-7-.2B*3
M#.47];B'=U7,D9T$%-N8^86FTX@H6=@$H6'>M(Q)")4.@M)]\4$&<NL15^_@
MK,<&SG-J"^ID!9-(VG%\.]C#XQ&9/H7EF\:YY+P"&827,%FMDK?)6@PX(F$.
MC89B1? \M>9,(WHQ!A# &7!=B #S=SHX\E9N(QA",R#38>4DD#0_;'+MNBDM
M+I/(AZ^E"K-6-L[5!O(R3;(18&$\FS<]V)'*LD"1E5;IAV2Z1W^$2,8=Y8-<
M3@+9&MCL70?2->PE]OHW-PD'4!4"2O:P#<L>YH9F0!CNQQ<+"6S"UP#;W>TX
M@>!*N![/Q"(LES'I]<<R(1@NF"+6,,5HZDEJI$2)XY^NM?P4B4H>Q.I.+!VD
MG+C8@8@W0;0A1+*KT"'99</\(F#"^SB7^DU@GD8'- I?I#)"UC[$Q[G%<F0_
M1BK>5^$_0QEV&X ;DYQB8XM),_HADA<VXQ;S#8!@](\:$SOV2)83NX5A".FV
MO+BI7DHZ.:.&3RWJ,*@O47:RTG8EEE'2L@-L;$A'#./;QZ+8AIIXMW6P,>3'
MLQAB#972M=5T^]+G.#FTX=4"H: R$  ,W#C("XO)^B;Z+U&.N=O"6-81!-NP
MUK2#+AA,3KND<22[>C 0 T 8R;B]$M8N)*+,R:M*I6[$W77E72TD^;GC7C9N
MI-@2+B#M&UE505<H0?=;]634/'M5!09QPHED%B \J$6R'XG.GFA($;0QIQM<
M1$2^3$Z . ,N%N !S@2YU\'U8,FT&V BCDOB)<06D R6:P@2D$B.[BZ[6Y!H
M&*V+]D;MO^-E!CAI\"\2<RC2,B'[>"=@21<IUBZRCTCI'P\42B&+V6AJRDUF
ME'KYM%Q\PL1^U6DR.6T093[+>S'OY6EK'/D896DL&^IF-+3YJ"]S8Y)BZ,-:
M7OC&%S6872'35S78=RQP+PUA#",1$<SC?Z<AC7.9&&OQ.#6O.(%UPPPMG$>F
M6/3>T*N"0CJIH/\ D=9P^,Q<1*I["J18M@09*2!I(B2;8XBFPC#G%M(JK-CC
M,-SX-DG&6U4UR)RS(!N(2 1 C=%P;@N2+XG@8F6=]&39=H#"'0QZQ!V9+K%E
MY#?&&W+A8<&WLXG)PV;S3K8IA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
(B81,(F$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g609070g00a36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g00a36.jpg
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M  (1 0,1 ?_$ !X  0 " 04! 0             &!P4! P0("0H"_\0 :1
M 00" 0$"!P<+# X&" 4%!0(#! 8!!P ($1()$Q05%U?5%A@A5966UADQ-3=3
M6':4E[74(B-!451WA(:2L;;7"AHT-CAA<W21DYBWT=(D,H&ST_ S.5)B<;*T
MPR4G1%:A0D.BI]C_Q  = 0$  04! 0$              0(#! 4&!P@)_\0
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MI8<!V"GHMUEZNJ)\T:_[/XN>)[32PX#L%4SU!Z]H(O4%NGC*/3QTYCS!XB;
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M6+%38S/?D^*=A9F.XCH=\4CO JUMFZ_IJ;;2>-O15?#/!O AF]8V[,;8)S9
M[J,*]1<$;.U[2G[)(*GXI2&1IUAV7XE-U/503&*/1*2.=G1(-6A]K+T T\W"
MDP6;9:W5;?L\MN/S[>-XR[;WZ[^/KV7X</%<<+;-7\'42H=<UA%H?4;;JW=-
M$77;QO2=V]P-+*>Y>D;NF.$KUKJTUV>EP;?(,PJ^^4B'I[HTH/FJ:S 3&CQV
MHZ6;Q;"!<7X;O'VWI;Q]>PV'6=O;[-G&S=4]"M,U-;M$705>+0;.::9WU.,D
M#L06[.V9<NH>:%)W>W'WX3<*,)D-$0_?&#1,%,1F$ZS#<6XJ+F3(@F]_-;Q
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M ,T3UO&6*&OVT*Z6+#)$D16R)):WCV6W^:]M_F/"E[>79Z3:_P!?)>K)LG4
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M5'2^&>_HWQB>%OKV[Z<RE>]W=]_<G?>_K\U8(5TO:G".0)@JXWR&7K<2K#*
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M%]VK^;\XKZN.?-=9U.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE4;U)?:6N?\
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M7E#TBY,L$&#PGH3:M&]$T04X4N:E^7,+^)*$Y[G4I"F6GK(R1FLIS-+,!@X
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M.97G"<^,\M+"W\&P=*%,I*<3<)UTAB.+<U=&Q3[C:5'Q))-MMK5E1392OYO
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MJENN.5+DZ,S'DM.2,"E2"\6T-K=P]]XOR ELH2A2E++SX;0@I SNA"4D*"0
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MMB4P^[F;=05M[*ON@L2%'8; A1V D&W BQW$$=508\<ZH]EM; N38O;KU6M
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MV(8BO#8$K&&%P7\05-D2V8SZ)F&85A^(XC.FQ6&A',&9J<-4B-A;[\T/N2$
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M_A6+NX9 PM$9IMF'(G3%J,E"U/S)XBM.NVLG5MHB0(3+;1+F5Q#[P7^V"VW
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M/E==H?H?B6F&)")$!9ALE*Y\]:26HK).X;@Y(< (88!!605**&D+6FM""L\
M-Y^O77F_X._PM[FZ[?(T]U-2:_7;Q9CTU_6MS'Q6@E9+Y*S7'X6O";&7%-#2
ML#QR!U2)OOK]T,5J.**2'+/AB;9/0^4#DIZ%B)Q?1M#\F#&80G$8BU%Z2UJD
M!*Y[9M=QIRQ<E-I YNHJ=;2(V9,>XXUE%TW(ZQO/E\_7P\F[WCYX=5BG%*<4
MIQ2G%*<4IQ2N3$JMS*)>F!MGFJQ <>[K0>%6Z<2CL+;990ZXF68"S9Z\ON84
M\I+DA24*7E#6$HPE.-G&F0&64MOX0Q+<!45/KE3FE*!42 4,/H;&4$)&5()
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MX>890A[")+?:EE;Z.]A>,.9QA.51IA%<9P705Y2D%,G1XJ;"2HJ2$2"#G!2
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M6AMCFCDW ,??T=F/179L=V(RMZ,MU<4JFQX\AHI6ZRRZ4I1)0'+LI(4%A(4
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M*6:'/>,'F%N$XTM:M]@DIV;A.'RGU!<AV*T9"PE*0J0E.1\I#=FRDO)7E6T
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MY^OT#T&_>3H?_P#XMH__ -IB58/--74TXI5J:K^R!7_,V?\ O\\T>.?>F/\
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M*4.%J;4#PIF7A<=S+D!V8B<RTIE]V.AF3'<=V,3"Y,UHO,NX<A 66R)>,81
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M?(&%?HE/15J_U;T+YGU[V=QW0X_^',8^4YOY^G<3H9^*.C'R!A7Z)3T5:O\
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M[4J%C;:F]K[#LVG@?'5HHZOGD1TQ_< UGNK K[_NG7CM\R57J(K.,=WW/_\
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M'"(@CG$BS*U"6R[F#)E627,P;[Z].HC8FM9_6%T('8%ZHTV$#);_ $F3,.S
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M8II*>2>AG*^0M$H/.'DA<^# @1UNY+,>?!Q1XPQ(:PY>,1(W,6XC7,N9' 6
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ME^2P0J45M8ZWB0,9I3C#!,=Z$I+;\EB0E@NM-NZLI( -APMM)[>%2ZS=3UJ
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M""+]6P@CJWUAOQ=:O.E022 """;VW$&_"PM;JO47]&)G]W#/Y<K]%YA]#O\
MA6O[?T:L\Q7X1/8:>C$S^[AG\N5^B\=#O^%:_M_1IS%?A$]AIZ,3/[N&?RY7
MZ+QT._X5K^W]&G,5^$3V&GHQ,_NX9_+E?HO'0[_A6O[?T:<Q7X1/8:>C$S^[
MAG\N5^B\=#O^%:_M_1IS%?A$]AIZ,3/[N&?RY7Z+QT._X5K^W]&G,5^$3V&G
MHQ,_NX9_+E?HO'0[_A6O[?T:<Q7X1/8:>C$S^[AG\N5^B\=#O^%:_M_1IS%?
MA$]AIZ,3/[N&?RY7Z+QT._X5K^W]&G,5^$3V&JX9Z3M>1RP4^QKO4[!VN0PX
M^O&6:8%:*@8%=81%K\(,00#3+&1 <9MN.'C0GF&1C"$-0D,MI2G&V4_I&IB1
M%5CV(*C2W)#LJ.K$)Q8DNRU%<IR0T7"AYR2LE3ZW$J4ZHE3A4=M3S-S;]T3M
M\1J0$.GL,6L NV% 5))6D(VEH/8YP=B6<%MH5)4VV/*OC')T1#2ILQ3*6'T8
M:5,EJ;PE4E[*\5IC%F(K\%C$GF84DWD1&Y$A$=XG)<NLI(;65:ML*S).8(0%
M7"$V<R7:VL3;R&MZ/H0;#;K3,0/3(K5,:RQ3VHPEAANJ,*&.!5,UM#0U*0;2
M@[SHK+8S$5&1KCD'*?)EJ:S2N+BCAF*7B+JU8@<T]2Y$A1FJ#PD!4LDDR"'T
MI>!>SD.@.>[ -.9.;?NB=N_8:V)'3R#EM2V)5>HDEB?#M ^<S(!Q'FIL"[R6
M)MT@RVW!2D28=NF18TNSQGL+9/R8[#Y5$MUEM2:T,XN@H4C$WT*:<A.MJ3)D
MI+;N'(4WA[B"""E<%"UHAK3949*U)9* H@N9.>$3U=1ZMW96^[H,:_$7 ?#T
MQZ"L^U:EPW1+#D5=H8+-'F+(J.L;EK)YDXPR9:+Y1YP;*M-$42$RVTO8I3&Q
M1*PZG$74N"*80<2_("Q#4R8RHF8'-S94=2F%,7U19):*<A*:<R<V'6)V"VX[
MJQ\GIMK,UBNQ9E5UY+C5"&R/J<>378#[%7@1UBW6(->:=$*;"PV' 81QJ,-3
M&9;6'%K0A*A\3+-U"<;;5+6WB\I"Y[BG9RT2Y253'5!X*<E*"@9#BA)D K=*
MU$/O FSJ\SF3GA1M\1J0HTTXV5D'6VZX@W+'PQ,LPB,I)64*'29TP>,D$$P<
M2WA\&64)RH<-QY4>+)(SGV&T.RY"G,0X=-+"(QEWC(=<?0P5NEE#[J&VW7D-
M$9$NN-LLH<<"0I:&FTJ)"$@1S)=K:Q-KWW'?60]&)G]W#/Y<K]%Y:Z'?\*U_
M;^C3F*_")[#3T8F?W<,_EROT7CH=_P *U_;^C3F*_")[#3T8F?W<,_EROT7C
MH=_PK7]OZ-.8K\(GL-/1B9_=PS^7*_1>.AW_  K7]OZ-.8K\(GL-/1B9_=PS
M^7*_1>.AW_"M?V_HTYBOPB>PT]&)G]W#/Y<K]%XZ'?\ "M?V_HTYBOPB>PT]
M&)G]W#/Y<K]%XZ'?\*U_;^C3F*_")[#3T8F?W<,_EROT7CH=_P *U_;^C3F*
M_")[#3T8F?W<,_EROT7CH=_PK7]OZ-.8K\(GL-3RH55RN-RUR)+<B3,\4E6&
M<+PRTVSXS*<)4O"5K4I3F<J5E",8QA.,8^OG.R@PC$"RI86MPIN4@@!*;V O
MM)))).SJV;-N3'8U(5=692K;MP O;SF^WL'$S/F?633BE.*5U!ZY>E2+UD=/
M=BTRJR>Y$P^4#6>K6%R(LA!@6, \ZN*@K!;=8>DC)\.5/&RLQWDR(>)B"#+<
MIR&F'(ZC0_216BN.,8L(_.F@V['DL!61:X[X 46ED$)<0M*'$Y@4KR%LE(7G
M3;<1K$%-[;B#XQ7SSY_L?WJ@[<]FX-"YQVY[,Y(;"QG./V,YQBA9QC/9]?';
MGL_;S]?GN?V[='.O"\;^+@?IPK%YJO\ C)]/LK3^U_NJ'UP:$^4-A_0'C[=N
MCGX+QOXJ!^G4YJO^,GT^RG]K_=4/K@T)\H;#^@/'V[='/P7C?Q4#].IS5?\
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M.*:4XTK+:EM-KRC*<J;0K.4XJ*"23LVD\?95(6  -NP#A[:E/OO]:?$=Y^3
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/$'9]1Y*A2P01M^I\M?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g609070g00a42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g00a42.jpg
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M 0$! 0$!_\  $0@ Z@)8 P$1  (1 0,1 ?_$ !\  0 " P$! 0$! 0
M   &!P0%" D# @H!"__$ &(0  $$ @$!! 0'"@@)" <&!P4" P0& 0< "!$2
M$Q0)%195%R%7=I.6U3$T-E:5M;;2T]8C-7-UE++4UQ@B,C=!46%Q=R0S.'21
MEYBT"B5'4X&ALQDF4F.Q\"="0X.WP>'_Q  < 0$!  ,! 0$!
M 0($!08#!PC_Q !)$0 !!  "!0<+ 08$!@,!  ,!  (#! 41$A,A,5$&%$%Q
MD='P(E)488&2DZ&QP=)3%2,RHN'Q!R1"LA8S-')TLS5B<T,E1(+_V@ , P$
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MRAT38HTC;2,ZRTV\2CELR:R\[74\+$ .'2,8PNGFCLS&+5V17D:W0=,W0GE
MF:36<V%K8P@HOCA9H56ZNQ?,O^<8YSLHHWP1:S3@US"<Q&[2BC)B<!,UTCB^
MF.KN#IC5U4U^!T!9*@6;IG4QO4\"EBC]5NIF+69='Z:35->*384T]@M7XQQ%
MH@@%E)18=)?&'(7FR4N,8<7N80;MJ6S)B$4S#-AU"-X?'- QTK9L2CG#&N;&
M62%AB=(&!CFA[#DT%BU<0%:".)E1\;M7=MN86OCE<(S%2=&7$%VDS2U@9I%S
M26O&;B'%7+<-K4O:;N0=YO-!77D]!^L3TJ. 7JRHOD-T'KAJ5F^BE%H05K#-
MS=%J.RYP5?;*#>0E3%#8\.)/:7IPU)Z@TX*]@2'';3 7BU*&THH[AKOT"\YP
MAVK:V3<_2 TBYS2MJ2>*QFV:6'0&%0O(9S>(NM.DKZUFD&;)"W2)9O;D3H@
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MQRXCH'0>(]7:LIGT8W28B32#$NMW8O<-<CQD2F;!.;)N1B_UZ>)W5&W_ ![
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MF2GOJ@S&75Y8=?9[,Y4V\ZWW7%.'3GPZL\^I%T%PBK2V_A]J?^<[=^B!'_\
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MW;MK$+4URY/-9LSN!DFL2OFF<&@-8UTCR7.#& -;GD !L 7W:UK&AK6AH&X
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M')DH;C.][!^2\^-,>^JZA$&VZ]%C;3WQNFMVH;,]>&+0AE;I2,J3 .D<R-I
MTWM:2X8F5P.1<_M/>J&VCZ0,Y6:[9BM3&GHQRJ5'=A O4[['>B%(-IU$6U5!
M>'2Y-;/%1OD),/9<.?WH$HB],9>B)9?A2(TV(KN89R'BLV*T5J:%T%FU@\<5
MJBYKXGUL5BQ-XD:VQ!%)K&OPY\>3VQM80_,/:YCEB9G]#G=1+L_KE]U+-']:
MI:XMWN1M&Y4RI5^MW>NZ^K&P%%+1KZMW.\&!<^>6H, +MJ'6["U<:PN$TB9
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M&S&)K7><_CO.[COZ/'2L<UZ0_7X:"4++=V1)!P[FQK\4?[E9#@[5:G:X]<)
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M08^<5]2--!*[+/2?L&TYG+/AOX^,MJHJV^DD(/!I1W6<*63B"J?N<D;C6<O
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M'H]O#L7/<STA6P1!U]XQK&](J0,AU6L61@.5JA2T("=-ANC#I%I'JEWP.%3
MQ!/6!^Q#)+JRJR0^(-JS)MK+$\OWF<A:4L+6PXG3YU-'R7-=TT=J*L9N44-U
M[:TFC1EFT]."!M>5HU0C>^2T83I,BQUL@/\ $[+,])SR'M.T=/\ 57G1>MRF
M[$VO-U)6S-K?+QEF8L8T[+ >J"!2NC!18V,0,C663=A:X4,LC#!2Q5$+7R\H
M<8AA3!&0/4VYQ;O(^[0PQF*6(ZPB<(7.A#9];''8DDBAD,KJ[:<NF^(Z45>U
M-/$U\3YHHVOS&0E<3_$_KS._?Q4)M/I#:O4,&UE@>UVHPO8EWUF,FR9NMP\*
MVGM:/V-J^R:U*L.S [*QU>Q7D8;P:6%*V"6>!":P+,F'2, 9N5N0ENUJ1%8P
MPNDH4L1D8UF(S/JP8BVN:+;#:^'2D/GYP<S#KHH&P3RV988FQODAE<,_*?LS
M_P!1W@]V1ZEEVCKLD1Z7M6YZ_IFU;Z#UG3+#8';<QZA$4>2>":Y%[,56B$LE
M9F;>)RU7C@M^>5>IJQJ7LS!(N05L#+ >5A6Y&:5S"Z=Z[AE&?$KE>N*CC/+=
M;!-B$N&BPQL=9U27.Q#*V.(7!)EH2RMB@<Z9K7/R)!?EQS.6?KV_=1J_>D&=
MJ@ZV@6@UM&[,$:8NFQA0\\9HY$$U9JIJ!W;+M5L0^I[&+7 :AN!CRSA)T-$
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MGXON>+![<?\ ,JS\?9C[DAK'Q?&R_GL7'(LOA%@%?XK)?]0F?^7<YDS^-O\
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MRLWL^Y_[V#V__P!9.?\ LCNX_P!;K'Q(?(LOA%@%?XK)?]0F?^7<YDS^-O\
MW-^H6+_X'?\ :[Z%<K<[RT4X1>:^RNA^ZW;;EDMPW88P7KX_=QLY5.<P5R[C
M7U^A1?\ "5JSR&H^82I>PS5=JYD%)[ZVXCZSR)RFVY#"5?H>'<LZ=/"J]22A
M++>@IR,%L&(#G]%[_P#AZR,SIAE"&Q9AG:,B\" L!+7%?,LS).>\_P!_[?-1
M^Z]"%OLA.R$67M73I=IB]1PEXP7]<,F@ W;6]V]MT]\3+CUF;(?E# KYVJF8
MN)@IL<FRF7!,TE'ERF)7WJ<MJE>.O&1B3&UG<GY1%%J3#/)A6"'"K0E8ZPQH
M;),V"S"XMD,G-XA*R-S&EK0.S=N^>_A[-N?L5\2.E\S$TQOS4M4)U>JC]C[,
M)7*BB1,6</JH2KRW*5/E44J-%QQ^1@2T2Z]81=FC &G6$BK20DQT2I3S\=?$
M;RDA=B^!XI:CLVI,/PZ.I=EE<R2S-98+C&W8I)72:V:LR>"6NZP0XRUF,<6L
M:URNCY)&S:<QU;.Y<[63H3OYH:A+(K0^&),'J"BB]>2W+,J@:?<W''U7!KLC
M5KK%00]XU&E4(S=F'$ *BA5IL,E@(S7TO-FAW?K<M:,,A+I<;TFOP)TE]@K<
M^Q880[$WV&XF'6R,KK+T--P,]K_+5VNF,Y!ADF@?5["?9T=!V^Q?[8N@*_V"
M;N]!:\5NTXV)2-@! EILBF<G2I6TA*K#JT*\PH]!=+R ]!-UI@Y7YLG85M;&
M380B;6ZM6B#1&205^75&!N#&*E8K?L^Y1FFJUM+4115IK+K+Z3W7A"V:]#8=
M#.QM"H9(WRQV+-F,QMCF@?5XR]7CH 6UM719M!W8-RMU.A=/48;,K%NI=3"'
M*U&17G:L9JU*K]0#6VK#=:J<*P* [4D2AXPU;+?79*TB\A0%0BPY0V?\JW+#
M#11IU;<F/.D99JW+4T-AW.!9ALW9[<U6U)B($4EYMO0DDAJU+#1K-=/;<YLC
M+H';EEM]9[/7_0=2_ /H1LT2MU"K.1M8@@(&O:SKQD$-+V,_#L2:EU%5G<EM
M+$I,ZH D2)MO#BR\)V&@7#&1B<Z,,BQX(!EKRMFY;5GV+=G2Q*>>>?$9X9Y(
MJ\#X#:P"QA-6*-K+4Y:RK+)$\/,KY'1L=(YSYR=*:!]7S[OHOHWT$V$0'GP:
MO/UT'41$7 >=$L1R\(#>AR^IP1M^BT>X8'BF)+U*C:J%O:F)-M(DJ!C"4D:'
M&$P/C19</+BO+,Q]EF(3:N6I)!*YT3YZ4@Y.2X5=NU#)*YHN/Q.1N*1DEHFD
MC;)-)'.0YMT#ZMVWU[<^&S9EV*.W;H(V/9J<3!,.Z:DI/57<8 )3"[EF]AM!
M2]C6P=90LW3*F:S(><R(AP7:]*7D)2\MQI[KXQE@2A^KSMBERXPZM<CG(QAN
MHM81/-;AYOSW'6X?5?7F9C -EK1K7O%AH$US-S&B4NE+;+&@>([3LZO9LVKJ
MK<NA+3?MO4C8@N#K&T"P5?$ $#MFMV1UW7I,;>QMLD;#UVS7VTNOVXF-BY!/
MMY-5!Q*1X9QX[,%I) YWF,(QRM1PFYA\C\2K23SRSF3#C7 OQR4I*K:%\SDA
MM6.1VO:=3;!+Y0V".75SLI:=FP'R0-N?1PR7.:.A6^26[# (&=<,L$5CXITY
M!78EG=WHQU&47<;MJW&V^(2RFSU^J54Q3Z\S&F6GQ7K,02DX# Y;$M>@/+6B
MTP21PWRZ,2.A@>*X@P8GD_>P@5L(+92[FT]JU#<L%S*V0K1_N)IP9CCH'U?/
M;UJ+;#Z(+34J;<)6OPE,F2C6-@A7*U6(!"*Z4#77JSU?L[7 Z9%B0!R7*_K3
M7  X$E0F9+2 ,=^7%K2'(,B1(YLT.6=6W;J-OS6V-AYC,+-E\;Q'-4Y+XEAV
M(R,<]\A$^)8A/!,UY:3.YK'V2'M:U71(]>PYY9[> W<=N?<MC:NAG;1X&/%"
MY6F*W 9M]^NH2K"$24!]0D;%::,=!C=:F9^LR9-H.S'J,]R>FK0-33XIZQRI
MT>80#1W:]/\ G5Y:85!/)+(W%YY#5HTYK4I:9L5BKUKL,TF(PLQ&*,RN=:C#
M.<R8I&Z&NUCF1S.$[)H'U?-;:]] UB.543% 3Z$U9)&PM_6F\*E(9B1+.UM.
MVV,IK^QOF2>O;O+S;=45XLV.!*C@QA,>Z2.IJEVJTA3!E[YT>7->"S*Z=EXU
MQ0P.K3#27OKG#*M>._7$4=^FSFF*3Q%\X=-)'(V. VJ=EH="+H'++9T_09='
M0<_Z9JR*;TEW.L]0M<VI/G4([  ;&O=VEWV:Z:<V_: UQU/,H0NFF\N!E#LB
MZ62>2\'4JR3(SXN0ZY&'@YS4QLWS;?*BI8P&QAC&787ST*5-M%@A&%5I:F)L
MO26X<IA)K+D;2V4"NQS9&M#I)F%IAH9D<]F0[=V[V<? B]LZ'KH?W(;N</88
MR'KHQL$/,52EX*)<3JVQV7&TMX51U#<=4)PGL#:XL!*CN]_$6/6$DV''F9KV
M$N[57EG4@PB&F^A*_$(J,K>>?NB/VG7K?LS!K()=IZJCA<L[7#^(V3&0TL;L
MFAM)SR'V.>?=\U'CW0=;2L@Z]ES5L^39Q6S Y V1P89-BXELZH2F\PJ1\EJL
MRGY:7*J7EU8RTJ<,\C-6[B"X3@2%N)V(N6]6-L+<L3C97EPZ9D,>J,,KZO)N
M+!9M8TV6-:19B99A.A)IL +Q'(T!30/J[3W>Q6-L?IVLU:Z9]VZQI00&41<-
MUC+E1*97(4F,"!5(MM/7YQT&H3$8'-CH R./.%"T((E$1F*Y+=ANY=6O..=0
MQ^O8Y18-B-N:>,U,'DJ7;=A[733VHL-O0B;6O=(9'RNDABB=,=)S@UKQD LB
M"&NRZ3F,N&84$;Z+-HQ(-H?#S-0@\V*L[5"CM=169Y#7=.@;$VQIRZ8IM=:*
MTF2,56_9[7=E2_+FT1P7!M=J3)Q0C 5F3 D;QY88:Y]9LS,5GYO9PR=^(/<Q
MF(6Y*&%XO3YY8,5QLG..<8A7+6,O"1]:L6\^BF+7C'0/J^?CZK[TCHNV-4).
MNW9J-,W&)4Y-D8'C;;FS28.JF"N]2FUX5GU9&KU>K#*;0FNDF*=)ACT:[&L^
MH0SD64JO8F5B1C=Y84+;;X8<7J.M-KNDEJ\W;)BCHL%BPM]?$W3V+)YN;$3K
M;7O-^0ZZ4.;SC0LMN@>G(^T_8#L47#]!.R!@LU$)'M?6Y]Z^:[LTJ+9)+N >
MU(E*V+8[N0G[)@!M;"Y*+$?'F&Z[)E&YNT2"XSY%$VQS0J!M>B[,O+C#Y)(7
M1P7ZH;1Q"LQ]=H,^&.N4*].*/#WS8A*TUX)(C8#868;&'",LKMF,EA[0/3EO
M]?\ 3Y9=:VD?H8V2RW5VEG-:..18L!D9/4Y9LS.G)R+O&V;8>_P>NP.GQVGJ
MW8QFN4^LGJ2_ZJJ(5;SKX%2JFQ@[EIASC9(@Q%H<][I(P*VAR@TL&JX6/V]^
M]\DBQ7EO_NQ<;K;<V0$_^:<T#Q'SX]']NDJYMY],UXVOOJ@;'CR->*J5/GZO
ME927B1V[:U J]Q.%;X!3)71CY(@+N%=,I@,Q(%VJ(5:V9HVS +%')1B8;CX+
MRCIX7@=_#RV^+5MF)-SB>XU3)9J0Q4IRT78(XY:D\6F7OIVY@',DK3UW1OCF
MI:2[/9ELV'/N*Y\5Z/"R"ZL+"57&H0A3.GPE%L)N"-R.E$C@#<C>R9D=SQ**
M7C%*Y?ZYA=*M<@U"E*9A);;G5NW"%OAW.\.7M>2U+/9.+31?M6:[!"^36-CA
MGP@X<QXRNQ.BL4;&5RLV%[=)^999JRALPA8=F[Y\3NV+H+1/23(US>J?>;E[
M*'I--UN6K5:B-J2672;$=V5>[=+547L5.IBAP:!6;ABJBW0]?K*84#SX@37P
ME?=8'(X.-\J6XA2MTZG.H&W,0BL67'.(7:\.'TJK>=CG5J62:2S4YU()9[&F
M_0EEGFG#I#0W++/(Y9^/9M/6=W2MGJGIONE$ZB[MMPF8J[H*P.[6=0Z-F'Y!
MX_'V-;*A8P0PC6R$)JJTANBPZPH5+*4Z8_.V1)?BG;<V@E"0I7SQ/E#3O<GZ
M>%1PV1/7&%C*1D#8('8?5MUYI([$;S9NFZ^SK6QVV-9A[0Z"J3&\H&D.)V;S
M\_9L[?4JF%]#5UA[BA7!_8X]6N8E]*O(IC."2GF]5C+O\-^LZPTT]%R/R6IV
M[)9-U.75K@KI"XL-3TJ4TB&QU)>6E-^$OJ-P]XQ!]&)IN.U8!Q.2E^QL2LDM
M<)-5<P9L8( #Q=#G -82XS0.>_9T=)R^2K,9Z/G:PZD+ 2+G3"TV-:*,4)!Y
ML@0JJ;59J838XF;8KY!GZ3+BHUN,3[P-L$B99JIMXQ*GU@>DQ<2LN)72U:Z4
MG+S#)+@G;4N1,=6NQ13,$W.L+-J;#Y65Z+V8Q%*ZI$RE) &5K6%1-99>8:D3
M'6(K$T#Q'5F>W</9XSG\'H8O@ZV3+.N]A[*U.UB.U:X$M)2R2(L>-G0D75Y2
M]P"<&!&.0-A1SXJ%%@6",001DT(I8822(<Q.<=?T'\M:,E5E849:Q9B4F)">
MM'7:\N&..Q**D^.1[X)*#H)7ND@=&8VWHX'ZN:%@:+H'B#ZCGENR\=0]G2W2
M;I6V:(H!VGV>55E,S+?*.5\756!*V HE\&!'.1")D+0-6P3Y&22&3R&2"J,,
MFM1)<6"0('YD5XQ*\[RHQBKC=Z"W6;:S949!/+:=*'32MFGD#HX9K^)O@C;'
M(R,1B[(PN:Y\<<#'")N301GGET;EU'SS2R3A%==V*:VH ^(9M\=@?!)%HX>/
M(8!%S*W"<UJ5)8:<8"#R,EAM;422M<R0RU#:RC"7I#:W6DKXFNF&Z1_O%;NK
M8?\ 2%!P.WNG"Q1Y$B)<:4.\JPJ6_%M2UT@FB V*BFWB>!%R9 E7!,<=+0[)
M*MPUCHSS!"%(E-SA9*-$:^;]1_O%75,\P</;P^2PY.ZNG",'L1]5A#R ]6=B
MME9X^OV(HRZW,E6*$W-!X&AI;EH%,RJ?;VIYBL(+BA>:C:E$ID1%<-*@M?-^
MH_WBIJV>:%N*GLS0MX,10%6+ABI>=Z]7"AX#F(:ID6NCJJ8(DHCI ;$8DAG0
M]WJ9@.;9=6(L8@[!*5Z:4@+7(0U\WZC_ 'BFJ9YH\9]Q6Z;N&B'D%G&KGJ]U
M $6V;.K;ME:6@*%>3%6R7+*22S@<+=1.A+;(3,LQ%IF15)>SB0UE;7S?J/\
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K<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g609070g00b42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g00b42.jpg
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MNW,VTC,D$C1O*FT8R58*64D*2H8A2VR &(4X) K7UOI^WO>0%-/:^$6N]8N
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M=.,B9Y(7.@PILB3&=:3M1W=C+-N(Y86FV=K=C&WC81\8('T@DB.R?7575F4
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M.!:S"R I1IJ(>OI:IUV>=4. 0RSQ"6M$=>:C;64]M;RPR.UR0%:-8=E0TT4
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M'PG(<U^.U.$SXLQV,_'<1CD&I6)3>>4*%W=Q*=M70B.U5&N&*NBLHB62-FR
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MC\>:A_L&Q>?-/T@_RFE?\EY_ZK:O;=$/J7__ #6WPGK]%A#'>@3L??AR<?\
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M3JHU8_33^6!+&W_D_P#9"S,QB'TLL3O.6.7]<78 &(\"P.G#Z+?R6 -[]?\
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MF,6U'$'N)2Q:-HXTWT[F8!(&#1RK%((O)PXV998)X?K$3JL6PD8?9=]B&,*
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M55 "J6B:>Z."4DD!C%Q((8]I@S+Y.\B[88C9E: ^6/$[.LL VF?.6N'O%=,
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M]HH/6JL9QH%10#;[1?-OV2X#"4G3.^]YFI3P^T%BT%]-VF"4#"$>>'"/$),
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MC)HK(?PT.K1!QK/9G! K)AB(&<9QVYQY'+DPXE>/<[K@1M.<Y[._C&,YQ/\
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MMT)#1I&Y;+!LL[ D':4DAA^F;88_1<I&%)Z.3':V03D1R^C@2#C/8<'-4'U
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MBE5()&&8[PXE"EQE1IBV9"6^Y(;:>_YK.>^TVK&<93C/.N_3K_O[-_TK3?\
MT2UVW^C3_P#+*'&?Y\U?F.O:@R>K@3Q':"#UUZ,:TUY&UF"( (9^PV"-.LM@
MLJ'K',;G28#EBGK)2QT-]+#3^1Z)KLB6VB6[*=1)F2\,.L0/!P(7QROT!7C[
MZK+]W>H_X:B?Q_\ &8^>?H/]#/\ -FM]GEUN#W^3L1[Q7Q?]*'^WZ7_0YO[Z
MN\JU7+-9^D_IZ'U37FJ=E$60VF)DX+N)3N*R/KD>,+Q:CPO#-?L3B[@.KRR2
M:DTJ'&C*,2(^)\^- Q)\I\=Z6_[S](/^KZARX?\ ZF2OIW1S^8-&_P"FV?\
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MY^;)7-+5/YMU'^@W?]Q)6WI_^WV6.?E=M_?)7YDO4<NS_*U,>YVYU';OX?\
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M/LFJ)9/*RLVZN'N/8.'$GEV=A!ZZ]G^*QJK O^FG8O\ 5KJ'[_I)N?\ W?\
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M.-NY<%S7GX*\N(;<RIC/?0E7;C"E2;UL=4G^VC1?_NWWG^'_ /<__%_U_?\
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M0E2K$XI3BE.*4XI3BE.*5&K;]IT?CNK?I.'Y1S]3? UB_P!4^KXBD7[L#O\
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MBE/.0[\/A?*F/\3BE/.0[\/A?*F/\3BE/.0[\/A?*F/\3BE/.0[\/A?*F/\
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M26"(P;\;<#W(FD,<ODJW*H':;7#.,X]G+/J]/83CC6C =?%:;I(Z_7VF':W
M,4G1UE8!1'JUY<7,W"+V26C.%;C9+96Z5%K;D+7SLD,6-D:S(?00%P9<)NQ&
MHP")S3]"+@WDEE8W<-P\5WK,#3NMQLRII,FGQ,(K2WM;B\:X#WP6:*&.X53'
M*Z.;>%IW@;MQQ.!@'OX^GT#/'EFI.]UFB6K>1&SZM/K5*#7:J@7KF57!*Q3
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MDN8[4ROY;+86]UY)=WD2;HP;N"42*5DG29]U(T<4BH30MC..)&>SL[_=SX'
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M/5IQ2G%*<4IQ2G%*N'5O_,&?_6P?^Y*YUU]SC[F^*UL0?\?]7_\ M5ED,YQ
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M_4+K=U,1:KTZ"!V)(!F<ZQC%[%YB#,B:06VV:?!U();L2;(R2:(>7B2Y19X
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MAJ,0@0\9F#81Q@T'BB['%)P8=BAC@9+F'0FYA2>2]OK6(1V]K/ B)>*USO\
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MK.C=64^V';K6Q94>;.FK&=.M>ON]3*W*.6N8\5L1!ZF3[/*IK$PA-E/37%M
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MI=6'QE6^X$:QBIV"CQZ#/?"@W+(]7H,XS0TL5^9:Q4"/8B A>4OF7<ON..=
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MZ_VDEBP3(==:>D$*0(IK];HY(J9MW@%OPW T>GBU%A)+@BZ<V$46EJ+$D6,
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M;$IB9+G3)9^+!D1XZ0^9I'GU7I18:AIL]O!9FTN+E+:V:)9(C96]G9ZAJ%_
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M:/NIS2>U&3[NCJ]=J1&IP1%K9K@-BH6UQ5-GSH5JC!YUBH5+SL:2D@<:7!!
M)5I0,.1"%ID"RRIZ.P^SJSVC_*IOJKKOUYN'9E(US5J!M4=Z\Q=GEXL-JKD,
M*-#3@$& 4@PB&62A!G#!\>X3<%S<34.$51Q,JOP3X$RZ=%*$8ZQ\_)[L<>K-
MWZ+W,_N>%LB8_4G:CBA;6M.MXK;IIDVH_  0PTZ%9E^1'CU@Y!1@PE,RJSVW
M#%=EQGH!=34]#T9A0C&/2,]U7GQ4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4J"!]940$?Q:X%8$)M*1\@2S8G8,9TQ&$R3MALCPR%-4U
MY2##<+VDY*?;B>0S,S,QB:J3Y!C+:G5CJK#F:=U$1\7YPU9KB=YPC18<_P 9
M1ZS*\;#@^!\%%E^7%K\3&A^;!OA6'N^U'\WP?(H1X1CR:F3VU+PU=K]<00;K
MP(.";+%)9PJV&&0A:"9LAY/QY@@F"PPF:4F^19\60DX<ER?)-^6>7W$]BE:9
MO7>OVG6WVJ+3FGV3R+4T\W6 B'6K.V]-DMV-MQ,'"T'FY!(B^@PE6""7I\UU
M,C"Y3ZG%*RRM*IIT<@0;J59,B6V%16Q94"*(CFXRYT$FN.B%+B/1D,*)"QA!
M3*6L-JG#H,O*<OQ([C:E:TOK'6U@<&O'M>T<VZ&%. A#I>I@23@H(\SF.Z'&
MKFCWE013K&<L.#XN6HBV<Y;4SE&<IXI6DMFD-27<=!$V;7]:(#AQ1LQ%B,P$
MC&O&MO*D+Q)P)5!5.@RWU9=(BIRI HHO",DH4KR:.ZIG'PJ0OZYU[))FC4FB
M4V09LC$>+8BS]8".DS\:([#>B1S4]R"J458BO#A[L=F<Z^VP[!AN-)2J*QE"
ME?R_K;74F")%R:#2I P!#+#@0Y^K W8(4>?BN03L$3$<@*CCH9J"Z[#+18;;
M+!**XY'F(>96I&5*CEPT7I^^UA=,M6NJN0K#C42,L/'&MB(RH<*9(GQQV5!<
MCW_-F)<N8\\,P[YODYF3$R8SS<N0EQ3Y]M2R;0Z,2)3#)&F50@8(HAM$"LVN
MB)1*<V/3E$!N9.?AN2I2(*,Y1#0^ZM,9.<I9PC&<XXI6;6ZN!J Q8>MC610U
MPJ=-N1F5ONX<+68V0L9V<X[)=>?<?)&RD^>^I;BL8=DJ0TEME+;:%*WW%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4K#(8
MSF!.QC/9G,.3C&?O9\BOLSQ3G69Q2G%*<4KEB[DNIX/LWUOZT8J]LJ=EB&[#
MY\O]?\W5S7>8]<0/!U91ZM6(2;*MR[6.P7=2BJVTU)AV29'D3ZZ."09<U5X>
MG/S^7SV5_.>ZUTA[0PB*A9YR5EX1,#*U5@5'D,HV:B#%K2#LK$K-3ER']*.V
M15RBOVQ,&%M_%>DQIBZ*W+4&.&>WCZ!PX\N^K-U=$Z@B])MM:V39"E;N:5P%
MUK8*JCKQ,SP\]3C\YYJO@3]MJ32QDJ/+#P0\Y962V'2(LI,S,)6*16ZFJ?/'
MY%1Z"2ZMF;C8JD+CTH]4ZV?;:3L;8%>=K<VQAIP^F6-]BN,52QKCE"8Y-EM5
M7@29%+!5Z&]3!F"=@L1@B>2-5>&.?'J S[3G\NWJJ/5G/63(A:WA'</CR&7Y
M?KV,SV-23(:,RIFO6I&;#"!3FWI P;#9W!*I[%%;B%).9.HF;C,=7Z_4PU.'
MSU_Y^GT]U737Q6X;)K*K#3]SG4'9(V'5DVX_"JM0*>=2C5.&YLT=B+)=,5Z1
M$DVB;->P5%0@S:'AV8, <T/1F1.4Z^WY]7Y56,^3U<5^WD:+3Y51V(-;JX.Q
M1]F;1JK57!QRYLO>HY&M+E4&P0)!)\%"KE7Q$$C:"^[EBU.EC]RA9B"Q)I3A
M\/GY]G9%"3W6YBHFV!,5I5X5MDZ\!F3U:IQ7&Z2BJG45V+/0Q*\?G6SUY<J3
MI12(SFY<4YBW88D-'<@&WE/#Y_P]_75MZ-9Z@TJ@R-QS9#D-VJ$67!Y*+06S
M<2Q,7^SK&RR\JA+6'D39M$?KK3[07R8*-X)O/<R8?)K4H<=7S^?M]U=(\5*<
M4IQ2L:3"AS<,8F1(TO$:2S-C8DL-/XCS(RN_'EL8=0O#4F.O]VR^WW76E?NF
MUIS[?%*R>*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI6&1SG ^?G'NXA2L
MX_CPPOBE9G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*
J<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g609070g00m54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g00m54.jpg
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M  (1 0,1 ?_$ !X  0 " @,! 0$            &!P4( P0) @$*_\0 7Q
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MTC8@19.F_!&>6C-D+Y!(8XG/$3.<E+&%PCC#FL,DA:"&,#WL9KNLW6>UM[N
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M'BWCBKCSJ5@O%KE+_?,Y$_SYMG\_'Y^A="_\&T3_ ,LH/_:Q+X?I;_BND_\
MF%;_ .YE4$SLUUZ81,(M,>3>FNX7BZ<A6*.MHL1'6X.57'B#3%EB2AYO7$C5
M(K,C(JA=,)?U!6M@>Q,)V\1H= [!3#2CV6VT^EH=-4U+34<+Z=TCZ9S \NB@
MD:Z(Z0-3.QG.%Q;SM.3"3JBY<6DZINNAK-$SU,]5*R<1MG:_5:))F$2"B-/"
M]_-VOS<UI1B;:H<!K  126Z8N6SK5-6EJZP3TQY>W+B+ 99;IZ7E5V"V\6VF
M)@9070) %<A8 2@R%20;!JD"#XF4'.(C=/-$@/<F/3NCFP10&EE$8=3B2%L%
M,8XQ#3U\$DK'%X?/),ZK94%DNHUDD;F-?8M>-#]#UKII)O*(S):?FY3+.)'\
M[/1S1QO&J6Q1QBF=!K1ZY<QX<YMP6G-B=._*A<RLVU66NSH4RB])-'=MO(S:
M*2FV\A\M6M]JI@QCD*)94S%:O]:J$EJRK $C!*2#Y>/F MC@"ZG:9H&Q!M/#
M/"^(TNJ13T9-3Y/1Z/IV\^]_.N@YJ:DGJ8^8#G/=4NN^)UWNS&BJQSRZ6:*1
MLGE%P9ZL"G$]56SD0M86"77BJHH'<YJ-8VG;9DC2&-A[?2KS -4HZ!$N< +H
M*&CX8>$%N7((,+#R(?%%5H0-XC)*-!!E'YFK6."E+;!P#PPD:8[//H>E(L\4
M:01R3R@T:Z=\KJ69VO*^5TKJ:C=+*QU?/5/I7L>]T;8IX964\LH<Y[1$+,>U
MSF+0-"UP@9&*B(:L;8Q&)ZIL;'-HH:9E0U[6M>Z2"6-\\<1#6.,AN]C@'"]>
M-N%;A2N2'+K*W-V=&/8Y9'FV7Y:=?7*IM=MH\W07/112E0H*JM&PEL&>: :'
M:$(LKZ(_3[)9KB>JKM*4M51"ECI1"YAT>8B(X@(S3T]5%5CG&_RKA.^6G(+R
MXN;""^SFM![&DT?44]6:A]09 X5HD!?*2\334\E-YA_DV\RV.8$- #3*0RX<
MXJD'>DWD%_=A9=E*2B'].TR;@*TS/7=Z#/+K/-,)R:<\QN7#F)?BV/E88"6A
MWJE5)2RUO4Y-KGQQPE@!LM]I\(:,<R6QU1DYJICFG=%2B5K9]&RT3 X1N9%7
MOCD?'(*BHC@FYJ+F7%X>XKKSH2J<907T_-F6GDCA$M1S;G0U\=6XM+VO?1L>
MQCX^8A=+%SDG.@-+6M&>][QS4[X*)*YP,M&PY%:&'@7;?>@!+K#05UY.L3_M
MHD08Q)T"24'>*ZM(T6B=;V?2(\0@Y^-(;V%I]^=& DLI9HWRMG<9A3TKW4LL
MU-10CF&.?J3,:ZFF%Y#$0RI>YK0]OG;3HO2!MK5$3VQF%HC,]2UM1''45<IY
MY[6:T;G-J(C9@D&O3M:7%A!;#@^D3F./KU,@ ^6-A"UMBLA/#05DFX-MAZ&X
MYH%0398U\JMV%*I*#EZM/RL/$K""0>BS//$ST46E_1')=RBT:^:JE?H\N=.9
MW!TD,4I<)*VKJ##(&S0V9+%/%')('/U3  (9&VMH;H.O9%!$VNU6Q"%I$<LD
M8;S=)34XF8712^?')#)(R/5:'\\=:1AO?8[A?BJ^<>7/E.8LEH9FZ]<9?<G
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M?/DG]0+ZN-<[AV]Z:@WGL[D]PF&^?)/Z@7U<:YW#M[TU!O/9W)[A,-\^2?U
MOJXUSN';WIJ#>>SN3W"8;Y\D_J!?5QKG<.WO34&\]G<GN$PWSY)_4"^KC7.X
M=O>FH-Y[.Y/<)AOGR3^H%]7&N=P[>]-0;SV=R>X3#?/DG]0+ZN-<[AV]Z:@W
MGL[D]PF&^?)/Z@7U<:YW#M[TU!O/9W)[A,-\^2?U OJXUSN';WIJ#>>SN6'
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MWO\ 44+7.J:0QL97PL?64#&AE12TWT;W0O<?K^1E'#I;1]3)IC138XV:1G,
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M CP 5.Z?4$&*)M](XXB7MC,(9V[H41MD0;3FT=_0XK30[.M^&RVAM*4ZY(P
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M-;(:P@K,I KY4<*!U(<N<\SL&*:]//N,LV:-Y35Q]*N-(:0Z'"N2I89H\JJ
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MA]1)$-HD1N*R-*,=5^K<N) :0,72EH\U[39K9 T6+2 T %N%FIQVDY<21MV
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M$3*-1ZHT[4[()>3QS"\ZA9$R( DZ@+2!>>F?E;5!+8WNLVX! L2XK'5-P0+
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M%65BF:#15F!8MX^"8056=8B.J: UKBUK8-1C;M-G-A+6@NN/.YVSP\,MJX7
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MAT+R:T;5 $15U'HR3RNG<01SE.ZJJZJ*.0 ^;)S1<TXM(0LN+.?(X',%Y(/
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M76D;J*JTRS33(I7Z1=1U&F9HF,KXH8W>1^]&DIZG4;%$P.AIM(4VCQ3U49?
MZ*KC@9(Z5\[B<&:AMJ@AM_--\=9H OG<B]]UCLM;SYSW2T)A%_?3P)=>3N/^
MBGIWGKG2[=?.14\4<<B6"#!%E#++IYRK,/-$3C(,9-3.Y3R@X8,DO<62ZFPF
MM[FWHP'TG+Q_X7Y5^1?";3WO=J>1>^U=S'-VYK5\H?K<U;S>9U];FM7S>;U=
M7S;+M67U&ZU[ZHOO[%>3]QDGHVJ6UR (B)R4I$QY2NRR31EC3LY.4*,BP#M&
M@Q<J,&Y*&BI=5(1$5+C@N;7(0T;(H?C6.A&1Z1?H =?L5)Q&PV/62W\5G2("
M*"7%-VN]SSDS.G:BHY;EL)J;<Q+^1,DU1,#"0IL2&Z\W'QTD<P PR?*^C8\H
MHPL[8A1NY?<!U ]I'LNJ1?:?0;>/%[J(1MCX3F@UR,/S.!+1[;Q@SAT;S@6>
M&V1'(#<D&%DBVQUA#P#<C'N&-*7I8J#PU/I0DIC:USN'U1W+&P^6?K+/*9X[
M3,!UY7(9Z9^0/DHH"#5RQ-ZF#I.& 'E9>-#C=V3SI)\5%F"24D&RPL@$ H<P
MIMH=]IQ2YX?5'<KJ_P!IW6LB-7V#HQJ:HMWEW'"&=D14D[92[G6Y/2=J\)HM
MB3,DQR8MYY&FRWH8J-E--:=0%*B.[[^E]X'4 >P>N_0@&T.)Z3<*7UR838:]
M SZ1U"IG(:+F$BJ7IU0R9,%@W0ZG=)1IQ3.G_#VO2$Z7M.U:2G6^S0BQ(W&R
MH-P#O%UF<BJ81=;S@?RH;Z]KU\RU'_)=]4]R)YT/Y6-]>UZ^-1_R7?5/<B>=
M#^5C?7M>OC4?\EWU3W(GG0_E8WU[7KXU'_)=]4]R)YT/Y6-]>UZ^-1_R7?5/
M<B>=#^5C?7M>OC4?\EWU3W(GG0_E8WU[7KXU'_)=]4]R)YT/Y6-]>UZ^-1_R
M7?5/<B>=#^5C?7M>OC4?\EWU3W(GG0_E8WU[7KXU'_)=]4]R)YT/Y6-]>UZ^
M-1_R7?5/<B>=#^5C?7M>OC4?\EWU3W(GG0_E8WU[7KXU'_)=]4]R)YT/Y6-]
M>UZ^-1_R7?5/<B>=#^5C?7M>OC4?\EWU3W(GG0_E8WU[7KXU'_)=]4]R)YT/
MY6-]>UZ^-1_R7?5/<B>=#^5C?7M>OC4?\EWU3W(GG0_E8WU[7KXU'_)=]4]R
M)YT/Y6-]>UZ^-1_R7?5/<B>=#^5C?7M>OC4?\EWU3W(GG0_E8WU[7KXU'_)=
M]4]R)YT/Y6-]>UZ^-1_R7?5/<B>=#^5C?7M>OC4?\EWU3W(GG0_E8WU[7KXU
M'_)=]4]R)YT/Y6-]>UZ^-1_R7?5/<B>=#^5C?7M>OC4?\EWU3W(GG0_E8WU[
M7KXU'_)=]4]R+G0M#B=+0I*T*_$I"M*3OLWV;[%:WO6_CUO7Q;_'K(00;$$'
M<<"BTQUR_;)_D+D&@+EZK)UT*#Y;T>P($:#.0!=8<>BHB#\)_:BC=EQCPDW+
MR!@046$\Z&_$S]@%N,7"U,W,=(]:AR/05NAD53")A$PB81,(NG'?[G@_Y&+_
M /01A%3G4';^4Z3QM)37#=1'NE]TXZS#PYT5)S$6M]$5*'"HE!H23CIAD63D
M@@*^R>"DMF/D9D$N;U%5QF9L<(149.W/JJD+/$MQ46#&0B;9>(69AM<66):$
MQ\5RWQP/3GV[DGD)G1>Y/B/5WLNK<( '4B3'GJ](0?MA2%#A7#LZ=AX88X<,
M\1BICTX[NCCLO>]K8;%F:#R/U735YI$?>.-*34*?)MOM6=U4?<39GS\(#*P=
MC:BI*%+L5;@PWK9!IM]./MY4<Q9^.[?7XD?NVZ+FEXPMMOZ/X]V_&R8W&5O3
MZ\/1MX9J*%SW485*1H<FQR7%T^ L$E#<HRM<KD.]9RXI^U\HD0$IQRUJ+D2+
M$*J/$XJ:G3J]&R!8=.GI%H-L>Y@3*8(?'4/'@)COW^P>WAQ69YCNG4[$6NL#
M<65-^;@H2'CIUU,W6S'7+$\7Q]RD'+O7*PP$\%'-^UZRIHYB^.J]5/3U@F%B
MDP4RT&M08(>..._9TICLW87ONV^FV&>9X*+1\MUE[MZ;(L2L$B61_C^ 2 BJ
M7_=5K,:47QV'8K4Q SM[J,BMH,2Q<ASY4;*UV$M#1D2%$R4V<! AC$,/7[/&
M(%^N>=?+MP''*YZ,.)M:W:3RKUE/Z);DN-:= BZKE!6\1'TOD"T6 &6GJ=1)
M"RRH<(-8HNO3  5YDKS3MUP:^LV>L#145:99F3@!2CY=AQ/9OSSQRWJX[+>+
M=& QW%)NZ=4E'*KA\9"IG@$=.W'TE:1+C!F$1#5^K-2YJGKZ^3<0+7#1]4F2
MIP3C&#E4241,ZF6IH8B*TRS"3!0C#'IPZ+C\+[NDWPF(L>&-[[ ?QMD"2MK.
M)[)<;95A9^Z1;<'(S L7-C0*8"1AGZ_'ST4'-"0$D6?-RR)Z;@V#VXJ?E 1X
M8'<T&>./&--LI4J>/'@JB^W#QXW*SL*IA$PBK_\ Y?5G_-?D[_U90,NP](]3
ME-HZ#ZVKGM/)G'U&.& NEQKU3>*B9&<:?L<F-#1J(N+.B8TLDJ7D%CQ(6_.S
M<>P(.8:P5([44N/9*;C9)8DL3D%5I9R+5.DZ;Y!9,?YE:8MLUS_6):0JO')]
M>M9N[ZX)01VJG8H"N5NT2=;BYJ7X/@IVP3<PS$ECR04^DNR1XL@^PC+$#*PM
MN]%^/Z5N@^E0@'/?A^(Z"!B.E33AGD3IMX*X\@ZI7>39"8J<A,<B.Q%A=IQH
ME4:(HSEI1<(Z-=HU$@>.*K%0HW'=PDQ(^,"A8V9"KUDM<*U)!+.DERQ)RL<,
M.P9^/0@L!G<8F_KR'2MH^1/[T)3_ *V*_GF/R*K5NKBF-VKJ3T_,$RS$; 7(
M8=,E9ZX<^(Y)NR$@5J+HD4-&R7'HK[C6MS!)H+S'(IS0-M8(:1IK9N0S;AMZ
M\?8L3D[H.'HOUF^*W1%WK0@V][UK6AF=[WOXM:UII/;O>_Y-:S%9+PSYYZ7_
M &*>X\BST_,\<V/5CD#RB+$5Q)*ST#53I=QU2C"FHUJ: KZ'W7MK6^17 !P"
MWE.$J60^XX\OZ'HWW3.6FC*6.CBTFV>&%H9#Y;305,S(VBS6<^]G//:T8-YU
M[RT -:0T #CNCA))U3?^R; ^B]NQ4Q[S?V)O\WW.OVNE?O)G/^-SEO\ /*'_
M  ^G_*L>:A^2[K/>GO-_8F_S?<Z_:Z5^\F/C<Y;_ #RA_P /I_RIS4/R7=9[
MT]YO[$W^;[G7[72OWDQ\;G+?YY0_X?3_ )4YJ'Y+NL]Z^O>=^Q/;4E6Z#SOM
M2-)TE7MOEN\G2-:TC2=^V3M3I&M:TG6NSNZUKL[.S)\;7+:UO*Z"QS'O=3V-
M\\-7:G-0YV=??K'O7S[S?V)O\WW.OVNE?O)E^-SEO\\H?\/I_P J<U#\EW6>
M]/>;^Q-_F^YU^UTK]Y,?&YRW^>4/^'T_Y4YJ'Y+NL]Z_?><>Q.=FT^Y_SMW=
M[UO>O;=*]F]ZUO6M[U[9.S>]:4K6M_CUK>^S\>\?&WRW^>4/^'T_Y4YJ'Y+N
ML]Z_/>;^Q-_F^YU^UTK]Y,?&YRW^>4/^'T_Y4YJ'Y+NL]ZN?@?I?]BGI_(L#
M/P_'-CW8@#QGZ\5RY*ST]5099MU*@R7HUV:/K[CS;VD+8?L8!$>(\ELE*AWV
MVWD=?I+W3>6FDJ66CETFV"&9I9-Y%304TLC' AS.?8SGF-(P=S3XRX$M)+20
MLFQP@WU3PUL1U7(ZUZH=5)<T!P#R1*5RQSM8F(V#T9'RE:.CX^:V3HEAD<>-
M+/#*[3WGWFMQ@@+\5(2<F@*+%FHSSJR4_/5O.1V>.@^G X+ 0BR5\>\.^<?.
M),;@*PP6_*E,&3+I0W)7$PY"YU\;:V/;!MYI?IYEM\O0TQYT;9\@IG9Q&3<C
MX_FN4)O;Q_.:LSS7T]"<TV7CJSF7FRU8KBN0]L=1$@AH9X+5P9L55G@9^73*
M!&$%I#9J^X+R<:_#O%0-BM,25(NQTX8(N7(]/CQ[%2+^C'QXWK2W?23P]Q*)
M4*3<>HQYJ9XY51^<*U&R\9'RTPRUP2)!<=TNRD1EBDK=-N5X8NQ"P,A6J^1"
MP<W+2</&4:(K)(!@\C03;IPX"^?"Y[SQ4(&.5[7WG#ANS!W@VNNYQYTJ\*6R
M\R9?'74MRA-23H<]>IPB,* #G3*SS55(Z,C+#%VJ,KT+"2#LX7$25B1<#(BS
MG3DD083H@:9CERVA<<B!A;9N0-&8)QQZQQO??U7O8+>C@SA<#@RDQ%'B[99[
M/&PT1'0L>F>5$"@1X,4_)."-PT% 1<1#0J=L2"!"6P VVR68\!;B?&:<<=Q[
M/'6LE(J=,Q%?XIIDQ/2L;"1 -(JCALK+G"QL:&VN'CFD.%'&.LBCH4ZXVTE;
MSJ$J<6A&M[4I.MUV9Z3ZU&Y#H'J7=5?HU\ML:"CI2V,O0D386I.LJAY")>BY
MPB5'C'QSW9<5DI)*H8UQ"Q?&9VSIIS3N].ZUI;"]P.OAN!WI?=CMPMMRS(7D
M]U\<V7.2N(/&(6YZJ5:/@@I*6B'W&PB9^2DW"%I=DMQQI+1<6*(T.V$&M];.
MB]F$/MK=T/Y?ZKR%T52>1/TG)''-4R3R11.<T.YB.(-'F!P\V1[RXN>,=34:
M+#6ORH&C5UK8DG/8,N.?L7G#GT);TPB81,(F$3")A$PB81,(F$5]<7\*#<EP
M:3V+6J/F5V1B*W!,Q !RA8!,E48Z1M)KY-FB#=C#OVQ@4("*B)<@R0'TP4[&
M!OKD1NCTEIAVCIBPTO.0BG=)S[I7L#I^;J9(Z5C6T\K-=S:8N>^66)K8W%S1
M(]HC=BYQ;LN+'''/&PR(QMF2++,.]--D*,'3!V6N/QTH/6C81Z;6=#RA@5K8
MH/HM9D:$+.BQY")/DRHP1C'I4E+,B>Z\AYV+ D) 74WE%3M8>>IZ@21FH;,V
M$,EC8ZF=7<YJR/="Y[3'HZJF8[FFDL8 0))(V/FN!F#MXY:W1?!I/1;>%$G>
M#[:,?28XHN$05=K+7*H..P62^1#R]HCH"9C6);2@V1OCA[+#GNN1Y1[#>B5"
MK?28.4PQRFZ:I7LK)&,F+:.GJ*IQ<UK6RQ4\D\+S$=<NQEIY6 /:QQU=:VHY
MKG76%G'&S02?02#QS!V+\,X5L"8\29CIFJOQ4D]&[#5+6*+K!3 <^%+R5;>E
MG;$1&P@1,R#"2*FPAYLYX=\9;9'<;<&??,TS3F1T+X:H2QB37YJGDJ&E\#XH
MZ@1B 23.;"^:.[W0L#FN!;<AP:UA>V-^ )&&>0V<;+)U_AN)D!*T9/<@1<*Q
M*SO(4)/N@ACS@];?HL#&3##:)+<S%04Z3/O2@@HKD;,>A1F2Q"ESCSBC PM<
M^EY6/J&04,DQBAH9H&O>Z%]0VMFDB)YOFI9H6PB)SG-DBYYSFO;S+1J.>+B+
MV!) :1LOK$CB1:QS%^"DUBZ;R*^ :IVRD:G(X:SOGPI\$*'Y1V @;G:F0]GA
M6.7'(*>@:'.HE-#Z6+%S;D?'"F3 KSDFUQJ?E )Y&6IV\Q(ZG#)F3.>7">:D
MIB_FWT\3FL$]; 8RZSI81)(YD3FB,P/!MN-K$7VD#:!M<.)%S;#'6+/2+-,(
MF$3")A$PB81,(F$3")A%LMTL\O6_C+EFF"0\F<NNVBS0U>L=<V^ZY&20<W(#
MQBBM [5ME,H!LE)<>6TELG3K/EE.[$)*9=\[RET52Z0T75OEC8*BFIYIX*C5
M DC="QTFIKVOS;]75>PDML=8#6:TC"1H<TWS )!W6X[M_>O4V4NO(KW4-R[Q
M_+64@NBQG"Y-BA*P+1MQH8K\L*8QN;)N2I$_4FR/Y#<0@%1(1C\R5)E-U=J,
M%8E1_A3<QTCUK@')W1^!Z_:,,+K=7(LDPB81,(F$3"+IQW^YX/\ D8O_ -!&
M$7<PBQ+\]!#3 5>)FHD>?DAB#8Z#?D0VIB0#$_\ U9848X\DTH87_P#D/L,.
M-,?\:M.$72E;A5X.>J]7EYV,CK%=GY<:I0Q9+;)]B(@8QR9F68IA6]++=C8E
MEV0+0WVJ:$;6\K7<2K>B*NQNHK@LV&G["+RM22(.KUN-N$_*-3@BA(NL3$S.
M5Z*FR'=*[-@2,[6IR(#=;\3S$C'/"-:4\IE#BQW>!GU*7&_8#Z#DL\_R]QT/
M R]F796EP4)9&Z@=(CQ\N6VY8W9ABOM1<6V+'O/SCSLZ0B':=A&I 9R302$A
MY1 A3;)6_CQV;UEY;D*EP4Y7:W,6$&.G+7I.X*.*\9M\O3CK0PVWM[9\..T<
M:\S'1OI-P/TG*NMQ4?YF16D79%C[+RK0*A+$P5BL+<?*AP\7/%":CY8S8\;.
MRA\'7U.N@ %,(,L<Y&'PM;B]N^E+#+C+C(4(X[:&%$O^';DNY,\CTFOU4B[3
M%@$#JXC33YLKMHM] ++HS9JG#QAAWC04B@.:D)+98S/HJ/0^?)>4$'(>:)=+
M=R/1Z&-$&V^RQL"%/&;"BS35N>3?=2&](NO.%LMNCA@# #O&F2AK@\:&*VI\
MHMEKL5LB^*MR70KJ9)QU7M,5+2,.:4!(1[3RF#V7PB2@R'&PBT#DE Z+!.&:
MDQ&GXTA\$UH<MU8A"6R+,UNUUNX@D2=6FXZ?CA)65A"#HLELL1N6A#GHV6!\
M=K:FUO G#O#/]Q2DZ=;5I*E:^/"*0815Q,O>A9FOVLIMU<, W<8"8(9:<>W$
M,3TM$R \V6AE+CNHH4JMM@2#Z&UI 1*-2AJAXH"1,'HR(Z#TVOW^GIP,V@](
MZ[=WH]53<B5+@7E&S1=BM5]JQ#(%>.@GXP:XPPS)^W3QS8DYPIF22\TY#)=G
MF666]>$5J=6Z1O;D>'M( [ >D J'5.9&[,;Q?U>M1B9X2Z09O4 I\JD"%5ZP
M1%E'D(V^" R!TC##&",)E2VICQ#A26#B=&LJVC;[BTOI6T^TTZBV=N./#>EV
MVM<;-HV&_;M73N?#/3G;]2*]\FBQ;\A"<RP>FA^1XPJ(%:Y\D)Z1Y+D1X0R0
M< 1,RC]C.\C(I2EV.:'C1$I>C1%@$+.W'9? XVR0EIVB]B!B,+[5?]AL]?MH
M+-9JDQ&620DY*';?3 G#2S$3%C2P1DI)RI(#KXT:R/'#E;!2<ZQN3D-#QP?B
MOO=B);?AXPZ_:K?=C^'%4+QA3+;+V'G.P3M;(JTU<8(B($%*A# !I0N7C=GO
MF$6 IPI^23!R)RJ:*TX;)!:"KB[%71:W$635?9"P(/&YZ\O&]2UP>(.?'M V
M6X==J\H25[D.+;O$P5%LHLP53Y@(0EN3JCCC;BXUUIW;" [&\:M]3/BI'2*P
MX5MY3?@-[=[NLH !&(SX]P0W(.!!MP]OJZEX0[UO6]ZWK>MZWV;UOXMZWK\>
MMZ_DWK-RTJP.,CZS%VA9]M9&(BAZ[;%M,E "2:')C=:E$P26P9 8R/?)W,;"
M\KH\=P-)/A+)UIE*]ZAR](ZKX]B*V4N\&VX0N2D-"TI[REG>$A@M$Z*0:0I[
M<*IU\2-0"[V/C#*T,VGR@;4DXP.!H)EPF.8X;<KGJO\ B4PQV<,UCR:_P0@>
MSJ;LC^W!H1#M5T,=*%/2+GE[$I!DJT578UF/G7"AZPV_"#D2(*6CY!*7ANXH
MN-8[O&''IZNNX>/3GV;\-JD,Y#].Q]FFBV)YL&/+D)(EH6*+EF8L*$?L$EI!
MT4E=8VYZ?$A]!+CZHXA,6O2M-JE-[3O6PO;C;;OL.L7S(ZMJ&U^%]FZYZL+;
M_P %$*A%\5NU^HO7-U8[)ICPTB8&2X*:T<3<X.-FE/NL G/.C5^C/C3T>&M"
M&5&D$J1I]3Y [PWN;8[NH\<[V]%O0W=/=P[^C?U8:3X:%-KNVHH\EU4#-BV5
MVT!.HBQY=VO+2 ?%(C[%)+,=;F$N(%2;'C"H\PR2Z)M;2$CL>C'IN..&'H3#
MI[+=&)OX]$UAI#B52:"H]RCALCUQX&WB$ &R:WF%1E4;>EVBVZ4";NUN2OM@
M(>ARB3E(# -$K5LBW9:)E%S''K';AGP%NT'%!;QZ,NWT;0;%49>QHT69!;C6
MF&/$JM,)DAQ4H0.S,E52'(EDI0W^ V\LUUUXUC6DZ&D'2QM-MZ9TVFC\3Z_'
M2,5#^ ]7CH4+UK>]]FM=N]_%K6OQ[W_@RHO9>W5'DFP=+%.J8,#[9+D37:B#
M,5Z44PG1@/H]+9P4OJ5LE>A'7!@]MZ+'M35I@2C&-CRU1L"7=,)T',])]:W6
M.J!P_#I'4;C8=ZF?HD^!I_$D)*#*#DHBO4^-.$7[6^^*4%R!P^.\,K5-@:O4
M];86WMK::W7(.#3W>[&180FFAT5N1\?S7(<QX_G-Z%<5QN];H4:)+6B01' F
MRP$,.ZO6U:46>M:E.+^/6FQ(\%@Z8E2E[TT!#1LC(/[TR(YO,52;=8'6M;N0
MY?I?Y@;%LLGS)5D%1%#NK,2=6KM6/2P<"/;JA<96UQ\20S*DR1-4M7#$8=&O
MNQDC#I<BYD4Z,E1R'F$W$;.&1VC+T@].Y,,<;&V.5^GT=6.*J;C#J,Z1N'*T
M;JKV6W.QX''_  R8_N8B)"3GHVB#\&PMOIHWHYD)F:9CXCBX23Y'L:'0%MB2
M9UU?0ZJ5=<AF1ONPQ.&6>-M^-AMV* CB<L<[X7MORQRMZ5OK5K3#W&(]-0;[
MCX2)6PP3^GF5L/BS-3L,I5;%&D-+UVI(BK!"R<81M&ULK>$6MAUUE3;JXLEK
MCRC(;CNE:+<T!:3UNU#CQMI--BR9.>9(9U G".B*#9**A5NE",A,VIH$]-2+
M+&LI ;XL6_K5=F>D^M8@7:.@9^CQ^!4KX$*,-AH N0?FRC2.&N)72G[*P\-8
M7'E'<A[7Z;;?WXNY1._P#GEH9V00EPC0PJ7=#--@Z3ZFH#?'^RW\?%]JK[JF
MZ5J[SJR%:F[$/2[=78YP-4X<PE^%/A&7'BTB3>MOC+%2 \\2^+)M.JV,V04V
M2,6VIC8OJN3?*6HT*Y]-S#JNEGD#^88XMF9,0&%\/FN#B]K6AT9'G%K2US2#
MK;XY"S XMSXCH_$'LQ7G3OHQ'UO>O?'=/_Q;_EN2-;_\==SXM_\ -GO?A:_Z
M/Z<^R%;/*(^/W?S+\]YB/]([I_\ MDCU,?"U_P!'].?9"GE$?'[OYD]YB/\
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M'].?9"GE$?'[OYD]YB/]([I_^V2/4Q\+7_1_3GV0IY1'Q^[^9/>8C_2.Z?\
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M%0ASUCE7JH.LJ&?G=!LK8VX X9XVRWG'UJD[L<;9CQPWWV*0R'4C9)CC6O\
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MGME$<8!C<W76N6%LEB3JD8:W#<<MN6(S*\8]^P;M=N__ ,[?!_\ XQ2=;_\
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M4AJLR!!<F %.AVN*X/O'.]AB5LMN'PY^A(:)J-5 \E+[9?M<]-CH+=;A6DR
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M_P"RQ'\W^Z?_ *[=O2M@,BR3"*G9EYW74!QPQIUS3#G#O-3SC.EJTTMUFZ\
MH:=6WK?<4XTA]Y#:U)VI"7G4IWK3B];[2$#WET@ZPUAI30X!L+@&DTX2 <P"
M6M)&1(%\@L3^D/[KO6Q66) 0H$M+3PD8&Q-3N@D2\HAE/GCVXT?0H##Y*NUS
M8P;/>T.,E26&G'7WDMZ>(?<<X#IYGQ10/D>Z&'7,41)U&&1VM(YK<M9YMK._
M2(#039K0,[FUM@V*,\C<9T[E>O*JUX D)&%6LU:QXVQ62KDJU)0<Q6I%E4G5
M9>%E%"GP,_,11H>S-BE"'O(?97O3:D:E%,(V/8BH\*,%<-=' &9$8=DI*0F)
M!QIA&FT+,E98HV3D25)3K;QD@8260OM<??<<4I>R*B>=.G6I<XC@$21A4!98
MAEP:-L0##12_)N.*=V!) NK93(!(>6X0.VDD1\9]QU3)*&R"6GLFN+>(6+FZ
MW K53X/!7\G+R?L#O[YYESG#M]BQYOCV>U/@\%_G>3]@=_?/'.<.WV)S?'L]
MJ?!X+_.\G[ [^^>.<X=OL3F^/9[4^#P7^=Y/V!W]\\<YP[?8G-\>SVI\'@O\
M[R?L#O[YXYSAV^Q.;X]GM3X/!?YWD_8'?WSQSG#M]B<WQ[/:GP>"_P [R?L#
MO[YXYSAV^Q.;X]GM3X/!?YWD_8'?WSQSG#M]B<WQ[/:GP>"_SO)^P._OGCG.
M';[$YOCV>U/@\%_G>3]@=_?/'.<.WV)S?'L]J^D>QYNMK2XWS!W%HWI2%HH:
MDK2K6^W2DJ3=-;3O6_CUO6];UO\ %CG.';[$YOCV>U<K7L?);';X',SK/;I>
MM^%1W6^W3B-MN:WW+JGXEM[VA?\ _9&]IWVIWV8YSAV^Q.;X]GM7WKV/T].V
M]ZYI(UME+R6MZI+VMM)([VR$M]EV_ 2_M:MO:3V:=[RN_P![MWVN<X=OL3F^
M/9[43['Z>E3*D\TD)4-K>AU)I+VE,:4A+:M,[U=M;:TIM"6]Z1W=;0E*-_@I
MUK3G.';[$YOCV>U<C?0')-1[T4WS0M$>06R<Z+JA_P!C44P.2*V]K?MR[Z-[
M'+?:=2A24/H4C3R7-LL[;<YP[?8G-\>SVKJ;]CT?4YMY7,6]O;7XFW=T1>W-
MN;5WMN;7NZ=[:]J_"[^]][O?'V]OQXYSAV^Q.;X]GM7*CV/LYOPO#YH>1X#J
MWF.Y2'D^"\YW?$>:[+MKPW5]Q/?<1V+5W4][>^[KL<YP[?8G-\>SVKE+Z )
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M>=$24EJ@Y7Z!E%.#!(73,IG.D@HWRTC'3QZ)D?JSOA@D='![]Z.$DCZ>)_\
MK !B;(R6.,8I,;.O8D6UK'^=:^-@3JNVG+/$7B$KTR\QU2^P-'NUP#B=R+/+
MA4W)05F=M2JRUP+#S4WRZ :$(:&E^>J0]<FPDQJ3F1):3"TV!*JCB1Y1SE1<
MHM%55#-64=*^74.BVPQS4XIO*#IN:&'13V/>Q]H:IU1"_G"POBC?_*1"1KHQ
M-1P(!=:^M<WO;4%W WMB,K;U,(7H>ZHK":(!#R <J^2/+..I@K!:;2J--@P:
M/+2<1+,U.$G2H^2&B.2*5)JT^QH+;,XV+HWTF)( "<6;ECR<IV/?,Q\36NB
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MT6C:J-[XG30,J&B".HGECJF4T+"&ZP>3YI=:Q&1 (S.5P<;&QRQ%]3/;#/\
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MB=7;)T(G5)XY& ES^4W'UR%0Y,)=C8ZN6DR%HT:\NI2EMTF2EJT"B\.RLLS
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M>U:6VM"TI5K?254]#54U;2R&*II)XJFGE%B8YH)&R1O ((.J]H-B"#:Q!"I
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MY]Z]DOO$.O<9K<?>>(Y0Y'?>==4MQUZ]6QU:E+GI)1.;?=7Y - #>3FDVAH
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M XS-/2\-?I+DDN:@!Q/$W!AR\S1H]4T*\DIZ*8<$<5MJ^;O.7;;U$\ IYVT
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MUW&L4_Y^NSU=V^U+1!HT""3!EQL_01>Y&[+IQPRRP\74L=AZ;D[CMV8^GC@
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M]/\ AA$]-Q/R\?\ 3_AA$]-Q/R\?]/\ AA$]-Q/R\?\ 3_AA$]-Q/R\?]/\
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MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%!+E_=(_P#Z!/\
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M9<O#RL\(725G:DVX?J3K_4BU#B'S]OGY@>&)F(N3JIS$W)68PV&E!S##R)
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2]_R[UK6M=N_Y-:U^+6L(O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g609070g00m55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g00m55.jpg
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M 0$            ! @,$!08'" G_Q !5$0 ! @,#!@L$!P0&!P<%   ! @,
M!!$%$B$&$S%14M$4%19!4Y&2E:'2U")687$R5%6!DY33!R.Q\"1"<G:BP30U
M-F*SM>$S0W6"LK;Q)D1%=+3_V@ , P$  A$#$0 _ (+U8:J]4,=U2:D8_']2
M.>V)A8\\9<:&1D9LPY#;&AG:6V?/Z-N:VMM12(A$WMR!(22E1(DA)*9*F*+(
M(*+*+"&W[JR1R2R5F<E,F9F9R9R?F)B8R?L=Y]]^QK-=>>>=L^76ZZZZY+*6
MXZXM2EN.+4I2U$J4223'+4I04JBE?2/.=9^,0!QQ-7'2FU&]M^3/,]>AY&9'
M^Z>37<5E^EBM]>TKM'?#CB:N.E-J-[;\F>9Z<C,C_=/)KN*R_2POKVE=H[X<
M<35QTIM1O;?DSS/3D9D?[IY-=Q67Z6%]>TKM'?&YD4B'VG$\B<"E,&U.93F"
MC(#]C)A20^/:L9*X3:,F9D<'9LQDY3=B+FE@Q9IE:ED<!%*5ZOTS,G++4R1,
MS$'DC'Y*95^S*2FIV6G<EK&E$R+%HOKFYC)24;DY@62VTY:+<F^9+^DNRR7F
MP4MIH\HE$NIY0(C($ND A1-2!0+J1>- 2*X ^'/2,C:L8?::/4W+@S?K DYB
MIY:\=N./GXW69($L8RV=EE:_M6.V?%SFJF!)LJ=Y*]123,99($:1*TNS(J2/
MZQIN>@$LP.S/[-&9,SB\CI )9<M!N>83D=*KF;+%EH8=GW;2;3)D2S4NS,R[
MQ)6I3K3R%L(= 7<77"JZ%ZJ&^:&]HH:XU.'SP,1#)7O[0F+86!G5;JNRHNBB
M9UCC1)F5BU42Q[F\$43)1+4T/'.(LW3$]9'K24Z#R8*!*>88Y)K-X!.Z%L"M
M074]67D/V>S-KFQD9)6,B:4W,.R[KV2LDS)SJ91,JJ;$G,N200_P=,[+%:DT
M;5G"&EN%#ER"' F\5&F%1?J16M*BN%:'XX8QK=QQ-7'2FU&]M^3/,]=_D9D?
M[IY-=Q67Z6*7U[2NT=\..)JXZ4VHWMOR9YGIR,R/]T\FNXK+]+"^O:5VCOAQ
MQ-7'2FU&]M^3/,].1F1_NGDUW%9?I87U[2NT=\3_ *;]5>J%]F\Q2/>I'/;P
ME2X U./*9,ZYAR&X)T[PP:><F/;$ZD$JY$<62Y,KR@0N[2N+"%4VN:)(O1FD
MJDQ)H//939)9*R\A)K8R9R?96K*')5A2VK&LUM2F9C*6RF)AE2D2R26GV''&
M7FR2AUIQ;:PI"E)-DJ54^TKZ*N<\R33GB ..)JXZ4VHWMOR9YGKT/(S(_P!T
M\FNXK+]+%;Z]I7:.^''$U<=*;4;VWY,\STY&9'^Z>37<5E^EA?7M*[1WPXXF
MKCI3:C>V_)GF>G(S(_W3R:[BLOTL+Z]I7:.^''$U<=*;4;VWY,\STY&9'^Z>
M37<5E^EA?7M*[1WPXXFKCI3:C>V_)GF>G(S(_P!T\FNXK+]+"^O:5VCOAQQ-
M7'2FU&]M^3/,].1F1_NGDUW%9?I87U[2NT=\..)JXZ4VHWMOR9YGIR,R/]T\
MFNXK+]+"^O:5VCOAQQ-7'2FU&]M^3/,].1F1_NGDUW%9?I87U[2NT=\..)JX
MZ4VHWMOR9YGIR,R/]T\FNXK+]+"^O:5VCOC:6'7^T;R!B4S+D/U2Y8?D8&\Q
M_*@;?JGEJC*JB)$3]GQ8?,2H"7,1.Q<>*R _-4:L8KW,Y'G*RW)*V'LG_.=>
M;FY;]G,C:8LN;R4L5A9<#!G7,EI)-F)FE2+UI)E#/&3#1?,BP[,43>;2E!;4
MXE[]W%P'%"H63STOF]2MVM*ZZ#[XDQYQ=]IG&YHGB$CUAR5A2G,\@<5$Y=-9
MDA(Q\@=(ED%)BF40Q3(PR\ST\X8,C+T,4<8XVHUZH*A64ZD#/CMC7DOGLS/[
M-)B45-2^1LB^H.L-IDV\C954\MJ:D56G+3:9?@8NR;\@A<RV^XM"2E):4$S!
M#)DI=!H5\Q-;^&!H16ND'"G^6,14O,^TR:(AJ0G+UG?44S1W2E,6['F85J_4
M!D&P&V<.,X38_P#5AA-32I2FDKDWOJL@UU$TJ#T;<U')'%0J"4YM05W21*_L
MT=F\GY)K)[)IV8RFE')^RD(R>LVKDDW)*GN$OA4HE4NVXPDAK.I2MQT+;2DE
MMVY%':+-540:*]HX&M*#'''32-8^.)JXZ4VHWMOR9YGKT7(S(_W3R:[BLOTL
M4OKVE=H[X<<35QTIM1O;?DSS/3D9D?[IY-=Q67Z6%]>TKM'?#CB:N.E-J-[;
M\F>9Z<C,C_=/)KN*R_2POKVE=H[X<<35QTIM1O;?DSS/3D9D?[IY-=Q67Z6%
M]>TKM'?#CB:N.E-J-[;\F>9Z<C,C_=/)KN*R_2POKVE=H[X<<35QTIM1O;?D
MSS/3D9D?[IY-=Q67Z6%]>TKM'?#CB:N.E-J-[;\F>9Z<C,C_ '3R:[BLOTL+
MZ]I7:.^''$U<=*;4;VWY,\STY&9'^Z>37<5E^EA?7M*[1WPXXFKCI3:C>V_)
MGF>G(S(_W3R:[BLOTL+Z]I7:.^-@,XZJM4#3'=.1[5J0SVV'/FG]L>7HYOS#
MD)$:\/!F4LKMYCLZ&)I$4-P<AH&YO0C7*[G*A(T"--<VY*4@ //6#DEDJ],Y
M2)>R9R?=2QE"\PP'+&LU899%E62X&6@J6(;:#CCC@;11 6XM5+RU$W4I0N44
MK% )Q.)J<=,:_P#'$U<=*;4;VWY,\SUZ'D9D?[IY-=Q67Z6*7U[2NT=\..)J
MXZ4VHWMOR9YGIR,R/]T\FNXK+]+"^O:5VCOAQQ-7'2FU&]M^3/,].1F1_NGD
MUW%9?I87U[2NT=\..)JXZ4VHWMOR9YGIR,R/]T\FNXK+]+"^O:5VCOAQQ-7'
M2FU&]M^3/,].1F1_NGDUW%9?I87U[2NT=\..)JXZ4VHWMOR9YGIR,R/]T\FN
MXK+]+"^O:5VCOAQQ-7'2FU&]M^3/,].1F1_NGDUW%9?I87U[2NT=\..)JXZ4
MVHWMOR9YGIR,R/\ =/)KN*R_2POKVE=H[XD+%F>=:^79NUP2-ZM,T-3BY)GE
MP.>)CJ2G$2BS*T1UE<)$^O#Y('F7)T*! V,S6N6#MMC5BP90$#8D7.2I(C/T
M;2R<R(LN3<G9C)"PG6VU,MAJ4R:L^:F7G9AYN78:989DU+6MQYU"!@$)!*W%
M(;2I:9"EDT"S]ZB!AB<2:?SKC:LW%7VIQ1<\-#J6RDH)AB(AQ9S4NJ^6'ARL
MD/Q#P_6,P_8$NV\Y,*PP(G(1Z=,%(I*:%*5$(G?]04SB\R)K]EQ,D#DO8Z3-
MK4VZ%9*20XL6FU>(Z6K_ $.DD#:P,BE2BI)=2I8.8!=B]UW'VC@*_3/M>S>]
MG''V<?\ KA%O;X!]IP\%XO&R:J\A/H\H2N-P<LADU<R=V-@4JET!591CS-DS
M<$P/+BBE=C]O=9.:*YBXEL2M#JB=S4#NA/;@Y%N_LS:-HY[).RF19TM,3A+V
M24FT)Z6E9U-FOO6=?DTF92B><:EA@@N*=:6T%M+#D+KN%%$U(&"ZT)%:*QPP
MJ?N.J-9<J9\UDXEG#O W;6/EF4.++9'96[X_U*S^7QDPY6C)5B2IGQODUDQZ
MM#<[<CDGM8)B)>2H2'!L:2*U>ALW)O(NU)-J=:R,L66;>OW6I[)FSI68 2LI
M"E,N2MX)72^VK$+0I*@:&*%2TFE\GY*)_P XCSCB:N.E-J-[;\F>9ZW^1F1_
MNGDUW%9?I8B^O:5VCOAQQ-7'2FU&]M^3/,].1F1_NGDUW%9?I87U[2NT=\..
M)JXZ4VHWMOR9YGIR,R/]T\FNXK+]+"^O:5VCOAQQ-7'2FU&]M^3/,].1F1_N
MGDUW%9?I87U[2NT=\..)JXZ4VHWMOR9YGIR,R/\ =/)KN*R_2POKVE=H[X<<
M35QTIM1O;?DSS/3D9D?[IY-=Q67Z6%]>TKM'?#CB:N.E-J-[;\F>9Z<C,C_=
M/)KN*R_2POKVE=H[X<<35QTIM1O;?DSS/3D9D?[IY-=Q67Z6%]>TKM'?&P&G
M[55J@>E.80O&I#/;L%LT_P"5GEM"Y9AR$OLWO#<T)S6]V0V52(VR1R0F"N8C
M7)_1JDH[W&0: 5[WKSN46262K";%+.3.3[)=RBLAAW-6-9S><9=>4'&7+DL+
M[3@ "VU50L8*!$70I1*JJ4?84=)TT..F-?\ CB:N.E-J-[;\F>9Z]%R,R/\
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M81*2"Y6=?E9M+*D6?/3/"5M3$C(3*'IJ43F [GGDJ6L*0LO5OBX4 '$@FIJ
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MQW&82TPX#$CC;=$1F":3;JDW@C^SV;<;D&C/V9+,IDI&S+59DI"<2E^3LS*
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MY?-& LM^:S##!! 66""P,8QC'>P0  $,7N(0A"O8(0AM>XKWM:UKWO0Y,6(
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M"&U.M2[:6IBV)I]Z8?6$,L,2TJ\],/O.*-$MLM+4:%1 2E1$I4XHT"CH)Q(
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M4I0_K*)ZR3$:UT(K"D(4A$\Z=?\ '67_ -@VI3_@!DBO.Y3_ .@27]XLE?\
MW+947;^D?[#G_#5$#5Z**0I"%(0I"-AM/.:4^'5V3[._K$M8I_A+,F.;,[*I
M!9&9*)]C&6P6*OCLA4KD:,],P*I2J,.5[52XHFY6Y!;B#C%1A!W!MZR%6LBS
M<UP=#TC;-D6AG7DF^):1M&5G9EEI:4+6E3Z99(":I;6XELN* 2"+H5=O5K0I
M4*#64D GY5C:\K7VG+@Y.-;-#GZE T0K=.)B+U/QY=[%DQ2QKFD$F!+Q$7F
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MPC>VO#Q>.FX-S>[(SVYU0HW-O5 L6J0N"4A8C4@L(([ /2J0&$' L,(1V"8
M5K""$6QLVM>R$=RD(4A"D(Z:!N;VM/=(V(4;<E$J7+1)D"4A&G$L<URAS<E=
MR4X"R[JG%R5JW!<HN'TJM<J4*U S#SC#!(1W*0A2$*0A2$*0A2$*0A2$*0A2
M$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0C5>MB$;
M LJES"SM(2VPHP 6U#8!EW  +C!9*58([@NGO<%Q!V!7#>]]K>^QLWV-FL)
MJ<1I.FNOX PBY;J=>:BOB0/#5%!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2
M!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:
ME!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K
M'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CN
MA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=
M3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS
M45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\
M2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X
M:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!
MK'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'C
MNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#
M=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3K
MS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45
M\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!
MX:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E
M!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'
MCNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA
M#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3
MKS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS4
M5\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2
M!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:
ME!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K
M'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CNA#=3KS45\2!X:E!K'CN
MA#=3KS45\2!X:E!K'CNA#=3MS45\2!X:E!K'CN$(ULK/"-DV+_ ;-_JIN_W0
MFL"M)^9_C"+K40A2$*0C#WZ7IF<^Z,DBZQ6&UKFA])8HHG;6L((1CL$8A&7#
M>PK@"&UK6O;9':_\-=*4LY<RC.*6&VR2$FEY2J&A(%0 FM14FM0<*8QE0T5"
MI-!S88G_ *=<8[PAJ.:R?>1]U6YQ,CIU?ACS1DS VCU"'"&HYK)]Y'W5.)D=
M.K\,>:&8&T>H0X0U'-9/O(^ZIQ,CIU?ACS0S VCU"'"&HYK)]Y'W5.)D=.K\
M,>:&8&T>H0X0U'-9/O(^ZIQ,CIU?ACS0S VCU"'"&HYK)]Y'W5.)D=.K\,>:
M&8&T>H0X0U'-9/O(^ZIQ,CIU?ACS0S VCU"'"&HYK)]Y'W5.)D=.K\,>:&8&
MT>H0X0U'-9/O(^ZIQ,CIU?ACS0S VCU"'"&HYK)]Y'W5.)D=.K\,>:&8&T>H
M0X0U'-9/O(^ZIQ,CIU?ACS0S VCU"'"&HYK)]Y'W5.)D=.K\,>:&8&T>H0X0
MU'-9/O(^ZIQ,CIU?ACS0S VCU"'"&HYK)]Y'W5.)D=.K\,>:&8&T>H0X0U'-
M9/O(^ZIQ,CIU?ACS0S VCU"'"&HYK)]Y'W5.)D=.K\,>:&8&T>H0OD0^UKWN
MV$6M:VS>]U0[6M:WXWO?T7W6M3B9'3J_#'FAF!M'J$=)+E5,N+(-1%MBPI2$
MX28Q*YEJ"U 4P[%J!$#)",)H2#!!+.N7<5BABL$>U%>UJNJPB@D+<=04T"@I
MDI*2H52""H$7@"172,1 ,I.A1-=%*16/R:%+8JZE(B36//*2D7/7V)L<I/%M
M24Y5S !](><+^$HD&V,,%]P WO4)L0*K==<5=25*NM5NI&E1HHT2.<G <YAF
M$[1\(YFY(&068<>@2DDE $8:::LN6666"UQ#&88,NP0 "&UQ"$*]@AM:][WM
M:U0+%2HA*7EDDT #8)).@ !523J$,PG:/A%3A#4<UD^\C[JHXF1TZOPQYH9@
M;1ZA%,W) R07,.0)2B[7 &XS5ERP6$8,)8 W$(NP;7&8(( 6V=D0Q!#;9O>U
MKR+%230/K)QP#8)P%3@%<PQ/PAF$[1\(I\)P?27*W(A]+8^R6Y>[[>DLI$GL
MK"GN#:;:QXDM[*;$['I+I[V.L'T=]M4\285SKE+MZN:PNWKMZMZEV][-=%[#
M3A#,)VCX10!EA(8F/6EA:C$:8PTI2K ZE#3)S2!^C/*//#:Y11A)G\!H#!A$
M6/\ A'8-_NJ382@I*"XZ%J *4%DA2@H524IK4A0Q! Q&(AF4[1\(K)\H%J[
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MH^S+LG3*0S-P6I4[1G%A<A*6=X>RGMK4IG5 L,D:9<!Q4K<?/B_&]T3G!A[
MPIJYM&E)^/W'"A%8GW*6AZ.3-Y:)1!I0CQI*H5B;'6(,:2!!%E9SO$8M#Y\V
MRF3MALDB\N@<Y4,N08LR-&.7=MC<PARY#&1R$@EZ4HY.YMET5"Z:145).--(
MPIA04-3H..@#3$6PC0CFFT+R7$\KZQ,I31%D,D^%.;.K-/F#+(L5(Y'.6\EN
MF_""K>A@E4QQC(F1ME3GB%)AI,FDC78;I:?-Y2LY]1)6*BB0*?<:X:"/C6E:
M_<='6;OL\LH-*"+)&[7!GI"-E5X[$^!1.DO2-4F;H5%'*)NR.S&1DP#?'54I
MV[%+E#@PA26+R V.DK>4DE.D:M(F0+@)/L#GU5Q^-,=6/-A@(9=^SNFN1Y_F
MC)D3U,K\.3G*I\C)03C'6-3&C(# QR=HPHP*&1YFR7(Z1WDB:/-&!86GAI35
MZF-;6H<)8N>VB3*7I.-M0#E !=J!3 G# DZN<DUT\VJ,YQUHAGL(F.5GM=JL
MR@[1+)$*U"Q=NA#>%^:DL-?<\Y249')R$VK7>>RI(KFN/"%B^.19UNR(QEIE
MZHTG>]OW.R)T05@T]@"A2:ZP!2F@8'^:QUM/6@-MPS+HI-WZ7Q-_>85D2>3^
M.M>/\7$XHA#2;+<)P#!#4W,,-1R^3I&0#%"H>Y%.;@H7OKW+7)]$Z.+LDW*%
M"8B5+J*4(J ,37^L5'&F.D:J1#CE]EHK=)!)YF=F''I,NDDCS/,;GDZ;&8^(
M(Y/EV'R+'RA=;'CIDIRB9Z,$,?&ALG#7N(E-EA=C;&[U-+J%Y61Q9,1.=T8'
M0!](U(!!TD5TUIJ!('-3972-HG8])\DR7(&>7ADA>0HSAZ+D-@6%U;BHX@Q)
M$#HDD(2N4AFDX>E;>H1B1(6ANNX)"V:/L;(A<S91(2W67.Z*K65 "FBITZ_A
M@/\ /XTPC>*D4A2$*0A2$*0A2$*0C5>MB$;&L:E.%E9PB/)L*S6WVO:YH+7M
M>R0FU[7M<6S:]K_=>U_OM>L)!)- =)YOC"+INI-R@CKB_FJ*'4>HPANI-R@C
MKB_FI0ZCU&$-U)N4$=<7\U*'4>HPCJ*R6E>"Q:VR)2$-]D-C1%"N"]_QN 6V
MVP-G^?:WML_SUD;=>9)+2UH)TW20#\QH/W@Q(4I.@D1;=XXQR1OZVW>UGX;.
M],YU#RQ;.+VC#>.,<D;^MMWM.&SO3.=0\L,XO:,-XXQR1OZVW>TX;.],YU#R
MPSB]HPWCC')&_K;=[3AL[TSG4/+#.+VC#>.,<D;^MMWM.&SO3.=0\L,XO:,-
MXXQR1OZVW>TX;.],YU#RPSB]HPWCC')&_K;=[3AL[TSG4/+#.+VC#>.,<D;^
MMMWM.&SO3.=0\L,XO:,-XXQR1OZVW>TX;.],YU#RPSB]HPWCC')&_K;=[3AL
M[TSG4/+#.+VC#>.,<D;^MMWM.&SO3.=0\L,XO:,-XXQR1OZVW>TX;.],YU#R
MPSB]HPWCC')&_K;=[3AL[TSG4/+#.+VC#>.,<D;^MMWM.&SO3.=0\L,XO:,-
MXXQR1OZVW>TX;.],YU#RPSB]HPWCC')&_K;=[3AL[TSG4/+#.+VC#>.,<D;^
MMMWM.&SO3.=0\L,XO:,-XXQR1OZVW>TX;.],YU#RPSB]HPWCC')&_K;=[3AL
M[TSG4/+#.+VC#>.,<D;^MMWM.&SO3.=0\L,XO:,-XXQR1OZVW>TX;.],YU#R
MPSB]HPWCC')&_K;=[3AL[TSG4/+#.+VC#>.,<D;^MMWM.&SO3.=0\L,XO:,-
MXXQR1OZVW>TX;.],YU#RPSB]HPWCC')&_K;=[3AL[TSG4/+#.+VC#>.,<D;^
MMMWM.&SO3.=0\L,XO:,-XXQR1OZVW>TX;.],YU#RPSB]HPWCC')&_K;=[3AL
M[TSG4/+#.+VC#>.,<D;^MMWM.&SO3.=0\L,XO:,-XXQR1OZVW>TX;.],YU#R
MPSB]HPWCC')&_K;=[3AL[TSG4/+#.+VC#>.,<D;^MMWM.&SO3.=0\L,XO:,-
MXXQR1OZVW>TX;.],YU#RPSB]HPWCC')&_K;=[3AL[TSG4/+#.+VC#>.,<D;^
MMMWM.&SO3.=0\L,XO:,-XXQR1OZVW>TX;.],YU#RPSB]HPWCC')&_K;=[3AL
M[TSG4/+#.+VC#>.,<D;^MMWM.&SO3.=0\L,XO:,-XXQR1OZVW>TX;.],YU#R
MPSB]HPWCC')&_K;=[3AL[TSG4/+#.+VC#>.,<D;^MMWM.&SO3.=0\L,XO:,-
MXXQR1OZVW>TX;.],YU#RPSB]HPWCC')&_K;=[3AL[TSG4/+#.+VC#>.,<D;^
MMMWM.&SO3.=0\L,XO:,-XXQR1OZVW>TX;.],YU#RPSB]HPWCC')&_K;=[3AL
M[TSG4/+#.+VC#>.,<D;^MMWM.&SO3.=0\L,XO:,-XXQR1OZVW>TX;.],YU#R
MPSB]HQ5):8XG,":2E;@F OL@%<18[AO;\!!L,8K6%;\;"M;9M?[[7M>JKFIM
M:2E3SI2<" 2*C4: 5'P@7%G"\8O&ZDW*".N+^:M:AU'J,4CC<])<5AW.37&$
M(@A'<PK;!".X;C#86VV;!%< +BM:^P*X WO:]PVV%%4I0TTTH:5%:'[JGK,(
M6/26%<=CDUAB"$(AV,*VP@@N.X W%MMFX0W&.X;7OL!N,=[6M<5]E15*4-,3
M2AI4TJ?OH*_(0CENI-R@CKB_FI0ZCU&$-U)N4$=<7\U*'4>HPANI-R@CKB_F
MI0ZCU&$-U)N4$=<7\U*'4>HPANI-R@CKB_FI0ZCU&$-U)N4$=<7\U*'4>HPA
MNI-R@CKB_FI0ZCU&$-U)N4$=<7\U*'4>HPANI-R@CKB_FI0ZCU&$-U)N4$=<
M7\U*'4>HPANI-R@CKB_FI0ZCU&$-U)N4$=<7\U*'4>HPANI-R@CKB_FI0ZCU
M&$-U)N4$=<7\U*'4>HPANI-R@CKB_FI0ZCU&$-U)N4$=<7\U*'4>HPANI-R@
MCKB_FI0ZCU&$-U)N4$=<7\U*'4>HPC5ZL\(V'9&YO&S- QH$8QC;$ QC$E($
M(8Q)2A"$(5P7N(0KWO<0KWO>][WO>^S>L"M)^9_C"+GO8V\W(?=$_=U$(;V-
MO-R'W1/W=(0WL;>;D/NB?NZ0AO8V\W(?=$_=TA#>QMYN0^Z)^[I"&]C;S<A]
MT3]W2$-[&WFY#[HG[ND(Q"?2>"XRADCG\T$V,\6BC6>[O3B<D3W"G2$;6W\(
M=I;;FG&C+3D%[(?2'FEE[:VVV;;<A(S-I3DO(2;2GIJ:=2TRVFI*EJ^0.  *
ME&F"03S1!( J< (RZS8V7M:]F]!>U[6O:]DB>]KVO]]KVO8O8O:]OPO6I$Q]
MWL;>;D/NB?NZ0AO8V\W(?=$_=TA#>QMYN0^Z)^[I"&]C;S<A]T3]W2$-[&WF
MY#[HG[ND(;V-O-R'W1/W=(1U5I+$WIQ*5B5N()!>UKB$D(O<0K[-[  &Q5Q#
M&+8OL #:XKVM>^QL6O>V1IIQY8;;25*/,.8<Y)-  .<D@=<2E)4: 5/\XQBU
MY1$;7O:S;:]K7_&S8EV+_P!=MD5K['_SM:_]5;_%,UK:[9\L9<PO6GK.Z/GK
M1$>;/VQ)\].*9K6UVSY89A>M/6=T/6B(\V?MB3YZ<4S6MKMGRPS"]:>L[H>M
M$1YL_;$GSTXIFM;7;/EAF%ZT]9W0]:(CS9^V)/GIQ3-:VNV?+#,+UIZSNAZT
M1'FS]L2?/3BF:UM=L^6&87K3UG=#UHB/-G[8D^>G%,UK:[9\L,PO6GK.Z'K1
M$>;/VQ)\].*9K6UVSY89A>M/6=T/6B(\V?MB3YZ<4S6MKMGRPS"]:>L[H>M$
M1YL_;$GSTXIFM;7;/EAF%ZT]9W0]:(CS9^V)/GIQ3-:VNV?+#,+UIZSNAZT1
M'FS]L2?/3BF:UM=L^6&87K3UG=#UHB/-G[8D^>G%,UK:[9\L,PO6GK.Z'K1$
M>;/VQ)\].*9K6UVSY89A>M/6=T/6B(\V?MB3YZ<4S6MKMGRPS"]:>L[H>M$1
MYL_;$GSTXIFM;7;/EAF%ZT]9W0]:(CS9^V)/GIQ3-:VNV?+#,+UIZSNAZT1'
MFS]L2?/3BF:UM=L^6&87K3UG=#UHB/-G[8D^>G%,UK:[9\L,PO6GK.Z'K1$>
M;/VQ)\].*9K6UVSY89A>M/6=T/6B(\V?MB3YZ<4S6MKMGRPS"]:>L[H>M$1Y
ML_;$GSTXIFM;7;/EAF%ZT]9W0]:(CS9^V)/GIQ3-:VNV?+#,+UIZSNAZT1'F
MS]L2?/3BF:UM=L^6&87K3UG=#UHB/-G[8D^>G%,UK:[9\L,PO6GK.Z'K1$>;
M/VQ)\].*9K6UVSY89A>M/6=T/6B(\V?MB3YZ<4S6MKMGRPS"]:>L[H>M$1YL
M_;$GSTXIFM;7;/EAF%ZT]9W0]:(CS9^V)/GIQ3-:VNV?+#,+UIZSNAZT1'FS
M]L2?/3BF:UM=L^6&87K3UG=%0J2Q P80"0EDV%>UO2&MB?:!V?YQ>C](.UOZ
M;V!?8J%65-@$@-JIS)7B?E>"1XQ!96-D_([P(RTM TG%@-*0MYA9@;# ,"5.
M((PBMLA$$5B]B]KV^^U[5SB"DE*@0H$@@BA!&D$<Q$8B"#0X$1:7M;$HX0B4
MO@F=L(<GEGCR Q60G+LL>Y XIVIF;$]O1W$:J<'!40F(+#:][B'<8KA+ ,8<
MK,N],*6EAM3A;9>F' D5N,L-J=><5J2A"2HG[AB0(1>=[&WFY#[HG[NL,(;V
M-O-R'W1/W=(0WL;>;D/NB?NZ0AO8V\W(?=$_=TA#>QMYN0^Z)^[I"&]C;S<A
M]T3]W2$-[&WFY#[HG[ND(;V-O-R'W1/W=(0WL;>;D/NB?NZ0AO8V\W(?=$_=
MTA#>QMYN0^Z)^[I"&]C;S<A]T3]W2$-[&WFY#[HG[ND(;V-O-R'W1/W=(0WL
M;>;D/NB?NZ0AO8V\W(?=$_=TA#>QMYN0^Z)^[I"&]C;S<A]T3]W2$-[&WFY#
M[HG[ND(;V-O-R'W1/W=(0WL;>;D/NB?NZ0AO8V\W(?=$_=TA#>QMYN0^Z)^[
MI"&]C;S<A]T3]W2$-ZVSFY#[HG[ND(UEK8A%JU!-6?'F-XC0855S!$V'K5)<
M]58Z?L8QF:I2SH:M3PMPN]998I/'$D*:):<B>9I9HC,GERDIN:DC;%)6R'R2
M..>!6D_,_P 8LD@5K3FI4$C3CHYR/_D1KTPM'VAI..,QO!ACKZ]OLFQ0XX_A
MDND6(3CV,Q-G&72K-B6,O,8LJ9T./77"#C!\:8_3RE[6RLM^C#W(7%JCYKON
MI=$6JBHPP -: TT "M><&I)IJTQ@F,()]J&W3>$,F49^I?&B+32*)3\@L+AB
M-+#9ICR/R'#;3,W3)T9.;@S N5S[',!RJ[LC7!H\%"SY)S9?T[Q'V.(-*Q B
M26Z&@T@X4-03>I0Z* D8Z:#GC*I?!OM(6U3*I1$ITW291),JS"4L4$,'%V)/
M!\91O-:)!"<>;]+I$K:WQ?D'!3LZ/*YX(96L4:DL<3-;BJ5N"U.Z4B 6]%,
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MI7(R?3KDJAH(<(FT-@1)%SHA5^MS:YHY$<@&Q"E.G:.3\A)24[,MVJT^]+3
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MB<,:8PQLW2N7,"O(TBG&/)4Q2R43F/)(M#6($1 V-SADQR()1@O%%DB>\?\
MF(SW$F@"@-=2"2?@ 10#$X\VDZ!$BAUUZD;J%B<[0+E1*F3LZE>1(SE.6E,;
M5J+94,@[8>!$U:<7') 69RB 2I\--?&]\DM0%!:%VQBBC9:N=)D1<3A[8_PZ
MJG&]3#1J.N+,?KOU6,IL[2.^@')CG:-*YZ*/O[%;*YC+)$++E1SBL0*);4&"
MI'*CKOL)2%/>[VEF=%:MYNF6VC3/CEX)GC<B2A&%%CFPPTT'/76>?1CI(QE>
M?YEU?8\7P9ZX.(_.HZT80QR^YABD7Q?E$]S<,P3B;QZ#.B2"S.*N^1'-'$X0
MF7RK(LOCC5B'*<V:XC%6]*5=6;*TSJVHK=2:XT]H@5(^B!48&F)T E0%8P.&
MZY=0&5H#EEXA6C3(C+((S'GQCABY<J.DK$CS.U'3J(.45G3:YM>,%#\Q1#*D
M.#%I,MP<_974I$JO=LE]12BU1R)$W$@BJAB17^S@:X5I4&HJ!\,<(ZI6M[5>
MC;6M4JT!9,?]^3XZ!&H0.$PCZU$&31%HE@;2F-+\5.RF.%Q]S<'3'#LK2NTA
ML5*8[=Y?$L5C;XG4MS^?Y_DPN)VP/G0\]-(..O1H^.FOF'5]JGQ?DS-MXIIB
MFV:<<8[4*FR)Q2+8>R\Q2F4W!%<'K&N3-&6-R2F)S%$\S*9Y<C]XW"<<.ZAG
M;,<$/K[(VDA4$MR0"$D#V@":5Q!I4FN&!% !B33&)&P]JNSM-LJS+'N1=*<]
MQS%XXPYPDY&4MYLBN# )/C3+"J 0N,(VU;CEI!-9/D6*DDY(9"X6_KQN[&?8
MN/M;FF"!T-1"DI J% G 4PYQ4G3@!HQY_OI'6GS4AKAR--,4()_@5JCV.98Z
M$HIK-G/&.6L5R:-)2HYJ F9BA9CB<.3R)@&M;6O3G#%YJJ8OC7'\C/&1FMF<
MI^U*6-R8D2I* #152- J#71SC3_6.@<V@UB...3K;$MD*\O D@,@S<#(CVSN
MI6D'49:>/$50L64&R'6!CASG3.,J9H<FPS'J:\/')K+<E8XS;')>E-QAZAY-
M!'$6N(P]H5PJ+PI7"N--1/-I%(VVTI99U+Y(DF2FW/<%C$3:(S%,)JHFYQ?'
MF8H4D>);(H@X"RXVB<,P$,JI_3LTR:+N; 7'(X)"PPZ4Q=ED4F>)TEE3<QHQ
MJ"12Z:UKS@Z#AHUC_P"!A&Z=(K"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A&J];
M$(V38O\  ;-_JIN_W0FL"M)^9_C"+K40A2$*0A2$*0A2$*0BU"8F4;V5)1M3
M>9(4[8:RIWLQ(2-T3-"A26M4MJ9:,%U"9$K5D)E*Q,0864K.2(S%(31)$URL
MH?>#)E@ZX)=3H>4R%$-J=2DH2XI -U2TH4I*5$$I"EA) 4JK^?X;A'QL8F5E
M-=SV=J;VLU_=3'U[&@2$I1.KT<C1(#G5?Z$ +*7 ]&W(4QRLVPCSBDA 3!B]
M&&]'7WG@TEYUQT,-!AD.+4O-,I6M:6F[Q-UM*W%J2@42"I5 *PB[5BA"D(4A
M"D(4A"D(Z3@W)'-.)*M)L:5>]A6^^X1ECM:]K#+';8$ =MF]MFU]B]KW"*UP
MWO:^5EYQA8<:44JI0\X(/,H:".>AYP",0(LE12:I-/\ /YQB(L?M-[WO94X!
MM>_W6](GOL?U;-TVS?8_FV?O_IV?QKH\<3'1L]2_/&7/JV1XQ\X/FKECA^=-
MX:G'$QT;/4OSPSYV1UF'!\U<L</SIO#4XXF.C9ZE^>&?.R.LPX/FKECA^=-X
M:G'$QT;/4OSPSYV1UF'!\U<L</SIO#4XXF.C9ZE^>&?.R.LPX/FKECA^=-X:
MG'$QT;/4OSPSYV1UF'!\U<L</SIO#4XXF.C9ZE^>&?.R.LPX/FKECA^=-X:G
M'$QT;/4OSPSYV1UF'!\U<L</SIO#4XXF.C9ZE^>&?.R.LPX/FKECA^=-X:G'
M$QT;/4OSPSYV1UF'!\U<L</SIO#4XXF.C9ZE^>&?.R.LPX/FKECA^=-X:G'$
MQT;/4OSPSYV1UF'!\U<L</SIO#4XXF.C9ZE^>&?.R.LPX/FKECA^=-X:G'$Q
MT;/4OSPSYV1UF'!\U<L</SIO#4XXF.C9ZE^>&?.R.LPX/FKECA^=-X:G'$QT
M;/4OSPSYV1UF'!\U<L</SIO#4XXF.C9ZE^>&?.R.LPX/FKECA^=-X:G'$QT;
M/4OSPSYV1UF'!\U<L</SIO#4XXF.C9ZE^>&?.R.LPX/FKECA^=-X:G'$QT;/
M4OSPSYV1UF'!\U<L</SIO#4XXF.C9ZE^>&?.R.LPX/FKECA^=-X:G'$QT;/4
MOSPSYV1UF'!\U<L</SIO#4XXF.C9ZE^>&?.R.LPX/FKECA^=-X:G'$QT;/4O
MSPSYV1UF'!\U<L</SIO#4XXF.C9ZE^>&?.R.LPX/FKECA^=-X:G'$QT;/4OS
MPSYV1UF'!\U<L</SIO#4XXF.C9ZE^>&?.R.LPX/FKECA^=-X:G'$QT;/4OSP
MSYV1UF'!\U<L</SIO#4XXF.C9ZE^>&?.R.LPX/FKECA^=-X:G'$QT;/4OSPS
MYV1UF*A4!9RQA&8<N.#:]K^C&:2$ OZA7+( /8O_ .Z,-_ZZA5KS)! 0TDG^
ML$J)'Q 4LBOS!'PB"^KF '68S0DDI.46006$HDH-@%E@M8(0!#;8M:UK?_V]
M_OOLWO7,4I2U%:R5*425*)J23SF,)))J<28P4>+L?GS%_P @+8HSN<QDT820
MEW?75(6Z+#88C&L.!$R-WV4%(HZH5N"]<XM*0LE(Z+59BER+5F (N3NBTY],
MHQ((FGFY26F5SK+#2RTA,XL(29I6;NE<PE#:$-NK*EM(2$ME )!B@T_"GW8F
MGRJ3%R@\'BV-XLUPJ%-)+#%F.RP#,RI1G#1-25:X*W(3>W@/,-NE;4IZPTEM
M;R1!1MB$*=N0$IT25.07BG9V:M&:=G9UTOS3UPO/* "W5(;2V''"D *<4E +
MCA%]Q=YQ94M2E&0*8#1&65JPA2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A
M2$*0A2$*0A2$*0A2$*0A2$:KUL0C.$T]>$29.B*3-HBDA!24L1A*JY@BTY82
M@7'<*P ;CN$%KBN$ 0W%LWL$-ONM0H!)../RW0BOPC/?)6KJ%?CJ7!K/ANA#
MA&>^2M74*_'4N#6?#="'",]\E:NH5^.I<&L^&Z$.$9[Y*U=0K\=2X-9\-T(<
M(SWR5JZA7XZEP:SX;H0X1GODK5U"OQU+@UGPW0APC/?)6KJ%?CJ7!K/ANA#A
M&>^2M74*_'4N#6?#="'",]\E:NH5^.I<&L^&Z$.$9[Y*U=0K\=2X-9\-T(<(
MSWR5JZA7XZEP:SX;H0X1GODK5U"OQU+@UGPW0APC/?)6KJ%?CJ7!K/ANA#A&
M>^2M74*_'4N#6?#="'",]\E:NH5^.I<&L^&Z$.$9[Y*U=0K\=2X-9\-T(<(S
MWR5JZA7XZEP:SX;H0X1GODK5U"OQU+@UGPW0APC/?)6KJ%?CJ7!K/ANA#A&>
M^2M74*_'4N#6?#="'",]\E:NH5^.I<&L^&Z$.$9[Y*U=0K\=2X-9\-T(<(SW
MR5JZA7XZEP:SX;H0X1GODK5U"OQU+@UGPW0APC/?)6KJ%?CJ7!K/ANA#A&>^
M2M74*_'4N#6?#="'",]\E:NH5^.I<&L^&Z$.$9[Y*U=0K\=2X-9\-T(<(SWR
M5JZA7XZEP:SX;H0X1GODK5U"OQU+@UGPW0APC/?)6KJ%?CJ7!K/ANA#A&>^2
MM74*_'4N#6?#="'",]\E:NH5^.I<&L^&Z$.$9[Y*U=0K\=2X-9\-T(<(SWR5
MJZA7XZEP:SX;H0X1GODK5U"OQU+@UGPW0APC/?)6KJ%?CJ7!K/ANA#A&>^2M
M74*_'4N#6?#="'",]\E:NH5^.I<&L^&Z$.$9[Y*U=0K\=2X-9\-T(<(SWR5J
MZA7XZEP:SX;H0X1GODK5U"OQU+@UGPW0APC/?)6KJ%?CJ7!K/ANA#A&>^2M7
M4*_'4N#6?#="'",]\E:NH5^.I<&L^&Z$.$9[Y*U=0K\=2X-9\-T(<(SWR5JZ
MA7XZEP:SX;H0X1GODK5U"OQU+@UGPW0APC/?)6KJ%?CJ7!K/ANA#A&>^2M74
M*_'4N#6?#="'",]\E:NH5^.I<&L^&Z$.$9[Y*U=0K\=2X-9\-T(<(SWR5JZA
M7XZEP:SX;H0X1GODK5U"OQU+@UGPW0APC/?)6KJ%?CJ7!K/ANA#A&>^2M74*
M_'4N#6?#="'",]\E:NH5^.I<&L^&Z$.$9[Y*U=0K\=2X-9\-T(<(SWR5JZA7
MXZEP:SX;H0X1GODK5U"OQU+@UGPW0APC/?)6KJ%?CJ7!K/ANA#A&>^2M74*_
M'4N#6?#="'",]\E:NH5^.I<&L^&Z$.$9[Y*U=0K\=2X-9\-T(<(SWR5JZA7X
MZEP:SX;H0X1GODK5U"OQU+@UGPW0APC/?)6KJ%?CJ7!K/ANA#A&>^2M74*_'
M4N#6?#="'",]\E:NH5^.I<&L^&Z$.$9[Y*U=0K\=2X-9\-T(<(SWR5JZA7XZ
MEP:SX;H0X1GODK5U"OQU+@UGPW0APC/?)6KJ%?CJ7!K/ANA#A&>^2M74*_'4
5N#6?#=",*] #^D7_ &V_]*O"/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g609070g00m56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g00m56.jpg
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M Q$!_\0 '@ !  (# 0$! 0$           8'! 4("0," 0K_Q !1$  !! ,
M 0 %" 0("0H& P $ @,%!@ !!P@1$A,45A47&!F5EM365Y33U0D6(5%35)*8
M(C$T57)TLM'2(S4W.$%U=[.VMR0R-GBUPD*T\?_$ !X! 0$  @,! 0$!
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M-[2WI+"M;7O6E;3KTJUW?!ZTX%D6I"G9AD6)"APXS"V"UCHA,2&YC:![X;:
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MNP;=]2<-U4Q]F!IMQ.&NF6I2'G$)Y&UCJ%6@K%,JDZ18]7J\7>5W#1C(PQ\
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MF1$BC1P(-YLM &(AL<14N=07XC[K2]V6 #0 %I<XN.X9= _(<BEG3>S<UX\
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M217T4P..0XL]7IH5VM4RILN*WNQ/!D2XQQP1;T?7YJM@..!D+'VL$&=.D32
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MH55J[#$XY8[Z;=JKV9[GY!P3P3)_3+.G<A%1LR(XU()<:>"DQ4$LJ2KV"?\
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M]&_^]9[_ "\_]S 6^!F[B'M56?P5?_.G;?\ 4*!__8N&=G])?]'8_P#CGO\
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M9(7Q\%!"@8_Y;L&JQ7I&5I%KF3(P24?878XTN>2+""VD."CAW=O1Z=6 WYJ
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M@A;D52N@U.X<SLDVE&MJWJO@WV"K^K"][-*W=B0;L@8AEMUYP=#;3BD]?:?
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MBK_;5A%F81,(F$3")A$PB81,(F$3")A$PB81,(F$7.OF!_U2_*+_ .W7MO\
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MQ[8 Y(V7UF#2MXTJ_'1Q: ,(#WDE@ 8TD-+R;H)I7 T7F[=IR.0S.66_):B
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M:!820T79*7:;#737$QAB"T$KBR@8_26'3&"<708! 8:^*QQ+0]UXPXCKS@X
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M3,K/HLD:!)6(R5C@!V*U$S<4, ,8Y/J9JTE["&PS#IHR#=,)T,B\(@<6U=>
M)):/%:YH *ES?@!3+^Z1B-8QRKNPH%E07@K,QLKS&3/Z/!2**'-.R'R=JD.1
M[<8+KI,7T9A54/@[!"GBV$DB.7%S=EEUR)\\EP$N72>)&.0TF;)D&$3$#M&2
M;MR@ T@B LNN:0_"A>22ZM36E' S$$D5&[?7/#I_(*T^B^*\S?NHR'8$=8G8
M"UQU@YP90 (^(AW("OUZB,G-&P\K[T*]8C2['JW],8*/@;!6AT"6P-DR/E/D
M1M16U\L7Q3%TKFN#H98 &W0UF8/[QO7HH-'- O@D.+<<BTDDU(-12FH >TU=
MB*8'<JK'\%#FJO4X%RP\J2=3Q9B#%G(_D2HZ1G(N7Y+-\P)L]F+U;2BI3HAC
M\A&VDZ<T\R*Y*137_P *M?LR&M7U/Q&MO0@6WF@B#0EIA&&7N.D),0U#R<J@
M#4*2YA2H_#N(SK6N1J:XA2Y[PJ87)3!B;SI0+SO,9&LPC\#[2-JLY 7#E5KZ
MK*!(^4]*=7U![C]75ZF_9*@9 NP&>TDFY<@;,OJ@!)#\*PRT7<&EKX3XI&/_
M !3!8<_%)<<0XA+GIR_*O+3K46I'B/-TKJ'((\,6/;YW1A)ZP7F:AHR#KT#>
MI""NUBM'#:^] M3TC8%V6@SEML-IEIAV*"@'DH@V(V1>)27'BXLEBR)" _HV
M!SGD -:\B(Y\!MT.+KT-SW/+J!M0VAS @90C*@J2<JXX:\Q4G+7GMLGI?B.#
MTSHUCNLW.0ID3/E+,W69BKMS S)".,VCE@3SJB9#W8AT&1L ]H&<4$E3+L:V
M.SMLE31[&R)+"(\O+A0FMTL#A_0NABM32H)#QA@6BE#B*65))IQ4KJHJBFO
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M3^,?8JP>+TWD]9Y3U4O?,GA98V(@[QT6VE*HFH^Y@Q58T]&= =JL8]-@6PT
M6)#F#B)B6<)<?Q? BQ";T5ITD(0HIT='$!\1WB4>&M\6)<\8/( K4G%"TFM2
M,0 <*8 DX8X9TW9XJ*V_P;G;,1<K&UVB49N'2"NK#7C9M:B2*H36>D- L@PT
M3'!_)]E:>JK-0Y@."5.6R?&<&IY308$7J:<V)K?)EU]PC.O1-*'U8TMNQ!@
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9,(F$3")A$PB81,(F$3")A$PB81,(F$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g609070g00r08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g00r08.jpg
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M<W2CL[8B(S(W.%%9=YBEL20E)V%QD39VM28U0U)UMT9B9&6!H?#_Q  < 0$
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M,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC/)YYJ+_IJ[3_\
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MJ->%!TJNT#JHVJ-P6V%91#BJQJ2X&;13;'-!G'L6H0R[93X_%TZ[>,]"2#U
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MM7>0S<:73*I1@+&O[9:IQ@[>#>I,CI->?L(D9?D5T]3);&R['KUV!VW&V_C
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MAGON(XD%*N^FP2)%6DCU&5I##J!DBD:6&5G5B(V*H7274*7"2U+CT=0F:Q!
M%I*99'\+G2_-&\D\;T(Q'VU(1RHL<T:H1NP#.J/H1??_ (//_P!!5_:M\[:7
M_1/_ !3F/P1^%FA_^<'_ .*3/5EYG3_H1].7_P @M_\ U@KSP[ZH7X:<0_\
MGO\ ],6>P8/]$GS'])S:B^W(1KFBW385@Q*R!HE3L=R-X@LXD3<B*P'F&R6(
M;"EM)?E9AP7L1V5.-X<=[A&5HPKNL<Q0IS:C>IZ?7Y>WO6Z].#G/*G;69D@C
MYVV/*O.Z\QV.PW.QR0G8$GN ).W?TZYJE+ZQ7JG8@%1V9J4_6K,?D4^='&5(
MLYLUQ-1O%.W%9Q!EEFN5YDG--#YVF+ !L5>C"U1AZIT(S /EQ#4N0UU*<(+;
MKV+FFZM!8K5UMHTMN$::/"Z5O1ZTL+&Q8:)(9$UF">O8:7FD$;PO!%*54V=I
MU 8;$['8;M[DAB#T'E4@CQ=^^<;1UY:48A28VM9[^T;<J;KN&&KPN#9!T$NC
M8UNUU48!))UNLF%(&AY>TJ>X85!$E""9):*&@C9II3L%A6X%UHNK:E&NF5 F
MH/-8E>O(\)T^IJ%N2,P&S"#),FFVQ"'EB0K$\TDB0 2-0RIM[D\Q]SL!N-^8
MJ-]]MNG,-_EZ=_3+V3UC:/=G/#8Y&WRR$;8 G6,F%#UY=9,N-<#[G>P0Z3&;
M"9D1_&_<2G8:GVFUXC#B4J2U'CP)+C>&>#];""5HZBQM0FU)'?4*:J]2N-YY
M%8S<K=ENH;E)4M)&JLS2*#7M4\I[]MN5N\]P[O'\O].VQRW&NN;1L4.P2L$Z
MRP'D@WSQ3 :C7^SB!D2'5I=ZG84<@5)EAY4"E#BEHFH7'C/118J>M]EMU,5J
M7D'@C6WF,==*TBF98(C-=HUI97>TE)-H)+19>>Y)%63W3!Y)4"L1SE':IMN2
M>[<[!CXMSXO$.I^3RY>KW5II)LC,$MG+#,(MF9  /%@46ZS7+F4@6UZBF6:%
MF,"<1=&J_;8TD,?E5]4Z,)=87*ENMCUL3'<(<*:T8UE,-=(S"MB9I+U-!2BD
MJ"]";_-.#3,]1EF@6<(TH;D4&0,BUYU[M_D[CUZ[=.G7KY-\R?J/84;;.L*%
MLV&,D!HE\JH:TQA4I[O\D>R9A-36XC[W>(N7'F$NX0XK,=C/=8SVM(SVIQK-
M6T]M*U._IKRK,U&U-5:5!RK(87*%U',^P8C<>Z;IXSWY56YE##Q@',B<U^79
M@/J WT)Z?Q>NC1L'),#+UM6N:WGRX\]@>U5!Q@18SQ:Z$52&7DR159#UD@1)
M16U,.KB(<<;?1EK*5[[0-"EU^7488)UAEHZ58U)$:-I#:DAFK014XPI'++9F
MLQQQN>90Q *]=Q8[<@!(W!8 ]=M@?'_1F*=6=<FJ=A5FN'S$*P4V19R[L.&/
M>$&[%'$B"%Z<U]2#]L-A@JA52B7RPYBC@3)Q^(K))]Z"MU>!\Z2SM-4X(U73
M[-B"%Z]Q:T09Y%F@KM+-'2%^[7JPS3"6T]&N&DG,"M]S4. .=%-JRJ1N=QN=
MO&>F^P)(&PW/0?+EQ1>M;I_F 6K$P>M:H+P]@\F/C6^P,E<5-ZFP-@+NZA":
MVHCBEQ:B2B&)5E\&R,:;>9C)>7-DQ([^.W!FOI.:[050XD:#F]<M/[+PI;CT
M!2[7PGL_#'MQM"M;F[0D%B BLRU$J$;[GR_>G?;;?<@#?;;QY#!NMC6Q.W-U
MV8"N(40_8+-56+7- %I(M1H!ML-IN$](R-'36(-<L-K/#61MDG38\%ER2F).
M3&D1R.($\W!>I15#82>G-**]:T:J6(5E[&?2I=7=5[21#)8KU89&DK1HTC!2
MZ<P:/GH)5WVZ@;E=_%N&Y?%XB2-CW=>N3E8ZU.GRZK@-5"SGK.Z2687%8 T6
MZEI.1H,.(L$P\[%@@GY+()P(=&D(1-UI+,WOSD"/W95A^ WCV>#-?I\YMUH*
MPC$/,T]ZG$O:3S2UT@#/.JF<3PR1O$"60@.WW)E<W"1#W'?O\1\77?N\F?H?
MK2T$>2+6*/V28DG.B#5.QZ)<7XPF<1N:->#8QZ<P%=@!E$[I(@5\>N=*:9E3
M"<)QIS,13\B.FX-UZ R"6O70QH\@#7JBM,D=,ZA(T"-,))A'362Q($4E$BD!
M'.%5@D0]Q)W^0^7E'7;8;GH-]OEVS,>M-MT3;PV88U^7<."X":[F3.P/GPHZ
M';14 %Z%Q,*G1X^534UFT 9Q"&G&9 MT@W!(-QYS;\=K4:EI-[29$AOPB"60
MV.1.T1V(JVYZ,K[(S;(;-:=(W^]E$9>,LA5C565ANIW'3R^, CO^0@[>+?KF
M2>:W+LU5ZNM+7'>%!J@.B3@XVSU#88W8P6><E2XD.'8*I5[<NG3.[A1);[G@
M-XF5B;):0EI61T>:XV[WYMIIWJ.$]9IZ)?M3WHYI:UO3Y=/FC@5&=X+5FH+:
M>[95'/22RBD[_=&0$;$D1R(74 ;;@\PW\H!V^O;^C-9=8]+/4YJX=3@0._"F
M(D>W.VFP3A=WL :(U8S-VI]BO=M.5MBMO0]DMW&OPKB#8JAZ5!'@R19@A#>:
MDS<F0/3:EQ1PUJ<EN>>A*SM4%6!):5>9S7AIW*]*I!9:R'TYJEAZD[6X%DDF
MCB:-@53L9[%1U"@'N/4[D=206;;;9MQOL#W;^:!:Z9>M&'XQ,C=D#85M-P=>
M"[8:\]BZR25J,U"N[-@RKG&*YK,9RM TW.V"K:*UCX&<IT8<MT;/"F!XM%3)
M3GB7@U^RAETV1ZL$NHRU8!I=,158;EC3'2DT1LL+$W@=26K+J7-!;:0"2.:*
M24VXW)+W\PW.P)YCU(W&_< !N=PO=Y0=MCETSI'JE7/H3@O9$E]M&V[;<=A$
M)&UMB0G\TV=O$*4"56OAH2FJ^H5C0D0E5<!9@]V(-L\O,T>_"(J79UZJ'6^%
MQ'?$NG*I.DU:FGQKI6GN/#$T26*:U8F<-.)?7UH[1F20-+67D=7CVK"O))T]
MU_M$L2S \O."  .GWHVZ^7Q=XPZ"Z4NK2/08FMBMZ"/52+HL7KM(=_8MN+C,
MFAE2:!S(\B"3"R(4N*5N,=5X'GTP(=@!")46F,$?$(E 27M;'%/"CW9-1AI3
M+;?6Y=0[9=.J0R"&6TTR,KQS!U:*FPI20&1X)YD:X8S-,9DH(Y-N4L-N0+MN
M2-P.OB[B>N_>!L!T!&9<B:OWCL_4G5553]EM*U6-ZUZXT<U;"5IJ$B54Q!JR
M6(+9C2W8[1Z#/+3+8G7TXT]!=58*KKT$6PU)%F%8DZI]3T33-6X7M05JNU=:
MNHZVU2*K<5;<T%>M-6A ;P>2.)*OAZ0AQV%J_/'S+)$.6O*S+("3UW5=R5W'
M4@GS\I/C \6^9.U5K;?X6^W8G>[6W/J!<-?H< ;+O]FML8C*.VV(1UCB($F"
M!&*,G6M!;FTBRRP1B3-V(5EIMA%[QFPB7G6ZIJ6@34:4=&H8[<4]!WD2A6J-
M&D%1X]3YYDEE\-.I7BEVLDT*QZ?$IJQCLV*9< ^[<Q'*01WD^/W.PZ;;+T/C
M8]<U*J?25U6T"HR*_K4_2]=05FZZI(<'<W(II7B:B'*\R7D7ZI:PH\RP P5A
M?KT^O@KZ#N)@B+'2LW\A=F&H54=ZNWQ9PM?MK/J5>YJ#B&QO--2#1?=KT%AH
MA1MZG=2O//76>.Q/0GJ11RNO@"4RSVA&(Y -E('4>/KW$;DA5)'<0#OU[]^[
M,M[#T9UC$7K+FH[J2H:Q=Y3=,&N7.TUN<Y0Y\'8E@A$#1L9!DR$V2MWB\5D
MS"?;,B"-$U77W#$:P9GFZM8-3I^N<(1K6\+T;:1J2&Y(*56R@O1OIU>2.&&5
MU4U[-*C:G+KV,L=[5+ B:OR06J]S))UV;?KT&Y&X]UMN1MU!('C&R@G<]#*D
MM(=5C=JJ)P7MR5)AJVGL2P7&!+OUKBPXU9(;4!F->9#"FH3P62/#ZLAV&M%:
M/.&/ 'B9UI.&GY+ RU5:*+6^%O!;<$NDHK^MFGP5)$H5'=K*:7/#J';2LXF6
M274WKV8KL<HG$4!.ZJTM6RY)-P>;_:8MN3W<VX(\7WHVY2-MS_2/WIRUINZ@
M[)!46P'CJM6:XU57"!1E"CK5<(;<+BVZHNLU<B3AP(MAHX:K!\V^?'&-O0(-
M]L>7Y.(Q>/(:Q3B'4M%O:;/>KP0>NFHZI/'$2(#9CTJ&0VA9LQQO(U>[-:E\
M$1I"LCT:^R\T+*<(K!@"3RJH\H',>FP[@0 -SMO[H^7+!@]-'577+3>+U O%
M.(KW6<@VK:]4K1^Z:U/,9KE]<)5RK!-FQ)EDE/N8UN>GT)^U *[KV:D31Z8*
M?C3,S)Q^#L'XDX6L5:5&2C;3UF@>KI5JS7I:E7/A%!8K%J;372NJCUQ@2^*L
M]B^AENW)E9.1('H$<$D%?='=@.8'H=P VY\1*D@+T &Q[Q,PNFCJ&AV2Y6,?
M;X@8X5>F6P(=>V/9[.]BY><MI*MBQT[,ZMBU^(U;&UK86+7,@0A>;513D2+(
M#1FF&08^)^)>'GJU*TE1YX8PE6:NNG5JJ^!^O.LV99$[.Q(.W];M1KFJCO+X
M+>@9EF8LT\E>1]R0=B>N_,3UY5 &Q'=N#OTZ@]=^X9(U?JCJBKFWJM8[YL]F
MST9NJ,O6F"U:#ZF<V8H"*OV8!!J\R"L)+#1]@%$&*J=4V/L(NJC1E904C!QZ
MP!36:GJO#%G2+5>CIAK7C:(JN:L (K13Q+6G>RDG;+,U"(Q6H=W@DM2RV#$T
MKBQ'55D# EMQMUZGO(.X \G,=QOU  &_3-WN<5DN.,9P<_@W/Y"OT<\HW<?F
M/Z,9X/\ 16ZL:*N]XM;83)V:9HESIHR*L@6&1F"-@=B8CSITL 7 G$0XW@B\
MO)$F!\U>5(PB1A'?$+]RZSI/KS4IUC-V*0W:MN1@D4C-' 'YD19XIX2S<PV[
M6)T[]QOL1JD?D).V^ZD#YS\VQ^O,XF>L"D745-)[-TA5+[LJ>")/2;3-%5X?
M&=NMMW-NRYWZ>XB.+>G+#&]?;B0'!IS(\9U&\TNI6T(^PZ)1E[41<+VZDB1:
M?J]FEI\<L2K622>1A4JZ3H]2B@9I0@EAO:499O<]G;IW+5696$NZW&0'JR M
MW[]!N2S$[[#N(;;OZ%0<R"[UC:!<Q($,Z/@0J[FQA[:IAG5VD,P[ <%!=_#1
M2K'3XM?&UUN!68^TJ#7HC -X<0/B-=2SRRU;M=E?G1<%>%=:4K*VL2//V$M;
MF.HZQSP0RRZ(\HKVFL26"]AM.O3LTXDC@EOI"(K%:N(VN[1-MN3Q@_>H-S[O
MO &VPY@.G?MXB<LHAUCT\9MPML2@:R<KX!K46S-84^F.$) H8 8N.U+O>JZR
MEVG%*Z2A!:X$M$ 'X*#*C).'!JO!740U):SE1\*VI-,BHW=0$\YU33M1M6Q&
MLDD[5--ITISM;CL1O+/-6>;FFCD7:3W0+CFRWM!S%@NPY2H&_0>Z)'<0=@.G
M_IDOZ->FW;R3G;HU>'N5D#8LADG8<T76Q=QVX6K8W4_L0L\W%.B<S)](EE-V
MTIR91GS4"(J1329$-/KUDEB[-#C]B5NGX2FDZC+4@E->*.#PR_$!5JT.':$2
MEH9>1+B1:/;"7%A=PMN..9)ZZR5WKVH.W.H/?N=E[RSL>\=V[#<;CN)W!.^7
M%GJ\Z5,'195GI3I\:- N&VR\,>O7^OYPX8!NYZU%ZM#+C'5L)V!)JT R&KP>
M!+G5 %610G*X4,R19#SQ4/L8XD[&2,\26V9ZFF1,_AUY)))Z<-:*R\4J[FBM
MEXIIY71+4UB2;9WAC,J2NTCWW[,;;MTV'3?<CQC?8D #H !W9K/7-ZUH'JWJ
M$HK8BVPD;BD*0"J(HZAO6E8BJN]*N,&:V,DY=*,& >*<T'R]WXGBQBW1,6:^
M*S7\O&=_/HUB;4=#N&6LYTH;S6I82=0L-X%<J.AD7:-HYO"S+MM'X/()602]
MORQ6!P%<;'W7< ?<CJ#W?)M_3T[MNN53G6X\<!URF3*#7"5-I^G*?4:\.LP,
M9=W$[1J6BJ]J(??I8R\.66JQ88R8.*E!(T!7PJ'&9D.8:8*'H;9!&MAX16&6
M>TEVPENUJMJU/)7FDICUNM:U/JDE))*0KV6:1)(XY))YYCS(Z1-% Y0W=KOL
M.4;!0!N-_=! H)WW'E/0>3Y\S+1^H_HZ/6,O/L^I*)K\3!%-$(39C5U.L+Y&
M"W8")).H@@@!K.PAYR!@V5 'PMK6MRN;#LC8MIFP7 <Q)>2C5W-"XJAKQ)6U
M2[=E>0QN8M1M0*CF"./USFEFU""9.TD5Y'TRL+%"N9"8*KE1O>'B).ZA1MTW
M4'Q[A>BGN[N8^Z/C(ZY8-6ZL^G0>LT[9^FVHG&I%OUV0""6]9Z@CPQE5I)[4
MYF8.3/B5X<1<G6.-4]D!;2V8S88=K@; @XEN"FPQJ-:\VSPUKL@B%;7[4!6K
M?260ZAJC-)9N0:I"DG(TSQA*[6M/FK=D(6JR47*"0RPM6L$B>- >J^)1L!R_
M)UWV.^^X._4#KO9*>I'59G8O379G-95RB>=?L&HGKP?JM'I-;46'Q*)HH,;)
MJ%4<&&P9DP=F4?:6SA4(@R_AA%Z9!0,1(K;D-G+.@ZE%0X@K^N-B[ZXT;4-.
M"S;MV!$[W=:FBC[2Y--V2OI]W3=.E>,KS>!&9P[D,7..9#R@<I!.P'7HH/<.
MON@S >+?;,JTCKAU=4QVH:RYK.QLP-&5>]U:FV828BD"4Q6W]'7W7^W2TL.1
M\3M-)L>S+,%V,+B-DF78\ 5,$2GD3)^)S&LN<'ZC:DU6P-0@9]9LTK-NO+$R
M(GK5K-&_I<:S)VI/8:?6FH2L8R&>5)57DC[-KA(HY1L=E! ([_=*5;H=N]B&
M WZ=1WG?(]GKXC1=GNV^**O[59<ZE.DS=KM>\J<Y1-"]/E4L@.ZBG(69*A\2
M9L<T3$V2,-0N6*#K&QATJ82\5CYRI&X++:<*C24C8]C_ !/HXG\& Y)==L5Y
MJDH8+SLE"**6NTA"22B1I$6/M'04[79B1S;%XWVW\2@AAW^,[;#Q; ;]!EM&
M.KFG$1UX%-3-VB<'9L6P0#5)/AZ 8/SF*#8Z-Y'W/O,RSH53HV#22D1^.^3>
MPU/MPE87&+&V2%Y$/#-J.2G*5TB7L4:%X;D$MZ*%3=KW/"JG,E<^%-V(C966
M-=XZLO:GP?LY!D!!&[^4$'8D[$;'J>G]/<3TZYC^S]2+-]H-G"VHI92$YKIR
MU]I^NCCY(B=Q)N@/<5&O)JZ177U/Q!;2ZS520IZ2Z^T6E.D8D/"94)R=F/FU
M]!-*[7FK1UT0Z]>U2=X(XX>6I-I-RE%48*%:0BS9CE"@&)1&SDJX3FM+[J0=
M_O O7RAPV_F&WERV=2;ZK.N];%*89HP^VDG+#<;0#?/A*O:*\-.&M8SZ57"4
MFNVL:6%3Y-?.R8QU&94"0WA,;&&D=_PG/,G4M&L7K\=J*Y)6C$-2O,()K-:>
M2*'4$MSQK/5DBE19X5:$\LBGW77W.XPK@*5(W.Y(W (W*[#H?)WYL>9ZT]-3
M05NJP;2RJ]5RN=G>( 0T+0FTCVKM7^K:NUZ-@FL2[,%MTN'OZB9$^!)F,Q_(
M<BS$B,-28W?M!%PGJJS5+$NKF>S%ZW=O/)+=/:&G/PQ8G8Q"4)*;;Z)=$H?D
M)\,1F9BK 7=HO4!=@>;H /\ :$@ WVZ<H<;?-W9<<OK9Z;UR&AT3ISKS55;+
M1C:Q#^KM4X&3CT6L[@JHVS%ZR.0-%SR0&#=*-)0*C3A@,T0KA66S&K+KP_+4
M"\(Z^%,C:].;)C:$2C4=2[1(&L:79>M%8D:21(YGJ7%,C))-%'/&A>P ^5[5
M.[D&VX_V5Z]&&Y'=N-Q\A(W^?7K<749K&]Z8FZUH>J86M91;9M7ODV$""U>"
M!ALU9S?;34=LY$C>6UB7-'[>"0X,2V%"L:IQ*L\-!2/ 9W<IW>EZ%J-/5DU"
M[J3Z@L6G6:2/-+8>9S9&BDL86;P. *^ERN[58HFLO8$DR\Z=;&<%2H4#=@>@
M '3G_I/WW3<G8#89I?SK,CQQC'&,<8QQC'&,<8S.O3?NTOT_;=J^QAO?WX$.
M1D;:13*L)\=U,BMILR.RE2DH6^EM#9 ;EW/>FB\$?(<QE#64YYWBKA^#B;1+
MFE2\JR2+VM.9A_\ +W8@QKR] 2%W+12[#F,$DJCJV7(W*P/]!^;/6A FQR<&
M$1B9<5%(1(TV-EYEZ,[F/+90^SEV/(0T^PYEMQ.5LOMMO-*[4.(0M*DX\621
MM%))$^W/$[QN%96',C%6V9258;@[,I*D=02"#F=E7RS&=(?69_I#73^AU3^Z
M@;GL?U)/P#T?^5U/_%+F>5O5._#/4_Y+3_\ #ZV:M\^DYP&;CCB'1])%0FYH
M,N.,1BXAMV4_)N\B(0@1ZM6I$IXE&A$758'D[5Y9#3JQ+PTN+BKJA*N0B+$4
MU (\++%QPL\ACLPRP/!.514T]7BE:Y;5%B>2(#M8J?@$M<3K-!,XN16I(F>"
M2+LHY.#FB0/!-'*LT(+,UYDDC6K69S(L<I/9RVO#(YS$T4T2FK)6214FCDN3
M!GHN:'%Q,$/+4U-N\HF&FGA]SDSXP<=.W(P)A6(F+)1R+=8D5\WK#*(%25!.
M3;"+DRK0Y.BC8J\XI@X],L$\DZ<T>GI#/'6EH)$\\L>A-/)5AFB:(W%M5]7^
MZW1)7CJS(E01/,X&3VW!0CEA2%^5[K2PO/'=:188WUE8DL2Q2+**S5Y],VCJ
M<D[V(G:T9%B0FRBY#I6A4V\(J4$M,LYZJ28=2Q;X9^1+K)2(>I\AF1*DC)C
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M.=RG'=+5GU>:JW:L7K,]RW*TUFS*\T\S!0TDLC%G=@H5068DG8 ;^++@ H
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M&'D6=9(F7M4QO&3NPYO==2.8>Y]QT '*.[G\6^^W7(>E;)Z-@E9%'GZ#%"[
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M&=4CIPU.E6,)[%8JD'&<?X:<?9[G_5ZG'L[XQ^,FK?G3Y<L,18;QKYODR ]
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M>RLQEG)HQI79T\'<1QO"<Z\.?3L^=YEO0/\ GWTI_O;UO_?$-S2\2?@[K_\
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MOI3_ 'MZW_OB&YI>)/P=U_\ F75?[C/FVT#_ %[HO\[:=_?(<]A$_P"WIO\
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M/2&IDN.ZI<>4^TY##JNHUYX[$-R=)HJZ5$D#;E:T858X-F!4Q(%7E1@0I56
M#*I#E4]-AW[_ -/E^0Y%V'1FG;9*K$NRZUIQMVF#8P6K-D <)^(##0WX<F((
M@P%-^ H%Q9 ^ ]''JCKB,N0XRFV4Y8;RF6OKFL55LI6U*Y"+DK3VC',ZO-,Z
MNKS.^_/VK+)(&D#!R'8%NIP44[;J#MT'D \FW=GQE:$TO-(Y+3=8TV9.4NQN
MO.2PL22U*=MT^U%+&].B/(7$GO%9]YNDE]V8P^XA=KL6&%-(,3TOU77=92/L
MDU*XD>U< ),RE14CJQ5PCJ0\8BCI4U 1E!%6OS!C$A5R+W\H\?B\NY/GW/GR
M.:Z;M#M."W4ZIIBW0S668#L@2U*=0CP\@33X2Y)RZN>MN:7+NLNSU2G&$ERS
M#*T1R<YI^4\1ZZ1*/72X!,>:0+*4!/9I$>4*!V>Z11!A'RAC%$S M&A6G(G3
MW(Z=W3Y=_P!.5@SI^TJ'D 9@W6E3B3:T3=,A9R!J%SHA1UT1(\-<FNJ7*FO,
MOU^OOQ/#W9283P $[$2PX&&JBQRZ_K,RSI+J5ITLQ"&9#)LC1*)5Y @ 5 5G
MG5^S"EUGG5RPFD#5Y%&WN1T[NG7S_P! \P\@SB=T%JFUO6Q5NJ0VUP[C:H-V
M(BK!%BSQ\*U0Z@+H;QD-C,=$P9(*U4/ $%VV9F8\^,F6AQG"2A5,VL&O:K56
MH*EJ2J].J]*.6!F222J]N6\(9O=%)5BM322PEDYHV*$-O%$4%5.^XWW(/7Q$
M#;<>3IT__LY1S^G+3,J8>,CJ%7JW:3P*> \L*Z)&0;($8G5!NAXG5R4]#E0P
MY2#4F(H&!,CP?\2*BL#'&WAR5Q%WIQ%K*I!%)?L6*T$Z6/!+$LCUYF2V;W)8
M4.KS1/;+3R(S^ZE8R@B39Q3D7KL "1MN!L1TVZ>0[=,R^)%#P0H8$$16H(H,
M/A"AD%C&<,PQX^,W$A16<*RI6&H\9EIEO&<YSA",=N<Y]7FHFEDGEEGF8O+-
M(\LKGO>21B[L?E9B2?E.7@;#8=PZ#)#D>,<8QQC'&,<8S@Y_!N?R%?HYY1NX
M_,?T8S^>+/\ MZ;_ $N3_;+Y[_3[Q?XJ_H&:?*3EV,_>W/J>KGU/L>K]CM^S
MV?\ KQC/SC&.,8__ ._]_L\8QQC'&,<8QVY_U_\ E_\ X_U?_P"\_P#OQC'&
M,<8QQC'&,<8QQC-A.F#I[LW4SM^NZSK_ 'Z)!D.>-+=8$-=]9K-2@NL^-R[F
M%8RVJ3E+K4 3'<RE$PQ-@17%M-.N/-<UQ;Q+4X4T2UJUGE>11V-*L3LUN[(&
M[& ;=0FX,DSCJD$<C@%@JM?&AD<*.[O)\BCO/S^(?*1XL]?0&D5G6M+J5"IH
MQD/5ZF+8"AA[/JX9B1&FT86\YG'=R9DES+DJ=,=RJ1-FOR)<A;C[SBU>([NH
M6]5OV]1O2M/;N2R3SRM_M.[ [*.Y$0;)'&NRQQJJ( J@#;Q +T V 78><95<
M@R;'&,<8QQC'&,MTQ]L-_P SC]-?,J#[P_QC^@9BS_?C^*/TG(GDV0XXQCC&
M.,8XQG2'UF?Z0UT_H=4_NH&Y[']23\ ]'_E=3_Q2YGE;U3OPSU/^2T__  ^M
MFK?/I.<!G804W[#"UJES9-!V7%FP<5V:T.M8$-+I%7J#&LR.OB<74TLC#1)K
MPJUFB(,Z2E,0T*GR$04))((Q'IUB^9P\-/8M7XTU'27BD-I&EI6)TU"Y?;5H
MM3A?6DB<K:FI016*T2/(PB4R$Q&)UCJ_0I=?2&M2=M/U-&C\'<16Z\,E&K3&
MF2:=*FE/(@:M%:GD@GD94!D8H.T$B&2SC[3O435-:4JJ5V8Q>)A ;9[,;)/0
M\"510>"E/M]7"$J*MXE&4,-CG[3()&GY,-,RP=D&'DV/C5P0A6SUWA>YJU^Y
M:C;3TCEIU*\2R=N'L&&_1N6(M1"Q-VU>5:2Q0*DG9UMY)/!Y7M3$:_1N(ZFF
M4JE:1;TDD5JS/(4$)2 2T[E:"6B6D4QSQM;:2=G3GL#LT[:-:T(-],]2E)(C
MWLP=6W*S1A^MMRA)Z5NBT,ZW=VN&2"D2*M-8&FH@^H#HJ18"%'6)KBQ;*#!O
M#Y(Y<#S<C7-PIJ$4J]IK%&H\FK:#8B/+,6U4:+.;*K<1I:\DMZ5S-9D83VQ,
MQ@K\L5>C6*9XXEHR(3'I5VRL>FZS!*"8N73CJL'@[&JZQ3)'3C015T4Q5C$H
MFG#2SW+'-:]+Z@ZK6-;B:6[52%@!XK@-JY08$*-'9C/0)FWQ[\$J5=CMRIP\
MS/O@6PMM+EK&-O39@KO>9'?&W,O4.&+ES59[ZW(JMD6K#4)9)&=G$L>ARK+#
M &*1RUX]-L52P02LL<<V_+L1BTN(:E73(:1JRV(/!JXNQQQJJHT;ZO&R2RE0
M[QSR7X; !<Q;R/%R\VX,65W9J\E0+%!%:EA@K"6K%PJL^P!*53HX@>Y8K<'L
MM6<?5EE^2X3P.KCX-HG&?!O@X3DQP*/)2<2I+LT.@:O%J562;6I+-6"W1N1U
MK&H7VGE%6C/4N!=F5!%VMI;#0NMA+,@06)8DY$6*76]+DT^RD.D+7L35;E22
MQ#2IK#&;-N&S5+'9F,O9UF@$JM T,9<PQR,&<S<':'3TS! A!VHWK<;:U@)K
MS\R#3JYWN1<3FO=:@B+"XC[&"Y.>+V(.N!V#=,O-&W"=E4#'L30&![V<>32.
M)VDL6)=;6E7.KS6E22]:W6C7U35;$3!U;L(8IM+EHUI*'*U<15!8E:.R95R:
M/5.'@E>"+1VMSC2X:[/'3K$-<GT[38)!R,O;221ZC'<G2YN)S)9,$:O!V9R2
M-=2>A["5,DSFE$&%S3#!"$U.&@V6((N3LN]W4G7AL0?,B0Z\RR-M0B$DB)8S
MFQRJ^ZT?&XAFYV<10<*<1U88(:^OF#LX&BD,<MAFDF32=.T^&U,\L;O:9I:4
MTABF8>"I9!K2F2"/)9^)= L2S2SZ()C),LB!XX J1-J5^[+7B2-T2NJQVH4$
MD2[V6K,+$82>3+ *;SH4AK6JX6NFZ_FJVDW9B[(0+7@;5A:-4*CU%]4*>+:A
MS(:8]@IQ<FJ$UC(Z4LT\X[AF;#4EW91</:DIU82:H;/AE.O4@:Q/9L-5:OJ6
MH74[2*8R))S5KT$(D;[J@KJ!S1N"N!+KNGL-,*::*XJVI[4RPP5H!8$VGTJ;
M%)(@CH%L4Y93&-XW,S$[.FQI+CL2A7REV*N4?7F )F87JRA@4&#82N3$$$;I
M*9.R/$D;O+T\.*.(K;[TKNIY-)UMQ3K[(M&6;Z.EZCIM^M:U#5/":\<%SM;%
MBPQ"//%IZ-67PA]UBGFKFVH3[G":Q79#,>:.YJ-"_2L5J.G=A.\M7LH8(%W=
M(I;CK._8)L9((IQ69FWDD\('5EB'+JPI*D*4A:<I4G.4J2K&4J2I.>S*58SV
M9QG&<9QG&<8SC..S/.Q!!&X.X/4$=Q'ESE2""0000=B#T(([P1XB,RUH'_/O
MI3_>WK?^^(;FEXD_!W7_ .9=5_N,^;;0/]>Z+_.VG?WR'/81/^WIO]+D_P!L
MOG@'/;64G&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<
M8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8S@Y_!N?R%?HYY1NX_,?T8S&N:!0
M\YSG-)J.<YSVYSFMALYSG/V<YSX%ZN<\E]<=0_AUS\YF_7RFP\@\PS\\[^A_
M<34?R;#?L7'KCJ'\.N?G,_Z^-AY!YACSOZ']Q-1_)L-^Q<>N.H?PZY^<S_KX
MV'D'F&/._H?W$U'\FPW[%QZXZA_#KGYS/^OC8>0>88\[^A_<34?R;#?L7'KC
MJ'\.N?G,_P"OC8>0>892SJ!1,17<XI52QG&$]F<5L-C./\-/\>(7'KCJ'\.N
M?G,_Z^7(!S#H/'XAY#EN>0='^XRJ?DZ(_8^/7'4/X=<_.9_U\FV'D'F&/(.C
M_<95/R=$?L?'KCJ'\.N?G,_Z^-AY!YACR#H_W&53\G1'['QZXZA_#KGYS/\
MKXV'D'F&/(.C_<95/R=$?L?'KCJ'\.N?G,_Z^-AY!YACR#H_W&53\G1'['QZ
MXZA_#KGYS/\ KXV'D'F&1Q.B4?$?'93:IC_&I_\ X=$?_E7_ /T?+'U'4 .E
M^X.O\*G^7_QY:ZKRGH/%XAY<@?(6D?<=5?R>$?L?(_7+4?X?=_.I_P!ID.P\
M@\PQY"TC[CJK^3PC]CX]<M1_A]W\ZG_:8V'D'F&/(6D?<=5?R>$?L?'KEJ/\
M/N_G4_[3&P\@\PQY"TC[CJK^3PC]CX]<M1_A]W\ZG_:8V'D'F&28VO@0JW7
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M[P_QC^@9BS_?C^*/TG(GDV0XXQCC&.,8XQG2'UF?Z0UT_H=4_NH&Y[']23\
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M]ST_HV&X-?H/IWV!K3; Q)0N5>UA0=7U^+!2J?"0$N&Y9PQJJ&K8!%Q#Y$I
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MO[Q[8G'O^[+4_/?_ '=CV"\%?[PM/\U+[=CT"W1;_M"]>?@]._?WCVQ./?\
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M#1#-GLIFS/*/2"^O+>Y*,H.[:57"]? G:W#&5BBCM54>0J[,F[M#FQ[K7HC
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M)4BDC-O3#8J2-#-(93!X,\Y(2?GB18AK;W%6L5KEBM>I44LUK\DLL227%1+
MM)8D1O!M0[&R@DB01"<V$AV9X.61VD,-.ZVMG$GN_3*_3>Q<XU,<;B*NP[N&
MSK&R&9T<;(@W-B:#5A6T[.^T2"RH!C+K8I#Y!^-#=CRLB/@#2(EY4LW^D<"
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M,F>AIUQQU>KC>5N+4XO/GD;"QVJ6K*E9[,63&,=N<YSV8QC&/XN?01ZK/'(
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M7\_QC'DV%]A?G$OY_C&/)L+["_.)?S_&,>387V%^<2_G^,8\FPOL+\XE_/\
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DALP:-V<]>:.>%_7#57Y)8762-^1[S(W*ZJ>5U96VV8$$C/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g609070g00r47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g00r47.jpg
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M0WBXX[LLYKGG,2T+7AXYSZ<NDE'_  =DDS2UH8Y[FAH;^X'!V;.]_?7!#18
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M49;M:)#=;Y\D^3>Z=9[Q#ZKB>OUSD+DVJ#!C$]'8A(C\J93-0!L]VBK[,9'
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M2_ZV=_Y.E7E'_P!H!_\ >;P._P"PD/\ ]08XN_>O6E\')1$HBK?<G\4.U?\
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M,F]6D0\\9!5)*H>\###"4^Q&89PDYS*+']6OMMLV[5AQ'=&N(CHC%(P<V\!
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M41/"J,><8'TP/^\41/"J,><8'TP/^\41/"J,><8'TP/^\41/"J,><8'TP/\
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M9LNEKVOML/);9R>5,VM[7L-+GRWO?R7L/1RZJUCVG8Y)2^CSY9 58OHT\[/
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MX3-X&EN:1X3DQ8HD26V^3R>?JUW**QWNBRTH=1)H%U, +8F[""APJ%W$T-@
MD<D)7BR*$XCS V!KI'9NTSY519>40]5(*R!)1DYFVE1A$E&EC!"+"_1Z3U+
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MUN6_ORU$67HB415GNAXNPU)LIVW'O"F24)DG;,QQ<6!(9,E!3E(BNP,&\L!
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M,"EEWZBSB[7% ;[!/K$G6*UF!2W;-6%W+ENEFQ72<.$DFZW9)*YK)D5/Z'E
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MY<-IVQPQOED=^T.5D;2]YL'ZV:";(61@$EHT%^96P1F?-8>F7OAL8V2<B">
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MV.=QX8<'B#J1R(N<.ON]Q 0:-$.,W9)XV364:M[K.4=+$,!X,4%)+5]RF"U
MA <Z.+"\'B+67'&2R2U3:>"*&%F:6:225N2-CBT/=9CI:^1QMQCQ_P#$X^8
M W)/( MEI/$^Z'@ 0\J*Y?;/FCUW)=A 7PZ,<B-JXC0#'6Q/9S(Y*9%/)"4
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M]$3J'O\ 21'T)[]_HB=0]_I(CZ$]^_T1.H>_TD1]">_?Z(G4/?Z2(^A/?O\
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MD1L\R/DT]'3[[7MT]%[;1C7+XWLYTAKF?*1'7CR4:^RL_9H:O<LANLTRFO\
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MUZYE.>1$J.4;C$<5"&+A@LV2?M2D>7R_K1:=K:QY]I/(Z??;:3,K)!B0N4"
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81*(E$2B)1$HB41*(E$2B)1$HB41*(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g609070g01a49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g01a49.jpg
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MP_>QPPQ47<+JY)MVC9)9TZ51;(JJX<4>/!EH,2/'B-A0832^)$>:-:T9R?4
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M$';5DVQRNNZ<H(8**XX1(C(4.)%B$B'"8^(\AKG$,8TN<0U@<YQ#02&M:7'
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MU#+89.)F9T47'8\-HV5:DQ+2\&6LTR_!RL?YN&S[9B+*S#IHQ&0W19B:9#A
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MDA@%##:*" XDQ.#)*Q_B<K$?_2Q&E@C6/&;_ $!NB0@TV@\Y,.I<3E!Y-3$
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M%'0$-KE%C@2AI/%_&EHU(R>M8=&RN>4YB14AC@BC73.L>U'&0R)2)+,@R<G
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M+71XF2(D2(0V*3E.<14K.6G(4Q?PH;&@2-JY44PO PS$ANE2UN2 YL)E2QC
M3# HT T"TUMWFGK=I MWCM93[,[MF91'B;"CVT&4'(1UWN4C!(OM8+O2:,G9
M8"V*1RY]A*HY&'1(VW 2F1CTGCB[6^+AWC;=D[$F3,2+IJ7R).#'M>.R5=';
M$;),F(LH^0@.#(A;%X-T&+%#6&)"A.(%;FE:LS:4$0IH0(V7,185GPG1Q"<P
MS+H4.9;-Q07,#F98B0X9<X-B/;4T-ZF6T.=.EP>:<S@,J:;/2:[HTW.]$Z:7
MU<K#V_&K6,2"F!NT=8$"S\0U"/V>P I-M"78>'$9 !*-V2TM)/FQA;!._#*6
M#.O_ *&8@F5)DIV!/SHF^&=:4U&?#?*S36->8C72\1CH[7QFPWL+A"8TL"Y8
M]J2S:1(,3AP)F6C2DL8'!B2@PVN;'@.<6Y!;%:X0BV$7L<&F(XA]%FH7S XC
M02<377>L)"O ]9P_6<)BN@]MGHQ-4'J+UYL=]L[=G?G&) #FPA;V:N#[6,)9
M)"5V!D-KP6 ,.F (NHXOA&L>UYB! F9J&)B:C3,>+:$FR+ +2ULLV5DLCAGP
MY=S8 AF+0ORFOF7Q&@Q& +*%:%GPHL6# >84"'!A0Y28>R*' F,Z/-97!L?&
M:8I>(=S:.9!:QQ:QQ*PH+G;I...@#*+F!<5B!,_SW,3N*B]8.VT<?7V.!:NN
M.:*T==L9(E<+>:(J%1T9P*&!D-6NC8O=%LU;JXYQ+ GHC8ABL?&C-AV R7BN
MFFF(WYM$<+1I$:Z$<L0"&.BY+'1@#D5+B#BRU99A8(;FPX9?:SHK&P"&'AF
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MVB)1$HB41*(E$2B)1$HB418Y_P#EA?G'^HOJ*'%NWH*R-%4HB410TR/;DI4
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M84,E<=Q+L4QHK9!B&1O93F:Z_>.X@J%!.&C-X5HP/KQIJ&>_1A33HQ(O!KL
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M+-0VX"S9N8(*:6:F'<D%MQZEB15(/&LI$HM&VN5[K%6CM9N5CC)Y@G@B[DH
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M--O855BZBR2B)1%%XA\DN_2B<>^D@JG'D;N"@PY7;RI1452B)1%A8T/7$QP
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M2:'R[1,5-P2!Q+6L:<O)#@PAT(QE"<=&W2.O\55V:,SUOJ:1I9%,^DJK9_!
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MEN 1D)*R'2;<) MD*N=GMW[0PW$A;.<25&!NTYM6:XWYSA<%B<1?HSZ_*&S
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MET=&6-[7O:N>48R+-2\-XRF/BL:YM2*M+@"*@@BHT$%9M ) /:Y4:_=LV?\
MZTJ?S4"_NROK_P"$V?\ U<><C=8N3(;H]9^*?NV;/_UI4_FH%_=E/X39_P#5
MQYR-UB9#='K/Q5N-.2(S*(4@5.O;OR&9$@ADXR0;-[W214PQ2P[6T101MU;7
MO;ILG;*__P U[U\U:L"%+S9AP69#.#8[)JYUYK4U<7&^FFBXW@ W:/BMJ5UJ
MQ2B)1%0S0.NH3#MR6CHS:2DU(Z9@DSUO%08_4SR,=X8W))-#Y+(&4\VHT;.
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MQ1!!W@S6250NFKVYLV<8Y=L:HYIYM8YU2W-=C3%8EP;2M;UH%7G%P*65++K
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M6QZ>CK8]/3U>CIMT]:^/6MCT=/3TWQM?+H_?ZMNG]ZHJO^J(J8[,VO/H_.9
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M^>ZIG6PYZV.Q%U S ]V]\#($I(9@I&6\Y<AE9(."DR$:D:P-$P1N#+F(ZQD
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MP_F-U>V%Z_WB^?ELETV *S9:5/3^125,UBTO25;DSK(=)RS 8>:MW6N=3$D
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MQ(O7KG<?XN6;LFO?9E;T+P;>7VBJKU]*N173X!^4:$]&I5[-O7R'=Q]@Q?\
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MB>]\0Y3WN>[#*>XN-!@*DDW*5TF]2[O.,_@2/_E?_P!ZQ1.\XS^!(_\ E?\
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M2LCWKSN_+(AS[TFBHCW/W*0S4LPR9)*Y6M:FM<ZE+@-&'-2_ITJ(C^QRP%D
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MV-U;P%:QW2,K;,S2L)6UD1=S1T(&#$HJ]U9,=:$">#-IK2;MB9A\E)T2!%#
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MV *)XO&N:%DQ:Y)BXZ':3>^:J.1 *4OPIHS?%;5AT?F 1U)5I3./#%N5+*/
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FB 30L7&94$75&&[76M?5MT0M-]#2N_>,!IV4N-YZQ6241*(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g609070g01a50.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g01a50.jpg
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M  (# 0$              0($ P8'!0C_Q !3$0 " 0(# P@%! T)" ,! 0$
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M]JHGW/DY^%\-]6O_ (%0U>5V<^&* 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M,\)04ZF)KM3C&E)4;S?HU!RH[4U&-2MLRFU*&W'T*H2C*^J>NU'PA0"@% *
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MB_>V2BH44 H!0"@% * 4!#(OX\V/YYL?J\@=5Z1Z/%D6LNGP1,ZA10"@% *
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M,DU0HH!0"@% * AT4\83GSQS]68S5>D>CQ9C'\;ZS\"8U#(4 H!0"@% * 4
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MW97*PQOAM!\45S;K T'257?D_/MSZB.^[=FN=\.RZTWWW'"<L]'NMKD^-<T
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M:4EJ^E]XCHNA=Q)JA10"@% * AT4\83GSQS]68S5>D>CQ9C'\;ZS\"8U#(4
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M=LN,KZYVW$NF[=*ME9Y7>6O3;S-IQ[QK"O.9WZFRVL5I+H\45ZQZ?!DFJ%%
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MP=?*Y=_ ?+/YJY1_9*QE#UX_6CWH_HI5^%#ZQ ]I^]AL?S#E_J\1K=Y-_".
M_+<+_CTS*'KQ^M'O1U@Z_19O"@% * ['7%CX/&H_,]C^D7KP/Y2_A[E3\JG^
MK$TJGKRZ3/U?#,#7'MGWQY;^5+_JZ%=ZY-_H&&_L_P!Z1S0]5=?>S'=;QD*
M4!;_ (R>*Y9^/B_U=W76/E!]\PWU*GZT3CJ;NOP+0UUXXQ0"@% * 4!#(OX\
MV/YYL?J\@=5Z1Z/%D6LNGP1,ZA10&E;EKC&IMR5'%2[P$%\#VT) ;#88[@T&
MB4<Q@7/]@IQ#N%A*QS^<Q8B62+DS3]C&U5"6*BT?528B92 &G+\D;J+M>^[)
MOAU<W,^*,'KNW)IO/+1JVGNOPWFPGD[I_9&[(\'B$3-:M'QC%\D7D3+8<<VD
M4?.3 AZQ?Q=\ ,ZMW!J8J&N+=(.G#G!=V1LZ<78*I7:]R9V7P32U3?0TNG<S
M)WYNM7\49!T1KTWJS5T=@\B?@21<.J:S=/8S:<XA5K$CI(HA9I;9$ZV3,;9)
MMWB23COK,2N'=."UQ^ \=W(-:':^5TN=W?;9=Q2<PK[S8EYL@?HII26KZ7WD
MCHNA=Q)JA10"@% * AT4\83GSQS]68S5>D>CQ9C'\;ZS\"8U#(4 H#K-_P (
MA_K?$7\7WO\ I-.U^@OL%^I\I_K<C=W*AIXO_=_I_NG6KKWXTQ0"@.P%_!]/
M?VWU^:41ZXCZ\2^S?^!N1?SG5_99FWA-9]$>]G:VK\V&Z:ENR<>,=-?B4[_3
MQ*O3OL=^IRO]; ]V+-BA^/\ H_O&K"O2C8% * V8]C/^_C9OFH'^E\Z\\^R'
M_0^3ORFM_A(X*^D>E]QN'KRHUBHG)W^O1#\4,_IAU=F^3_J8KZU+NJ')3W]7
MB5:KL1R"@% 6?XR>-I7^3AOZRXKK_P H/O6'_M)_JHXZF[K\"X-=7.,4 H!0
M& .3TU80O2DVP6+R\(;FPA_K:$OM?QTK*YPC.IR-? HRYBH -DD_?F!CYQ8T
MABFY98HIC5E\WC:R766J5VNUWTLN(?Q\=YAG@_K8E$XO)9ZVGR\XU_MI&-2K
M6]W\BVK(S ^.KJ20RC8UGMD\=-AB+9C)!454!LU$$L$X@D9*X^$!LLBV-[K6
M:O?3PZ.UO<19YWU2]U_C1=%R\M0I&3WC6%><SOU-EM5:2Z/%$>L>GP9)JA10
M"@% ?F5NECECTLL>EC>W2Q[5LL>W;M=+&][7M;*W]-NW:]NW_3:] 5-B/##3
MD-U=M'33-YL@QK[;[,NTF 64['E$DO=21.#+R2D@[HH]7<!S$E>G7SV0%F>>
M+XN[P9N'JRRC-#+"W>3X<R)99\^N;.?VSQ9U]N8X$D$ODNV&[^,S#P[C&$;V
MA+(ZRC4GQBHR'HD8^R&ODVXC)J+'N'#/!C@CBU,'I,91Z!$Z_<*KV_T7QT\5
MEH&D^/:_,]NV^+&K-VHF$I_C)""A@$&C"CMN=4;.V,?%,9>+>BQBN3=6S3"4
M#)W)V4I>=!0F4P=L'.#YJ_CT;=B(7X_T^/$L=CC;#'''&W:QQM;'&W_E:UNU
M:WN^[[EK?[Z _: TB]GQ^!I!?\1D+^KS;%>O?85_K7C?S#B_V_DPU\3]Z_27
MB=0&OU$?/% * S-QQ^$+H?\ /-J_UW!U\KEW\!\L_FKE']DK&4/7C]:/>C^B
ME7X4/K$#VG[V&Q_,.7^KQ&MWDW\(X#\MPO\ CTS*'KQ^M'O1U@Z_19O"@% *
M ['7%CX/&H_,]C^D7KP/Y2_A[E3\JG^K$TJGKRZ3/U?#,#7'MGWQY;^5+_JZ
M%=ZY-_H&&_L_WI'-#U5U][,=UO&0H!0%O^,GBN6?CXO]7=UUCY0??,-]2I^M
M$XZF[K\"T-=>.,4 H!0"@% 0R+^/-C^>;'ZO('5>D>CQ9%K+I\$3.H44!J&W
MQ'BVT^6I2W'R5:L,32#CM6I; A\=1T.E/D70R03*\HD4[,SK7<FF:PZ(H$-;
M#,4XE)&18,S-E46+1M(TQR!/-.RS3L[I:[[6RNEQUR?:8O.]MS6EMSNU?CV;
MN<V\U@9"@(S"OO-B7FR!^BFE66KZ7WDCHNA=Q)JA10"@% * AT4\83GSQS]6
M8S5>D>CQ9C'\;ZS\"8U#(4 H#K-_PB'^M\1?Q?>_Z33M?H+[!?J?*?ZW(W=R
MH:>+_P!W^G^Z=:NO?C3% * [ 7\'T]_;?7YI1'KB/KQ+[-_X&Y%_.=7]EF;>
M$UGT1[V=K:OS8;IJ6[)QXQTU^)3O]/$J].^QWZG*_P!; ]V+-BA^/^C^\:L*
M]*-@4 H#9CV,_P"_C9OFH'^E\Z\\^R'_ $/D[\IK?X2."OI'I?<;AZ\J-8J)
MR=_KT0_%#/Z8=79OD_ZF*^M2[JAR4]_5XE6J[$<@H!0%G^,GC:5_DX;^LN*Z
M_P#*#[UA_P"TG^JCCJ;NOP+@UU<XQ0"@% 54YC$=1!-18R+=K39N4)C,F823
M(UJ=],1,JBA<**./QLA[\P,J&D@9CA=%81<BV>IM4B!<>F0S;L5EWC:QO?)I
M7RSMGIEF1VMG?JONSW:'P<16&@1,6/"./LEV:;C(U0*W=#MAR#<YEM'L>YWV
M8YC&&NW\[V$,54LG.;MM%L$V*JJ:&;VUU<&MZLMK\;P\ K9VZ]?$MU6)2,GO
M&L*\YG?J;+:JTET>*(]8]/@R35"B@% * T:]DLW5MW76^8T#@6S)Q#0SG5(
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M+]3Y3_6Y&[N5#3Q?^[_3_=.M77OQIB@% =@+^#Z>_MOK\THCUQ'UXE]F_P#
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M1C)4[.,JD(R3VGDTY)I]*.:#6RLUOWKBR!=NW_G;_P![5N?;6&_XBA_?4_\
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MAW0VS5;+7S0653S: KPIP6XMK103"5];OG,<!/3CP4U<[&VFY>LT)0%#QR3
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MG.1'6DS9V'0Q@\9RP8@*8OR-I"WLV;.V;L#''/Q\-0G?^%[=3WEIZA10"@%
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MJBEF_(*X888JO'>2KE3'''')2]L;6L*<M0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0$,B_CS8_G
MFQ^KR!U7I'H\61:RZ?!$SJ%% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
74 H!0"@% * 4 H!0"@% * 4 H!0'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g609070g01b48.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g01b48.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M%H;3OJ(FSN+L6AL3GB1Q<""T!I)&(P1M-4NB,[:>=T+029FQ2&(!M]8F0-+
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M!HJ])F@$S="GP;P,2B9L9GX,^$FE$XX01:UM>]FZ]M06&',TP7&GH15F,Z3
MF\(,9B+N!UQP G,)U"^U]6V.K?6Q-S/7#)CM:2<6M=1V(Q7C+S&UQA/)@O.-
M$;B=Q>![ XV/ER:-L9)%)T?ES!^@&FC"RT@6+APC]R,<*Y(#6;UUF73:T-,N
MI(]*5,DLND]#U/ 0B&OHQ+/3Z2:&F\4L$<3FE\+K1ACWM#@ 7.:-2]O1HG?0
M0,CCH=(P\-(9:2I+(IJ(EPL]DKY 0R5MWES6.+22 ''6 D@"$A45G7=!8SP
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M:>L9L*%N6;1T-:-S0E,IGV=%4U1I'1FCY=).J(9&%KW4[&QP15#8*KAZ:6:
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M,T&F<K O#N<$'MRISP2/R=/<,,QRAH*[>#%"Z G B@,S(/,T,K]J+<C?"&:
M=?.H(OOSV>O/!0)IN);U9[>C9F6C"0-GE$Q[Z?X*+DE8ZV4=:EUR(2@$76SG
M<F#OP\<V&./D RR(Q,VV62EBI5ZDF5;2/:$FV-CA?#?_ +8=?7:!>^7/SD9[
ML+6PWWL!GGG4+)*(E$2B)1$HB418Q<IHQ*)3$(RA%T9@Z="9,0-781(>W)IE
MB"$%F(Z.!Y4T4E<3=7BC^2$Q7?J[-YG=F02%O7K@$/;NI*'D6QO[8CD/MOR,
M'+*_0#VD;<_5F*=I\'O]KNS94DVP. M8Q(()"F493C$].2".A5@$FG6#8,,C
M92(@4V!=R#(LR\S+YD"CEP6<LF34J6!HBF4886'3?#F]O4-H7N;\EO3[>O*V
M5U0I2B)1$HB41*(L"M[PO;Q+8\S-Z\'SDF3+:WDD4%71<M@8 ")5U1L6P\[!
MY.C+VJ0[85]G$X^*2;F0K=?-N1R?=7$8.:2F/2+;<@1TXCU>V*@C.V9!%_;E
MYO0IYXXAI8 U^]&2M(GAEA,Y<ZCZI5F\#.%XP1*YD1=F\7)&Y*3B(QEF[="Q
M,>(R H\1&,&C]2X[$A@&&CU(!86]L^7T*?*A2E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B*%8[R2X\2^6/(%%-[:>DDY'JED7T-!;*AQ65-%@-
ME\CB3B/L3*Y9)0-BU<Y%,,VELA^+=?)U9*R*E\9L<[&V^RBXWA2?&Y+'9B!$
MRF)'0\GC)]BW* Y#'R3,P$,C7>%E&I 64'K.&3]DX3O91!TU7515PO;+#/+&
M_34*56Z(J"6E49 D8Z'.2$('+2\DX#Q083*,F!"3%F@QZ:=# +-TNDX+D&P<
M:0*KLV":[A$<Q>/5$\6S993 BKU$2B)1$HB4108,Y.<>#1/8083NK6I$KJ<0
M;/['8LY<&7<0X'&<U4I(8-XINLN]AD=715:GGMKYM@SW"[(DHV=WLC>;'<5%
MQO"NC5NY=4[N O91J'843V1'1I=8 _-0\RS.#69INS8D5Q;ATR4523?),28]
MVHWRRLIB@\;J7MU5<;WBQ&8LIN#D;J2Z(E$2B)1$HB4119M3=^G]'#!AK<.R
M8;K42:?YBQ!"9'6()J2(I-\W:C-FJ^52Q7<)MD\U\TT[Y98IX];+HM>W2L3D
M+I<#,V7A:\A-&OIU'=9,]LP!SL*6@&4HC,-1DXK.0G ),8J:&D1PVSGOAPD0
M"H.#+%/#"Z[P2W<$FZ2C)!9?";'<5%Q>VU3#4*4HB41*(E$2B*'"O(71P2(R
MN>E]K04?#(/+'<#E<F=2%@D'"35@Y:,G<4=/;J]EE($7CYHSR%(76>W=K8ML
M$<EK988K'<EQO7E*<E./H3XN/"VY]:,,=OI-'&L%'$P"8)3IJ_69MF+R-K6>
M72),GCLB/8M7B.=VJY!\S8)*Y/'2"&<V..!PSY.=1<;QCERJ;:A2E$2B)1$H
MB41*(E$2B)1$HB41*(E$4)1[=HR039*+81LVQ$%#T_B<8F+I<3D)D4IU<17%
M34.B/0?JF6%V;\=($!CM\Q2;D[18\KTM$K!LS,VPOALPVV.7JRWJ+X^V._I'
MMD;3;4*4HB41*(E$2B)1%INXZ<')Z1&@YQMR2F :.L]]<C]H:]U A (F$,>&
M9+--G,8T8-[&3L[EYR/F@TFO(FD>Q5','/?PQ)[WPW'-TJR)V;PV_0!Z_8+$
M#$'<7;,[D[5CR'@7,^)0SBU%(M!M_P +):HU;Q2;+6CTBFJT2(8M9Y:VZ1!J
M)QN<Q6 BR(2,WNRD;78D9VN8E(O-LVBPB.-&[HZUG#RLL2ZV6[#8>C+IR48^
M3G8:M_7U6QO?-2\1CW-"\?WXUC@SE6GR9=#^0]L9>ZV*Q3XW/0#R<I.=1-]4
MQ@^<> 64GOKB[<?"EX2/B!V/22Q=Q/GJUUT,D&%Q>UL-F. Q)'/G>_(GE6-K
MWQVX<ENC*UAORLK)OJGD$:'Z:,3:/<KIEKR'<GSLHP%-EIK&]T0[7;CCK(XU
M('$;E4BW;,MRJQ\E-""J:-B<O"RWMWQT5!VZP][&\E&%SE<CG&)%LA:X'1?I
M0W(PUK ]-K&]KFYOUK]B45YQ_%W!49ZTY;EL[:$VBTU&VU=L',7/H]O=YMB7
MN=0/.1Y,1+1%SN++4BVN&9!Y,W,BB#5ZSER<L9O#KA19>,,;6&.-P;6MC;IW
M"]CLL5.(M>YPV';?;E?#>;&V(N0MWL"3EJ,&AB,^79.IVE$XZG-70W'# <YE
MJ8=GC(UV&"6"2>+)8Q9XHUQ333PQ0R3MAAAC:V-L?;VS60R%\]JNRB)1$HBT
M?JZDVGN SR$6V!P\V?!P6.H]HZDT+K6 '=':R@[76<OE0:13C#&6,)-)'F&X
MMSOF=R;G,E 64+!HMG =0DH^+D)*KE<88W-P2<;X<XR'65AG>X.1MA;E(OCB
M=_5B54HWH/DS-9%! LA8<@ ''BVUMVO1<7F&VKAMKA-;N^/3$=$1^QY)KJ=X
ME"0I_NYH]5B(?.1FB8P1FV:&E$0:^+:RXY+VQPVWV;C;;ENLI OLP)O;;E_U
M;\0.?,J&Y7K#E/I?1^<JE4KVG'19/BWQSSWZ_F7(%ZT=&MJCM_BFVS(F&FLE
MGJK&!RZ0ZK>YP]B<$%(]&UFKID,N:0=KY.L9P)P S=; G9AACMQRPY%&-A<G
M(7Z\<;BQR&>(WE9U]S>E"TL%<HB+%::6A+3DF^$Z\%S;8]MK/8W%V6I]5J81
MMG,FTOGHAVW%D'+W!P/"2\^/#$%78KPF[<M'"V>)%K#DQZSOL<K*1>[L[86O
M;IR]M^-ULGJ%DE$2B)1%KNYY:QEDX6UC(X;KO>4RDT-";?;0R0:+V7$8,6A$
M^E\8$C(H2DPJ4.P:AN.OW+-9D[)L)&FT M+D$3\>/C#5TF\C/$@<XOU8%00#
MLO[<XW!8JA..'*53=D0:SV#KG#)KD3Q4Y*3C>H@E$D(.S;ZBXUM]=[-B]VV!
M9K*&QM[/63T1& PR+J"'D;DN1&[T>S0>M\)N.86.&)VWY.3'DQ&2Q -]MS8W
ML-@RY#F,+X=:C09Q%Y9XZF;W>+\AK;"SX.21\\3OR*F]EUN7P*?IJ:XLMV6S
M+#\B8F(.7R(Y##*T*[VQ24)8K%&S9=-<7R%KWRV7[.BXR2Q OML.O*_/;<<=
MR\YF=3IERTCT3D,KG9C;#[GEJ1FX+Q[?C'*(M=$*P065^*8IHL5L/ PS? WS
M,L=DKMWJA ,LA9W(%INZ:&F[$G( (RR:=FW''FSMMPQR2YVYW&1P'%N/;#'.
M^!Z#JP6:41*(J<8$L#PDH"*H9.19H<^$DFV*[AKDX8$6RK-XABY:*H.V^2K=
M91.R[5=%PC?*RB*J:F..>)%IT;\8-E:P@Z&<)TV^4C6I.Z;E.0P#54-5B;0C
M(M%MHP^B8AY"1S\X)!*.QJIEJ=%@RQ<.[6Q!+WZJ9#O.RF0.=SF"+G'_ '6)
M&6>!!PMLYRL;'_"WD^)U<*A&&JBQ@QN3C*AI[%<9((8HQT++GW,67;^OE,W#
MN1,KHA8_!9H.2Q)0M&39*2*")"&:*F*HAS>;X<QOMQPL=FW&]]^W%18^BPP&
M&.&VXL+97QQQMCE!AQ<WG*MSL3DR7W>G$)-RRY26G'@W>TY A_DX%8,9*:A8
M- \=V /0%1LAL1J$R;,@;!J<QNODS+X(A.E!%=MC:U[#9MR.SV.26-QF!=V6
MT9B]O;8L!MVR/?>LM8KQ3=LLVFOO%KQ#T..UFW \D&$3D6LYOA-)&!V*YFD-
M:;0"2#9I[8B5P L6>!QK9;DRHQ\"K.ABS9T2&R+$X 6N;X&QW8X\]L!R+$W
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MG.?X[7V[XL^YS_Q_0G^%4'^G7*UW_O.^\>]/E)<B?+YNG_%.<_QVGBS[G/\
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M5GV@L@^02=OAJE\K9W48.W&"CAGGU\<<NLW43RZUK9=/3:UZ>"TWS>#\&/\
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M>F,,"DEGT"8KV9%CT,1>V)-D%\$1TDL78C2"\;<,N4V].7MEL4F]L<^07QY
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M%-K#,&YRO>UN;#NZ4O<Y'+.UNC'KY>C'9I6*E*(K5F1YS&Q#,@T1075<2J"
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9?1:UNG_VM1;5(5$2B)1$HB41*(E$2B+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g609070g01b49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g01b49.jpg
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M 0$! 0'_P  1" $\ E@# 1$  A$! Q$!_\0 'P !  (" P$! 0$
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MD#D1VG:0 ]^L),%14,C8F#$XQ[^=:4T/<$LN;1K<K=I34%3Y55%-#3MGI7;
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ME/3;587<E5NVC! #NAHJ"!@<!P?+)*3GFZYL!98*J+FFPYJ!P'*4XHI9B/\
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MLW+\7@OJ;E:[*ZJ9S7#);F1>:;S(SR?*.QNU:<=W9^?BMH+!9,I?N@7E-01
M<17+R!0FLW6RW^IE"W-N;V(]3K!=3+E@N?Q0-GZH2(5H9;"K\B0?$AWXD&>U
M)EPELI@S)49[6GV!LNH?(^6!YY6&."9C*FICCFCA9R</+,CE:V5T+0!&]X<Y
MI:UU\301GBVM70M:UDK/,E?+&YT,#WQOD<7R<F]\;BQLCB2]K2 02+820<9$
MO*+MA8?4!,RUQ-CJ'UH[W&J1&*Q5HK0KI5C,,'2YU/O<,TJ3&?)QF'F@<M3X
M*(A&H\4:S'WMK>TW9=$QTSFPG%/21T,I,LI+Z:)AC9'F\V(:2"]MI#J7$YK
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M;C;<DR'77Y"W=2+9&SX8Z*&. MCV?+)/2-Y68\E)*Z1SW$F0F2[I'FTA>!<
M   +8?M&LD?4R/EN^LC9%4'DXQRC&!K6ML& ,L&-%V!I-KDDDE=WQSS@\D^$
M4V/0>=W@?&K LM-L-7A6.ETJZ/4:Q$4+;G':+/MH S.J9*3[5UUU0>1&CJE/
M2)OO?WY(?D.8ZS8FS:^8SU$#C*]C8Y71S30B>-ML,<[89&"5HL ,8)L +V
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M#ZF']2$+APMQZC8.S!35-*Z%\D=88C5/EJ*B2>;D'-?"'3ND,N&,L;@:UX:
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MWJO[Z!9JV %GK>D1[%E<5HS/DLN2&69<MN3,89D-XJ786S*.=M1!3ELD>/D
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M1[\YO*)?:9'?Y'4)4OI$RK.4.9(E@:P_6)?/WD[2[09%&6&W35TYS>]OJ!?
M>H?PAO9?2=&-[(9B_ >RQ1#9XI6MIFRB=H;)*)6U TJ!/CY83C028[X?,^;\
MU9/PI7<Y-69R9C'R1)9&6&'?"8L/)<GOP8+8O.^5YRY#WG;Y1.=9&=G9Z.F!
M;PU-5S<7 &U:HP*/#YPXK:WZ"CGD<&BE.U.2YO3\D5(!O(?F-L$'%J(18LIF
M!L+9?-'41IL4+YN<O<Z69T[JG=4&H+^6Y4#(/#\@2T>:2".U*XU#:GEK2-BY
M!H;'&(A!_N>1#.2,9WM+#<V)S (^97SH\FB_1@O4';]#A6.L4H_SNJ0!5.I8
MNH5.F6@?)%G@E;I$, U5!*"<.4ZB5.C"4E'7$QWESE.Q(BF)9L39K*=]*("Z
M.2>.IE<^:9TTLT3@^-\DYD,K\):+-+\ %QAS-SMJ5KIFSF4!\<3H8PV.-L<<
M3P6N8R(,Y-N($@D-Q:9W M&N(>6W<O'H,7K7.+&%16#)T;;'ZS;J53K\ AW(
M,TED/<PXNY@SD8+:AK3;3<<T+1%E.(CQ$2E2$PH>F,E;LFAV@]DM3&_E61NA
M$L,\U/(87F[X7N@DC+XG7-V/N!=UK8G7I3;0JJ1KF0O;R;GB0QR113,$K19L
MK6RL>&R-RLYMCD+W %L7/]6O\WJ:>U$[).+=,^.T;HCUI(J2]-DVZ(9:/,E7
MDH2TUK:";#3J(["&8S#:$1X[3+#;;:-H4M.VEYDV-K*;D#3B)N31"6&,L&I^
M22"3<DYDDDK!R\IGYR7ETW*B;&=3('8P[*WZPO86 T%@K+]G\NSA?HG>C/#2
M1BD<^\CKGSKKM]JI8)7'2<3IE5G-WMY(TUM!6>T, =/(V(@#GCIHATV*>@[.
M#&W-+A-<VBV2QE-01US63U&SH:FDIY622AIII6\@,3/,:724K(VO:YKPQV+
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M2SMV%ZM2HEVK4B/86:BVZ]:W0;[)-;19NL-,/NV%<!4A(5MEU9+<9+:]Z6/
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M;"7>^/TCM=>+4STQ)<<KJJ7530X5?1YEF8:'V^,X^]J47*L$8).%.DQG9#R
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M0QEA-L5 [3F(M1Y35.1_&2.>*0B+YWJ&Z9-^![W9HR8+348C%KU6C>^5NDI
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M1,(F$3")A$PB81,(F$3")A$PBPST[M@7EQNN!"E8MIW9X46/RR5>:K:QU:
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M3@-BRDB?: I6 VS+B;C%:C;#E0)H?&SU.3@TS<X%(7. 39$R6 FJ?"R2!%Z
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MNI@9;"M0,L3!/5=6UZO;%D*@=-QGEQHU3DZ*)E;ANQ9[SD%++FHJI#PCIO\
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MR/@ED-*A*]^Z8)379A!AJ2E<^.[CKW^K=91A'K![M/5E_GFN),\"O':57*Z
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M#>.TDPKGC84S2^CU2WTNSB(MA,(AWFM%DF-/2/5)QB\-QZ*I^#MI;Z"M.O\
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MI1<'4.>S/CD3YPKIUYU<%4%QE@I-FLMJ9TU+TMUO;+FM.Z3_ (1*E:2O?AW
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MK?$*384IA$PBK!YH_DL=N^A4K]<A9>/Y;>M0[0]1\%Y3LW5@3")A%OB]R/\
MQ9]9^G0G]WV\UI]6]1\5E9H>O[@MMV8%=>%[W6C_ !A?D=_6]$_A31,_8O\
M9G^@VP?X59_W*M7-J/GG_P!W[+5KHSW:PIA%;'P/_+3\5/S^\L_? 5GFO++]
M$O*3^2;2_I)5DB^=9^\%_0'S\2+J*@?NCGXB /YS@'[N6_/;^0/YZG_ET_\
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MI9B(\X%A#ED5D]P^Z^YMWJO\M[*Y.Y33O%VW<B>ZJ?CVF&?KD6F<E=K,PS>
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M:?BI^?WEG[X"L\UY9?HEY2?R3:7])*LD7SK/W@OZ ^?B1=14#]T<_$0!_.<
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MC]B0<EVIZSXJ&Z#J'@IED*4PB81-[UK6][WK6M:].][^YK6M?R[WO_PUK"+
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M2=P0FVZ_:/4-YZ%<S(4IA$PB81,(F$3")A%#*']XYWTSZ/\ Q#M&2=>QO@%
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M+=5$&*Y>ZX<LU6YQV3HMH%2I5FY>;KE2CN<1O5%L]"&$3E?AWB9<YLU<9U5
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M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%#*']XYWTSZ/\
MQ#M&2=>QO@% T[7>)4SR%*81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
@B81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g609070g01b53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g01b53.jpg
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MXG&3(UMZF"-PRZ7<6O<,SG96-N<I-G-UYG2-EIPUP$;WO:]H9F<;02O:;ZV
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M:+!AM<W#-_>C;DV\<N\,S;MR 6&&S4CF/J#"#20**U& 2*;5><>0*S0]UUQ
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M&$HT* 2F#GD2&)FU'R1J5.D,#IY"8RW&9$MQV8LCL?>B>(U'6R[OT]778;M
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MVJKES*3L(:1KCU7"G!D&=8V+#"+07QS@Q#^FO"E-$]#GQI)J&L;VMJA(&_\
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M/D*4PB81,(F$3")A$PB81>$_@U_JU_Y81><(F$7\YSW<S_2H=5/_ 'SB'_Z
M\5:_Y_\ /^;/NWX'?^6^SFMO!Q73_P#V\3W<O*=+6YRO%]J_^(,0-N6F%_\
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MQ?RL.L3O&=PC":I5;P2KE,U925[A&B50KU?*%&_?\-%B.44?)+RIA1R).F$
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M1=?E!6$1U&:_44OA05>E&T^.?L#%8C@H1&4ZAS49AEAF.C$&Q!MNOIY_+O\
M3=9'7TCU$%5'?NAHQ=>2.1+)$Y=<JU1NA?DZ_!QXBK/*NE5Y3Y0Z>8G3D2.1
M[4NRM09E=$5J._9!@A " 4U8)GBMG6H<1E2I#K :;K<NE@;[N37EU\R@MN2;
M^:W(;6/EYN58OBOH_MG%5GX7%L2ZR]5JQS==.>32*$ <H]!I"H_ $G@X'1:;
M5RMJM5@:<NY.T3^0K'*U/D"WR<*S>4:&OSAB28NO??NMSW\+-KN^8 *0.?GO
MINW6]I\Z['\Q4IA$PB81,(F$3")A$PB\)_!K_5K_ ,L(O.$3"*OS7$_%ED)R
MC=BXTX_/F9NVMS2QJFUTJ3E[CL-16-RI\X:_*D;9C,,QFMNNK\6PRTRCP6VT
M)UO0XGB5/&V&#$*Z")E\D4-7/'&W,XN=E8R1K6W<XN-@+N))U)5+J:G>XO?!
M"]QWN=$QSC86%R6DFP &IW"RQ?F*X1[G.*_5[4?X1EG=G&.E<2Z]5?WJQXI2
M?JU/]3'V4\Q7"/<YQ7ZO:C_",=V<8Z5Q+KU5_>IQ2D_5J?ZF/LJ45FA4:EJF
M+IU,J=3612PD@NLUT.!5.3%V[N,F8H7#B[E)C[??VQI_:],[>=VWI.W%^%K5
M%;6588*NKJ:H1YBP5$\LP876S%G"/=ES91FM:]A?<%9'#%%?@HHX\ULW!L:R
M]KVOE O:YM?=<\ZEF:RL4()<9<;&9TDF7X^HY4E,<\;,($JF!G3I3O@Z3XR3
M+E0'9#[G@I2GPW7%*\%.M=O9K6LU'T%#*]TDE'22/<;N>^GA>]QYW.<PDGRD
ME<U3[2;14D$=-28_C5+30MR0T]/BM=!!$PDDMCBBG;&QMR3E:T"Y)MJIJE*4
M)2A"4H0A.DH0G6DI2E.NQ*4IUK6DI3K6M:UK6M:UKLUKLS;W;EPQ))))))))
M)-R2=223J23J2=ZQ)RNU^SPTCK("#6$>A]$I$$X,A%H:)3:'&VY*8T]B0PE]
MMMYU"'M(TXA#KB4JTE:M;JEAAG;DGBBF9<.R2QMD;F%P'97@BX!(!M<7/.MN
MBQ"OPV8U&'5U903NC=$Z>BJ9J68Q.+7.C,D#XWF-SF-+F%V4EK202T6XX"IU
M6JMR6JO6J_6VIBVW)C8 ,.#MRG&4J2TN2@=&CI?6TE:TMJ=TI2$K5I.]:5OM
MB&GIZ<.%/!# '$%PAB9$'$7L7!C6W(N;7O:Y6=?BN*8HZ-V)XE7XBZ$.;$ZO
MK*BK=$UY!>V,U$DA8'$ N#2 X@$W("D&7+03"+4GKM_S2^:/Z!$_\5 ,*6[Q
MYQ]ZM'@;_)%0_P"KP_\ L[>$=O/G/WJY<*$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+5?FVE=3%B)1W>&^9_
M-X.0G>GXFZ?13^G5=FM:WXZRUDP^G^??8EU/X?\ PPI&7EO\WS:??S*AO-)[
MH1]+%'JLX>]@<)ISGT#VIYI/="/I8H]5G#WL#A-.<^@>U/-)[H1]+%'JLX>]
M@<)ISGT#VIYI/="/I8H]5G#WL#A-.<^@>U/-)[H1]+%'JLX>]@<)ISGT#VIY
MI/="/I8H]5G#WL#A-.<^@>U/-)[H1]+%'JLX>]@<)ISGT#VIYI/="/I8H]5G
M#WL#A-.<^@>U/-)[H1]+%'JLX>]@<)ISGT#VIYI/="/I8H]5G#WL#A-.<^@>
MU/-)[H1]+%'JLX>]@<)ISGT#VIYI/="/I8H]5G#WL#A-.<^@>U/-)[H1]+%'
MJLX>]@<)ISGT#VK!6;IPZT.1 <^E\D]2B;-2#VHT>P@D\>\8B=D84>9'G)8]
M\0M.'E(O9(BLN>,AS8[O\CP=KVA2DJ*1E&NIMNT ].I78=1:NFGU(%6M.;=T
M''QX6G/D_E:9;2CM_!_/X/;A03<D_C^"K;F4L4&RP*1Q(A 2['G[=3"F2(NG
M=H<C:1MS3#C>E[3I2M)VKMVG6]]G9V[SFL)BBD;-PD<<EG,MG8UUKAU[9@;7
MY;+-@!O< [M_SJE?A19OSB.^ER'VC.7XK3?J\'U,?96=AS#T!/A19OSB.^ER
M'VC'%:;]7@^IC[*6',/0$^%%F_.([Z7(?:,<5IOU>#ZF/LI8<P] 3X46;\XC
MOI<A]HQQ6F_5X/J8^REAS#T!/A19OSB.^ER'VC'%:;]7@^IC[*6',/0$^%%F
M_.([Z7(?:,<5IOU>#ZF/LI8<P] 4.Y YBE\:T\W=['8;8H,!9CO34#)A&<0<
M\KFQA\=J)$3+;V^\[*EL-I1X:=?RMJVK6M;S;H<(9B-7#1T]/2\-.7!AD9&Q
M@R,=(XN=D-@&,<;V.Y0[*UI<0+#F )4/JG4_7+3 /S';\9J,BJD#HVRB;V:>
MJ94*[60U?L1Z3*8)$D,.#!(*U5TJ1+PY,H9 BEX?EDMAU:VD;55LW/3/@8*"
M&J;4LADIY:*%M5%,*B6>"!K71QDB26:FGCCB>ULCW1/R-< "<&OC<"=&Y20<
MUA:P!._D <"3N%]5- O,PNRF2]=KO*T _8*^M]L\""WJ.5,!'(L^2*E(+C()
M1^:-7&*0Y8V0F8PRIF?%D0W-)D,N-IU)L(DIXHJBHPM\$$^4PS341BBF#HVR
MM,4CXFLD#HGLD:6$YF.:\7:05F"PD@%A(W@6)')J!J-=-5@0?456#\P,)B\M
M08]BL"I>@U5FWP>S:"6H4DI%=5"!MFWITQ&U!2CJ%16WM;8A2G%>#Y-(2U?-
M@%1 V:5V%N=3P9.%J64+S31YVQN;GF,+6,/Z:,>$6^$]HUS-OB'1FPNRYO8$
MMN;$[A?R%67\*+-^<1WTN0^T9QW%:;]7@^IC[*SL.8>@)\*+-^<1WTN0^T8X
MK3?J\'U,?92PYAZ GPHLWYQ'?2Y#[1CBM-^KP?4Q]E+#F'H"?"BS?G$=]+D/
MM&.*TWZO!]3'V4L.8>@)\*+-^<1WTN0^T8XK3?J\'U,?92PYAZ GPHLWYQ'?
M2Y#[1CBM-^KP?4Q]E+#F'H"O7B6Z/DT/UXO+=DSVO&2A\F4ZMY^3'WOPI$9;
MSJE..NQU;VZUX2E*VPIQ.NQN/K.&Q2C;&6SQ,#6&S9&M #6NW-<&C0!PT-@!
MF )U<L'MMJ!YU=V<.JUKWU-'S=;XS42KY8@%(?" 2QY:,EO0I/B'43-N->.8
M6ASQ;FT)VM'A>"KP==NM]FL[7L;2TU9C' U4$51%Q6=W!S1MD9F:8[.RN!%Q
M<V-KBY76]JJB>FPKA:>:6"3C,+>$B>Z-^4A]QF:0;&PN+V-EUX>=[E/O#N/U
MA)_:,]7[@X)T3A_5(>PO->[.+=)5W6INVGG>Y3[P[C]82?VC'<'!.B</ZI#V
M$[LXMTE7=:F[:>=[E/O#N/UA)_:,=P<$Z)P_JD/83NSBW25=UJ;MIYWN4^\.
MX_6$G]HQW!P3HG#^J0]A.[.+=)5W6INVGG>Y3[P[C]82?VC'<'!.B</ZI#V$
M[LXMTE7=:F[:>=[E/O#N/UA)_:,=P<$Z)P_JD/83NSBW25=UJ;MIYWN4^\.X
M_6$G]HQW!P3HG#^J0]A.[.+=)5W6INVGG>Y3[P[C]82?VC'<'!.B</ZI#V$[
MLXMTE7=:F[:>=[E/O#N/UA)_:,=P<$Z)P_JD/83NSBW25=UJ;MIYWN4^\.X_
M6$G]HQW!P3HG#^J0]A.[.+=)5W6INVGG>Y3[P[C]82?VC'<'!.B</ZI#V$[L
MXMTE7=:F[:>=[E/O#N/UA)_:,=P<$Z)P_JD/83NSBW25=UJ;MIYWN4^\.X_6
M$G]HQW!P3HG#^J0]A.[.+=)5W6INVGG>Y3[P[C]82?VC'<'!.B</ZI#V$[LX
MMTE7=:F[:>=[E/O#N/UA)_:,=P<$Z)P_JD/83NSBW25=UJ;MIYWN4^\.X_6$
MG]HQW!P3HG#^J0]A.[.+=)5W6INVGG>Y3[P[C]82?VC'<'!.B</ZI#V$[LXM
MTE7=:F[:>=[E/O#N/UA)_:,=P<$Z)P_JD/83NSBW25=UJ;MIYWN4^\.X_6$G
M]HQW!P3HG#^J0]A.[.+=)5W6INVGG>Y3[P[C]82?VC'<'!.B</ZI#V$[LXMT
ME7=:F[:>=[E/O#N/UA)_:,=P<$Z)P_JD/83NSBW25=UJ;MIYWN4^\.X_6$G]
MHQW!P3HG#^J0]A.[.+=)5W6INVGG>Y3[P[C]82?VC'<'!.B</ZI#V$[LXMTE
M7=:F[:>=[E/O#N/UA)_:,=P<$Z)P_JD/83NSBW25=UJ;MIYWN4^\.X_6$G]H
MQW!P3HG#^J0]A.[.+=)5W6INVGG>Y3[P[C]82?VC'<'!.B</ZI#V$[LXMTE7
M=:F[:>=[E/O#N/UA)_:,=P<$Z)P_JD/83NSBW25=UJ;MIYWN4^\.X_6$G]HQ
MW!P3HG#^J0]A.[.+=)5W6INVGG>Y3[P[C]82?VC'<'!.B</ZI#V$[LXMTE7=
M:F[:>=[E/O#N/UA)_:,=P<$Z)P_JD/83NSBW25=UJ;MIYWN4^\.X_6$G]HQW
M!P3HG#^J0]A.[.+=)5W6INVGG>Y3[P[C]82?VC'<'!.B</ZI#V$[LXMTE7=:
MF[:>=[E/O#N/UA)_:,=P<$Z)P_JD/83NSBW25=UJ;MIYWN4^\.X_6$G]HQW!
MP3HG#^J0]A.[.+=)5W6INVGG>Y3[P[C]82?VC'<'!.B</ZI#V$[LXMTE7=:F
M[:>=[E/O#N/UA)_:,=P<$Z)P_JD/83NSBW25=UJ;MIYWN4^\.X_6$G]HQW!P
M3HG#^J0]A.[.+=)5W6INVGG>Y3[P[C]82?VC'<'!.B</ZI#V$[LXMTE7=:F[
M:E=(Y[Y!K=H$%C-IL5A#QY*4%1!$K+FL2Q[VMM2=-M27EMIELMJV_#=_D^!)
M;;TO>VE.)5HXELQA5913P4]%24E0YA,$\,$<;F2M\)F9S&@F-Q&61O*PFWA
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MW5(:999:2IQUUQ26VT)4M:M)UO>JFM<]S6,:7.<0UK6@N<YSC8-:!<DDD
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MDQ(K9/45<B2I+#25N[TC>XS"<4D%.Z/#<0D%6'&E+*.H>*D,;G>:<MC(F#6
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M%I0I*=I2I"5:WI*M)4I.MIUK>D[WK7R;WK )!)!()WD$@GEU^?5" 18@$<Q
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MJB?FKJ@0C@(I>R?#7\(F#8]%#LS@K:7$HZ6ICJZK&6%DT4<S&.:VFPR9I+9
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M\F_D_P"S>.]Y+TK'U1WO"<!_3^S_ )EX^,V#=SY/ZZ1?9O'>[EZ5CZF[WA.
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M:''YG[6?LSC_ .Z*_P!W3A(_&,^DWVI]V]T:?2OZ<_7/QY[0X_,_:S]F<?\
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M-RM(+6Y1E!!N"!:P(.HL-#J%%ANL+<UEP)7%_&<X:D+-X[HLL.BO(J*1,JI
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MW!1>+C^+D^(WXA));N^+<DY=UR39+#F'H6;$TBE@*SNE JC6 M-W%F0=U(2
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MT13=:Y%#.@+1"6B)(9;=<D"I,V-"EN)5*%^7SG8#L=V2XO>4D$<I#GMN0Q[
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M;2\ 36./KDW=J\QI06SUX_#,0ROE+T&UBC<0\/EN1Y6WIT>*H=)P?2L+,K
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+1,(F$3")A$PB_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g609070g40x42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g40x42.jpg
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M 0$! 0$! 0$!_\  $0@!/P)? P$1  (1 0,1 ?_$ !X  0 " @(# 0
M       &!P4(! D! @,*_\0 8A    8" 0$#! D,# H(! <  0(#! 4&  <1
M$@@3(105%C$B,D%15*&BT=()&",D-#524V)CD947,T)A=(&2PM/6XO 9)557
M6'&4E[/7-C=$<G9WM+<F@\'A5F2"DY:QU/_$ !T! 0 !!0$! 0
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M_82+MUJIFS6V(JFG&]Y'.TR7-\J\F!(V;F"-1-)*>:N]HNCO0VJ@Z/U/S?C
M;C&.S]&]D[%H?0?'(QC<4>]N'@F3TFDT; R&[R-H=F-K9+Y07C,R[6"3Z)W6
M-V[_ &FY_"GNTMLD^Q*GVR)AS5:S$2%C[#G9KO;V7CD)'SXLK;IUI*J0CMZX
MD5FCB)B57)RQI4XYN[+U',X=..H +MNCF'##ZKHA"VJJ98Z?IITCHF12.CV+
M12021"9C&QM<V64-!D)D<TZ96MLJ9#<2&P!,49)UOJ=V_APT7&[-VOV<3VT.
MS[6XC1M9[&]CJ>MYJ_3A(_:,Y=G':;J$_5BQJ,? MV<$PJ2@04FDXG9^-D9
M\U'IE</6;)08;RA*KI%7/DZ'8_42XW4]+Z:KQ&'#X=IAL%$WHU5P5)D,D[GS
MR50VT9;!!*Q@ADNQCWC;928+2L&01D-+C9Q.T!%A;2VAU(.O);N[BV)+=JOL
MX;L2IH=HCLXQ]#K-EE[@2\ZN] ;!L>!;T:W/0J5=E)Y5ZNQA7DFQCSV>8AD?
M.0QJ8P::C9*;6<I<5A%!%T6Z0X.:S_P_TADKJBGBI.I8GU^GPZ=U;2LZW41P
M!C7S,C?(*:&5VSVAVYN8&M==<[:,=;.P &]VV)T)L"?;IV*D9J*T&/86[$EH
MWVUM][95[6%"8:^T!6GYCM=Y['M.O8F(KE?D*RU:*2-@?PZO6^A'*#]@S@E7
M#QY(ED$5B1Z^[@EQW_QOTSI<"=24+ZC$J^3$,>J8_3P3#J6OEEJ)XZESQ' R
M869,QT<CYPUC&&,M,C:2&;*(N!=9K0U@_><6BP(X\^0[=RI/;URO'9P['FJ^
MR#L2XRU$ME^H&RK5L"T,V]FN9:'KD'MBE:[I"NSL6QG%'<[/+NHS6ZLR]<*0
ME<K3*Q./+#L1@CJ;K":.BZ1=+L4Z6T%'#74M#7X=2X?2O=34?7\0R4\-1C51
M#*^G:V"!K9,1$3&MGJ*A].W()-L!0XN9&V,D@N#B3J;#4AM[$DG=K:P79]V!
MK9 6[L==GAU7GIWR$+JNFU.2.=E(,1;S]8@(^'G&122+5HHX(SD6RR!'K8JT
M>\*0%V+IRV.18WF?3JDJ*/I=C[:A@C=/BE95Q /CDS4]54230/)C>\-+XW-<
M6.+9&7RR,:X$"]"08F6X- ]:V^SDE=3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3"*S*K]Z2_PA;^;A%),(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*O+A]W-OX
M('_&5PBB6$3"+\NUWT\#BZ6]QY,(]_:)];GN1'GO99V?GGH\>>KUY]1T6)D4
M5(,Y%J6G&\C=$P;N"7:-YUX^D/)1?]A@/@H__LC]#,KYT/USXE,S/AP\EW_]
MAZ$]'>S'KF(Z.CR1:Y#T]/3QY1>[*Y]7 >OON?5[N?/_ $YEV_2?$9+WS-HM
M;WW4-,W\$T.[=WW6V6<DB810[8.OZ=M2G3NO]@0;>RTZS-4F<[!NUGC=O(MD
M73=ZDDJLP<-'B92.FK=8!0<)&$R8 )A*)BCF4%?5X9605]!.ZGJZ9Q?!.UK'
M.C<6N82&R->PDM<X>DT[[[[%00' @BX.\*(S&A-16!_=Y.8I+!\^V/0&VK;L
MX4>2Q#3]!:).T&U;<E1D$R(-4DGSL@.&1&S\06,)G9A @ERXL>Q>".BBBK9&
M1X=7NQ.B:&1$05[W-<ZH:3&2YQ<UI+7ET>GT%!8TW)&\93OU;R[E@I+LNZ$E
MV-DC)'7$6Z8V^@U75]C;GD)TI92A4@R9JK7%C)RI%$FL.9),4'#8Z+Y;I#RI
MTN'/-Z/I-CL3Z:2/$96OI*ZJQ*F<(X#LJZMN*JH ,1!=-F.9K@6-OZ#6H6--
M[M&H#3V@;AZE*[)I;5]NE=;3MAJ+%_-Z@?ED=;2Y74DRDZFY!NU:*D8/F#UJ
MY69.VK)HWD(U\J[CI)%NFG(-7)2\9BT^,XG218C!3U;XX<788\1ARQOBJFES
MW@R1O8YH>USWNCD8&21EQ,;FW0M:2TD:M^B=;CXMKSXJ>3L)%6:#F:W.LR2,
M)8(J1A)F/5.JFF^BI9HLPD&:BB"B2Y".6CA9 YT54U2E.)DU"' #!@P32TTT
M-1 \QS02QS0R  EDL3Q)&\!P+26O:' .!!MJ"-%41<$'<="M>[WV..S3LVLZ
M[IMZU7%6&KZGA#UW7D,ZF+0W:5B&4;1;-1FS\AG&JJ_6UA8M SA^H[=&39)
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MTD*5_L5I_J_C_!QTW_T<KO&G_P"<FS?]4I_A,^PE_I(4K_8K3_5_'^#CIO\
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MUQ>NW#(VR/;,6M[[35IM%<.WD&;XSN(=S%E7176(U55,T4%-T@(H. 36*)A
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M(Z53-?\ GE\C:EM;1TU:VIJ653FR.J(&QR11.@C$8I)X"V-D3C&UA):&@:7
M(M_-C&.A=35$],8('TX,8@D+V22-E>Z3K$,UWOD;G<\6)<7$[ROE/]EFU3]Y
MJ6R5NTOMA&[4ZGN:A%31ZAHB3303D9!T]F9YA"S6I9& @+).(+-(>7EZW%P[
ME]"Q3",6,9J5<BZ/%H8X)J8852&">83.CV^(,^BT!D9DCJV2R1QD%[&2O>&O
M<YV^Q!^'2/FCJ#7U.UBC,;';.C<!<DN>UCZ5S&2/!#7O8UI<UK6[A93&<[.$
M3;:)N.F6^ZVFPOMVUB&J5KN*K:N1]A2BH6E1]32\WMXN%:5YJJXD$Y^W*HH0
MJ,:A.6N7391[6-*T9H6(\3?#444\$$,3:"5\T,%Y7QE[YW3>D7R&4@-,<.LA
M<61,)<7%SC=?0MEAJHI9I)#5L;')*1&UX:V)L?HAK!&"2'RFS T/D=9H;9HP
MEU[(NNKO-[ZGWTM9V+WM :\<:]L*;%U'@SKC>4A(BO6.?JS5S'+IM)ZT155H
MS>=</?+F[OT(@#>3%%%;OKD&,U-.S#XVLB<W#JD5,68.S2%LCY(XY2' F.)\
MU06!N4C;R:ZBU$N&P2OK'N=(#6P[%]B+1@L8R1\8+39\C8H0\G,#L8]-#>06
MS0+M_=IK8>M]L7K3MGMT5#0]Y-5H^CV"&MR=>;*,8*9?PE[JMF9L;3$1J@13
M2>B19'<1B+-C+M95NP8$:VH<1:V!E-54=/6Q0O>^#:NGBDA,AS2,;)3RQ.="
M]_IF-^:SBYS',+B37)1$ROFIZF:EDE:QLVS;"]LN096.<R:.0"1K?1#VY26@
M!P<&MM[4;LT4/7D[K*?KTA9#O-9US:T&BK+R#>3>VZ2W+8ZG;;S;[C)+,BO9
M.T2EAJA),[MJHQ9@M*R"1&!&A(]NR5&*5%3'51R-BM524CR&-+&PLHHY8H(8
M6AUFQ-CE+;.S.LUOI7S%T0X?# ^GDC=)>G94L&9P<9753XY)I97$7=(Y\8=<
M91=SO1M8-OB0B8N6(FG*QL?))I&$Z2<@S;/")'$.D3IE<IJ%(82^Q$Q0 1#P
M$>,U[7O826/<PG0EKBTD<C8A9KFM<+.:UP&H#@"+\]05#;)KB(LMXUI>W3R0
M;2.KU[6O"LF@M2Q[T;=7CUQZ21(HW47$C5H<5F8-%VPE<  K"JE]CR]'4OC@
MJ8 &EM4(@]SKEPV,FT;E-P+EVCK@Z;K'56WP,DE@F)<'4YD+ +93M&;,YK@G
M0:BQ&N^XT7,ID1;HIQ=3VJP^?FTM=I*7J" E:=Y7*BO&0S=E7E%FD3$%<>3R
MK28D43+I/7;=K)H,7$M**-!>*Q.^%X@$,>S+(&,F.H$DP<\ND +WVNTL:;%H
M):7!C ;!$V5IFVK\X=,YT0T_9Q%K &$AK;^D'N%\Q <&ESK76O$QV2DGK.Z4
MZ$W3M.J:<V+*6F4N&HHA.AN(94+V_?2=ZAZW:)>F2-WJ=>M[^4E74M%Q%@(9
MFK+2@UQU @Z*".R9C&4P324-)-6TS(F0UCS4!XZNUK*=\L+)FP320M8P,>^/
M7(W:"0C7!=AEQ+$RKJ(Z6=TCI:5HA+3MBYTS62.B=+&R5SG%S6OTS.R%E]+M
MLFJ*]8[%IVPF7?19M*6&5L-7C(T6I(YRI*Z]M&MQCY$B[==86#2&M3MPU(S6
M:K%>M&8J+*-RK(*X,59+''6QV:_KT;(Y7ON7#)415.9I! S.?$ <P(L387L1
MF24T<DE+(2YO5'NDC:VP:2Z&2"SK@G*&2$@ @W UM<&/UOL_:^A:Q?:S+L N
M1=G66_V:[RUF:QKF5FG.PGCPTBQ,NU9-2-XV*A5V=7@VS=-,S*"B8Y$RBSA-
M5RK<EQ&H?+!*QVPZM'3Q0,B+FL8*<-RNL7&[GO!ED)/I2/<; $ 41T4#(YHW
M-VO6))I)G2!I<\SDY@2&@!K6$1,  RQL:-2+GAU?0,-6W>AY%>UVNP2.@:)9
M]?UV0FE8I1U88JS1E5B%GMH4:QC;RN59L:A&%1=,08%<+JNW#U)RJJ DF7$7
MRC$&B&&)N(SQ5$C8P\-B?$^5X;$"XY6.=,Z[79K"P:0 J8Z)D9HW;25[J*&2
M",O+27MD;&TF0AHNX")MB,M]2;DJ.WSLR,K[)75J^V=L6/UQL^2BY79.JVB]
M<=5RRKQK&)C';)C+RL _M=5A+/'P<8SML/7)MBUE$DG:C 8AW*RSI]=I\4-.
MR MI:9U52M<REJSM1+$'.>]KG,;(V&62)\CG0ODC<6W =G:U@;1-0"9TH-1.
MV"H<UU13#9F.3*UK2UKW,,L39&L:)&QO;FL2TL<YQ-T5:)MT=/;">6*P^=X6
M:M#%]1HOI:<UFN(U"M1[R+,HWB8Q41=6IG8I8J3MQ-KII/TC!+]TJG%1>#,^
M%\=.(X\CV1.;4/U_:RF:5P?JYVZ(QMN P$M/H7!>_*C9(U\Q>_,QT@,+=/V<
M8CC!;HUIUD#W:EY&;Z5K-;1-I[*D-.IRKB$V)>*7/O\ M"%[2#*QPC:FR3Z%
MNA=?HZZ\VL6-HJ\]!N($89(S@6\I%OW?ERIU =]T":1-A%B[XRS:4T$\;,.^
M;'1/,[&R0=8-1F<Z*6.029S:['M&4;KZK$DPYC\Q;/-$\UHK@]@B<YDHA$&4
M"2-["S(+V<UQS<;:*W*7KR5A8M=CL&_3.Z'HR*CR.FKW5];QSV';*MVJ)XU@
MVHM,J46+8RS<79G#I@XD#K+&3.\,W2;HHX<]2R1X=34S*!N7*Z.GFJGM>02<
MSC43S/O8Y;!P;87RW))R8H'-:1-,^J.:[731P!S!8#*T0PQ-M<7N6EUSOM8"
MK7?9<@G4^^$M\NK?6DOM!GNB8T^D2L&J<AL5G8F5S\N-+JUY2X(5]]>(YG>)
M.KHV L<\LR:RW4E$O7T.YRFXM(V-O^+P&J92NHF5I,NV;3.B,&4,$@A,C8'.
M@9*8\S8C:Q>&O&.[#F.>[]M**=]0VJ?2C9[)T[9!+FS%AE#'2M$KXP^SI!>^
M4N89.CV=-?JZPV;J.<+(6*H;6MNS[A8DI)1J5XVD=HVZ6NDB$0Y:-6_D1Z_-
M2O?UA\!%)&-681[P72SYN#@;1Q*HZW2UD>6*:DBI88RV^4MI860-S@DW$D;+
M2M^BX.<VP:;*L4$ IZBE?FDBJ9:B60/M<.J)'2NRD-%LCW7C=;,TM:;EPNL,
MRU9:%MH:8<3LK+V*L:'U[. RNEB<Q2EAOVQK>P0IA)*00BR-BI.J[3(ZPK3[
MQ2+CFDQ)WR.4BNL8R601N.JXA25HC8R.7$*F/-!&'[.GIH7&<M:7WN))W1B,
M9W%C('9_I,)I%/(:FE+W/?'1P/RRR%I?-/*T19G90+&.)KR\Y6ASIQE^BX+9
M3-6L],(F$3"*S*K]Z2_PA;^;A%),(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")ZO7A%U:]M'=3IW98VA4^P/&S:"066L;B'?
MK-RN)!WT E'*K-%4S*$:H$[Q=$PG2,=9$?$Q! /%_E!Z0OEK(L,H:E[8Z9KG
M53H)7-#Y9+ 1.<PC,&-'I-)(NX<ER..5Q?,VGAD(;&#M"QQ +W<"01>PWC7>
MM;M)[WG],3DS,-&06!.9C#,EV#Z0702!T10%6CT5 3<&.*!A5*=/H**I5?VT
MO0 &Y/H[TDJ>C]3/4,CZT)X3&Z*25S6YPX.9(2 XG*;@BP)OOTL=90U\E#(]
M[1M,[2TM<X@7O<'<=Q^."W*TOVSK!<++%4VU5-![*6"9*TCG\"<&J+9NMUGZ
M731R=4QP9HD,<ZR:IC+$*<PIIB  /?\ 1_Y0:JOK(*"MH6R3550(XI:8Y QK
MKFSXW9KB, DN!NX W X;NAQR665D,T(>^23*UT?HV!X%IWY=]^(!OS'8CGJJ
MZ9,(F$3")A$PB81,(H;;(]58B+Y(HG! ADEP* B)4Q-U$4X#QZ2F$X''W ,
MCX (@10'")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81>Q2F.8I"%,<YA I2E 3&,81X   .1$1'P  \<(K
M9A61V$<@@IX*^R45 /W)U#"82^'@(D#I((@(@(E$0\.,(LKA$PB81,(F$3")
MA%K[VC>TOK#LPT5:Z;%E>%W +MZS5(\Z*MDMLHD0#>00[)10G"*(G2-(RCDR
M4=%HJ)G=+@LNU;N>CZ,]%L5Z5U[:'#(?1;E=5UD@<*6CB)(VDT@!])UB(H6W
MEE<"&-RM>YFGQK&Z' Z4U-9)Z3KB"G809JB0#Z$;2=PN,\CK,C!&8W+6N_--
MO'ZI/VH=P3SMS"WN7U)506/YHJNMY-U KLVW4()#)6IEY)8YA^9+H!TL=ZTC
M3K%,HQB(\BAD<^HL!^3#HI@M.QD^'P8Q5Y1MJO$XF5#9'6UV5))GI8(P;Y (
MWRAI DFE(#EXIBG33'<1E<Z.KDP^GN=G3T4CH2QO#/4,RSROM;,2YK"1=D3+
MD**:^^J%]L#73I)5CNBR6AH4P"O&;!%O>FKL@#SW2KNQ)/9IN41XY4CI5BX$
M Z06 HB Y>)?)QT,Q-A;)@=+2/((;+AH=A[V$_O!E,8X'$<!+#(W^RL>CZ7]
M(J)P+,3GG:-[*PBK:X<BZ</E'>R1CNVVBWOIOU:^\,VZ*.P-&5:PN0*!5WU1
MMTK4DS"'@*I(V7BKD(F'UBGYR3*(B/2<@<%SS^N^0N@>YSL.Q^KIF;VQUM'#
M6'N,L,U#IV[(GL*ZNF^4VJ: *S"J>9W%U-424P[\DD=5?NSC7B%MQJSZK[V<
M;M)LX:\0ESU2Y>JIHEEYANRL%4044,!"%=RT(N:6:D%0P 9RO72,4"<K.W3=
M(ASEXW%OD9Z34$3YZ">AQ=C 3L8724U8X#4ED,[=B\@?NMJC(X^BQCB0%T-!
M\HF#54C8ZJ*IH"X@"20-FIP3IZ4D1VC=?WC#D U<YH"[4XZ1CYB/8RT2^9R<
M7)M&[^-DH]RB\8/V+Q$CAH]9.VYU&[IJY0436;N$%#I+)'(HF<Q# (^22Q20
MR20S1OBEB>Z.6*5CHY(Y&.+7QR,< YCV.!:YK@'-<"" 0N]8]DC&R1O:^-[0
M]CV.#F/8X M<US26N:X$$.!((((-ES,H5281,(F$3")A$PB81,(F$3")A%5^
MX-APNMJ'/STJ_2:. C7B$0W%8$G;^35;J$:-F0![,5S*B E,4.$^D5#F*4HF
M#2X]BM/A&&5-3-*V-^RD9 W-E?),YI#&QV]+-?4$?1M<[EAUU2REII7N<&N+
M'-C%[.<\@@9;:W&^^X6WKI #;&SP6.N&P;EWBAA.8?2.5Z.H1$1Z4O*NZ('(
M^!2$*4/< ,^=/GO&,Q?\YUV8FY/6IK7[L]@.P"W8N"ZU4WOMY;[_ .D=YK[N
M=P[4=H';.-@VXZ*A1*<@3C],3%'P$!.FL0_ AX#P;Q#P]65OQ[&GM+'8I7%I
M%B.L2"XY$AP-O7NT4FLJB"#42V/#.[COW%5THH=50ZJISJ*J',HHHH83J*'.
M(F.<YS")C',81,8QA$3"(B(B(YJB2XESB7.)))))))WDDZDGB2L<DDDDW)U)
M.\GF5Z9"*9Z^O$MKBW1%R@TF2\E#*JJ-T9!$RS50%VZK94IRD.FH ]TL?H.1
M0IB'Z1'J)U$-GX7B,^$UT%?3MC=-3N+FME;F8<S2TW ((-G&Q!!!L=1<&]3S
MOIIF3,#2YAN X7&ZRV_3[>VP3*(E4J]923%1,%U2B^4,"0F*"IB$%0 $P$ZA
M*'(ASP \YW8^4S%26@T=&T$C,X;0D"^I OJ;;@MU_P"(:DV_91#=<ZGO-N?K
M6[U5[3FE[4=BS:79@WD7G<(D;22+J+.J[5Z2 @D5ZDER=18>A(@"(G$2@'(B
M&>C473'H_6F.-F(Q,FDRM#)FOA)>;#*,[0+EQLT7UX76]AQ:AERMVX:]UA9P
M<V[N0N.>Z]EL  @( (" @(<@(>(" ^H0'W0'.HW[ELTPB81,(F$3")Z_7A%C
M%(:*5,)SL6_4(\B)2= "(^L1 @E#D?6(\<B/B.$7IYBB/@*/R_I81/,41\!1
M^7]+")YBB/@*/R_I81/,41\!1^7]+")YBB/@*/R_I81/,41\!1^7]+")YBB/
M@*/R_I81/,41\!1^7]+")YBB/@*/R_I81/,41\!1^7]+")YBB/@*/R_I81/,
M41\!1^7]+")YBB/@*/R_I81/,41\!1^7]+")YBB/@*/R_I81/,41\!1^7]+"
M)YBB/@*/R_I81/,41\!1^7]+")YBB/@*/R_I81/,41\!1^7]+")YBB/@*/R_
MI81/,41\!1^7]+")YBB/@*/R_I81/,41\!1^7]+")YBB/@*/R_I81/,41\!1
M^7]+")YBB/@*/R_I81/,41\!1^7]+")YBB/@*/R_I81/,41\!1^7]+")YBB/
M@*/R_I81/,41\!1^7]+")YBB/@*/R_I81<EO&L&ANMNU12/ZNLI $X /K #F
MY, #[H ( .$7-PB81,(F$3")A$PBZR^V]]47JG9E5=:ZH;%C>-SJ,TUG+)TJ
M<:S1DGB(+,W-G.U43<OI1PBHDZ9UIFNU7,S43?23^/068)27J?03Y-*SI2&8
MGB$DE!@8>0U[0.M8@6.+7MI \%D<+7 L?5/:]N<&.*.1S9#%P_2CIE3X(745
M(QE5B9:"YKB=A2!P!:Z?*0Y\C@0YL#7-.4A\CV L$GYH]J[=V-NVX/KWL^U2
M5KLCX 3\J?'*1LP9E.<Z,9#QS<J3"(BVYE%#(1\<W;M2***K"F9=9953ZBPC
M!L,P*BCP_"J2*CI8]<D8)?(\@!TLTKBZ2:5P #I)7.>0 V^5K0/%*_$*S$ZE
M]773OJ)WZ9G$!K&W)#(V"S(XVW.5C &BY-KDDUOFS6$F$3")A%^AOZCKVB7U
MBKEO[.MFDE'3JF-_3+7OE2HJ+$J[QZFTLL&B8XAPUAIIY'23%$.\4 L_(%+T
M-62)"?-_RU=&HZ:JHNDM+$&,KG=1Q+(VS35QL+Z6H=8:OG@9+%(XV'^+1'5[
MW$^P?)QC#YH:G!IWEQIF]9H\QN1 YP;/$+_NQRN8]@U/[9^YK0!W>YX.O4$P
MB81,(F$3")A$PB81,(F$3"+2_M>:,D-C0*5S@9!?SS48]T<T*JJ864DPY!9<
M&Q3& C>1*!.4E  "N. 06X R:J' =.>CLN*4PQ"FE<9Z&)]Z=SOV<L0.9V0'
M1LHUL?W_ *)X%NDQBA=4,$\;CGB:;L)T<R]SEY.&_D=;VWKJ Y'WQ_2.>'+D
MDY'WQ_2.$3D??'](X1.1]\?TCA$Y'WQ_2.$3D??'](X1;%]E2L15LW56&4RB
M+EG'D>316XAU)*NXU,JC/OP_%IN#IK /(?94T^>0Y*/4=#J."MZ04450W/'&
M7SY"+M<^%N9@=_9#K'O '%9^&1,FK8FO%V@EY' EHN >R]O79=XGJ]6?1"[E
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBX4D\+'1S^0,05"L&3I
MX9,H\&4*U047$@#P/ F @E >!X$>>,KB899(XP0#(]C 3N!>X-N>P7NJ7NR,
M>^U\K7.MSR@FWL7X5K=:9N\6JQW*R/%9"?M4W)V"9>K&,=1S)2[Q9\\5$3B8
MP%%=<_03GA-,"D+P4H 'WY1TD%!24U#2QB*FI((J:"-H #(H6-C8-+:AK1<\
M3<G4KY7J)Y:J>:IF<7RSRR32..]SY'%[CXDV' :!1W,E64PB81,(F$5[=FC=
MLGV>-W4+;$<FLZ;UR6 D_&(' IYBK2B*D98XPH',5$SA>*=.3QYE^I)O*),7
M9BB9N40Y_I1@4723 L1P>4M:ZIA)IY7"XAJXB):64V!.5LS&"0-LYT1D8#Z1
M6UP3$Y,'Q.DQ!@+A!)^UC:=98'@LFCU(!+HW.R9M&R!CM[0OVC5FR0=RKD%;
M:U(H2U>LL1'SL))M3"9N_BI5JD]8NTA$ ,!5FRR9^@Y2J$$1(H4IRF*'P_5T
MM10U511U43H:FEFEIYXGBSHYH7F.1AX7:YI%Q<'>"005]+03Q5,,51 \20SQ
MLEBD;N?'(T.8X=[2#KJ-QU6<S'5U,(F$3")A$PBPJ)%9<!<J.%DHX_5Y$@S7
M5;'=)=0 F^7>(&2<]"P$[QFBV521\F5[QR+HZJ:;.?CX^.[MC?Y;OCN\>S[^
M:6GXR1\1 WC,2X^(*"I[K[U=0B E]J).$A 4B@0(2W?XE/-#3@ [R2X   /\
M<S'/ $,F'(^7<B/281$1$1$X%4$14*4P$MW^)\URV[5)J!P2,X,"A@,;OW;I
MT("!0*'0+I984R\ ')4^DIC<F, F$1$I7V,8I"F.<P%(0HF,8P\%*4H")C"(
M^    (B(^H,@D $DV !))W #4D]R;MZZ7NT?V@+;>;G9*_#V%\THT:_6C&4<
MP5\E1D 9_:SIR[50 BKM)PX(MW:9U3-CH D?NS";J'P+I5TEK<2KZNF@JI&8
M=%*Z***-V1L@C]!SWEMB\.=FL"2TMMHN*Q&OEJ)I&M>X0M<6M8#8&VA)YDF_
MJ6J6<:M8F$3")A$PB81;F]D/:^L-8RTT-T1<Q\U-&0:,+,9,'$>SCP O4Q6(
M0HK,15<B95=YXMSI=!5Q3!N03=WT(QK!\'GG.(-DCJ)\K(JNV>*./BQS0,S,
MSM7/U!%@;95M\)JZ:ED>9FD/?9K9!J&@[P1PN=2[@-_9V^-G+=XW0=M52+MG
M**:[==,W4FJBJ0#IJ$,'K*<A@, ^\.>YL>R1C9(W!['M#V.:;AS7"X(/(@W7
M8-<'-#FD%K@""-Q!U!7#&(:"''>27'''A,S #[04_6#X!YZ3"////><*_MI2
MG"I+=_B>_G\;MR#$M!$1[R1Y'GU3$N >/1Z@!\ !^UEXX ..3@' **=9+=_B
M?/X]07GS2T 1'O)'Q$!^_$L(<@<RG@ ON #J,(" !P) *F("F0A2DMW^)\UZ
M^:&?'3WDEQP ??F8ZN 3%/VWE_5STB(B//(J<*B(JE X$MW^)7@\40H&.U>2
M#9QP?NU3/WCQ(IC 3V[1ZX7;*$Y(7D.[*H4HJ BJB90YQ?'P?CV);Q]GAN7(
M8N5'*:A5TRI.FRQFSI,A@.0JQ2$4*=(P"(BBN@JBY1 _"A4EB$6*18IR%*?P
M7-PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A%P'KE5,R#5J4IG;L3]V90IS(H(H@45W2P$$HF(EUI
MD(D!TS++K(I=:9#*+)E'X]F[O7Q"*(8"F<O9-RL % RH2+ID!N"G+]SQJK-J
M'[88?!#J$03$QC&22$CX^/U2W?XD>ZR\^9VG AWTKXE$H_X\F^>!(5,>!\X<
M@;I( @8! P'$R@""ASF--^[P'DEN_P 3YKV+$M2F*<%9(1(<#@!IF8.43 J"
MW!B'?&(<G6  *9RF3%+E 2BB84Q7[O <K?';KO2W?XGS62R%*^+A!-R@NV5+
MU).$5$%2CZC)JD,F<O\ &4PAE37%CFN;HYK@X'D6FX]H4$!P(.H(((["+%?@
MU=H"U=.6PCU"W<+("/OBBH9,1_CZ><_01KLS6N^LT.\1=?*)%B1R)'@5Q\J4
M+W224643113.JLJ<B2221#***J*& I$TR% 3'.<P@4A"@)C&$  !$0#()#07
M.(#0"220  !<DDZ  :DG0! "2  22; #4DG< .)*V]?:KTQH=!JW[0+JVW?:
MR[5N_=Z2US+Q=9;4E-RBFY:L-G[$D8NQ"RL2[=9-5U4*O7WLA#%Z4IF:CWQQ
M8I\;'B^-]('/?T<914&$->Z-F.XG#+5/KRUQ:^7"<-BFI=I2M<TAE;5U,<<^
M^""2,;4]$^@PW"@UN+NJ*JO+6O=AE')' VE#@"UE=621SY)RT@NIH(7OBW2R
ML>2P8UO:^R!;E B9S46SM/D7'NVUTI6RT=D%C%#^P3<35)MU<ACS3%$3 L[3
MA[7 O3)D,#4JAQ*B:ZZCZ9T8VT&,X5C1;JZAKL+=AAE U+8*^CJIQ \VRL,U
M'4,N?3(&HH%1T=J#LY<.KL.!T;4TU<*W9DZ RTU1!$96#>[9U$3[#T03HJNV
M]J"7U-*0XC+Q-PI5PBS6#7FQ*V+@];NM?!P=JHZ:%=)I/(R7BW:9XVR5J320
MEZ]+)*,WJ(IG:NG6UP;&8<8BG_8S45=12]6Q+#:K**JAJ<H>&/R$LEAF81+2
MU41=!4PN#XW7#V,P<1PZ3#Y(_P!I'4TM2S;4=9#?8U4.8M+FY@',DC<"R:&0
M"2&0%KA8M<ZHLW*UR_3Y]2 V1+7#LTS%/EUU7/[&-\DH.$64,8XIUV;8LK$T
M9"<XB8PM)9]. D7JZ46:C1NF4B:)2Y\J_+/AD-%TH@K80&_.N'Q3SM%A>IIW
MOIG26&@#X8Z>^EW/:]Q)+BO<?DZK9*G!)::0EW4:M\41-S:&5C9FLN;_ $9'
M2VX!I:T#1=J+EDB[Z>].[)T%4('DS]\RY!3IZA-Y&Y0ZS!T!W9S]1TN3=T8G
M6?J\A7?KC^:&GXV4]?/W[FO7WG>_#_5U>''J[O[#QW/L,F_=X!1;OY[SY^S<
MO'F=H''V:4\"@4/\>38^ %.0.>9#V1N%#")C<F,8"'$1.FF8J_=X!+=_/>?/
MV;D\SM/'[-*>("4?\>3?J$I"CQ_C#V(\$*(&#@Q3"<Y1 ZBAC+]W@/+M^+!+
M=_B?-/-#7U@M*<\\_?N9'Q[SO?4+\0XZO#I$!+W?V'CNO88OW> Y6^.W7>EN
M_P 3SO\ '9IN7Q4<*0XD,^=E5BSAT&>O#)I+,%@ 12!TN4J2"S1P  @FLH"3
ME%T"*:AWPONMFW\[_'QY6U;MYTYGX_7OOI]H,.(6( 3";B+CPZC'%0QOM1'V
M1E#$3,<1]8G%,@F'V0D*(](#O/?W>S@@W#N"RF0I3")A%PY!F$@P>L#*J(%>
MM'+0RR(\*I X1.B*B8^X<@'ZB_E &6Y8Q+%)$26B2-\9<W>T/:6W':+W"I>W
M.Q[+VS-<VXWC,"+CNNNM^5^I^+'55/#;((1(3&,D25@S+K" CR4%5VKU HF_
M".5  $?$"AZL\HG^3*0N<:?%6!M_1$],YSO]YS)&B_:&^I<V_ 'W.2I;;AG8
M2?601[EI%M;6LIJ>Y/J;+/F<BY:(-71'C(%"HK(.TQ.F/=J^S2. E.4R8F-Q
MP ]7LN \ZQK#)\$Q"7#YWQ2OC:Q^>,.#7->+C0FX/,:]ZT-7#)23.@>6.<T
MW;>Q!]:KU!!9RLBV;(JN'#A5-!NW03.JLNLJ<$TD44DP,HJJJ<Q2)ID*8YSF
M I0$1 ,UC2][FL8W,][@UK6@ESG.-FM:!J220 !J2;!8X<XD "Y)   )))T
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MO.^Z[#L]573)A$PB81,(F$6-;??&3]?_ &+U]YQ^T&]75]C_ -?=^[[?V6%
M.I'*WM'=YK)84IA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$6,'[\AX!][#>/!>K[J)X<]?7Q[O'=]/
M/[OG@N%''U;^_P#N]JR>%*81,(F$7R<().D%FRY 40<)*(+)F]JHDJ0R:A!X
M\>#$,8H\>X.2UQ8YKFFSFD.:1O!!N#ZB+J" X%I%P001S!%B/!?B;[1.CK7V
M>-MVW6-J9.4#1$BX5K\FLD8K:R59PX6&"L$>MT@DX;OV92@N"1C"SD4GL:X[
MMXR<))_=/1K'Z3I+@]'BM(]I$\;14Q W=2U;6CK%-(-[71O)RD@;2(QRMNR1
MKC\QXQA=1@^(5%#4-<#&\F&0@AL\#B=E,P[G->W?:^5X?&ZSV. I#-\M8KF[
M/VR(W56V*S:[ R7E*BJ2:JUZBFPAY1)42[P4E3[BU;%-[!1X%>FW[B/(H()C
M(H-!,8@%ZRZ3I'A<N+X/54=/(V*L!@J\/F?]&+$*"HBK:%[R-1'UF"-LI&NR
M<\ &]CLL(K64%?!43-+Z<B6GJHV[WTE5$^FJ6@'0NV,KRP'3.&ZC>/7=.F9[
M3UD2:JKIV*CV)(\SK;8T4F=6L; J:Y^J/F8AZ4#(E>$0.DC.PJB@2-?E2N(V
M01352(91@>-T^-4I>&FFKZ8B#%,,F(%5AU8T6E@FCOF+"X%U/.!LJF$MEB<6
MN(#$\-EPZ8-)$U+,#+15C!>"KIR?0EC=NS $":(G/#)=CP"-:A;MW#M=!JU0
M6<NG*R;=LV;I'67<+K'*FB@@BF4RBJRJABD333*8YSF*4I1,(!FZ<YK&N>]S
M6,:TN<YQ#6M:T7<YSC8!H )))  %SHM< 7$-:"YSB UH!)))L  -22= !J2M
MO[Y$G[/NAW.GYSI;;CW+8*O=-DUP3%.^UWKZHMI%U1:C8D@$1C;=:9F;6MTQ
M"J&*_A8F+K2,JW;/7ID$>,P^8=(^D#<9@N_!<$IZJBPRIL1'B6)5CHV8A6TS
MM-K1TD$#:."< QSS353H7.CC#G=#5QG",*=ALHRXEB,T%36P[WT='3M>ZDII
MAKDJ*B24U,D1L^*.. 2-#GY6Y3ZGYH%OVA.TK4:_-L?+J542+7Z[HJ)];9W#
MU]9MY##N0,'0HA.S[J(BGB'4512+<R*J7(H"(6?E%Z1.Z-]%ZVI@DV==6%N'
M4#@;.9/4M=GF;Q#J>G9-,QUB!*R)KOI*YT1PD8QC=-#*S/2T]ZNJ!'HNBA+<
ML;M+$2S.CC<+@F-SR#<+]?P !0 I0 "@         <   '@  '@ !X &?&._
M>OHI><(F$3")A$PBC]J 30+\"@)A'R7@ *8PC]NMQ'V)%D##X>/@J3CUCU!R
M49&_X\C[E2Z]C;3UVX\US(3CS+$=(  >:X_@  @  >2(\  )&,F  'J!,QB
M'M#"7@<'>>_M_'7QU4C<.[L_#3PT64R%*81,(F$5>;,UC5MK5MQ6K2T[U XB
MJR>H])'T8\ HE3>,EA >A4G4(&*/*:I!,FJ4R9S%'58Q@U%C=(ZDK8\S3Z4<
MC=)(9+6$D;MX(XC<X>BX$$A8M720UD1BE':UP^DQW,'WCBM.-^P.F]#:B)2X
MVJ0LO9I]%1M%KRC9)S*F6 .'5A>.P K@IFG5RAW1B$*N9!ND"2?08G ])Z;
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ME,(F$3")A%26T.S]KG;CU"4MK%^>5:,C,&CYE)NVAD$1,8Y>4$U ;JB10W6
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M(CY+P  )A'[=;<^ +-Q'P_.D]_V7M3%#MQ\K\>5C[ES83I\RQ'2  7S6PZ0
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M\->&N[6ZXZO;]TXE:&,"9E+DB_/&LZQ8;&O/:Y9^C5HVO%U.5K44K4'MW;[
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M$7%K8VD=?BM;K0B%X-0-Y($4Q)NZ$-#2US03I:W!8:RNIZLY0UI_QJ.W].&
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MRDM. UC6IEK"4VJX("+L#1\: /Y;JC#"JS%E"E7OUA[P_%\^$6.:" R,J(
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MY]R^$/(!YIB^3!SYN9<\]0CSY,ESR)DTS"//K$4R"(^(D*/L0L[9@Y^"I#R
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MSM\$SGD/;YIYP+^$7] _-C;,[?!,YY#V^:><"_A%_0/S8VS.WP3.>0]OFGG
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M_&A_*#Y\=:',_:'FFV[?O)Z3!^-#^4'SXZT.9^T/--MV_>5@T%]Y>C,+@83
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MEOYSX_[..O,[$VP[/ K:70<@$E7IUQR!A"=[L1 "\^QC6)@ 1 >H>.KPZBE
M.1Z1-R/'78%*)J-SQN$[V^#(S^*WV&.ST[CRD<.-OHM-@#X^M7OFY6Q3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(J-W4_\WL8U;J H'=HI\=0 /(HR!O4)0'C@GK[SC\C]T&_Z.Q[
M6LF;RIG.WVW2Q#\5I\:EV5/&Z]KS-&AMO9(>/^JM=_2</QGRB_2SL>I]GWES
M77#]8_:">DX?C/E%^ECJ?9]Y.N'ZQ^T$])P_&?*+]+'4^S[R=</UC]H)Z3A^
M,^47Z6.I]GWDZX?K'[03TG#\9\HOTL=3[/O)UP_6/V@GI.'XSY1?I8ZGV?>3
MKA^L?M!/2</QGRB_2QU/L^\G7#]8_:">DX?C/E%^ECJ?9]Y.N'ZQ^T$])P_&
M?*+]+'4^S[R=</UC]H)Z3A^,^47Z6.I]GWDZX?K'[03TG#\9\HOTL=3[/O)U
MP_6/V@GI.'XSY1?I8ZGV?>3KA^L?M!/2</QGRB_2QU/L^\G7#]8_:">DX?C/
ME%^ECJ?9]Y.N'ZQ^T$])P_&?*+]+'4^S[R=</UC]H)Z3A^,^47Z6.I]GWDZX
M?K'[03TG#\9\HOTL=3[/O)UP_6/V@GI.'XSY1?I8ZGV?>3KA^L?M!<9Y8R*M
MU"'4*!3='(G40*7P4*8.3+%53#Q ..I,W(\ '!A P6*FDRP/-MV7C?\ ?:-W
M%78*HOE:W,=<V\BVC2?P5W&[-]'EXUB\;/K!$NG+)JX/Y.]0=-^^60344$R3
M]B=P8!.8P\ L@("/B4OM \1J>BV'S.>]DM5 ]SG..21CVESB3<MD8\VN=S7C
M32_%=')A%,^[FOFC)UT>"VYUW.;?U CU* RW95F2=1H*Z,''//0C+13AET^\
M!G+-T_Z_<Y,#0G_=\/'3S=#J@7-/B+'\FS0NCMV%['27[PP=W%84F"2C^BJ6
MGLD8YOWFO?\ RJKY?L^[BB^L6T1&3A"<B)XB8:>(!SXD2E31;@_[Q2(F./(<
M$'QXU,_1G'(;Y(XZ@#C!/'J.8;,87GN#;]BPI,+Q&.^5C)0/ZN0>($CHR>ZU
M^Q59,5G8<!U#,4NRL4R<B9PI"OSM. ]8@\114:FX]WI6'@! 1\!#-1/28G37
M,]'6QM&]YIY#'_$:TQGU./-8$D59%?:4T[0.)C>6_:!+3ZBH0:RF*(E,(%,4
M1 Q3 (" AX" @/B @/@(#XAFN-6 ;%[@1O!T(]2QNL.[?;^9>/2;\HO]_P"/
M'6Q_6'V)U@]OM_,GI-^47^_\>.MC^L/L3K![?;^9/2;\HO\ ?^/'6Q_6'V)U
M@]OM_,GI-^47^_\ 'CK8_K#[$ZP>WV_F3TF_*+_?^/'6Q_6'V)U@]OM_,GI-
M^47^_P#'CK8_K#[$ZP>WV_F3TF_*+_?^/'6Q_6'V)U@]OM_,GI-^47^_\>.M
MC^L/L3K![?;^9/2;\HO]_P"/'6Q_6'V)U@]OM_,GI-^47^_\>.MC^L/L3K![
M?;^99:+<3LXIW4+#RDNKST]W%QSR04ZA]1>AHDL;D?>XYR]"^>H.6GCGG=RA
MB?*?!C7%5L?-*;1QRR'DQCGGP:2K1A]0;CFN@S>DR+-,W BI,*LH;H ?=.A)
MNFSKP]TI$#G#W2^O-Q#@>.3V+:*=@/&8QP6[2V5['^H-)[%G1T.)2VM32-!X
MR%L=N\/>'>H GL5I1'9@V$ZZ#R\Y6XA,W'41 [Z3=$]\#)D;-&PB'Y#TP#[X
M9MX>B.)OL9JJFA!WAIDE>/4&,9X2>"SH\&K'?TDT,8["][O"S6_>\%9L5V68
M)'H&:MDS(F#@3%C6;*)3,/NA]L>=S@7GU\' PAZA*/B&U@Z'T[?\HKJF7LB9
M' /O;<V[B#W+-9@D8_I*B5_^H!'_ #&1791:="T9*5A($K@K,SIL]4\J<BZ7
M,Y7:)I**'.*:?0!B-TN"$Y3#I$Q2D$Q@'I:&A@P^#84X>&%[I#G>7N+G!H)N
M=VC1H !I>UR5LZ>GCIF&./-ES9KN=F)) !-[]@T :%/,S%D)A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$4"N%-B+NJC$S0O2MD$ ?)'8KG;JD<IG5;D/UF(JW-PFY5#H.B<PB(&]J7
MC,[#\0J,-F=/3B,O=&8W"5F=I87,>18%I!NP:@@VOS6)644-=&(IB\-:X/!C
M=E<' .:"#8BQ#G @@\.2I^3[-3%3J&&ML@T]TB<FP0D.?R3*M5HSCG\($3<?
M@#G2P],)!;K%!%)S,,KHN\AKV37[LP[UHI>C+#?8ULK.0EC9(.Z[3%;OL>XJ
MN97L\;$9]1XU]7Y=,/:D(\=L71O]:;ML5L7GW/MT?W^,VT'2O"9+":*JISQ)
MCCE8/6Q^?_VUK)NCN)LN8I8)AP D=&\^I[,@^VJVE=<;5ANH7=+F5BDY$3QA
M$YDHE#]T'FE=Z8 X\1ZB@)0]L <#FW@Q? ZBVSQ&!I.EIKTYOR_;MC]FAX$K
M638;B\%R^CG('&*TP[_V.<JNWLC)1JHH2+%XP7#GE%ZW<-50X]?*:Y4SAQ[O
ML?#-K''!*W-%(R1OUHRQ[?%I(]JULDTL3LLK9(W?5D:YCO!S05P_2$_]Q'Z6
M5]79S]@5'6C]8^W\J>D)_P"XC]+'5V<_8$ZT?K'V_E3TA/\ W$?I8ZNSG[ G
M6C]8^W\J>D)_[B/TL=79S]@3K1^L?;^5/2$_]Q'Z6.KLY^P)UH_6/M_*GI"?
M^XC]+'5V<_8$ZT?K'V_E3TA/_<1^ECJ[.?L"=:/UC[?RIZ0G_N(_2QU=G/V!
M.M'ZQ]OY4](3_P!Q'Z6.KLY^P)UH_6/M_*GI"?\ N(_2QU=G/V!.M'ZQ]OY4
M"PG$> \1'P  $>1'WO;8ZNSG[ G6G?6/M_*I;$PEYG.DT14["_3/QTKMXI^9
MMP/J$SH4BMR@/N"94 _?S"FJL,IKB>NI8B-[7S1!_J9FSGN#2LR&#$*BQAI:
MJ0'<YL4F3[98&^U65%:0VS)=)EH=E#IGXX4E99H7@!]TR+!5^Y)Q[I3H%/\
MD^KG43]),"AN&U$DY&\04[SX.E$3#WAQ':MG#@>,2_2B9"--9IF#?_9CVCA;
MC=H/9=61%]FJ;/TFFK='M>.!,E%Q[I]U>^!5W;B.Z/WC"W/_ -W-1-TPIA<4
M]!*_DZ:6.*W>UC)K]V<=ZV<71FH-MO6L;S$4;I/4'/,?CE]2E;S0=3AHER\5
MD)^2=) @ =;HC9#E1PBD82(Q[/RL/8G-X=^H ?NO8@8<T]3THKJAIC;%30QN
MM]%CGOT(< 7/?EW@;F-6SAP"DIR)#+42O;?Z3VM;K=OT6,:=QXN.O@M@(4!"
M'B0'GD(Q@ \@8!Y\E2YY YU#@//K YSF#U&.8>1'FCO/Q[M/!;T;AW?'-9+"
ME,(F$4?F*G5K"!@GJW S0&#@?.L1'R _Q&=-U3 (<!P(" AP' AP&8T]'25(
MM4TM/4</VT,<O\[765J2"";26&*7_P#)&Q_\P*J>:[-&F)KJ,:H)QBQN>%X6
M1DXWHY_!:HNQC_7XAU,S<<<!P'(#I:CHG@-1<FA$+C^]3RS0V[F-?LO_ &S;
M@M?+@N&RZFF##SB>^/[K79/%O<JDFNQ13G/6: N-EB#&Y$I))O'3:"8CZ@*1
M%*&6$@>H .X.?WU!S1U'R?T+[FFKZR$G<)1%.T:<FM@=:]M[B;7UXC7R]&:9
MU]E431G^V&2@>H"(^+O6JBF^Q7L)IUG@;35YE,O(E(]"2A72@>X!$BMI1L!A
M]T%'I"A^&.:2HZ 8FRYIJVDG:.$FVIWGE9H;,R_?(!VE:Z7HU6-_HIZ>0<GB
M2)Q[@!(/%P[U4$WV<MXP769:CO9%$O(@M"/8V8[P ]8D;,7BK\/W@.T(8?<*
M.:2HZ*](:>Y=02R-&YU/)%/F[0R*1TGBP'L6ODP;%8KDTN8<XW-DOW-8XN\6
MA58\J]VCES-I"HVABX+[9!Y RK98ON<BFLU(< \/7T\9IY**OB<62T=;&\;V
MOIJACAZG1@K!=3U;#E?!(QPWM=%(TCU%H*E,)J/;MBZ!BM>VM1-3CNW#N*<1
M;0X#ZA(\E09-3%]\Q5A*'NB&9E/@>-55MCAM<0=SGPR0L/\ ^R81LMVYK#BK
M\6'8C-_1TDI!W%T;V-/<Y^5I\5;\)V0MSR?0:12KE<*/ G"4FRNEBA[H 2#;
MRR9C@'J**Q"B/@)P]>;NGZ#X]-;:BFI1Q$U3G<.X4S9P3R](#F0MA%T>Q-_T
MQ3PCCM),Q\(A(#XCO"MZ$[$(AT*6/81C>KO&L)!@7CW^A^_?GY]X.J-#W_WL
MW=/\GIT-5BA[64]/[I9)??$MC%T8W&>KOS;%%;P>]Y_D5N0O9$U#%] OT+#8
MC%X$WG:;4;IF,'O$@T8<P%Y]13*''CP,8WCSO*?H1@<-MHVKJB-3MZES0?53
MM@T[+GM)UOL(^CV',^DV:;_\DI'_ ,0CT^#=6U#:AU?7^@T50ZPBJ3CH<+Q3
M9^[((>Z5Y($=.BC[X@L C[O.;NGP3"*6VQPZD:1N>Z%DL@[I)0]_WM>.Y;"+
M#Z&'^CI( 1N<8VO<.YSPYP\582222"9$D4TT4B!TD22(5-,A0]12$( %* >\
M  &;, - #0&@;@  !W :++  %@  -P L!Z@OIDJ4PB818UKSYQE/7Q]I<<@I
MP'V WJ$P]V/[_=@''[ODV% M<\]+[N7CX^I9+"E,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBQ@\>>
M0\ Y\V&]EP3JX\K)X<]7><<^/ %Z.?6;JX#"CCVV[.?C^'+BLGA2F$3"+CN6
MC5ZD9!XV;NT#>V1<HIKI&]SV2:I3D'P]\,J8]\;@Z-[F.&YS'%KAW%I!'BJ7
M,8]I:]K7M.]KFAS3W@@@JOI?3VL)OJ\OI,"4Q^>M2/:>9UC"/K,9:(.Q5,<?
MPQ.)OW\VL&/XS36V6(U) W"5_6&@::!M0)6@:;@+>)6NFP7"I[[2AIP3O,;3
M X]I="8W7YF^O%5=,=E+6S_K-&N[+!*#ST$:2:3QL4?RTY-J[<'*'O \3-X>
MV]?.Z@Z;XO%82QT=2.)DA,;_ %&%\; >^,CL6IGZ(X9)?9/JJ<\,DH>T=XF9
M(XC_ 'P>U59,=CR6)U'@+VT<<\]"$Q$N&?3[P&=LG;_J_?,#(G_='-U!T^@-
MA588]@XN@F9)?NCDCBMW&0]ZU$W0N87-/B+7<FS1&.W*[V.DOWY!W*JYCLR;
MDB^LS6,BYTA.1$\1-M0$2A^Z*E+>:ES_ +Q")&4'U 41S=0=,<!FMGEEIB>$
M]._?R+H-NP=Y=;M6JFZ*XU%?*QE0!QAGCW<P)A"X]P;?L553%!V/7^L9BFV9
MBF3GJ<*1#\[3V///#Q%%1H;@ Y'I6'@/'U" YNJ?%,+J["GKZ*5QM9@GA$FN
M[]FYPD'K;OT6IGP[$J>^VI*Q@&]Q@D+/XC6%A]3E'V$98Y5;R>+AIB2<>'V!
MA'O7BWCZOL3=%0_C[GL?',N6:F@;GFFIX6?6EEBC;]I[@/:L:.*HF=EBCJ)7
M?5CB>]W@UA*LV'T7N6;Z1;TJ39IFX$5)A9I"] #[ID91RU<C^^4B!S_D^O--
M4=)<!IKA^(0/(X4[7U-^P.@9(SUEP':MK#T?QJ>Q;1SL!XS&."W:6S.8[U!I
M/8K4A^R/L1WT'F9^MPZ9N.HB*S^4=D#W>I)-HT:B(>X!'Q@$?= .!'2S].L*
MCN*>EJZ@C<7,BAC/<XO>_P 8A^"VL/0[$GV,U53P@[P'/E>.]HC8SPD/XJU(
MCL?UQ#H&=N4])"' F+%LV,.0P^'L?MD9H_3[@\&*80]0E'QS2S]/:QU^K8?2
MP\C,^2H(^QU<7]1 Y%;:#H93-_RBOJI>R)L4 ^\)S;N(/<K2B.SKJ6(Z3#6S
MRBQ>/L\O)R+SJX_";%<HL#<CXC]J>/J]7AFFJ.EF.3W'6VP-/[M/!#';N>6.
ME'JD6WAZ-X/#8]6,KAQFEE?XLSB,_85GQ-3JT%T^9:Y!1(E .#QT2Q9J>'NF
M400(H8WOF,83"/B(B.:6>NK:F_6*NIG!WB:>60>IKG$ <@!8< MK#1TE/;84
MT$-MQCAC8>^[6@W[;W4@S%60F$3"*/6L.8!^'2!_N7V)BE, _;K;UE,J@ \>
MOQ5+P(<AU#[$2I=>QMIZ[<>:YL)T^98CHXZ?-<?T\=WQT^2(]/'=?8N....Z
M^Q_@>QXR3O/?V_CKXZJ1N'</C33P64R%*81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A%C&O'G*5X .?M'D0 @"/V W'4)3"<> ]764O'[GJ#QPH&\Z<K&^
M_P K+)X4IA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$6,$1\\@'/AYL,/'/N^5$\>.[^/O?WN[_ '6$
MX_%^W\%D\(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB811VV<>8'_)BE#[
M5Y$YDBE#[=;>LRZ:J0<^H.HAN1X O!N!"1:^OQ[1[U2[<=;=NO/L60A>1AXD
M1YY\V,.>1,(\^2I<\B<B9Q'GUB=,AA]9B%'DH0I!N >8NJ G.U5J>N3$G S*
M]C92L0]<1[]JK7W?4BY;*&34*!@.)5$S"7K25()DUDC$52,9,Y3#RE1TSP6D
MGEIJAU5'-!(Z.5AI7W:]AL1<&Q'$$$AP(()!!6GEQ[#X9'Q2.F;)&YS'M,+]
M'--CV$<B-"+$$@K+0O:/US/OJ"QC@L1AV5=)FA59VO"*-F;BPP&O[7LN3375
M66(9)HA6J=+?;2::Q!D3LV/ &64.AN,*Q:DQB"2HHML88W[,OEB=$'/ !<&9
MM790YN8C0$VN2"!FT==!7,=)3[0L:[+F>PL!< "0V^IRW%R-+D#G:PM8[#KV
MV]<T7:-2%\-7V'4X&YUX9-L#*1&&L<:VE8X7S0JJX-G7DCI+OT 65!)3J("A
M^.H=GN69O59[#[2^O]:6&;@IR,NS]E3H^O2VQK; 5A>4J.M8NTN7"$*^N$J#
MA!<B2J;5:2D$H!C/.X"$!.=L+>*B'#9ZM-K_ (?'FH) OV?'K]7O7*;=HNBN
M-B-->'C+HS-*7*9UO!W5_6'32A3VQ:] REFFZ5%3BJH.E95A#P4\J#]>+;5M
M\]A)2'BYU],M#QXPE_CX^/9>S;Q:UJ7 +3J%2MUV41<-D @:/'L)2?6!RJ"8
MN$6DE*0[4S=L ]XY.9\0Y$P$Q"*&]CA2M5B]N_4K367[,UJJ6V:)JXTY7H%*
MZ6ZHQS6*6<3]I4J)W:9(NQ2[X(Z DD'+BQ.U6:81\:U</$R.BI] S8WMQ49M
M+D$#U<[<"?C==6KL_M+:XU0I8T)\EAE7%;HM5V$NA68QO+&DH&Z7DNO*^G#J
M'D&B#V0>6-1),$#+(H%9JINP<F*(E !?V^S5+^ONMYJ9ZZV4[V">7(YUEL_7
M@116)B'V+!PL.26\M%V!BQ Q-CGA<&9>2@+X%P:@D#IIW8K"H<$H3U$=]OP)
M4[5G(1!\I&+S$6C)(H-G*L>K(-$WR39XZ(R:.%&AU@7(@Z>J)M&RIDP37=*$
M;I&,J8I!*5P[;9HREU6S7&:%P$-4Z_-6:6%HD"[H(R!C7,H_%L@)TP6<>2M5
M>Y2%0@**=).LO5U WH= 3R4,H&X:?LF9L$%6C2@OZS7M>V:3\O8@U1",V9!N
MK#61;J NKWK@8]FL+]+I(#1?I2 ZO5U!)!'B1ZQO4 W\ ?%9_8.Q*5JJHR]Z
MV#88^L5:$1*J^E)%00 RJRA4&<>Q;)%4>2DO)NU$F$1#1J#J4EY%=O'QK1T\
M<(H'@"^@4DVU*Y=%N$1L.DTZ_P!?\J\P7FJUZX0GER -GOFBS1#2:C?+&Q5%
MBMW7D3U#RA JJH)+=:8*' O4(Z$CD@U /-5I9>T/KRJ6J:I\J:;"8@;;I:E/
MP;1A5FOGK?4\K7:&"*XNB"HT&11/YY<"F48Y#A4J;D1Z FV@/.]O4HOJ1RM[
M5>F0I5$4+M#4K8UF;5^OPUY3CIAO97=/O$G5'C.B7MO4)-")L*U6GP46%1)L
MZ<$5BUYEG#(6J,*M-T]2?A4%I DD6^/CX[5 (/X=MN7-7OD*5C6OWQE/'G[B
MX#D!X^P&]SH*(<^OQ.ISZPZ?5A1K<\M/7S_#DLEA2F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB818T0
M'SP4?'CS88/4IT\^5$]WGNN?WNGO./4(%Y 2CCZA[SY'EZ^&IG:<[:VN^RA*
MUJ/V12=HR;&VL73N&L50A:Q)0*SE@N"4A#K.9:X03M"69)JLWBJ!V/<*-'S=
M1LY7.1VFV[GHET!Q3IG#5RX5B&#PR44C&3TM=45D52UDK<T4[604%3&Z"0MD
MC:X29@^)X>QH+"_D.D_37#NBDM-'B5%BLK*MCW0U%'!2RTY=&ZTD+G35D#VS
M,!8\M+,I8]I:YQ#PV%]GWZHAJ3M+;#;:WUQ0=Q!*J1S^8D9:<@*>SK\#$QY"
M][(3+QA>Y-VW;K.UF<8U!NP=++R#]HB"0$.HJEG])ODPQOHIAC\5Q7$L"V(E
MC@BAIZJN?4U,TI-HH(Y<-A8]S6-?*_-*QK8HWNO< '"Z/_*'A'27$6X;AM!C
M.V,<DTDL]/1LIX(HP+R3/CKY7M:Y[F1-RQO+I)&-M8DC?G/-UWJ81,(F$3")
MA% ;?L: I5CUA6)=&24D=M7*3HU8.Q;H+-4)F*U]=]E.5)=55TW4:,#5^@S:
M**[9%ZJ:35CVQFY$%UG;9S[/,#\4_%>-5;'@-P:UHNU*JE)(5K856A;?!(S+
M=!I*I1<ZQ1D&1)%JV=/F[=X5!<@.$47CE,B@&*1=0H 81T)')0#<7YJ,WS?6
MMM=W[6VKYZ766OFU)M*'K-;B6PR+]L@JRF79+#8"IG(2!K2AX&0CVLK('3+)
M2J1XZ*1?.&[TC5;C\?JE^'$_'GX&RB,QVDV4!M&IZKF=0[E8R-YM\G4*G930
M])<U>:/#,WLI*6- S*_.;(C4V$2P6E'LR[K;<&;=9B@[;H2$@Q9.)MI>X[M?
M*WM2^MK'OX?&JV3R%*81,(F$3")A%'[4(A OQ #"/VKX$%<#?=K?U"V RW^O
MH ?#GJ]AU#A4NW'4CNW[_4N;"@(0\2 \\A&, 'D# /(-4@'D#'4, ^^!E#F#
MU"<P\F&3O/?\<E(W#N^.:U#[2?9S>['L%<M5/200F'SYC!6LQ^@B7FPP@FVL
M:I>I,5E(A$IFSQ,@G<.FGD2:)0!F/7P/2OHK)BU52UM"&LGDDCIZXFP&QW-J
MR+C,Z!HR/:+O>S9AMMF;\WC6#/K9H)Z<-$CG-BJ"=!L]S9CNN8P"UP'I.;E
M^BI+<M-R3*U]D%O1(0%ZGIW9URG+6[%[&M58V&ENSONJD-YEPBZ=-7,H[E;G
M<(1LZ2BF[QT5>55D%FR,:V>.FW9T%'!AU'#14S<L-/$(V#BXWS/>XC0OD>72
M/.EWN)L+V6^IZ>.EAB@A;:.)F4<R2;N<[FY[KN<>+G7MRJ[LP,-ZPW9TU-V>
M9_4VV-!W"@Z<H]/>;@D'W9OO-29V"G1$%&R"<+$0.X+W.R:<T#-ZA&K3%%:M
MB-%#N7AXQX5LF;,-KDW!N3IK^GO5T7L!8BP&NGZ^Y8O:\9V@+%<(#5]UU)MS
M<NAZM&U:5L=HH$GV;JV[WS=$7OG92.O$7;MT:UD*MKBKN&\8>4JT!63J["E4
MEV<D_0IK)U#72!S!L=>>[LT/;O*&^ZUQIRU[]1V<"/PD=UJ.V[_OS5-@5U1/
MUJ7U-MB4>--K_LAPLQJ&1TFZAK4P=)LM>NK<XEV^UK3$6%*KOI$NKXV5@G:<
M@=IL):H)M6,RX</Q]W9QX'352>'9[N/;^HU6WE MIKU4(6V&@9:LC,H.%O,D
MX://),RH/7+0AE5HE[(Q;I!V5N#UB]CG[QD]8.6SMJX516(<84K2F$T-L0.S
M+H#6<U4&SB>J6]J/:[M7G<G6WC1M3HW=$G:)QRY6&36B)5N6L.RNUHQFY?.W
M::IF*3-=WUM0JN+D\[^T%4VT [O81[[>:U[NG8]WJW>[LUS"1:UIU&&L-/T3
M0TXVN<?"VF/I\5V@F6Q);6\@]=SL7.1[W5$$,JQJ5I2<MQ>TUK4F323<V^/?
M@H! L>-CV\-/'CO\%-MXW@[N%N!'#3EZ^R_80&BY*L55U7]3;?VI2)*0G64N
M^LMTN5G[0$H9HU8O&BD,P#>T_>B0K!VJNV>+A#F9"9PQ3,)3"LN)HOV#PM[K
M);D3[S[;K1^7[.VQ@O;-&2T"38=E:=MBJ[ZDNT O-:RC$YC5B5H@W,:U35<V
M9G>U)[7,82+9^@;JNM:P>)UZ5]7Y-_*#6H>1FXY_NVM:UC^IU[=QL%%CKI^]
M??O'Z#AV7"WHMCV9W'V?=KM(*K2T58+-4MT4.%KDVYAD'KV7C%;A0XUPF_0D
MW$(6,LSR-0EX204DR-3PLK'O'BK43+$1@:$'D0I.H(Y@K6G6,;NC1VQ;I(..
MSEL_8L/<=8=G"":S&O[7V?DFD7-:YHDC7[5'2S;86[:!+ HSD7R9$',9&R;!
MZDFJJU>*%!/O)-C?7BX\=;VMP4"XMH=S1PX7OQ[5M6SH=Z;1^QB6G8KO9B5@
M1?*TN$DZG3Z\G3#F0FR(L(^0A6+)>4,L208,RR,XNJY0)&D6*NF=V].I3ZO?
MYJKU^[R46TBK/ZUUWV9-,6:J2R-E2T5!QUD>M'<&^B:C-ZTJ%"A9:(EUVDJL
MJZ._DI=5I&R4(C*0QE8U<KF1;^6Q'G"3J2>WWJ!H .SU:66M^\=/;=>[$VC?
MJKKJ5NK%QM?L.7J B(*PT*.FK/$Z/OC^Q;#;Q1;C;ZM$LI&,CC(^1I626@6T
MHNN1)@[7 JQTIT(:+[KWW^I18@N-KWM;U;ULZR6VUM/T>GT2;,[,Z%=L"Z,_
M1+E#Z(N<CL.)#S(]37"6I=VVJQ@(LQ"RD,DJRGXFP=^L^<KQR:+>'>N(W<CX
MZ>[\5._F/#7W_@M0NRCV=]D:>LFE*\%(N-/2U11+A1]P[&F=AQMCJ6\V;5M'
M0^M_1:OM;K/30%9'9-[)&K6>HTQ?7T,U<TF(\I:RCE$1MK;=O W6OZO5H==.
M2@#=S L3S_O)ONW@^OL^R%4L:U^^,I[;_L7'(* '[0;VHF$2#^_W8%X'V_)O
M'"@;SVVX]G*VGM62PI3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(L6/'GHO@'/FLWCP3GCRLGASU=Y
MQS[@%Z.?6;JX#"CCZOCX\.*HKM3=GNO=IG3=EUG,]PTDUTPEJ;/+)=X:N7"/
M26&(DPZ2F4\D5%5:,ETD@[UQ#/WZ"0D7.DJGU'0_I/5=$\=I,6@S/A:=A7TS
M76%70RENWAUTSMRMF@<=&3Q1N==H<T\]TIZ/4_2;!JG#)\K97#;44Y%S35D;
M7;&70$Y#F=%, +NADD:+.((IGL!]DLG9;U*)+*V:&VO>E&\O?7:"B#LL6FW!
M4L+46;U 3HKM(-!995XLW451=S3Z251<.&2; R>]^4GIH>E^-7I'O&"X<'08
M:QP<S;%UC45LD;K.;)4.:UK&N#7,IXXFN:V0RWTW0'HD.B^$VJ6,^=JXMFQ!
M[2U^R#;[&D8]MPYD#7$O+26OG?(YKG,$=M[\\Z7=IA$PB81,(F$5 [@H=FMN
MQ^R[8H)DDZBM9;GLUQN*ZCQHV/'0$EV>MX4!H[10<+)K/U%+1=:\Q,U9$7<I
MI.U'ATRM&KE9*1Q[1^(/X*#P[#^!5#=F: WS =GW6'9XLVNM@:/GJ1JJL5%Q
MN:*L6A[E'L9JK,8QHNI!P2]@O*KLLP#5RW;*3=)7;HM5E%'!&3L&ZB8FY)YD
M^U + #E;=V*X-@:ONTJU[.K9.:>[ E==[HK=MNMPGDJK!3$C 1=1V'%KRSMA
M7XVNP1W"3ZQQ[<D= Q#8!(LHNDRX*Z5P./:/Q"'>._7NL?-9B"H-C>=I"_;6
MM+),(.'UQ3M:ZC.+QJY\G92,C*VS:\LDT254<QSJR3*=$A7OE2;<SII0(I5
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:+HHE!($.\%5NY>7X>_Q31P[/?^._NW<E_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g609070g40x90.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g40x90.jpg
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M52F",AOPZ[9KB'/3V(\PI71AL%F 5G2TQR"YFM;5X98;FXMHI]%VMP@UL&O
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M6U)>ARY<,M#F#F.S88K!B)RBBN(B;:"[CUZ1KK;>X,JI(FKEDR >)U97T&S
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MXRZ5PK$0HZR9E%TU)$8>0&,9CPB>58V$]LIEYMHHS2Z0-X&YL&T864&1D9
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M%5H@!$0JYIFJD?(/LOJ$OFRK[O8*7F&=A5ZAG#%WM$4158[(77T^O0-+E%(
M^;8U>'A8];M@RECQX4.U@-"FP?,T6%F"Q)BGML/@MK>Q= EO).B01%Y27N%D
M:]7^)I&1G,D+SLSN=-E;3+:1!+/=RS2W2L6F6)VED"Q@+"R"V;V-$(JZ$BQ
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M\^NKYZGDLGX._P#Y+GT>*4\ED_!W_P#)<^CQ2GDLGX.__DN?1XI3R63\'?\
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MA,I%3.A(N3 0?+2 <M'2'M#1%@%!"DS:A$9YDG[)MX"UK35J+K6'*K<1Z4;
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M&J=([#XK4YY*M.*4XI3BE.*4XI3BE.*5!=GZ\K>V==W76=O&"S%;O-:+UHM
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MS(30!EMSSS/1ZZ<N_+KJ'//8-G^1U]O1U[=U;*_RC.GO^W?37_>?2/MSDR/
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MN>9]S/"[QVCQI\ZXW\G?I_\ [#-._P#=E2OL3C,\3WU,AP'#=T<*?R=^G_\
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MEE6@K= /1TY#XG,'([MF>\YY=/8;[%)[+'HO;(W9&N]P]35.NF^+7U/3!-$
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MHUD"@0M"U]0<5\>5I>L*BXL22AZVKQ@HU/1->E%VTJ\>B! $01X[3GQV[_\
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M]Q';*VBV@KRRB%&D*AM!"Q&9.>0SWY5<]@W;1L!-43J+JA'[*U+>]LDJLD-
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M<PW$0FTI+R8RP7 ELY<H]9;,4!J!0./;Z]=PK;S&.S&,8][&,8QVYSG/N?\
M'.>W.?[\Y[<_U\^5K5;<\^?KT*<4IQ2J5W7_ $;7'XTJ]^J;%S2_U?VG[5EO
MZ?[A]ZNE/O8_NQ_IS-:KSQ2G%*@R?PE._(AK]>N<O0>T>#5.D=A\5J<\E6G%
M*<4K6RX??,7_ .LX_P#!:Y[-M_T(^P_^HUTI/YV[:J;8="!;-J).E63,Y(8L
M^(D2LCI"(LSQ@0T./0O%/N,R$H3F<+C8>QEI7C&/&-XRC*\+3B]LX;^VDM9]
M/52&)FT&"MG%*DRY$A@/;C7/9M&8V9YUX'*3D]8<J<&NL"Q,W LKQ[.28VLB
MQ3Z5C?6V(0Z$C1RJH,]K$'S0EHRZ@J2&%'W+I"U+<Y9N9*[P"E&KD]?TQ14D
M*\+#6LG7I%8LY4(&.@38B(]<1K[<BQ^/A2O&FX<.Q"\BSS:R+GDW7)K#;II7
M;71F6Y-YHQM$8XKAX#;SR1130RQJ;E"&FS5LY56:/5RC3/P.-_L8Y'8Y-?S3
M?O*S-_C;\H1%:2V+VEEB]UALF%XK=V-CB&'W]G"^-6SK)B6G!+I7T,.)6AM,
M05KEN0KI,U=Y[C$V95PBAXIJ%9DTF,?0W3W++#UPYJ?)YR!F HCYPF4930B7
MXHLU%4N*U.8BL3G)<B3K_AS#]:) URL8E2?FJS 6QG2R.'ZTIH:>F]KE&V4@
M4E0X57+%N5OV/<DS?17238U#917T&*# HL15<%;$X.33<D3B#6YMFN><38"4
MM)M&[6(M$MPD4<[S22X@7T=Z]#LPW8%PVBQ8A&*2BNW--E%8L]:8U_6K72Z]
M%#/)KB1*(J:A<CE>(,3A$Y!&*\U.E86;0LJ[Q1\F;*(*4N<0$\?-=3=:^/G$
M LX+BUA6(B 1A>;7,L+AXWTU(9OXH,AZ=K^Q7DW9)"]OC7*R/$K,8$N&XV,5
MM!BN%Q\G<+Q? \-BLG&&"T$0P;&[_#KA+BSN!<Q.D\N=\&NGR4?I&U5%MDVY
M-2;BHT3!^:",N38<3B<Z=FCLZ[S:95IGP9-V=LJZQ'9;>DJL_FV061W@D"W3
MJW""^0<F\.%PUR&NM:\)B=FF#R.QM!9&X:X=&NC.8  6U^@9!KC&927/9C_8
MUR1CQB?&UEQHWUS8&SN99<16XN;B<X G)HXK+BMQ;RXX^)MA<:*\AQ3FLMXO
M[QEM'OV:X:P].:4IVC@9L%3E3W&+%8G[07?G-A(?E!=\:,$+>8%5@+7*X-0J
M$(A8>0*"0E3I>)!,BN83F2YC_=PS"[;"HI8K;3(GF-Q*6$2:4A2./,1V\4$"
M#0C7/5Q*7;2DD+R,S'Z;D5R%P7D'87UA@IN&3$L2?%;V2X6QA,MY):VMF7CM
M,*L<-PRU4P6< <6EA 9YA)=7+3W4\T[QF#TSZW'UVAUB.Y8O-NN1>Q1%>RX4
M85)5$VA )#;-YP=Q 2F2ZF.5E9&K0VQB(YAI3B9&$92KZ]^4.(27%[<L+?67
M\EA+.!&P4-ASQR6^K&L)4:42ZP$MI#, KGF/L-$;.K/Y[ZDH+2=/KA&HE14@
MZQ.I.H'=)@7\D6LJ:I[K];D^4/93#3EPZV]512VB*<MM(SB1_P CSXU/B^O/
MC%W<1W44JPE+S%1C$XU9VW86X717VSE"1<R@QG,GV?;V;=5]'=*TMS2*- -^
M>(E";UY&UFVN$2S$/(KT4(T!;>P4890E11<1I+LF2N*MB9)6\J7$>8?>CK@Q
MB\&,G'#JGOC?MB)TX]. W#3&<C5,3_"#G)5#9HH 5@5!$R&66[L[<]GK9T54
M8CHNU"'%&A+4JV/LGZ_M^N$G<S0 _P *#O"OT6N7E<. "K8D,,=5#UZ#?"L#
M1D0:'DND$QH&83L6%#]67E=BLLD,A6U4P3X5<1@)/)D^#SWMQ9AWGN)9I 'O
MYEF,DC/*HCTGTPSN"@9\",LNKQZ34CK'2QKNHWP'? Q:[MN5NQG[@$JKYZ,]
M4(%HME.>I-J-MC<BTSW)9\8\J9+;?*NPXI;QLP3%'(G$H\WKW/*6_NK*:RFB
MLR+BW@M)KE8&6Z>VM;M;VVA,@EU86"0:"$1!VBR65I"D;( R.>9V]>ST.BI[
M9]-4^VV.VV@JHM@G=-42=-&<19K3,;%/ESC1%U4-I45Q3!;R@].\&:IQUK#?
MB$YBYRWE2^C;XM=VMO:VL8BU5IB:XM%I(2QNU2&,!R&&<6C"F:  YZ1TMHR9
M;<^K+O\ ]JB4CIGUO*KM_K#J[%YMV36Z!5;'E)1C$G O6PE@+7<CW?(,IBR5
M0X[>2#RVWTRGO"6VVQC/@8[2\HL06XL;D"WUF'W%]<V^<;:.LQ"5IKC6#3]I
M=-CJP"I4;"6WTRW]9![LO*IGL[4M?VDU6GB)2RUBQ4LR\>I]SIA1L-::V1EB
MYH,EF!+D0R,!^&6#$9HPH,*#2(V;&>2IV)F3'B/L=3#L4GPTW*QQV]Q;WD*P
M7=I=Q&:VN(TE2:/316C=7BFC22.2.2.1&'LMDS LL\CPJH&^C/3K=EH5L\*U
MR3E#@AX&)Y8Q$L$ZUH!6PM>1TBTEK **FES$6H\9*2I-=)UU9!D@X%(>4U]B
M&)C>J>5N+&WO;7*U6&]>630BB:!+4S6T5G(+6."6*(*;:&&-5GCG$9C$L>C.
MSR--$;<MF>7KXY[>_?MKB*Z*M0IKI*LQIMOCP2@2EU^5EZ97333PVB&[^>#1
MYP:R5@U6#;#\W9-CP1A6$$7&R$H$OM0H\\7'FXU_Q=BNOCN&2U+Q37<Z:*3Q
M%9+V&Q@E9)H+B*YA94P^WU;P3Q2*3*"[)(RTT!GGMSSS]?XJR9'3[1U:XUEK
M ?-LX4%J(I2C%*(#BS3IV%.HB?%"%RYI6"3C3FI$=;\8@P]!\4MB2XB&B#EN
M*J/T%QV\_>&)8E(EM--BL=Y%>1R1$0.EZ=*4(D3QLA5@K1D/F"HT]/-@URW;
M3LS^>?GT5Q-5=.%!U ;P<K4VUD'!]8>H]1@6,VDH-H-&D&DV%^H5%AN%$>8#
MO%6(+RW3,@T7PP*%0$E$P($>,G6)X_?8K#J;A+:,27*WMT]O"8Y+Z]6$P+=7
M3%W#2K$T@ B6&+2EE<QEW+4 R^&SUV='"H+-Z)-!DL@%$01::Z"H&PM8J?<+
M*9D&J=LB07EF!IR1$C1GI+@J2?-/UJ9%7"E!G2<IQMUU:DY1W5Y8XY'K]7-$
M@GOK#$=$19K#=X>L2120JS,%$JP0K<(P=9A&H( !SFB.WMRVYG//=Z RW5+*
MCTR42J6T-?WCEXME[$'R%B<MMN.Q"1@S+F456N8T4OY&)&P5CP]54J*+C0(0
M]6)BWR<]V?/ES)$CJW7**]N;6:Q$-E:V4T$=N+6U@:.*)4O1?L\6G+(XDFN0
M&E:1Y!H 1QB.-45:  <^K+X>O6ZL4*Z1M3AX( ?#<M/D];":7KX[QIF.M>8&
MA]CE=I4;,A6!J?&OKLQB6@VXG#>" SQ41E$-U&9*N27E3BDSSR/S;2N)L7GD
MRA8#3QNPBPV]T1K#DO-X4,().KDS8EP=$31&>>W/9\AZ/^-E1ZF]$>GJ.4BE
MQ4ZZ29<,[1S\=1 H%5G,K7EIL=OK+<U^#78,LMEHM:C'G(H8DD+";8>:\[F9
MDEE$GG8N^6&*WD;12)9JCP7L#".*8>S?VUO:W!17N'6+.*UAU<4*QV\+*=5"
MBL5IH@',9]_P\/$]65G6C1 FQ;-5MB#>]DTVS2*Q6Z@58IYL- #FP55-V$^)
MB%81.NEWG<HFV@PA]R-+BJ=C2$M8\!2,.9\VVQJ6WP[]V/9X?=VRW-Q=QF[A
ME>6&>YA@@E:-XYX@,TMHB RMDRY[<\JN0S)XY=/"JN$]#6BPM'ONO8,6PLUJ
M^1 T#+<><*'D*G#K9]ZT5Y%5*B@< @W-"GG69\$Y87[%8>T>,C2"TB&/BQV_
M2EY9XU->65^[P&XLGEDS*2.ET]Q +:<W44DSQE)H R/# L$'\25EB5Y&8S1'
M7Y<<N&?#=EN K,S.C72DBZO7:*,)")4FMP*U($"W [0ER.'H;NM DUM^2%E6
M&'($4Y489$@0#T6OO/#!9(@$FDH+,O'$G*W&%M%M&DCE5+A[A9I1*90TM\,1
MF0A9E@=9KO2D=WA:<"66-)DC<K5R[?7;T].9V]>6RN=4NDS5U-V/4MGC9%FE
M6"CUR)6:TV3FAY+,"#$I<*@X\,HV"CVJ9%=K\%&<UV98WZ=%+O/G!U;@EE-R
MV^.ZY3XE=X?=8=(MNL%Y</<W!C252[O>/?;(S,ULC"=S_'2W6[:("&2X>+21
MIHC,';F,_G\.LUL[SYVM5?VNOO;;_P"N2_\ YD<\F\_ZQ_M7PKMP_P @[34Z
MYU:Y:<4JIM[_ (&]D_)(M^CYY5WCM'C67_E/P\14OHWWG5G_  4?^CHX;>>T
M^-5=P[!X5BJ5]VMG_+]O]@:)P=R]GW-!O;M^PJ?\E6G%*^3[#4EAZ,^GPV9#
M3C#R.U2?#:=1EMQ/A(RE2?"0K..U*DJQV]J<XSV9Y02""-A!!!ZQM%0@$$'<
M1D>PU%^XM5^*L?/2'UOG/SJ?\3Z4_36-5'[OS;SIW%JOQ5CYZ0^M\<ZG_$^E
M/TTU4?N_-O.G<6J_%6/GI#ZWQSJ?\3Z4_3351^[\V\Z=Q:K\58^>D/K?'.I_
MQ/I3]--5'[OS;SIW%JOQ5CYZ0^M\<ZG_ !/I3]--5'[OS;SIW%JOQ5CYZ0^M
M\<ZG_$^E/TTU4?N_-O.G<6J_%6/GI#ZWQSJ?\3Z4_3351^[\V\Z=Q:K\58^>
MD/K?'.I_Q/I3]--5'[OS;SIW%JOQ5CYZ0^M\<ZG_ !/I3]--5'[OS;SIW%JO
MQ5CYZ0^M\<ZG_$^E/TTU4?N_-O.G<6J_%6/GI#ZWQSJ?\3Z4_3351^[\V\Z=
MQ:K\58^>D/K?'.I_Q/I3]--5'[OS;SIW%JOQ5CYZ0^M\<ZG_ !/I3]--5'[O
MS;SIW%JOQ5CYZ0^M\<ZG_$^E/TTU4?N_-O.G<6J_%6/GI#ZWQSJ?\3Z4_335
M1^[\V\Z=Q:K\58^>D/K?'.I_Q/I3]--5'[OS;SIW%JOQ5CYZ0^M\<ZG_ !/I
M3]--5'[OS;SIW%JOQ5CYZ0^M\<ZG_$^E/TTU4?N_-O.G<6J_%6/GI#ZWQSJ?
M\3Z4_3351^[\V\Z=Q:K\58^>D/K?'.I_Q/I3]--5'[OS;SIW%JOQ5CYZ0^M\
M<ZG_ !/I3]--5'[OS;SIW%JOQ5CYZ0^M\<ZG_$^E/TTU4?N_-O.G<6J_%6/G
MI#ZWQSJ?\3Z4_3351^[\V\Z=Q:K\58^>D/K?'.I_Q/I3]--5'[OS;SIW%JOQ
M5CYZ0^M\<ZG_ !/I3]--5'[OS;SIW%JOQ5CYZ0^M\<ZG_$^E/TTU4?N_-O.G
M<6J_%6/GI#ZWQSJ?\3Z4_3351^[\V\Z=Q:K\58^>D/K?'.I_Q/I3]--5'[OS
M;SJ6\Z]<E.*4XI5*[K_HVN/QI5[]4V+FE_J_M/VK+?T_W#[U=*?>Q_=C_3F:
MU7GBE.*5!D_A*=^1#7Z]<Y>@]H\&J=([#XK4YY*M.*4XI4;F5&NSY+TR6.P]
M)?5X;KGE4U'AJ[,)[? ;DH0GW$XQV)3C'N>]SF6XF10JODHV :*'+O4FL&-"
M22N9._:?.N-W%JOQ5CYZ0^M\USJ?\3Z4_34U4?N_-O.G<6J_%6/GI#ZWQSJ?
M\3Z4_3351^[\V\Z=Q:K\58^>D/K?'.I_Q/I3]--5'[OS;SIW%JOQ5CYZ0^M\
M<ZG_ !/I3]--5'[OS;SIW%JOQ5CYZ0^M\<ZG_$^E/TTU4?N_-O.G<6J_%6/G
MI#ZWQSJ?\3Z4_3351^[\V\Z=Q:K\58^>D/K?'.I_Q/I3]--5'[OS;SIW%JOQ
M5CYZ0^M\<ZG_ !/I3]--5'[OS;SIW%JOQ5CYZ0^M\<ZG_$^E/TTU4?N_-O.G
M<6J_%6/GI#ZWQSJ?\3Z4_3351^[\V\Z=Q:K\58^>D/K?'.I_Q/I3]--5'[OS
M;SIW%JOQ5CYZ0^M\<ZG_ !/I3]--5'[OS;SIW%JOQ5CYZ0^M\<ZG_$^E/TTU
M4?N_-O.G<6J_%6/GI#ZWQSJ?\3Z4_3351^[\V\Z=Q:K\58^>D/K?'.I_Q/I3
M]--5'[OS;SIW%JOQ5CYZ0^M\<ZG_ !/I3]--5'[OS;SIW%JOQ5CYZ0^M\<ZG
M_$^E/TTU4?N_-O.G<6J_%6/GI#ZWQSJ?\3Z4_3351^[\V\Z=Q:K\58^>D/K?
M'.I_Q/I3]--5'[OS;SIW%JOQ5CYZ0^M\<ZG_ !/I3]--5'[OS;SIW%JOQ5CY
MZ0^M\<ZG_$^E/TTU4?N_-O.G<6J_%6/GI#ZWQSJ?\3Z4_3351^[\V\Z=Q:K\
M58^>D/K?'.I_Q/I3]--5'[OS;SIW%JOQ5CYZ0^M\<ZG_ !/I3]--5'[OS;SI
MW%JOQ5CYZ0^M\<ZG_$^E/TTU4?N_-O.G<6J_%6/GI#ZWQSJ?\3Z4_3351^[\
MV\Z=Q:K\58^>D/K?'.I_Q/I3]--5'[OS;SK/CAL(3&Q$'L>3Q\+6YAOQCKO8
MM?9E6?"><<7[O9CW/"[,?U8QSB=VD;2<YMEEGD!L'4 !6U4*,@,A\3XUSN8J
MTXI53;W_  -[)^21;]'SRKO':/&LO_*?AXBI?1OO.K/^"C_T='#;SVGQJKN'
M8/"L52ONUL_Y?M_L#1.#N7L^YH-[=OV%3_DJTXI3BE.*4XI3BE.*4XI3BE.*
M5\5R8[?C/#?91XK",N^&ZA/BL.9[$9<[58\#"\^XCPNSPL^YCMXI7T\8C^;_
M #T?S\Y2G^=C^<I/;X24^[[N4^#GMQCMSCLSV^]GBE>W%*<4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4K"3+-6QY@?7I]@"03Y9ER0*!S"L",8)L,N):=?'C'I")LQEI
MU:&G'(S#B$.+2A2L*5C&5*]0]HK-AD&(E?L0(Y*KI)X/8(P<N/)R 9>.I:'Q
M1AF%(?<&$F%H6EZ#-2Q*;4A:5M)RG.,*5G>*4XI3BE.*4XI3BE.*4XI3BE4K
MNO\ HVN/QI5[]4V+FE_J_M/VK+?T_P!P^]72GWL?W8_TYFM5YXI3BE09/X2G
M?D0U^O7.7H/:/!JG2.P^*U.>2K3BE.*4XI3BE.*4XI3BE1FZ'IU6J5DLHROS
M+5/ AB!:-7!TT8-G&G($9R3YOB3C4J"*BR)"6U(:>(3(T5*NSQKR$^[Q2M":
ME[)5J^SA*?)DZTVP$M-PM73;7V:C(#"IV1(OJAE:XB4&XD[7 +NT]RNBY.TJ
MC MF!1HD7#ERD(7YKD/S&%9>-/7?7WMOLCNNZ+IVJ[>M&N-@Q8]OI&VME!JY
M <K!"?,H.I-C436\RU1".3<85*%VZ?LNDGZ8MJ1XTI6#;)20U"RA3')Y^O7W
MV4JZ+MU>:WJY,""!1YMZ,F,&$$\5\C7V@U)E#M.W/=@R-=CA$K&CBE6>IT0^
MD$Y!9+-KE0I2Y^8,6*Z_RTK!USK;UC)JP$U?P%ZU98S5TIVNY&O[#7I!ZU@;
ME;]'U?J#4)-M4OO%!AM5?75F\NMI54S(H-+"&HKDQU;$?,I2J!B>R[=)LO8E
M'I>7-C0P&PZ"]>ZUL(CK^QC@.6FMDT#5J!)L+-A,7&LNNV/8$-S!JP5X=6<#
MADN5YY5B>#254KM'XI3BE.*4XI3BE.*4XI3BE=9I'KLVS3.I"WZ:O_31'D46
M!L"3KNE["U=M"5;CY@I/E],<:FD[A3+IKC5X2JA#[_5/2 Y.77]@7R173X2V
M>.B3JJ%EVQI2I05]D'K-0USIZY7?46R(A[:6C0>Z9U9K+E9)Q:JDQ&@^-J:3
MEK-45VSE!1&6XP:D 0SS=8#--6RZL5:MRFI^)F.G9ZZ\O7PI6$TM[(G!VAN:
M!IX_I&_4N1:+_LZCTVRHD0S8M>=;V7; O,^YQEL!R%:S8 FLVRT!0B/; T0@
M;P&('F,-B"-@M*[)>*4XI3BE.*4XI3BE.*4XI3BE5-O?\#>R?DD6_1\\J[QV
MCQK+_P I^'B*E]&^\ZL_X*/_ $='#;SVGQJKN'8/"L52ONUL_P"7[?[ T3@[
ME[/N:#>W;]A4_P"2K3BE.*4XI3BE.*4XI6OO5%N(QH?25QV16Z\JTV<4V/AU
MD"L'>CL(F=+$8P\?#(,:[K%ML,9F4X_F-$D9%L#7B[PT80+AF2&"4=2I=HW8
M,O;&FM6[.GQ1T&9?Z%5K?)AB%EUBXSU@#Q";C,!1\6$-9BH5(REG!,5"EX1C
M&'6LYQX:U*M3BE=;%W]C>JESL=YLCNS9[<FW; ,[ ;CF=5:=N+3DRQO7IV>'
MODBTTXD0VJ!K'?\ (IU0'NDR6*UED'4,B1\Y%>9;?4]>L\_.LX$Z7:Q5=AZC
MDVG?P(ZG1NT=F;'I=0/5>BC+-#?WT=L#T$+)L+!&/8F&V#=G(#:XX.8&Q;*A
M(\66%&I$&,XA4RW#,]^TY9>CV]==A?%6G%*<4IQ2G%*<4IQ2NL;V3/9>]-=5
M;1Z]-6E-,C&]NPX%N-B+$<@7"="2!-.1JL+KPO2.WX9B#8&?.#<::3?KK4&^
M1J$-RQ8(QR7"9G^/67W^PI79SRTIQ2G%*U0W=TG!-R[,H^XHFS-BZPV/KD!,
MK]3L-&9H!!$".0/#3LR4\'V%1KN$G2WLCLCO^6#WH[<&9)6U'1/3%FQE*SW3
MOTS5?IO1L5NKW"_6AO95[M.PR[%S*"9<,;8+I=+AL"R.A!X0("@0_.=GO)QU
M^2[&D3UBHU>".S'!]=%M,J5LCQ2G%*<4IQ2G%*<4IQ2G%*<4JE=U_P!&UQ^-
M*O?JFQ<TO]7]I^U9;^G^X?>KI3[V/[L?Z<S6J\\4IQ2H,G\)3OR(:_7KG+T'
MM'@U3I'8?%:G/)5IQ2G%*<4IQ2G%*<4IQ2O5:$.H6VXA+C;B5(<;6G"T+0O&
M4K0M*L92I*DYRE258SA6,YQG&<9XI46:HE'9\1XFFU1GR7 ;$;Q5=$-^3XKC
MXJ37L,>!#QXG &2#"2 V&_!P+?#BG8/B'!\13*E8XIJ[6YM8%1>BU0DBK@RE
M8KT:8"'/P1%<-*!N% ,(>Y'S!:#S7*Q777AN(^8?C08EU+*7($93:E<P=KV@
MAZZ.IXBCT\74A&"*1-7'5H+!KHM)>.4B%DC@D:$T,A8*13AJ,1Q&BM8FQS!1
MF3XULA+2\I1[7U&E.D7YM2KQ%TM:QUZ(+*"H9/,BY!Q8@((M'_.#4G#1P2(
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M_"4F7''BL.>%ED;YV\^3D.C14UI:E5'J L8,=9_52Z9JI*IO1-(=)\")%)D
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M$8*,-"8;A))CYAI%>:0:4+@IGK) 0 FEDJ9I'&95.W2A9W$N>B&49EOYMO\
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M()<T34KOL'8M2"'8(J9+>9J:#6JTP!YTGAQX:)E*G9L.QQK$P<5='J6@>D.
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M*4I3A.,8YY+LSLSNS.[L6=W)9F9B2S,Q)+,Q))))))))SKL          9
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MQ2G%*<4IQ2G%*<4IQ2JFWO\ @;V3\DBWZ/GE7>.T>-9?^4_#Q%2^C?>=6?\
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M&9XGO-,AP'<*=QJ=Z,A?S?'^AQF>)[S3(<!W"G<:G>C(7\WQ_H<9GB>\TR'
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%Y*M?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g609070g43a95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g43a95.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1.64&AO=&]S:&]P(#,N,  X0DE-! 0
M    $WJ^288X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 )3,S  !  $ E,S,
M  $  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))301$       0     @
M D    )      #A"24T$'@      !      X0DE-!!H      T$    &
M          !F   "E     8 4@!I &0 90!R #$    !
M          $              I0   !F                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   !F     %)G:'1L;VYG   "E     9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG    9@    !29VAT;&]N9P   I0    #=7)L5$585     $
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M!!$       $! #A"24T$%       !     (X0DE-! P     ".H    !
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M" D*"Q   00! P($ @4'!@@% PPS 0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                      #_X43O
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X]
M(N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M
M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!8
M35 @0V]R92 W+C(M8S P," Q,38N9&5E,V$W-RP@,C R,B\P.2\P,2TQ,SHU
M-SHP." @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O
M=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(@H@(" @
M(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @
M(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS.G!H;W1O
M<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(*(" @
M(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O(@H@(" @(" @(" @("!X;6QN<SIT:69F/2)H='1P.B\O;G,N861O8F4N
M8V]M+W1I9F8O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z97AI9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]E>&EF+S$N,"\B/@H@(" @(" @(" \9&,Z9F]R;6%T
M/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @(" @/'AM<$U-.DEN<W1A
M;F-E240^>&UP+FEI9#HX,V0R-F5C.2UB96$T+3!E-#,M8F5E82TY939A-3)F
M9&0P-#$\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$;V-U
M;65N=$E$/F%D;V)E.F1O8VED.G!H;W1O<VAO<#IA,64X8V(W9BTQ-F0Y+38T
M-#,M8F(X,2TQ8V%B938W860Y9C8\+WAM<$U-.D1O8W5M96YT240^"B @(" @
M(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^-$(S,3 X.45"-3!!-4,V
M.$)#0D(T.3<W.#8X,#E!.#0\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*
M(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N
M8V5)1#YX;7 N:6ED.C%E-F,P9#DV+34V-S@M,V$T9"UB-#$R+6(U,S Q.3@Q
M931D9CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.G=H96X^,C R,RTP.2TP.%0P.#HT.#HU,BTP-SHP,#PO<W1%=G0Z=VAE
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O
M8F4@4&AO=&]S:&]P(#(S+C4@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G
M96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V
M=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R
M;VT@:6UA9V4O:G!E9R!T;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S
M:&]P/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R
M86UE=&5R<SYC;VYV97)T960@9G)O;2!I;6%G92]J<&5G('1O(&%P<&QI8V%T
M:6]N+W9N9"YA9&]B92YP:&]T;W-H;W \+W-T179T.G!A<F%M971E<G,^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C-D86%D.3DW+34Q
M-C$M-F0T9"UA,C=D+35B-S8S-F1E8SDP83PO<W1%=G0Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,RTP.2TP.%0P.#HT
M.#HU,BTP-SHP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(S+C4@*%=I;F1O
M=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.FEN<W1A;F-E240^>&UP+FEI9#HS,V(P,F)A,RTR939C+34Q-#,M.3<X
M9"TU9&$Y93 W,3EF8V0\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IW:&5N/C(P,C,M,#DM,#A4,#@Z-#DZ,30M,#<Z,# \
M+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R
M94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,RXU("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R
M86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @
M=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO
M=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A
M;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HX
M,V0R-F5C.2UB96$T+3!E-#,M8F5E82TY939A-3)F9&0P-#$\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C,M
M,#DM,#A4,#@Z-#DZ,30M,#<Z,# \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R
M,RXU("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*
M(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R
M:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C,S8C R8F$S+3)E-F,M-3$T
M,RTY-SAD+35D83EE,#<Q.69C9#PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HS9&%A9#DY-RTU,38Q
M+39D-&0M83(W9"TU8C<V,S9D96,Y,&$\+W-T4F5F.F1O8W5M96YT240^"B @
M(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^-$(S,3 X.45"
M-3!!-4,V.$)#0D(T.3<W.#8X,#E!.#0\+W-T4F5F.F]R:6=I;F%L1&]C=6UE
M;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @
M/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*
M(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C,M,#DM,#A4,#@Z-#(Z,34M
M,#<Z,# \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A
M=&4^,C R,RTP.2TP.%0P.#HT.3HQ-"TP-SHP,#PO>&UP.DUO9&EF>41A=&4^
M"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C,M,#DM,#A4,#@Z-#DZ
M,30M,#<Z,# \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z0W)E
M871O<E1O;VP^061O8F4@4&AO=&]S:&]P(#(S+C4@*%=I;F1O=W,I/"]X;7 Z
M0W)E871O<E1O;VP^"B @(" @(" @(#QT:69F.DEM86=E5VED=&@^-C4Y.3PO
M=&EF9CI);6%G95=I9'1H/@H@(" @(" @(" \=&EF9CI);6%G94QE;F=T:#XY
M-S@\+W1I9F8Z26UA9V5,96YG=&@^"B @(" @(" @(#QT:69F.D)I='-097)3
M86UP;&4^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \
M<F1F.FQI/C@\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3XX/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^.#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO=&EF9CI":71S4&5R4V%M
M<&QE/@H@(" @(" @(" \=&EF9CI0:&]T;VUE=')I8TEN=&5R<')E=&%T:6]N
M/C(\+W1I9F8Z4&AO=&]M971R:6-);G1E<G!R971A=&EO;CX*(" @(" @(" @
M/'1I9F8Z3W)I96YT871I;VX^,3PO=&EF9CI/<FEE;G1A=&EO;CX*(" @(" @
M(" @/'1I9F8Z4V%M<&QE<U!E<E!I>&5L/C,\+W1I9F8Z4V%M<&QE<U!E<E!I
M>&5L/@H@(" @(" @(" \=&EF9CI84F5S;VQU=&EO;CXS,# P,# P+S$P,# P
M/"]T:69F.EA297-O;'5T:6]N/@H@(" @(" @(" \=&EF9CI94F5S;VQU=&EO
M;CXS,# P,# P+S$P,# P/"]T:69F.EE297-O;'5T:6]N/@H@(" @(" @(" \
M=&EF9CI297-O;'5T:6]N56YI=#XR/"]T:69F.E)E<V]L=71I;VY5;FET/@H@
M(" @(" @(" \97AI9CI%>&EF5F5R<VEO;CXP,C,Q/"]E>&EF.D5X:69697)S
M:6]N/@H@(" @(" @(" \97AI9CI#;VQO<E-P86-E/C8U-3,U/"]E>&EF.D-O
M;&]R4W!A8V4^"B @(" @(" @(#QE>&EF.E!I>&5L6$1I;65N<VEO;CXV-C \
M+V5X:68Z4&EX96Q81&EM96YS:6]N/@H@(" @(" @(" \97AI9CI0:7AE;%E$
M:6UE;G-I;VX^,3 R/"]E>&EF.E!I>&5L641I;65N<VEO;CX*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0]
M(G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_P  1"  A -,# 1$  A$! Q$!_\0 '@   @(" P$!
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MI%;Q6G*D-([92GC97=79XHI<,LHB X98\A_>?>^?TD(TJ]3[Q_<##3LL&\;
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M.-M/K<;0M65I3A6<YZT70O14=9<;X*RCI:L1T-*8UJJ>&H5"U0P8HLR.%)
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M[D&25WE9W9ZJA0%&3CM)R3[Y/[#N &J?TSN/1N_>YQ=MM\NK:N,T1!;&M"V
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MNE?!#44TJR02=V,J1G.\I.=Y<;I4@%7!!P<X<AQ@XQ:NXEZHA=3ZLBO1P _
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MW@SAS]?_ "+^[#7?YJ>JD]>O:KW/V?\ Q6X_ZKIQX+'Y3^E?JZGO!G#GZ_\
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M_P!MZ]\+/D#TG_#4_3$%W_@STG[ZDO\ D=T>L51?\P5W]%Q?K>CPL^0/2?\
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@6]L'VS-\0?SB:-:+@?G2)_$]\H=ZW$_MK^<?,-&O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g609070g47p47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g47p47.jpg
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M86)C@<'1&28T-5ATL[6VM]0G0S)%<W6%LK3_Q  < 0$  P$! 0$!
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M<?EYYYYY_+SSU_6W_P -MDV6YR)P-[FS;.[LFW2SV;;,8Q/;0)9E),  "3P
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MI'C?NE 0RC%?O-7ODN27X,3,<\1CG*_R]R)!+R1VGSSV=L\(X_!23K'7_/\
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M_$+NO]6H?ZN=.9_OCY/>G'?N*G.&YY QO]C_ 'Q3\?!7XA=U_JU#_5SIS/\
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MA%+EE3+!R%$H.L\1W!]RK;AAGP@B009@@@P2#KIH000>P@@CB"#0&"#IH9U
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M\G/7JB2 2() D=A[*\\Z$QJ),&N]Q^?_ +,O]G/0\/C7]XJ*XZFE.E*TT[?
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M&]!!#J"#((1@01V$7)J#D((*L0=""P^I7;$B1X$6-!A* X.%#4*8H0(%T8:
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M5:62"Q#)A+%)G'GCES89R 0]L@B00A(([01<@BJG*"05<$:$%@"#V$%-*^4
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M7BYX2?-M]I593P6^4/J5SQQ)Y?\ ^/#\W/\ ^WE_FY_ZSJ"+GA)Q'XC=H_\
MF4E/!;Y0^I7'DD_2P^3R^TZF+GA)\VWVE)3P6^4/J4\DGZ6'R>7VG2+GA)\V
MWVE)3P6^4/J5$6=_1TK&SFY/*<I84P9!GMYL["( XU5H3=%C2K#9R*D:G$ ,
M81-A:! M+SC0I72XNK9L1SWZD<M68K.:[:6 6.92(4$ L9NC0$@$\)('75@H
M;O;=QI,"#.I!(&B<2 3'& >RN@ V?K-R3[[XK;&U^UH-",GR3<P#4 .)].(3
M%S*9YOL0XI:"UXQD'&4A/W1<PQI1<<YVO1X>7GJ ^92XNV603+!941QEA=C3
MKUTH5*L%-NXK&(4F&UX0"DZ]58! V?HTK-:UQK#9>IS%O7(G@<024IQ52U])
M"K><(+FJ2 !C%FX H!)8H!$F%VM5AH381TI/12\8Q]0CKWB7K!R""JB2H734
M"Z2 .&O#A4NK#IO;NC,=&;0,3KH3; )/'S\:DIG9>NUQ.J[%8=AHH+7UZH*(
M47HRS@Q:=<H'<() EVJSWB< 2Q4,QVJV8JS#>SA(86(,JF<W$L?.5BY50YNV
M0A (<K"D'@0QNP0>K77JJ LL4%NX6$@J#+ CB"H2=.O33KKOA<E(L6,LJ]96
MRAF:L%73QH/-2OW>:@NO88U\(2N4[$TF$-*HYV3HP?/GCC'6:,R=>+B(OQ/.
M4$DLKVB3 9@A)T$@$BYV-('8T]="8 5E<#4@%@!J8) R=H@GS1U5*/))^EA\
MGE]IU:+GA)\VWVE5E/!;Y0^I7/DD\G']O#\_/_[>7_-_UG41<D]). _$;M/_
M ,RDIX+?*'U*X\DGZ6'R>7VG4Q<\)/FV^TI*>"WRA]2GDD_2P^3R^TZ1<\)/
MFV^TI*>"WRA]2JDM[^T90,K"Y?W=J&DPNV(_-, V]B)]8RW8%C%I>%9K N8[
MA>/XDS]*Z#'Y"H+?%TQ4M#*W,EVO+!AGO5! -^P"T91I+28$#>R9(($<3IQJ
MXML02+5TA9S$20L"3)W<" 03/49KM; >M.:_N"F7:3SK-%O!H;,8<Z]LRXJS
MT*A_+"G;@J$#Q2AE'3,S#H(IZ^$ON:_:&5<LXY;(^OE =@A#7+ME")REQEC-
MH8FZ-#'ZO-15+ A+=U@>(4YN'P6SPG]?GKN MOZI:2P4 L[3UNQ'6->C;EX*
M"<ULN6/*<W,N,+.%&CR]BX47I<H)N(S5&&<;)S#+QC9YYCS\DBYF(5;UEBPS
M* ))7P@!=DC0ZC32H*%02;=P '*23 #=A)30ZC3C6</LBA0DD7V5F61EDD)L
MV\A)8Q0&W;820@-7K5V.M9OU[68_Q8^&"R78L?0X%#(NAZ;&X0IQ2RQ(Z+7+
M0D'0J02LA2?ZT&)8">T@<2*@ '4(Y@\00=8)\#L!/P G@#6>'CJ@FA1%"JE$
M:,&4ZP\<.H4XZE&A0I0X5J=*E4K\QP5:E6O''!6KP1X0P0QX11X8X8XX\2%<
M  ,@    MM  T _K.JH)4DDAB29)SC4G_P E5;O[B3\1VW?+EAY/Q<./E_L9
M<?D\!O>7R<^DY\G/D_-SY.?)^?R<_FZ]SDV'YP8)+(1^%-AD!"#_ *S;Z]X8
M]!KQ^4)7\!8Q :?P;MG%@?\ 9[G5E'[ZXU#_ ,)M/_6VS?\ RM>ZKBG]1@G^
M!['_ /Z[34X9_68O_C.V?_A8JX>O)KU:UZ+ZFL,7<FK;0,!@$BOK[7):)5M<
M15.3,^SFTGP)*FKN/%;BUEDM(0K$(O79+6>$-=W::T4..67$F-PT(5!,LPGL
MRK) 'PDDG_PKV50K+AB!"J8T$YB1KVZ 0.R3VUIP\=LV]*VS=WL:A0.E$?86
M\QFR[Z^ [A'?6!9["6.WL8@#:D1L->QOJ5G7NU!.;+>'UK%"BTKUI>J\37ZJ
M(OK,6@N(50,!*H5DVT8*=Z6F#$YD)':"3UL6K-DN!F*R59@3%QE)&2.T05<2
M1,,($D "LIW,]K.\-N:&TTEXE*#CN0)J)HU(_P"PK#*&$!\[VQ$%?7G%LN!F
M1"9I#PVXR+U(O8O@95-[&UX,_>[-'.9NXT%NXB.QB$SAU6"2 K$J <RP0I(@
MY@3QT&JY;9E4=\P4HS$@=\H#&,ITD=4$=0UBO2L94S'C1]"6S+=DI4:E22Y/
M_P /;SK01PYV9ORY?X6?+#F63^UE_;SY_+S^?K"M^'G\_;^^N[TI3I2G2E.E
M*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*IG?J6V;!
MUO(III8H%*$'K4-HD0"M!E,*XI83;J,>V-4H,B];H&AM@EKX8SC</#;M2S<]
MU\C\+$7%KG/C*\K/;*J2"6MDPQ4Y1<4N P((E PT(F8K2TRHX9@" K@2 PS%
M&"F#(,,0>&D36OA'6NPD_2VOUX],;:*B3W;\N1.A,=..Y>72OK0-+%JN.R7+
MV"!J[4U<G%=9M-^*];MSA@R!9HXS6<AL6,N+6V6T@:6";0&(DL=WOV*2222$
M4HQDF IXQ6@=6N,5@%K&4$ *,^Y4/   !8AU$1);3C4-@[=-J:NW;1<=*"X:
M"3*ZA EF@8/"S]JHDD[NK;.P37&;'8RL!U4@G 2B.'6EW"PW!&#6.MS VQX
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M0[;BZW"H;=-R@Q,7%E0T,HVTP0IDQ(C4$C6J["N/88<EV!9K]RQ>JI:WL(]
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M9O2\0T:/HJ(D35FMR4P(*CAQ1  ZXX+3YRK4(LN:;1>.T7[EXJJ&XV;*O :
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MD!'$,2K".T$=58T-WH=J3%[U.0>_-:%<'DE7$*4M)BK30'2-RT*'T:U*?'_
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MIE)4[H^&U0M#5MB(5[4E,$5GJ.XMK+*G<]W,ZEU!0@E05!.O""Z @P0741+
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M3::OGIG$E ":*RB8\*8-AY+,KJ<A<)5G%^LS&;2S'<YI6&;W#Q9,&>;L)&'
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M4Y9V:Q/!9F<^VOAI8G*!9'&*&L^V#;Y+?J:+Q]Z*J'S?G0XZXTDTXUN5[&Y
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M+JDMER\=<X)43$!F )"DYB 2!&M199[S]!M8I2K#257#9;ZJ+[$HZILXV,&
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M=@[*=HA!U,1F8/P*VGMJOO%CU]#$SZ(,W:"O7V5R:,B#8R]2V52H-1\!F^V
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MR@OYOM7V%/6KT#\85;]PM?\ (NG,[E+Y+N?/[)[13G3@/E!?S?:OL*XY[J]
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M=57:+@:'"%1<M(S)F@/=9DW:DDYC;?=AG$ AF&566*DV4RRI<,4N.JO )6V
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M7"(XI:9DX>.%*S!1+C"=,H#- APJA4'$P5P;=@A@\G$W/,L_,GD"[<!!"7!
M(&MN(,R(+P09,@Z&=:]8VT,RRF2">_XB #WNA '575_$'IOF478YUN YLA-9
ME=."K7,&7NJEK,YQ6X+*,5GW5Z?D?>]R1\S39R9W_.DMY8V\<KUWFPWMS7H7
M-6S'I6^^UU_K//\ !P[!#=IVIWI7@_>GB.]Z_3Z36$C[7] 1G+K%QJA<S)D
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M+/\ 7']IUOF;\F_IM_:5E \-?0_U:J#N#RY_$+NS_!Y\?_I)L;\O/.'DX_\
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M#()H)+56T;AYWVE$8JRW 9A>B.FV94A):>_=5!8*IF0Q4$C9;#. 0R=6;4]
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MTGAH "2= ":IU8[I=7-A#30@7BU\%MX9M,*M4E6;LM,1:3!K??/U&EEH975
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M[LA@#U074'0: 91I61O2[W,H#.+@.I@9P5D:3(4D22229)FI_K]"*@MA[KV
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M?PI@48KR*!)LE382_P!KM3M+!EC313M!N#:+!KP?18K^O,0P[*]L"#@S U4
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MX<>"]4B?AKD9L!%-G,5@,\)Q=ES7Z39@O#&(/?.9*Q+T7AS+B)J$);^2_?\
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M,&!9MZ862]L]18")P)-?'WY+%RE;ECG-:9E"VTAKG2E$G(5MCHL1"P=X0 5
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MNW7NV<+^P1I L7(C3!]JO&;A[;EX\E;!'R]Q&OGO3L:)K<C:E$ZDFUAJL"=
MLN0^@"S/E<\(I,W"2[B;HU#VP!H)R@"% *G=,KYF !?,Y!$YH'@G2KE+I+ D
MP<W%R5(S@IE4SD(40T1)\*21'MBZ^[OTH+LQO,N&PJH6G9*V7VZ)VSL%C_&P
M**]R*&?6JNGUA/JFSO;SP&T/6<=?GC2N%6XQMM@K%B4ENB M;!'@ULE0%63
M4E5&6+; ERQBX-X58!I)@B=0M0PN ,22.V&8YIN @( #DZ$J8 X^;-6*UYKK
MNRV"G</(0ELF(#=O/@Z$"P;><A#\P:YI]X,3+645]_9+(IR%V3VBQ-L$G["M
M3 [ED78H^A,!JY:(K!)-M6CH\%DA%RA]U&8J 5T<@E8(D&0Q$& +S2Q+02P
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MH R,%!WIML#=WC,3;8HQN92;H)&4DDFMQM%K-FU']22&!/\ 5AP1;R !74,
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M%+WK'$_;*>J9H?X*GOI+VE]].G/'E#X[8]685[#3FI@7BE[UCB?ME/5,T/\
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M+P&>Y.VN8%EOD:1:S)<M;QA%>W<:U?+6U=1&T0D';&VH ID*F5;=-FS !$9
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ML<P3*I/57#FIFI=2_.O)Q B)3@S3IM98*=9=O!S7NXYL&.P:L#]@-5$DI/5
M_P#?K^'Z!V"K3T8IC]3:V&*5\U7*'[A]]?G$C2JWHAEW8&VM@-&UMAV0T$\'
M%BJ!F>'1@S T['.5BF'YHU;$DDT.<F2H/\_%PJW/'Q/M?\"S]CTI3Q\3[7_
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M 94 3DLQ>Y20AA8W-^F:]A-X? K4:W(]>Y$61RD^8=?Z]#^KLBMV/'Q/M?\
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MPKX;,7][*%->.2B9536XKNR:A1SN38TK(2FT7,@TM649=@7JSTWMB\!8[$%
M+07UOGBE45(/#3@0?.8X>;]5;UQFPL4>$45C'".+#&./#&O9XQPPPQXQPPQX
MXA\G&../''''''YN./)TJM?"^=%9T;F&-KRY95+&./'H+/'EYRASXXX\O,/'
/''EYY_/SSQQ_GZ4X5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g609070g52a52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g52a52.jpg
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M P$! 0            8'" D* P0% @$+_\0 5!    8" 0$!"0@-"P,#! ,
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MT3;.<T:Q>&C6!)#3=;S-#5\C(WL9"XS0B>*(5-.)Y(G-+PYL)D$COD@FP;?
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M1LM#M-DI-PAWD!:JA-25=LD*^*0'<3,Q#Q6/D6+@4CJ(F.W=HJ)=]15506Z
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MS=6HN=LU7=KMVR!!,JZ<)-4 $0*4ZZQRIID$YA A1$QR]1,8 * ]1$ \^0D
M$G  $D\0Q*H!) &^;#E]RIMM'6=PTWL&V:OO\<C$W.DRRL)8HUN_92B#.113
M35413D(U=RQ=E BI!!5LNJD/40 XB ].&FJ8:RGBJJ=Q?#.P21N+7-):<B6N
M <.0@%<M1!+3324\S0V6)Q8]H<' .&-M9I(.>8)4"[)NSVN@]GJ)>UT'L]H
M 1#K[W4 $!$/?Z" YSKA4NO5(F=>6N8ILZO!O):#%H#UQ6+#"VV#/X:P:2*)
MF5@KCV2AI A4'J":YV;U8K=V"S-<2.4%DB<4$S*B)DT8D#'WL)8WQ/&JXM.M
M'(UKVXM-K@7%B+@@KDEB=#(Z)Y87,M<QO9(S$!PL]A<TX$7L38X'$$+MV;7%
MLJ56U]=9ABD6L;/B9J7ITNU=MW;9^2N6!]69^/<=X.92/F(B48_^NBWA$7:;
M%_$294SL)9@X7QCJ(I9:B%CCNM,]C)F$$%NZ1MEC<+X.8]KODN%QK->WQF.
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M,#)U6*9+W*PUEWK).!*#)NFV*D93EJ=%:1DEF)I99:R;\G&@TG\8B#=&B".
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MR0FO]05RIT&A*[(8K2%ZJUOAU%XN]ZGN-'G-6Q+EJP*_F+!NS7VRZ_8+K(E
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M5[@MUZSV/:.9'(.48R-MT[QJWRXY8<>MA+UF79U6T["D:2I0VFKUI6>81RC
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MM'*T9%=O'CHK5N": .73E<$^^KJF/!W?Q-UBW1!:7.UG$5C1K.L!K.M28NL
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M7FPBXR/F2IR)I/&JBBIG!$TR.$CG4.U,!712$*<3',V,8I7!2@(HF$ 4 HB
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M=17<]W)R;/W0\M"V8.FTMT&TTILP%ZP.HS<12+EU,>8*A[J?=F,@7<!3;)*
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M]+KK^RQKEU*33:+082DVC$A'U9Q&R!G#A26&) O<-( O87OQWMAMW\5+G"Y
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M"@ ] I%B1L-E ;@':+KT\BJ81,(F$3")A$PB81,(@@ @(" " AT$!\X" ^^
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M*M[-CE(VXJ5Q-M!2\HDJL1<RZDDT;=].\[X3J#I<JZ@=I0.O],W6@D6XLE"
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M=Y38DT% R9UM@69495I$&31".+)B<7Q61440:HKI-S-VJB1VJ-=F>;J'+UE
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M]\\;/5RU_2/<L\<?"5]=]/\ [>E_ 4BW8_$;R+(;GPRS3")A$PB81:&?=/\
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M+7:'< ,[.2N6.KGS7)RMO7L!LN-["^]C<7RQ._M]ML/^[ Y6,Q6281=1_P#
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MVV:LIG7])EV;%P5XQ:2=4@G[9F[*Q:19735!TP52;N"QC!C'%71(14&+)HT
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/"E*&*R7H81,(F$3"+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g609070g52b52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g52b52.jpg
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M(U9J/)TX2E><8M.I*;6=G>4FXH)2<L[N_#>[O8EOXW/I!TE?^Q@3_P#K)_\
M^8+Y^?>5'_:];_TJ'_MHYJW[;]2.E^?/&H< < < < < < < < < < < < <
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M7 G7<*]?\2[9_HX8_P#)\X_QV"_C,+\Q2_G+KP_>C\2[QW"O7_$NV?Z.&/\
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MNO\ T]=SH"F]1XJYR-=-09,YEG9@VY2PC^2,&5D:7IZQ4I^F6-B(\ZZ&NSX
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M,8_HX!O. . . . 5CW6+^S9^>C@#NL7]FS\]' '=8O[-GYZ. .ZQ?V;/ST<
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M!4X<C*ITR7(DFB1LDIQI,_$9@0M+NL7]FS\]' '=8O[-GYZ. .ZQ?V;/ST<
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M6W':!_HOJBXN"#@#@#@#@#@#@'$TS:VXZ[KKJ(G68F'DV.K[_K^L*391516
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M$B++,(6H5WY&#[<,DQ7@]WC+^OVR.Z^"#@#@#@#@#@#@#@$%[Y+^'I^JSX'
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M?)?P]/U6? X [Y+^'I^JSX' '?)?P]/U6? X [Y+^'I^JSX' '?)?P]/U6?
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M7?)?P]/U6? X [Y+^'I^JSX' '?)?P]/U6? X!J3-C#' YH,?""BH$B.GBK
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MB9ZPO" TM^?V\+=62\=?B_>51TW=-^TM<;88V[@+7(=?L="K0E0&R$A[5VK
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MIILQ6*O"A5RYSDC1N9]^O6UY<+9$V6^Q)ED(=(?G'"\VP*EO3!/'CV?ZG<O
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M@#@#@&#VF-^(P?JX_B< =IC?B,'ZN/XG ':8WXC!^KC^)P!VF-^(P?JX_B<
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M[IN#0FK+Q:TGF+$)F3ZZ^/'BA@(Z?%$PUG:WOZ\FE[DW;<2K1OX?G2_T\[6
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MKSH^>VVE2X<E+0%D\ < < < < < < < < < < RI'^\P?^BK_P"VS. 8O '
M' ' ' ' ' ' ' ' ,J;_ (W(_P YG_NX!B\ < < < < < < < < < RF_P#%
M)7^<C?\ C< Q> . . . . . . . . . 6=5O^"&_\\__ -?@$BX X X X!1_
M /C]O/\ "9K^[K=M&ZSML20-HVI=-AV,_;(X.VE+%)KFP**UK1S7Q$65V?(U
M?.K(.F!Z,/&NM:S@F'I>MJ1+(DIC8M^+,&:E96MPX;G?@W]=[M8W0#\-6]A+
MWIK8[W4H-(VG2)*=-KDP?T_:XUPDY FDWC/=>TYTR_K21(J""<J9*FUP'( #
MK+F;):N+=C86EI FLL\GG;??9PNGXV&+M;\+$5N&X;9V#9[S18-ZW87O#^P+
M?7-4G!-B+4[8W3I3^F>WZG46SMB3,<UB1I]$K5NB@9SLT@%V;!S< 9D:IY8_
M(NM:VW+9FLFFVG:UKW;]CL5ZU^$;9'#XM)?J%"&*&P(J/>RI_DP, ?FI9Z=O
MJS=0X<SL"33K96EQ4#]@EPQ2/C7#NOY4_%=B03SQ8=,,QRP:RO>SO:VW8K6R
MRX$PKWX5<X+!L+!3>T:XD[/I[9NB"MBLVLUM&%:TV7J_5>FUAH[=7OE:"1I=
M,U]I^IAJB9:#X+.O/&REREW H2];8!RZFO4^MOAQ9K!'X3A@%9"EX%]1N(VP
M)5I WP-?,:;JJ[+4;V/.C[/9K4 <<,J&27MC'X+A.Y5RT#+)2(SL^0S1ZM3(
M<0-&%B:RRR=E?*_'V;MQ92OPXRRJYTM5?.V:QV9TB4BF4#5N<ZS/JDS@=%V_
MTP[L"NW!U>V%)+D5V_I+UC&G21S85IX).MT1J/'FE!I$*+K;<G^9MO-;6I+A
M_M,\K'^'5>C5*Z?J,+Z@J[5A_39(.R]>D8G3[1;D47-.RX4M9(GC;938XF&9
M%JAK8"GJD)JQT?%($HZ"2VY:L)$UEGD\]N=OLE]2TK3T@[/N6^:MOX]N>DS#
M--BS% *.YIJ8Y0(MAG4:ZZTD6UYA[9[MREDG*+L&TU]X!(NCE DXFL&9=,?L
M<"$98"ZLTD\]]_;PLU=%4@/PW#H4!O\ JTO= >QU[J4U?&U=LP:;U[94HDPW
M*HY6+);!DD-ML1-C7.ZRY12Z60G,DD(&+U8;3808H*JT'XQ +[,MFRVWWM/)
M;EPVW)EJ/H;V-J"YGMEP-[5RZ;(M@+8 BXW&\:EEJF6V;L8[4CINP%A--V33
M:R/+1L4:L!AC-7!5X''#CE>G"RBLJ65?!M/*SW;^%^KK9R=5OP;;1"UKKNCV
MWJL*V"=3JQJVM%9K.MH,82?%:BH]*IE#KLFO)LR 3H>D-TQJ=4+ Z)QLJ$^9
M/I(7DA'+28V!=99_EVWW\=KV7_3J-]9_P<(5O4XZ<WJQ-?S$2"97+U.)(QF*
M0NP]11XAK]0DM:" ,A6BS74WL$"0EF!A*W=BCZKZG:(9@>4+FA-96M9^_P!6
M>S;E]RSI_P"&.5E%AYV'NL,&+#+H>O$25 U6])1@E9^H7:_4@?@/03>PC Z4
M()V[<]XK3L>3#=E,TF5 AQ)L>QP46A8:RWIOV]26Y7V*UKVZC;4'\..SZ^T.
MYT\0MYBC5%5N;6N[XKIG5\R/."V/5%OUE=JG7*N)K.QZ[1ZA04&=4UU9"J56
MGAHDM1&T$DNL'[#-,Y!R3=[;FMO&^;RS>>UF: _#RN-3T[=M+5+?4&K@KR$T
M0!(6(+KHQ'MPZ#T]476VNJ6@9+=V>^#=8,UG5H"%>A1L 9 VN.0L8R8);!%U
MB&0;3=VF]N]9W;;OEUE6QOPG<@Z/"J(S9%(L\4)!DQQX>XZT-1P1Q#G3OOKI
MH2'LW=[8D1:0,G7O45>US&0\&(^@W' 3XGHHL"6-)"Z^])KV]:EPXJ_]"PY7
MX=E_,].6D.G<]O\ KZHNF9I>PKOXG4Y=NZ7ZYWC6^U-:[;L]RDV/:]H&S9NU
MQV[MHF+5(BC8A-FP6=9D(3%$8462@-97;MMZU9;+65MUE;ZD/,_A5D"5MNUU
M&;XC5$Y>:G5ZS-DU;5Z(D@/-JU0U'KUFU5\H2O!4]"*FZ%I.CTZTUR27G:TL
M0)!Q@C0G7SY*0\&MNM]5GFWGE;?]N"(W#_"!;A EUA&^$.5Y=)L%)4)SJ^+'
MC)9LNH-^Z.)'F50+A#DQ3?<#J+ND**S$?8KD:<(JDYNO>=",MGA-97O;??;U
MI\.K[FQ/?A'0+!L,[LF5MP$T8M+-C8LHY&ITS Y9!M=\DBEMH,7LH5 2:63V
M5<"]7FU4L!F.32++=I?LPX? @1Q=96M9V]?JZK9VWEU:QZ"[KJ+;@O<M+W56
MHEE'P;R)EC)FJ"$VNFPU_P!;=,&M"XDG$<V;@DQ&B0>D33UB%R 98,29LD:Q
MYESIM>.N5Z.)K*UK/<]O"_5_M,YOTU^$M>:)/5*N^\Z3<1@6F#=54FKJUC9T
MA06K0NHMJ:.&5AN9#V@"L30^+KK;9T.+8DF#%H%K&"IQ?8-O).DILH76ZGMO
M>^UWO=Y._P!GP65I(Y^$V>DJASI_4V3(617:D*TVU_6(=DU?*P1'=-@F-3;-
M%@6.'7(0(*-Z2=$Q!LNF *E:)":I.=.6,Q(L]F>*AK+AP>W>KV>SK>W(Z3Z)
M.BBS]*LZV'KIM]C;=@L]5"TF&ZS2FJA"J%2KFP]J;(#UBOHBFYZY@ANQ[ANI
M*1)LB#5G=E$68G>7L,8+$1!BVG:RM;KV]?KR\.]_H-P0< < < < < < < <
M< < RI'^\P?^BK_[;,X!B\ < < < < < < < < < RIO^-R/\YG_ +N 8O '
M ' ' ' ' ' ' ' ' ,IO_%)7^<C?^-P#%X X X X X X X X X X!9U6_P""
M&_\ //\ _7X!(N . . . 8?9P_W&'],Q]G '9P_W&'],Q]G '9P_W&'],Q]G
M '9P_P!QA_3,?9P!V</]QA_3,?9P!V</]QA_3,?9P!V</]QA_3,?9P!V</\
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MI<<X#'>G@N2Q&K.WCA8["[.'^XP_IF/LX(.SA_N,/Z9C[. .SA_N,/Z9C[.
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MM-["<V #)QX[,GM*D7^L!J_?0E',QYD".W-?F:U+$#!*PC5NU]Z<,'2:U-.
M+.+)-A;QX\>YVZJ[.'^XP_IF/LX(.SA_N,/Z9C[. .SA_N,/Z9C[. ?N8$%6
M<J5"B*5G/ESG,9G.<Y_MSG*/+G/_ #\ _.SA_N,/Z9C[. .SA_N,/Z9C[. <
MZ[UVR:U$:U?"":HC7H;?BFQ0TN1'-C0Y2,:IVD=H[?KX (+D#Y*"D^VNZSF
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MY#F&T>0";=[1GLYGRFO'X [VC/9S/E->/P!WM&>SF?*:\?@#O:,]G,^4UX_
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M[$2"Q>B*-6I%FKM/Z=&*?K.YR;%+L :OZJ;K6O\ 8 5H!B4:E%H2<"ZK;@[
MFK8>G/2()<:R*KJ5.,-CQ>&1;O>W_3Q<V%:7T;0[G(N]-K&@H6Q"(>LKDW&K
M!-8Q+O- W.&-K--<<L8?T9]\5:H#P<!5W,S51#<1T8+$JDM+B,9$S\?4D<*B
M=/\ .F1C];I=9A.1;+5IQ*7410$?'/&-.1R%4I0JT.B/,2:8U?/C(17A$]Q:
M:I8:P)]6:B20;3#8MWX\>+LNGO:,]G,^4UX_!!WM&>SF?*:\?@#O:,]G,^4U
MX_ /1-I&J;6YAN7YK:D)5_@FO+Y7/.\WR8]-Y,X_F9\OZ<?U?T_U >?>T9[.
M9\IKQ^ .]HSV<SY37C\ JG:(GI[M,8=<MU4+6ECB:V8*F!-KVC5*67C4&+([
M/EG"HX[;&9#568?[$%22LZ-*@MN]D#WI;JO4(RF@/TE-TE=-<2ZBQW?SK[;D
M>Q-P\U:4%'#K5,O_ &U;#9NL$0TMIF;8CTN8=NRCX=UXI*+*GVO$IR:F1.P%
M]_#]#1V\1TN;;3696PZ)I[:2K'-A2JC-NM3UW=%V(I6P5J3 F5UXQ&GH*$0E
M;/7C,5X3AUX6$-VO$?U8<1+8> UQD?TA5RZP;W8*/HD#L:M. A0RY&:OK07=
M0#IXK8B-9'0;%-:8.BG#)LC;)X*''F,*(E9]BE#VWI<HDXL7/KMW?T,HC4.F
MRW2W&F:O3%'"XT@!ESP$.ML60W5:ALR!9;K3YI"$M1,G4G-B>9%V0 =<='S"
MQ><.L;6)Y1W#@9_Z^K+Z;/H7QWM&>SF?*:\?@@[VC/9S/E->/P!WM&>SF?*:
M\?@'KF-7#.8UAF"AK\D9'(QXA,E A.S1T.6UALHU'ENH==B19C#>$36VGD-R
M6483(2M"<8P!_G[,=<VW-BVG5D*V=-%0UE%_/V5L>DF=F:8V Q$QI!06"5Z:
M+_.&']N:6#?F2F0]L" 9B$2MFAU^UTX78ZI2V2>!BAPR:2W[L\]CSRR3V^S?
MF=\5SK'O6U=,'MGU;I!+VB^5[?L744W34HO+E'C<2NAXER@'AE_<UPYK<68
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M2(MF0U,C5YU;>9"*I!F,+<8ECJBP\U61LMA>69, 3&?:2AMQ*$B/:[%N\ <
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MG:VQ;_5K21 MS"T^M,GS8.K/6 A7")B#6Q@B8.P\(^KQXZKKK9U+P0< < <
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MKW!SYZ?"X [Y->X.?/3X7 '?)KW!SYZ?"X [Y->X.?/3X7 '?)KW!SYZ?"X
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MEH(?KP*J ISJ6T6N5;'HIY2="Z0^7F7SWHG.VD,(O_[X]7^UG>V=R&M= /2
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M:)Z1PG;0[Q^?>E_UG4W^-Q/OX]%/*3H72'R\QYZT3TCA.VAWC\^]+_K.IO\
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MJN2\I.SZ8I*EYSA6#<3.,X_MQGS^/13RDZ%TA\O,>>M$](X3MH=YC_GWI?\
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MY_1QR]?GJO:3[QR=/FX?#'N.+:MLV^9TK5#EQ&T9>P3G5-:-'&38&I."*D.
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M3]18JM+R\5AX+75%^V-K<&L+(]0CX=V!55)(JQ-D8B"V;SZ[?K^C]SN>9?\
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MD;]KOW< =\)GND;]KOW< =\)GND;]KOW< =\)GND;]KOW< =\)GND;]KOW<
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M6DW],U(0S"L3(GM<)80T0&+.%B4M!EN(]#'!C@X03L$<J,]1&R&2D=2Q;/\
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M0$5^&-0Q);RT[AUU649RE6<84KRISY4*5C]./^7@&ZX X X X X X X X X
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MB<>''+/-6XYVSX;MI@[H9_&+L02R:OK=<NQ0--UIUGT";L&#:.F2K2+FQ/\
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M_P!.'K1VKP0< < < < < < < K/<4>7+UM9HT(?>";SS(Y#D/7!>0#N:X>3
M[)!X00@66G%THB0,29A2)7;0$M1,.P0&52<U8Y@O"@.+8CG5/7]6],M99>QC
M:+M?VZ'CS]D64_%'6#: NK'(^H7MJ2A3FPSZ*^2U_BY[&*U0R5O!.!<*Y5:L
M>OA^RP\7.>+EGP]_NV7]O&]N%2; I_6=.Z/]9Z\BKVV)W6!M-Z=NMOK=^+W*
MQ3PA$!U&B-<KE6D%:=%V&TSLVA&I2,Y,>96:_4YYBGV&Q!3E! VRN(#*[X>[
M>KVV[KV+8$U_J1UMNF,4EIO^S-;VNY.3CT0Y="S >CDMD$ATRT(B/^O369-5
MTQ1"11-9+-1ZEKLW@,0K,:H"=EL5JQFPR]WUZ_MEGOW'6G3<2LYC0VIBEP?(
MRSLZD!)#L\TI_)XH-7&QD 8L>)7^Z464P [,*6-J0EM]DY+GM/,LN(4T@1[7
MX^V7N+MX X X X X X!J+!B5D";Q"CDI<W(@EB)%#2X, O)E9AO>KQQ4XF]'
M&PB3SOF-P99!]B#'E*:>EO-L(<6D#YYU/&[Z=I<BV73L>$+D=5VN&JU(V!:;
M,Y>V-*&K%K!*19H@:N6UKH'&XO,@Q0[M/.W&T^OU3-LV"%B5ND&Z]4*T*[<;
MY;LE?W+=U9O+>1D8!ZV(^D^HBM;'C'5[5MFZZ=9ZK8M;[!/6VO!]=N#NG!S9
M\"B.X:T]=!-+$N/;:35M=5TI5;]8A06Q@!%_%WDF-V(7%RNL]W"V>?&^W+/=
M?=8AT&F]8^MJQKN_1W=M[8L(ZHA"%VU>;N9V$V:(5F=4JW2@4B<JUVR1 D6F
M2"3LLLQ!>-GJHLA>*GN^^[:KEJBE0873O:R]G5M]FSVW44T?0C1A.P$H^UNU
M)1 C78&\-DC:"3+/R)!&77(I"+D[&<<EK7(P.K^S7-@52LM9PB/'J8$#'')R
M,:A+6(_T\>/ML5Y<$' ' ' ' ' ' /F<(:ZP:IJSK:/[H6R/-F;3!L]%(T'8
MQZY0:KK>3K^EC;U$U3%ETNCD*Y^7P,<>F5S,<;@O:=AQS%CEC^U"699H7++J
M6?7M=OTO]#(TH+ZD:\2ZFFMJ!-JV^!:N^C5.DU2U%!Q!+[EUWZ4JHS5LVX;G
M/4X#&DZM7JU@%<*^*U/ %6(Y60MK9G%P9MZD!EEQW\-W5Z[[=F\K1O6759!H
MXJTC;-NHC/@63:L-JDE;-=X<XKI^/:-DVT,\105V-=K.(*V<':@>M!PTB<N.
MYH+-;H%UIMHI2Z[9: 3%37^J7]%U[EN=T=L:$M6P+5;=G3;:')5V$^#TF7)U
M8H3=+=PMN']90">S==A9KF&F7@%;$.:YGX='QV!TJSG[7.0C$^41;;$??XZO
M&2W].<$' ' ' ' ' ' ' *Q[TE_:,_(1P!WI+^T9^0C@#O27]HS\A' '>DO[
M1GY". .])?VC/R$< =Z2_M&?D(X [TE_:,_(1P!WI+^T9^0C@#O27]HS\A'
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M,_(1P!WI+^T9^0C@#O27]HS\A' '>DO[1GY". .])?VC/R$< =Z2_M&?D(X
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IX!.P$9R(.0RYE"E8==5Y495E/D4KRX_2I*<^7^W]' -UP!P!P!P#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g609070g53p53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g53p53.jpg
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M1/Z-#)Q,]W3^M=G%B+C6VU22YS&L MZWK-OV7XFTCZ3+2>C_ )>&'CY&\9$
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MVO0L9UL2,E3JW5[FPDJH(IZ>FD?JSU?'>CLU7D2>CL$DHUPTL:6L<' /<TN
M=JAVJ;9QTTTD,]0QFM%3F(3.UF@LXYQ9'ZI.LX.<"+M! -KVN%<+KXL]*:[:
M71,=-<Y@&+7NH<][-U*XRJ/<0K6&!"L)^_\ J_"=E'W;.96U",B #[5IBF(?
M-J1"LYZ\^$>I!IG1M3%#/!4B2.HJ_087-BFN^J+7/XO5,8<T:C2\R.#8@VQ+
MP"+[,NBZZ&26*6'4?#3>ER R1V;!<-U]8.U7'6(:&-)>77&K@;:L\[-=>L^2
M-8.VQ1[^44 ^!6CK!(N;%=ILB(NAV'4*!<,"M%<8R-RI*1RC*, FMU0%X72.
M?5KN>.IE7@L2Q<$U3#3N@;,_4-3.VGA&J]VO,YCY&LNUK@V[(WG6?JM%K%UR
M >:*GEG;,Z-NLVGB,TIUFC5C#FL+K.(+O6>T6;<XWM8%8#SG7"MG*7CCT;=/
MZ\6<==34B^T-9V=RJL9IA50%/#5M/J]G:>&8J;-CQ26!@KC[%O.RW70N7V7.
MG/C'WC?H_:.M.F-'".HD])#F4M2*.4LCFD/I3M6T$;(XW/FD)<&VA;)CK D:
MKK;XT96E\#.)LZH@-3&'OC8.(%R97N>YK8FV:3>0MPL<G"_XM>1]TB2NX ;,
M+750KI%&J;";J9EO7ILR:\3HP%0DZ/F#OF8GF,V)GZ*T2:UF07XJ&'SR1D?\
M^IC9#2U$]E(^)\DK:V<T\)9#(-61KBUXFXQK.(XMPU7-EU9"XV:QUG6AT=5-
M=4LD:R-U+$)I Z1AUF.;K-,6H7"4.;ZP<PEEL7.%Q?6;G9+13A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1=MK01\[>A*OG;<1_U*.TA0TUYF2=.; UX/&N.6[*+3JY?-AZ'6
MI* T'*L'@KY8M5+>-RRV!H@\1,E@:SPG^T=1?E(VZ0H#I&D9HMU<ZMTG-605
M#G0^A.BJI&/=Z67R"6-]. 6D")^N6-+!:U_T<CJ*M%'5/T@VE%-0Q4TT+1+Z
M4V2!CVCT=H9J/;,X@_;:&ASM8@W5@IOJ_6D&M--:A-;$7<]=8^"][I.PULF%
M@N89[?(7]FD==!2]R0+-?F-U+UM=(K4M:WE2#$"5BY4L4K%XA))KS:*J355M
M8RGD](.GJ&>FE;(0?0VBF%0]H#PT,+1(V76;=[6ZI!#6@<T>D8.(I:9T[.)_
M%%7%,QS01Z23.8&/):3KAQ8YF-FN=<$%Q)L IN_S?1\NU-<2;O4'S,:$\@G-
M?CS$52H97S*EL1,M[>JCT)>T^HKNN;0('.PCR5J\XNCCL49 0,EC1*:?+JQP
M,H=(NTH:D4,M/KR:794.826/9+3S"D+JB2LEDJ!(\1N:&PPPT[RV-D;!]GF=
M5T+: 0>E136;HU\(=JA['13Q&H A93QL@+&:[7$RRR3-!<YQ)-\A'^F]([=V
M]8!-\H3;H(-\3 "RZ91EK7^!<G-I(D"V!3MD%9<"K>! VOV669083JWU6N%&
MDM'E<E$%"]N;N7C.C*VDI->$.I)'\&I(ZV>6HU&>FM?3N:V65\A:R41":..2
MX;"TZNNQ@PS;74M34EDA94L9IQDE+%'#K.]%+)@71L8S6>POXM[V %TCA<M<
MXXV@4;5+553S*U>JMB*6PSF6\O6=2MM&77A]0'AV3/6ZZ)UX5+TFC5] _>@1
MSY 12R/RH+*.1"F=.A1B*TTF'O'4;#+5'2<6BZ>6G9Z#HEQI141RN?&*F1]0
MR-T52Z-IGC8]P8)XG3M#G'5=,0=ATL5.*&32$\<S_2]( 3NA?&&OXAC87/$E
M.'D1.<P%YA>V)Q  <(@NIKW!MQ;9MS:Q;=>G54PYI&OU&%IV(G'[;CVPO04Z
M6+CBA]H(ZWUG2;FL)0E#C;S'35)*).K0&5I[MZU1M]8?K-"4DL5'4Q5#)613
MU$QBIYHVP\7 ^-C'-CC945)ABD<'N;$9=9I+G!K0YM_SNE:ECZJGDA?&Z6*&
M,231/,NO*Q[G-<^0P0-ED:"UI>([.#6@DD%;O>BO=(._9]S,^N-M@B;@T,GF
M%;T<<C T+97+7H57=>MF1JE@JOY]C\*Q5I*T"MV;[,3DKG+=6K8DJ98X1=)H
M[0<C1H.*II)&PQ1Z4DK6<8X,](?+!Z*9@R3UB61,<P8M!C:2 X+M:W2S"=*R
M05+'2/?01TC@QI=Q+8Y?2!'K,P =(YKB;&SB ;6 ;1]!^>2>N'R&MM+6!_1Y
M]!T*&\V^<Q";<I;$TELM9NHTKNRL%F5,H0 /NS[L>9F-BA;3/>Q(6"*KA)>@
MRCAP4VC](-J8":6ICKHYZ]^DM(OF:ZGK::5LXACC F<7EVO (HS"ST8QD^J1
M<IZVB=#,!/ ^D?%1MH:)L1$U+/&8N->\\4T,U;3%[Q(X3!UL00#GS)[QU]&]
ML5T#M1*C$4_B+:[LJ=FJGA\,1ODTL,MY;4F#2=J_5@>J,1"B*D<(X.X2YZQ8
MMR7(K>5^]E-P1Z"GXA@?2S\8[@[4"4&9YU]+,<WT4/'&V=+&US^)OZD8 #2W
M5;;EDTO#QLA941:HTU#Q9$;+-T<YI](+?R>$;RUO&6]9Y)O>YOH?YQ?_ #UK
M?VMM[T VEQ\>N=1G-P;'TXL JT<%A]9\V$D/U4!4:M@;/0'=T(B\#6-M%*D(
MT7^'J7VNO)AW]CE[S2,&D*G0M)01,=Z35QT=-62O)(IX^+:ZJ?*6N#G:Q887
M!KBYW&.L0?6'4T4M%!I2IK)'#B*9]3-3,98&9_&%M.R(%MA8.$C2X!K=07%L
M#O-KKTWY.<7/2VXH=B?@]J5-$[R\PMHSTO<Z:R[$.E2;-C3S6]D$53J#V):M
M6SYE,8+%,/B7E'4Q]&>K/E!C:L=)4Z-TK%#6T9I^.BEKZ+2<3]&MXIL;N. K
M(H&SS%T<@$;)HPY^H'N<X$7L.U@KM'2RTM2)^+DCI*N@E%<==SVF(FFDE,48
M:]A+WQ/+6ZQ:&@C"YJ?9;AYW?ZOD37S)O[16O2^K=J/KJX-?E0#LE0U,DZXD
MB76&&X(%L2V-NWMY,;$!^[@9A?$9_9\,!N9SZ*@ZI/)M4T6D*=VEZB*@KJAE
M52P0PQ:5?32U<]3^4B+7NCE>!0QQR:SV2/LZ[]3UG."UYY:*;\6P/K*2%U/4
M32RR:/;/%310$,>"T/8"ZJ>]NJUS&D@6#\&@J7W7[(\M[BWOIOVNRY.A.94I
M."-<\]]6 Y5D06M<OF2FHML!:S!7K*1U:O=%HFIB#R391U=B#(*]^$Z+N7,<
M\:+0^DZ.AK-"Q<2T2NAG;I ![(JB*0,;64KRPF9DC=3BHW  FF>2"QS0LZK2
M5!4U=-I60RN,;9(31W8Z2&2,N=35#0_5C>PZW&/;?"9HOK-)5G'_ %IYM:W#
M:09)V@![:]O>1/.RQ0V-Z>7Q;OKC#8VJ2"\;E7=@4H51GJV66R,POSL)$TO%
ME?-^$0SU/GULZ,<^K'HG244-,^>F?Q5'I?2$KJ;1<CH*GT>J;)&)*=QFB(B#
MRT1M9(R44[R#8ZQ&P_2-#)+.R*H9QE3HZBC$U>QLM/QU.YK]28")X+RTDO<Y
MCH^.:",+!</2WKCP-J[T%LX4F].FOEIY>FTN9V*I#PPO63*N5-'EE^LGUQ9B
M"5O!(EO91-M:%)?H"Z4,K"10Y3/RPZW2HCK6Z)T]5:/IGS<142P4\3&4\SGO
MJ8Y#6M>9BYA$,DXI6Q12R.<X\6V<,.O*XNQIM(Z'@K*AL7&PLFFD<^>-K6P/
MC%(Y@B#7CC&1&=TDD3 UH+S#K68P!O4;<VUJM,6@4N@%+:NM-RAC;)6M[HEV
MQEW<-H9VBW I@T"D$71>"L:(KIP10+DA;/<ASZI%X:T&,!?K[)^M;254TD@K
MYJ6IHY&1$40I/59/&Z&0/,SY'F5C98W.8U\33BPDW98_G#4T\3&>AQU$%2US
MP:HU'K/B>)&%HC8QO%N<Q[0YS9#DX#!V'94[;OT/MS=WQ%$JINA-30GHD_YU
M9M:[59<&*NDWH=.M*^>9Q5F\,!DRP^Y?&YWK(7JR*CJWBP&*C)8KRV*N>?YJ
MGH:ZDHN#LSJ*:9^CH](Q5-+'Q9G::R*2.)P:][6.#7:H?9]VLD+@" 0N\FJZ
M2HJ]-1"JBC;6OHY(*B37$1%-(Q[VES6N<TN;<MNVQ<P-)%P5?B?[+\SL6P]K
MO46RM>K*W?\ 6>S]CM6&RPCKD]]ZL)ZH':^ .WF&0*&LRJ>RV7.B3S)V(9@K
M=C/(N2%,HQXR*OUHS:'TE'3TD!IJB61NB:6FB]%DAX@53:IU1)#I,/>T2TT>
MLW5%GPVXW4NYQ*W(M)T+YJB7CX6,.D*B>3CVR\=Q!IVPQRT&JT\7.^SKN!9)
M]@NP: NK[X>&QM=ZTWZ[%G1F3U-</:/W.F B&TJI"^FV#;4NYC%L6Z5 (\E=
MM!2%B2. _!1HS934/ML<$>66<>&7Z?A!3U%300LABFED96T4SVTI:V8,BE#Y
M70N>YH:]H!,9<X6=JW*Z#0LT,%7,Z62*-CZ2JB8ZH!=$7R,U6-E#6DECC@\
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M/]^B]R_QI^7NV1^THD?P >_4''+^F]G3^_C\"<CI_OT7N7^-/R]VR/VE$C^
M#WZ@XY?TWLZ?W\?@3D=/]^B]R_QI^7NV1^THD?P >_4''+^F]G3^_C\"<CI_
MOT7N7^-/R]VR/VE$C^ #WZ@XY?TWLZ?W\?@3D=/]^B]R_P :?E[MD?M*)'\
M'OU!QR_IO9T_OX_ G(Z?[]%[E_C3\O=LC]I1(_@ ]^H..7]-[.G]_'X$Y'3_
M 'Z+W+_&GY>[9'[2B1_ ![]0<<OZ;V=/[^/P)R.G^_1>Y?XT_+W;(_:42/X
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M)JH=YL#2H2S>$RV0%]S!1V!O=[$E/%F3M4ZEBJ .S#26^7QR5?Y>U//D!E1
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M:0QN?7':BGU)+O"0TON+ELE VA<#&8Q'HI?1;*#T618UHE10D/6KN81YUX3
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M]\MKDW7LZL&!>YC:)?;WXWZ;^;65O;4T[%L?72IKVJQWQ$"ILOSL_P !@O\
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MP:*0WMK5/]#1#',F4HM6Z922YIAA+[651^KL*<K'J$ZSU45SUVOM"*HEP.!
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MNL'9$3VHD<QI;#U2[;>7G<(L'F=)LKR<TZD3Z@NL:7!Y7[U9W<YN92H(@ '
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MKHBUZ=?-*N[;Q3]_V';9H)U25NJHAAZ^QC(57%?Z8<V0W1Z"E !;,?FYV.J
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MVIY%5 K?^J^_WH?_ .O$N4Y]3>X+%GV1U]Y4]R+):]^M_P"JEZ;_ +/>Z/\
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MCL8=MXQ:C"7:MLSCL'8.UG?8M$JXLC/BK439!#$+5?"[,W]$#K&]MEL>8X?
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M7/@OX<OS?@W_ )VE/X*!;$'Z_P#I_P!R]GKGGE;"<(G")PB<(OFE7_Z==_\
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M_+)5KJ?R;OVQM'SBY[#JO@A7TZ[ZN9&-><_1KALTE>V6M^;?7>OMR;C!D97
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M5VOW>$U+?70.>F5'R#)<;$<F-FKW1/'Z?6%GJ;O"L?/0X98QFB>-I<[_ #Y
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M-C!#RDJ'"+?#&NZTUMJ?:18R+,+B,2DM&2"[N51I#@Y<2 7(3D!R$P]"A%"
MU=[6DX",K6Q5$6G*9E#/24$T-54P,I'&?2&D-*:-BADAJ*R,-BCJ-$U3Y)HI
M9YS"Z%T-'+*]T+(9+&VJ;@D$#' -:Z]P#F'#"PQO<@"ZY%OXCZW6VO/ICK5#
M1D[X,U!'@J2EX:U65U:-L4TQ 79YI@_4U*TU:PFO[VM?:*W4BZEA[U6_!-/W
M6N38,X U#M&-TM^,J849IGUKGB(N<*2FT8^KKIP&RV>VFTBUFA6:KB*BLE8Z
M-P;K-#C;'5+3? =9=8#+"X];&U@K@V-Z]':SWZ*TXQI5@<LD!PN63:)8L2'
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MJ'3LG:Z:2&.E="8&.+:HU ]&$XVU]9I%FW-KD ZNM;+*VV^>RV*LA)]3[)Z
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MB,=SN:^#AM34@T')2Z6AHN#T -3#1,K?18FS5,^EXZBN= 74SY(9:F5\50X
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M#2E#I4<87.C@FH-)_C.*/4PXV-TMHWAQ:2P&V)PR+ ; DX-<W#<X 'H."P]
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M<X0Y#6B'MS;8V@;OWKD]V^QK\E:C\H#AG#VVB>%0T)H"&FI2)]*,TU!6Q<;
M1'1T4-10UM13&?C;S1Z0K=%:+DDA8QC6,IYPYUYB'8NCUGW/V=4C#,N((!RP
M(#G8WVC<L$/_  U\6'7)#7]G?CA4Q9<7.J[WJ(>_'5;*3-KQ/UN(S)49W2P0
MOE%(,F4Y!4S&>9 >69,E4Q7*M"BI5E?=@_" 8-(1US="4KO1S2.HV/E874KZ
M>OJM(3"-XI R..KEJWB44\%/,!'&[CW/?5.J88KM+2XXWOSW ;CCB0!A>XYK
M8*PGWP8'<DPHLT=C7UXJ4W'L+<'3537<H#(LGL43('OU@9=?8UEL"W0\'<,@
MHD-:ZU2YW7BI- 1C$==C>:%%PTEI*N*H?0,GBBT30Z*]&?.'0R1T$HE8Z:*>
MGJ*:9DIN)8Y*9SV:Q?334\OY19&.XL#;UB;XW%Q; @@W&%C?9B"MZP(O(&##
M!<R) OD(%#A>18M+'.5*9#Z<-3LB3GBB@BF(7>X>[-V6*"&.2S++GA%'CEUA
MU^-FDXZ:6;BXXN-EDDXJ(%L4>NXNXN-I)+8V7U6 DD- !)S7(,!OYSGUJ5YQ
1(G")PB<(G")PB<(G")PB_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g609070g56a56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g56a56.jpg
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MMB8X.6%XHK?_Q  = 0$!  (# 0$!             0(#! 4'!@@)_\0 5!$
M @$" @4'!P@(!0$&! <   $" Q$$$@43(3%1!D%389&2T10B<8&4H=(5%E)5
MD['3\ <7(S)6P=7A"#-"<_&R-#5B=;.T)'2"U#8W<G:BM<+_V@ , P$  A$#
M$0 _ /[^* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@/A2]\<;7M_3FGC_
M /+)3'&__A>_^:@'D\?FO^EE]M /)X_-?]++[: >3Q^:_P"EE]M /)X_-?\
M2R^V@'D\?FO^EE]M /)X_-?]++[: >3Q^:_Z67VT \GC\U_TLOMH!Y/'YK_I
M9?;0#R>/S7_2R^V@'D\?FO\ I9?;0#R>/S7_ $LOMH!Y/'YK_I9?;0#R>/S7
M_2R^V@'D\?FO^EE]M /)X_-?]++[: >3Q^:_Z67VT \GC\U_TLOMH!Y/'YK_
M *67VT!KMR4V.=U=%H27CMTL71W:D-B3SRV-U,;C#=R76\<;97OXN=^JI^+E
M;Y<?EZ*/9[O>[%2N[>FWI-B$<KYI)9Y?W6:>&5^CY+=.6-KW^3_/>A#DH!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M4LJU^(@YMJ47)984UENME2$E9)N>W7'GD[OK9._R^L]FZHM#XM?5PB9CGHB
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MU+U\_P"SX?\ ZE^N?Q?+KK;G1^+\C7M^BU[6_%T?_O\ CM?HMT5\_P#IP_\
MR_Q__P _HS_W43G\CO\ ORCLW4<3ZOV;_P"#_0-K\2'KXH!0"@% * 4 H#3+
MF[_B#J[_ &^ZU_\ ,W4>[UQ^]&4/WEZ_N9N.W_O=#^I2_P!S&J8G-0"@% *
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MA4M)G6+W/D0*W1)%F8N-I)2)!6."%VHN=['PZY;[6OOV/T6[-A'MB^"3!0Z
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M0^_3)/Z,NZ_ #M$?].9]Y0^_3)/Z,NZ_ #M$?].9]Y0^_3)/Z,NZ_ #M$?\
M3F?>4/OTR3^C+NOP [1'_3F?>4/OTR3^C+NOP [1'_3F?>4/OTR3^C+NOP [
M1'_3F?>4/OTR3^C+NOP [1'_ $YGWE#[],D_HR[K\ .T1_TYGWE#[],D_HR[
MK\ .T1_TYGWE#[],D_HR[K\ .T1_TYGWE#[],D_HR[K\ .T1_P!.9]Y0^_3)
M/Z,NZ_ ';QRQRQQRQRMECE:V6.6-[7QRQO;IMEC>W3:]KVO:]KVOT7M\MJQW
M;P?M * 7O:UKWO?HM;Y;WO\ BM;Y[T!U>O,OIC7O"7WZSU=3HY]V7@8:RGTD
M.]'Q'7F7TQKWA+[]-74Z.?=EX#64^DAWH^(Z\R^F->\)??IJZG1S[LO :RGT
MD.]'Q'7F7TQKWA+[]-74Z.?=EX#64^DAWH^(Z\R^F->\)??IJZG1S[LO :RG
MTD.]'Q'7F7TQKWA+[]-74Z.?=EX#64^DAWH^(Z\R^F->\)??IJZG1S[LO :R
MGTD.]'Q'7F7TQKWA+[]-74Z.?=EX#64^DAWH^(Z\R^F->\)??IJZG1S[LO :
MRGTD.]'Q'7F7TQKWA+[]-74Z.?=EX#64^DAWH^(Z\R^F->\)??IJZG1S[LO
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M5T._L&_VT%WQ?:Q\#[B[]5T._L&_VT%WQ?:Q\#[B[]5T._L&_P!M!=\7VL?
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M*X+%R0>&&IHP8#_*'4Y&4=CBK%LR>EF^(K**?%;.K?S<7_<R=*RV/;?9=/\
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MNJ/_ (LUK/F>W<B2:L[F[5?'F@4!BCO^ S/^JB/_ "BU;\+_ -IP_P#OT?\
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MXNO94\HP_3T?M8?$-17Z&K]G/P'8QCT42[BZ]E3RC#]/1^UA\0U%?H:OV<_
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MB!3#I$RK#36T,<7@\E+85Y("<0O=G+Z2[>A,=DW&IM ];.CVP@T\D^<F[>N
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MT* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M#U^HSS04 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% 5EMW
M;L)TC"7<\GCP@@)2)@H^.'A Y*1R62RB5&&<>BT4BT<#-W98](Y&<(,A8H8P
M;***+K^67R;LT'+I#=0H5,145.FDY992;E)0C&$(N<YSE)I1C&*<I-O<N.PU
MU:L*4,\[VO&*44Y2E*348QC%)MRDVDDD1&$<E-53"*WE10J_U;@E-G.MW@'=
M(U75,D9SINBV=81FPV7YC\"C]^Q>LGXE4"Z+,2[1S@H-=N<DG&".53"UJ<\B
M2K?LU54J#UT'3=_/O"]DFFGF47%K:ELOC"O3G',VZ?GY'&JM7)3V>;:5KMWV
M6NGS-F>EV_M)01I,7<JVM A66OXU()?,AMY.*>'P,<BJ62L@)NXT/<NY!DF,
M\6R"Z+<8LYR>J(,$4%'KA!NIC##UZC@H4:DM9.,(/(U&4INT4IM*.WF;:5MM
M[;2SK4H*3E4@LD93DLR<E&'[SRJ\G;<[)N^S>['$RY"Z(?";',-R:P;CL8T+
MF#I9].XNPS&Q@RV .QIPLB\*(JBAKM&51G)-V_P;H7RD 7#Q_&)LK+UX;$*6
M745F\[@DJ<W><7).*M':UDEL5WYLN#"KT6KZVFEE4]LXJT7E:;N]B>:.U_27
M%'V'WIK>0S*6P@$;L9*0S6<(VX3?B\,"$?>0;8;R<,HL4"'&BRS$Q=\KKV1J
M7P9J9XX-TV2]E,TWJ5Z2P]6%.%64<L9U:E%)[)*I25-S4HM7C;61W\]US%56
M#E*"=W"G"HVMJR3<U%I[G^Y+=U<2E].\Z=%;G="VPR\\@B<AU4[W?%2FV(,9
MUY'I9JD:N 0*S>/24WA@ ?!A-Y5'%B.>9)!=NS,LWWD,F=EUT=]?1^(PZDWJ
MZF6LL/-4:D:LH5FI-4YQCYRE+)-+9M<6M]D]-+%TJK26>&:FZL74@X1E332<
MHR>RRS1OM6QI[C83/;VITTH<NIL_7>".Q%;(Z_6SFL:Q2G2UU44;)0Y3(G;"
M3JW6<()63"7?975713M;QE,+9<;45KU%J:MZ7^:M7.]/_<V>9_\ 58WZRGYK
MUD+3_<>>/G__ *=OG>JY5DRY;Z-A<U=:\<2U"0R\=&S\G,!H>HPDCD"TC,VU
MO # ^068/\NQ#K<_M6)7Q#$[-GRC!5^]P2O@Q4QRW4\%B*E-55!Q@Y1C&4[P
M4L].K4C*-UYT<M&?G*Z3LN<USQ-*$\F;-))R:C:67+*$&I6>QIU(['MM=\Q:
MR&V=5NGD@'-=EZ_<D(F.)F)2Q0F4<6>1H2%?NA1@I(&J9+)<,.$E&+T:3?$<
M&S9@_9NF;I5)PW63PT:FLE%NE4M-J,'JY6E*24E&+M:3<6FDKMIIK8S9K*;;
M2J0;BFY+-&\4G9MJ^Q)IIM[FK;S(A-@P*2Q][+(Y-X@?BHQ-58C)0DE#%8^/
M20'-C"ZKTRQ>KCFB:(EXT**YKN4\4QSIL^SO9LNDKE)4JD)*$J<XSENA*$E)
MW;BK1:3=Y)QV+>FMZ*IPE%RC.,HK?)23BMB>UIV6QI^AI[BH3W*[1P>6Z5A(
M^:"ID<W\5-CM;V@Q,+)AI)M&L,,I"<<%F16PY(*)553:.%V[AT[7>W5:L63M
M5H]Q;;XX/$2AB*CING'#*+JZQ2A).;M&*BU?,]^U));6U=7UO$4E*E!24G6;
M5/(U)/*KR=T[67IN^9.S,<+Y708[MF6ZB PO<!PE YJAK^:3,5K@N[UI%Y,M
M& $QS:FYMBI88Q1:1Z4 B#UPK:R;9,@CX_X^FK+!U(T(5Y5*$54INI3IRJI5
M9P4Y4[QIVN[RA))=1%B(.I*FH5&X2R3DH-PC+*I;97LO-DFWUEHH[LTTY"')
M*WVWK%Q'(SD+QDD@1GL55"1_(XFBJ%Q.%4RN3 3D82<-U1=GZ[>Y!-='-IY;
M%7"^6ET*ZE&+HU5*=\D73GFEE_>RK+>67GLG;G,];2M)ZRG:-LSSQM&^U9G>
MRNMJO:_,1W7_ "-TSLF/PJ1 IY'F*&QR<I$047(RXL!(98^ATG+Q$XG'@9!Z
MF0,XH& KS%+(:BZ\LUNW=6M9-PGTYU<+7I3J0E3DW2C"51P3E&"G"-2+E)*T
M;QDGMM;:N8D*]*<824TM8Y*"DU&4G&3B\J;N]J>Z^S:2K#;^I56LP?);1UTH
MRUZOU6?/,)M&LVL'=>55;]6F#C$G=&,K^7161\B:S9*>5253\7QT\\;8:BM>
M"U-6]7;26KG>HM]X;//V?1N9:VGYSUD+0V3>>/F/A+;YOKL=O':.L\WD2'8;
M$@N1"?-.OP1AC+H_D\FK#R=ENNQ)K8A=>1M/(WLKUD/@\1\G>RGC^+>UZFJJ
MVF]54M3=JCR2M3?";M:+ZI6&LIWBL\+S5X+-&\UQBK^<O1<ZHW;VIS+MRP$;
M0UV5?,B 82\9#9K&GSMH5D;G)G'ACELU)JK($#KS#-H&9*X8.2CG#)!BDNKC
M?"U=&M%)RHU4FI23=.:3C%7DTVMJBMLGN2VNR"J4W=*I!M-)VG%V<G:*=GO;
MV);V]Q,A9D0<07=!2HTNV;$"0ERX%OFI!!N5#OEQA<8NLT5632("B35R/),U
M,L7+%\W7:.DTET5$\=;C*+M).+LG9IIVDDT[/F:::>YIIK89)I[4TU=JZ:>U
M.S6SG3V-<SV&2J%% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!
M0/([2+C>L%"@@\KM!IG"-B0#;6O):N$M)Q@6=:VD;21 E#T8N3!Y2*//[H.1
M!P2B;#.W T@XS8%1[])L[2Y.%Q"P]24I0UE.I2JT:L%+(Y4ZL'"66=I99*ZE
M%N,DFE>+5T::])U8)*6249PJ0E;,E.$E)9HW6:+M:2NFTW9IFE^]> &V>1X2
M(.MO<AX[*IN%=;K'$6]M8RF,ZN:0/=T?AT=)0^*Q6#;BBLV3QB3>&HNPY.9;
M+F3@TM(I:R-XV%DA30#SL/I*CA95%1PTH4Y*@T]="59U,/*<E.<ZE"=/SW-J
M2A1II*,''SDW+BU<'4K*+J5E*:=5-9)*FH55&+C&,:D9O*HW3E4E?-)/8TH_
MLI\&6&D:4O32V&.8JRV6<H3SHDM [%#/9O(GC_CH\>)?E7<IZ\85@JR#*6=?
M?+Y7/N&2#*Z EQAB5QL=*N.1ZIO)#"1252R3PV)\H<HI0M'6)NG9?NIMWE?*
M)8'-G\])REB'=PNTJU%44F\UWE:S;]N[9O.=/P><C1BNQL&FRM>CM@[)G7'B
M4EY$,U$_'BD(YH[4VK=:O8"/48;$:3T&(D9#72DO&FHE/(S(HP_)(MF#_-1N
MX(/,7I*#G2O2JRI4J>)A&$JZ;<\16JU=8[TG3DXJIJW&=.49I7:5U%7R.66I
MY\%.I.C)R5-JRI4Z<'!-34TI.&=.,TXM[-JN[(XM\(77'!J:;+;*0F%BO'G6
M^ADLTHF["=7MKR8[RE"<ERN\EDB<+V)H;B0'W$JN\U6BD=4=9%WEBN* _7C,
M>L5EM2<+8FKB-LU*^MA0ADV0BE9T6[\^:V56N\\/A7033FI7H0H[(M6R2K2S
M;9-NZJI6O_IO=WV:SC_!"QJ,:V_ "#;-&1I22<>-6:AV:7SU^Z?+RN=Z=FD+
MGL:V,">)3AA)H2$EI>*.!VTM< Y-@(F I\.>MR0>3@TCSOE/34IU=95HN>7$
MUJU*.L24*=>%2G*E):MQJ2@IWI591S0DFG&49.)H6C8QIY(347*C3ISED=W.
MG*,XU(M34HJ3BU4@I6DFK-25WD3W@NY09 P./M=UQD*. %BTMD3!G ]B/&[F
M9E-_"][.2@ F5WH\E"C$@N-2CQ4%/I!/(UD_\O.Q,>$2EWBLRD-+0C*I)X>;
M<DH0>LI)J"PSPZC)+#*-TGF4J<:<K?LY2E!6=E@)2C&*JQBDW*24)V<G655M
M-U7+:TE)3<XW6914G<^\_!;'%5R3//<\01 -8ELF%119CIM9I-EA6Q.46L.3
M2A'8\LML91&;G!#Z!$8>W=-0D<1<(&;2)1'!]<@Q>EI>*L_)YYG.E.=ZZU>:
ME@ZN$M2IZK]G&2J*;3E-^;EO:S1X"3?^;"R52,;4K3M/$4Z_GSS^>UD<5:,=
M]]][\>Y/!K$'>OY>]ALA:R*:9L>899,,'B,?"$YZ;Y(<C(!R#BHDP3D4N'A"
M3& Y0%K#'PJ3%&(N<BWJZ"AJ",U<\DF'TJE4IJ<<M.^!BY2G*2IPPN%J86;B
MHP<DZFL=12@G*G)*RJ-"K@7DFXM2DUB791C%SE6KPKQNW))Y,B@U)I36QN*)
M?IOB+L^=\6>5&L-T-F&HI5R3WG*MH,VPN+1!)G'F[@9K!(3<YKZ';-V1%>R"
MYW7[E8]"FNVI.J6BI18<7EUBY(@X;85\;1IXS"5<.W7AA</"BW*<[R:=7-EJ
MSI4IW4:BRU'0AEFKJ&6*OE2PU2>'Q%.JE2E7JRJ648VC=4[7A&=2-G*#;@JD
MKQ=G*[=K%U%P3<0/;L2W=)YM#2TM';"W9LB1@89K'*&P?$MMJ!:PU^Q&P,.\
ME\F>Q(='&&L6ILBX>D3[^3R<^>,**B+NL6V&JMI!5*$\/&G44'3P]*$JE765
M+4:M:JW4DH04W)UG%645",8QL[7,Z6$<*L:TI0<\]6I)1AEA>I"G!*"<I.*2
MIIMMMRE*4FU>QAVW XX+Y,;/WXP,<="R6S=C8SM0A-N.\AD6[(4R7UO%=<$(
MW!MML=W !0AEFRC;DH/5>:Z)V9$) 8ZPW?H+XI85Z1C+"4L,XXJ.JI.G:GBH
MQP]1ZV=53J4'AY.3O))VJJZC&S31%A)+$5*R=!ZRHIWG0<JL5DC!QA456*5U
M%M/([-NZ>XKP3X,%:)BM7Y1#9\.:2#56O.'L<')&=1Y$(3+IGQ9\\#<E+IU%
MATZ#NC3;8C3;SUQ@P2.-BT7/@11N\A/*)V;)[9:6SRJYZ,W&M5QLWEK6J0IX
MQ4+0IS=.2BZ;HI7RN,XRE')'>81P&14\M2"E3AAHJ].\)2P^MO*45--J:J/8
MI)Q<4[O<84'X*TF##QR-I[DB#L.X PB-3Y\OI?Q)*Q':ZY'[ Y%Q]SH@IAL3
M)OIU^2(SU>+'NL,9JTZN($2 8@T),4D+Y3TQ&4I3U$TU*I*FM?YKE5PM+"R\
MH6JO725+/&SIN\G%MIW(L U&,=;&UH*?[-W2IUYUHZEY_P!DVYY6_/W)K;>_
M?%>#&E(-:<N!6[8VV9O)[KG8NOH2YUQ*I!K@8>UOMXKMIDWE\?ENW9$7<QDR
MN57#OX5 ))K^'L"2CJ:" C4HLU'CL9:5A+5WP\KJG5IU*BJPC5<:M"-%N$X4
M(I2CES*=2%6;5H2DTFW8X&47.U6*3J0J0ADE*"E"HZGG*=63:DW9QA*$4_.2
M4B3$?!R'B\A#E7VT-:-F1EMHB^R4X[H =%R@I_H+<,DW*!^#R\#3E =I<9)S
M$D6#2=L\#SE\X0;JR&Q):2%2+Q3%:3A&,HJC6;B\1JLV)<HM8BA"A+RE2IMU
MW!04HVE36Z%E&**\$W)-U(;=3GRT5%IT:KJK4M3_ &2DW:6R3WROF;-:0_@^
MMW1SC_)SY<"+-[C%:HV)!=,ZRUD#@43DH&?R?DF+WU!=F;)V9(]II0Z9JP";
MPV$2=@N,P D!,65E3-$1)98_ZJZY<M)8>>)A&,I1H.M2J5ZM652<)4X866'J
M4J5*%%U*>MISJ0E?,G/+YT::;-/D=54I2:3JJ$XTH04(RC.6(5:,YU'4R2R2
MC"2LDU'-LE)V?K]QSU-YC=(:VU<L^Q+&(Q'$+RP]CT__ (FGAIPXD.P97GTI
MI9>6E4W+'Y"MXR>&7E26=KXVO\E=)BJWE&(JUDLL9S>2/T*<;1I0]$*<8P74
MCL:%/54J=-N\HQ\^7TIOSIR_^J;E+UEU5H-HH!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4!BF35-5FT545>9**-D%,\NT']O&SS2
MPRROT6<VM;IRO>_1:UK6_HM:U <;S,0/R98/R5F.9)ZF-'8/#;EMD_(JI+N$
MF#+%9[A=T]40;.5DVJ%E%\TFZZF*=\$E,L0/IGD*(X+J#R-WR;9V['N,V9IT
MZP;OV"^;5\R7R0>YXI.V3E-1N[;*7Q6;KIYI+88*8Y8V P9"4081G=,K,0@Q
M2SQ(==,A+TF6=B"Z9)9!C?!R42RL\62#&%4FO1Y=1,22SPPRQ8NKI 2!TF/8
MMG#QZ\59LVB*KET[=%GC=LV;HX9*++N%U7>"2**2>.2BJJF>.">&.6665L;7
MO0&.<DXTSR)XNS[-KD$29N#.+F1YH9"$"%U+,%B=E2&-V"3ZZ2MF:CJR6#FZ
M2GD<L_$RZ ,QU%#_ "WG_P!1(?M- =$FJ&"CGQ<R4Q$B1C5=\2*$SCA@.'LF
MJ>2SEX^>NGJ39HU;I89*KN%U4T4D\<LU,\<<;WL!^"EPAT:Q,A"N!@03;(O1
MI44=7(#2#-QA91!VQ?-'RS5VV73RMFBN@JHDIA>V6&>6-[7H#O\ 44/\MY_]
M1(?M- 8QP]C[0H/!NC2#8V71>N10=Q(%42A-N.Q2R(.!X]1_B[>HL,5T,GJK
M9%5-KBLE=?).RF'2!US!>*QYJ^>GY&P!LQB#)R2=F)-<8U'MB3I5B.</G#TB
M@DT0?O4%V;)5QFFFZ=(JMT,E%4\\+ 9JS)O>UKV4=WM>UKVO8B_O:]K_ "VO
M:]G71>U[?+:]OQT!],;Y70O;++++Q'#U+&^>66>?B)/%TD[99YWRSROBGACC
MXV65\K]'3E>]^F] =N@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MLX]L9LI)PLD"^VZZ^9<_-NV_SW616XGB)RB%BF;%':01IT*JE+M8YM79FNF
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MFB\:>6\IY'K;)?!)VU\MY)6Z/6$4_*V3SNGXUL,KV6_/YWD33W,R="B@% *
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M=G:GUE[ ]<I'[RKLODS1OU=@?9,/^&967!=B'G9VI]9>P/7*1^\J?)FC?J[
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M+5,'YH)C"C+()D0D)*8Z(W'KJ3@1K,VW<IOR">KYGL"1M$V2=W;!>/8'%<'
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@-')!ES!%;W.8Q=B5-:A,[4B)$<X>N-5+ A$!R"\= ,
MM'*IOC8J>CQ;9DER,DC1$8P)GW.PT86MBK:)+OQ!X79^;]?IZES>CG5<25/G
MB,F11*&@S)N&I[GE19=X=.:QQ(,-9%E]B)C<M3IXSQI:1/F<=)!\F$<W<Q9
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M+752ME;!?!);'-/ #)T H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M^7NVL@!N[0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@%[6O:]KVM>U[=%[7^6U[7_':]OZ;7H!0"@%
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MUZ,\/6K8>JDJE"K4HU$G=*=*;A-)\Z4HNSYS);4GQ,M6H"@% * 4 H!0"@%
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M<K6RQRQO;+'+&]K7M>U[=-KVO:]KVO;Y+VO:]ODKFD/V@% * 4 H!0"@% *
M4 H"B.4O_P"6;D1_L.VO_P#8AZNZY-__ (AT%_YQHW_WE$UUO\JK_MS_ .EG
MI7I7_P!CFIO]F<#_ /M857GVF/\ O;2G_F.-_P#<U35'<O0ON+,KKBB@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4!XV\<;VL[Y,HW^15#F=RCQ63O\F:62VTB[M&RF-_Y6%U6KENY3\:U
MO'0725QZ<%,,K^KZ>_<Y.OF?)+DW9\SMHVE%V]$HRB^#36]%P_[L_P#=J?\
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M2HU.366\9P5I649.2<)1C=.F[MI>:+[/N]]^;;]ZYCV%KGD% * 4 H!0"@%
M* 4 H"A>5*J:/&3D/FJI@GAYD-IX>,IE;#'QU80<22PZ<KVMXRBN>":>/X\\
M\L<,;7RRM:_=\FDWRBT$DFW\L:-=DKNRQE%M^I)M\%M-=;_*J_[<_P#I9Z8Z
M:241U!JI%;#-)5+6T&2524QO@HFHG&!>&>&>.5K98YX96OCEC>UKVO:]KVZ;
M5YYI9J6E=)R333TAC6FMJ:>)JM-/G36U&J.Y>A?<6377E% * 4 H!0"@% *
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) 4 H!0"@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g609070g59g59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g59g59.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( .0"6 ,!$0 "$0$#$0'_Q  ?  $
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M[5-QYI<ZZ$</*IMMQYN,HM6I6LIM1BG+::R;44Y.WG1G9FF, 8 P#?WLX_\
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M 6/3G^]VJ_\ F/!_^YQ>:N.^A8S^5Q'W,S8PGTO"_P Q1^\B?JISY"?2!@#
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MD# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MORG"HX3L[.=.4HVC))5.[:MH]>*:NG\?X5=YOF0P!@# & 10C_MJ_P#[Z?\
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M;,/_ '!=<5VHC+^G;<W=K;:U98^VO/.GT;:P>3<\<_\ X]./[N>!?/'/]_\
M=GG<9C\!+$U91QN$DG)6:Q-%I^2M&IV9\ZY7P^(J<I8N<*%:<)5%:4*4Y1=J
M<$[246GFFLGJCA_4W;W\*K(_D:3_ -+S6Z=@O/,+]HI>,ZWHF+\VQ'<U/"/J
M;M[^%5D?R-)_Z7CIV"\\POVBEXQT3%^;8CN:GA'U-V]_"JR/Y&D_]+QT[!>>
M87[12\8Z)B_-L1W-3PCZF[>_A59'\C2?^EXZ=@O/,+]HI>,=$Q?FV([FIX1]
M3=O?PJLC^1I/_2\=.P7GF%^T4O&.B8OS;$=S4\(^INWOX561_(TG_I>.G8+S
MS"_:*7C'1,7YMB.YJ>$?4W;W\*K(_D:3_P!+QT[!>>87[12\8Z)B_-L1W-3P
MCZF[>_A59'\C2?\ I>.G8+SS"_:*7C'1,7YMB.YJ>$?4W;W\*K(_D:3_ -+Q
MT[!>>87[12\8Z)B_-L1W-3PCZF[>_A59'\C2?^EXZ=@O/,+]HI>,=$Q?FV([
MFIX1]3=O?PJLC^1I/_2\=.P7GF%^T4O&.B8OS;$=S4\(^INWOX561_(TG_I>
M.G8+SS"_:*7C'1,7YMB.YJ>$L"IJDM5E:E9O'E96"T9M+ AKETZ<PR1H-FS9
M"1C55W#A=4;HDB@BEILHJJIMJFFGKMOOMKKKSSQK8S&X.6#Q<8XO#2E+#5U&
M*KTFVW2FDDE.[;>22S;R.?"X7$QQ.&E+#UU%5Z+;=&HDDJD6VVXV22S;>21^
M@WMPMX]?[]?3GRH^@CMPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?
M[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?
M[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?
M[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?
M[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?
M[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?
M[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?
M[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?
M[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?
M[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?
M[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?
M[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?
M[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?
M[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?
M[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@#MPMX]?[]?3@')9F2BC
MQHGN]6VTW<H:;Z\\\?1MKLKKKMQS_=_Y<\<\\<X!T. >$GM@>M&Z:/F%)5;T
MUG)ZPL&)@Y/U962,KVK)Y:3F906LW&@>!4C+D()$9@K#HA?DL6E LA-) W!Q
M\0E '6K^1C-7''[X<D(IWO:V4<[+7>KM9JVG7H4] NI2TNH_K\M(U!K<M][T
MW(SOHRD-=,XQU24K3T* UY:_3?1EIE=2M3S:%'YI9C<P[E9,T:&120#79#9^
M]C;)=L25272$:2BKJSL[Y/52DM;VR/T>8,!@# & , 8 P!@# & , 8 P!@#
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M$1 AR8+.!@UXZ69,%RA%9HBDH]<[*A\?'8BCDNC3I 0,BI&ATI]-J,A!;A5
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M0JWMA5LIPT) ^[[11XE(]FPPE;*VS_\ G;]NU^!Z>8,1@# & , 8 P!@# &
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M=S)VQTRB96WW_>/DR;SA;;;]_O\ 2+=\7VLN&>=*O3;:$1A$!L.CZSF$+K4
M3BE?Q@Y$Q+T-#(P:A;FN2\>C;'=O^Y$!"D#=N8@0%L]4F3N/*["UT5&G&J?
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MREP&L!T) IJ2</*5M'X>6)D.5'Y8 ?D0[0@UV,.G&P7?%Y:=1HG!!@# & ,
M8 P!@# *YD]/5)-@<GC,SJVN9=&YJ<9R>91^3PB-'@DMDHYH'8#Y%)A148Z8
MGCK%C'8^R9ERB#H@U: @[=!PFB,9:(!=\3J)C1]>2VJ-*9;!6T)A8U**[PYI
M F B-\5X7@!X/+*Z/P8>B-6 !24 ED=CTEBR&X9V&:$PK#1T*>L-5F2P7^/C
MB3GN;$/W<N1YBL;Y2L!QN\GJ?88O]W-WBD;$PU1W+]/=?V9(Y4B($'%=US/#
MU3:-AA(/;;D8.9M40(7#Z%HRO1H4/ :8J>#B(W("<LCHN(5U$(T. RHU'7T0
M,28*R#!V387("T3)DHN2,L4D"+Z.D'P1TY5&NUVR@7?$AN_2C0;*,-81#*SA
M=70OFR(5:4CBE5PZ(0$).)-7IH;)HKQ,6L> M.2C)E)@,9,N=$E&CLGQ'6 0
MD\=1ER7"$Q;OCU9YFBL$& , 8 P!@# & 5;:5&TI>+ 4*NNGZMN 6!>K$@8V
MTJ_B=@, Q%PARU</Q3.6""[<<]7:\\MEG3--%=5#GE'=39/G]G!4VM&UZ#J!
MW3;T[!S4&D@FA*6%R*L1#:/UJ>'5;!V)JO0++E_LS"P<HV!)/HF):<E2G+4<
M!78,V_)(ARDCI[XY_>A=\7VG:R"G(3)Y^G89ACR\(N:UDU22<(Y0&OHM.X')
M20TMR$FP8@/=IG4 ;QH4XCZ:BJ2#%I+IFR61=M9$\2P2_P"?83<G%XR:":QD
MS'01:-Z<#==8^3$#WX374,Z:OA&NHETW58<<"GK%B\&\<-^.&+IFU<-?W2K=
M'?0"#S.B:0L=B<%V%3=53L;)Y$-E\E'S*O8C)V,AE@:/M(F(E!QH;$/D"TB%
MQ5@QC(XT_3<$F4?9- K9RD-;HMM N^)R@U410'9!FT6B;G>0DX)%*T&M-^&*
M02)0J)D3IAN%B8UHQ;<"DC!4\J]D*NRSE8KP)C3-3=-A&P[5H!9> , 8 P"I
MNWB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]&
M.WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]&
M.WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]&
M.WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]&
M.WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]&
M.WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]&
M.WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]&
M.WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]&
M.WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]&
M.WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]&
M.WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]&
M.WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]&
M.WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]&
M.WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]&
M.WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& .WB_CE?E3]& <EF;*J.VJ>[U
M7;11RAIOKSPG]&VNRNNNW'/T:?3]'/'//']V 1_ /SC>T&]H/U141U,=3T(K
MNRCL.B-.5'TZFJV&#^G")V?7QJV+O6L4. C]Z6W))9"F-+PN52Z-1F/L9>9/
M-!K-,F9=:KZ+BT6SP<D8JT6][E?.V2MHK7;M?);[&JEO:L;)VM).GY]34A1F
MT-4^JB>V'&2#201B(=1.E#(6^58IQ+1LY+KU$%)O6,*VL=^42T4E+X>TW!K
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MPX.=)[!TG"J[A,.L]?++"=%UUEN!ZC;A597?]K?8&K-I;FT7Q@@P!@# & ,
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MB*&J8-WX=B7N-$X(, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# *TL^G:SN<0.!V=$!LM'!R6Y<1J\W>-'@DBN,( W;D84&.6)0?L1
M!%RX$LFS>(I%@)8H$)INQ9%XT6"[6CM\7]Z3)X*%"P0L:#"#F(<*&8,Q0@0+
M:(,!@L6.;ILQXX<Q:II-63%BT12;-&C9)-!LW23113T3TUUX Y^ , 8 P!@#
M & , 8 P"G3/3[2\ALAA;IJN8X1L0:N%>H2-PW5Y46)QI)VA%S9(=HOJ',2&
M*H/WB,5D)8>].1E)PHD"(#].?V> (Q9O3#5UO2TT?GX9O(P4RKP#7-B0LBDI
MN$G(V!S]*RZI(%%6[EL];$*RE3Z9OH[LS6T25WG!G=]HLJV&*-14VO4[KJXY
M=>5_02@#0%/QN"O*T%0<?K!2$@'RE[''[PL99N#XHB%+C26ZAD@0=\+,2D="
M/VNFKC5!%T.06T2XWY4YW"[O>^?$D1"K:]*O79$G%!;]X^G4<LQTL\T5<?O)
M[$!(4%&91JFJKLDB3""XZ$;,%$=$TT>1S=Q^[Y=<;K;"'"8UB-;VY(;B>OG!
M&0%(-'ZY!LU44DV,5BX@P8D9;0;SQLHNH2EYXJT<R1YONDBZ916',4F2*@5=
MX1#=;X^%N]++,P!@# & , 8 P!@'P<MFSULX9O&Z#MF[05;.FKE)-=LY;+I[
M)+MW""NNZ2R"R6^Z:J2FNR:B>VVF^NVNW/'(%5570U/TBD52JJ @H7P;0#,2
M*@Q-RHX5$1I)XA%XZ@Z?.';EC%8H@1)(12)L56T;BZ)(BD!%#DWSO585MO5M
M^GKU[3K850D(B-="JJ>-$91!XK.TYO!@YIHELG$=@MCZVC7P<?RCOKHHSJ^2
M-Q3>#K<I)+CP\=CK5W[\\8."+X&[N_Q\/>?#GIEH7F82:??5?&>)9+VTE;GB
MNJ#G3API-!B(69$V;#1SJ,#R"7B&Z(V4R4*R'R&1,TM&Y@F\3X_9P0Y>W3M2
MVL^86HVKF,)6,(29["I.HS<+;MR@N,K0P/(7([AVD.(2@3$%U8BPE;I#:4LX
MFJM&69ML&5V:8+=VMN^/R)#459B*?KN.U\'>/"J8C4H_+GB6J.I652V4&R4K
MG$S,:MM$VNIJ:3,X>E9G5HDBTX*&'?#5!!OPFEH(\RR< 8 P#EL/]N9?\6V_
MZVF 6CV()\ W^3\\ =B"? -_D_/ '8@GP#?Y/SP!V()\ W^3\\ =B"? -_D_
M/ '8@GP#?Y/SP!V()\ W^3\\ =B"? -_D_/ '8@GP#?Y/SP!V()\ W^3\\ =
MB"? -_D_/ '8@GP#?Y/SP!V()\ W^3\\ =B"? -_D_/ '8@GP#?Y/SP!V()\
M W^3\\ =B"? -_D_/ '8@GP#?Y/SP!V()\ W^3\\ =B"? -_D_/ '8@GP#?Y
M/SP!V()\ W^3\\ =B"? -_D_/ '8@GP#?Y/SP!V()\ W^3\\ =B"? -_D_/
M'8@GP#?Y/SP!V()\ W^3\\ =B"? -_D_/ '8@GP#?Y/SP!V()\ W^3\\ =B"
M? -_D_/ '8@GP#?Y/SP!V()\ W^3\\ =B"? -_D_/ '8@GP#?Y/SP!V()\ W
M^3\\ =B"? -_D_/ '8@GP#?Y/SP!V()\ W^3\\ =B"? -_D_/ '8@GP#?Y/S
MP!V()\ W^3\\ =B"? -_D_/ '8@GP#?Y/SP!V()\ W^3\\ =B"? -_D_/ '8
M@GP#?Y/SP!V()\ W^3\\ =B"? -_D_/ '8@GP#?Y/SP!V()\ W^3\\ =B"?
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M;(0NZWW<N!#=\^73%.'.^R[@?JV66YY44VP5JS:X.Q>V"# & , 8 P!@# &
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MB1[#14A>GHF&![NO/T9O3/.W7;/JS=,P[J?OAA2A6U;83@"4@KWKBYHNQ(Q
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M8&9D$6.LX/9;N-/YH,&%8P6#OA) J^B$<=MI,,7:2D(X&)K #0M1=ULN)?\
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MP!WJ+?:;^3^K '>HM]IOY/ZL =ZBWVF_D_JP!WJ+?:;^3^K '>HM]IOY/ZL
M=ZBWVF_D_JP!WJ+?:;^3^K '>HM]IOY/ZL =ZBWVF_D_JP!WJ+?:;^3^K '>
MHM]IOY/ZL =ZBWVF_D_JP!WJ+?:;^3^K '>HM]IOY/ZL =ZBWVF_D_JP!WJ+
M?:;^3^K '>HM]IOY/ZL =ZBWVF_D_JP!WJ+?:;^3^K '>HM]IOY/ZL =ZBWV
MF_D_JP!WJ+?:;^3^K '>HM]IOY/ZL =ZBWVF_D_JP!WJ+?:;^3^K '>HM]IO
MY/ZL =ZBWVF_D_JP!WJ+?:;^3^K '>HM]IOY/ZL =ZBWVF_D_JP!WJ+?:;^3
M^K '>HM]IOY/ZL =ZBWVF_D_JP!WJ+?:;^3^K '>HM]IOY/ZL =ZBWVF_D_J
MP!WJ+?:;^3^K '>HM]IOY/ZL =ZBWVF_D_JP!WJ+?:;^3^K '>HM]IOY/ZL
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M('RW+?E^8?(,6:+H@NX73:M]%-4M!"0X P!@# & , 8 P!@# & , 8 P!@#
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M ?X"GGK>K '=@/\  4\];U8 [L!_@*>>MZL =V _P%//6]6 .[ ?X"GGK>K
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MUO5@#NP'^ IYZWJP!W8#_ 4\];U8 [L!_@*>>MZL =V _P !3SUO5@#NP'^
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M3]-LNMKK.IZI>LSCIY?V:@PCHL\WJ"CXA:$RW+O28Y+217A:[FFNGF/\/!3
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MOA^'6;LP08 P!@# (!WQ<^#0\Q3 '?%SX-#S%, =\7/@T/,4P!WQ<^#0\Q3
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MX-#S%, =\7/@T/,4P!WQ<^#0\Q3 '?%SX-#S%, =\7/@T/,4P!WQ<^#0\Q3
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M('!]@2IV08Q08Z*!@^TH;H#1;=>=D^JSMOOKFMW$VK@@P!@# & , 8 P!@#
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MQ^*[\Q'\# '=IC\5WYB/X& .[3'XKOS$?P, =VF/Q7?F(_@8 [M,?BN_,1_
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C4U->-MTN=>=M-^-N..>.$..?HYYX_O\ HYXY^C_RYXP#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g609070g60a60.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g60a60.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M 0$  P$! 0             ! @,&! 4'_\0 1Q$  @$" P0"#@8)! ,! 0
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M1WDINZ3WXJZZ[-H[;=<8=.- - - - - - - - - - - - - - - - - - -
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MMK_[9C?W$_R-0US!^8#0#0#0#0#0#0#0#0#0#0#0#0'9OV7G\JMB_P##Y/\
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MU_\ ;,;^XG^1J&N8/S : : : : LP8N3<,RD2\5<88D9\!IQ?[?9N+?X 7$
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M,?\ F!-/ZUY]_B6O5VQ;4[[3]33]QI[$X'O<O65/B'X&O9C_ ,P)I_6O/O\
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M7"-3P*RT87)1)"QY]>D'!PNRI!!*>(A$^/EE2VKYT?GINR)*!C\+:[R2-#!
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M?U@-(-&RVXIWC#MGLU8;UTB1F;40V2GBF\3WP5D2*HG851;=N-TL^OYX7)H
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MV*9/8P0>.!C86^"/"0--6TS5_P#):W0@T T T T T T T T T T T T T T
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M7!'\3KYC93MH+!.W#YMPY:W\W(Q,AX_S&.4%QDJ"/$'%ADJ=M/C0^/R!QDR
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M#G;CR)BX]\F4.0:N.P.(ILF(>,+D)I(&,EP/QEA*%Y@<CD; 0TTB$'I3@-*
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MO?>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z
M=(C/:O?>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z =(C/:O?>
MH_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z =(C
M/:O?>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+
MZ =(C/:O?>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z =(C/:O
M?>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z =
M(C/:O?>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z =(C/:O?>H
M_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z =(C/
M:O?>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z
M =(C/:O?>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z =(C/:O?
M>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z =(C/:O?>H_+Z R(
MT(T%JJ*M\W&62B?V>6RV:>6.V/UMLOX-L$D]_I^G';^'???;Z/\ ZT!#7)SD
M? N)].F[OLMA+2<1!2.N8JY'P8%M)92[+VC8\4JV+HBP?IC#,AOG*)D'V=HM
MU\G>+'TE1FV>NL$6:XJ3D[+7/V*_Y%#6O:]4K)<I5%Q-9WW74Y&L>4\;&N[<
MK(2VAXZZ>)L&-SZSZJ-N8M8A-<J?!Q83A*_MHV\7AYT,KF*%SU&4(OA(\7=?
M5P\SR3\5\N9UT6UVW?(:)S>7 H0SXSE786G>'\[JVICU6\E']L\GY[R8I0+9
M^59U<_KTW+XW#Y&^+/5PL/%RT>5<)IOF/I[HL@+,EL1DH)\]7=Y=REQ>?#JU
MT1W#<K.;#FG^.EYSVC8K#;QOZE*X+32<4:QM6OT2-08C848F!,]<R"<F0."H
MQ&&H9UL\'!6+B3RM[Z$&C+/',GD6&GDF^1BHYJ^2;UL\_%^5[%;KYYW\J:OC
M?$:RXM7E &X9?P/C Q2KXG()FK=]V6M><A"HSZ!4/&@[A5E%QE05^1<V:6F$
MVQEHQR%:/VA-$"V$+G7@**:>N5WU)+F^O16SOP)*X^]H<[Y%\^K=XUPN)!-J
M"K^DW\QA5OJ.EUB]M3N)VXK5=AO(ABD1W'*5E&Y(T.PP>3S%Y.Y!)HA(30HD
MYBRPA=X#C:*=\V].2M=>7CXFNLR0_M8.,I^Z;&H6(!;8FT]@;J\ (5O%8S&2
M"%L3_CD-S*7!657,EIJTD9*:1I!J70'XRD!$8U,7L?/,X1))&L,6QT&Z[7X6
M3?4GHWU/JOUZHUZ.]K]QLGL+KRP*LKSD;:L8N*VG-'TZ[AE7C\'-I6.+JDO;
M$F$Q(=*I=&'^X^'- )F%2R2'6X2.!I\(-B%BN0N/R X+#=>=[*RN[O1726E]
M;JRUXZ-7] [MCN)Y?U0[%Q^]'L=RXZGN4D^ER=:)(QVEJHA\OMZNYTXMI5U(
MFY0%)878=)S.#EXJ$%R0P1D6XMO%4)$T6?O!P;KO;*][:K-Y:<]4:JKVWO#A
MO7F\X>#+4&&/TH0ZJ-ZW--JI 2I([85<';8A!)[*3EMCJ7$A9/"XR>6%;&+7
M'G5I$+=P90&E.,.G=PW'?@\KW6?)/KR;2>6O5F3)AVI/'5>^*CXZ,X[;3BQK
M=A-1SUBQ6C<7#.8F"NS<GC#,Y)%9%-@]C%<&F8AWC-"M<PB?1N XY-UIB<#-
MW"2N0FZ[7\:\JU7+SVOPN0S&>U]J837#*0SR+698LI9#N2=D6,A0=2DB(RHZ
M"H+D795%/K;L(;()NZ(,8^V=5^20<[1TG*9-)7<>E)Z/PMH';;CV NZ^KA:[
MU;2:MIS5^5U=HF1IVIG'(E<["GA4<N0LS(7=7?'E.XQL)&.J63L^WJI!7'5@
MC>4XRC8VX:SF(R!GL-(#XL\0%DL<4I1Z@8D@1 L&Z[7RTOUV3:?X>X]=S=HE
M#N/=^6[6MBBI!(0$($\/!L9 UK GYZPR<\Y:6-:5;Q9AFX=R]L)/L"!V$#&C
M(:)"#"@=11XLY<G_ %DR;#@46UE;_EJ_NI-^QDAANT"I8IQ/NSEZ^CMHQB$<
M=G=R![B@DDC EI:D-D]#E28>Q8FY!,9*1C1 V/>"UO0E!,O?!B"2[91$OM]=
M7%%\_-QNNZCD[VLUH[Z$%K]L-Q<$3V"US,HI>-=R&89UIZ[3GD+C(#>K6]W3
M\M7=)O++&93IQ(AJ%I%!:)D*E' DH>QB)FP,BLII!6)';=(-U\+.][6=[V2;
M\R?EX7-,O#M@H7"N.G(._*@XZ\A[.C=21>:&8'812OU8W1%O.H+:8^FY0O';
M-;D2Z@P9'9@^<O<VTN!Q,Y,(X!/%X"/D(\>[(- 4;M)NUVD^:OIEU^7A?57E
M6QNU$J:O;4 T/(JWN:"6E.XD^?P12Q(G&!$6=3A*DREVI08DV93]S-W:PL,+
M=@)%+(Y%2U9LIDR?P]&PE#3?)/$-UV;RR]]KZ6U:RO?C:Q'DF[1BS(MP\[,/
MDIM53.92?FY-N-,8L*OH&'*%BK/"[N/L\M<LQJ@>1E8I),RA)XP,#@W,UD:P
M$<%=OG<E((HMU3#,'%;TE?\ 5OGXG;/QAKVO-#KG'<O(/#L9IZ.\9[9MR;1J
M15J?2NV,675')6+<:3=8/QPR2D1FTK3L0[E"&L+8ABBQZ2O@Y0/,\@"V.[T7
M<=O*E>^5FKW\WN-W7[6&D&KT7#G--<H4+O)6_C1Z_'%6LH[A=0>=OZ>+WK&=
MBHK>?='[1N8UR%>%P$L'S4A'DLL'&$@( D19QP*$W7S5K7O?*U[>>[T,1%>V
M.XD3J>497,-8VO()->T;C,F%#\(S& I6'-I):,PIA<?*(E)YN#G9TO#[(@$P
MCUAM*GBEF80/8&N6DRXX*Y8$'8.+5[V5O<GRXIJU[7(\>]L_Q[JL*6RNU<Z3
MD ^RN5[$FVK"$IM6\%IWC->IBG#=BS)E+[ ].)MQKMHV;.TH.M(99,7C(X8B
M-;HC&+IB/!0;=LE^K:[UWDFO/?\ S8M%4/:0<?+SY-S;BS7#6<')? G\@$')
M<BTARL+3+1D,'.DFZK%G-G=F!1;IB::XQR8RFN(_ IDZ2<M8?*CJV*.*PCBT
MD^>GSIX[.ZXV+^:$&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@
M&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@(+
MY'TI6M_U.4KVW7CX= FTGKBR2I >:;1Y1@^I>QXI<,=>NR[M%=JT$-))!A*Y
MS=?#!)8.F^;YN&NROI*0J;3NM<UYU;\RIRW ?A[,9>='MI2:)R_"PN35[FX\
M)L8*Y+CC/-NLB]7V85=AF[)<@QC12(GWBD&](1P08/LT'Z;PHGALCD&\\NI)
M>9W..X[,?AL]AURT<42D91M>=4\=8A(QCV<-\)G'P/$^(LZYI2PX$X9LVA>+
MRR(9-!A+:8M4ET59:U;+Y))HJ+#5Q=YY/1IM^?7R=7+)EC3E <>I)7-Y04BT
MBNR]CUB<J'D)9HQ*%AK3D00Q U09DC94W#B&*^4GSC)?([N^.-DV[/-ZD50'
M(,5$D]-27>75H5VDO9GT=/+3HN_ ER<D(G)Z,I:)TM5#VL[?:A(\UK -Z$[S
M;HH-XV^P<J3I!F-PFID>\;+2T6S','*OJQDR;(BJ5E:R:O?-?/DY7?,D6K.S
M=X64?R)WY04Y0-<U=:&]?D:\Q4@4.BL5 ILS)UP<,R9,6%!LU,)L8V<J!"DE
MV>^E/H[M@(<)YH8_3N#E)JS;:O?-M_GH:4.[,2@X[9%NV9"9I>M>D[@5N,L1
M!P>R< ,;B$SOU'9.U+"A+5,"J39R\\LJ3)"5I 7D@.#FCAHW 0<7+/MWB8;S
MM9V=K:K@N'BR1763=C?6D8>\=(WQCGU@4'4M3<BW5\F8K&9\6;%(>2WXWSBD
M]R-&D'00[G'S\ID1J-3.PF$I=%XI+'S:3O7XI5:3&V!D7?>;>;:M=YW[I//R
M*W^"RD"[+OB37L8E<,'1F5&HM/.+CSB-.1$GEY OM+:Q-S^U+0EI8R1V3;&<
MY_,YW<]@2*1RUH2:+*/RR2HMH*R9-M\!-YY9Z--9+59+S)::&B ^R\X[.:C-
MU2%NGD.:%.)XQ)&Y'M;@*0N,G4)BKJN6]=2&%.8B_I8[%PHM9YL2C$OJTR]5
MF&6<U-.G$[01/HOGYY^4;SO>R^?;[=,M+'[GV0?$K+?CZ-Q=7!O!>-C*HD*\
MK!]8ZY^"ID:1D.\K@T@Q0DPHU(XB;4D&R9"7JU9(Z]8SW9NW8S-@<&(X,M@W
MGGS=[OCGD_/_ 'U/$[V0O%8L!:1X8?O:$M',:N>O9TY@=K/HP_MFI+[N.87I
M8E062Y9B\MBL$=SV?2Y83L%3C\J"B#I,2PE";=^]W< I/J>EKI.UE9.W-)>7
MC<F1OV=_'!B76+"ADH#XY\FZAY8M1 LZBU"B[-H^L8Q44 'BV.PS+T2%,89$
M K5W'OM<\W+M)5Q@00Q4V1P#>?L:\C;?GNV96S^!=$6Y;Q6[9;M,^MC,DXJR
MIYN,D2+(1ZTX<V3*;5I[[)AD,7RP;;2J8&.J4=W&6YL;Z*S2S'Y(;KJ"7:5N
M&?MM?\$<XAP;H\E0W)GCFYVE_P"CKEE,;QG-K[)R!+ [N<Y"%'A>P>FBGJW?
M ,SW=OE_4C=1H^W&I?4PS5=?5^MN&\[I\8VMY-#3Y[V<_'^?WU'N1+@A9T7F
MXL=5(J4#X3-LHY&[/8TD5(%ZS0L%L@,6-.DP"Y1\R?)QD[%TI8!7WC,S3D,<
MPP%X@I-)K*SZE\^[569&R_9+\9G,.N"LEY9R"4J2V8C:,+8U#E<AK]&=1BKC
MG+>RYXXJ.)[,]F(8H_G#5 Z*?2G>8Y1K_P"0(CN L _(BG8N\^2O=.]L\E;Y
MZ\]<ST?A*<;U[1VMXO-KZD,O7FH:S2RIV?A7C616:.HE7CH3GT@WPAJ!$D<E
M%;KN&Y=GF1PC0PP[?DX:!BNY(B@[#>=K96LUY&][CU\=?83!+^S\I*7<?N,'
M'+$_:T4B/#XM5\@HR30N<>H+!CL@IVN)!6$",OI(F)71+.1H&1O7;UJY%["C
M1-)OB7'O ^;X0\#>=V\FW>]U=9N[R^;<,R*6?9&</$8F1B!,58TC9GJ;L6G)
M.7/6"3<2F4X6I>0CDE,+.-R9F@Q,9VXYND$-G Z7L73%N'?-4&@P.V'-6;-N
M&\^?%/S*RUX)96X\;D4V)V2 $O-J,E\%N^Y&4LCG(\K?=Z7Q*[)?/^1\Z<-.
M-\YHBO6T7F+*,[1@;T,D<C38?'%XPRAJ\69R!D5%&%SQ5(J*I6ODM+)6R7=*
M6GD_#@K&^$^QWXCE05,PYV0NA>OZ6PC"XROB%F+GXK*I!&;,)W#O-I G)A!H
MQ'YW*K%-%9#/I=51BMS4[V>>J)0Z)@FC 8T$WGGIG?@K9JVBRR6B>2X*YS)9
MV0W%*4/VAIJ4N6&23"3WJ>*RF#6)C'I)(0_(NVE+LLJ#$B^()RY81A6?JJ$H
MR_C&4?G,205<M@$S8^FOE'(;SSTSW?\ \JR^>/$E05V=%"#>58#E\[+VG);*
MAA66'( (ETVQDD6K\K-X2O7LBZ4<DA"T];1U6*/20\/7A&=$JRBRA)R]BD+"
M/<&:[42[M;@]?Q\6OEZ[%]-"#0#0#0#0#0#0#0#0#0#0#0#0#0#0%).T;-VW
M$^$O)6<TO9N533&NZ8M.PNJV4::R&09L(574JD6 :+.7Y%J/BIDJ8'B$%98Y
M%R1<6$Q,(A13"1/0\ICL;LF^2N6-MY75U=9&U\N[O/4_73-O!Q4W(S6>2D17
MS"1P2I+$N[*HFL@8&B)*V9=!ZOB<UDC@1%P8 PM&F+D'L(ED_P XG#RA$.).
M$CPBA*_^4OQ^?'H=*T(Y><@YS35#V.\E%K.X93G9J\).2UDRW"QG]*6+*9[.
MI59\4NN:,:^EU02-'DN;>94ZR0CT&EJT+K*3L)=F<CD@,O[.K>0C7RS)I+DN
MZDN>65K\EF\\WYCZ6=# : : : : : : : : : : Z[KVBDGEW,;C[!X#<-UP
MUX_:EKRMT=';#),X"VJ.GG\6 L(6E#-TE1.!FY;"E\<%D7;E-?9S HQ:N3+=
MC(?4A1B*K6;?B2\=\_)^-N%RNW-F^+BC=]61M%RLI8TWQOXJU5R/,$X!<HZM
M3R[Z17'=4<L-['XBYK>P17(J31V-U#'!(:H9>2B$$6<2]^,*%,I?+H0[#"I9
M+FVUI?@K=26;Z^K(Y5,6]?++E_ HE)B5E2=&S;GYO1B?%5YU6DLH!2M:HDDM
M6IW.H8[%9.4D$3/U>T$P>KK/R>1V-%!=@GI;&K:4/3%>(O6H65GXESU_#/-^
M:W$[D-#$: : : : : : : : : J=S0ETIB--".E)(3ABTSO7C-54AF059!J9
MC$)MOD-6=;S9^'(N$5TPQA[&).3!")#@GZ3&R9=H?9YI/!J"F JUYY-^9-KV
ME4"-UV5 N'7,Q8/8Y@B;I"U;EK6LK6DCT?))<*KT"8BC0O,R)0NV<M94_H7.
M7R4"ZD$C:%LU%*Y:JSY8V6]>.R MLU?C9OYYM<.OR*-VLDG[_E"<X?/;YMX5
M1L?L^PEF5EHV&NA9B90'Q7HNTQ].OK;>)+2!^U"F+*F5S;I$7[@PY$!Q\:-.
MW]>"GL>=!E9/5ZVX:O/Q96M:V9%-7<]+OLFT.RW83#.XH:"FZM8 ;=S;<=[>
M:Q'D?/KAX$W%:CJ4#YP-KE>OF=;P*<H0!XB)"RG=5K(7%B229#([!:2VE#L5
MI+>T=KV=U=6=M+ZM>-<KMY=_VA@- - - - - =<?:Q*$?N.6(S2R5PBQJQ>-
ML:MG-'?+;?:BI/R6J./WHF[VV^C#<*YJ<E+VDF^V_P#8QC#@RHM]">&6^PRC
M^MY&UJLTFUI9ZV.IB15#R7HB].;=MQE?EU%J[NGM,8.'NRT:JJ%">W4.XC-.
M+,9D+2440-'4])YG)80RNEU':GD4@@@6=N8M!8CDS#BL9"'F$B<#+)J*RR@[
M7=NZ<GJ[ZVS2=EY".'[KM.=VI&_$(+R(5N5GP"FE?QRSU:832N=U5&7:51-0
M:^*0U&(XP]IRN<\,T"-BH5BF 2E2DC:I/]X7@>]("X"]SI=6WN>5]WG]U2RO
MGEQ>I<;B;#+3:\>.V7.#8YR1ESBTIK9$@H8YR.I,[&;7ND+MPDJR*Q EM74K
MK:&NIE@\/!<X>R9/Z_P)'W O<3+1"\I4.L\ABVKPT66=GIW<GJM-;]1%4,<=
MH^).P^1CB_*&+1BLK9[(2!1ZE@]-BQ%6EJJLZJ*7!<T5C #&JMC"P"#/2,MR
MEC@*;#A*5-B"JBZ<><#UTV<7'QY>9?G<O<Z9:3SOI:[CQU;LL[WT-6>V[VB[
MBC>3*PH[VA>'-!&.SW*1PS'C0&<<::PD;+EQ$8_6OW>),YK5@0GSMW0SQV_$
M,:X*7%')'",91+;1(@I$.%J*W^_SG\L6CE^K;Q]T\N-GE9\[//*ZO:5#!?M(
MZM[1&,4\%GO)"=T7%; X\#H!)9A#C$RB-O4*6ASPUR6-6C+H+QH2J-I8K"8.
MI$"#'9;=5-F(@J&JYI&8/(09HPZ+AW+BW:*URN[I\+7E>V:X-:W>EJI1"]>U
M/E,5Y$/F!/FU7PD_3]/38.O:/'RSY_**\LI+DVH%MN"-'\=XG5"38NE*@?-&
MLQ;<=:XN$?"H^HO*JMWGQ6-&"+2?/5Y_GV,6C=?JVNUDTKY9/-M6OSM?1]7/
MGE^=K2^J;CHH!$<LJ];*P'D@U&3'H6<V1,9M?\;N04(HXC88:-\'<;!4J Y7
M2SPO (?>E/<<LIE&MR2MK6@A)1(LT4HM&\M+9972RSO9N5KY+1O7)6NCN8X5
MJR='ESVE(IQ@V1BJ-D<8C11F(W6WC0^_)%Q8K]Y=;0'LKEGBCZ0'0JDT30Q4
MW6S(&%2#[;(@0=++/EF+TCSL_-=V]MSLTT,1H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H#%'0(.4A#$9DP85(XY(1CX(?CYT<S
M+A#@8HU59$Q!@401<,"8PBS76:/F#UNNU=M5E6[A)1)3/#<#P;1X R-EI*S!
MAVDC/,A TZ?;#&2!LT.C^9-0"P+%4D,'Q%D$S-&,Q#5XNL@-S+$\F::.[]UN
MJ!H!*AJ-,[USN8IBJ"N]/)#T*DW)5U$'V]6H"<1N I&N?2@ZO1"(S ,'Q'IQ
MGU9@RQ$C-FV*6S!KLD+=YYO/7K\9*^A!H!H!H!H!H!H!H!H!H!H#$[ 0>)S.
M3[!1.TE4$I 5)#L.9['% :#Q8@B%S+;(^GYB47[A=\D.R<;LTWBZSG!'993/
M/(".RE!44<6AC@U2M2EUZY+OY!7JY2N8>_6@A\H83D),W#5'897.,%R)])(X
M_)!,F+QV823)N%E'N&*^P7?,S(&I*IBLTE%D1>LJ^C=B3=--*:3T##(X'FDO
M21R1S23E$I'C6YP^FEFV;Y)X%7SO'#)NAOCMMNDGOB+=\V2#H0: : : : :
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IH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g609070g67a67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g67a67.jpg
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M  (1 0,1 ?_$ !X  0 " P$! 0$!           )"@8'" 4$ P(!_\0 41
M 00" @ !!P<(!P4%!P4!!0,$!@<  @$("1$2-SAWM;83%!46=':W"C4V.767
MM-<7&"%7>):X&3%55K,:05C5UB)1<925L=,C)"4F@=3_Q  < 0$  04! 0
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M%-CBF1*%-M).-MT3;:5:)MOC*U=:MMOE;JS5'/13IWRYC[K^KC5/&\6B"$"
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M@6.1D.,CX ,P3X18B0@9D@.%#&2/'//"31@Q;(-6Z?'//&B*6FO'/]F"A[&
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M0\KPY>.C=,+KZ*_EOPJ8_IV(\6/D JHEUSB+HE_5\D%WL#"\'*CT'LC$LY1
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MA#331?5B6'\JJ)($ARBZ2/+P8]X3Y<C"2&JC JP4;$AKAT/=M7*PH9'@# &
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M#T8=2-:9L2X[[\./T[G?9D?^(HCGQ&?V\LCUC(\/:C#/W"Z2U,F]SCQ%& ,
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MWOM+.?;(7T')_6X^YB,,_<+I+4R8W.4$48 P!@# (@N[=WVU7]U\ (7/9!'
MWU0 OOHX:ZT1;?.W*Y/5=QYFR>_/RBNJ*7&_/E_MXTU_LSJ69^1LEV[)#GVR
MQ2+1._E<Z#RDR%N+:0PRG##5-7)MTTDF5!#%!5I-U9R%_6G[#_WN3#_YY/\
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M)$J9#MK3*AB2CERX8DHH6X6D[TVG<63885!$U#"G=>DD\43=YQXB# & , 8
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MAT7V20^=OUW"_P BELHIRFE\IYFG.^_.NO'.VWE\O[+LB19\[89=GDRI$O\
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M-5D9-Z>F[<K(U=4=R!#AP+G2ESH^-4=^GBY7[N(F4P6CR\?^_C_?Y/\ _?\
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M^--]GR])V3FH!7&M^4DR/C+5B[E6YFOW@0_ :V8Q3BVJH(2V:1P^^D)^$3"
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M].'XD5AQ6E:RJMGI4GC ,DM#]7=WH^T=8/QH;Y%L'#K,WHYQ_9)#MOFUV_%
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MKIV/_N'K_P#?TZ_D_G)S,/KIV/\ [AZ__?TZ_D_@#ZZ=C_[AZ_\ W].OY/X
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M!0VMKMKOKKOIMQMKMQQMKMKSQMKMKMQY>-M>>/+QSQSQSQSQSQSSQSQSY>,
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M_P#0=SQ(X:0E8B-L8?,9X/+R"HYG*RXEX,2BP(GL_+#Y;2LV(Q8>TW5=S%*
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M-_.%^%M.2_,=CT8\K37C33YNV^BXP,X^0YY4Y^<<.%O/\BO&F@I]QE& , 8
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M;;Y/DA') "D(M;R<MBH(R+,#EG0Y^U<J@TUBJ?--=4^1IK$VW@H, 8 P!@#
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M?B%ZNN0G%IS\T+U:</>'O$*0&BN2/)E!Q(78KMG[J=E$M27LTF&C?"=HN,;
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M"(C8-@@D@@@R#@A[<6,:(H-4D&R*39DU0132;H(H)Z:<:(I)IZZZ:BT]W &
M, 8 P!@')O9WJ)$^T!.I) 9L2QJTDU+'94?AA^O1]0&E=G,RB[B('&ID%==3
M7!#R;14,Z6T:\[1M%ZR=;<.VKU-9-/G453I58IX]AHV<^%QU\L\;,1]C2JVY
M<K81TU)IJ2<&X.!>'3TBZ4".B)DC\A#Z]C8D+R[J@,WEB3.-C PX=9JRY86S
M8Q+5K"FHKMJ.J2YEQ8[;C;X^7B,3.^$O3DH;3=:2WIV8,RJUU;E'7)/%C]-L
M9/;$ [!P.BJZN2JI.V#T@-B06$S8#UTK)51[7L7A,_CA%@37A\XCS<JNTU#;
M/D5*II7TJJTX^=XUKQGV:>$Y0C"96=8$8LB[H1+;#L:+6V*(0QY3P%C6UCPZ
MPWUDAIE&8VA36\6F\EX*DG@1[(;Z"7(<>Q)=8 N1V;KN5%A3;.[F37'@^W50
M\NVO"HKNP0-A?-KCNTI(YC"GZBPZP)-%9!#)3?C+K%(>JL.["6(NS@+*PB,R
M%5L;18% <:FT=K4BX',B_-=_2[)JZ3%5%2ER^^E=M3'EX\>*M#XA_A#4:5CF
M^MG6?>$_L,O'" B1V&[D,#%%MWCNN*7K< X"LX_68,"S1K(71$$=5[LZ!.G;
MHBV(D;*7L)V6?;*!MGQ4I[>-NC>+K6__ %.JI;T[B=BU1 :KLZTKFLC>!VLU
MN32PY0=A>D]DLQ9F)&8;IGN0$"!0EC'&^\F=CV4:AD*B0D4(8BQPAN/1:;_+
M"E<;E>J')%H>$131^D9M7=?32?B):[ITY74"-2PL"* !QO7H#,_#XB125,!$
M0&D"8EG6$N5DAYH*=#73V:-^"8]5D(\L<W%5$Z\7/RTVRBUJXV1&O"ZHMLO,
MC5AS.V[=EMHUO?-86K(IJ>A[-Q-XSV)K#KO3<R9N4(+ H2S$\QRL^L590^#.
MX\T#/6;'0^6DZ\JE!M<ZD&VPHE<TTN*ZO*WBVV_P/Y_V6'7TNG&'MB3*Y;8F
MD>ORN^P1"Q9M(82QEDU,U;!XO740KV9M*_KR#0PC4J<5A$.:'X:.B(G>7/HV
M.,RHJ8,;/'SL%$U@DKJ:%S5JZUOK70>= O"8ZQUU*%95'RMB<.4;686M'VBN
MM5M/JRZ'/KA*(PUK( M5B9K)89R4NZ7/N$K"E,SE#;=E'6K"4M!PU=F^%'$W
MCR4X^9<M%AQ7<QA,B\%SJ?(HQ#(PO([;1T@T'K&M1)-RXJ.4N'4&K*AAO71,
M 5#3RGY;#G>DQ@ <8XEA32,('$)*S2+PLI#D]E62@NV[OPO;=+Z7NO$ZW/#V
M.J-G33PMNODR9%6NLJMR+K/W?8(B/?QDW!TW$;*=B[JHF^Y,0!M3E>G!.RD2
MGG7>OOJ(S-#3 MF#V.BY.PE?T@V<,!3;/FXO<FJ8\=;^<D?;I;H-T$57"SQ1
M%%))1VXU;ZN'6Z>FNF[A?5H@U:ZK+[<<JJZMFS=OQOMMPB@BGQJGJ+3]L 8
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LS.[Y(43F0V+AH[&M83NWC<-!0_=HW))BFV?-QKL:VM.Q8<?+4D>P6C /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
